<SEC-DOCUMENT>0001213900-23-025399.txt : 20230331
<SEC-HEADER>0001213900-23-025399.hdr.sgml : 20230331
<ACCEPTANCE-DATETIME>20230331155351
ACCESSION NUMBER:		0001213900-23-025399
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230331
DATE AS OF CHANGE:		20230331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PolyPid Ltd.
		CENTRAL INDEX KEY:			0001611842
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38428
		FILM NUMBER:		23787276

	BUSINESS ADDRESS:	
		STREET 1:		18 HASIVIM STREET
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			495376
		BUSINESS PHONE:		972-74-7195700

	MAIL ADDRESS:	
		STREET 1:		18 HASIVIM STREET
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			495376
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>f20f2022_polypidltd.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 19:22:19 UTC 2023 -->
<html xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:pypd="http://Polypid.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
WASHINGTON, DC 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">20-F</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentRegistrationStatement">&#9744;</ix:nonNumeric> REGISTRATION
STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric> ANNUAL REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric> TRANSITION REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentShellCompanyReport">&#9744;</ix:nonNumeric> SHELL COMPANY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File No.: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-38428</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="-sec-ix-hidden: hidden-fact-0">POLYPID LTD.</span></b><br/>
<i>(Exact name of registrant as specified in its charter)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Translation of registrant&#8217;s name into
English: Not applicable</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>State of <ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode">Israel</ix:nonNumeric> </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><i>(Jurisdiction of incorporation
or organization)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1"><b>18 Hasivim Street</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Petach Tikva</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">495376</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Israel</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><i>(Address of principal
executive offices)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName">Dikla Czaczkes Akselbrad</ix:nonNumeric><br/>
Chief Executive Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PolyPid Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1"><b>372 Franklin Ave.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2"><b>P.O. Box 558</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown">Nutley</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode">07110</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Telephone: <ix:nonNumeric contextRef="c1" name="dei:CityAreaCode">(908)</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber">858-5995</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><i>(Name, Telephone,
E-mail and/or Facsimile number and Address of Company Contact Person)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(b) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Title of each class</i></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trading Symbol(s)</i></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Name of each exchange on which registered </i></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary Shares, no par value</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PYPD</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq Global Market</b></span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered or to be registered pursuant
to Section 12(g) of the Act: None&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act: None&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate the number of outstanding shares of
each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">19,851,833</ix:nonFraction> ordinary shares as of December 31,
2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric>
&#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this report is an annual or transition report,
indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act of 1934.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric>
&#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9746;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">No</ix:nonNumeric>
&#9744;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160;&#160;No
&#9744;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric> &#9746;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging Growth Company <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange
Act. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The term &#8220;new or
    revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting
    Standards Codification after April 5, 2012.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744;&#160;&#160;&#160;&#160;No
<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If securities are registered pursuant to Section 12(b) of the Act,
indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to
previously issued financial statements. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether any of those error corrections are
restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers
during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark which basis of accounting
the registrant has used to prepare the financial statements included in this filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" name="dei:DocumentAccountingStandard">U.S. GAAP</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">International Financial Reporting Standards as
issued by the International Accounting Standards Board o</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If &#8220;Other&#8221; has been checked in response
to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9744; Item 17 &#160;&#160;&#9744;
Item 18</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this is an annual report, indicate by check
mark whether the registrant is a shell company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744;&#160;&#160;&#160;&#160;No
<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1.5pt; width: 9%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 3%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 80%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTRODUCTION</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</span></td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="3"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></a></td>
    <td style="text-align: center">iv</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUMMARY RISK FACTORS </span></a></td>
    <td style="text-align: center">v</td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="3" style="text-align: center"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I</b></span></a></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</span></td>
    <td>&#160;</td>
    <td><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</span></td>
    <td>&#160;</td>
    <td><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OFFER STATISTICS AND EXPECTED TIMETABLE</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</span></td>
    <td>&#160;</td>
    <td><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KEY INFORMATION</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization and Indebtedness</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasons for the Offer and Use of Proceeds</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</span></td>
    <td>&#160;</td>
    <td><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION ON THE COMPANY</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">History and Development of the Company</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Overview</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organizational Structure</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, Plants and Equipment</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.A</span></td>
    <td>&#160;</td>
    <td><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNRESOLVED STAFF COMMENTS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5.</span></td>
    <td>&#160;</td>
    <td><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Results</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity and Capital Resources</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and Development, Patents and Licenses, etc.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trend Information</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical Accounting Estimates</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6.</span></td>
    <td>&#160;</td>
    <td><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors and Senior Management</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board Practices</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><a href="#a_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Ownership</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7.</span></td>
    <td>&#160;</td>
    <td><a href="#a_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major Shareholders</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party Transactions</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interests of Experts and Counsel</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 8.</span></td>
    <td>&#160;</td>
    <td><a href="#a_034"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL INFORMATION</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_035"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements and Other Financial Information</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_036"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant Changes</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9.</span></td>
    <td>&#160;</td>
    <td><a href="#a_037"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFER AND LISTING</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_038"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer and Listing Details</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_039"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_040"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Markets</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_041"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Shareholders</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><a href="#a_042"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td><a href="#a_043"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses of the Issue</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 10.</span></td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 80%"><a href="#a_044"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADDITIONAL INFORMATION</span></a></td>
    <td style="text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_045"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Capital</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_046"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Memorandum and Articles of Association</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_047"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Contracts</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_048"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Controls</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td><a href="#a_049"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td><a href="#a_050"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends and Paying Agents</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span></td>
    <td><a href="#a_051"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement by Experts</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.</span></td>
    <td><a href="#a_052"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documents on Display</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span></td>
    <td><a href="#a_053"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary Information</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span></td>
    <td><a href="#a_054"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual Report to Security Holders&#160;</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 11.</span></td>
    <td>&#160;</td>
    <td><a href="#a_055"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 12.</span></td>
    <td>&#160;</td>
    <td><a href="#a_056"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#a_057"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt Securities</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#a_058"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants and rights</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#a_059"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Securities</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td><a href="#a_060"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">American Depositary Shares</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: center"><a href="#a_060a"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART&#160;II</b></span></a></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 13.</span></td>
    <td>&#160;</td>
    <td><a href="#a_061"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">127</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 14.</span></td>
    <td>&#160;</td>
    <td><a href="#a_062"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATERIAL MODIFICATIONS TO THE RIGHTS O7F SECURITY HOLDERS AND USE OF PROCEEDS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">127</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 15.</span></td>
    <td>&#160;</td>
    <td><a href="#a_063"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTROLS AND PROCEDURES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">127</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td>&#160;</td>
    <td><a href="#a_064"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></a></td>
    <td style="text-align: center">128</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A</span></td>
    <td><a href="#a_065"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUDIT COMMITTEE FINANCIAL EXPERT</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B</span></td>
    <td><a href="#a_066"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CODE OF ETHICS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C</span></td>
    <td><a href="#a_067"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">129</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D</span></td>
    <td><a href="#a_068"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">129</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E</span></td>
    <td><a href="#a_069"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">129</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F</span></td>
    <td><a href="#a_070"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">129</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G</span></td>
    <td><a href="#a_071"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CORPORATE GOVERNANCE</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H</span></td>
    <td><a href="#a_072"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MINE SAFETY DISCLOSURE</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I</span></td>
    <td><a href="#a_073"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: center"><a href="#a_074"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART&#160;III</b></span></a></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 17.</span></td>
    <td>&#160;</td>
    <td><a href="#a_075"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 18.</span></td>
    <td>&#160;</td>
    <td><a href="#a_076"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 19.</span></td>
    <td>&#160;</td>
    <td><a href="#a_077"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBITS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>INTRODUCTION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a Phase&#160;3 clinical-stage
biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using our proprietary
Polymer-Lipid Encapsulation matriX, or PLEX, technology. Our product candidates are designed to address diseases with high unmet medical
needs by pairing our PLEX technology with drugs already approved by the U.S. Food and Drug Administration, or the FDA, or innovative
drug candidates to achieve a novel therapeutic effect. Our PLEX technology is designed to deliver drugs directly to targeted treated
sites in the body at predetermined release rates and predetermined durations ranging from several days to several months. We believe
that our PLEX technology and product candidates have the potential to significantly improve the management of a variety of medical conditions,
including surgical site infections, or SSIs, and cancer. Our lead product candidate, D-PLEX<sub>100</sub>, is in a pivotal Phase&#160;3
confirmatory trial for the potential approval for prevention of open abdominal SSIs. D-PLEX<sub>100</sub> pairs our novel proprietary
PLEX technology with doxycycline, a first-line, broad spectrum and FDA-approved antibiotic D-PLEX<sub>100</sub> is administered directly
into the surgical site during surgery and provides a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting
in high local concentration of the drug for a period of 30 days for the prevention of SSIs, including SSIs caused by standard of care
antibiotic-resistant bacteria. Infections resulting from surgery can be fatal and create a significant public health burden despite the
extensive use of systemically administered antibiotics both pre- and post-operatively and other measures taken to reduce infection risk
in the intra-operative setting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The World Health Organization,
or WHO, estimates that SSIs result in up to $10&#160;billion of additional hospital costs per year in the United States alone, and a
further &#8364;11&#160;billion per year in the European Union. The Centers for Disease Control and Prevention, or CDC, estimates that
SSIs are the most costly healthcare-associated infection, or HAI, type of event in the United States.<b>&#160;</b>SSIs occur in approximately
2% to 5% of all patients undergoing inpatient surgery worldwide and account for 20% of all HAIs in United States. In their last guidelines,
the WHO and the CDC have labeled SSIs as a high priority unmet medical need due to the associated morbidity, mortality and economic cost
burden.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that D-PLEX<sub>100</sub>,
if approved, would be a significant improvement over the current standard of care, which includes systemic administration of antibiotics.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We initiated two Phase&#160;3
trials of D-PLEX<sub>100</sub>, which we refer to as SHIELD I (Surgical site Hospital acquired Infection prEvention with Local D-PLEX<sub>100</sub>)
and SHIELD II, for the prevention of abdominal (soft tissue) SSIs in the third and fourth quarters of 2020, respectively. In May 2021,
the FDA agreed in a Type B meeting that a single pivotal Phase 3 study is sufficient, provided the study results are adequate, for potential
approval of a D-PLEX<sub>100</sub> new drug application, or NDA, for the prevention of SSIs in colorectal surgery.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we announced
top-line results from the SHIELD I Phase 3 study of D-PLEX<sub>100</sub>&#160;for the prevention of SSIs in abdominal surgery. SHIELD
I study did not achieve its primary endpoint of reduction in SSIs, re-interventions due to SSIs and mortality in the Intent to Treat,
or ITT, population, the local administration of D-PLEX<sub>100</sub> and standard of care, or SoC, (n=485) resulted in a decrease in
the primary endpoint of 23% compared to SoC alone (n=489) (p=0.1520). That said, in a pre-specified subgroup ITT analysis requested by
the FDA of a total of 423 subjects with large incisions (&gt;20 centimeters), the local administration of D-PLEX<sub>100</sub>&#160;resulted
in a significant reduction of 54% in the primary endpoint,&#160;compared to SoC alone (p=0.0032). Within the first 30 days post-surgery,
SSIs decreased from 9.7% in the SoC treatment arm (n=211), as compared to 4.4% in the D-PLEX<sub>100</sub>&#160;treatment arm (n=212).
In addition, the SHIELD I study also showed a 34% reduction in the primary endpoint in patients with one or more personal risk factors
(post hoc analysis; p=0.047; n=680) compared to standard of care. The SHIELD I study demonstrated a good safety profile of D-PLEX<sub>100&#160;</sub>with
no increase in serious or severe treatment emergent adverse events compared to standard of care.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2022, we provided
the FDA with available data from the SHIELD I study as part of a Type D meeting request. Following positive type D meeting communication
with the FDA, which took place in January 2023 on the SHIELD I Phase 3 data, we now have a clear regulatory pathway toward a potential
new drug application, or NDA, submission. Based on the data, particularly the 54% reduction observed in the primary endpoint in complex
surgeries in a pre-specified subgroup analysis of patients with large open incisions (p=0.0032, n=423) compared to standard of care,
the FDA acknowledged that the SHIELD I results may provide supportive evidence on this population and recommended that we conduct an
additional study to support a potential NDA submission. The FDA stated that the ongoing SHIELD II study, which to date has enrolled over
200 patients, including approximately 40 patients with the appropriate large open surgical incisions, could potentially serve as such
a study. The FDA also recognized that D-PLEX<sub>100</sub>&#8217;s proposed indication is for the prevention of infection and has the
potential for wide use. </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SHIELD II patient recruitment
is expected to resume in the second quarter of 2023 with the enrollment of an estimated 550 additional patients. Total recruitment time
into the study is anticipated to be approximately 12 months and top-line results are expected in mid-2024. Unblinded interim analysis
is planned to be conducted once approximately 400 patients complete their 30-day follow-up. </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we received
confirmation from the European Medicines Agency, or EMA, that D-PLEX<sub>100</sub> is eligible for submission of a Marketing Authorization
Application, or MAA, in the European Union, or EU, under the EMA&#8217;s centralized procedure. The centralized process eligibility is
granted to D-PLEX<sub>100</sub> under the Therapeutic Innovation criteria which underscores that D-PLEX<sub>100</sub> potentially provides
a new alternative to patients in preventing post abdominal SSIs.&#160;As we have done with the FDA in the United States, we are currently
preparing for expected near-term interactions with the European regulatory authorities regarding D-PLEX<sub>100</sub>, which are anticipated
in the first half of 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">In
addition to our lead program D-PLEX<sub>100</sub>, our pipeline includes an early-stage oncology program, OncoPLEX, PolyPid&#8217;s lead
intra-tumoral cancer therapy drug candidate. OncoPLEX utilizes our PLEX technology to provide controlled local exposure to docetaxel,
one of the most widely used chemotherapy agents, directly at the tumor site for several weeks to potentially reduce local tumor reoccurrence,
the potential spreading of cancer cells, and ultimately improve the overall survival rate of cancer patients. Local delivery of drugs
directly into the tumor site, especially in difficult to access tumors such as in the brain, may significantly improve the clinical outcome.
The OncoPLEX intra-tumoral cancer therapy program has been evaluated successfully in various animal tumor models, including colon carcinoma
and glioblastoma. We are currently finalizing chemical, manufacturing and control, or </span>CMC<span style="font-size: 10pt">, processes
for OncoPLEX as we continue our efforts to begin clinical development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an Israeli corporation
based in Israel near Tel Aviv, and were incorporated in 2008. Our Ordinary Shares are currently traded in the United States on the Nasdaq
Global Market under the symbol &#8220;PYPD&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain information included
or incorporated by reference in this annual report on Form 20-F may be deemed to be &#8220;forward-looking statements&#8221;. Forward-looking
statements are often characterized by the use of forward-looking terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221;
&#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;believe,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221;
&#8220;project&#8221; or other similar words, but are not the only way these statements are identified.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These forward-looking statements
may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections
of results of operations or of financial condition, expected capital needs and expenses, statements relating to the research, development,
completion and use of our products, and all statements (other than statements of historical facts) that address activities, events or
developments that we intend, expect, project, believe or anticipate will or may occur in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Forward-looking statements
are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on
assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions,
expected future developments and other factors they believe to be appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Important factors that could
cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements
include, among other things:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our dependence on enrollment
    of patients in our clinical trials in order to continue development of our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the outcomes of our anticipated
    interim analysis in our SHIELD II clinical trial;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to raise capital
    through the issuance of&#160;securities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to advance
    the development of our product candidates, including the anticipated starting and ending dates of our anticipated clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our assessment of the potential
    of our product candidates to treat certain indications;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully
    receive approvals from the U.S. FDA, EMA, or other applicable regulatory bodies, including approval to conduct clinical trials, the
    scope of those trials and the prospects for regulatory approval of, or other regulatory action with respect to our product candidates,
    including the regulatory pathway to be designated to our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the regulatory environment
    and changes in the health policies and regimes in the countries in which we operate, including the impact of any changes in regulation
    and legislation that could affect the pharmaceutical industry; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to commercialize
    our existing product candidates and future sales of our existing product candidates or any other future potential product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to meet our
    expectations regarding the commercial supply of our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the overall global economic
    environment; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact on us (including
    our ability to enroll patients in our clinical trials) of COVID-19 and its variants and resulting government actions;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of competition
    and new technologies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general market, political
    and economic conditions in the countries in which we operate;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">projected capital expenditures
    and liquidity;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to regain and
    effectively comply with the listing requirements, including the minimum bid requirement, of Nasdaq Stock Market LLC;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in our strategy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">those factors referred
    to in &#8220;Item 3. Key Information &#8211; D. Risk Factors,&#8221; &#8220;Item 4. Information on the Company,&#8221; and &#8220;Item
    5. Operating and Financial Review and Prospects&#8221;, as well as in this annual report on Form 20-F generally.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Readers are urged to carefully
review and consider the various disclosures made throughout this annual report on Form 20-F which are designed to advise interested parties
of the risks and factors that may affect our business, financial condition, results of operations and prospects.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should not put undue
reliance on any forward-looking statements. Any forward-looking statements in this annual report on Form 20-F are made as of the date
hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the section
of this annual report on Form 20-F entitled &#8220;Item 4. Information on the Company&#8221; contains information obtained from independent
industry sources and other sources that we have not independently verified.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
all references to &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;PolyPid&#8221; refer to PolyPid Ltd., its wholly
owned subsidiaries, PolyPid Inc., a Delaware corporation with operations in New Jersey, and PolyPid Pharma SRL, a company organized and
existing under the laws of Romania. References to &#8220;U.S. dollars&#8221; and &#8220;$&#8221; are to currency of the United States
of America, and references to &#8220;shekel&#8221;, &#8220;Israeli shekel&#8221; and &#8220;NIS&#8221; are to New Israeli Shekels. References
to &#8220;Ordinary Shares&#8221; are to our Ordinary Shares, no par value. We report our financial statements in accordance with generally
accepted accounting principles in the United States, or U.S. GAAP.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the context otherwise
indicates or requires, PolyPid, BonyPid, Bacfenssi, Opzifend, Ssisurg, Elyfssi and Bacyssio are our proprietary trademarks. These trademarks
are important to our business. Although we have omitted the <sup>&#8220;</sup>&#174;<sup>&#8221;</sup> and <sup>&#8220;TM&#8221;</sup>
trademark designations for such marks in this annual report on Form 20-F, all rights to such trademarks and service marks are nevertheless
reserved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Summary Risk Factors&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The&#160;risk factors&#160;described
below are a&#160;summary&#160;of the principal&#160;risk factors&#160;associated with an investment in us. These are not the only&#160;risks&#160;we
face. You should carefully consider these&#160;risk factors, together with the&#160;risk factors&#160;set forth in Item 3D. of this annual
report on Form 20-F and the other reports and documents filed by us with U.S. Securities and Exchange Commission, or the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
    Related to Our Financial Condition and Capital Requirements</i></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never generated
    revenues, have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for
    the foreseeable future, and we may never achieve or maintain profitability.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect that we will
    need to raise substantial additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding
    on acceptable terms and on a timely basis may require us to curtail, delay or discontinue our product development efforts or other
    operations. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
    Related to the Discovery, Development and Clinical Testing of Product Candidates</i></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We depend on enrollment
    of patients in our clinical trials in order to continue development of our product candidates.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are heavily dependent
    on the success of D-PLEX<sub>100</sub>, including obtaining regulatory approval to market D-PLEX<sub>100</sub> in the United States
    and the European Union.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The outcome of our planned
    unblinded interim analysis in our SHIELD II trial may require that we enroll more patients than would have been the case without
    an interim analysis, in which case we will need to spend additional time, effort and financial resources on the SHIELD II trial,
    which may not ultimately be successful or support regulatory approval of D-PLEX<sub>100</sub>.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improvement in standard
    of care infection prevention and control measures being undertaken in hospitals globally as a result of the COVID-19 pandemic may
    have decreased the rate of SSIs, which may adversely impact the ability of our clinical trials to demonstrate an improvement over
    the standard of care and may ultimately reduce our commercial opportunity even if our trials are successful.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory approval processes
    of the FDA, the EMA and comparable foreign regulatory authorities are lengthy, time-consuming, costly and unpredictable, and if we
    are ultimately unable to obtain regulatory approval for D-PLEX<sub>100</sub> or any future product candidates, our business may fail.</span></td></tr>
  </table><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLEX is a novel technology,
    which makes it difficult to accurately and reliably predict the time and cost of development and of subsequently obtaining regulatory
    approval of D-PLEX<sub>100</sub> or any future PLEX product candidates. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical drug development
    is difficult to design and implement and involves a lengthy and expensive process with uncertain outcomes. We may be unable to successfully
    complete clinical development for any product candidates we may develop, including D-PLEX<sub>100</sub>. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
    Related to Our Reliance on Third Parties</i></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on third parties
    to conduct certain elements of our preclinical studies, clinical trials and analytical tests, and perform other tasks for us. If
    these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements,
    we may not be able to obtain regulatory approval for or commercialize our product candidates.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on third parties
    to manufacture the raw materials, including the active pharmaceutical ingredient, that we use to create our product candidates. Our
    business could be harmed if existing and prospective third parties fail to provide us with sufficient quantities of these materials
    and products or fail to do so at acceptable quality levels or prices.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our reliance on third parties
    requires us to share our trade secrets and intellectual property, which increases the possibility that a competitor will discover
    them or that our trade secrets and intellectual property will be misappropriated or disclosed. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
    Related to Our Intellectual Property</i></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to obtain
    and maintain effective patent rights for our product candidates or any future product candidates, we may not be able to effectively
    protect our products and business and compete effectively in our markets. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to protect
    the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be successful
    in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
    Related to Our Business Operations</i></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our future success depends
    in part on our ability to retain our senior management team and to attract, retain and motivate other qualified personnel.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to our limited resources
    and access to capital, we must, and have in the past decided to, prioritize development of certain product candidates over other
    potential candidates. These decisions may prove to have been wrong and may adversely affect our revenues.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European data collection
    is governed by restrictive regulations governing the collection, use, processing and cross-border transfer of personal information.
    Failure to comply with such regulations may result in substantial fines, other administrative penalties and civil claims being brought
    against us.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business and operations
    have been and are likely to further continue to be adversely affected by the COVID-19 global pandemic.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
    Related to Commercialization of Our Product Candidates</i></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have limited manufacturing
    experience and could experience production problems that result in delays in our development or commercialization programs or otherwise
    adversely affect our business.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently have no marketing
    and sales organization. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties
    to market and sell our product candidates, we may be unable to generate any product revenue.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are subject to significant
    regulatory oversight with respect to manufacturing our product candidates. Delays in establishing and obtaining regulatory approval
    of our manufacturing process and facility or disruptions in our manufacturing process may delay or disrupt our product development
    and commercialization efforts.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It may be difficult for
    us to profitably sell our product candidates if coverage and reimbursement for these products, or the procedures in which they are
    used, is limited by government authorities and/or third-party payor policies. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
    Related to Ownership of Our Ordinary Shares</i></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market price of our
    Ordinary Shares may be highly volatile, and you may not be able to resell your Ordinary Shares at or above the price you paid.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our executive officers,
    directors and principal shareholders have the ability to exert significant control over matters submitted to our shareholders for
    approval.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be or may become
    classified as a passive foreign investment company. If we are or become classified as a passive foreign investment company, our U.S.
    shareholders may suffer adverse tax consequences as a result.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a United States person is treated as owning
    at least 10% of our shares, such holder may be subject to adverse U.S. federal income tax consequences.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#9679;</td>
    <td>If we are unable to comply with Nasdaq Stock
    Market LLC minimum bid requirement, our Ordinary Shares could be delisted from Nasdaq Stock Market LLC, and as a result we and our
    shareholders could incur material adverse consequences, including a negative impact on our liquidity, our shareholders&#8217; ability
    to sell shares and our ability to raise capital.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
    Related to Israeli Law and Our Operations in Israel</i></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our headquarters and other
    significant operations are located in Israel, and, therefore, our results may be adversely affected by political, economic and military
    instability in Israel. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We received Israeli government
    grants for certain of our research and development activities, the terms of which may require us to pay royalties and to satisfy
    specified conditions in order to manufacture products and transfer technologies outside of Israel. If we fail to satisfy these conditions,
    we may be required to pay penalties and refund grants previously received.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions of Israeli law
    and our amended and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of,
    us, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.
    </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 2.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>OFFER STATISTICS AND EXPECTED TIMETABLE</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 3. KEY INFORMATION</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. Selected Financial Data.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">[Reserved]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B. Capitalization and Indebtedness.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C. Reasons for the Offer and Use of Proceeds.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D. Risk Factors.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business faces significant
risks. You should carefully consider the risks described below, together with all of the other information in this annual report on Form
20-F. The risks described below are not the only risks facing us. Additional risks and uncertainties not currently known to us or that
we currently deem to be immaterial may also materially and adversely affect our business operations. If any of these risks actually occurs,
our business and financial condition could suffer and the price of our Ordinary Shares could decline. This report also contains forward-looking
statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking
statements, as a result of certain factors including the risks described below and elsewhere in this report and our other SEC filings.
See &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Financial Condition and
Capital Requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We have incurred significant losses since
our inception. We anticipate that we will continue to incur significant losses for the foreseeable future, and we may never achieve or
maintain profitability. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a Phase&#160;3 clinical-stage
biopharmaceutical company. We have incurred operating losses each year since our inception, including operating losses of $38.9&#160;million
and $43.1&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated
deficit of $214.4&#160;million. We have devoted substantially all of our financial resources to designing and developing our PLEX product
candidates, including conducting clinical trials and preclinical studies and providing general and administrative support for these operations.
We expect that we will continue to incur expenses and operating losses for the foreseeable future as we continue clinical development
of D-PLEX<sub>100</sub> for the prevention of SSIs and develop other product candidates using our PLEX technology. Our ability to ultimately
achieve revenues and profitability is dependent upon our ability to successfully complete the development of D-PLEX<sub>100</sub> and
any future product candidates, obtain necessary regulatory approvals for and successfully manufacture, market and commercialize our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 10; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate that we will
continue to incur expenses based on a number of factors, including to the extent that we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue our clinical development
    of D-PLEX<sub>100</sub>, including our ongoing Phase&#160;3 trials of D-PLEX<sub>100</sub> for the prevention of SSIs in abdominal
    (soft tissue) surgeries; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require an increase of
    sample size in our SHIELD II clinical trial as a result of our anticipated interim analysis;&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek regulatory and marketing
    approvals for any product candidates that successfully complete clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">build the necessary commercial
    and medical infrastructure in the United States to successfully launch any products, including hiring field and office based staff;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance our preclinical
    and research and development programs, including, without limitation, our OncoPLEX program; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify, assess, acquire,
    license and/or develop other product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture current good
    manufacturing practices, or cGMP, material for clinical trials or potential commercial sales, either at our manufacturing facility
    or through third-party contract manufacturers; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a sales, marketing
    and distribution infrastructure to commercialize any products for which we may obtain marketing approval; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire personnel and invest
    in additional infrastructure to support our operations and expand our product development; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter into agreements to
    license intellectual property from third parties; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop, maintain, protect
    and expand our intellectual property portfolio; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience any delays or
    encounter issues with respect to any of the above, including, but not limited to, failed trials, complex results, safety issues or
    other regulatory challenges that require longer follow-up of existing clinical trials, additional major clinical trials or additional
    supportive studies in order to pursue marketing approval. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have financed
our operations primarily through the sale of equity securities, convertible loans made by certain of our shareholders, royalty-bearing
and non-royalty bearing grants that we received from the Israeli Innovation Authority, or the IIA, and non-royalty bearing grants under
the European Commission&#8217;s Seventh Framework Program for Research, or the FP7. The amount of any future operating losses will depend,
in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations
or grants. Even if we obtain regulatory approval to market one or more product candidates, our future revenue will depend upon the size
of any markets in which such product candidates receive approval and our ability to achieve sufficient market acceptance, pricing, reimbursement
from third-party payors for such product candidates. Further, the operating losses that we incur may fluctuate significantly from quarter
to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our
future performance. Other unanticipated costs may also arise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We have never generated any revenue from product
sales and may never be profitable. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have no products approved
for marketing in any jurisdiction and we have never generated any revenue from product sales. Our ability to generate revenue and achieve
profitability depends on our ability, alone or with strategic collaboration partners, to successfully complete the development of, and
obtain the regulatory and marketing approvals necessary to commercialize, D-PLEX<sub>100</sub> or any future product candidates. We do
not anticipate generating revenue from product sales for at least the next few years. Our ability to generate future revenue from product
sales will depend heavily on our ability to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete research and preclinical
    and clinical development of D-PLEX<sub>100</sub> and any future product candidates in a timely and successful manner, including our
    ability to resume enrollment in our SHIELD II Phase&#160;3 trial of D-PLEX<sub>100</sub>;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain regulatory and marketing
    approval for any product candidates for which we complete clinical trials, including, without limitation, with respect to safety
    and efficacy data; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain and enhance a
    commercially viable, sustainable, scalable, reproducible and transferable manufacturing process for D-PLEX<sub>100</sub> and any
    future product candidates that is compliant with cGMPs; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 11 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish and maintain
    supply and, if applicable, manufacturing relationships with third parties that can provide, in both amount and quality, adequate
    products to support clinical development and the market demand for D-PLEX<sub>100</sub> and any future product candidates, if and
    when approved; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launch and commercialize
    any product candidates for which we obtain regulatory and marketing approval, either directly by establishing commercial and medical
    infrastructure, and/or with collaborators or distributors; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expose and educate physicians
    and other medical professionals to use our products; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain market acceptance,
    if and when approved, of D-PLEX<sub>100</sub> and any future product candidates from the medical community and third-party payors;
    &#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensure our product candidates
    are approved for reimbursement from governmental agencies, health care providers and insurers in jurisdictions where they have been
    approved for marketing; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">address any competing technological
    and market developments that impact D-PLEX<sub>100</sub> and any future product candidates or their prospective usage by medical
    professionals; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify, assess, acquire
    and/or develop new product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiate favorable terms
    in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such collaborations;
    </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain, protect and expand
    our portfolio of intellectual property rights, including patents, patent applications, trade secrets and know-how; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">avoid and defend against
    third-party interference or infringement claims; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract, hire and retain
    qualified personnel; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">locate and lease or acquire
    suitable facilities to support our clinical development, manufacturing facilities and commercial expansion. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if D-PLEX<sub>100</sub>
or any future product candidates are approved for marketing and sale, we anticipate incurring significant incremental costs associated
with commercializing such product candidates. Our expenses could increase beyond expectations if we are required by the FDA, the EMA
or other regulatory agencies, domestic or foreign, or ethical committees in medical centers, to change our manufacturing processes or
assays or to perform clinical, nonclinical or other types of studies in addition to those that we currently anticipate. Even if we are
successful in obtaining regulatory approvals to market D-PLEX<sub>100</sub> or any future product candidates, our revenue earned from
such product candidates will be dependent in part upon the breadth of the product label, the size of the markets in the territories for
which we gain regulatory approval for such products, the accepted price for such products, our ability to obtain reimbursement for such
products at any price, whether we own the commercial rights for that territory in which such products have been approved and the expenses
associated with manufacturing and marketing such products for such markets. Therefore, we may not generate significant revenue from the
sale of such products, even if approved. Further, if we are not able to generate significant revenue from the sale of our approved products,
we may be forced to curtail or cease our operations. Due to the numerous risks and uncertainties involved in product development, it
is difficult to predict the timing or amount of increased expenses, or when, or if, we will be able to achieve or maintain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The report of our independent registered
public accounting firm contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern,
which could prevent us from obtaining new financing on reasonable terms or at all. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The report of our independent
registered public accounting firm on our audited consolidated financial statements for the period ended&#160;December 31,&#160;2022,
contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.&#160;Our consolidated
financial statements do not include any adjustments that might result from the outcome of the uncertainty regarding our ability to continue
as a going concern. This going concern opinion could materially limit our ability to raise additional funds through the issuance of equity
or debt securities or otherwise. Further reports on our consolidated financial statements may include an explanatory paragraph with respect
to our ability to continue as a going concern. Until we can generate significant recurring revenues, we expect to satisfy our future
cash needs through debt or equity financing. We cannot be certain that additional funding will be available to us on acceptable terms,
if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for,
or commercialization efforts with respect to our products. This may raise substantial doubts about our ability to continue as a going
concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We expect that we will need to raise substantial
additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding on acceptable terms and on a
timely basis may require us to curtail, delay or discontinue our product development efforts or other operations. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently advancing
D-PLEX<sub>100</sub> through clinical development in order to obtain regulatory approval. Developing product candidates is expensive,
and we expect to continue to incur research and development expenses in connection with our ongoing activities, particularly as we advance
product candidates through clinical trials and regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 12 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have financed
our operations primarily through the sale of equity securities, convertible loans made by certain of our shareholders or other loan facilities,
and royalty-bearing and non-royalty bearing grants that we received from the IIA and FP7. As of March 26, 2023, we had cash, cash equivalents
and short-term deposits of $10.4 million. We will require significant additional financing to fund our operations. Our future funding
requirements will depend on many factors, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress, results and
    costs of our ongoing and anticipated clinical trials of D-PLEX<sub>100</sub> and any future product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost, timing and outcomes
    of regulatory review of D-PLEX<sub>100</sub> and any future product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of maintaining
    our own commercial-scale cGMP manufacturing facility, including costs related to obtaining and maintaining regulatory compliance,
    and/or engaging third-party manufacturers therefor; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, progress, results
    and costs of product development, laboratory testing, manufacturing, preclinical development and clinical trials for any other product
    candidates that we may develop or otherwise obtain in the future; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of our future
    activities, including establishing sales, marketing and distribution capabilities for any product candidates in any particular geography
    where we receive marketing approval for such product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms and timing of
    any collaborative, licensing and other arrangements that we may establish; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of preparing,
    filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual
    property-related claims; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the level of revenue, if
    any, received from commercial sales of any product candidates for which we receive marketing approval. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Identifying potential product
candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years
to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales.
In addition, our product candidates, if and when approved, may not achieve commercial success. Our product revenues, if any, will be
derived from or based on sales of product candidates that may not be commercially available for many years, if at all. Accordingly, we
will need to continue to rely on additional financing to achieve our business objectives. Any additional fundraising efforts may divert
our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot guarantee that
financing will be available in sufficient amounts or on terms acceptable to us, if at all, and the terms of any financing may adversely
affect the interests or rights of our shareholders. Even if we believe that we have sufficient funds for our current or future operating
plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. The issuance
of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares
to decline. Further, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions
and the disruptions to and volatility in the credit and financial markets in the United States and worldwide.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that we raise
capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of such securities
may include liquidation or other preferences that adversely affect your rights as a shareholder. Debt financing, if available, may involve
covenants restricting our operations or our ability to incur additional debt. If we raise funds through collaboration and licensing arrangements
with third parties, it may be necessary to relinquish certain rights to our technologies or our product candidates, or to grant licenses
on terms that are not favorable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to obtain
funding on acceptable terms and on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our
research, development or manufacturing programs or the commercialization of any approved product, or be unable to expand our operations
or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and
results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 13 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Risks Related
to the Discovery, Development and Clinical Testing of Product Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We depend on enrollment
of patients in our clinical trials in order to continue development of our product candidates. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
completed the SHIELD I trial and will resume the SHIELD II trial for the prevention of open abdominal SSIs. Our anticipated time to data
in SHIELD II trial is subject to our ability to recruit sufficient eligible patients and the number and size of cohorts that will need
to be enrolled prior to observing activity, if achieved at all for the dose escalation and expansion arms of the trial. There can be
no assurance that we will complete enrollment or have data from the trial when we anticipate or at all. The timely completion of the
clinical trial in accordance with its protocol depends, among other things, on our ability to enroll a sufficient number of patients
that are in line with our inclusions and exclusion criteria and our ability to monitor these patients as required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. Patient enrollment is affected by
many factors including the size and nature of the patient population, the eligibility criteria for the trial, the design of the clinical
trial, the size of the patient population required for analysis of the trial&#8217;s primary endpoints, the proximity of patients to
study sites, our ability to recruit clinical trial investigators with the appropriate competencies and experience, the number of enrolling
clinical sites, our ability to obtain and maintain patient consents, the risk that patients enrolled in clinical trials will drop out
of the trials before completion, and competing clinical trials (including other clinical trials that we are conducting or will conduct
in the future) and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation
to other available therapies, or competing drugs against the same target as well as any new drugs that may be approved for the indications
we are investigating.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Additionally,
we must compete for clinical sites, clinicians and the limited number of patients who fulfill the stringent requirements for participation
in clinical trials. Also, due to the confidential nature of clinical trials, we do not know how many of the eligible patients may be
enrolled in competing studies and who are consequently not available to us for our clinical trials. Our clinical trials may be delayed
or terminated due to the inability to enroll enough patients. The delay or inability to meet planned patient enrollment may result in
increased costs and delay or termination of our trials, which could have a harmful effect on our ability to develop products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We are heavily dependent on the success of
D-PLEX<sub>100</sub>, including obtaining regulatory approval to market D-PLEX<sub>100</sub> in the United States and the European Union.
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have invested
all of our efforts and financial resources to: (i)&#160;research and develop our PLEX technology, our lead product candidate, D-PLEX<sub>100</sub>,
and our preclinical and research and development programs, including conducting preclinical studies and clinical trials, and providing
general and administrative support for these operations; (ii)&#160;develop and secure our intellectual property portfolio for D-PLEX<sub>100
</sub>and our PLEX technology and (iii) invest in our current manufacturing facility. Our future success is dependent on our ability
to successfully develop, obtain regulatory approval for and commercialize one or more of our current and future product candidates. Our
product candidates&#8217; marketability is subject to significant risks associated with successfully completing current and future clinical
trials, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to complete
    our ongoing&#160;SHIELD II Phase&#160;3 clinical trial of D-PLEX<sub>100</sub> for the prevention of open abdominal SSIs in a timely
    fashion and that such Phase&#160;3 clinical trial, even if successfully completed, will be sufficient to support approval of an NDA;
    </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance by the FDA,
    EMA or other regulatory agencies of our strategies for seeking regulatory approvals for D-PLEX<sub>100</sub> and any future product
    candidates, including our proposed indications, primary and secondary endpoint assessments and measurements, safety evaluations and
    regulatory pathways; </span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the acceptance by the FDA,
    EMA or other regulatory agencies of the number, design, size, conduct and implementation of our clinical trials, our trial protocols
    and the interpretation of data from preclinical studies or clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully
    complete the clinical trials of D-PLEX<sub>100</sub> and any future product candidates, including timely patient enrollment and acceptable
    safety and efficacy data and our ability to demonstrate the safety and efficacy of the product candidates undergoing such clinical
    trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the willingness of the
    FDA, EMA or other regulatory agencies to schedule an advisory committee meeting in a timely manner in connection with our regulatory
    submissions, if such advisory committee meetings are required; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the recommendation of the
    FDA&#8217;s advisory committee to approve our applications to market D-PLEX<sub>100</sub> and any future product candidates in the
    United States, and the EMA&#8217;s approval to market D-PLEX<sub>100</sub> in the EU, if such advisory committee reviews are scheduled,
    without limiting the approved labeling, specifications, distribution or use of the products, or imposing other restrictions; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the satisfaction of the
    FDA, EMA or other regulatory agencies with the safety and efficacy of D-PLEX<sub>100</sub> and any future product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prevalence and severity
    of adverse events associated with D-PLEX<sub>100</sub> and any future product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timely and satisfactory
    performance by third-party contractors, trial sites and principal investigators of their obligations in relation to our clinical
    trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our success in educating
    medical professionals and patients about the benefits, administration and use of D-PLEX<sub>100</sub> and any future product candidates,
    if approved; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our success in educating
    payers and hospital administrators about the potential cost savings benefits that D-PLEX<sub>100</sub> can deliver;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability, perceived
    advantages, relative cost, safety and efficacy of alternative and competing treatments for the indications addressed by D-PLEX<sub>100
    </sub>and any future product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of our
    marketing, sales and distribution strategy, and operations, as well as that of any current and future licensees; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to scale, validate
    and maintain a commercially viable manufacturing process that is cGMP-compliant; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain,
    protect and enforce our intellectual property rights with respect to D-PLEX<sub>100</sub>, any future product candidates and our
    PLEX technology; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes to regulatory guidelines.
    </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of these clinical, regulatory
and commercial risks are beyond our control. Accordingly, we cannot assure you that we will be able to advance D-PLEX<sub>100</sub> and
any future product candidates through clinical development, or to obtain regulatory approval of or commercialize any product candidates.
If we fail to achieve these objectives or overcome the challenges presented above, we could experience significant delays or an inability
to successfully commercialize D-PLEX<sub>100</sub> and any future product candidates. Accordingly, we may not be able to generate sufficient
revenues through the sale of our product candidates to enable us to continue our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, approval of
a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other
countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other
foreign countries or by the FDA. We may never obtain approval outside of the United States, which would limit our market opportunities
and adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The outcome of our planned unblinded interim
analysis in our SHIELD I</b>I <b>trial may require that we enroll more patients than would have been the case without an interim analysis,
in which case we will need to spend additional time, effort and financial resources on the SHIELD I</b>I <b>trial which may not ultimately
be successful or support regulatory approval of D-PLEX<sub>100</sub>. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SHIELD II patient recruitment
is expected to resume in the second quarter of 2023 with the enrollment of an estimated 550 additional patients. Recruitment time into
the study, once it resumes, is anticipated to be approximately 12 months and top-line results are expected in mid-2024. Unblinded interim
analysis is planned to be conducted once approximately 400 patients complete their 30-day follow-up. The anticipated interim analysis
will allow for an early trial stopping due to efficacy or futility, or sample size reassessment. This interim analysis may not result
in positive findings for the prevention of open abdominal SSIs sufficient to support submission of an NDA for D-PLEX<sub>100</sub>, in
which case we may need to significantly increase enrollment in the trial to improve its statistical power. Any increase in enrollment
in the trial would cost us significantly more and cause us to delay any final analysis to determine whether or not the trial was successful
to support an NDA submission. Increasing the size of the SHIELD II trial because of the interim analysis may result in pursuing further
development of D-PLEX<sub>100</sub> for an indication in which it may ultimately be unsuccessful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our decision to implement
an interim analysis for the SHIELD II trial may lead to an erroneous decision to stop the trial early or continue the trial with the
expenditure of time, effort and financial resources to a conclusion that may ultimately be unsuccessful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Improvement in standard of care infection
prevention and control measures being undertaken in hospitals globally as a result of the COVID-19 pandemic may have decreased the rate
of SSIs, which may adversely impact the ability of our clinical trials to demonstrate an improvement over the standard of care and may
ultimately reduce our commercial opportunity even if our trials are successful.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of heightened
awareness and attention to infection prevention and control within hospitals and in society at large as a result of the COVID-19 pandemic,
the rate of SSIs may be declining relative to their historic rates. Because our clinical trials and business plans are based on historic
rates of SSIs, any reduction in their occurrence may decrease the likelihood of success for our product candidates to show an improvement
over the standard of care, and even if successful in clinical trials, a reduction in SSIs, even temporary, may decrease the perceived
commercial need for our products if they are approved by regulatory authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Regulatory approval processes of the FDA,
EMA and comparable foreign regulatory authorities are lengthy, time-consuming and unpredictable, and if we are ultimately unable to obtain
regulatory approval for D-PLEX<sub>100</sub> or any future product candidates, our business may fail. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The research, development,
testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, recordkeeping, marketing, distribution, post-approval
monitoring and reporting and export and import of drug products are subject to extensive regulation by the FDA, the EMA and by foreign
regulatory authorities in other countries. These regulations differ from country to country. To gain approval to market D-PLEX<sub>100
</sub>and any future product candidates, we must provide data from well-controlled clinical trials that adequately demonstrate the safety
and efficacy of the product for the intended indication to the satisfaction of the FDA, EMA or other regulatory authority. We have not
yet obtained regulatory approval to market any product candidate in the United States or any other jurisdiction. The FDA, EMA or other
regulatory agencies can delay, limit or deny approval of D-PLEX<sub>100</sub> or any future product candidate for many reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory requests for
    additional analyses, reports, data, non-clinical and preclinical studies and clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to demonstrate
    that a product candidate is safe and effective for the target indication to the satisfaction of the FDA, EMA or other regulatory
    agencies; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s, EMA&#8217;s,
    or other regulatory agencies&#8217; disagreement with our trial protocol, the interpretation of data from preclinical studies or
    clinical trials, or adequacy of the conduct and control of clinical trials; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical holds, other regulatory
    objections to commencing or continuing a clinical trial or the inability to obtain regulatory approval to commence a clinical trial
    in countries that require such approvals; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the population studied
    in the clinical trial may not be sufficiently broad or representative to assess safety in the patient population for which we seek
    approval; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable or inconclusive
    results of clinical trials and supportive non-clinical studies, including unfavorable results regarding safety or efficacy of a product
    candidate observed in clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to demonstrate
    that clinical or other benefits of a product candidate outweighs any safety or other perceived risks; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any determination that
    a clinical trial presents unacceptable health risks to subjects; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to obtain
    approval from institutional review boards, or IRBs, to conduct clinical trials at their respective sites; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s determination
    that the 505(b)(2) regulatory pathway is not available for a product candidate; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the non-approval of the
    formulation, labeling or the specifications of a product candidate; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure to accept the
    manufacturing processes or facilities at our manufacturing facility or those of third-party manufacturers with which we contract;
    </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential for approval
    policies or regulations of the FDA, EMA or other regulatory agencies to significantly change in a manner rendering our clinical data
    insufficient for approval; or </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">resistance to approval
    from the advisory committees of the FDA, EMA or other regulatory agencies for any reason including safety or efficacy concerns. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, we
will be required to submit an NDA to obtain FDA approval before marketing any product candidate. An NDA must include extensive preclinical
and clinical data and supporting information to establish the product candidate&#8217;s safety and efficacy for each desired indication.
In the case of an NDA covered by Section&#160;505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or the FFDCA, we may rely in part
on data not developed by us and for which we have not obtained a right of reference or use, including published scientific literature
or the FDA&#8217;s findings of safety and/or effectiveness for a previously approved drug. The NDA must also include significant information
regarding the chemistry, manufacturing and controls for the product. The FDA may further inspect our manufacturing facilities to ensure
that the facilities can manufacture any product candidate and any product, if and when approved, in compliance with the applicable regulatory
requirements, as well as inspect our clinical trial sites to ensure that our trials are properly conducted. Obtaining approval of an
NDA is a lengthy, expensive and uncertain process, and approval may not be obtained. Upon submission of an NDA, the FDA must make an
initial determination that the application is sufficiently complete to accept the submission for filing. We cannot be certain that any
submissions will be accepted for filing and review by the FDA, or ultimately be approved. If the application is not accepted for review
or approval, the FDA may require that we conduct additional clinical or preclinical trials, or take other actions before it will reconsider
our application. If the FDA requires additional trials or data, we would incur increased costs and delays in the marketing approval process,
which may require us to expend more resources than we have available. Even if the FDA agrees that results from our SHIELD II trial evaluating
D-PLEX<sub>100</sub> for the prevention of SSIs in open abdominal surgeries are sufficient to support the submission of an NDA, the FDA
may determine that the data from this trial support a narrower indication than we may propose, if the FDA were to approve such NDA at
all. In addition, the FDA may not consider any additional information to be complete or sufficient to support approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory authorities outside
of the United States, such as in the European Union, also have requirements for approval of drugs for commercial sale with which we must
comply prior to marketing in those areas. Regulatory requirements can vary widely from country to country and could delay or prevent
the introduction of a product candidate. Clinical trials conducted in one country may not be accepted by regulatory authorities in other
countries, and obtaining regulatory approval in one country does not mean that regulatory approval will be obtained in any other country.
However, the failure to obtain regulatory approval in one jurisdiction could have a negative impact on our ability to obtain approval
in a different jurisdiction. Approval processes vary among countries and can involve additional product candidate testing and validation
and additional administrative review periods. Seeking foreign regulatory approval could require additional non-clinical studies or clinical
trials, which could be costly and time consuming. Foreign regulatory approval may include all of the risks associated with obtaining
FDA approval. For all of these reasons, if we seek foreign regulatory approval for any product candidate, we may not obtain such approvals
on a timely basis, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we eventually complete
clinical testing and receive approval of any regulatory filing for a product candidate, the FDA may grant approval contingent on the
performance of costly and potentially time-consuming additional post-approval clinical trials or subject to contraindications, black
box warnings, restrictive surveillance or Risk Evaluation and Mitigation Strategies, or REMS. Further, the FDA, EMA or other foreign
regulatory authorities may also approve a product candidate for a more limited indication or a narrower patient population than we originally
requested, and these regulatory authorities may not approve the labeling that we believe is necessary or desirable for the successful
commercialization of any product candidate. Following any approval for commercial sale of a product candidate, certain changes to the
product, such as changes in manufacturing processes and additional labeling claims, as well as new safety information, will be subject
to additional FDA notification, or review and approval. Also, regulatory approval for any product candidate may be withdrawn. To the
extent we seek regulatory approval in foreign countries, we may face challenges similar to those described above with regulatory authorities
in applicable jurisdictions. Any delay in obtaining, or inability to obtain, applicable regulatory approval for D-PLEX<sub>100</sub>
or any future product candidate would delay or prevent commercialization of such product candidate and would thus negatively impact our
business, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Clinical drug development is difficult to
design and implement and involves a lengthy and expensive process with uncertain outcomes. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical testing is expensive
and can take many years to complete, and its outcome is inherently uncertain. A failure of one or more of our clinical trials can occur
at any time during the clinical trial process. We do not know whether future clinical trials, if any, will begin on time, need to be
redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can be delayed, suspended
or terminated for a variety of reasons, including failure to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">generate sufficient preclinical,
    toxicology, or other <i>in vivo</i> or <i>in vitro</i> data to support the initiation or continuation of clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain regulatory approval,
    or feedback on trial design, in order to commence a trial; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify, recruit and train
    suitable clinical investigators; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reach agreement on acceptable
    terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive
    negotiation and may vary significantly among CROs and clinical trial sites, and have such CROs and sites effect the proper and timely
    conduct of our clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain and maintain IRB
    approval at each clinical trial site; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify, recruit and enroll
    suitable patients to participate in a trial; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have a sufficient number
    of patients complete a trial or return for post-treatment follow-up; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensure clinical investigators
    and clinical trial sites observe trial protocol or continue to participate in a trial; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">address any patient safety
    concerns that arise during the course of a trial; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">address any conflicts with
    new or existing laws or regulations; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add a sufficient number
    of clinical trial sites; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture sufficient
    quantities at the required quality of product candidate for use in clinical trials; or </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">raise sufficient capital
    to fund a trial. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may also experience numerous
unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or
commercialize any product candidate, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may receive feedback
    from regulatory authorities that requires us to modify the design of our clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical trials of a product
    candidate may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical
    trials or abandon drug development programs; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of patients
    required for clinical trials of a product candidate may be larger than we anticipate, enrollment in these clinical trials may be
    slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our third-party contractors
    may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators or IRBs may
    not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or amend
    a trial protocol; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may have delays in reaching
    or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and CROs;
    </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we or our investigators
    might have to suspend or terminate clinical trials of a product candidate for various reasons, including non-compliance with regulatory
    requirements, a finding that a product candidate have undesirable side effects or other unexpected characteristics, or a finding
    that the participants are being exposed to unacceptable health risks; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of clinical trials
    of a product candidate may be greater than we anticipate; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the supply or quality of
    a product candidate or other materials necessary to conduct clinical trials of such product candidate may be insufficient or inadequate;
    </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there may be changes in
    government regulations or administrative actions; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a product candidate may
    have undesirable adverse effects or other unexpected characteristics; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to demonstrate
    that a produce candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to demonstrate
    that a product candidate provides an advantage over current standards of care of future competitive therapies in development; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators may revise the
    requirements for approving a product candidate, or such requirements may not be as we anticipate; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any future collaborators
    that conduct clinical trials may face any of the above issues, and may conduct clinical trials in ways they view as advantageous
    to them but that are suboptimal for us. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, disruptions
caused by the COVID-19 pandemic has caused and may continue to increase the likelihood that we encounter such difficulties in initiating,
enrolling, conducting or completing our planned and ongoing clinical trials. We may also encounter delays if a clinical trial is suspended
or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the trial&#8217;s data safety monitoring
board, by the FDA, EMA or other regulatory agencies. Such authorities may suspend or terminate one or more of our clinical trials due
to a number of factors, including our failure to conduct the clinical trial in accordance with relevant regulatory requirements or clinical
protocols, inspection of the clinical trial operations or site by the FDA, EMA or other regulatory agencies resulting in the imposition
of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in
governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, conducting clinical
trials outside of the United States, as we have done and continue to do and plan to expand for D-PLEX<sub>100</sub> and any future product
candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients
in the countries outside of the United States to adhere to clinical protocol as a result of differences in healthcare services or cultural
customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks
relevant to such foreign countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we experience delays in
completing any clinical trial of a product candidate or successfully obtaining regulatory approval, the commercial prospects of such
product candidate may be harmed, and our ability to generate product revenues from such product candidate will be delayed. In addition,
any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process
and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business
and financial condition. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical
trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 18 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The results of earlier studies and trials
may not be predictive of future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of
our product candidates. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Results from preclinical
studies or early-stage clinical trials are not necessarily predictive of future clinical trial results. Preclinical tests and Phase&#160;1
and Phase&#160;2 clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand
the side effects of product candidates at various doses and schedules. Success in preclinical or animal studies and early clinical trials
does not ensure that later, large-scale efficacy trials will be successful nor does it predict final results. Our product candidates
may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies or after having
successfully advanced through initial clinical trials. This failure might cause us to abandon further development of D-PLEX<sub>100</sub>
for the prevention of SSIs, which is currently our most advanced product candidate. Further, data obtained from the SHIELD I pivotal
clinical trial are not necessarily predictive of future results from the ongoing SHIELD II pivotal trial, and are susceptible to varying
interpretations, which could delay, limit or prevent regulatory approval. For example, even if the SHIELD II protocol is now focusing
on patients undergoing surgeries with incisions greater than 20 cm based on positive results observed in the SHIELD I pre-specified subgroup
ITT analysis of a total of 423 subjects with large incisions (&gt;20 centimeters), there is significant risk that we will fail to reproduce
the same results of achieve favorable results in SHIELD II at all and receive regulatory approval. Further, data obtained from pivotal
clinical studies are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is a high failure rate
for product candidates proceeding through clinical trials. Many companies in the pharmaceutical industry have suffered significant setbacks
in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained
from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval.
In addition, we may experience regulatory delays or rejections as a result of many factors, including due to changes in regulatory policy
during the period of our product candidate development. Success in preclinical testing and early clinical trials does not ensure that
later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product
candidate. Frequently, product candidates that have shown promising results in early clinical trials have subsequently suffered significant
setbacks in later clinical trials. Additionally, even if we are able to complete clinical trials, the results may not be sufficient to
obtain regulatory approval for our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Interim, &#8220;top-line&#8221; and preliminary
data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are
subject to audit and verification procedures that could result in material changes in the final data. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
publicly disclose top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data,
and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related
to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data,
and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary
results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such
results, once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification
procedures that may result in the final data being materially different from the top-line or preliminary data we previously published.
As a result, top-line and preliminary data should be viewed with caution until the final data are available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are
subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient
data become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further,
disclosure of interim data by us or by our competitors could result in volatility in the price of our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, others, including
regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret
or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization
of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose
regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with
what we determine is material or otherwise appropriate information to include in our disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the interim, top-line
or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions
reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business,
operating results, prospects or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 19 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>If the FDA does not conclude that D-PLEX<sub>100
</sub>satisfies the requirements under Section&#160;505(b)(2) of the FFDCA, or Section&#160;505(b)(2), or if we are unable to utilize
the hybrid application pathway in the European Union, or if the requirements are not as we expect, the approval pathway for D-PLEX<sub>100
</sub>will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated,
and in either case may not be successful. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to utilize the
FDA&#8217;s Section&#160;505(b)(2) regulatory pathway, and the hybrid application pathway in the European Union, which is analogous to
the Section&#160;505(b)(2) pathway, to seek approval of D-PLEX<sub>100</sub>. The Drug Price Competition and Patent Term Restoration
Act of 1984, also known as the Hatch-Waxman Act, added Section&#160;505(b)(2) to the FFDCA. Section&#160;505(b)(2) permits the filing
of an NDA where at least some of the information required for approval comes from trials or studies that were not conducted by or for
the applicant, and for which the applicant has not received a right of reference or use from the person by or for whom the investigations
were conducted, which we believe could expedite the development program for D-PLEX<sub>100</sub> by potentially decreasing the amount
of preclinical and clinical data that we would need to generate in order to obtain FDA approval. However, while we believe that D-PLEX<sub>100
</sub>is a reformulation of an already-approved drug and, therefore, will be eligible for submission of an NDA under Section&#160;505(b)(2),
the FDA may disagree and determine that D-PLEX<sub>100</sub> is not eligible for review under such regulatory pathway.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to pursue
these regulatory pathways as anticipated, we may need to conduct additional preclinical experiments and clinical trials, provide additional
data and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required
to obtain FDA approval for D-PLEX<sub>100</sub>, and complications and risks associated with D-PLEX<sub>100</sub>, would likely increase
significantly. Moreover, inability to pursue the Section&#160;505(b)(2) or similar regulatory pathway could result in new competitive
products reaching the market more quickly than D-PLEX<sub>100</sub> or any future product candidates, which would likely harm our competitive
position and prospects. Even if we are allowed to pursue the Section&#160;505(b)(2) or similar regulatory pathway, D-PLEX<sub>100</sub>
may not receive the requisite approvals for commercialization, and there is no guarantee the 505(b)(2) or similar pathway would ultimately
lead to faster product development or earlier approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, notwithstanding
the approval of a number of products by the FDA under Section&#160;505(b)(2) over the last few years, certain competitors and others
have objected to the FDA&#8217;s interpretation of Section&#160;505(b)(2). If the FDA&#8217;s interpretation of Section&#160;505(b)(2)
is successfully challenged, the FDA may be required to change its 505(b)(2) policies and practices, which could delay or even prevent
the FDA from approving any NDA that we submit under Section&#160;505(b)(2). In addition, the pharmaceutical industry is highly competitive,
and Section&#160;505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved
drugs that are referenced in a Section&#160;505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays
in approval of our potential future NDAs for up to 30&#160;months depending on the outcome of any litigation. It is also not uncommon
for a manufacturer of an approved product to file&#160;a citizen petition with the FDA seeking to delay approval of, or impose additional
approval requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval
of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers
and responds to the petition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, even if D-PLEX<sub>100
</sub>or any future product candidates are approved under the Section&#160;505(b)(2) pathway, as the case may be, the approval may be
subject to limitations on the indicated uses for which the products may be marketed or to other conditions of approval, or may contain
requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>PLEX is a novel technology, which makes it
difficult to accurately and reliably predict the time and cost of development and of subsequently obtaining regulatory approval of D-PLEX<sub>100
</sub>or any future PLEX product candidates. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have concentrated our
efforts and product research on our PLEX drug delivery technology, and our future success depends on the successful development of this
technology and products based on it. There can be no assurance that any development problems we experience in the future related to our
product candidates will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may
be unable to maintain and further develop sustainable, reproducible and scalable manufacturing processes, or transfer these processes
to collaborators, which may prevent us from completing our clinical studies or commercializing our products on a timely or profitable
basis, if at all. To our knowledge, no regulatory authority has granted approval to any person or entity, including us, to market and
commercialize therapeutics using our novel delivery system. We may never receive approval to market and commercialize any product candidate
that utilizes PLEX.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 20 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>As an organization, we may be unable to successfully
complete clinical development for any product candidates we may develop, including D-PLEX<sub>100</sub>. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will need to successfully
complete pivotal clinical trials in order to obtain the approval of the FDA, EMA or other regulatory agencies to market D-PLEX<sub>100
</sub>or any future product candidates. Carrying out clinical trials and the submission of a successful NDA is a complicated process.
As an organization, we have limited experience in conducting later stage or pivotal clinical trials and have limited experience in preparing,
submitting and prosecuting regulatory filings. Consequently, we may be unable to successfully and efficiently execute and complete necessary
clinical trials, including our ongoing SHIELD II Phase&#160;3 trial, in a way that leads to marketing approval of D-PLEX<sub>100</sub>.
We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product
candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay
us in commercializing D-PLEX<sub>100</sub>. See &#8220;Risks Related to Our Reliance on Third Parties&#8221;. We rely on third parties
to conduct certain elements of our preclinical and clinical trials and perform other tasks for us. If these third parties do not successfully
carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory
approval for or commercialize our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may find it difficult to enroll patients
in our clinical trials due to various reasons, including possible disruption due to the COVID-19 pandemic, which could delay or prevent
us from proceeding with such trials. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Identifying and qualifying
patients to participate in our clinical trials is critical to our success. The timing of our clinical trials depends in part on the speed
at which we can recruit patients to participate in testing our product candidates, and we may experience delays in our clinical trials
if we encounter difficulties in enrollment. Patient enrollment and retention in clinical trials depends on many factors, including the
size of the patient population, the nature of the trial protocol, our ability to recruit clinical trial investigators with the appropriate
competencies and experience, the existing body of safety and efficacy data with respect to the study drug, the number and nature of competing
treatments and ongoing clinical trials of competing drugs for the same indication, the proximity of patients to clinical sites, clinicians&#8217;
and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available
therapies, including any drugs that may be approved for the indications we are investigating, the eligibility criteria for the trials,
our ability to obtain and maintain patient consents and the risk that patients enrolled in clinical trials will drop out of the trials
before completion. We have experienced and may further continue to experience disruptions in patient enrollment due to the COVID-19 pandemic,
including difficulties in initiating clinical sites and enrolling and retaining participants, the diversion of healthcare resources away
from clinical trials and challenges related to travel or quarantine policies that may be implemented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to identify,
recruit and enroll a sufficient number of patients to complete our clinical trials because of the perceived risks and benefits of the
product candidate under study, the availability and efficacy of competing therapies and clinical trials, the proximity and availability
of clinical trial sites for prospective patients and the patient referral practices of physicians. We may also face challenges in identifying
trial sites and enrolling patients in global trials such as our ongoing SHIELD II Phase&#160;3 trial of D-PLEX<sub>100</sub>. If patients
are unwilling to participate in our trials for any reason, the timeline for recruiting patients, conducting trials and obtaining regulatory
approval of potential products will be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 21 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our product candidates and the administration
of our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval,
limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any.
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Undesirable side effects,
including toxicology, caused by D-PLEX<sub>100</sub> or any future product candidates, or the drugs encapsulated by such product candidates,
could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or
the delay or denial of regulatory approval by the FDA, EMA or other regulatory agencies. Results of our trials could reveal a high and
unacceptable severity and prevalence of these or other side effects. In such an event, our clinical studies could be suspended or terminated,
and the FDA, EMA or other regulatory agencies could order us to cease further development of or deny or withdraw approval of our product
candidates for any or all targeted indications. Moreover, during the conduct of clinical trials, patients report changes in their health,
including illnesses, injuries and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product
candidate being studied caused these conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drug-related, drug-product
related, formulation-related and administration-related side effects could affect patient recruitment, the ability of enrolled patients
to complete the clinical trials or result in potential product liability claims, which could exceed our clinical trial insurance coverage.
We do not currently have product liability insurance and do not anticipate obtaining product liability insurance until such time as we
have received FDA, EMA or other comparable foreign authority marketing approval for one of our product candidates and such product is
being provided to patients outside of clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, if one or more
of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products,
a number of potentially significant negative consequences could result, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities
    may suspend or withdraw approvals of such product; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities
    may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional restrictions
    may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;
    </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to create
    a REMS, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication
    plan for healthcare providers and/or other elements to assure safe use; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to recall
    a product, change the way a product candidate is administered or conduct additional clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held
    liable for harm caused to patients; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the product may become
    less competitive; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer.
    </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these events could
prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly
harm our business, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Even if we complete the necessary clinical
trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize any of our product candidates, and the approval
may be for a more narrow indication than we seek or be subject to other limitations or restrictions that limit its commercial profile.
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot commercialize a
product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if our current
or future product candidates meet safety and efficacy endpoints in pivotal clinical trials, the regulatory authorities may not complete
their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA
Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. This may include approval of a
product candidate for more limited indications than requested or they may impose significant limitations in the form of warnings. In
addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative
action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 22 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory authorities also
may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of
warnings or a REMS. These regulatory authorities may require precautions or contra-indications with respect to conditions of use or they
may grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve
the labeling claims that are necessary or desirable for the successful commercialization of any of our product candidates. For example,
the FDA may disagree that our Phase&#160;3 trials evaluating D-PLEX<sub>100</sub> are sufficient to support either NDA submissions seeking
approval for the specific indications under evaluation in our ongoing and potential future Phase&#160;3 trials or NDA submissions seeking
approval for broader indications covering the prevention of SSIs. Although we intend to pursue a broad label for D-PLEX<sub>100</sub>,
to date we have not had any discussions with, nor received any feedback from, the FDA with respect to the possibility of pursuing a label
broader than the prevention of SSIs following abdominal surgery. Even if the FDA were to agree that these trials were sufficient to support
one or more NDA submissions, the FDA may determine that the data from these trials support more narrow indications than we may propose,
if the FDA were to approve such NDA submissions at all. If the FDA does not agree that our ongoing and potential future Phase&#160;3
trials support the submission of an NDA for any indication, we will be required to conduct additional clinical trials to support our
proposed indications. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates and materially
and adversely affect our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Although D-PLEX<sub>100</sub> has been granted
Qualified Infectious Disease Product designation by the FDA for the prevention of sternal wound infection after cardiac surgery, for
the prevention of post-abdominal surgery incisional infection, and for prevention of post-colorectal surgical site infections, these
designations do not guarantee a shorter FDA review process, or that D-PLEX<sub>100</sub> will ultimately be approved by the FDA for any
indication. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Generating Antibiotic
Incentives Now Act, or GAIN Act, the FDA may designate a product as a &#8220;qualified infectious disease product,&#8221; or QIDP. In
order to receive this designation, a drug must qualify as an antibacterial or antifungal drug for human use intended to treat serious
or life-threatening infections, including those caused by either (1)&#160;an antibacterial or antifungal resistant pathogen, including
novel or emerging infectious pathogens, or (2)&#160;a so-called &#8220;qualifying pathogen&#8221; found on a list of potentially dangerous,
drug-resistant organisms established and maintained by the FDA under the GAIN Act. A sponsor must request such designation before submitting
a marketing application. We requested and received QIDP designations for D-PLEX<sub>100</sub> for the prevention of sternal wound infection
after cardiac surgery, for the prevention of post-abdominal surgery incisional infection and for prevention of post-colorectal surgical
site infections. We anticipate that the QIDP designations will provide, among other benefits, an overall increased level of communication
with the FDA during the development process. The benefits of QIDP designation also include eligibility for priority review and an extension
by an additional five years of any non-patent market exclusivity period awarded, such as a five-year exclusivity period awarded for a
new molecular entity or a three-year market exclusivity period awarded to an applicant whose application relies on new clinical investigations
essential to the approval. This extension is in addition to any pediatric exclusivity extension that may be awarded. GAIN Act exclusivity
may not be awarded if the indication for which we obtain approval does not meet the definition of a qualified infectious disease product.
However, there is limited precedent for understanding the way in which the GAIN Act will be implemented. Receipt of QIDP designation
in practice may not result in a faster development process, review or approval compared to drugs considered for approval under conventional
FDA procedures, and does not assure ultimate approval by the FDA or related exclusivity benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fast Track Designation from the FDA may not
actually lead to a faster development or regulatory review or approval process. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We received Fast Track Designation
from the FDA for D-PLEX<sub>100</sub> for topical use for the prevention of post-cardiac surgery sternal infection, for the prevention
of post abdominal surgery incisional infection&#160;and for prevention of post-colorectal surgical site infections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a product candidate is
intended for the treatment of a serious or life-threatening condition and the product candidate demonstrates the potential to address
unmet medical needs for this condition, the product sponsor may apply for Fast Track Designation. The FDA has broad discretion whether
or not to grant this designation, so even if we believe one of our product candidates is eligible for this designation, we cannot assure
you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, such as the Fast Track Designation received
for D-PLEX<sub>100</sub>, we may not experience a faster development process, review or approval compared to conventional FDA procedures.
The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development
program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 23 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Breakthrough therapy designation by the FDA
may not lead to a faster development or regulatory review or approval process. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We received a breakthrough
therapy designation for D-PLEX<sub>100</sub> for the prevention of SSIs in patients undergoing elective colorectal surgery. A breakthrough
therapy is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious
or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early
in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between
the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number
of patients placed in ineffective control regimens. Product candidates designated as breakthrough therapies by the FDA are also eligible
for priority review if supported by clinical data at the time of the submission of the biologics license application, or BLA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, the receipt of a
breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared
to product candidates considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA.
In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product
candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not
be shortened.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Eligibility by EMA for submission of an MAA
in the EU under the centralized procedure may not eventually lead to an approval for submission of an MAA under the centralized procedure
nor a faster regulatory review or approval process.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we received
confirmation from the EMA that D-PLEX<sub>100</sub> is eligible for submission of an application for a EU Marketing Authorisation (centralized
Procedure) under Article 3(2)b &#8211; Therapeutic innovation (EC) No 726/2004. The centralized process eligibility is granted to D-PLEX<sub>100
</sub>under the Therapeutic Innovation criteria which underscores that D-PLEX<sub>100</sub> potentially provides a new alternative to
patients in preventing post abdominal SSIs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, the receipt of a
confirmation from the EMA that D-PLEX<sub>100</sub> is eligible for submission of an MAA in the EU under the EMA&#8217;s centralized
procedure may not eventually result in an approval by the EMA that D-PLEX<sub>100</sub> is eligible for submission of a MAA in the EU
under the Agency&#8217;s centralized procedure nor result in a faster review or approval compared to product candidates considered for
approval under conventional EMA national procedures and it would not assure ultimate approval by the EMA. In addition, even if D-PLEX<sub>100
</sub>is eligible for submission of an MAA in the under the Agency&#8217;s centralized procedure, the EMA may later decide that the product
candidate no longer meets the conditions for qualification.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Even if we obtain regulatory approval for
a product candidate, our products and business will remain subject to ongoing regulatory obligations and review. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our product candidates
are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion,
sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including
both federal and state requirements in the United States and comparable requirements outside of the United States. Accordingly, we and
others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing,
production and quality control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any regulatory approvals
that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may
be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase&#160;4
clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS as a condition
of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional
elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. We will also
be required to report certain adverse reactions and production problems, if any, to the FDA, EMA or other regulatory agencies and to
comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription
drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s
approved label. As such, we may not promote our products for indications or uses for which they do not have FDA, EMA or other regulatory
agency approval. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain
changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical
trials to verify the safety and efficacy of our product candidates in general or in specific patient subsets. An unsuccessful post-marketing
trial or failure to complete such a clinical trial could result in the withdrawal of marketing approval. Furthermore, any new legislation
addressing drug safety issues could result in delays in product development or commercialization or increased costs to assure compliance.
Foreign regulatory authorities impose similar requirements. If a regulatory agency discovers previously unknown problems with a product,
such as adverse events of unanticipated severity or frequency, or disagrees with the promotion, marketing or labeling of a product, such
regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we
fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue warning letters asserting that we are in violation
    of the law; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek an injunction or impose civil or criminal penalties
    or monetary fines; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 24 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend or withdraw regulatory
    approval; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend any of our ongoing
    clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse to approve pending
    applications or supplements to approved applications submitted by us or our strategic partners; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrict the marketing
    or manufacturing of our products; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize or detain products,
    or require a product recall; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse to permit the import
    or export of our product candidates; or </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse to allow us to enter
    into government contracts. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any government investigation
of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity.
Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate
revenue from our product candidates. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company
and our operating results will be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA&#8217;s and other
regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay
regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption
of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we
may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also cannot predict the
likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either
in the United States or abroad.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Disruptions at the FDA and other government
agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and
other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or
at all, which could negatively impact our business. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ability of the FDA to
review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory,
and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that
may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent
years as a result. In addition, government funding of other government agencies that fund research and development activities is subject
to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time
necessary for new drugs or modifications to approved drugs to be reviewed and/or approved by necessary government agencies, which would
adversely affect our business. For example, over the last several years, including for 35&#160;days beginning on December&#160;22, 2018,
the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees
and stop critical activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Separately, in response to
the COVID-19 pandemic, in March 2020 the FDA announced the postponement of most foreign and routine surveillance inspections of domestic
manufacturing facilities, and only restarted domestic inspections on a risk-based basis in July 2020. In the absence of in-person surveillance
inspections of manufacturing facilities, the FDA has relied and may in the future rely on alternative tools to evaluate facilities. Regulatory
authorities outside the United States have adopted similar restrictions or other policy measures in response to the COVID-19 pandemic.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a prolonged government
shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular
inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities
to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 25 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may be subject, directly or indirectly,
to U.S. federal and state healthcare fraud and abuse laws, false claims laws, physician payment transparency laws and health information
privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current and future operations
may be directly or indirectly through our relationships with U.S. healthcare providers, patients and other persons and entities, subject
to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain our business or financial arrangements
and relationships through which we research, market, sell and distribute our products in the United States. In addition, we may be subject
to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect
our ability to operate include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S. Anti-Kickback
    Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting, receiving
    or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering
    or arranging for or recommending the purchase, lease or order of any item or service reimbursable, in whole or in part, under Medicare,
    Medicaid or other U.S. federal healthcare programs. The U.S. Anti-Kickback Statute has been interpreted to apply to arrangements
    between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers, among others, on the other.
    There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the
    exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S. federal false
    claims laws, including the False Claims Act, or FCA, and civil monetary penalties laws, which prohibit any person or entity from,
    among other things, knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or
    approval by, the U.S. federal government or knowingly making, using or causing to be made or used a false record or statement material
    to a false or fraudulent claim to the U.S. federal government. As a result of a modification made by the Fraud Enforcement and Recovery
    Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. In addition,
    manufacturers can be held liable under the FCA even when they do not submit claims directly to government third-party payors if they
    are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting
    as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share
    in any monetary recovery. FCA liability is potentially significant in the healthcare industry because the statute provides for treble
    damages and mandatory penalties per false claim or statement. Government enforcement agencies and private whistleblowers have investigated
    pharmaceutical companies for or asserted liability under the FCA for a variety of alleged promotional and marketing activities, such
    as providing free product to customers with the expectation that the customers would bill federal programs for the product; providing
    consulting fees and other benefits to physicians to induce them to prescribe products; engaging in promotion for &#8220;off-label&#8221;
    uses; and submitting inflated best price information to the Medicaid Rebate Program. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S. Health Insurance
    Portability and Accountability Act of 1996, or HIPAA, prohibits, among other actions, knowingly and willfully executing, or attempting
    to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling
    or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly
    and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement
    in connection with the delivery of or payment for healthcare benefits, items or services. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Physician Payments
    Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation
    Act of 2010, or collectively, the ACA, imposes, among other things, annual reporting requirements for covered manufacturers for certain
    payments and &#8220;transfers of value&#8221; provided to physicians (defined to include doctors, dentists, optometrists, podiatrists
    and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners), &#160;and teaching
    hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members.
    </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 26 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations <span>established standards to protect individuals' medical records and other individually identifiable health information (collectively defined as &#8220;protected health information&#8221;). This legislation requires appropriate safeguards to protect the privacy of protected health information and sets limits and conditions on the uses and disclosures that may be made of such information without an individual&#8217;s authorization. HIPAA also gives individuals rights over their protected health information, and</span> imposes, among other things, specified requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities, which include certain healthcare providers, health plans and healthcare clearinghouses, and their business associates, which include individuals or entities that perform services for covered entities that involve the creation, use, maintenance or disclosure of, individually identifiable health information as well as their covered subcontractors. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many states have analogous
state laws and regulations, such as state anti-kickback and false claims laws, that may apply to our business practices, including but
not limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by
non-governmental third-party payors, including private insurers. In addition, certain states require pharmaceutical companies to comply
with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S.
federal government. Certain states and local jurisdictions require drug manufacturers to report information related to payments and other
transfers of value to physicians and other healthcare providers and register pharmaceutical sales representatives. Additionally, certain
states also require pharmaceutical companies to file reports relating to pricing information or marketing expenditures and have laws governing
the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and
may not have the same effect, thus complicating compliance efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of the breadth of
these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities
could be subject to challenge under one or more of such laws. In addition, the ACA has strengthened these laws. For example, health care
reform legislation, has among other things, amended the intent requirement of the U.S. Anti-Kickback statute and certain criminal healthcare
fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. Moreover,
the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback
statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ensuring that our internal
operations and business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly.
It is possible that governmental authorities will conclude that our business practices, including arrangements we may have with physicians
and other healthcare providers, some of whom may receive stock options as compensation for services provided, do not comply with current
or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
were found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant
civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, possible exclusion from government funded healthcare
programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight
if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and
curtailment of our operations, any of which could substantially disrupt our operations. If the physicians or other providers or entities
with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions, including exclusions from government funded healthcare programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 27 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legislative or regulatory healthcare reforms
in the United States may make it more difficult and costly for us to obtain regulatory clearance or approval of our product candidates
and to produce, market and distribute our products after clearance or approval is obtained. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, legislation
is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory clearance or approval,
manufacture and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised
or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations
of existing regulations may impose additional costs or lengthen review times of our product candidates. We cannot determine what effect
changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business
in the future. Such changes could, among other things, require:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes to manufacturing methods; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">change in protocol design; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional treatment arm (control); </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recall, replacement, or discontinuance of one or more of our products; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional recordkeeping. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in the United
States, there have been a number of legislative and regulatory proposals to change the health care system in ways that could affect our
ability to sell our products profitably. The pharmaceutical industry in the United States, as an example, has been affected by the passage
of the ACA, which, among other things, imposed new fees on entities that manufacture or import certain branded prescription drugs and
expanded pharmaceutical manufacturer obligations to provide discounts and rebates to certain government programs. There have been executive,
judicial and Congressional challenges to certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a
challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was
repealed by Congress. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other
things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The
IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary
maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or
Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration
will impact the ACA and our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other legislative changes
have been proposed and adopted in the United States since the ACA was enacted. These changes include, among others, aggregate reductions
to Medicare payments to providers of up to 2% per fiscal year, which went into effect in 2013 and, due to subsequent legislative amendments
to the statute, will remain in effect until 2031 unless additional Congressional action is taken. Under current legislation, the actual
reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. Congress is considering
additional health reform measures. For example, Congress is currently considering the Pioneering Antimicrobial Subscriptions to End Upsurging
Resistance Act, or PASTEUR Act, which, if passed, would establish a program to foster antimicrobial innovation. Further, the Developing
an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2021, or DISARM Act, is also pending in Congress and, if passed,
would encourage the development and use of antimicrobial drugs. It is uncertain if or when either of these bills will be enacted or whether
either bill will be enacted in its current form.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 28 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, there has been particular
and increasing legislative and enforcement interest in the United States with respect to drug pricing practices in recent years, particularly
with respect to drugs that have been subject to relatively large price increases over relatively short time periods. There have been several
recent U.S. Presidential executive orders, Congressional inquiries and proposed bills designed to, among other things, bring more transparency
to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient
programs, and reform government program reimbursement methodologies for drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, in July 2021,
the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions
aimed at prescription drugs. In response to President Biden&#8217;s executive order, on September 9, 2021, the Department of Health and
Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform
and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can
take to advance these principles. Further, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure,
single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize
price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may
be subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on
the pharmaceutical industry. Additionally, the Biden administration released an additional executive order on October 14, 2022, directing
HHS to report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs
for Medicare and Medicaid beneficiaries. Individual states in the United States have also become increasingly active in passing legislation
and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints,
discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and in some cases, designed
to encourage importation from other countries and bulk purchasing. In the future, there will likely continue to be proposals relating
to the reform of the U.S. healthcare system, some of which could further limit coverage and reimbursement of drug products, including
our product candidates. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in
payments from private payors. Our results of operations could be adversely affected by the ACA and by other health care reforms that may
be enacted or adopted in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We face intense competition in an environment
of rapid technological change and the possibility that our competitors may develop products and drug delivery systems that are similar,
more advanced or more effective than ours, which may adversely affect our financial condition and our ability to successfully market or
commercialize our product candidates. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pharmaceutical industry
in which we operate is intensely competitive and subject to rapid and significant technological change. We are currently aware of various
existing therapies in the market and in development that may in the future compete with our product candidates, including other therapies
that address the management of SSIs, as well as other drug delivery mechanisms that utilize polymer and/or lipid technology to deliver
APIs at the local level. Other approaches may also emerge for the prevention or treatment of any of the indications on which we focus,
and new technologies may emerge in localized drug delivery.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have competitors both in
the United States and internationally, including major multinational pharmaceutical companies and specialty pharmaceutical companies.
Our competitors may succeed in developing, acquiring or licensing on an exclusive basis products that are more effective or less costly
than any product candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization and
market penetration than we do. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical
or obsolete, and we may not be successful in marketing our product candidates against competitors. See &#8220;Item 4. B. &#8212; Business
Overview &#8212; Competition.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Even if we obtain and maintain approval for
D-PLEX<sub>100</sub> or our other product candidates from the FDA, we may never obtain approval outside of the United States, which would
limit our market opportunities and adversely affect our business. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Approval of a product candidate
in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions,
and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the
FDA. However, the failure to obtain approval from the FDA or other regulatory authorities may negatively impact our ability to obtain
approval in other foreign countries. Sales of D-PLEX<sub>100</sub> or our other product candidates outside of the United States will be
subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval
for a product candidate, comparable regulatory authorities of foreign countries also must approve the manufacturing and marketing of the
product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review
periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials.
In many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale
in that country. In some cases, the price that we intend to charge for our product candidates, if approved, is also subject to approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to submit a marketing
authorization application to the EMA for approval of D-PLEX<sub>100</sub> in the European Union, but obtaining such approval from the
European Commission following the opinion of the EMA is a lengthy and expensive process. Even if a product candidate is approved, the
applicable regulatory agency may limit the indications for which the product may be marketed, require extensive warnings on the product
labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Regulatory authorities
in countries outside of the United States and the European Union also have requirements for approval of product candidates with which
we must comply prior to marketing in those countries. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements
could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates
in certain countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, clinical trials conducted
in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for a product candidate may
be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced and our ability to realize the
full market potential of D-PLEX<sub>100</sub> or our other product candidates will be harmed and our business, financial condition, results
of operations and prospects will be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The misuse or off-label use of our products
may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations,
fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly
to our business. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prescription drugs may be
promoted only for the approved indications in accordance with the approved label. The FDA and other agencies actively enforce the laws
and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may
be subject to significant liability. If the FDA does not agree that our data support the submission of an NDA seeking approval for the
prevention of SSIs, we will train our marketing and sales personnel to not promote our products, if approved, for any off-label uses.
We cannot, however, prevent a physician from using our products off-label, when in the physician&#8217;s independent professional medical
judgment he or she deems it appropriate. For example, if we obtain approval of D-PLEX<sub>100</sub> for the prevention of SSIs in patients
undergoing abdominal surgery, physicians may nevertheless decide to use D-PLEX<sub>100</sub> in an attempt to prevent infections in connection
with other types of surgeries, and there may be increased risk of injury to patients if physicians attempt to use our products for these
uses for which they are not approved. While the FDA does not regulate the behavior of physicians in their choice of treatments, the FDA
does restrict manufacturer&#8217;s communications on the subject of off-label use of their products. Furthermore, the use of our products
for indications other than those approved by the FDA or any foreign regulatory body may not effectively treat such conditions, which could
harm our reputation in the marketplace among physicians and patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 30 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA, EMA or any foreign
regulatory body determines that our promotional materials or training constitute promotion of an off-label use, it could request that
we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance or imposition
of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure, civil fine or criminal
penalties. It is also possible that other federal, state or foreign enforcement authorities might take action under other regulatory authority,
such as false claims laws, if they consider our business activities to constitute promotion of an off-label use, which could result in
significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion
from participation in government healthcare programs and the curtailment of our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><b>Risks Related to our Reliance on Third
Parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We rely on third parties to conduct certain
elements of our preclinical studies and clinical trials and perform other tasks for us. If these third parties do not successfully carry
out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory
approval for or commercialize our product candidates. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have relied upon, and plan
to continue to rely upon, third-party vendors, including CROs, to monitor and manage data for our ongoing preclinical studies and clinical
trials. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to
be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical
protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be
able to obtain regulatory approval for or successfully commercialize our product candidates. We rely on these CROs for execution of our
preclinical studies and clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for
ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards,
and our reliance on the vendors and CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are
required to comply with good clinical practice, cGMP, the Helsinki Declaration, the International Conference on Harmonization Guideline
for Good Clinical Practice, applicable European Commission Directives on Clinical Trials, laws and regulations applicable to clinical
trials conducted in other territories, and good laboratory practices, or GLP, which are regulations and guidelines enforced by the FDA,
the Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable foreign regulatory authorities for
all of our product candidates in clinical development. Regulatory authorities enforce these regulations through periodic inspections of
study sponsors, principal investigators, study sites and other contractors. If we or any of our CROs or vendors fail to comply with applicable
regulations, including Good Clinical Practice, or GCP, and cGMP regulations, the clinical data generated in our clinical studies may be
deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before
approving our marketing applications. Our failure to comply with these regulations may require us to repeat clinical trials, which would
delay the regulatory approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our relationships
with these third-party CROs or vendors terminate, we may not be able to enter into arrangements with alternative CROs or vendors or do
so on commercially reasonable terms. In addition, our CROs are not our employees, and, except for remedies available to us under our agreements
with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical, nonclinical and preclinical
programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be
replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols,
regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain
regulatory approval for or successfully commercialize our product candidates. CROs may also generate higher costs than anticipated, which
could adversely affect our results of operations and the commercial prospects for our product candidates, increase our costs and delay
our ability to generate revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Replacing or adding additional
CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO
commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.
Though we carefully manage our relationships with our CROs, we may encounter similar challenges or delays in the future, which could have
a material adverse impact on our business, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 31 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b>We rely on third parties to manufacture
the raw materials, including the active pharmaceutical ingredient that we use to create our product candidates. Our business could be
harmed if existing and prospective third parties fail to provide us with sufficient quantities of these materials and products or fail
to do so at acceptable quality levels or prices. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on third- party suppliers
for certain raw materials necessary to manufacture our product candidates for our preclinical studies and clinical trials. Some of these
raw materials are difficult to source. Because there are a limited number of suppliers for these raw materials, we may need to engage
alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for
our clinical trials, and if approved, ultimately for commercial sale. In several cases, we rely on a sole provider, and there may be a
need to identify additional providers in the future. We do not have any control over the availability of raw materials. If we or our manufacturers
are unable to purchase these raw materials on acceptable terms, at sufficient quality levels, or in adequate quantities, if at all, the
development and commercialization of our product candidates or any future product candidates, would be delayed or there would be a shortage
in supply, which would impair our ability to meet our development objectives for our product candidates or generate revenues from the
sale of any approved products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Even following our establishment of our own cGMP-compliant
manufacturing capabilities, we intend to continue to rely on third- party suppliers for these raw materials, which will continue to expose
us to manufacturing risks including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced control for certain aspects of manufacturing activities; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination or nonrenewal of manufacturing and service agreements with third parties in a manner or at a time that is costly or damaging to us; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions to the operations of our third-party manufacturers and service providers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or service provider. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our raw material
suppliers will be required to become cGMP-compliant and establish a drug master file for the applicable ingredient before we can submit
our NDA for D-PLEX<sub>100</sub>. If these suppliers do not successfully carry out their contractual duties or manufacture our raw materials
in accordance with regulatory requirements, we will not be able to submit our NDA as planned or complete, or may be delayed in completing,
the clinical trials required for approval of D-PLEX<sub>100</sub>. In such instances, we may need to locate an appropriate replacement
third-party relationship, which may not be readily available or on acceptable terms, which would cause additional delay or increased expense
prior to the approval of D-PLEX<sub>100</sub> and would thereby have a material adverse effect on our business, financial condition, results
of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we have not
yet entered into binding agreements with certain third-party manufacturers to produce the raw materials and products that we use to manufacture
our product candidates. Although we intend to rely on third-party manufacturers for the raw materials and products to support the manufacturing
of our product candidates for commercialization, we have not yet entered into agreements with certain manufacturers. We may be unable
to negotiate binding agreements with the manufacturers to support our commercialization activities at commercially reasonable terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Although we have established our own manufacturing
facility, we may utilize third parties as needed to conduct our product manufacturing. Therefore, we are subject to the risk that these
third parties may not perform satisfactorily. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we expect that our
manufacturing facility will be the primary source of clinical and commercial supply for D-PLEX<sub>100</sub> for at least the first 48&#160;months
following a commercial launch, if approved, we intend to evaluate potential third-party manufacturing capabilities if necessary to meet
further commercial demand if and when required. In the event that we engage third-party manufacturers and they do not successfully carry
out their contractual duties, meet expected deadlines or manufacture D-PLEX<sub>100</sub> in accordance with regulatory requirements or
if there are disagreements between us and any third-party manufacturer, we may be delayed in producing sufficient clinical and commercial
supply of D-PLEX<sub>100</sub> or other product candidates. In such instances, we may need to locate an appropriate replacement third-party
relationship, which may not be readily available or on acceptable terms, which would cause additional delay or increased expense and would
thereby have a material adverse effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacture of pharmaceutical
products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques
and process controls. We and our contract manufacturers must comply with cGMP requirements. In the event that our contract manufacturers
fail to meet cGMP requirements, we may be delayed or unable to supply our products. In addition, manufacturers of pharmaceutical products
often encounter difficulties in production, particularly in scaling up and validating initial production and contamination controls. These
problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance
testing, operator error, and shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign
regulations. Furthermore, if microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing
facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time
to investigate and remedy the contamination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 32 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also rely or may in the
future rely on third- party manufacturers to conduct quality control reviews, packaging and serialization services for our product candidates
or any approved products. We cannot assure you that any stability, sterility or other issues relating to the manufacture of any of our
product candidates or any approved products will not occur in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, our third-party
manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political
environments. If our third-party manufacturers were to encounter any of these difficulties, our ability to provide any products to patients,
once approved, would be jeopardized. Any adverse developments affecting commercial manufacturing may result in shipment delays, inventory
shortages, lot failures, product withdrawals or recalls or other interruptions in the supply of an approved product. We may also have
to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation
efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could
materially adversely affect our business and delay and could have a material adverse effect on our business, prospects, financial condition
and results of operations. Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial
suspension of product manufacture.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our reliance on third parties requires us to
share our trade secrets and intellectual property, which increases the possibility that a competitor will discover them or that our trade
secrets and intellectual property will be misappropriated or disclosed. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we rely on third parties
to provide us with the materials that we use to develop and, if appropriate in the future, manufacture our product candidates or approved
products, we may, at times, share trade secrets and intellectual property with such third parties. We seek to protect our proprietary
technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research
agreements, consulting agreements, or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning
research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our
confidential information, such as trade secrets and intellectual property. Despite the contractual provisions employed when working with
third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known
by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements.
Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade
secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite our efforts to protect
our trade secrets and knowhow, our competitors may discover our trade secrets, either through breach of these agreements, independent
development or publication of information including our trade secrets by third parties. A competitor&#8217;s discovery of our trade secrets
and knowhow would impair our competitive position and have an adverse impact on our business, financial condition, results of operations
and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>If we are unable to obtain and maintain effective
patent rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets. If
we are unable to protect the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete
against us. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely upon a combination
of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our technologies and
product candidates. Our success depends in large part on our ability to obtain and maintain patent and other intellectual property protection
in the United States and in other countries with respect to our proprietary technology and product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 33 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have sought to protect
our proprietary position by filing patent applications in the United States and in other countries, with respect to our novel technologies
and product candidates, which are important to our business. Patent prosecution is expensive and time consuming, and we may not be able
to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that
we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 26, 2023, our
portfolio of owned patents and patent applications consists of seven families that protect our technology, including 146 issued patents,
including utility and composition of matter patents, five patent applications that have been allowed, 10 pending patent applications in
the United States, Canada, China, Europe, Japan, Israel, the Eurasian Patent Organization, India, Mexico, New Zealand, the Philippines,
Singapore, South Korea and Thailand and one published Patent Cooperation Treaty, or PCT, application. We cannot offer any assurances about
which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable
or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after
patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop.
Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent
protection could be reduced.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, the patent position
of pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles
remain unsolved. This renders the patent prosecution process particularly expensive and time-consuming. There is no assurance that all
potentially relevant prior art relating to our patent applications has been found, which can invalidate a patent or prevent a patent from
issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates,
third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable
or invalidated. Furthermore, even if they are unchallenged, our patent applications and any future patents may not adequately protect
our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. Any of
these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we cannot obtain and maintain
effective patent rights for our product candidates, we may not be able to compete effectively, and our business and results of operations
would be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may not have sufficient patent lifespan
to effectively protect our products and business. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents have a limited lifespan.
In the United States, the natural expiration of a patent is generally 20&#160;years after its priority date. Although various regulatory
exclusivity extensions may be available, including pursuant to the QIDP designations we have received for D-PLEX<sub>100</sub>, the life
of a patent, and the protection it affords, is limited. Even if any of our patent applications mature into issued patents, if we do not
have sufficient patent terms or regulatory exclusivity to protect our products, our business and results of operations will be adversely
affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Patent policy and rule changes could increase
the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents.
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in either the patent
laws or interpretation of the patent laws in the United States and other countries may diminish the value of any patents that may issue
from our patent applications, or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to
the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual
discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after
filing, or in some cases not at all. We therefore cannot be certain that we or our licensors were the first to make the invention claimed
in our owned and licensed patent or pending applications, or that we or our licensor were the first to file for patent protection of such
inventions. Assuming the other requirements for patentability are met, for United States patent applications filed prior to March&#160;15,
2013, the first to conceive a claimed invention is entitled to the patent, while outside the United States, the first to file&#160;a patent
application is entitled to the patent. After March&#160;15, 2013, under the Leahy-Smith America Invents Act, or the AIA, the United States
has moved to a first to file system. The AIA also includes a number of significant changes that affect the way patent applications are
prosecuted and may also affect patent litigation. The courts have yet to address many of these provisions and the applicability of the
AIA and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. In general, the AIA
and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement
or defense of any issued patents, all of which could have a material adverse effect on our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 34 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>If our trademarks and trade names are not adequately
protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our registered or unregistered
trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.
We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners
or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and
trade names, then we may not be able to compete effectively and our business may be adversely affected. If other entities use trademarks
similar to ours in different jurisdictions, or have senior rights to ours, it could interfere with our use of our current trademarks throughout
the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>If we are unable to maintain effective proprietary
rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the protection
afforded by any patents that have been or may be granted, we rely on trade secret protection and confidentiality agreements to protect
proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any
other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology
that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and
processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors.
We also seek to preserve the integrity and confidentiality of our data, trade secrets and intellectual property by maintaining the physical
security of our premises and physical and electronic security of our information technology systems. While we have confidence in these
individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any
breach. In addition, our trade secrets and intellectual property may otherwise become known or be independently discovered by competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we expect all of
our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties
who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any
assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will
not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent
information and techniques. Misappropriation or unauthorized disclosure of our trade secrets and intellectual property could impair our
competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets
and intellectual property are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade
secret.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual property rights of third parties
could adversely affect our ability to commercialize our product candidates, and we might be required to litigate or obtain licenses from
third parties in order to develop or market our product candidate. Such litigation or licenses could be costly or not available on commercially
reasonable terms. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is inherently difficult
to conclusively assess our freedom to operate without infringing on third- party rights. Our competitive position may suffer if patents
issued to third parties or other third- party intellectual property rights cover our product candidates or elements thereof, or our manufacturing
or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize products or our product
candidates unless we successfully pursue litigation to nullify or invalidate the third- party intellectual property right concerned, or
enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may also
be pending patent applications that if they result in issued patents, could be alleged to be infringed by our product candidates. If such
an infringement claim should be brought and be successful, we may be required to pay substantial damages, be forced to abandon our product
candidates or seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable
terms, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 35 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that we
have failed to identify relevant third-party patents or applications. For example, U.S. applications filed before November&#160;29, 2000
and certain U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. Patent
applications in the U.S. and elsewhere are published approximately 18&#160;months after the earliest filing to which priority is claimed,
with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates
or platform technology could have been filed by others without our knowledge. Additionally, pending patent applications which have been
published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our product candidates
or the use of our product candidates. Third- party intellectual property right holders may also actively bring infringement claims against
us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to
successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming
litigation and may be prevented from or experience substantial delays in pursuing the development of and/or marketing of our product candidates.
If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing
our product candidates that are held to be infringing. We might, if possible, also be forced to redesign our product candidates so that
we no longer infringe the third- party intellectual property rights. Any of these events, even if we were ultimately to prevail, could
require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Third-party claims of intellectual property
infringement may prevent or delay our development and commercialization efforts. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends
in part on our avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings
involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement
lawsuits, interferences, oppositions and reexamination proceedings before the <span>United States Patent
and Trademark Office, or</span> USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending
patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the pharmaceutical
industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement
of the patent rights of third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third parties may assert that
we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims
to materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates.
Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in
issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use
of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the
manufacturing process of any of our product candidates, any materials formed during the manufacturing process or any final product itself,
the holders of any such patents may be able to block our ability to commercialize such product candidates unless we obtain a license under
the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similarly, if any third-party
patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture, or methods of
use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless
we obtain a license or until such patent expires or is finally determined to be invalid or unenforceable. In either case, such a license
may not be available on commercially reasonable terms or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 36 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parties making claims against
us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one
or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and
would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us,
we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign
our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary
expenditure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may not be successful in obtaining or maintaining
necessary rights to our product candidates through acquisitions and in-licenses. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because our programs may require
the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire,
in-license, or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively
and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions,
methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for our
product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more
established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider
attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical
development and commercialization capabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, we sometimes
collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions.
Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology
resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or
under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other
parties, potentially blocking our ability to pursue our program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, companies that
perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party
intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully
obtain rights to required third-party intellectual property rights, we may have to abandon development of that program and our business
and financial condition could suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may be involved in lawsuits to protect or
enforce our intellectual property, which could be expensive, time consuming and unsuccessful. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may infringe our
intellectual property or that of our licensors that we may acquire in the future. If we or a future licensing partner were to initiate
legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that
the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims
alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any
of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion
could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading
statement, during prosecution. Under the AIA, the validity of U.S. patents may also be challenged in post-grant proceedings before the
USPTO. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interference proceedings provoked
by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our
patent or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology
or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us
a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may
result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation
could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research
programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product
candidates to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 37 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results
of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative,
it could have a material adverse effect on the price of our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may be subject to claims that our employees,
consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees
have wrongfully used or disclosed alleged trade secrets of their former employers. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We employ individuals who
were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors.
Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how
of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently
or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employees&#8217;
former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely
impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a
distraction to management and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may be subject to claims challenging the
inventorship of our intellectual property. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to claims
that former employees, collaborators or other third parties have an interest in or right to compensation with respect to our current patent
and patent applications, future patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship
disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation
may be necessary to defend against these and other claims challenging inventorship or claiming the right to compensation. If we fail in
defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive
ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even
if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management
and other employees. To the extent that our employees have not effectively waived the right to compensation with respect to inventions
that they helped create, they may be able to assert claims for compensation with respect to our future revenue. As a result, we may receive
less revenue from future products if such claims are successful which in turn could impact our future profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in United States and international
patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success is heavily dependent
on intellectual property. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity.
Therefore, obtaining and enforcing these patents is costly, time consuming and inherently uncertain. In addition, the United States has
recently enacted and is currently implementing wide-ranging patent reform legislation. Recent United States Supreme Court rulings have
narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations.
In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created
uncertainty with respect to the value of patents, once obtained. Depending on future actions by the United States Congress, the federal
courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain
patents or to enforce patents that we might obtain in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 38 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may not be able to protect our intellectual
property rights throughout the world. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting and defending
patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights
in some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some foreign
countries do not protect intellectual property rights to the same extent as federal and state laws in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may use our technologies
in jurisdictions where we have not obtained patent protection to develop their own product candidates and may also export otherwise infringing
products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products
may compete with our product candidates. Future patents or other intellectual property rights may not be effective or sufficient to prevent
them from competing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies have encountered
significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection,
particularly those relating to biotechnology products or methods of treatment, which could make it difficult for us to stop the marketing
of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions,
whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business,
could put our future patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and
could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other
remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around
the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Kreos Capital VI (Expert Fund) LP <span>may
seize our owned equipment, intellectual property and all shares we hold in PolyPid Inc. and PolyPid Pharma SRL if we fail to repay a loan.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 5, 2022, we entered
into a secured loan agreement, or the Loan Agreement, for up to $15 million with Kreos Capital VI (Expert Fund) LP, or Kreos. For more
information regarding the Loan Agreement please see &#8220;Item 5.C- Liquidity and Capital Resources&#8221;. Under the Loan Agreement,
we granted Kreos a first priority fixed charge over all of our owned equipment and intellectual property, including without limitation,
copyrights, patents, trademarks and trade names, as well as all shares we hold in PolyPid Inc. and PolyPid Pharma SRL. That means that
our owned equipment, intellectual property assets and our ownership of the shares of PolyPid Inc. and PolyPid Pharma SRL are used as collateral
for the loan. Additionally, PolyPid Inc. entered into a guaranty agreement with Kreos, all as security for monies borrowed by us under
the Loan Agreement. Kreos may seize our owned equipment, intellectual property all shares we hold in PolyPid Inc. and PolyPid Pharma SRL
if we fail to repay the loan, which could materially and adversely effect our operations. On March 29, 2023, we entered into an amendment
to the Credit Line. Pursuant to this amendment, 70% of the remaining principal and interest repayments will be delayed and repaid on a
monthly equal basis from August 2024 to May 2026. The amended secured loan now bears interest at a rate of 10.00%, and we will pay a restructuring
fee to Kreos consisting of 1.00% on close of the amendment and an incremental 3.00% at maturity. In return for this additional deferral
of repayment, Kreos has the right to receive a potential claw back payment on account of the then outstanding principal amount. This claw
back mechanism will be triggered by additional incoming funds from future partnership agreement or additional financing. If triggered,
the minimum claw back to be paid is $1.5 million but will not exceed $3 million. Further, the outstanding warrants Kreos received were
repriced to have an exercise price of $0.42 per share.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 39 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Risks Related
to Our Business Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Due to our limited resources and access to
capital, we must, and have in the past decided to, prioritize development of certain product candidates over other potential candidates.
These decisions may prove to have been wrong and may adversely affect our revenues. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we have limited resources
and access to capital to fund our operations, we must decide which product candidates to pursue and the amount of resources to allocate
to each. Our decisions concerning the allocation of research, collaboration, management and financial resources toward particular product
candidates may not lead to the development of viable commercial products and may divert resources away from better opportunities. Similarly,
our decisions to delay, terminate or collaborate with third parties in respect of certain product development programs may also prove
not to be optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the market potential
of our product candidates or misread trends in the pharmaceutical industry, in particular for our lead product candidate, our business,
financial condition and results of operations could be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may not be successful in our efforts to
identify, discover or license additional product candidates. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although a substantial amount
of our effort will focus on the continued clinical testing, potential approval and commercialization of D-PLEX<sub>100</sub>, the success
of our business also depends upon our ability to identify, discover or license additional product candidates. Our research programs or
licensing efforts may fail to yield additional product candidates for clinical development for a number of reasons, including: lack of
financial or personnel resources to acquire or discover additional product candidates; new product candidates may not succeed in preclinical
or clinical testing, or may be shown to have harmful side effects or may have other characteristics that may make them unmarketable or
unlikely to receive marketing approval; our competitors may develop alternatives that render our product candidates obsolete or less attractive;
the market for a product candidate may change during our development program so that such product may become unprofitable to continue
to develop; new product candidates may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and
new product candidates may not be accepted as safe and effective by patients, the medical community, or third-party payors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be forced to abandon
our development efforts for a program or programs that are unsuccessful, or we may not be able to identify, license, or discover additional
product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. Further,
research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts
and resources on potential programs or product candidates that ultimately prove to be unsuccessful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>European data collection is governed by restrictive
regulations governing the collection, use, processing and cross-border transfer of personal information. Failure to comply with such regulations
may result in substantial fines, other administrative penalties and civil claims being brought against us.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may collect, process, use
or transfer personal information from individuals located in the European Union in connection with our business, including in connection
with conducting clinical trials in the European Union. Additionally, we intend to commercialize D-PLEX<sub>100</sub>, and any of our product
candidates that receive marketing approval, in the European Union. The collection and use of personal health data in the European Union
is governed by the provisions of the General Data Protection Regulation ((EU) 2016/679), or the GDPR, along with other European Union
and country-specific laws and regulations. The United Kingdom and Switzerland have also adopted data protection laws and regulations.
These legislative acts (together with regulations and guidelines) impose requirements relating to having legal bases for processing personal
information relating to identifiable individuals and transferring such information outside of the EEA, including to the United States,
providing details to those individuals regarding the processing of their personal information, keeping personal information secure, having
data processing agreements with third parties who process personal information, responding to individuals&#8217; requests to exercise
their rights in respect of their personal information, reporting security breaches involving personal data to the competent national data
protection authority and affected individuals, appointing data protection officers, conducting data protection impact assessments and
record-keeping. The GDPR imposes additional responsibilities and liabilities in relation to personal data that we process and we may be
required to put in place additional mechanisms ensuring compliance with the new data protection rules. Failure to comply with the requirements
of the GDPR and related national data protection laws of the member states of the European Union may result in substantial fines, other
administrative penalties and civil claims being brought against us, which could have a material adverse effect on our business, prospects,
financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The United Kingdom&#8217;s withdrawal from
the European Union may adversely impact our ability to obtain regulatory approvals of our product candidates in the United Kingdom, result
in restrictions or imposition of taxes and duties for importing our product candidates into the United Kingdom, and may require us to
incur additional expenses in order to develop, manufacture and commercialize our product candidates in the United Kingdom.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the result of a
referendum in 2016, the United Kingdom left the European Union on January 31, 2020, commonly referred to as Brexit. A trade and cooperation
agreement that outlines the future and trading relationship between the United Kingdom and the European Union was agreed to in December
2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 40 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since a significant proportion
of the regulatory framework in the United Kingdom applicable to our business and our product candidates is derived from European Union
directives and regulations, Brexit has had, and will continue to have, a material impact on the regulatory regime with respect to the
development, manufacture, importation, approval and commercialization of our product candidates in the United Kingdom. For example, Great
Britain is no longer covered by the centralized procedures for obtaining European Union-wide marketing authorizations from the EMA, and
a separate marketing authorization will be required to market our product candidates, including D-PLEX<sub>100</sub> in Great Britain.
It is currently unclear whether the Medicines&#160;&amp; Healthcare products Regulatory Agency in the United Kingdom is sufficiently prepared
to handle the increased volume of marketing authorization applications that it is likely to receive. Any delay in obtaining, or an inability
to obtain, any marketing approvals, as a result of Brexit or otherwise, would delay or prevent us from commercializing our product candidates
in the United Kingdom and limit our ability to generate revenue and achieve and sustain profitability. We could face significant additional
expenses to obtain regulatory approval for our products in the United Kingdom.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>If we fail to comply with environmental, health
and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect
on the success of our business. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research, development
and manufacturing activities and our third- party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage,
use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our
manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these
hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217;
facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization
efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under
applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although
we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally
comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of
accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages, such liability
could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt
our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more
stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological
or hazardous waste insurance coverage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our employees and independent contractors may
engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to the risk
of fraud or other misconduct by our employees and independent contractors. Misconduct by these parties could include intentional failures
to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply
with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized
activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and
regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may
restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and
other business arrangements. Employee and independent contractor misconduct could also involve the improper use of information obtained
in the course of clinical trials, including individually identifiable information, creating fraudulent data in our preclinical studies
or clinical trials or illegal misappropriation of product candidates, which could result in regulatory sanctions and serious harm to our
reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take
to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from
governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally,
we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such
actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have
a significant impact on our business, including the imposition of significant fines or other sanctions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Under applicable employment laws, we may not
be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise
of some of our former employees. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generally enter into non-competition
agreements with our employees and certain key consultants. These agreements prohibit our employees and certain key consultants, if they
cease working for us, from competing directly with us or working for our competitors or clients for a limited period of time. We may be
unable to enforce these agreements under the laws of the jurisdictions in which our employees work and it may be difficult for us to restrict
our competitors from benefitting from the expertise our former employees or consultants developed while working for us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, Israeli courts
have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities
of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts,
such as the secrecy of a company&#8217;s confidential commercial information or the protection of its intellectual property. If we cannot
demonstrate that such interests will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our
former employees or consultants and our ability to remain competitive may be diminished.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>International expansion of our business exposes
us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United
States or Israel. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than our headquarters
and other operations which are located in Israel (as further described below), we currently have limited international operations, but
our business strategy incorporates potentially significant international expansion, particularly in anticipation of approval of our product
candidates. We plan to retain sales representatives and third- party distributors and conduct physician, infectious disease specialist,
hospital pharmacist and patient association outreach activities, as well as clinical trials, outside of the United States, European Union
and Israel. Doing business internationally involves a number of risks, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits, and licenses; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us to obtain regulatory approvals for the use of our product candidates in various countries; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional potentially relevant third-party patent rights; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities and difficulties in obtaining protection and enforcing our intellectual property; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in staffing and managing foreign operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities associated with managing multiple third-party payor reimbursement regimes, government payors, prince controls or patient self-pay systems; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits in our ability to penetrate international markets; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an outbreak of a contagious disease, including COVID-19, which may cause us or our distributors, third- party vendors and manufacturers and/or customers to temporarily suspend our or their respective operations in the affected city or country; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural disasters, political and economic instability, including wars, terrorism, and political unrest, boycotts, curtailment of trade, and other business restrictions; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain expenses including, among others, expenses for travel, translation and insurance; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act its books and records provisions, or its anti-bribery provisions. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these factors could
significantly harm our future international expansion and operations and, consequently, our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our business and operations have been and may
further be adversely affected by the COVID-19 global pandemic. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
business and operations have been and, although COVID-19 pandemic continues to decline
globally, may further be adversely affected by the effects of the
COVID-19 virus. The COVID-19 pandemic has resulted in travel and other restrictions in order to reduce the spread of the disease, including
public health directives and orders in Israel, the United States and the European Union that, among other things and for various periods
of time, directed individuals to shelter at their places of residence, directed businesses and governmental agencies to cease non-essential
operations at physical locations, prohibited certain non-essential gatherings and events and ordered cessation of non-essential travel.
Government orders or other restrictions on the conduct of business operations related to the COVID-19 pandemic may negatively impact productivity
and may disrupt our ongoing research and development activities and our clinical programs and timelines, the magnitude of which will depend,
in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.
Further, such orders also may impact the availability or cost of materials, which would disrupt our supply chain and manufacturing efforts
and could affect our ability to conduct ongoing and planned clinical trials and preparatory activities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 42 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Commercialization of Our Product
Candidates </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We have limited manufacturing experience and
could experience production problems that result in delays in our development or commercialization programs or otherwise adversely affect
our business. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited experience
manufacturing D-PLEX<sub>100</sub>. Although we have established our own manufacturing facility to support current and future clinical
trials, and have received regulatory approvals for clinical manufacturing, and an initial commercial launch, we may be unable to produce
commercial materials or meet demand for D-PLEX<sub>100</sub> if we are unable to receive or maintain commercial regulatory approvals for
our facility. Any such failure could delay or prevent our development of D-PLEX<sub>100</sub> and would have a material adverse effect
on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacturing process
we use to produce D-PLEX<sub>100</sub> has not been validated for commercial use. Although we have increased the scale of our manufacturing
process in order to produce sufficient quantities of D-PLEX<sub>100</sub> for our ongoing and planned clinical trials and at least the
first 48&#160;months following a commercial launch, if D-PLEX<sub>100</sub> is approved, in the future we will need to increase the scale
of our manufacturing process either at our facility or at third-party manufacturers, or both. We may not be successful in producing sufficient
quantities of D-PLEX<sub>100</sub>, due to several factors, including equipment malfunctions, facility contamination, technical process
challenges, raw material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions in
the operations of our suppliers. Problems with the manufacturing process, even minor deviations from the normal process, could result
in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory.
We may encounter problems achieving adequate quantities and quality of clinical- and commercial-grade materials that meet FDA, EMA or
other applicable standards or specifications with consistent and acceptable production yields and costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Slight deviations in the manufacturing
process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result
in lot failures or product recalls. There is no assurance we will not experience such failures at our own manufacturing facility or that
of a third party in the future. Lot failures or product recalls could cause delays in product supply or clinical trials, which could be
costly to us and otherwise harm our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also may encounter problems
hiring and retaining the experienced specialist scientific, quality assurance, quality control and manufacturing personnel needed to operate
our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory
requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any problems in our manufacturing
process or facilities could make us a less attractive collaborator for potential partners, including biopharmaceutical companies, which
could limit our access to additional attractive development programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We currently have no marketing and sales organization.
If we are unable to establish sales and marketing capabilities, or enter into agreements with third parties to market and sell our product
candidates, we may be unable to generate any product revenue. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have no experience selling
and marketing our product candidates, and we currently have no marketing or sales organization. To successfully commercialize any product
candidates that may result from our development programs, we will need to develop these capabilities, either on our own or with others.
If our product candidates receive regulatory approval, we intend to establish a sales and marketing organization independently or by utilizing
experienced third parties with technical expertise and supporting distribution capabilities to commercialize our product candidates in
major markets, all of which will be expensive, difficult and time consuming. Any failure or delay in the development of our internal sales,
marketing and distribution capabilities would adversely impact our ability to commercialize our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, given our lack of
prior experience in marketing and selling pharmaceutical products, our initial estimate of the size of the required sales force may be
materially more or less than the size of the sales force actually required to effectively commercialize our product candidates. As such,
we may be required to hire sales representatives and third-party distributors to adequately support the commercialization of our product
candidates, or we may incur excess costs if we hire more sales representatives than necessary. With respect to certain geographical markets,
we may enter into collaborations with other entities to utilize their local marketing and distribution capabilities, but we may be unable
to enter into such agreements on favorable terms, if at all. We also may enter into collaborations with large pharmaceutical companies
to develop and commercialize product candidates. If our future collaborators do not commit sufficient resources to develop and commercialize
our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we will be unable to generate
sufficient product revenue to sustain our business. We may compete with companies that currently have extensive and well-funded marketing
and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable
to compete successfully against these more established companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our efforts to educate the
medical community, including physicians, hospital pharmacists and third-party payors on the benefits of our product candidates may require
significant resources and may never be successful. If any of our product candidates are approved but fail to achieve market acceptance
among physicians, patients or third-party payors, we will not be able to generate significant revenues from such product, which could
have a material adverse effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We are subject to significant regulatory oversight
with respect to manufacturing our product candidates. Delays in establishing and obtaining regulatory approval of our manufacturing process
and facility or disruptions in our manufacturing process may delay or disrupt our product development and commercialization efforts. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of drug products
for clinical trials or commercial sale is subject to extensive regulation. Before we can begin to commercially manufacture D-PLEX<sub>100</sub>
or any product candidate, whether in a third-party facility or in our own facility, we must obtain regulatory approvals from the Israeli
Ministry of Health, or MOH, the FDA and similar regulatory agencies, as applicable for our manufacturing process and facility. A manufacturing
authorization must also be obtained from the appropriate regulatory authorities in the European Union and worldwide. In addition, we must
pass a pre-approval inspection of our manufacturing facility by the FDA before D-PLEX<sub>100</sub> or any product candidate can obtain
marketing approval. In order to obtain approval, we will need to ensure that all of our processes, methods and equipment are compliant
with cGMP, and perform extensive audits of vendors, contract laboratories and suppliers. If any of our vendors, contract laboratories
or suppliers is found to be out of compliance with cGMP, we may experience delays or disruptions in manufacturing while we work with these
third parties to remedy the violation or while we work to identify suitable replacement vendors. For example, in the past, a cGMP audit
by the MOH of the manufacturing process in the facility of our contract manufacturer for D-PLEX<sub>100</sub> resulted in certain critical
observations, which have since been resolved. There can be no guarantee, however, that future inspections by regulatory authorities of
our manufacturing facilities or those of our contract manufacturers will result in MOH&#8217;s agreement that these critical observations
have been resolved or that similar inspectional observations will not be identified. If we do not demonstrate to the satisfaction of the
applicable regulator that our manufacturing facilities, or those of our contract manufacturers, are in compliance with applicable requirements,
we may be materially delayed in the development of our product candidates, which would materially harm our business. The cGMP requirements
govern quality control of the manufacturing process and documentation policies and procedures. In complying with cGMP, we will be obligated
to expend time, money and effort in production, record keeping and quality control to assure that the product meets applicable specifications
and other requirements. If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be
permitted to sell any product candidate that we may develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 44 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our failure to comply with
applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays,
suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions
and criminal prosecutions, any of which could significantly and adversely affect supplies of any approved products and our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operating our own manufacturing
facility will require additional investment, will be time-consuming and may be subject to delays, including because of shortage of labor
or compliance with regulatory requirements. In addition, operating a manufacturing facility may cost more than we currently anticipate.
Delays or problems in the build out of our manufacturing facility may adversely impact our ability to provide supply for the development
and commercialization of D-PLEX<sub>100</sub> as well as our financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>If we receive marketing approval for our product
candidates, sales will be limited unless the product achieves broad market acceptance by physicians, hospital administrators, third-party
payors, hospital pharmacists, infectious disease specialists and others in the medical community. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commercial success of
our product candidates will depend upon the acceptance of the product by the medical community, including physicians, hospital administrators,
healthcare third-party payors, hospital pharmacists, infectious disease specialists and patients. The degree of market acceptance of any
approved product will depend on a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the demonstration of clinical safety and efficacy of our product candidates in clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the efficacy, potential and perceived advantages of our product candidates over alternative treatments; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of treatment relative to the cost of treating SSIs; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prevalence and severity of any adverse side effects; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9679;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the prevalence and severity of the disease the
    product is designed to treat or prevent;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">product labeling or product insert requirements
    of the FDA or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribution and use restrictions imposed by the FDA or agreed to by us as part of a mandatory or voluntary risk management plan; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain adequate reimbursement; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the demonstration of the effectiveness of our product candidates in reducing the cost of treatment; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the strength of marketing and distribution support; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of market introduction of competitive products; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of products and their ability to meet market demand; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publicity concerning our product candidates or competing products and treatments. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our product candidates
are approved but do not achieve an adequate level of acceptance by physicians, hospital administrators, third-party payors, hospital pharmacists,
infectious disease specialists and patients, we may not generate sufficient revenue from the product, and we may not become or remain
profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our product candidates
may require significant resources and may never be successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>It may be difficult for us to profitably sell
our product candidates if reimbursement for these products, or the procedures in which they are used, is limited by government authorities
and/or third-party payor policies. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to any healthcare
reform measures which may affect reimbursement, market acceptance and sales of our product candidates, if approved, will depend on, in
part, the extent to which the procedures utilizing our product candidates, performed by health care providers, will be covered by third-party
payors, such as government health care programs, commercial insurance and managed care organizations. Our product candidates will be purchased
or provided by health care providers for utilization in certain surgical procedures. In the event health care providers and patients accept
our product candidates as medically useful, cost effective and safe, there is uncertainty regarding whether our product candidates will
be directly reimbursed, reimbursed through a bundled payment or if the product candidates will be included in another type of value-based
reimbursement program. Third-party payors determine the extent to which new products or procedures will be covered as a benefit under
their plans and the level of reimbursement for any covered product or procedure which may utilize a covered product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 45 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When used in connection with
surgical and certain other procedures, our product candidates may not be reimbursed separately but their cost may instead be bundled as
part of the payment received by the provider for the procedure. Treating physicians are unlikely to use and order our products unless
coverage is provided and the reimbursement is adequate to cover all or a significant portion of the cost of the procedures which utilize
our products. A decision by a third-party payor not to cover or adequately reimburse for our product candidates or procedures using our
product candidates, could reduce physician utilization of our products once approved. Therefore, coverage and adequate reimbursement for
procedures which utilize new products is critical to the acceptance of such new products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A primary trend in the U.S.
healthcare industry and elsewhere has been cost containment, including price controls, restrictions on coverage and reimbursement and
requirements for substitution of less expensive products and procedures. Third-party payors decide which products and procedures they
will pay for and establish reimbursement and co-payment levels. Government and other third-party payors are increasingly challenging the
prices charged for health care products and procedures, examining the cost effectiveness of procedures, and the products used in such
procedures, in addition to their safety and efficacy, and limiting or attempting to limit both coverage and the level of reimbursement.
We cannot be sure that coverage will be available for our product candidates, if approved, or, if coverage is available, the level of
direct or indirect reimbursement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to experience pricing
pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence
of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly
prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are
being erected to the successful commercialization of new products. Further, the adoption and implementation of any future governmental
cost containment or other health reform initiative may result in additional downward pressure on the price that we may receive for any
approved product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Reimbursement by a third-party
payor may depend upon a number of factors including the third-party payor&#8217;s determination that use of a product is:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a covered benefit or part of a covered benefit under its health plan; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safe, effective and medically necessary; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appropriate for the specific patient; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effective; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither experimental nor investigational. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, third-party
payors, including private and governmental payors such as the Medicare and Medicaid programs, play an important role in determining the
extent to which procedures using new products will be covered and reimbursed. The Medicare and Medicaid programs are increasingly used
as models for how private payors and other governmental payors develop their coverage and reimbursement policies. It is difficult to predict
at this time what third-party payors will decide with respect to reimbursement for fundamentally novel products such as ours, as there
is no body of established practices and precedents for these new products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining coverage and reimbursement
approval for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide
supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. Additionally, we may not be able
to provide data sufficient to gain acceptance with respect to coverage and reimbursement. We cannot be sure that coverage or adequate
reimbursement will be available for our product candidates, if approved. Also, we cannot be sure that reimbursement amounts will not reduce
the demand for, or the price of, our future products. If reimbursement is not available, or is available only to limited levels, we may
not be able to commercialize our product candidates, or achieve profitably at all, even if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 46 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our business entails a significant risk of
clinical trial and/or product liability and our ability to obtain sufficient insurance coverage could have a material effect on our business,
financial condition, results of operations or prospects. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business exposes us to
significant clinical trial and/or product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic
treatments. Clinical trial and/or product liability claims could delay or prevent completion of our development programs. If we succeed
in marketing products, product liability claims could result in an FDA investigation of the safety and effectiveness of our products,
our manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement
action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the
merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to
defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants
or patients and a decline in our company valuation. While we currently have clinical trial liability insurance, we do not have product
liability insurance and do not anticipate obtaining product liability insurance until such time as we have received FDA or other comparable
foreign authority approval for a product and there is a product that is being provided to patients outside of clinical trials. Any insurance
we have or may obtain may not provide sufficient coverage against potential liabilities. In some countries, the institution or the doctors
involved do not have sufficient insurance to cover their activities. Furthermore, clinical trial and product liability insurance are becoming
increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses
caused by clinical trial and product liability claims that could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Ownership of Our Ordinary
Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our executive officers, directors and principal
shareholders will maintain the ability to exert significant control over matters submitted to our shareholders for approval. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 30, 2023, our
executive officers, directors and principal shareholders who own more than 5% of our outstanding Ordinary Shares, in the aggregate, beneficially
own shares representing approximately 19.8% of our share capital. As a result, if these shareholders were to act together, they would
be able to exert significant influence over all matters submitted to our shareholders for approval (including a prospective acquisition
or other change of control of our company), as well as our management and affairs. On March 31, 2023, we issued additional ordinary shares
in a public offering, or the Offering. The percentage above does not give effect to the number of shares issued in the Offering. For more
information, see &#8220;Item 5 &#8211; Liquidity and Capital Resources- Financing Activities.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We may be or may become classified as a passive
foreign investment company. If we are or become classified as a passive foreign investment company, our U.S. shareholders may suffer adverse
tax consequences as a result. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, for any taxable
year, if at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable to assets that
produce passive income or are held for the production of passive income, including cash, we would be characterized as a passive foreign
investment company, or PFIC, for U.S. federal income tax purposes. For purposes of these tests, passive income includes dividends, interest
gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce passive
income (including amounts derived by reason of the temporary investment of funds raised in offerings of our shares) and rents and royalties
other than rents and royalties which are received from unrelated parties in connection with the active conduct of a trade or business.
If we are characterized as a PFIC, our U.S. shareholders may suffer adverse tax consequences, including having gains realized on the sale
of our Ordinary Shares treated as ordinary income, rather than capital gain, the loss of the preferential rate applicable to dividends
received on our Ordinary Shares by individuals who are U.S. holders, and having interest charges apply to distributions by us and gains
from the sales of our shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our status as a PFIC will
depend on the nature and composition of our income and the nature, composition and value of our assets (which, assuming we are not a &#8220;controlled
foreign corporation,&#8221; or a CFC, under Section&#160;957(a) of the Internal Revenue Code of 1986, as amended, or the Code, for the
year being tested, may be determined based on the fair market value of each asset, with the value of goodwill and going concern value
determined in large part by reference to the market value of our Ordinary Shares, which may be volatile). Based upon the estimated value
of our assets, including any goodwill, and the nature and estimated composition of our income and assets, we may be classified as a PFIC
for the taxable year ended December&#160;31, 2022 and in future taxable years. In particular, so long as we do not generate revenue from
operations for any taxable year and do not receive any research and development grants, or even if we receive a research and development
grant, if such grant does not constitute gross income for United States federal income tax purposes, we likely will be classified as a
PFIC for such taxable year. Because the determination of whether we are a PFIC for any taxable year is a factual determination made annually
after the end of each taxable year, there can be no assurance that we will not be considered a PFIC in any taxable year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax consequences that
would apply if we are classified as a PFIC would also be different from those described above if a U.S. shareholder were able to make
a valid qualified electing fund, or QEF, election. At this time, we do not expect to provide U.S. shareholders with the information necessary
for a U.S. shareholder to make a QEF election. Prospective investors should assume that a QEF election will not be available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>If a United States person is treated as owning
at least 10% of our shares, such holder may be subject to adverse U.S. federal income tax consequences. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a United States person
is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of our shares, such person may
be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation&#8221; in our group
(if any). Because our group includes one or more U.S. subsidiaries, we expect that certain of our non-U.S. subsidiaries will be treated
as controlled foreign corporations (regardless of whether we are or are not treated as a controlled foreign corporation). A United States
shareholder of a controlled foreign corporation may be required to annually report and include in its U.S. taxable income its pro rata
share of &#8220;Subpart&#160;F income,&#8221; &#8220;global intangible low-taxed income&#8221; and investments in U.S. property by controlled
foreign corporations, whether or not we make any distributions. An individual that is a United States shareholder with respect to a controlled
foreign corporation generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States
shareholder that is a U.S. corporation. A failure to comply with these reporting obligations may subject you to significant monetary penalties
and may prevent the statute of limitations with respect to your U.S. federal income tax return for the year for which reporting was due
from starting. We cannot provide any assurances that we will assist investors in determining whether any of our non-U.S. subsidiaries
are treated as a controlled foreign corporation or whether such investor is treated as a United States shareholder with respect to any
of such controlled foreign corporations or furnish to any United States shareholders information that may be necessary to comply with
the aforementioned reporting and tax paying obligations. A United States investor should consult their own advisors regarding the potential
application of these rules to its investment in the shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>As a foreign private issuer, we are permitted,
and intend, to follow certain home country corporate governance practices instead of otherwise applicable Nasdaq requirements, and we
will not be subject to certain U.S. securities laws including, but not limited to, U.S. proxy rules and the filing of certain Exchange
Act reports. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we will be permitted, and intend, to follow certain home country corporate governance practices instead of those otherwise required by
the Nasdaq Stock Market for domestic U.S. issuers. Following our home country governance practices as opposed to the requirements that
would otherwise apply to a U.S. company listed on The Nasdaq Global Market may provide less protection to you than what is accorded to
investors under the listing rules of Nasdaq applicable to domestic U.S. issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we will be exempt from the rules and regulations under the Securities Exchange Act of 1934, or the Exchange Act, related to the furnishing
and content of proxy statements, including the applicable compensation disclosure requirements. Nevertheless, pursuant to regulations
promulgated under the Israeli Companies Law, 5759-1999, or the Israeli Companies Law, we are required to disclose the annual compensation
of our five most highly compensated office holders on an individual basis. Such disclosure will not be as extensive as that required of
a U.S. domestic issuer. Our officers, directors and principal shareholders will also be exempt from the reporting and short-swing profit
recovery provisions contained in Section&#160;16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file
reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered
under the Exchange Act and we will be exempt from filing quarterly reports with the SEC under the Exchange Act. Moreover, we will not
be required to comply with Regulation&#160;FD, which restricts the selective disclosure of material information, although we intend to
voluntarily adopt a corporate disclosure policy substantially similar to Regulation&#160;FD. These exemptions and leniencies will reduce
the frequency and scope of information and protections to which you may otherwise have been eligible in relation to a U.S. domestic issuer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 48 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We would lose our foreign
private issuer status if a majority of our shares are owned by U.S. residents and a majority of our directors or executive officers are
U.S. citizens or residents or we fail to meet additional requirements necessary to avoid loss of foreign private issuer status. The regulatory
and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly higher. If we are not a foreign private
issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are
more detailed and extensive than the forms available to a foreign private issuer. We may also be required to modify certain of our policies
to comply with accepted governance practices associated with U.S. domestic issuers. Such conversion and modifications will involve additional
costs. In addition, we would lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges
that are available to foreign private issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We are an emerging growth company and the reduced
disclosure requirements applicable to emerging growth companies may make our Ordinary Shares less attractive to investors. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an emerging growth
company, as defined in the Jumpstart Our Business Startups Act, or the JOBS Act, and we may take advantage of certain exemptions from
various requirements that are applicable to other public companies that are not emerging growth companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For as long as we remain an
emerging growth company we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to
other public companies that are not &#8220;emerging growth companies.&#8221; These exemptions include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 107 of the JOBS Act, which provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. This means that an &#8220;emerging growth company&#8221; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to delay such adoption of new or revised accounting standards. As a result of this adoption, our financial statements may not be comparable to companies that comply with the public company effective date; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced disclosure obligations regarding executive compensation; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will remain an emerging
growth company until the earliest of: (i)&#160;the last day of our fiscal year during which we have total annual gross revenues of at
least $1.235&#160;billion; (ii)&#160;December 31, 2025; (iii)&#160;the date on which we have, during the previous three-year period, issued
more than $1.0&#160;billion in non-convertible debt; or (iv)&#160;the date on which we are deemed to be a &#8220;large accelerated filer&#8221;
under the Exchange Act. We have opted out of the extended transition period made available to emerging growth companies to comply with
newly adopted public company accounting requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 49 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When we are no longer deemed
to be an emerging growth company, we will not be entitled to the exemptions provided in the JOBS Act discussed above. We cannot predict
if investors will find our Ordinary Shares less attractive as a result of our reliance on exemptions under the JOBS Act. If some investors
find our Ordinary Shares less attractive as a result, there may be a less active trading market for our Ordinary Shares and our share
price may be more volatile.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>If we are unable to comply with Nasdaq minimum
bid requirement, our Ordinary Shares could be delisted from Nasdaq, and as a result we and our shareholders could incur material adverse
consequences, including a negative impact on our liquidity, our shareholders&#8217; ability to sell shares and our ability to raise capital.
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 6, 2022, we received
a written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC notifying us that we were not in compliance
with the minimum bid price requirement because the closing bid price of our Ordinary Shares was below $1.00 per Ordinary Share for the
previous 30 consecutive business days. We were granted 180 calendar days, or until June 5, 2023, to regain compliance with the Minimum
Bid Price Requirement. In the event we do not regain compliance with the Minimum Bid Price Requirement by June 5, 2023, we may be eligible
for an additional 180-calendar day grace period. To qualify, we will be required to meet the continued listing requirement for market
value of publicly held shares and all other listing standards for Nasdaq, with the exception of the minimum bid price requirement, and
will need to provide written notice to The Nasdaq Stock Market LLC of our intent to regain compliance with such requirement during such
second compliance period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We monitor and intend to continue
monitoring the closing bid price of our Ordinary Shares and may, if appropriate, consider implementing available options to regain compliance
with the minimum bid price requirement, including initiating a reverse stock split. If we do not regain compliance within the allotted
compliance period(s), including any extensions that may be granted, The Nasdaq Stock Market LLC will provide notice that our Ordinary
Shares will be subject to delisting from Nasdaq. At that time, we may appeal The Nasdaq Stock Market LLC&#8217;s determination to a hearings
panel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurances
that we will be able to regain compliance with the minimum bid price requirement or if we do later regain compliance with the minimum
bid price requirement, that we will be able to continue to comply with all applicable Nasdaq listing requirements now or in the future.
If we are unable to maintain compliance with these Nasdaq requirements, our Ordinary Shares will be delisted from Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that our Ordinary
Shares are delisted from Nasdaq, as a result of our failure to comply with the minimum bid price requirement, or due to our failure to
continue to comply with any other requirement for continued listing on Nasdaq, and is not eligible for listing on another exchange, trading
in our Ordinary Shares could be conducted in the over-the-counter market or on an electronic bulletin board established for unlisted securities
such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price
quotations for, our Ordinary Shares, and it would likely be more difficult to obtain coverage by securities analysts and the news media,
which could cause the price of our Ordinary Shares to decline further. Also, it may be difficult for us to raise additional capital if
we are not listed on a national exchange.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Israeli Law and Our Operations
in Israel </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our headquarters and other significant operations
are located in Israel, and, therefore, our results may be adversely affected by political, economic and military instability in Israel.
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive offices, research
and development laboratories and manufacturing facility are located in Petach Tikva, Israel. In addition, the majority of our key employees,
officers and directors are residents of Israel. If these or any future facilities in Israel were to be damaged, destroyed or otherwise
unable to operate, whether due to war, acts of hostility, earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters,
employee malfeasance, terrorist acts, power outages or otherwise, or if performance of our research and development is disrupted for any
other reason, such an event could delay our clinical trials or, if our product candidates are approved and we choose to manufacture all
or any part of them internally, jeopardize our ability to manufacture our products as promptly as our prospective customers will likely
expect, or possibly at all. If we experience delays in achieving our development objectives, or if we are unable to manufacture an approved
product within a timeframe that meets our prospective customers&#8217; expectations, our business, prospects, financial results and reputation
could be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 50 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Political, economic and military
conditions in Israel may directly affect our business. Since the establishment of the State of Israel in 1948, a number of armed conflicts
have taken place between Israel and groups in its neighboring countries. In addition, several countries, principally in the Middle East,
restrict doing business with Israel, and additional countries may impose restrictions on doing business with Israel and Israeli companies
whether as a result of hostilities in the region or otherwise. Any hostilities involving Israel, terrorist activities, political instability
or violence in the region or the interruption or curtailment of trade or transport between Israel and its trading partners could adversely
affect our operations and results of operations and the market price of our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial insurance does
not cover losses that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli
government is currently committed to covering the reinstatement value of direct damages that are caused by terrorist attacks or acts of
war, we cannot assure you that this government coverage will be maintained or, if maintained, will be sufficient to compensate us fully
for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business, financial condition and
results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, our operations could
be disrupted by the obligations of our employees to perform military service. As of March 26, 2023, we had 58 full-time employees based
in Israel. Of these employees, some may be military reservists, and may be called upon to perform military reserve duty of up to 36&#160;days
per year (and in some cases more) until they reach the age of 40 (and in some cases, up to the age of 45 or older). Additionally, they
may be called to active duty at any time under emergency circumstances. In response to increased tension and hostilities in the region,
there were, at times, call-ups of military reservists, and it is possible that there will be additional call-ups in the future. Our operations
could be disrupted by the absence of these employees due to military service. Such disruption could occur and, therefore, harm our business
and operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Furthermore,
the Israeli government is currently pursuing extensive changes to Israel&#8217;s judicial system, which has sparked extensive political
debate. In response to the foregoing developments, a series of civil unrests and demonstrations throughout Israel took place. Additionally,
individuals, organizations and institutions, both within and outside of Israel, have voiced concerns that the proposed changes may negatively
impact the business environment in Israel including due to reluctance of foreign investors to invest or conduct business in Israel, as
well as to increased currency fluctuations, downgrades in credit rating, increased interest rates, increased volatility in securities
markets, and other changes in macroeconomic conditions. Such proposed changes may also adversely affect the labor market in Israel or
lead to political instability or civil unrest. To the extent that any of these negative developments do occur, they may have an adverse
effect on our business, our results of operations and our ability to raise additional funds, if deemed necessary by our management and
board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our operations are subject to currency and
interest rate fluctuations. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our functional currency
is the U.S. dollar, and our financial records are maintained in U.S. dollars, we also incur expenses in Euros and NIS. In the future,
we expect that a substantial portion of our revenues will be generated in U.S. dollars, Euros and other foreign currencies, although we
currently incur a significant portion of our expenses in currencies other than U.S. dollars, mainly NIS. As a result, we are affected
by foreign currency exchange fluctuations through both translation risk and transaction risk, and our financial results may be affected
by fluctuations in the exchange rates of currencies in the countries in which our prospective product candidates may be sold. We currently
partially hedge our foreign currency exchange rate risk to decrease the risk of financial exposure from fluctuations in the exchange rates
of our principal operating currencies, but these hedge agreements may not be sufficient to fully protect us from the risks related to
exchange rate fluctuations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 51 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We received Israeli government grants for certain
of our research and development activities, the terms of which may require us to pay royalties and to satisfy specified conditions in
order to manufacture products and transfer technologies outside of Israel. If we fail to satisfy these conditions, we may be required
to pay penalties and refund grants previously received. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
efforts have been financed in part through royalty-bearing and non-royalty-bearing grants in an aggregate amount of $6.5 million that
we received from the IIA as of March 26, 2023. The last IIA approved research and development grants ended on November 30, 2022. With
respect to the royalty-bearing grants we are committed to pay royalties at a rate of 3.0% on sales proceeds from our products that were
developed under IIA programs up to the total amount of grants received, linked to the U.S. dollar and bearing interest at an annual rate
of LIBOR applicable to U.S. dollar deposits. In September 2021, the Bank of Israel, which determines annual interest rates, published
a directive which stated that annual interest at a variable rate linked to the LIBOR rate for loans in U.S. dollars will be replaced by
the Secured Overnight Financing Rate, or the SOFR, in June 2023. While it is not currently possible to determine precisely whether, or
to what extent, the replacement of LIBOR with SOFR would affect us, the implementation of SOFR may increase our financial liabilities
to the IIA. Management continues to monitor the status and discussions regarding&#160;SOFR. We are not yet able to reasonably estimate
the expected impact.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2022, our
contingent liabilities regarding IIA grants received by us were in an aggregate amount of $4.9 million. We are further required to comply
with the requirements of the Israeli Encouragement of Industrial Research, Development and Technological Innovation Law, 5744-1984, as
amended, and related regulations, or the Research Law, with respect to those past grants. When a company develops know-how, technology
or products using IIA grants, the terms of these grants and the Research Law restrict the transfer or license of such know-how, and the
transfer of manufacturing or manufacturing rights of such products, technologies or know-how outside of Israel, without the prior approval
of the IIA. Therefore, the discretionary approval of an IIA committee would be required for any transfer or license to third parties inside
or outside of Israel of know how or for the transfer outside of Israel of manufacturing or manufacturing rights related to those aspects
of such technologies. We may not receive those approvals. Furthermore, the IIA may impose certain conditions on any arrangement under
which it permits us to transfer technology or development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer or license of
IIA-supported technology or know-how outside of Israel and the transfer of manufacturing of IIA-supported products, technology or know-how
outside of Israel may involve the payment of significant amounts, depending upon the value of the transferred or licensed technology or
know-how, our research and development expenses, the amount of IIA support, the time of completion of the IIA-supported research project
and other factors. These restrictions and requirements for payment may impair our ability to sell, license or otherwise transfer our technology
assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any product or technology
outside of Israel. Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside of Israel
of technology or know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts that we are
required to pay to the IIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Provisions of Israeli law and our amended and
restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, us, which could prevent a
change of control, even when the terms of such a transaction are favorable to us and our shareholders. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli corporate law regulates
mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving
directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions. For example,
a merger may not be consummated unless at least 50&#160;days have passed from the date on which a merger proposal is filed by each merging
company with the Israel Registrar of Companies and at least 30&#160;days have passed from the date on which the shareholders of both merging
companies have approved the merger. In addition, a majority of each class of securities of the target company must approve a merger. Moreover,
a tender offer for all of a company&#8217;s issued and outstanding shares can only be completed if the acquirer receives positive responses
from the holders of at least 95% of the issued share capital. Completion of the tender offer also requires approval of a majority of the
offerees that do not have a personal interest in the tender offer, unless, following consummation of the tender offer, the acquirer would
hold at least 98% of the Company&#8217;s outstanding shares. Furthermore, the shareholders, including those who indicated their acceptance
of the tender offer, may, at any time within six months following the completion of the tender offer, claim that the consideration for
the acquisition of the shares does not reflect their fair market value, and petition an Israeli court to alter the consideration for the
acquisition accordingly, unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek such
appraisal rights, and the acquirer or the company published all required information with respect to the tender offer prior to the tender
offer&#8217;s response date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 52 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, Israeli tax considerations
may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel
exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent
as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent
on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction
during which sales and dispositions of shares of the participating companies are subject to certain restrictions. Moreover, with respect
to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no
disposition of the shares has occurred. These provisions could delay, prevent or impede an acquisition of us or our merger with another
company, even if such an acquisition or merger would be beneficial to us or to our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>It may be difficult to enforce a judgment of
a U.S. court against us and our executive officers and directors in Israel or the United States, to assert U.S. securities laws claims
in Israel or to serve process on our executive officers and directors and these experts. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated in Israel.
Substantially all of our executive officers and directors reside outside of the United States, and all of our assets and most of the assets
of these persons are located outside of the United States. Therefore, a judgment obtained against us, or any of these persons, including
a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and
may not be enforced by an Israeli court. It also may be difficult for you to effect service of process on these persons in the United
States or to assert U.S. securities law claims in original actions instituted in Israel. Additionally, it may be difficult for an investor,
or any other person or entity, to initiate an action with respect to U.S. securities laws in Israel. Israeli courts may refuse to hear
a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum in which to bring
such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable
to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses,
which can be a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding
case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment against
us in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Your rights and responsibilities as a shareholder
will be governed in key respects by Israeli laws, which differs in some material respects from the rights and responsibilities of shareholders
of U.S. companies. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rights and responsibilities
of the holders of our Ordinary Shares are governed by our amended and restated articles of association and by Israeli law. These rights
and responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S. companies. In particular,
a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing
its obligations towards the company and other shareholders, and to refrain from abusing its power in such company, including, among other
things, in voting at a general meeting of shareholders on matters such as amendments to a company&#8217;s amended and restated articles
of association, increases in a company&#8217;s authorized share capital, mergers and acquisitions and related party transactions requiring
shareholder approval, as well as a general duty to refrain from discriminating against other shareholders. In addition, a shareholder
who is aware that it possesses the power to determine the outcome of a vote at a meeting of the shareholders or to appoint or prevent
the appointment of a director or executive officer in the company has a duty of fairness toward the company. However, Israeli law does
not define the substance of this duty of fairness.<span>&#160;</span>See &#8220;Item 6.C. Board Practices&#8212;
Duties of Shareholders&#8221; for additional information. There is limited case law available to assist us in understanding the nature
of these duties or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities
on holders of our Ordinary Shares that are not typically imposed on shareholders of U.S. companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 53 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The market price of our Ordinary Shares may
be highly volatile, and you may not be able to resell your Ordinary Shares at or above the price you paid.&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading price of our Ordinary
Shares is likely to be volatile. The stock market in general, and the market for pharmaceutical companies in particular, has experienced
extreme volatility that has often been unrelated to the operating performance of particular companies, which has resulted in decreased
stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Broad
market and industry factors, including potentially worsening economic conditions and other adverse effects or developments relating to
the ongoing COVID-19 pandemic, may negatively affect the market price of our Ordinary Shares, regardless of our actual operating performance.
As a result of this volatility, you may not be able to sell your Ordinary Shares at or above the price you paid. The following factors,
in addition to other risk factors described in this section, may have a significant impact on the market price of our Ordinary Shares:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to obtain the approvals necessary to commence further clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unsatisfactory results of clinical trials, whether final or interim, such as the recent results from the SHIELD I trial; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of regulatory approvals or the failure to obtain them, or specific label indications or patient populations for their use, or changes or delays in the regulatory review process; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of therapeutic innovations or new products by us or our competitors; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes or developments in laws or regulations applicable to any candidate product in any of our platforms; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the structure of healthcare payment systems; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any adverse changes to our relationship with manufacturers or suppliers, especially manufacturers of candidate products; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any intellectual property infringement actions in which we may become involved; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements concerning our competitors or the pharmaceutical industry in general; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achievement of expected product sales and profitability or our failure to meet expectations; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our commencement of, or involvement in, litigation; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any major changes in our Board of Directors or management; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">legislation in the United States or any other territory relating to the sale or pricing of pharmaceuticals; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">coordinated buying or selling activity in our Ordinary Shares, including market manipulation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our quarterly operating
results fall below the expectations of investors or securities analysts, the price of our Ordinary Shares could decline substantially.
Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially.
We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication
of our future performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the past, following periods
of volatility in the market price of a company&#8217;s securities, securities class-action litigation often has been instituted against
that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert management&#8217;s
attention and resources, which could seriously harm our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 54 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our business and operations would suffer in
the event of computer system failures, cyber attacks or a deficiency in our cybersecurity. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the implementation
of security measures intended to secure our data against impermissible access and to preserve the integrity and confidentiality of our
data, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware,
natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments
to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or
disruption, particularly through cyber attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists,
has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.
Moreover, following COVID-19 and sometimes due to COVID-19, our employees are <span>frequently</span>
working from their homes and remotely access our IT networks. Such remote working mode creates the risk of attacking the end-point user
stations, connection channels and gateways. If such an event was to occur and cause interruptions in our operations, it could result in
a material disruption of our drug development programs. For example, the loss of clinical trial data from completed or ongoing or planned
clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce
the data. To the extent that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate
disclosure of confidential or proprietary information, we could incur material legal claims and liability, including under data privacy
laws such as the GDPR, damage to our reputation, and the further development of our drug candidates could be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our future success depends in part on our ability
to retain our senior management team and to attract, retain and motivate other qualified personnel. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are highly dependent on
the members of our senior management team. The loss of their services without a proper replacement may adversely impact the achievement
of our objectives. Our employees may leave our employment at any time. Recruiting and retaining other qualified employees, consultants
and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently
a shortage of skilled personnel in our industry, which is likely to continue for the foreseeable future. As a result, competition for
skilled personnel is intense, and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms
given the competition among numerous pharmaceutical companies for individuals with similar skill sets. In addition, failure to succeed
in preclinical studies or clinical trials may make it more challenging to recruit and retain qualified personnel. The inability to recruit
and retain qualified personnel, or the loss of the services of any members of our senior management team without proper replacement, may
impede the progress of our research, development and commercialization objectives. We do not maintain key man insurance for our senior
management team.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We will continue to incur significant increased
costs as a result of operating as a public company in the United States, and our management will be required to devote substantial time
to compliance initiatives. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company whose
Ordinary Shares are listed in the United States, we are subject to an extensive regulatory regime, requiring us, among other things, to
maintain various internal controls and facilities and to prepare and file periodic and current reports and statements, including reports
on the effectiveness of our internal control over financial reporting pursuant to Section&#160;404 of the Sarbanes-Oxley Act of 2002.
Complying with these requirements is costly and time consuming. In the event that we are unable to demonstrate compliance with our obligations
as a public company in a timely manner, or are unable to produce timely or accurate financial statements, we may be subject to sanctions
or investigations by regulatory authorities, such as the SEC or The Nasdaq Global Market, and investors may lose confidence in our operating
results and the price of our Ordinary Shares could decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our independent registered
public accounting firm was not engaged to perform an audit of our internal control over financial reporting, and as long as we remain
an emerging growth company, as such term is defined in the JOBS Act, we will be exempt from the requirement to have an independent registered
public accounting firm perform such audit. Accordingly, no such opinion was expressed or will be expressed any during any such period.
Once we cease to qualify as an emerging growth company our independent registered public accounting firm will be required to attest to
our management&#8217;s annual assessment of the effectiveness of our internal controls over financial reporting, which will entail additional
costs and expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>We have never paid cash dividends on our share
capital, and we do not anticipate paying any cash dividends in the foreseeable future. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends on our Ordinary Shares. We currently anticipate that we will retain future earnings for the development, operation
and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. As a result, capital
appreciation, if any, of our Ordinary Shares will be investors&#8217; sole source of gain for the foreseeable future. In addition, Israeli
law limits our ability to declare and pay dividends, and may subject our dividends to Israeli withholding taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>If securities or industry analysts do not publish
or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations or publish
negative reports regarding our business or our shares, our share price and trading volume could decline. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
Ordinary Shares will be influenced by the research and reports that industry or securities analysts may publish about us, our business,
our market or our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts will cover
us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation regarding our shares,
or provide more favorable relative recommendations about our competitors, our share price would likely decline. If any analyst who may
cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets,
which in turn could cause our share price or trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
4.</b> </span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b> INFORMATION
ON THE COMPANY</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. History and Development of the Company.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated in the
State of Israel on February 28, 2008. Our Ordinary Shares are currently listed for trading on the Nasdaq Global Market under the symbol
&#8220;PYPD.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive offices
are located at 18 Hasivim Street, Petach Tikva 4959376, Israel. Our telephone number in Israel is +972 (74)&#160;719-5700. Our website
address is <i>www.polypid.com</i>. The information contained on our website or available through our website is not incorporated by reference
into and should not be considered a part of this annual report on Form 20-F, and the reference to our website in this annual report on
Form 20-F is an inactive textual reference only. PolyPid Inc. is our agent in the United States, and its address is 372 Franklin Ave.,
P.O. Box 558, Nutley, NJ 07110.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an emerging growth
company, as defined in Section 2(a) of the Securities Act, as implemented under the JOBS Act. As such, we are eligible to, and intend
to, take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not emerging
growth companies including but not limited to not being required to comply with the auditor attestation requirements of the SEC rules
under Section 404 of the Sarbanes-Oxley Act. We could remain an emerging growth company until the earlier of (1) the last day of the fiscal
year (a) following the fifth anniversary of the date of our first sale of common equity securities pursuant to an effective registration
statement under the Securities Act, which was in June 2020, (b) in which we have total annual gross revenue of at least $1.235 billion,
or (c) in which we are deemed to be a large accelerated filer, which means the market value of our Ordinary Shares that is held by non-affiliates
exceeds $700 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt
during the prior three-year period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a foreign private issuer
as defined by the rules under the Securities Act and the Exchange Act. Our status as a foreign private issuer also exempts us from compliance
with certain laws and regulations of the SEC and certain regulations of the Nasdaq Stock Market, including the proxy rules, the short-swing
profits recapture rules, and certain governance requirements such as independent director oversight of the nomination of directors and
executive compensation. In addition, we are not required to file annual, quarterly and current reports and financial statements with the
SEC as frequently or as promptly as U.S. domestic companies registered under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, 2021 and 2020, our
capital expenditures amounted to $2.2 million, $4 million and $0.8 million, respectively. Our current capital expenditures are primarily
for manufacturing facility and equipment, computers, software, research and development equipment and office improvements substantially
all in Israel, and we expect to finance these expenditures primarily from cash on hand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Business Overview.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a Phase&#160;3 clinical-stage
biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using our proprietary
PLEX technology. Our product candidates are designed to address diseases with high unmet medical needs by pairing our PLEX technology
with drugs already approved by the FDA or innovative drug candidates to achieve a novel therapeutic effect. Our PLEX technology is designed
to deliver drugs directly to targeted treated sites in the body at predetermined release rates and predetermined durations ranging from
several days to several months. We believe that our PLEX technology and product candidates have the potential to significantly improve
the management of a variety of medical conditions, including SSIs and cancer. Our lead product candidate, D-PLEX<sub>100</sub>, is in
a pivotal Phase&#160;3 confirmatory trial for the potential approval for prevention of open abdominal SSIs. D-PLEX<sub>100</sub> pairs
our novel proprietary PLEX technology with doxycycline, a first-line, broad spectrum and FDA-approved antibiotic D-PLEX<sub>100</sub>
is administered directly into the surgical site during surgery, and provides a prolonged and continuous release of the broad-spectrum
antibiotic doxycycline, resulting in high local concentration of the drug for a period of 30 days for the prevention of SSIs, including
SSIs caused by standard of care antibiotic-resistant bacteria. Infections resulting from surgery can be fatal and create a significant
public health burden despite the extensive use of systemically administered antibiotics both pre- and post-operatively and other measures
taken to reduce infection risk in the intra-operative setting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The WHO estimates that SSIs
result in up to $10&#160;billion of additional hospital costs per year in the United States alone, and a further &#8364;11&#160;billion
per year in the European Union.<b>&#160;</b>The CDC estimates that SSIs are the most costly HAI type of event in the United States. SSIs
occur in approximately 2% to 5% of all patients undergoing inpatient surgery worldwide and account for 20% of all HAIs in United States.
In their last guidelines, the WHO and the CDC have labeled SSIs as a high priority unmet medical need due to the associated morbidity,
mortality and economic cost burden.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that D-PLEX<sub>100</sub>,
if approved, would be a significant improvement over the current standard of care, which includes systemic administration of antibiotics.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We initiated two Phase&#160;3
trials of D-PLEX<sub>100</sub>, which we refer to as SHIELD I and SHIELD II, for the prevention of abdominal (soft tissue) SSIs in the
third and fourth quarters of 2020, respectively. In May 2021, the FDA agreed in a Type B meeting that a single pivotal Phase 3 study is
sufficient, provided the study results are adequate, for potential approval of a D-PLEX<sub>100</sub> NDA for the prevention of SSIs in
colorectal surgery.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we announced
top-line results from the SHIELD I Phase 3 study of D-PLEX<sub>100</sub>&#160;for the prevention of SSIs in abdominal surgery. SHIELD
I study did not achieve its primary endpoint of reduction in SSIs, re-interventions due to SSIs and mortality: in the ITT population,
the local administration of D-PLEX<sub>100</sub> and SoC (n=485) resulted in a decrease in the primary endpoint of 23% compared to SoC
alone (n=489) (p=0.1520). That said, in a pre-specified subgroup ITT analysis requested by the FDA of a total of 423 subjects with large
incisions (&gt;20 centimeters), the local administration of D-PLEX<sub>100</sub>&#160;resulted in a significant reduction of 54% in the
primary endpoint,&#160;compared to SoC alone (p=0.0032). Within the first 30 days post-surgery, SSIs decreased from 9.7% in the SoC treatment
arm (n=211), as compared to 4.4% in the D-PLEX<sub>100</sub>&#160;treatment arm (n=212). In addition, the SHIELD I study also showed a
34% reduction in the primary endpoint in patients with one or more personal risk factors (post hoc analysis; p=0.047; n=680) compared
to standard of care. The SHIELD I study demonstrated a good safety profile of D-PLEX<sub>100&#160;</sub>with no increase in serious or
severe treatment emergent adverse events compared to standard of care.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 57 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2022, we provided
the FDA with available data from the SHIELD I study as part of a Type D meeting request. Following positive type D meeting communication
with the <span>FDA, which took place in January 2023 on the SHIELD I Phase 3 data, we now have a clear
</span>regulatory pathway towards a potential NDA submission. <span>Based on the data, particularly the
54% reduction observed in the primary endpoint in complex surgeries in a pre-specified subgroup analysis of patients with large open
incisions (p=0.0032, n=423) compared to standard of care, the FDA acknowledged that the SHIELD I results may provide supportive evidence
on this population and recommended that we conduct </span>an additional study to support a potential NDA submission. The FDA stated that
the ongoing SHIELD II study, which to date has enrolled over 200 patients, including approximately 40 patients with the appropriate large
open surgical incisions, could potentially serve as such a study. The <span>FDA also recognized that
</span>D-PLEX<sub>100</sub>&#8217;s <span>proposed indication is for the prevention of infection and
has the potential for wide use. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_002.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><i>Figure 1: SHIELD I
Study Population</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><img alt="" src="image_003.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><i>Figure 2: SHIELD I
Large-Incision Subgroup Analysis</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>SHIELD
II is a prospective, multinational, randomized, double blind Phase 3 trial designed to assess the efficacy and safety of D-PLEX</span><sub>100</sub>
<span>administered concomitantly with SoC, compared to SoC alone arm, in the prevention of post abdominal-surgery
incisional infection in patients undergoing surgeries with incisions greater than 20 cm. The primary endpoint of the trial is measured
by the proportion of subjects with either an SSI event as determined by a blinded and independent adjudication committee, reintervention,
or mortality for any reason within 30 days post-surgery. Patient safety will be monitored for an additional 30 days. The trial will enroll
patients in centers in the United States, Europe and Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SHIELD II patient recruitment
is expected to resume in the second quarter of 2023 with the enrollment of an estimated 550 additional patients. Total
recruitment time into the study is anticipated to be approximately 12 months and top-line results are expected in mid-2024. Unblinded
interim analysis is planned to be conducted once approximately 400 patients complete their 30-day follow-up.

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2019, we reported
topline data from our Phase&#160;2 clinical trial of D-PLEX<sub>100</sub> for the prevention of SSIs in patients undergoing abdominal
(soft tissue) surgery. Patients treated with D-PLEX<sub>100</sub> and the standard of care had a statistically significant reduction
of 59% (p=0.0086) in deep or superficial incisional SSIs or mortality for any reason within 30&#160;days of surgery, which was the primary
endpoint for the trial, as compared to patients who received the standard of care alone. In addition, there was a statistically significant
difference (p=0.0290) in patient deaths within 60&#160;days of surgery, with no deaths observed in the D-PLEX<sub>100</sub> treatment
arm, as compared to five deaths observed in the standard-of-care arm. In this trial, D-PLEX<sub>100</sub> was observed to be generally
well tolerated, with no confirmed drug-related serious adverse events, or SAEs, and did not increase wound healing impairment at the
incision site as compared to the control arm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2018, we reported
data from our Phase&#160;1b/2 clinical trial of D-PLEX<sub>100</sub> for the prevention of sternal SSIs after cardiac surgery. None of
the 58 patients treated with D-PLEX<sub>100</sub> and the standard of care had a sternal infection within 90&#160;days post-surgery, which
was the primary endpoint of the trial, as compared to one patient in the group treated with the standard of care alone, representing a
4.3% infection rate. In this trial, D-PLEX<sub>100</sub> was observed to be generally well tolerated, with no drug-related SAEs and no
drug-related wound healing issues at the incision site. The results of this trial were published in the <i>Journal of Cardiac Surgery</i>
in October 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019, we initiated
a potentially pivotal Phase&#160;3 clinical trial of D-PLEX<sub>100</sub> for the prevention of post-cardiac sternal (bone) SSIs, and
we enrolled the first patient in February 2020. We paused enrollment in this trial as we determined to initially focus on abdominal (soft
tissue) surgeries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2020, we held
an end of Phase&#160;2 meeting with the FDA and in May 2021 we held a Type B meeting with the FDA to discuss our D-PLEX<sub>100</sub>
development plans following which the FDA agreed that a single pivotal Phase 3 study is sufficient, provided the study results are adequate,
for potential approval of a D-PLEX<sub>100</sub> NDA for the prevention of SSIs in colorectal surgery. Following this agreement, we determined
to focus on our SHIELD I clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
intend to pursue a broad label for D-PLEX<sub>100</sub> for the prevention of SSIs, the scope of which will depend on the clinical data
generated from our Phase&#160;3 clinical trials and discussions with the FDA and the EMA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to seek approval
of D-PLEX<sub>100</sub> under Section&#160;505(b)(2) of the Federal Food, Drug and Cosmetic Act, or FFDCA, which provides an abbreviated
pathway for marketing approval by the FDA in the United States, and will seek approval under the comparable hybrid application pathway
in the European Union. Such abbreviated approval pathways may not lead to a faster development or review process compared to traditional
approval pathways and do not increase the likelihood that D-PLEX<sub>100</sub> will receive regulatory approval in the United States or
the European Union. We received three QIDP designations from the FDA for D-PLEX<sub>100</sub> for the prevention of post-abdominal surgery
incisional infection, for the prevention of sternal wound infection post-cardiac surgery, and for prevention of post-colorectal SSIs.
The QIDP designation from the FDA confers, among other benefits, a five-year extension to any period of non-patent exclusivity awarded
upon approval, such as a three-year period of exclusivity for new clinical investigations of previously approved products, which we expect
for D-PLEX<sub>100</sub>, if approved. Additionally, in November 2018 we received Fast Track Designation from the FDA for D-PLEX<sub>100</sub>
for topical use for the prevention of sternal infections post-cardiac surgery, in July 2020, for the prevention of post-abdominal surgery
incisional infections and in September 2021 for prevention of post-colorectal SSIs. Fast Track Designation could potentially expedite
the FDA&#8217;s review of D-PLEX<sub>100</sub> and enables early and frequent communication with the FDA as we continue to generate data
from our ongoing and planned clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2020, we received
breakthrough therapy designation from the FDA for the prevention of SSIs in patients undergoing elective colorectal surgery based on the
clinical results of our Phase 2 trial. The breakthrough therapy designation is granted based on preliminary clinical evidence indicating
that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The breakthrough
therapy designation is designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening
condition so patients may have access to therapies through the FDA approval as soon as possible. The breakthrough therapy designation
allows for frequent discussions with the FDA and ensures that a dedicated senior team from the FDA reviews our product filling.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Europe, on August 2, 2022,
we entered into a license, distribution and supply agreement with Mercury Pharma Group Limited, under the trade name Advanz Pharma Holdings,
or Advanz, pursuant to which we granted the exclusive right to Advanz to market, advertise, promote, distribute, offer for sale, sell
and import our product D-PLEX<sub>100</sub> for the prevention of (i) post abdominal surgery incisional infection and/or (ii) post cardiac
surgery sternal infection in the European Economic Area and the United Kingdom. The term of the license is until the later of December
31, 2035, or 10 years after the first commercial sale of D-PLEX<sub>100</sub>. The license is also terminable by either party under certain
limited circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Under
the terms of the agreement, we received an upfront payment immediately upon signing and are entitled to additional development-related
milestones for a total of up to &#8364;23 million (approximately $24.4 million) as follows: upfront payment of &#8364;2.5 million (approximately
$2.6 million), up to &#8364;12.25 million (approximately $13 million) contingent upon positive top-line results of our SHIELD I Phase 3
study and additional development-related milestones of up to &#8364;8.25 million (approximately $8.7 million). Upon commercialization,
we will receive up to &#8364;87 million (approximately $92.2 million) in sales-related milestones. In addition, we will also supply D-PLEX<sub>100</sub>&#160;to
Advanz for a transfer price and will be entitled to royalties on net sales in double-digit percentages of up to mid-twenties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we received
confirmation from the EMA that D-PLEX<sub>100</sub> is eligible for submission of a MAA in the EU under the EMA&#8217;s centralized procedure.
The centralized process eligibility is granted to D-PLEX<sub>100</sub> under the Therapeutic Innovation criteria which underscores that
D-PLEX<sub>100</sub> potentially provides a new alternative to patients in preventing post abdominal SSIs.&#160;As we have done with the
FDA in the United States, we are currently preparing for expected near-term interactions with the European regulatory authorities regarding
D-PLEX<sub>100</sub>, which are anticipated in the first half of 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to our lead program
D-PLEX<sub>100</sub>, our pipeline includes an early-stage oncology program, OncoPLEX, PolyPid&#8217;s lead intra-tumoral cancer therapy
drug candidate. OncoPLEX utilizes our PLEX technology to provide controlled local exposure to docetaxel, one of the most widely used chemotherapy
agents, directly at the tumor site for several weeks to potentially reduce local tumor reoccurrence, the potential spreading of cancer
cells, and ultimately improve the overall survival rate of cancer patients. Local delivery of drugs directly into the tumor site, especially
in difficult to access tumors such as in the brain, may significantly improve the clinical outcome. The OncoPLEX intra-tumoral cancer
therapy program has been evaluated successfully in various animal tumor models, including colon carcinoma and glioblastoma. We are currently
finalizing CMC processes for OncoPLEX as we continue our efforts to begin clinical development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to expand research
collaborations with biopharmaceutical companies leveraging our PLEX Technology. SHIELD I pharmacokinetic data validated the PLEX technology
platform in a large clinical trial, providing local and controlled release of drug molecules directly at the disease target organ over
a pre-determined period of time. PLEX can be paired with a wide variety of marketed drugs or product candidates, including small molecules,
peptides, antibodies and nucleic acid-based drugs. Pairing biopharmaceutical companies approved drugs or product candidates with PLEX
has the potential to overcome limitations in terms of efficacy or safety due to their systemic delivery and potentially extend the drug&#8217;s
clinical benefit and lifecycle before and after patent expiration. We intend to further engage in discussions with leading biopharmaceutical
companies regarding licensing our PLEX technology for potential application in various therapeutic areas, including oncology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 60 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>We
continue to invest in our state-of-the-art, sterile manufacturing facility that is cGMP certified by</span> the <span>IMOH
and inspected by an EU-qualified person enabling cGMP manufacturing of D-PLEX</span><sub>100</sub> <span>for
our SHIELD II trial. We have recently successfully completed the expansion of our manufacturing capabilities and are currently in final
stage of commercial process validation. We intend to use this manufacturing capacity as the basis to build a fully integrated biopharmaceutical
company, supported by our in-house research and development and regulatory team and our anticipated commercial infrastructure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Pipeline</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_004.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our PLEX technology consists
of a proprietary matrix of several thousand layers of chemically inactive and biocompatible polymers and lipids that physically embed
the drug within the layers. A drug stored within the PLEX layers is released over time in a controlled manner and in customizable, predetermined
amounts at the local site where it is administered. PLEX technology is designed to protect the embedded medication from the natural enzymes
and other biochemicals in the body that would otherwise degrade or alter the drug. Over time, natural hydration in the body disintegrates
the layers of PLEX, from the outer layer to the inner layers, which triggers a release of the medicine in an unmodified, active form.
We believe that these characteristics may enable our PLEX product candidates to be efficacious using only a small fraction of the medicines
required in systemic administration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our PLEX platform
technology may have broad therapeutic application for other localized medical conditions. Because our PLEX technology is designed to be
agnostic to the nature and size of the underlying drug, we believe it has the potential to be paired with a wide variety of currently
marketed drugs or product candidates in development, including small molecules, peptides, antibodies and other proteins, as well as nucleic
acid-based APIs, to create novel therapies in a broad range of locally delivered applications. We are pursuing research and development
programs for our PLEX platform in a variety of other potential indications where we have identified a targeted active pharmaceutical ingredient,
or API, for use with our PLEX technology, including for the treatment of cancer, inflammation and pain. We will consider licensing rights
to our PLEX technology for use with various biologics and small molecules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 26, 2023, we have
146 issued patents, including utility and composition of matter patents. Additionally, we have five patent applications that have been
allowed in Canada, New-Zealand and in the Philippines, and 10 pending patent applications in the United States, China, Europe, India,
Singapore, South Korea and Thailand, and one published PCT application. Our issued patents expire between 2029 and 2035.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 61 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>State-of-the-Art
Manufacturing Facility </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently lease approximately
18,000 square foot, state-of-the-art, sterile manufacturing facility in Israel to enhance supply chain control, increase our supply capacity
and meet clinical demand for our ongoing and planned clinical trials of D-PLEX<sub>100</sub>, as well as for initial commercial demand
if D-PLEX<sub>100</sub> is approved. The facility is designed to comply with the FDA&#8217;s current good manufacturing practice, or cGMP,
regulations, and EMA regulations. In 2019, the facility was cGMP certified by the IMOH and inspected by an EU-qualified person, enabling
cGMP manufacturing of D-PLEX<sub>100 </sub>for our ongoing and planned potentially pivotal Phase&#160;3 clinical trials to be conducted
in the United States and Europe. The manufacturing process was scaled up to increase our commercial supply capacity to meet the expected
market demand for at least 48 months from product launch.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our goal is to leverage our
PLEX technology to develop and commercialize a pipeline of potentially transformative therapies for the local and prolonged delivery of
drugs to address diseases with high unmet medical needs. The key elements of our strategy are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-underline-color: black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Successfully complete clinical development of D-PLEX<sub>100</sub> for the prevention of SSIs.</i></b>&#160;We completed the SHIELD I trial. Patient recruitment under the SHIELD II trial for the prevention of open abdominal SSIs is expected to resume in the second quarter of 2023 with the enrollment of an estimated 550 additional patients. <span>Total recruitment time into the study, once it resumes, is anticipated to be approximately 12 months and top-line results are expected in mid-2024. Unblinded interim analysis is planned to be conducted once approximately 400 patients complete their 30-day follow-up. </span>We intend to pursue a broad label for D-PLEX<sub>100</sub> for the prevention of SSIs, the scope of which will depend on the clinical data generated from our clinical trials and discussions with the FDA and the EMA. We may also seek regulatory approval of D-PLEX<sub>100</sub> outside of the United States and Europe. &#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pursue expedited regulatory pathways for our product candidates.</i></b>&#160;We are pursuing expedited pathways to approval for our portfolio of product candidates. PLEX is paired with unmodified FDA- and/or EMA-approved drugs with established clinical safety, efficacy and tolerability. Additionally, the polymers and lipids that we use in PLEX have been used in other medical products that have been approved by the FDA and/or the EMA. Accordingly, we will pursue expedited clinical development and make regulatory submissions for our product candidates, including D-PLEX<sub>100</sub>, that allow us to rely in part on previous findings of safety and efficacy for the API, including the Section&#160;505(b)(2) approval pathway in the United States and the comparable hybrid application pathway in the European Union. Further, D-PLEX<sub>100</sub> has received three QIDP designations from the FDA for the prevention of post-abdominal surgery incisional infection, for the prevention of sternal wound infection post-cardiac surgery and for prevention of post-colorectal surgical site infections, which will provide an increased level of communication with the FDA during the development process. We also received the FDA&#8217;s Fast Track Designation for D-PLEX<sub>100</sub> for topical use for the prevention of post-cardiac surgery sternal infections in November 2018, in July 2020 for the prevention of post abdominal surgery incisional infections and in September 2021 for prevention of post-colorectal surgical site infections, which could potentially expedite the FDA&#8217;s review of our NDA. We obtained breakthrough therapy designation in November 2020 for D-PLEX<sub>100</sub> for the prevention of surgical site infections in patients undergoing elective colorectal surgery.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Execute on our go-to-market commercial strategy.</i></b>&#160;If approved, we intend to launch D-PLEX<sub>100</sub>, and other future product candidates, in the United States using our commercial capabilities. We are also exploring potential partnering opportunities with leading pharmaceutical companies focusing on hospital business to maximize our commercial success and launch of any approved products in the United States. We believe that the cost-effectiveness and potential clinical benefits of D-PLEX<sub>100</sub> will support its commercial launch under existing Medicare rates given the associated mortality, morbidity and cost burden of SSIs and the associated penalties imposed on hospital reimbursement from the CMS. In addition, we believe that there may be opportunities for reimbursement for D-PLEX<sub>100</sub> under CMS&#8217;s New Technology Add-on Payment program. Outside of the United States, we intend to find a suitable partner or partners to launch our products in markets where respective commercial coverage is better served through such a partnership, as we did with the agreement signed with Advanz in August 2022 for the exclusive license, distribution and supply D-PLEX<sub>100</sub> in the European Economic Area and the United Kingdom.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expand our product pipeline for additional indications using our PLEX technology.</i></b>&#160;In addition to the development of D-PLEX<sub>100</sub> for the prevention of SSIs and OncoPLEX for treatment of solid tumors,&#160;PLEX has the potential for the prevention or treatment of other important, localized medical conditions. We intend to maximize the commercial potential of PLEX by exploring these additional indications, either independently or through collaborations with other biopharmaceutical companies.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pursue research collaborations with biopharmaceutical companies.</i></b>&#160;We believe that our PLEX technology can be paired with a wide variety of marketed drugs or product candidates, including small molecules, peptides, antibodies and nucleic acid-based drugs. Many leading biopharmaceutical companies have marketed drugs or product candidates in development that have limited efficacy or safety due to systemic delivery and owing to potentially poor drug penetration from the blood stream into the needed organ or other target tissues, or viability for systemic administration due to instability, toxicity and cost. Pairing these drugs or product candidates with PLEX has the potential to address these limitations and potentially extend the drug&#8217;s clinical benefit and lifecycle before and after patent expiration.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Build a fully integrated biopharmaceutical company utilizing our manufacturing facility.</i></b> Our state-of-the-art, sterile manufacturing facility is cGMP certified by the IMOH and inspected by a European Union-qualified person, enabling cGMP manufacturing of D-PLEX<sub>100</sub> for our ongoing and planned Phase&#160;3 clinical trials&#160;in the United States, Europe and Israel. Our manufacturing facility will serve to enhance supply chain processes, increase our supply capacity and meet clinical demand for our ongoing and planned clinical trials of D-PLEX<sub>100</sub>. We estimate that our facility will meet commercial demand for at least the first 48&#160;months following a commercial launch of D-PLEX<sub>100</sub>, if approved. We intend to use this capacity as the basis to build a fully integrated biopharmaceutical company, supported by our in-house research and development and regulatory team and our anticipated commercial infrastructure. If necessary to meet further commercial demand in the future, we may expand our manufacturing capabilities or employ third-party contract manufacturing organizations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>The Problem: Limitations
to Current Drug Delivery Systems </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The systemic administration
of drugs may have significant disadvantages for the treatment of localized medical conditions in the body, including limited efficacy
due to poor penetration from the blood stream into the needed organ or other target tissues and challenges related to sensitivity to blood
factors. These limitations are especially challenging for the prevention of SSIs during surgeries, as the surgical incision itself creates
an interruption of the blood stream and therefore limits the local concentration of administered prophylactic systemic antibiotic into
the surgical site. This limited efficacy often results in the need to use a significantly higher quantity of drugs over a prolonged period
of time, which can result in substantial side effects. Additionally, systemic administration can be associated with complexities of drug-drug
interactions in the context of polypharmacy for patients with comorbid conditions. In the case of antibiotics, systemic administration
results in challenges related to the emergence of antibiotic resistance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Localized delivery of medications
for site-specific conditions may have significant advantages over systemic administration because it has the potential to increase the
efficacy and clinical benefit of the treatment. Localized delivery may also reduce the risk of overall toxicity and adverse side effects,
improve patient compliance and enable a much lower amount of medicine to be used in treatment. In order to address the limitations of
systemic administration to treat localized medical conditions, an effective localized drug delivery system must be able to selectively
deliver the needed medication to the specific target site, ensure the appropriate concentration needed and release the active medication
in a controlled, consistent method over the entire desired treatment period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 63 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Existing localized treatments,
including extended release formulations based on polymer-only or lipid-only technologies, such as liposomal-based technologies, frequently
suffer from one or more of the following limitations:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Short release periods.</i></b>&#160;An effective regimen to treat serious localized medical conditions, including infections, often needs to span weeks. For example, in the case of post-operative wound management, bacteria have the potential to proliferate in the wound, where blood supply is restricted. Most local delivery systems are able to generate sustained, local concentrations that are effective for only up to several days; however, the post-operative recovery phase may span for a longer period of time. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lack of controlled drug release rates.</i></b>&#160;For a localized delivery system to be effective, it must deliver a non-toxic but adequate and constant dosage of the API to the target site throughout the release period. Current systems, often based only on polymers or only on lipids, have limited ability to control drug release rates. As a result, these systems often release the drug with an initial high burst manner, followed by a rapid decline in the release rate, ultimately generating low local drug concentration. This drug release profile is both less effective than a steadier more controlled delivery approach and may cause safety issues. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Active drug degradation.</i></b>&#160;Drugs often need to be isolated from body fluids to prevent rapid degradation and chemical changes to the underlying drug. In order to effectively administer such drugs locally over prolonged periods, the implanted drug reservoir needs to be protected until released, ideally in a non-hydrating form. We are not aware of any biodegradable, localized drug delivery systems in the market that can protect drugs from hydration inside the body over prolonged periods and subsequently release them unaltered in their active forms. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Susceptibility to drug migration.</i></b>&#160;Locally administered drugs reservoirs are more effective when they are anchored at the treatment site and unable to move or migrate in the body after application. Many localized delivery systems are susceptible to migration away from the treatment site after application. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Potential chemical modifications to underlying drug.</i></b>&#160;Currently developed localized delivery systems can modify or form chemical bonds with the underlying drug, which may alter its mechanism of action, potentially impeding the regulatory process for approval and making development longer and more expensive. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Limited application to different drug types.</i></b>&#160;Many localized delivery systems are suited only to a particular drug, or class of drugs, and are therefore limited in their broader clinical scope. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Difficult to use.</i></b>&#160;Localized delivery systems may require extensive training in their application and are difficult to use. Improper use can adversely affect the therapeutic benefit and physician acceptance of the product. &#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These disadvantages are significantly
challenging for the management of SSIs, where the controlled and prolonged local delivery of a drug is likely to be more effective in
preventing and managing an infection than a release profile of an initial high burst of drug over a shorter duration. While we believe
that localized drug delivery systems are well suited for the management of SSIs, it is important for these systems to overcome these limitations
in order to change the treatment paradigm for infection management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These limitations are particularly
problematic in treating infection caused by bacteria that are resistant to currently available treatments, such as <i>methicillin-resistant
Staphylococcus aureus</i>, or MRSA. The inability to generate a sufficiently high local concentration of a drug for an extended period
of time limits the drug&#8217;s effectiveness in treating antibiotic-resistant bacterial infections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Our Solution:
PLEX Technology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our PLEX technology is designed
to overcome the limitations of both systemic administration and current localized delivery systems. PLEX consists of a proprietary matrix
of several thousand alternating layers of chemically-inactive and biocompatible polymers and lipids that physically embed an active medication
in a protected reservoir between the layers. The technology is designed to enable localized drug delivery at customizable, predetermined
release rates and durations directly at the target site over periods ranging from several days to several months. For example, D-PLEX<sub>100</sub>
consists of approximately ten thousand layers of biodegradable polymers and lipids. Medications stored between the PLEX matrix layers
are released over time in a controlled manner and in customizable, predetermined amounts by the gradual disintegration of the layers,
from the outer layer to the inner layers. PLEX is designed to protect the embedded drug from the body&#8217;s natural hydration and enzymes
that would otherwise degrade or alter the underlying drug. Over time, natural hydration in the body disintegrates the outer layers of
PLEX, which triggers release of the drug in an unmodified active form, similar to continuous direct administration, as illustrated below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_005.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe PLEX has a number
of key design benefits:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Constant, predetermined drug release rates over prolonged periods.</i></b>&#160;PLEX enables the pre-designed constant local release of active medication over a customizable, predetermined period to optimize the drug&#8217;s clinical impact. This localized, targeted delivery is designed to generate effective and non-toxic concentration of the medications to reach clinical benefits not attainable by the systemic route. The release rate and period can be customized to range from a few days to several months based on the number of layers and the disintegration rate of the layers, as illustrated below: </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_006.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Direct access to, and penetration of, difficult-to-reach tissue.</i></b>&#160;Application of our PLEX product candidates may provide long lasting treatment even in challenging medical conditions or in tissues that are not easily or safely accessible using systemic or topical modalities. This includes surgical sites or other tissues with limited or interrupted blood supply. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anchored to the treatment site.</i></b>&#160;PLEX physically embeds an API in a manner that anchors it to a specific location in the body and allows for administration where the medication is needed. Due to their particle mass, our product candidates have not been observed to move or migrate once applied to the intended treatment site. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Potential for improved drug safety profile.</i></b>&#160;Our PLEX product candidates can use a fraction of the medication required in systemic administration of currently marketed therapies, and these medications are physically embedded to minimize exposure to body fluids. Through controlled release, PLEX is designed to generate local concentrations of the needed medication that are therapeutically effective but not toxic. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>No chemical modification required to the embedded drug.</i></b>&#160;PLEX embedding does not require any chemical changes to the drug, which we believe will streamline our development process by allowing us to rely in part on prior studies of safety and efficacy and maintain the already proven mechanism of action. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Biocompatible.</i></b>&#160;The PLEX matrix gradually disintegrates in the body at predetermined rates, eliminating the need for additional medical procedures to remove the medication reservoir once depleted. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Easy to use.</i></b>&#160;D-PLEX<sub>100</sub> is supplied as a sterile powder that can be administered locally as a powder or paste during surgery directly to a variety of tissues and solid organs, as illustrated below. No additional training is required for the surgeon or medical provider. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_007.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Broad potential applicability.</i></b>&#160;Because PLEX is designed to be agnostic to the nature and size of the underlying drug, and no chemical bonds develop between the embedded medication and the PLEX components, we believe PLEX can be used for the improvement of a wide variety of medicines, including small molecules, peptides, proteins and other nucleic acids-based drugs. In our research and development programs, we have paired PLEX with small molecules, proteins, antibodies, peptides, nucleic acids-based drugs and growth factors. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Efficient and scalable manufacturing process.</i></b>&#160;Our PLEX product candidates are manufactured using a scalable process with well-defined operations. We believe that this highly specialized and precisely controlled manufacturing process enables us to manufacture product candidates reproducibly and efficiently for clinical and commercial applications. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 66 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Benefits of D-PLEX
for the Prevention of SSIs </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Doxycycline received FDA approval
in 1967 and is on the WHO&#8217;s Essential Medicines List for drugs deemed to be among the safest and most effective for addressing important
public health needs today. Doxycycline has been safely used for decades in millions of patients globally and has the following additional
advantages over many other antibiotics:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">broad spectrum of anti-infective activity against both gram-positive and gram-negative bacteria; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">highly effective against <i>Staphylococcus aureus</i>, one of the most common bacteria associated with SSIs; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potent against many MRSA strains; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">good tissue and cell penetration. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D-PLEX<sub>100</sub> is designed
to overcome the limitations of prophylactic systemic antibiotics in terms of activity and penetration into the surgical site because of
the surgical incision that impairs the local vascularization and creates an interruption of the blood stream.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D-PLEX<sub>100</sub> is designed
to prevent SSIs by releasing doxycycline locally to the surgical site at predetermined release rates and durations for thirty days. The
plasma concentration of doxycycline following treatment with D-PLEX<sub>100</sub> is lower than the plasma concentration following the
commonly used daily dose of orally administered doxycycline. We believe that this prolonged delivery following a single administration
and subsequent high local concentrations of the antibiotic supersedes any existing antibiotic delivery system, and as such may offer advantages
over systemic treatments in the prevention of SSIs, including against many antibiotic-resistant bacterial strains. We believe that, by
combining doxycycline with PLEX, D-PLEX<sub>100</sub> has the potential to overcome these limitations and deliver significant advantages
in the prevention of SSIs, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">localized, targeted delivery of an antibiotic at therapeutically effective concentrations for thirty days; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significantly lower amounts of drug required, which may improve safety and reduce overall toxicity and adverse side effects due to lower systemic exposure; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applicability to a wide range of bacteria strains that are considered resistant to commonly used antibiotics, including vancomycin-resistant bacteria, MRSA and doxycycline-resistant bacteria; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased penetration and access to the site of infection; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">simplicity of administration during surgery that requires no additional training; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">biodegradability of the technology components, such that no further procedures are required to remove the delivery system; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">minimized undesirable changes to the patient&#8217;s microbiome; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improved patient compliance. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D-PLEX<sub>100</sub> has the
potential to positively impact the treatment paradigm for SSIs. For example, we have observed in our clinical trials that surgeons applying
D-PLEX<sub>100</sub> directly to an open wound during an initial surgery avoided repeated surgical interventions to treat an active infection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, we believe D-PLEX<sub>100</sub>
has the potential to treat antibiotic-resistant bacterial infections, where the required concentrations of drugs to overcome the infection
cannot be delivered safely via systemic administration. In three investigator-initiated compassionate use cases, patients with severe
bone bacterial infections, including MRSA, were treated with D-PLEX<sub>100</sub> or D-PLEX<sub>1000</sub>, a predecessor product candidate
to D-PLEX<sub>100</sub>. After a single application of D-PLEX, the infection was eradicated in all patients. In preclinical studies, we
also observed that a single application of D-PLEX<sub>100</sub> substantially reduced MRSA and vancomycin-resistant bacterial infections
in surgical sites. Moreover, because it uses a smaller dose of doxycycline and only applied locally, we believe that D-PLEX<sub>100</sub>
should not contribute to the growing worldwide problem of antibiotic-resistant bacteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>The Burdens of
SSIs </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Hospital acquired infections,
or HAIs, are infections that patients acquire when receiving medical treatment in a healthcare facility. According to the WHO, HAIs are
the most frequent adverse event affecting patient safety worldwide. SSIs are the most common HAI in the United States and occur in approximately
2% to 5% of all patients undergoing inpatient surgery worldwide despite accepted antibiotic strategies intended to prevent infection.
However, these figures are likely underestimated for a number of reasons, including surgeon underreporting and negative reimbursement
implications, and because approximately 50% of SSIs become evident only after a patient has been discharged. Further, the incidence and
morbidity of SSIs may differ based on the surgical procedure performed and underlying patient risk factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SSIs prolong patient recovery
and cause a substantial increase in the clinical and economic burdens of surgery, due to longer hospital stays, as well as increased costs
related to diagnostic tests and management of the infection. Certain patients may require readmission, subsequent surgeries and other
interventions, as well as further outpatient care, due to SSIs. According to the WHO, SSIs account for an estimated $10&#160;billion of
incremental hospital costs per year in the United States and &#8364;11&#160;billion per year in the European Union. Directly attributable
costs of SSIs range from approximately $11,000 to $26,000 per infection. In more complex infections involving a prosthetic joint or an
antimicrobial-resistant organism, the costs per case can exceed $90,000. SSIs are associated with approximately seven to eleven additional
post-operative hospital days, and patients with an SSI have a two to eleven times increased risk of death compared to infection-free patients.
Following discharge from the hospital, SSI patients may also require healthcare from other community care services, further contributing
to the overall economic burden of the infection. The CDC estimates that the financial costs of treating SSIs will continue to increase,
both because more surgeries are being performed and because surgical patients present with increasingly complex comorbidities. Moreover,
in the United States, CMS tracks SSI rates, particularly those following hysterectomies and colorectal resection surgeries, and are increasingly
using these statistics to deny reimbursement claims for certain SSIs or reduce total annual CMS payments for hospitals that CMS deems
to not meet certain quality metrics for the prevention of infection. CMS also publishes the SSI incidence rate for hospitals, and, consequently,
hospitals have economic and reputational, in addition to human, incentives to prevent SSIs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 68 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><img alt="" src="image_008.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><i>Figure 4: Our Initial
Focus: Enhancing Post-Operative SSI Prevention</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_009.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><i>Figure 5: Key CMS Programs
are Strong Drivers for D-PLEX<sub>100</sub></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the high incidence
of SSIs, a large proportion of SSIs are estimated to be preventable with the use of evidence-based measures. The prevention of SSIs is
complex and requires the implementation of a range of prevention and treatment approaches before, during and after surgery. Most significantly,
the WHO, CDC and other health organizations recommend the use of systemic and antiseptic measures prior to surgery to help prevent SSIs;
however, systemic administration of antibiotics comes with the risk of further development of antibiotic-resistant bacteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 69 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Health Economic
Benefits of D-PLEX<sub>100</sub></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that D-PLEX<sub>100</sub>,
if approved, may provide significant health economic benefits that play an important role in formulary decision making. Members of our
management team have experience in applying health economic outcomes research to support the launch of successful commercial products.
Our goal is to work directly with hospital customers, group purchasing organizations, integrated health networks, third-party payors,
quality improvement organizations and key opinion leaders in the field of SSI prevention to deliver data showing the potential for demonstrable
pharmacoeconomic benefits from the use of D-PLEX<sub>100</sub>, if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Reimbursement for surgical
procedures is typically capitated or fixed by third-party payors based on the specific surgical procedure performed. However, for many
patients undergoing high-risk surgeries or those with co-morbidities, the incidence of SSIs remains high, potentially leading to significant
healthcare cost burdens relative to the capitated reimbursement related to prolonged lengths of stay in the hospital, readmissions and
additional surgical procedures and other interventions due to the infection. In addition to the direct cost of SSIs, the prolonged length
of stay impacts the hospital&#8217;s capacity and its ability to admit new patients. Furthermore, hospitals continue to focus on quality
improvements to reduce SSIs to support optimal reimbursement and reduced penalties under CMS initiatives, such as the Hospital Acquired
Condition Reduction Program, Hospital Readmission Reduction Program and the Hospital Value-Based Purchasing Program. Following discharge
from the hospital, patients with an SSI may also rely on healthcare from other community care services, which further contributes to the
overall economic burden of the infection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D-PLEX<sub>100</sub> is designed
to be applied directly to the surgical site during the initial surgery and is intended to prevent SSIs and improve associated mortality
and morbidity, with potential broader healthcare economic benefits by reducing lengths of stay in the hospital, readmissions and additional
surgical and other interventions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, in our Phase&#160;1b/2
clinical trial of D-PLEX<sub>100</sub> for the prevention of sternal SSIs after cardiac surgery, we observed that patients treated with
D-PLEX<sub>100</sub> plus the standard of care had a 67% reduction in sternal wound discharge within 90&#160;days post-surgery, as compared
to the control arm. We also conducted a post-hoc analysis, which showed an 85% reduction in patients who were treated with intravenous
antibiotics due to sternum wound discharge within 90&#160;days post-surgery, as compared to the control arm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to complete pivotal
Phase&#160;3 trials in the abdominal (soft tissue) and sternal (bone) surgery (the latter being currently paused) settings. In such trials,
we plan to evaluate health economic outcomes in order to generate further evidence to potentially support approval by the FDA and EMA
and, if D-PLEX<sub>100</sub> is approved, broad adoption among healthcare providers and third-party payors. We intend to further support
any such data with publications and post-marketing studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Our D-PLEX<sub>100</sub>
Market Opportunity </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are initially focused on
developing D-PLEX<sub>100</sub> for the prevention of SSIs, where we believe there is a high unmet medical need, especially in surgeries
that are at high-risk for infection or infection-related complications. Further, patients with co-morbidities, including those who are
diabetic, obese, smokers, immunocompromised, aged 60 or over and those who are undergoing surgeries with a longer duration or a longer
incision size, are particularly at risk for SSI-related complications, even if they are not undergoing high-risk surgeries. We believe
that D-PLEX<sub>100</sub>, if approved, also has the potential to address the needs of these patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>SSIs in Soft
Tissue Surgeries</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SSIs are one of the most frequent
complications in abdominal surgeries, and they represent a significant cause of mortality and morbidity. SSIs occur in approximately 5%
to 30% of soft tissue surgeries, including approximately 10% to 15% of open abdominal surgeries, which represent the majority of the &#8220;Selected
Gastrointestinal Surgeries&#8221; below. Patients undergoing colorectal surgeries are at particularly high risk of developing SSIs because
of the high risk of additional bacterial contamination originating from the operated gastrointestinal organs. Abdominal SSIs are associated
with an average of 18&#160;additional post-operative hospital days. Patients undergoing abdominal surgery and that are subjected to an
SSI are at greater risk of additional complications such as hernias, which can significantly affect health outcomes and require additional
corrective surgery.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below provides the
estimated sizes of our soft tissue surgery addressable market opportunity in selected gastrointestinal surgeries and selected gynecological
and urologic surgeries in the United States and the EU-5, which, for purposes of the following data, includes France, Germany, Italy,
Spain and the United Kingdom based on the number of procedures performed in 2019 according to IQVIA database as well as the rest of the
world, or ROW, which, for purposes of the following data, includes India, China, Brazil and Japan, based on the number of procedures performed
in 2017, according to a study we commissioned from Life Science Intelligence,&#160;Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Surgeries</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">Selected Gastrointestinal Surgeries</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 20pt">United States (2019)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,420,605</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">EU-5 (2019)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,110,556</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">ROW (2017)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,789,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Total Gastrointestinal Surgeries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,320,961</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left; text-indent: -10pt; padding-left: 10pt">Selected Gynecological and Urologic Surgeries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">United States (2019)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,445,405</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">EU-5 (2019)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,022,218</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">ROW (2017)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">827,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Total Gynecological and Urologic Surgeries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,294,823</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>SSIs in Bone
Surgeries </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the context of cardiac
surgeries, SSIs can occur in 5% to 8% of procedures but carry a mortality rate of up to 40% for deep sternal wound infections, which are
more difficult to treat than superficial infections. Deep sternal wound SSIs are associated with an average of 35 post-operative hospital
days, compared with a mean of 11&#160;days for infection-free patients. The cost of care for a patient that develops a deep sternal wound
SSI can be as much as three times greater than the cost of care for an infection-free patient.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the context of orthopedic
surgeries, SSIs can occur in 0.5% to 4.0% of primary hip, knee and spine surgery and in 10% to 15% of general trauma and open fracture
surgery. Orthopedic SSIs are difficult to treat and associated with lifelong infection recurrence risk of 10% to 20%, including MRSA infections.
Further, bone healing may also be impaired, which can result in disabling complications, including amputation. Orthopedic SSIs have been
estimated to prolong total hospital stay by a median of two weeks per patient, approximately double readmission rates and increase healthcare
costs by more than 300% compared to infection-free patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 71 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below provides the
estimated sizes of our bone surgery addressable market opportunity in open heart surgeries and selected orthopedic surgeries, including
both primary and revision knee and hip replacements, open fractures and spine fusions, in the United States and the EU-5 based on the
number of procedures performed in 2019 according to IQVIA database as well as the ROW, based on the number of procedures performed in
2017, according to a study we commissioned from Life Science Intelligence,&#160;Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Surgeries</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">Open Sternum Surgeries</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 20pt">United States (2019)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">474,968</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">EU-5 (2019)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">346,331</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">ROW (2017)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">441,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt">Total Sternum Surgeries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,262,299</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left; text-indent: -10pt; padding-left: 10pt">Selected Orthopedic Surgeries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">United States (2019)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,824,213</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 20pt">EU-5 (2019)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,278,020</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">ROW (2017)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,922,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total Orthopedic Surgeries</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,024,213</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TOTAL D-PLEX<sub>100</sub> global addressable market</b></span></td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">30,902,296</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Clinical Development
of D-PLEX<sub>100 </sub></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Completed Clinical
Trials of D-PLEX<sub>100</sub> for the Prevention of SSIs </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Phase&#160;2 Clinical
Trial for D-PLEX</i><sub>100</sub> <i>in the Prevention of SSIs after Abdominal (Soft Tissue) Surgery </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2019, we reported
topline data from our Phase&#160;2 clinical trial of D-PLEX<sub>100</sub> for the prevention of superficial and deep incisional SSIs after
elective abdominal colon surgery involving resection. This prospective, multicenter, randomized, controlled, single-blind, two-arm clinical
trial of 201 patients assessed the safety and efficacy of D-PLEX<sub>100</sub> with the standard of care, a prophylactic antibiotic administered
intravenously prior to surgery, compared to a standard of care control arm. The primary endpoint was the combination of incisional SSIs
and mortality rate as measured by the number and proportion of subjects with either an SSI event, as determined by a blinded and independent
adjudication committee, or mortality for any reason within 30&#160;days post-surgery. All subjects were followed 60&#160;days post-surgery
for the assessment of safety.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We enrolled 201 patients between
the ages of 19 and 92, with a median age of 64, who underwent surgery at eight sites in Israel between October 2018 and August 2019, and
101 patients were randomly assigned to receive D-PLEX<sub>100</sub>. Of these patients, 74% underwent surgery for cancer and 13% for treatment
of Crohn&#8217;s disease, and 65% of the surgeries were minimally invasive (laparoscopies) and 35% were open surgeries (laparotomies).
The treatment and control arms were balanced across patient baseline characteristics such as age, sex and BMI, reason for the surgery
and type of surgery performed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 72 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patients treated with D-PLEX<sub>100</sub>
had a statistically significant reduction of 59% (p=0.0086) in deep or superficial incisional SSIs or mortality for any reason within
30&#160;days of surgery, which was the primary endpoint for the trial, as compared to patients who received the standard of care as illustrated
below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_010.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A result is considered to be statistically significant when the probability of the result occurring by random chance, rather than from the efficacy of the treatment, is sufficiently low. The conventional method for determining the statistical significance of a result is known as the &#8220;p-value,&#8221; which represents the probability that random chance caused the result (e.g.,&#160;a p-value&#160;=&#160;0.01 means that there is a 1% probability that the difference between the control group and the treatment group is purely due to random chance). Generally, a p-value less than 0.05 is considered statistically significant. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in the 179 patients
who completed the trial without any major protocol deviations, patients treated with D-PLEX<sub>100</sub> achieved a statistically significant
reduction of 69% (p=0.0024) in the primary endpoint events of deep or superficial incisional SSIs or mortality for any reason within 30&#160;days
of surgery as compared to patients who received the standard of care, as illustrated below. Two patients in the control arm developed
deep SSIs, as compared to no patients in the treatment arm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_011.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, there was a statistically
significant difference (p=0.0290) in patient deaths within 60&#160;days of surgery, with no deaths observed in the D-PLEX<sub>100</sub>
treatment arm as compared to five deaths observed in the standard-of-care arm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 73 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D-PLEX<sub>100</sub> was observed
to be generally well tolerated, with no confirmed drug-related SAEs, and did not increase wound healing impairment at the incision site
as compared to the control arm. There were eight treatment emergent adverse events, or TEAEs, in eight patients treated with D-PLEX<sub>100</sub>
that were determined by the blinded investigator to be possibly drug-related, as illustrated below, versus 18&#160;TEAEs observed in 13
patients in the control arm. Patients in the treatment arm also had 15 post-operative wound infection AEs, as compared to 23 in the control
arm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D-PLEX<sub>100
    </sub>Arm&#160;(N=99)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Control&#160;Arm
    (N=100)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 76%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Number of Possibly-Related TEAEs</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Patients with at Least One Possibly-Related TEAE</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8
                                            (8.0</b></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13
                                            (13.1</b></span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    disorders and administration site conditions</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4
                                            (4.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
                                            (3.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Infections
    and infestations</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
                                            (2.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10
                                            (10.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Injury,
    poisoning and procedural complications</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
                                            (1.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0
(0.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nervous
    system disorders</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0
                                            (0.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
(1.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Skin
    and subcutaneous tissue disorders</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0
                                            (0.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
(2.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surgical
    and medical procedures</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
                                            (1.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0
(0.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vascular
    disorders</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0
                                            (0.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
(1.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, patients in both
the treatment arm and the control arm had a 4% rate of wound healing impairment, suggesting that D-PLEX<sub>100</sub> did not increase
wound healing impairment. We also evaluated patients using the ASEPSIS scale, a common method of assessing wound healing based on the
need for additional treatment, the presence of serious discharge, skin redness and/or drainage, the separation of deep tissue, the isolation
of bacteria and the duration of inpatient stay. Patients treated with D-PLEX<sub>100</sub> had lower average and cumulative ASEPSIS assessment
scores than patients in the control arm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">More than 70% of the bacteria
strains isolated from patients&#8217; SSIs were resistant to more than one type of commonly used antibiotics, with more than 60% considered
multidrug resistant bacteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patient pharmacokinetic data
collected from treated patients showed evidence of D-PLEX<sub>100</sub>-released doxycycline for approximately 30&#160;days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Phase&#160;1b/2
Clinical Trial for D-PLEX</i><sub>100</sub> <i>in the Prevention of Sternal SSIs after Cardiac Surgery </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2018, we reported
data from our Phase&#160;1b/2 clinical trial of D-PLEX<sub>100</sub> for the prevention of sternal SSIs in patients undergoing cardiac
surgery through median sternotomy. This two-part trial was conducted in 81 patients at four sites in Israel, with a six-month safety follow-up
period. An independent, blinded adjudication committee reviewed all patients with an SSI as identified by the principal investigator.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first part was an open
label, single arm trial of 20 patients who received D-PLEX<sub>100</sub> together with the standard of care, which generally consists
of a systemic antibiotic given within one hour prior to surgery. Based on feedback from the FDA, the second part of the clinical trial
was designed as a randomized and single-blinded trial of 61 patients, divided in a two-to-one ratio between treatment and control arms.
This trial was not powered for statistical significance. One arm received D-PLEX<sub>100</sub> and the standard of care, and the second
arm received the standard of care alone. One patient randomized to the standard-of-care arm received D-PLEX<sub>100</sub>, and two patients
randomized to the D-PLEX<sub>100</sub> treatment group did not receive the study drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of the 58 patients treated
with D-PLEX<sub>100</sub> and the standard of care had a sternal infection within 90&#160;days post-surgery, which was the primary endpoint
of the trial, as compared to one patient in the group treated with the standard of care alone, representing 4.3% infection rate. According
to recent literature, the expected infection rate for patients receiving the standard of care alone is 5% to 8%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In patients treated with D-PLEX<sub>100</sub>
plus the standard of care, we observed a 67% reduction in the number of patients with sternal wound discharge within 90&#160;days post-surgery,
as compared to the control arm. We also conducted a post-hoc analysis, which showed an 85% reduction in patients who were treated with
intravenous antibiotics due to sternum wound discharge within 90&#160;days post-surgery, as compared to the control arm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 74 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D-PLEX<sub>100</sub> was observed
to be generally well tolerated, with no drug-related SAEs and no drug-related wound healing issues at the incision site. Patient pharmacokinetic
data collected from treated patients showed evidence of D-PLEX<sub>100</sub>-released doxycycline for approximately 30&#160;days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Phase&#160;3
Clinical Trials of D-PLEX<sub>100 </sub></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Phase&#160;3 Clinical
Trial for the Prevention of SSIs after Abdominal (Soft Tissue) Surgery </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following our end of Phase&#160;2
meeting with the FDA in February 2020, we initiated two Phase&#160;3 clinical trials of D-PLEX<sub>100</sub> for the prevention of SSIs
after abdominal (soft tissue) surgery. In May 2021, the FDA agreed in a Type B meeting that a single pivotal Phase 3 study is sufficient,
provided the study results are adequate, for potential approval of a D-PLEX<sub>100</sub> NDA for the prevention of SSIs in colorectal
surgery. We initiated the first Phase&#160;3 trial (SHIELD I) in this indication in Israel in the third quarter of 2020, with additional
sites in the United States and Europe. We also initiated the second Phase&#160;3 trial (SHIELD II) in December 2020. Both trials are designed
to be prospective, multinational, multicenter, randomized, controlled, two-arm, double-blinded trials to evaluate the efficacy and safety
of D-PLEX<sub>100</sub> in combination with the standard of care, which includes a prophylactic antibiotic administered prior to surgery,
in patients aged 18&#160;years and older at screening, undergoing an elective colorectal surgery involving colon or rectal resection and
with at least one incision measuring greater than 7 centimeters (SHIELD II) or greater than 10 centimeter (SHIELD I).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we announced
top-line results from the SHIELD I Phase 3 study of D-PLEX<sub>100</sub>. SHIELD I is a prospective, multinational, randomized, double-blind
Phase 3 trial designed to assess the efficacy and safety of D-PLEX<sub>100</sub>&#160;administered concomitantly with standard of care
(SoC) compared to a SoC alone arm, in the prevention of post-abdominal surgery incisional infection. The primary endpoint of the trial
is the combination of incisional SSIs and mortality as measured by the proportion of subjects with either an SSI event, as determined
by a blinded and independent adjudication committee, re-interventions due to SSIs or mortality for any reason within 30 days post-surgery.
A total of 977 patients were randomized into the study, consisting of 488 subjects in the D-PLEX<sub>100</sub>&#160;treatment arm and
489 patients in the control arm. SHIELD I study did not achieve its primary endpoint of reduction in SSIs, re-interventions due to SSIs
and mortality: in the ITT population, the local administration of D-PLEX<sub>100</sub> and SoC (n=485) resulted in a decrease in the primary
endpoint of 23 percent compared to SoC alone (n=489) (p=0.1520). That said, in a pre-specified subgroup ITT analysis requested by the
FDA of a total of 423 subjects with large incisions (&gt;20 centimeters), the local administration of D-PLEX<sub>100</sub>&#160;resulted
in a significant reduction of 54 percent in the primary endpoint,&#160;compared to SoC alone (p=0.0032). Within the first 30 days post-surgery,
SSIs decreased from 9.7% in the SoC treatment arm (n=211), as compared to 4.4% in the D-PLEX<sub>100</sub>&#160;treatment arm (n=212).
In addition, SHIELD I study also showed a 34% reduction in the primary endpoint in patients with one or more personal risk factors (post
hoc analysis; p=0.047; n=680) compared to standard of care. SHIELD I study demonstrated a good safety profile of D-PLEX<sub>100&#160;</sub>with
no increase in serious or severe treatment emergent adverse events compared to standard of care.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2022, we provided
the FDA with available data from the SHIELD I study as part of a Type D meeting request. Following positive type D meeting communication
with the <span>FDA which took place in January 2023 on the SHIELD I Phase 3 data, we now have a clear</span>
regulatory pathway toward a potential NDA submission. <span>Based on the data, particularly the 54% reduction
observed in the primary endpoint in complex surgeries in a pre-specified subgroup analysis of patients with large open incisions compared
to standard of care (p=0.0032, n=423), the FDA acknowledged that the SHIELD I results may provide supportive evidence on this population
and recommended that we conduct </span>an additional study to support a potential NDA submission. The FDA stated that the ongoing SHIELD
II study, which to date has enrolled over 200 patients, including approximately 40 patients with the appropriate large open surgical incisions,
could potentially serve as such a study. The <span>FDA also recognized that </span>D-PLEX<sub>100</sub>&#8217;s
<span>proposed indication is for the prevention of infection and has the potential for wide use. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>SHIELD
II is a prospective, multinational, randomized, double blind Phase 3 trial designed to assess the efficacy and safety of D-PLEX</span><sub>100</sub>
<span>administered concomitantly with standard of care (SoC), compared to SoC alone arm, in the prevention
of post abdominal-surgery incisional infection in patients undergoing surgeries with incisions greater than 20 cm. The primary endpoint
of the trial is measured by the proportion of subjects with either an SSI event as determined by a blinded and independent adjudication
committee, reintervention, or mortality for any reason within 30 days post-surgery. Patient safety will be monitored for an additional
30 days. The trial will enroll patients in centers in the United States, Europe and Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SHIELD II patient recruitment
is expected to resume in the second quarter of 2023 with the enrollment of an estimated 550 additional patients. <span>Total
recruitment time into the study, once it resumes, is anticipated to be approximately 12 months and top-line results are expected mid-2024.
Unblinded interim analysis is planned to be conducted once approximately 400 patients complete their 30-day follow-up. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 75 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Phase&#160;3 Clinical
Trial for the Prevention of Post-Cardiac Sternal (Bone) SSIs</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019, we initiated
a potentially pivotal Phase&#160;3 clinical trial of D-PLEX<sub>100</sub> for the prevention of post-cardiac sternal (bone) SSIs, and
we enrolled the first patient in February&#160;2020. We have paused enrollment in this trial. We are currently focusing on our SHIELD
II clinical trial, which we believe has the potential to serve as the basis for an NDA. We are currently evaluating next clinical steps
for an open-heart surgery trial, while we ensure that the SHIELD II trial continues to progress as planned, and intend to submit the bone
surgery data as a supplement after the approval of the NDA for abdominal (soft tissue) surgery.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Additional
Clinical Data in Support of D-PLEX<sub>100</sub></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We completed a clinical trial
of the safety and efficacy of D-PLEX<sub>1000</sub>, a predecessor product candidate to D-PLEX<sub>100</sub>, for the prevention of infection
in contaminated bone following open tibia fractures in 51 patients. Given that D-PLEX<sub>1000</sub> is another product candidate from
the D-PLEX family, we believe these clinical trial results may also be relevant to the clinical development profile of D-PLEX<sub>100</sub>.
At the six-month follow-up period, patients treated with D-PLEX<sub>1000</sub> with the standard of care had no infections or infection-related
bone morbidities, including non-union of the bone, following surgery, as compared to 11.1% of the patients treated only with the standard
of care. D-PLEX<sub>1000</sub> was observed to be generally well tolerated, with no drug-related AEs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also conducted two pilot
clinical trials of D-PLEX<sub>1000</sub> in a total of 19&#160;patients with infected open long bone fractures. In these trials, patients
treated with D-PLEX<sub>1000</sub> with the standard of care had no bone infections at the treatment site in the six months following
treatment. In contrast, according to recent literature the expected infection rate for patients receiving the standard of care alone is
7% to 19%. Additionally, at the six-month follow up date, no deaths, amputations or drug-related SAEs were observed in the treatment arms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not plan to pursue further
independent development of D-PLEX<sub>1000</sub>, as we believe the prevention of SSIs in the orthopedic market can be adequately addressed
by D-PLEX<sub>100</sub>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>OncoPLEX -
Preclinical Development Program for Cancer </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to our lead program D-PLEX<sub>100</sub>,
our pipeline includes an early-stage Oncology program, OncoPLEX, PolyPid&#8217;s lead intra-tumoral cancer therapy drug candidate. OncoPLEX
utilizes PLEX technology to provide controlled local exposure to docetaxel, one of the most widely used chemotherapy agents, directly
at the tumor site for few weeks to potentially reduce local tumor reoccurrence, the potential spreading of cancer cells, and ultimately
improve the overall survival rate of cancer patients. Local delivery of drugs directly into the tumor site, especially in difficult to
access tumors such as in the brain, may significantly improve the clinical outcome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2020, we announced
positive preclinical data in a syngeneic mouse model for solid tumors of colon carcinoma using cancer cells highly resistant to docetaxel.
A single local application of OncoPLEX at the intra-operative setting post tumor resection showed improved overall survival and significantly
less tumor recurrence, compared to the group treated with six subsequent cycles of systemic docetaxel treatment with 2-4 days gap between
cycles. In addition, reduced systemic toxicity was demonstrated following the application of OncoPLEX compared to systemic docetaxel treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2021 we announced
positive preclinical data of Intra-tumoral OncoPLEX in Brain Cancer. We identified brain tumors as the initial target indication for OncoPLEX
because there is currently almost no meaningful chemotherapeutic treatment option for brain tumors, primarily due to the limited ability
of chemical agents to penetrate the blood-brain barrier. Due to the localized and prolonged nature of OncoPLEX, we believe it will be
highly beneficial compared to systemic treatments, as well as the currently available local treatment, in these devastating tumors that
often cannot be fully resected surgically. OncoPLEX was evaluated for tumor growth and survival in two GBM animal models. Key results
included:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoPLEX induced strong inhibition of tumor growth and recurrence in a partially resected human glioblastoma subcutaneous mouse model. A single local OncoPLEX application induced 98% tumor growth inhibition (day 41 post operation) compared to the untreated control (p&lt;0.001), and 66% compared to multiple injections of systemic chemotherapy treatment arm (p=0.0165). The day 41 survival rate for OncoPLEX was much higher than the systemic treated mice, or untreated with 60%, 20%, and 10% survival, respectively.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoPLEX was also tested in a GBM brain rat model. OncoPLEX, applied locally next to the non-resected tumor in the brain, showed a 40% survival rate at day 23 following the beginning of treatment, as compared to a 0% survival rate in the standard systemic treatment arm (Temozolomide 33.5 mg/kg, 5 treatment days), the placebo arm (OncoPLEX without Docetaxel) and in the untreated control arm. Only OncoPLEX significantly enhanced the overall survival compared to both the placebo arm and to the untreated arm (p&lt;0.02).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dose response was demonstrated for OncoPLEX in the different animal models.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Local application of OncoPLEX
in a rat brain model showed good safety profile at the different doses studied. We conducted in November 2021 a successful Pre-IND meeting
with the FDA supporting a Phase 1/2 clinical trial of OncoPLEX as a potential part of first-line combination therapy for patients newly
diagnosed with GBM.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Future Development
of PLEX in other Medical Applications </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our PLEX platform technology
may have broad applications for other localized medical conditions other than the prevention of SSIs. We have conducted research and development
for our PLEX platform in a variety of potential indications, including for the treatment of infection, cancer, inflammation and pain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>PLEX for Other
Applications </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our research and development
programs, we have paired PLEX with small molecules, proteins, antibodies, peptides and nucleic acids-based drugs. We continue to evaluate
these research and development programs for potential development by us or in collaboration with leading biopharmaceutical companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>Competition</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biopharmaceutical industry
is intensely competitive and subject to rapid and significant technological change. Our potential competitors include large and experienced
companies that have significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel
and marketing resources, greater brand recognition, and more experience and expertise in obtaining marketing approvals from the FDA and
foreign regulatory authorities. These companies may develop new drugs to treat the indications that we target or seek to have existing
drugs approved for use in the indications that we target.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 77 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These potential competitors
may therefore introduce competing products without our prior knowledge and without our ability to take preemptive measures in anticipation
of their commercial launch. Competition may increase further as a result of advances in the commercial applicability of technologies and
greater availability of capital for investment in this industry. Our competitors may succeed in developing, acquiring or licensing on
an exclusive basis, products that are more effective, easier to administer or less costly than our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The current standard of care
for preventing SSIs involves the implementation of a range of treatment and prevention measures before, during and after surgery, including
prophylactic antibiotic administration, antiseptic measures and wound care. We anticipate that D-PLEX<sub>100</sub>, if approved, could
be used as a complementary part of many surgical protocols, rather than competitive, in addition to the current standard of care for the
prevention of SSIs. In addition, we are aware of other approved treatments that can be applied locally during surgery for the prevention
of SSIs, including triclosan-coated antiseptic sutures, negative wound pressure therapy, the CleanCision wound retraction and protection
system and a resorbable gentamicin-collagen sponge, which is approved in the European Union and Canada. In orthopedic surgeries, we are
aware of approved treatments for localized SSI prevention that pair bone cement or bone graft substitutes premixed with an antibiotic
as developed by companies such as BoneSupport AB (STO: BONEX) or Biocomposites Ltd. Further, we are aware of prior clinical development
of a vaccine against <i>Staphylococcus aureus</i> that was halted due to lack of efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may also face competition
from companies that are developing localized extended release delivery systems, including, among others, Pacira Pharmaceuticals,&#160;Inc.,
Heron Therapeutics,&#160;Inc., Urogen Pharma&#160;Ltd. and LIDDS AB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Manufacturing </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our PLEX product candidates
are manufactured using a scalable self-assembly process with well-defined operations. This highly specialized and precisely controlled
process enables us to manufacture product candidates consistently and efficiently for clinical and commercial applications. We have constructed
a state-of-the-art, sterile manufacturing facility that is designed to be cGMP compliant for the production of our product candidates
adjacent to our administrative headquarters in Petach Tikva, Israel. The manufacturing facility is cGMP certified by the IMOH and inspected
by a European Union-qualified person, enabling cGMP manufacturing of D-PLEX<sub>100</sub> for our ongoing and planned potentially pivotal
Phase&#160;3 clinical trials to be conducted in the United States and Europe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate that our facility
will meet commercial demand for at least the first 48&#160;months following a commercial launch of D-PLEX<sub>100</sub>, if approved.
We intend to use this capacity as the basis to build a fully integrated biopharmaceutical company, supported by our in-house research
and development team and our anticipated commercial infrastructure. We have already started planning expansion of our manufacturing capabilities
or employment of third-party contract manufacturing organizations to meet further commercial demand in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we rely on third
parties as needed for the supply of certain raw materials necessary to manufacture our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 78 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Marketing, Sales
and Distribution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given our current stage of
development, we have limited internal marketing, sales and distribution capabilities. We have established a wholly-owned United States
subsidiary, PolyPid&#160;Inc., a Delaware corporation with operations in New Jersey, to support our potential commercialization efforts
in the United States and our clinical development program. We would intend to launch D-PLEX<sub>100</sub> and any future product candidates
in the United States following the FDA approval using our commercial capabilities. We are also exploring potential partnering opportunities
with leading pharmaceutical companies focusing on hospital business to maximize our commercial success and launch of any approved products
in the United States. We believe that the potential clinical and economic benefits of D-PLEX<sub>100</sub> will support its commercial
launch under existing Medicare rates given the associated mortality, morbidity and cost burden of SSIs and the associated penalties imposed
on hospital reimbursement from CMS. In addition, we believe that there may be opportunities for reimbursement of D-PLEX<sub>100</sub>
under CMS programs. Outside the United States, we intend, where appropriate, to pursue commercialization relationships, including strategic
alliances and licensing, with pharmaceutical companies and other strategic partners that are equipped to market and sell our products
through their well-developed sales, marketing and distribution organizations in such countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 2, 2022, we entered
into a license, distribution and supply agreement with Advanz, pursuant to which we granted the exclusive right to Advanz to market, advertise,
promote, distribute, offer for sale, sell and import our product D-PLEX<sub>100</sub> for the prevention of (i) post abdominal surgery
incisional infection and/or (ii) post cardiac surgery sternal infection in the European Economic Area and the United Kingdom. The term
of the license is until the later of December 31, 2035, or 10 years after the first commercial sale of D-PLEX<sub>100</sub>. The license
is also terminable by either party under certain limited circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Under
the terms of the agreement, we received an upfront payment immediately upon signing and are entitled to additional development-related
milestones for a total of up to &#8364;23 million (approximately $24.4 million) as follows: upfront payment of &#8364;2.5 million (approximately
$2.6 million), up to &#8364;12.25 million (approximately $13 million) contingent upon positive top-line results of our SHIELD I Phase 3
study and additional development-related milestones of up to &#8364;8.25 million (approximately $8.7 million). Upon commercialization,
we will receive up to &#8364;87 million (approximately $92.2 million) in sales-related milestones. In addition, we will also supply D-PLEX<sub>100</sub>&#160;to
Advanz for a transfer price and will be entitled to royalties on net sales in double-digit percentages of up to mid-twenties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we may out-license
some or all of our patent rights to more than one party to achieve the fullest development, marketing and distribution of any products
we develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our patent estate includes
patents and patent applications with claims directed to our PLEX technology platform, D-PLEX<sub>100</sub> product candidate and claims
for potential future product candidates. As of March 26, 2023, our patent estate includes 146 issued patents, including utility and composition
of matter patents, five allowed patent applications, 10 pending patent applications and one published PCT application for our product
candidates and methods of treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our patents and patent applications
primarily relate to a polymer-lipid-based platform for sustained release of an active pharmaceutical agent at a target site. We have 35
issued patents, and one pending patent application in various countries worldwide related to compositions for sustained release of an
API, including a lipid-saturated matrix formed from a biodegradable polymer, as well as methods for producing such compositions and methods
of treatment through the use of such compositions. We also have 17 issued patents and one pending patent application in various countries
worldwide related to compositions for sustained release of an API including a lipid-saturated matrix formed from a non-biodegradable polymer,
as well as methods for producing such compositions and methods of treatment through the use of such compositions. We also have 12 issued
patents in various countries worldwide related to compositions for sustained release of a nucleic agent including a lipid-saturated matrix
formed from a biodegradable polymer, as well as methods for producing such compositions and methods of treatment through the use of such
compositions. We also have an issued Australian patent related to compositions for sustained release of peptidic molecules, as well as
methods for producing such compositions and methods of treatment through the use of such compositions. We also have 25 issued patents
and two pending patent applications in various countries worldwide related to methods for treating bone fractures through the use of biocompatible
fillers coated with sustained release antibiotic compositions, along with 15 issued patents and two allowed patent applications in various
countries worldwide related to methods for treating peri-implantitis and 41 issued patents, three allowed and six pending patent applications
in various countries worldwide related to methods for preventing and treating SSIs through similar processes. We also have one published
PCT application related to compositions and methods for the treatment of solid tumors. Our patent estate includes 11 issued United States
patents as well as issued patents and/or pending patent applications in Australia, Brazil, Canada, China, the Eurasian Patent Organization,
the European Patent Office, Hong-Kong, India, Israel, Japan, Mexico, New Zealand, the Philippines, Singapore, South Africa, South Korea,
Thailand and the United States. Our issued patents are expected to remain in effect between 2029 and 2035.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to patents, we
have seven registered trademarks. &#8220;BonyPid&#8221; which is registered in the European Union Intellectual Property Office and in
Israel, &#8220;PolyPid&#8221; which is registered in the United States, Israel, China and in the following European Union countries: Benelux,
France, Germany, Spain, Austria, Italy, the United Kingdom, Ireland and Portugal, &#8220;Bacfenssi&#8221; which is registered in the United
States, the European Union Intellectual Property Office, Great Britain, China, Israel and Russia and pending in the Switzerland, Iceland,
Liechtenstein and Norway, &#8220;Opzifend&#8221; which is registered in the United States, the European Union Intellectual Property Office,
Great Britain, China, Israel and Russia and pending in Switzerland, Iceland, Liechtenstein and Norway , and &#8220;Ssisurg&#8221;, &#8220;Elyfssi&#8221;
and &#8220;Bacyssio&#8221; which are registered in Israel. Furthermore, we rely upon trade secrets, know-how and continuing technological
innovation to develop and maintain our competitive position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preparing and filing patent
applications is a joint endeavor of our research and development team and our in-house and external patent attorneys. Our patent attorneys
conduct patent prior-art searches and then analyze the data in order to provide our research and development team with recommendations
on a routine basis. This results in:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">protecting our product candidates that are under development; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">encouraging pharmaceutical companies to negotiate development agreements with us; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preventing competitors from attempting to design-around our inventions. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We initially submit applications
to the USPTO as provisional patent applications. Then typically we continue by filing non-provisional patent applications under the PCT,
which is an international patent law treaty that provides a unified procedure for filing a single initial patent application to later
seek patent protection for an invention in any number of the member states of the PCT. Although a PCT application does not itself issue
as a patent, it acts as a placeholder allowing the applicant to seek protection in any of the member states through national-phase applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Government Regulation
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA and comparable regulatory
agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacturing
and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate research and development
activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, packaging, recordkeeping, tracking,
approval, import, export, distribution, advertising and promotion of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>U.S. Government
Regulation of Drug Products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
FDA regulates drugs under the FFDCA and its implementing regulations. The process of obtaining regulatory approvals and the subsequent
compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and
financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval
process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal
to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product
seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution,
disgorgement or civil or criminal penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 80 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process required by the
FDA before product candidates may be marketed in the United States generally involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nonclinical laboratory and animal tests that must be conducted in accordance with good laboratory practices; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission of an IND, which must become effective before clinical trials may begin; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval by an independent institutional review board, or IRB, for each clinical site or centrally before each trial may be initiated; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed product candidate for its intended use, performed in accordance with good clinical practices, or GCPs; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of an NDA and payment of user fees; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of an FDA advisory committee review, if applicable; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-approval inspection of manufacturing facilities and selected clinical investigators for their compliance with cGMP and good clinical practices, or GCPs; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA approval of an NDA to permit commercial marketing for particular indications for use; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval studies. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The testing and approval process
requires substantial time, effort and financial resources. Preclinical studies include laboratory evaluation of drug substance chemistry,
pharmacology, toxicity and drug product formulation, as well as animal studies to assess potential safety and efficacy. Prior to commencing
the first clinical trial with a product candidate, we must submit the results of the preclinical tests and preclinical literature, together
with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part
of an IND. Some preclinical studies may continue even after the IND is submitted. The IND automatically becomes effective 30&#160;days
after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the conduct of the
clinical trial by imposing a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the
clinical trial can begin. Submission of an IND may not result in FDA authorization to commence a clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials involve the
administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP
requirements. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development,
as well as amendments to previously submitted clinical trials. Further, an independent IRB for each study site proposing to conduct the
clinical trial must review and approve the plan for any clinical trial, its informed consent form and other communications to study subjects
before the clinical trial commences at that site. The IRB must continue to oversee the clinical trial while it is being conducted, including
any changes to the study plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory authorities, an
IRB or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are
being exposed to an unacceptable health risk, the clinical trial is not being conducted in accordance with the FDA&#8217;s or the IRB&#8217;s
requirements, if the drug has been associated with unexpected serious harm to subjects, or based on evolving business objectives or competitive
climate. Some studies also include a data safety monitoring board, which receives special access to unblinded data during the clinical
trial and may advise us to halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds,
such as no demonstration of efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 81 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, for purposes of
NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase&#160;1&#8212;Studies are initially conducted to test the product candidate for safety, dosage tolerance, structure-activity relationships, mechanism of action, absorption, metabolism, distribution and excretion in healthy volunteers or subjects with the target disease or condition. If possible, Phase&#160;1 clinical trials may also be used to gain an initial indication of product effectiveness. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase&#160;2&#8212;Controlled studies are conducted with groups of subjects with a specified disease or condition to provide enough data to evaluate the preliminary efficacy, optimal dosages and dosing schedule and expanded evidence of safety. Multiple Phase&#160;2 clinical trials may be conducted to obtain information prior to beginning larger and more expansive Phase&#160;3 clinical trials. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase&#160;3&#8212;These clinical trials are undertaken in larger subject populations to provide statistically significant evidence of clinical efficacy and to further test for safety in an expanded subject population at multiple clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. These clinical trials may be done globally to support global registrations so long as the global sites are also representative of the U.S. population and the conduct of the study at global sites comports with FDA regulations and guidance, such as compliance with GCPs. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may require, or companies
may pursue, additional clinical trials after a product is approved. These so-called Phase&#160;4 studies may be made a condition to be
satisfied after approval. The results of Phase&#160;4 studies can confirm the effectiveness of a product candidate and can provide important
safety information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials must be conducted
under the supervision of qualified investigators in accordance with GCP requirements, which includes the requirements that all research
subjects provide their informed consent in writing for their participation in any clinical trial, and the review and approval of the study
by an IRB. Investigators must also provide information to the clinical trial sponsors to allow the sponsors to make specified financial
disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the
trial procedures, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated and a statistical analysis
plan. Information about some clinical trials, including a description of the trial and trial results, must be submitted within specific
timeframes to the National Institutes of Health for public dissemination on their ClinicalTrials.gov website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacture of investigational
drugs for the conduct of human clinical trials is subject to cGMP requirements. Investigational drugs and active pharmaceutical ingredients
imported into the United States are also subject to regulation by the FDA relating to their labeling and distribution. Further, the export
of investigational drug products outside of the United States is subject to regulatory requirements of the receiving country as well as
U.S. export requirements under the FFDCA. Progress reports detailing the results of the clinical trials must be submitted at least annually
to the FDA and the IRB and more frequently if serious adverse effects occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrent with clinical trials,
companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics
of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP
requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among
other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate
packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo
unacceptable deterioration over its shelf life.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 82 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Orange Book
Listing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In seeking approval for a
drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA patents whose claims cover the applicant&#8217;s
product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in Approved Drug Products
with Therapeutic Equivalence Evaluations, also known as the Orange Book.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any applicant who files&#160;a
505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA (1)&#160;that no patent information on the drug product
that is the subject of the application has been submitted to the FDA; (2)&#160;that such patent has expired; (3)&#160;the date on which
such patent expires; or (4)&#160;that such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug
product for which the application is submitted. This last certification is known as a Paragraph&#160;IV certification. Generally, the
505(b)(2) NDA cannot be approved until all listed patents have expired, except where the 505(b)(2) NDA applicant challenges a listed patent
through a Paragraph&#160;IV certification.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the applicant has provided
a Paragraph&#160;IV certification to the FDA, the applicant must also send notice of the Paragraph&#160;IV certification to the holder
of the NDA for the reference listed drug and the patent owner once the application has been accepted for filing by the FDA. The applicant
may also elect to submit a &#8220;section&#160;viii&#8221; statement certifying that its proposed label does not contain (or carves out)
any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. The NDA holder or patent owner
may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&#160;IV certification. The filing of a patent
infringement lawsuit within 45&#160;days of the receipt of a Paragraph&#160;IV certification prevents the FDA from approving the application
until the earlier of 30&#160;months from the date of the lawsuit, expiration of the patent, settlement of the lawsuit, a decision in the
infringement case that is favorable to the applicant or such shorter or longer period as may be ordered by a court. This prohibition is
generally referred to as the 30-month stay. In instances where a 505(b)(2) NDA applicant files&#160;a Paragraph&#160;IV certification,
the NDA holder or patent owner regularly take action to trigger the 30-month stay, recognizing that the related patent litigation may
take many months or years to resolve. Thus, approval of a 505(b)(2) NDA could be delayed for a significant period of time depending on
the patent certification the applicant makes and the reference drug sponsor&#8217;s decision to initiate patent litigation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 83 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exclusivity</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA provides periods of
non-patent regulatory exclusivity, which provides the holder of an approved NDA limited protection from new competition in the marketplace
for the innovation represented by its approved drug for a period of three or five years following the FDA&#8217;s approval of the NDA.
Five years of exclusivity are available to new chemical entities, or NCEs. An NCE is a drug that contains no active moiety that has been
approved by the FDA in any other NDA. An active moiety is the molecule or ion, excluding those appended portions of the molecule that
cause the drug to be an ester, salt, including a salt with hydrogen or coordination bonds, or other noncovalent, or not involving the
sharing of electron pairs between atoms, derivatives, such as a complex (<i>i.e.</i>, formed by the chemical interaction of two compounds),
chelate (<i>i.e.</i>, a chemical compound), or clathrate (<i>i.e.</i>, a polymer framework that traps molecules), of the molecule, responsible
for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept for review or approve an Abbreviated
New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. An
ANDA or 505(b)(2) application, however, may be submitted one year before NCE exclusivity expires if a Paragraph&#160;IV certification
is filed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a product is not eligible
for the NCE exclusivity, it may be eligible for three years of exclusivity. Three-year exclusivity is available to the holder of an NDA,
including a 505(b)(2) NDA, if one or more new clinical trials, other than bioavailability or bioequivalence trials, was essential to the
approval of the application and was conducted or sponsored by the applicant. This three-year exclusivity period protects against FDA approval
of ANDAs and 505(b)(2) NDAs for the particular condition of the new drug&#8217;s approval or the change to a marketed product, such as
a new formulation for a previously approved drug. Five-year and three-year exclusivity will not delay the submission or approval of a
505(b)(1) NDA; however, an applicant submitting a 505(b)(1) NDA would be required to conduct or obtain a right of reference to all of
the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, under the GAIN
Act, which was enacted as part of the Food and Drug Administration Safety and Innovation Act, or FDASIA, which was signed into law in
July 2012, the FDA may designate a product as a QIDP. In order to receive this designation, a drug must qualify as an antibiotic or antifungal
drug for human use intended to treat serious or life-threatening infections, including those caused by either (1)&#160;an antibiotic or
antifungal resistant pathogen, including novel or emerging infectious pathogens, or (2)&#160;a so-called &#8220;qualifying pathogen&#8221;
found on a list of potentially dangerous, drug-resistant organisms to established and maintained by the FDA. A sponsor must request such
designation before submitting a marketing application. We obtained QIDP designations for D-PLEX<sub>100</sub> for the prevention of post-abdominal
surgery incisional infection, for the prevention of post-cardiac surgery sternal infection and for prevention of post-colorectal SSIs.
Upon approving a marketing application for a QIDP-designated product, the FDA will extend by an additional five years any non-patent marketing
exclusivity period awarded, such as a three-year exclusivity period awarded for new clinical investigations of previously approved products.
This extension is in addition to any pediatric exclusivity extension awarded, and the extension will be awarded only to a drug first approved
on or after the date of enactment of the GAIN Act. The GAIN Act prohibits the grant of an exclusivity extension where the application
is a supplement to an application for which an extension is in effect or has expired, is a subsequent application for a specified change
to an approved product, or is an application for a product that does not meet the definition of QIDP based on the uses for which it is
ultimately approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Hatch Waxman
Amendments and the 505(b)(2) Regulatory Approval Process </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#160;505 of the FFDCA
describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A
Section&#160;505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A Section&#160;505(b)(2)
NDA is an application that contains full reports of investigations of safety and efficacy, but where at least some of the information
required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained
a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant
to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy for an existing product, or published literature, in support
of its application. Specifically, the applicant may rely upon the FDA&#8217;s prior findings of safety and efficacy for an approved product
that acts as the reference listed drug for purposes of a 505(b)(2) NDA. The FDA may also require 505(b)(2) applicants to perform additional
studies or measurements to support any changes from the reference listed drug. The FDA may then approve the new product candidate for
all or some of the labeled indications for which the referenced product has been approved, as well as for any new indication sought by
the 505(b)(2) applicant. Lastly, the FDA permits marketing applications through Section&#160;505(j), which establishes an abbreviated
approval process for a generic version of approved drug products through the submission of an ANDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 84 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An ANDA provides for marketing
of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance
characteristics and intended use, among other things, to a previously approved product. ANDAs are termed &#8220;abbreviated&#8221; because
they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic
applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug
through in vitro, in vivo, or other testing. The generic version must deliver the same amount of active ingredients into a subject&#8217;s
bloodstream in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for
the reference listed drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Special FDA
Expedited Review and Approval Programs</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has various programs,
including Fast Track Designation, breakthrough therapy designation, accelerated approval, and priority review, which are intended to expedite
or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening
diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important
new drugs to patients earlier than under standard FDA review procedures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the fast track program,
the sponsor of a new drug candidate may request that FDA designate the drug candidate for a specific indication as a fast track drug concurrent
with, or after, the filing of the IND for the drug candidate. To be eligible for a Fast Track Designation, the FDA must determine, based
on the request of a sponsor, that a product is intended to treat a serious or life threatening disease or condition and demonstrates the
potential to address an unmet medical need, or that the drug qualifies as a QIDP under the GAIN Act. The FDA will determine that a product
will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to
existing therapy based on efficacy or safety factors. We obtained a Fast Track Designation in November 2018 for D-PLEX<sub>100</sub> for
the prevention of post-cardiac surgery sternal infection, in July 2020 for the prevention of post abdominal surgery incisional infection
and in September 2021 for prevention of post-colorectal SSIs. Fast Track Designation provides additional opportunities for interaction
with the FDA&#8217;s review team and may allow for rolling review of NDA components before the completed application is submitted, if
the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines
that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. However,
the FDA&#8217;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. The FDA may
decide to rescind the Fast Track Designation if it determines that the qualifying criteria no longer apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 85 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a sponsor can
request breakthrough therapy designation for a drug if it is intended, alone or in combination with one or more other drugs, to treat
a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early
in clinical development. We obtained breakthrough therapy designation in November 2020 for D-PLEX<sub>100</sub> for the prevention of
SSIs in patients undergoing elective colorectal surgery. Drugs designated as breakthrough therapies are eligible for intensive guidance
from the FDA on an efficient drug development program, organizational commitment to the development and review of the product including
involvement of senior managers, and, like fast track products, are also eligible for rolling review of the NDA. Both fast track and breakthrough
therapy products are also eligible for accelerated approval and/or priority review, if relevant criteria are met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the FDA&#8217;s accelerated
approval regulations, the FDA may approve a drug for a serious or life threatening illness that provides meaningful therapeutic benefit
to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical
endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible
morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability
or lack of alternative treatments. A drug candidate approved on this basis is subject to rigorous post marketing compliance requirements,
including the completion of Phase&#160;4 or post approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct
required post approval studies, or confirm a clinical benefit during post marketing studies, will allow the FDA to withdraw the drug from
the market on an expedited basis. All promotional materials for drug candidates approved under accelerated approval regulations are subject
to prior review by the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once an NDA is submitted for
a product intended to treat a serious condition, the FDA may assign a priority review designation if FDA determines that the product,
if approved, would provide a significant improvement in safety or effectiveness. A priority review means that the goal for the FDA to
review an application is six months, rather than the standard review of ten months under current The Prescription Drug User Fee Act, or
PDUFA, guidelines. Under the current PDUFA agreement, these six and ten months review periods are measured from the 60-day filing date
rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review
from the date of submission. Most products that are eligible for fast track breakthrough therapy designation are also likely to be considered
appropriate to receive a priority review.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if a product qualifies
for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide
that the time period for FDA review or approval will not be shortened. In addition, the manufacturer of an investigational drug for a
serious or life threatening disease is required to make available, such as by posting on its website, its policy on responding to requests
for expanded access. Furthermore, fast track designation, breakthrough therapy designation, accelerated approval and priority review do
not change the standards for approval and may not ultimately expedite the development or approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>NDA Submission
and Review by the FDA </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assuming successful completion
of the required clinical and preclinical testing, among other items, the results of product development, including chemistry, manufacture
and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling, as part of an NDA. The submission
of an NDA requires payment of a substantial user fee to the FDA. These user fees must be filed at the time of the first submission of
the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in some circumstances.
One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates,
the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into
interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, under the Pediatric
Research Equity Act, an NDA or supplement to an NDA for a new active ingredient, indication, dosage form, dosage regimen or route of administration
must contain data that are adequate to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric
subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may, on its own initiative
or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for
use in adults or full or partial waivers from the pediatric data requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA must refer applications
for drugs that contain active ingredients, including any ester or salt of the active ingredients, that have not previously been approved
by the FDA to an advisory committee or provide in an action letter a summary of the reasons for not referring it to an advisory committee.
The FDA may also refer drugs which present difficult questions of safety, purity or potency to an advisory committee. An advisory committee
is typically a panel that includes clinicians and other experts who review, evaluate and make a recommendation as to whether the application
should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such
recommendations carefully when making decisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA reviews applications
to determine, among other things, whether a product is safe and effective for its intended use and whether the manufacturing controls
are adequate to assure and preserve the product&#8217;s identity, strength, quality and purity. Before approving an NDA, the FDA will
inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that
the manufacturing processes and facilities, including contract manufacturers and subcontracts, are in compliance with cGMP requirements
and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the
FDA will typically inspect one or more clinical trial sites to assure compliance with GCPs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once the FDA receives an application,
it has 60&#160;days to review the NDA to determine if it is substantially complete to permit a substantive review, before it accepts the
application for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. The FDA&#8217;s NDA
review times may differ based on whether the application is a standard review or priority review application. The FDA may give a priority
review designation to drugs that are intended to treat serious conditions and provide significant improvements in the safety or effectiveness
of the treatment, diagnosis, or prevention of serious conditions. Under the goals and policies agreed to by the FDA under PDUFA, the FDA
has set the review goal of 10&#160;months from the 60-day filing date to complete its initial review of a standard NDA for a new molecular
entity, or NME, and make a decision on the application. For non-NME standard applications, the FDA has set the review goal of 10&#160;months
from the date that the FDA receives the application to complete its initial review and to make a decision on the application. For priority
review applications, the FDA has set the review goal of reviewing NME NDAs within six months of the 60-day filing date and non-NME applications
within six months of the date that the FDA receives the application. Such deadlines are referred to as the PDUFA date. The PDUFA date
is only a goal and the FDA does not always meet its PDUFA dates. The review process and the PDUFA date may also be extended if the FDA
requests or the NDA sponsor otherwise provides additional information or clarification regarding the submission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once the FDA&#8217;s review
of the application is complete, the FDA will issue either a Complete Response Letter, or CRL, or approval letter. A CRL indicates that
the review cycle of the application is complete and the application is not ready for approval. A CRL generally contains a statement of
specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing,
or other information or analyses in order for the FDA to reconsider the application. The FDA has the goal of reviewing 90% of application
resubmissions in either two or six months of the date that the FDA receives the application, depending on the kind of resubmission. Even
with the submission of additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria
for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA may issue an approval letter. An approval
letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may delay or refuse
approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing
testing and surveillance to monitor safety or efficacy of a product, or impose other conditions, including distribution restrictions or
other risk management mechanisms. For example, the FDA may require a REMS as a condition of approval or following approval to mitigate
any identified or suspected serious risks and ensure safe use of the drug. The FDA may prevent or limit further marketing of a product,
or impose additional post-marketing requirements, based on the results of post-marketing studies or surveillance programs. After approval,
some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are
subject to further testing requirements, FDA notification and FDA review and approval. Further, should new safety information arise, additional
testing, product labeling or FDA notification may be required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 87 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If regulatory approval of
a product is granted, such approval may entail limitations on the indicated uses for which such product may be marketed or may include
contraindications, warnings or precautions in the product labeling, which has resulted in a Black Box warning. A Black Box warning is
the strictest warning put in the labeling of prescription drugs or drug products by the FDA when there is reasonable evidence of an association
of a serious hazard with the drug. The FDA also may not approve the inclusion of labeling claims necessary for successful marketing. Once
approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained
or if problems occur after the product reaches the marketplace. In addition, the FDA may require Phase&#160;4 post-marketing studies to
monitor the effect of approved products, and may limit further marketing of the product based on the results of these post-marketing studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Post-approval
Requirements </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any products manufactured
or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including manufacturing, periodic reporting,
product sampling and distribution, advertising, promotion, drug shortage reporting, compliance with any post-approval requirements imposed
as a conditional of approval such as Phase&#160;4 clinical trials, REMS and surveillance, recordkeeping and reporting requirements, including
adverse experiences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After approval, most changes
to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also
are continuing, annual user fee requirements for any approved products and the establishments at which such products are manufactured,
as well as new application fees for supplemental applications with clinical data. Drug manufacturers and their subcontractors are required
to register their establishments with the FDA and certain state agencies and to list their drug products, and are subject to periodic
announced and unannounced inspections by the FDA and these state agencies for compliance with cGMPs and other requirements, which impose
procedural and documentation requirements upon us and our third-party manufacturers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes to the manufacturing
process are strictly regulated and often require prior FDA approval before being implemented, or FDA notification. FDA regulations also
require investigation and correction of any deviations from cGMPs and specifications, and impose reporting and documentation requirements
upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend
time, money and effort in the area of production and quality control to maintain cGMP compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Later discovery of previously
unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to
comply with regulatory requirements, may result in withdrawal of marketing approval, mandatory revisions to the approved labeling to add
new safety information or other limitations, imposition of post-market studies or clinical trials to assess new safety risks, or imposition
of distribution or other restrictions under a REMS program, among other consequences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA closely regulates
the marketing and promotion of drugs. A company can make only those claims relating to safety and efficacy, purity and potency that are
approved by the FDA. Physicians, in their independent professional medical judgement, may prescribe legally available products for uses
that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. We, however, are
prohibited from marketing or promoting drugs for uses outside of the approved labeling.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the distribution
of prescription pharmaceutical products, including samples, is subject to the Prescription Drug Marketing Act, or PDMA, which regulates
the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug
distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose
requirements to ensure accountability in distribution. The Drug Supply Chain Security Act also imposes obligations on manufacturers of
pharmaceutical products related to product and tracking and tracing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 88 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure to comply with any
of the FDA&#8217;s requirements could result in significant adverse enforcement actions. These include a variety of administrative or
judicial sanctions, such as refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, imposition
of a clinical hold or termination of clinical trials, warning letters, untitled letters, cyber letters, modification of promotional materials
or labeling, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production
or distribution, debarment, injunctions, fines, consent decrees, corporate integrity agreements, refusals of government contracts and
new orders under existing contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement
or civil or criminal penalties, including fines and imprisonment. It is also possible that failure to comply with the FDA&#8217;s requirements
relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and
abuse and other laws, as well as state consumer protection laws. Any of these sanctions could result in adverse publicity, among other
adverse consequences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Other Healthcare
Regulations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business activities, including
but not limited to, research, sales, promotion, distribution, medical education and other activities are subject to regulation by numerous
regulatory and law enforcement authorities in the United States in addition to the FDA, including the Department of Justice, the HHS and
its various divisions, including CMS and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department
of Defense and state and local governments. Our business activities must comply with numerous healthcare laws and regulations, including
those described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal Anti-Kickback
Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any
remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, the referral of
an individual for, or purchasing, leasing, ordering, or arranging for the purchase, lease or order of, any good, facility, item or service
reimbursable under Medicare, Medicaid or other federal healthcare programs. The Anti-Kickback Statute has been interpreted to apply to
arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other hand.
The term remuneration has been interpreted broadly to include anything of value. There are a number of statutory exceptions and regulatory
safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and require strict
compliance in order to offer protection. Practices that involve remuneration that may be alleged to be intended to induce prescribing,
purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the
requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the
federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative
review of all of its facts and circumstances. Additionally, the Patient Protection and Affordable Care Act of 2010, as amended by the
Health Care and Education Reconciliation Act of 2010, or collectively the ACA, amended the intent requirement of the federal Anti-Kickback
Statute, and other healthcare criminal fraud statutes, so that a person or entity no longer needs to have actual knowledge of the federal
Anti-Kickback Statute, or the specific intent to violate it, to have violated the statute. The ACA also provided that a violation of the
federal Anti-Kickback Statute is grounds for the government or a whistleblower to assert that a claim for payment of items or services
resulting from such violation constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act, or FCA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal civil and criminal
false claims laws, including the FCA, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented,
a false claim for payment to, or approval by, the U.S. federal government, including the Medicare and Medicaid programs, or knowingly
making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease
or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery
Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. In addition,
manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to
&#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221;
to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. FCA liability
is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties. Government
enforcement agencies and private whistleblowers have investigated pharmaceutical companies for or asserted liability under the FCA for
a variety of alleged promotional and marketing activities, such as providing free products to customers with the expectation that the
customers would bill federal programs for the products; providing consulting fees and other benefits to physicians to induce them to prescribe
products; engaging in promotion for &#8220;off-label&#8221; uses; and submitting inflated best price information to the Medicaid Rebate
Program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 89 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a condition of receiving
Medicaid coverage for prescription drugs, the Medicaid Drug Rebate Program requires manufacturers to calculate and report to CMS their
Average Manufacturer Price, or AMP, which is used to determine rebate payments shared between the states and the federal government and,
for some multiple source drugs, Medicaid payment rates for the drug, and for drugs paid under Medicare Part&#160;B, to also calculate
and report their average sales price, which is used to determine the Medicare Part&#160;B payment rate for the drug. In January 2016,
CMS issued a final rule regarding the Medicaid Drug Rebate Program, or MDRP, effective April&#160;1, 2016, that, among other things, revised
the manner in which the AMP is calculated by manufacturers participating in the program and implemented certain amendments to the Medicaid
rebate statute created under the ACA. In addition, the MDRP requires pharmaceutical manufacturers to enter into and have in effect a National
Drug Rebate Agreement, or NDRA, with the Secretary of HHS as a condition for states to receive federal matching funds for the manufacturer&#8217;s
outpatient drugs furnished to Medicaid patients. On March&#160;23, 2018, CMS finalized updates to the NDRA, or the Updated NDRA, to incorporate
a number legislative and regulatory changes, including changes to align with certain provisions of the ACA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drugs that are approved under
a biologics license application, or BLA, or an NDA, including a 505(b)(2) NDA, are subject to an additional requirement to calculate and
report the manufacturer&#8217;s best price for the drug and inflation penalties which can substantially increase rebate payments. For
BLA and NDA drugs, the Veterans Health Care Act requires manufacturers to calculate and report to the Department of Veterans Affairs a
different price called the Non-Federal AMP, offer the drugs for sale on the Federal Supply Schedule, and charge the government no more
than a statutory price referred to as the Federal Ceiling Price, which includes an inflation penalty. A separate law requires manufacturers
to pay rebates on these drugs when paid by the Department of Defense under its TRICARE Retail Pharmacy Program. Knowingly submitting false
pricing information to the government creates potential federal False Claims Act liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HIPAA created additional federal
criminal statutes that prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud
any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or
property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the third-party payor is
public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal
investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick, scheme or device
a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for,
healthcare benefits, items or services relating to healthcare matters. Additionally, the ACA amended the intent requirement of some of
these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific
intent to violate it, to have committed a violation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the federal
Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section&#160;6002 of the ACA and its implementing
regulations, requires some manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare,
Medicaid or the Children&#8217;s Health Insurance Program (with specified exceptions) to report annually information related to specified
payments or other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors),
certain other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, or to entities or
individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually specified ownership
and investment interests held by physicians and their immediate family members.. Failure to submit timely, accurately and completely the
required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 90 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we may be subject
to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended
by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose requirements
relating to the privacy, security and transmission of individually identifiable health information held by covered entities, their business
associates and covered subcontractors. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business
associates, defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health
information in connection with providing a service for or on behalf of a covered entity. HITECH also created new tiers of civil monetary
penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general
new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217;
fees and costs associated with pursuing federal civil actions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many states have also adopted
laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any third-party
payor, including commercial insurers. We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical
industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and/or state
laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare
providers or marketing expenditures and pricing information, state and local laws that require the registration of pharmaceutical sales
representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ
from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ensuring that our internal
operations and business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly.
It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes,
regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations were found to
be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil,
criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from government funded
healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations
and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with
these laws, and curtailment of our operations, any of which could substantially disrupt our operations. If the physicians or other providers
or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant
criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Coverage and
Reimbursement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to commercialize
any products successfully will also depend in part on the extent to which coverage and adequate reimbursement for the procedures utilizing
our product candidates, performed by health care providers, once approved, will be available from government health administration authorities,
private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers
and health maintenance organizations, determine which procedures, and the products utilized in such procedures, they will cover and establish
reimbursement levels. Assuming coverage is obtained for procedures utilizing a given product, by a third-party payor, the resulting reimbursement
payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who undergo procedures for
the treatment of their conditions, and their treating physicians, generally rely on third-party payors to reimburse all or part of the
costs associated with the procedures which utilize our products. When used in connection with surgical and certain other procedures, our
product candidates may not be reimbursed separately but their cost may instead be bundled as part of the payment received by the provider
for the procedure only. Treating physicians are unlikely to use and order our products unless coverage is provided and the reimbursement
is adequate to cover all or a significant portion of the cost of the procedures which utilize our products. A decision by a third-party
payor not to cover or adequately reimburse for our product candidates or procedures using our product candidates, could reduce physician
utilization of our products once approved. Therefore, coverage and adequate reimbursement for procedures which utilize new products is
critical to the acceptance of such new products. Coverage decisions may depend upon clinical and economic standards that disfavor new
products when more established or lower cost therapeutic alternatives are already available or subsequently become available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 91 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Government authorities and
other third-party payors are developing increasingly sophisticated methods of cost containment, such as including price controls, restrictions
on coverage and reimbursement and requirements for substitution of less expensive products and procedures. Government and other third-party
payors are increasingly challenging the prices charged for health care products and procedures, examining the cost effectiveness of procedures,
and the products used in such procedures, in addition to their safety and efficacy, and limiting or attempting to limit both coverage
and the level of reimbursement. Further, no uniform policy requirement for coverage and reimbursement exists among third-party payors
in the United States, which causes significant uncertainty related to the insurance coverage and reimbursement of newly approved products,
and the procedures which may utilize such newly approved products. Therefore, coverage and reimbursement can differ significantly from
payor to payor and health care provider to health care provider.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be sure that coverage
and reimbursement will be available for any product that we commercialize, or the procedures which utilize such product, and, if reimbursement
is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product
candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to
limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Healthcare
Reform Measures</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The United States and some
non-U.S. jurisdictions are considering or have enacted a number of legislative and regulatory proposals designed to change the healthcare
system. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare
systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical
industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, the pharmaceutical
industry in the United States has been affected by the passage of ACA, which, among other things: imposed new fees on entities that manufacture
or import certain branded prescription drugs; expanded pharmaceutical manufacturer obligations to provide discounts and rebates to certain
government programs; implemented a licensure framework for follow-on biologic products; expanded health care fraud and abuse laws; revised
the methodology by which rebates owed by manufacturers to the state and federal government under the Medicaid Drug Rebate Program are
calculated for certain drugs and biologics, including products that are inhaled, infused, instilled, implanted or injected; imposed an
additional rebate similar to an inflation penalty on new formulations of drugs; extended the Medicaid Drug Rebate Program to utilization
of prescriptions of individuals enrolled in Medicaid managed care organizations; expanded the 340B program which caps the price at which
manufacturers can sell covered outpatient pharmaceuticals to specified hospitals, clinics and community health centers; and provided incentives
to programs that increase the federal government&#8217;s comparative effectiveness research.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 92 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been executive,
judicial and Congressional challenges to certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a
challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was
repealed by Congress. Further, on August 16, 2022, President Biden signed the IRA into law, which among other things, extends enhanced
subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the
"donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket
cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges
in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA
and our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other legislative changes
have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other
things, included aggregate reductions of Medicare payments to providers of 2.0% per fiscal year, which went into effect in April 2013,
and due to subsequent legislative amendments, including the BBA, will remain in effect until 2031, unless additional U.S. Congressional
action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final
fiscal year of this sequester. In addition, in January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012,
which, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations
period for the government to recover overpayments to providers from three to five years. Additionally, the Medicare Access and CHIP Reauthorization
Act of 2015, or MACRA, ended the use of the statutory formula for clinician payment and established a quality payment incentive program,
also referred to as the Quality Payment Program. This program provides clinicians with two ways to participate, including through the
Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. In November 2019, CMS issued a final
rule finalizing the changes to the Quality Payment Program. At this time, the full impact to overall physician reimbursement as a result
of the introduction of the Quality Payment Program remains unclear. Any reduction in reimbursement from Medicare or other government programs
may result in a similar reduction in payments from private payors. Congress is considering additional health reform measures. For example,
Congress is currently considering the PASTEUR Act, which, if passed, would establish a program to foster antimicrobial innovation. Further,
the DISARM Act is also pending in Congress and, if passed, would encourage the development and use of antimicrobial drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, there has been
particular and increasing legislative and enforcement interest in the United States with respect to drug pricing practices in recent years,
particularly with respect to drugs that have been subject to relatively large price increases over relatively short time periods. Specifically,
there have been several recent U.S. Presidential executive orders, Congressional inquiries and proposed and enacted federal and state
legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer
patient programs, reduce the cost of prescription drugs under Medicare and reform government program reimbursement methodologies for pharmaceutical
products. The Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals,
executive orders and policy initiatives. . Additionally, in July 2021, the Biden administration released an executive order, &#8220;Promoting
Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to President Biden&#8217;s
executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for
drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative
actions HHS can take to advance these principles. Further, the IRA, among other things (i) directs HHS to negotiate the price of certain
high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare
Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023,
although they may be subject to legal challenges. Additionally, the Biden administration released an additional executive order on October
14, 2022, directing HHS to report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for
lowering drug costs for Medicare and Medicaid beneficiaries. In addition, individual states in the United States have become increasingly
active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures,
and, in some cases, designed to encourage importation from other countries and bulk purchasing. In the future, there will likely continue
to be proposals relating to the reform of the U.S. healthcare system, some of which could further limit coverage and reimbursement of
products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>The Foreign
Corrupt Practices Act </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Foreign Corrupt Practices
Act, or FCPA, prohibits any U.S. individual or business from paying, offering or authorizing payment or offering of anything of value,
directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the
foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose
securities are listed in the United States to comply with accounting provisions requiring the companies to maintain books and records
that accurately and fairly reflect all transactions of the companies, including international subsidiaries, and to devise and maintain
an adequate system of internal accounting controls for international operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Non-U.S. Government
Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that any of
our product candidates, once approved, are sold in a country outside of the United States, we will be subject to similar foreign laws
and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and
abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to market our future
products in the EEA (which is comprised of the 27 Member States of the European Union plus Norway, Iceland and Liechtenstein) and many
other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EEA, medicinal products can only be
commercialized after obtaining a Marketing Authorization, or MA. There are two types of marketing authorizations:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use of the EMA, and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the European Union; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the above described
procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit
balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 94 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Data and Marketing
Exclusivity </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the EEA, new products authorized
for marketing, or reference products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon
marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical
trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the
European Union during a period of eight years from the date on which the reference product was first authorized in the European Union.
The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the European Union
until 10&#160;years have elapsed from the initial authorization of the reference product in the European Union. The 10-year market exclusivity
period can be extended to a maximum of eleven years if, during the first eight years of those 10&#160;years, the marketing authorization
holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization,
are held to bring a significant clinical benefit in comparison with existing therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Pediatric Investigation
Plan </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the EEA, marketing authorization
applications for new medicinal products not authorized have to include the results of studies conducted in the pediatric population, in
compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#8217;s Pediatric Committee, or PDCO. The PIP sets out the
timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing authorization is being
sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient
data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data
can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children,
the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a
significant therapeutic benefit over existing treatments for pediatric patients. Once the marketing authorization is obtained in all Member
States of the European Union and study results are included in the product information, even when negative, the product is eligible for
six months&#8217; supplementary protection certificate extension.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Environmental,
Health and Safety Matters </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to extensive
environmental, health and safety laws and regulations in a number of jurisdictions, primarily Israel, governing, among other things: the
use, storage, registration, handling, emission and disposal of chemicals, waste materials and sewage; chemicals, air, water and ground
contamination; air emissions and the cleanup of contaminated sites, including any contamination that results from spills due to our failure
to properly dispose of chemicals, waste materials and sewage. Our operations use chemicals and produce waste materials and sewage and
require permits from various governmental authorities including, local municipal authorities, the Ministry of Environmental Protection
and the Ministry of Health. The Ministry of Environmental Protection and the MOH, local authorities and the municipal water and sewage
company conduct periodic inspections in order to review and ensure our compliance with the various regulations. These laws, regulations
and permits could potentially require the expenditure by us of significant amounts for compliance or remediation. If we fail to comply
with such laws, regulations or permits, we may be subject to fines and other civil, administrative or criminal sanctions, including the
revocation of permits and licenses necessary to continue our business activities. In addition, we may be required to pay damages or civil
judgments in respect of third-party claims, including those relating to personal injury (including exposure to hazardous substances we
use, store, handle, transport, manufacture or dispose of), property damage or contribution claims. Some environmental, health and safety
laws allow for strict, joint and several liability for remediation costs, regardless of comparative fault. We may be identified as a responsible
party under such laws. Such developments could have a material adverse effect on our business, financial condition and results of operations.
In addition, laws and regulations relating to environmental, health and safety matters are often subject to change. In the event of any
changes or new laws or regulations, we could be subject to new compliance measures or to penalties for activities that were previously
permitted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C. Organizational Structure.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have two wholly
owned subsidiaries: PolyPid&#160;Inc., a Delaware corporation with operations in New Jersey, and PolyPid Pharma SRL, a company organized
under the laws of Romania.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D. Property, Plant and Equipment.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive offices
are located at 18 Hasivim Street, Petach Tikva 4959376, Israel, where we lease an approximately 49,000 square foot facility. This Israeli
facility houses our administrative headquarters, research and development laboratories and state-of-the-art manufacturing facility. Our
monthly rent payment is NIS 264,844 (approximately $79,221).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 4A. UNRESOLVED STAFF COMMENTS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 5.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>OPERATING AND FINANCIAL REVIEW AND PROSPECTS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 95 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF<br/>
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. Operating Results.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following discussion
and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements
and the related notes included elsewhere in this annual report on Form 20-F. The discussion below contains forward-looking statements
that are based upon our current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially
from these expectations due to inaccurate assumptions and known or unknown risks and uncertainties, including those identified in &#8220;Cautionary
Note Regarding Forward-Looking Statements&#8221; and under &#8220;Risk Factors&#8221; elsewhere in this annual report on Form 20-F. Our
discussion and analysis for the year ended December 31, 2020 can be found in our Annual Report on Form 20-F for the fiscal year ended
December 31, 2021, filed with the SEC on February 28, 2022.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception in 2008,
we have incurred significant operating losses. Our operating loss for the years ended December&#160;31, 2021 and 2022 were $ 43.1 million
and $38.9 million, respectively. As of December&#160;31, 2022, we had an accumulated deficit of $214.4 million. We expect to continue
to incur significant expenses and operating losses for the foreseeable future, and our losses may fluctuate significantly from year to
year. We anticipate we will continue to incur expenses in connection with our ongoing activities, as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue clinical development of D-PLEX<sub>100</sub>, including our SHIELD II Phase&#160;3 clinical trial for the prevention of SSIs in open abdominal surgeries; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">file NDAs seeking regulatory approval for D-PLEX<sub>100</sub> pursuant to the FDA&#8217;s Section&#160;505(b)(2) regulatory pathway in the United States and the hybrid application pathway in the European Union; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to invest in the preclinical research and development of OncoPLEX and any other future product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to invest in our manufacturing facility and complete commercial process validation for the facility; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish commercial infrastructure to support the marketing, sale and distribution of D-PLEX<sub>100</sub> if it receives regulatory approval; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire field and office-based employees to prepare for and launch any approved product;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire additional research and development and general and administrative personnel to support our operations; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain, expand and protect our intellectual property portfolio; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur additional costs associated with operating as a public company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any product
candidates approved for sale and have not generated any revenue from product sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During October 2022, we announced
a cost reduction plan, including a 20% reduction in headcount across all departments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Operating Expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current operating expenses
consist of three components&#160;&#8212;&#160;research and development expenses, marketing and business and development expenses and general
and administrative expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 96 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not generated
any revenue from product sales and do not expect to generate any revenue from product sales for at least the next few years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Research and
Development, Net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development,
net consists primarily of costs incurred in connection with our research and development activities. This includes conducting clinical
trials and preclinical studies, manufacturing development efforts and activities related to regulatory filings for product candidates,
as well as overhead costs. Our research and development expenses primarily consist of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">salaries and personnel-related costs, including benefits and share-based compensation expense, for our scientific personnel for executing clinical trials, preclinical studies, regulatory activities and for performing research and development activities; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs related to executing clinical trials and preclinical studies; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs related to acquiring, developing and manufacturing materials for such clinical trials and preclinical studies, including costs related to CMC activities; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs related to our manufacturing facility, including the production of development batches; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs of third-party suppliers; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees paid to consultants and other third parties who support the development of our product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses related to regulatory activities, including consulting fees, filing fees paid to regulatory agencies and other costs incurred in seeking regulatory approval of our product candidates; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocated facility-related costs and other related overhead costs. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
are expensed as incurred. We record accrued expenses for research and development activities conducted, on our behalf, by third-party
service providers, which include the performance of clinical trials and the conduct of preclinical studies and contract manufacturing
activities. We record these accrued expenses based upon research and development activities performed by such third-party service providers
and reported to us, and we include these costs in accrued liabilities in the consolidated balance sheets and within research and development
expense in the consolidated statements of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We typically use our employee,
consultant and infrastructure resources across our development programs. We track outsourced development costs by product candidate but
we do not allocate personnel costs, other internal costs or external consultant costs to specific product candidates or preclinical programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From inception through December&#160;31,
2022, we incurred $135.5 million in research and development expenses, net to advance the development of our clinical-stage product candidates,
as well as other preclinical research and development programs. As of December 31, 2022, we received royalty-bearing grants of $4.9&#160;million
in the aggregate from the IIA. Pursuant to the terms of the grants, we are required to pay royalties of 3.0% to the IIA on revenues from
sales of products for which the research and development was funded, in whole or in part, by the IIA, up to a limit of 100% of the amount
of the grant received, plus annual interest calculated at a rate based on 12-month LIBOR. In September 2021, the Bank of Israel, which
determines annual interest rates, published a directive which stated that annual interest at a variable rate linked to the LIBOR rate
for loans in U.S. dollars will be replaced by the SOFR in June 2023. In addition, we must abide by other restrictions associated with
the receipt of such grants under the R&amp;D Law that continues to apply following repayment to IIA. These restrictions may impair our
ability to outsource manufacturing, engage in change of control transactions or otherwise transfer our knowledge outside of Israel and
may require us to obtain IIA approval for certain actions and transactions and pay additional amounts to the IIA. In addition, any change
of control and any change of ownership of our Ordinary Shares that would make a non-Israel citizen or resident an &#8220;interested party&#8221;
as defined in the R&amp;D Law requires prior written notice from the IIA. As of December&#160;31, 2022, we also received non-royalty bearing
grants of $1.6&#160;million in the aggregate from the IIA and $0.7&#160;million in the aggregate from the FP7.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Substantially all of our research
and development expenses for the years ended December&#160;31, 2021 and 2022 were related to the development of D-PLEX<sub>100</sub>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 97 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue to incur
research and development expenses for the foreseeable future as we seek to advance D-PLEX<sub>100</sub> through Phase&#160;3 clinical
trials, including the cost of manufacturing drug supply for these clinical trials, further our preclinical studies and other research
and development programs. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that
will be necessary to complete the development of our product candidates. We are also unable to predict when, if ever, material net cash
inflows will commence from sales of our product candidates. This is due to the numerous risks and uncertainties associated with developing
such product candidates, including the uncertainty of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful enrolment in and completion of clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing an appropriate safety profile; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt of marketing approvals from applicable regulatory authorities; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercializing the product candidates, if and when approved, whether alone or in collaboration with others; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continued acceptable safety profiles of products following approval; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">retention of key research and development personnel. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A change in the outcome of
any of these variables with respect to the development of any of our product candidates would significantly change the costs, timing and
viability associated with the development of that product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>General and
Administrative </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of salaries and personnel-related expenses, including benefits and share-based compensation expense, for employees
performing functions other than research and development. This includes personnel in executive, finance and administrative support functions.
Other general and administrative expenses include directors and officer&#8217;s insurance, professional fees for auditing, tax and legal
services and other consulting fees, as well as facility-related costs not otherwise allocated to research and development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that our general
and administrative expenses will increase if any of our product candidates receives regulatory approval and we determine to build a commercial
infrastructure to support commercial sales and marketing of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Marketing and
Business and Development </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Marketing and business and
development expenses consist primarily of salaries and personnel-related expenses, including benefits and share-based compensation expense.
Other marketing and business and development expenses include professional fees and pre-commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our marketing and
business development expenses will increase if any of our product candidates receives regulatory approval and we determine to build a
commercial infrastructure to support commercial sales and marketing of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 98 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Financial Expense
(Income), Net </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial expense (income),
net consists of financial expense of the loan provided by Kreos, as well as interest income on our short-term and long-term deposits and
our foreign exchange gains and losses.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Comparison
of the Year Ended December&#160;31, 2021 and 2022 </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our results of operations for the year ended December&#160;31, 2021 and 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,553</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27,990</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Marketing and business development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,983</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,888</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,609</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,010</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,145</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,888</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial (income) expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(544</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">540</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss before income tax</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">42,601</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">39,428</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">129</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">42,601</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">39,557</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Research and Development,
Net </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development,
net decreased by $2.6 million for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021. This decrease
was primarily related to a decrease of $3&#160;million in costs related to the completion of the SHIELD I trial and paused the SHIELD
II trial, a decrease of $0.3 million in research and development costs related to D-PLEX<sub>100</sub> and OncoPLEX, and a decrease of
$0.1 million in non-cash share-based compensation. These decreases were offset by an increase of $0.9 million in our manufacturing facility
expenses, an increase of $0.1 million in personnel costs and an increase of $0.2&#160;million in IIA grants recognized in 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Marketing and business development </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Marketing and business development
decreased by $0.1&#160;million for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021. This decrease
was primarily related to a decrease of $0.3&#160;million in personnel costs. This decrease was offset by an increase of $0.1&#160;million
in pre-commercialization activities for the product candidate D-PLEX<sub>100</sub>, and an increase of $0.1 million in non-cash share-based
compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>General and Administrative
</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
decreased by $1.6&#160;million for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021. This decrease
was primarily related to decreases of $1.2 million in directors&#8217; and officers&#8217; insurance premiums, a decrease of $0.4&#160;million
in in personnel costs and a decrease of $0.4&#160;million in non-cash share-based compensation. These decreases were offset by an increase
of $0.4&#160;million in legal, professional and other costs associated with the Company&#8217;s status as a publicly traded company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Financial Expense
(Income), Net </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial expense (income),
net changed by $1.1 million for the year ended December 31, 2022, compared to the year ended December 31, 2021. This change was mainly
driven by the loan provided by Kreos during 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 99 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Income tax expense</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: 26pt">Income taxes amounted
to $0.1 million and $0 for the years ended December 31, 2022 and 2021, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: 26pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Net loss </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net loss decreased by $3.1
million for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021. This decrease was primarily related
to the decrease in research and development, net of $2.6 million, a decrease in general and administrative of $1.6 million, and the decrease
of marketing and business development costs of $0.1 million. These decreases were offset by a increases in financial (income) expense,
net of $1.1&#160;million and an increase in tax expense of $0.1 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Qualitative and
Quantitative Disclosures about Market Risk </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Foreign Currency
Exchange Risk </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate primarily in Israel,
and approximately 50% of our expenses are denominated in NIS. We are therefore exposed to market risk, which represents the risk of loss
that may impact our financial position due to adverse changes in financial market prices and rates. We are subject to fluctuations in
foreign currency rates in connection with these arrangements. Changes of 5% and 10% in the U.S. dollar/NIS exchange rate would have increased/decreased
operating expenses by approximately 1.2% and 2.4%, respectively, during the year ended December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently partially hedge
our foreign currency exchange rate risk to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal
operating currencies. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Interest Rate
Risk </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At present, our investments
consist primarily of cash and cash equivalents and short-term deposits. We may invest in investment-grade marketable securities with maturities
of up to three years, including commercial paper, money market funds, and government/non-government debt securities. The primary objective
of our investment activities is to preserve principal while maximizing the income that we receive from our investments without significantly
increasing risk and loss. Our investments may be exposed to market risk due to fluctuation in interest rates, which may affect our interest
income and the fair market value of our investments, if any.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Inflation-Related
Risks </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inflation generally affects
us by increasing our NIS-denominated expenses, including salaries and benefits, as well as facility rental costs and payment to local
suppliers. We do not believe that inflation had a material effect on our business, financial condition or results of operations during
the years ended December&#160;31, 2022, 2021 and 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>JOBS Act Transition
Period </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#160;107 of the JOBS
Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B)
of the Securities Act for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption
of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of
the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements
available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation
timing for new or revised accounting standards as other public companies that are not emerging growth companies which may make comparison
of our financials to those of other public companies more difficult.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 100 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>B. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
and Capital Resources</span></b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Sources of
Liquidity</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception, we have
not generated any revenue and have incurred operating losses and negative cash flows from our operations. Prior to our IPO, we funded
our operations primarily through the sale of equity securities and convertible debt. On June 30, 2020, we closed our IPO, whereby we sold
4,312,500 Ordinary Shares to the public (inclusive of 562,500 Ordinary Shares pursuant to the full exercise of an overallotment option
granted to the underwriters). The aggregate net proceeds received by us from the IPO were $62.8 million, net of underwriting discounts
and other offering costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 5, 2022, we entered
into the Loan Agreement for up to $15 million with Kreos. The Loan Agreement is comprised of three tranches in the amount of $10.0 million,
$2.5 million, and $2.5 million, respectively. Drawdown of the first tranche was available upon the execution of the agreement. The second
tranche of $2.5 million was available after we met the second tranche milestone in May 2022. The third and final tranche of $2,500,000
will not be drawn since the third tranche milestone has not been met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first tranche in the amount
of $10 million was drawn on April 26, 2022. The issuance costs due to the Loan Agreement amounted to $0.2 million and the second tranche
in the amount of $2.5 million was drawn on July 19, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Loan Agreement provides
for interest-only repayments of the first tranche until December 31, 2022, followed by 36 equal monthly repayments of principal and interest.
For the second tranche, which was drawn in July 2022, and the third tranche, if drawn, we will make repayments of interest only until
August 31, 2023, followed by 33 equal monthly repayments of principal and interest. The senior secured loan initially bears interest at
a rate of 9.25%. The loan is prepayable in full, at any time at our option. The loan is secured by our owned equipment, intellectual property
and all shares we hold in PolyPid Inc. and PolyPid Pharma SRL, and we paid a customary fee to Kreos for the establishment of the loan.
Additionally, PolyPid Inc. entered into a guaranty agreement with Kreos, all as security for monies borrowed by us under the Loan Agreement.
On March 29, 2023, we entered into an amendment to the Credit Line. Pursuant to this amendment, 70% of the remaining principal and interest
repayments will be delayed and repaid on a monthly equal basis from August 2024 to May 2026. The amended secured loan now bears interest
at a rate of 10.00%, and we will pay a restructuring fee to Kreos consisting of 1.00% on close of the amendment and an incremental 3.00%
at maturity. In return for this additional deferral of repayment, Kreos has the right to receive a potential claw back payment on account
of the then outstanding principal amount. This claw back mechanism will be triggered by additional incoming funds from future partnership
agreement or additional financing. If triggered, the minimum claw back to be paid is $1.5 million but will not exceed $3 million. Further,
the outstanding warrants Kreos received were repriced to have an exercise price of $0.42 per share.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As part of the line of credit,
we issued to Kreos a 7-year warrant to purchase our ordinary shares equal to 8% of the amount of each tranche, if borrowed, with an exercise
price of $5.14 per share. Pursuant to the March 2023 amendment, the outstanding warrants Kreos received were repriced to have an exercise
price of $0.42 per share. The Loan Agreement contains customary affirmative and restrictive covenants and representations and warranties.
The expiration date for each warrant issued will be seven years from the issuance date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the amounts
withdrawn, we issued to Kreos a warrant in the total amount of $1.0 million to acquire 194,742 Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2021, we entered into
a Controlled Equity Offering Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald &amp; Co., or the Agent, pursuant to which
we may offer and sell, from time to time, our Ordinary Shares, through the Agent in an at the market offering, or the ATM, as defined
in Rule 415(a)(4) under the Securities Act, for an aggregate offering price of up to $45 million. During the year ended December 31, 2022,
we sold 1,065,057 Ordinary Shares under the ATM for a total amount of $4.6 million, with issuance costs in the amount of $0.2 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December&#160;31, 2022,
we had $12.6 million in cash, cash equivalents and short-term deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Cash Flows</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
information regarding our cash flows for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(32,386</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(34,317</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net cash provided by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,575</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,034</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,428</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net increase (decrease) in cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,548</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,314</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Operating Activities
</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities related primarily to our net losses adjusted for non-cash charges and measurements and changes in components of working capital.
Adjustments to net loss for non-cash items mainly included depreciation, revaluation of convertible preferred share warrants and share-based
compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $34.3 million for the year ended December 31, 2022, as compared to $32.4 million for the year ended December 31, 2021.
This increase was primarily related to the on-going and closing costs of SHIELD I and continued patient recruitment until we paused SHIELD
II Phase 3 clinical trials in abdominal (soft tissue) surgery.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Investing Activities
</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by investing
activities related primarily to the purchase and release of short-term and long-term deposits and the acquisition of laboratory equipment,
office equipment and furniture and leasehold improvements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by investing
activities was $16.6 million for the year ended December&#160;31, 2022, as compared to net cash used in investing activities of $36.9&#160;million
for the year ended December&#160;31, 2021. This change in net cash used in investing activities primarily related to the release of short-term
and long-term deposits, partially offset by purchases of laboratory equipment and leasehold improvements to our manufacturing facility.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Financing Activities
</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities was $16.4 million for the year ended December 31, 2022, as compared to $1.0 million for the year ended December 31, 2021. The
increase in net cash provided by financing activities is primarily related to the net proceeds from the loan provided by Kreos and proceeds
from the sales of Ordinary Shares under the ATM.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2021, we entered into
the Sales Agreement with the Agent, pursuant to which we may offer and sell, from time to time, our Ordinary Shares, through the Agent
in an at the market offering, or the ATM Offering, as defined in Rule 415(a)(4) under the Securities Act, for an aggregate offering price
of up to $45.0 million. In that regard, we registered up to $200,000,000 of our Ordinary Shares on a Registration Statement on Form F-3
(File No. 333-257651), or the F-3. The $45,000,000 of our Ordinary Shares that may be offered, issued and sold under the Sales Agreement
prospectus is included in the $200,000,000 of securities that may be offered, issued and sold by us under the F-3. Upon termination of
the Sales Agreement, any portion of the $45,000,000 included in the Sales Agreement prospectus of the F-3 that is not sold pursuant to
the Sales Agreement will be available for sale in other offerings pursuant to the F-3, and if no shares are sold under the Sales Agreement,
the full $45,000,000 of securities may be sold in other offerings pursuant to the F-3. During the year ended December 31, 2022, we sold
1,065,057 Ordinary Shares under the ATM for a total amount of $4.6 million, with issuance costs in the amount of $0.2 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt"></p><div>

</div><!-- Field: Page; Sequence: 102 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 5, 2022, we entered
into the Loan Agreement for up to $15 million with Kreos. The Loan Agreement is comprised of three tranches in the amount of $10 million,
$2.5 million and $2.5 million, respectively, in which the first tranche in the amount of $10 million and the second tranche in the amount
of $2.5 million were drawn on April 26, 2022 and July 19, 2022, respectively. In addition, in accordance with the Loan Agreement, we will
issue to Kreos warrants to purchase our Ordinary Shares equal to 8% of the amount of each tranche, when and if borrowed, with an exercise
price of $5.14 per share. The expiration date for each warrant issued will be seven years from the agreement date. Accordingly, as a result
of the first tranche and second tranche withdrawal, the Company issued to Kreos 194,742 warrants with an exercise price of $5.14 per share.
The loan is secured by our owned equipment, intellectual property and all shares we hold in PolyPid Inc. and PolyPid Pharma SRL, and we
paid a customary fee to Kreos for the establishment of the loan. Additionally, PolyPid Inc. entered into a guaranty agreement with Kreos,
all as security for monies borrowed by us under the Loan Agreement. On March 29, 2023, we entered into an amendment to the Credit Line.
Pursuant to this amendment, 70% of the remaining principal and interest repayments will be delayed and repaid on a monthly equal basis
from August 2024 to May 2026. The amended secured loan now bears interest at a rate of 10.00%, and we will pay a restructuring fee to
Kreos consisting of 1.00% on close of the amendment and an incremental 3.00% at maturity. In return for this additional deferral of repayment,
Kreos has the right to receive a potential claw back payment on account of the then outstanding principal amount. This claw back mechanism
will be triggered by additional incoming funds from future partnership agreement or additional financing. If triggered, the minimum claw
back to be paid is $1.5 million but will not exceed $3 million. Further, the outstanding warrants Kreos received were repriced to have
an exercise price of $0.42 per share.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Loan Agreement is denominated
in U.S. dollars and bears interest at an annual rate equal to 9.25%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The third and final tranche
of $2.5 million will not be drawn since the third tranche milestone has not been met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In March 2023, we completed the
Offering, pursuant to which we sold 14,660,000 Ordinary Shares at a public offering price of $0.42 per share, for total gross proceeds
of $6.2 million. In addition, we granted to the underwriter a 30-day option to purchase up to an additional 15% of the Ordinary Shares
offered in the Offering at the public offering price, less underwriting discounts and commissions. The underwriter exercised its option
in full at the closing of the Offering. The securities were offered by us pursuant to a "shelf" under the F-3. Concurrently
with the Offering, we entered into a private placement with some of our existing shareholders, pursuant to which we issued pre-funded
warrants, or the Pre-Funded Warrants, to acquire an aggregate of up to 10,357,139 Ordinary Shares for total gross proceeds of $4.4 million.
The exercise price per Pre-Funded Warrant is $0.0001 per Ordinary Share. Exercise of the Pre-Funded Warrants is subject to an increase
in our authorized share capital. We are obligated to hold an annual and/or extraordinary general meeting of shareholders by May 30, 2023
and include in the agenda of such meeting a proposal to obtain shareholder approval to increase the number of our authorized share capital.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Current Outlook </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not generated
any revenues from the commercial sale of our product candidates, and we do not expect to generate revenue for at least the next few years.
We expect to continue to incur expenses in connection with our ongoing activities, particularly as we continue to conduct clinical trials
and seek marketing approval for our product candidates, and as we continue the research and development of our other existing and future
product candidates. In addition, if we obtain marketing approval for any product candidates, we expect to incur significant commercialization
expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and
distribution are not the responsibility of potential collaborators. Accordingly, we will need to obtain substantial additional funding
in connection with our continuing operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 103 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; ">We expect
that our existing cash and cash equivalents and short-term deposits will enable us to fund our operating expenses and capital expenditure
requirements well into the first quarter of 2024. We anticipate that we will need to raise additional capital in order to complete our
clinical and regulatory program for D-PLEX<sub>100</sub> towards potential NDA submission, including the SHIELD II clinical trial, as
well as continue to invest in the research and development of OncoPLEX and any other future product candidates. If we are unable to raise
additional capital when desired, our business, operating results, and financial condition would be adversely affected, and there is substantial
doubt about our ability to continue as a going concern. We have a shareholders&#8217; equity of $5.8 million as of December 31, 2022,
and negative operating cash flows in recent years. We expect to continue incurring losses and negative cash flows from operations until
our products reach commercial profitability. Our plans to reduce the going concern risk include the continued commercialization of our
products, maintaining cost efficiency and raising capital through the sale of additional equity securities, debt or capital inflows from
strategic partnerships.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
future capital requirements will depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, progress, results and costs of our ongoing clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs, timing and outcome of regulatory review of D-PLEX<sub>100</sub> and any future product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs and timing of establishing and validating manufacturing processes and facilities for development and commercialization of D-PLEX<sub>100</sub> and any future product candidates, if approved, including our manufacturing facility; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number and development requirements of any future product candidates that we may pursue; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval, which may be affected by market conditions, including obtaining coverage and adequate reimbursement of our product candidates from third-party payors, including government programs and managed care organizations, and competition; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish and maintain collaborations with biopharmaceutical companies on favorable terms, if at all; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which we acquire or in-license other product candidates and technologies. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Identifying potential product
candidates and conducting clinical trials and preclinical studies is a time-consuming, expensive and uncertain process that takes many
years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales.
In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived
from sales of product candidates that we do not expect to be commercially available for few years, if at all. Accordingly, we will need
to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to
us on acceptable terms, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until such time, if ever,
as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, including
pursuant to the ATM Offering, debt financings, grants, collaborations, strategic alliances and licensing arrangements. If we are unable
to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product
development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer
to develop and market ourselves.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 104 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_021"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.C  Research and development, patents and licenses, etc.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the past three years,
we have focused our preclinical and clinical development efforts on our lead product candidate D-PLEX<sub>100 </sub>for the prevention
of abdominal (soft tissue) SSIs after abdominal surgery and the prevention of sternal (bone) SSIs after cardiac surgery. We also continue
to evaluate the development of D-PLEX<sub>100</sub> for other types of surgeries. Our pipeline also includes an early-stage oncology program
focused on the preclinical development of OncoPLEX, an intra-tumoral cancer therapy. We continuously evaluate additional product candidates
for our clinical pipeline program that have been developed by us or that may be the subject of in-licenses from third parties or out-
licenses to third parties. Our R&amp;D team is comprised of 48 scientists, doctors and clinicians, who are based out of our corporate
headquarters in Petach Tikva, Israel. For a description of the amounts that we have incurred over the last two years pursuant to our research
and development programs, please see &#8220;Item 5. Operating and Financial Review and Prospects&#8212; A. Operating Results&#8212; Operating
Expenses&#8212; Research and Development Expenses, net&#8221; and &#8220;Item 5. Operating and Financial Review and Prospects&#8212; A.
Results of Operations &#8212; Comparison of the year ended December 31, 2021 and 2022 &#8212; Research and Development Expenses, net.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our patent estate includes
patents and patent applications with claims directed to our PLEX technology platform, D-PLEX<sub>100</sub> product candidate and claims
for potential future product candidates. As of March 26, 2023, our patent estate included 146 issued patents, including utility and composition
of matter patents, 5 allowed and 10 pending patent applications and one published PCT application for our product candidates and methods
of treatment. For a description of our intellectual property, please see &#8220;Item 4. Information on the Company&#8212; B. Business
Overview.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_022"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.D
Trend Information</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not generated
any revenue from product sales and do not expect to generate any revenue from product sales for at least the next few years. From inception
through December&#160;31, 2022, we incurred $135.5 million in research and development expenses, net to advance the development of our
clinical-stage product candidates, as well as other preclinical research and development programs. We expect to continue to incur expenses
in connection with our ongoing activities, particularly as we continue to conduct clinical trials and seek marketing approval for our
product candidates, and as we continue the research and development of our other existing and future product candidates. In addition,
if we obtain marketing approval for any product candidates, we expect to incur significant commercialization expenses related to product
sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the
responsibility of potential collaborators. &#160;For a description of additional factors that may affect our future performance, please
see &#8220;Item 5. Operating and Financial Review and Prospects&#8212; B. Liquidity and Capital Resources&#8212; Current Outlook.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 105 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.E
 Critical Accounting Estimates</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our consolidated financial
statements are prepared in accordance with accepted accounting principles generally accepted in the United States. The preparation of
our consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets,
liabilities, costs and expenses. We base our estimates and assumptions on historical experience and other factors that we believe to be
reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from
these estimates. Our most critical accounting policies are summarized below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Share-Based
Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for share-based
compensation in accordance with ASC No.&#160;718, &#8220;Compensation&#8212;Stock Compensation,&#8221; which requires companies to estimate
the fair value of equity-based payment awards on the date of grant using the option-pricing model. We recognize compensation expenses
for the value of our awards granted based on the straight-line attribution method over the requisite service period of each of the awards.
We recognize forfeitures of awards as they occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize compensation
costs only for those shares expected to vest using the straight-line method over the requisite service period of the award, which is generally
the option vesting term of three to four years. We recognize forfeitures of awards as they occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Option Valuations
</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We selected the Black-Scholes-Merton
model as the most appropriate fair value method for our option awards. The Black-Scholes-Merton model requires a number of assumptions,
of which the most significant are the share price, volatility and the expected option term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Key Assumptions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Black-Scholes-Merton option-pricing
model requires the input of highly subjective assumptions, including the fair value of the underlying ordinary shares, the expected volatility
of the price of our ordinary shares, the expected term of the option, risk-free interest rates and the expected dividend yield of our
ordinary shares. These estimates involve inherent uncertainties and the application of the management&#8217;s judgment. If such inputs
change and different assumptions are used, our share-based compensation expenses could be materially different in the future. These assumptions
are estimated as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair Value of Ordinary Shares - The fair value of each ordinary share was based on the closing price of the Company&#8217;s publicly traded ordinary shares as reported on the date of the grant.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 106 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-Free Interest Rate - The risk-free rate for the expected term of the options is based on the Black-Scholes option-pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Term - The expected term represents the period that options are expected to be outstanding. For option grants that are considered to be &#8220;plain vanilla,&#8221; the Company determines the expected term using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the options.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected Volatility - As the Company has a short trading history for its ordinary shares, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expected Dividend Yield - The Company has never
    declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. As a result, an expected
    dividend yield of zero percent was used.&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the assumptions used in the Black-Scholes-Merton
    model change significantly, the share-based compensation expenses in future awards may differ materially as compared with the current
    awards granted.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We incurred non-cash share-based
compensation expense of $4.3 million, $4.8&#160;million and $4.6 million during the years ended December&#160;31, 2022, 2021 and 2020,
respectively. We expect to continue to grant share option awards in the future, and to the extent that we do, our actual share-based compensation
expenses recognized are likely to increase.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Accrued Research
and Development Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">As
part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development
expenses. This process involves reviewing purchase orders and open contracts, communicating with our personnel to identify services that
have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the services when
we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears
for services performed, on a&#160;pre-determined&#160;schedule or when contractual milestones are met; however, some require advance payments.
We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances
known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary.
The significant estimates in our accrued research and development expenses include the following costs incurred for services in connection
with research and development activities for which we have not yet been invoiced:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vendors in connection with clinical development activities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CROs in connection with clinical trials; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investigative sites in connection with clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Although
we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of
services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are
too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued
research and development expenses.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Warrants to
Purchase Convertible Preferred Shares </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrants to purchase our convertible
preferred shares were classified as a liability on the balance sheet, and measured at fair value, as the underlying shares are contingently
redeemable (upon a deemed liquidation event) and, therefore, may obligate us to transfer assets at some point in the future. The warrants
are subject to re-measurement to fair value at each balance sheet date and any change in fair value is recognized as a component of financial
income, net, in the statement of operations. On June 30, 2020, as a result of the IPO, the warrant liability to convertible preferred
shares has been classified to Warrants to Ordinary Shares in equity. Our outstanding issued warrants to purchase Ordinary Shares as of
December 31, 2022, were as follows: (i) 200,596 warrants with an exercise price of $15.95 per share which expire in August 2023, (ii)
17,925 warrants with an exercise price of $16 per share which expire in September 2024 and (iii) 194,742 warrants with an exercise price
of $5.14 per share which expire in April 2029.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 107 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Grants and Participation </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Royalty-bearing grants from
the IIA for funding approved research and development projects are recognized at the time we are entitled to such grants, on the basis
of the costs incurred, and are presented as a deduction from research and development expenses. Since the payment of royalties is not
probable when the grants are received, we do not record a liability for amounts received from the IIA until the related revenues are recognized.
Non-royalty-bearing grants from the IIA MAGNET program and from FP7 for funding approved research and development projects are recognized
at the time we are entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development
expenses. In the event of failure of a project that was partly financed by the IIA, we would not be obligated to pay any royalties or
repay the amounts received.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December&#160;31, 2022,
we have received royalty-bearing grants totaling $4.9 million. Pursuant to the terms of the grants, we are required to pay royalties to
the IIA of 3.0% on revenues from sales of products developed financed in whole or in part by IIA, up to a limit of 100% of the grants
received, plus annual interest calculated on the 12-month LIBOR rate as published on the first business day of each calendar year. Through
December 31, 2022, no royalties have been paid or accrued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we must abide
by other restrictions associated with the receipt of such grants under the R&amp;D Law that continue to apply following repayment to the
IIA. These restrictions may impair our ability to outsource manufacturing or otherwise transfer our knowledge outside of Israel, or engage
in change of control transactions, and may require us to obtain IIA approval for certain actions and transactions and pay additional amounts
to the IIA. In addition, any change of control and any change of ownership of our Ordinary Shares that would make a non-Israel citizen
or resident an &#8220;interested party&#8221; as defined in the R&amp;D Law requires prior written notice from the IIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Leases</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">On January 1, 2022, we
adopted the new lease guidance for our operating lease agreements using the modified retrospective approach and elected to use the effective
date as the date of initial application. We elected to use the &#8220;package of practical expedients&#8221;, which permits us not to
reassess our prior conclusions about lease identification, lease classification and initial direct costs. Consequently, comprehensive
periods were not restated.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">The guidance had a material
impact on our consolidated balance sheets which resulted in the recognition of operating lease rights of use, or ROU, assets and lease
liabilities of $3.4 million, on January 1, 2022, which included reclassification of rent prepayments as components of the ROU assets.
The standard did not have a material impact on our consolidated statements of operations.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">We determine if an arrangement
meets the definition of a lease at the inception of the lease. ROU assets represent the right to use an underlying asset for the lease
term and lease liabilities represent our obligation to make lease payments arising from the lease agreement. ROU asset is measured based
on the discounted present value of the remaining lease payments, initial direct costs incurred and prepaid lease payments, excluding lease
incentives. The lease liability is measured based on the discounted present value of the remaining lease payments. The discounted present
value of remaining lease payments is computed using Incremental Borrowing Rate, or IBR, based on the information available at the inception
of the lease. Our IBR was estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and
in economic environments where the leased asset was located. Lease term may include options to extend or terminate the lease when it is
reasonably certain that we would exercise that option. We elected the practical expedient for lease agreements with a term of twelve months
or less and did not recognize ROU assets and lease liabilities in respect of those agreements. Lease expenses for lease payments are recognized
on a straight-line basis over the lease term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 108 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 6.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. Directors and Senior Management.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding our executive officers, key employees and directors as of the date of this annual report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 67%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dikla Czaczkes Akselbrad</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Director</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noam Emanuel, Ph.D.&#160;</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Scientific Officer</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dalit Hazan</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President, Research and Development, Clinical and Regulatory Affairs</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ori Warshavsky</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Chief Operating Officer</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">- US</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonny Missulawin</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; font-size: 12pt"><span style="font-size: 10pt; font-weight: normal">Senior Vice President of Finance</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Non-Employee Directors</i></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob Harel <sup>(1)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yechezkel Barenholz, Ph.D.&#160;<sup>(1)(2)(3)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nir Dror <sup>(1)(3)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chaim Hurvitz <sup>(1)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itzhak Krinsky, Ph.D. <sup>(1)(2)(3)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anat Tsour Segal <sup>(1)(2)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert B. Stein, M.D., Ph.D.&#160;<sup>(1)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="width: 0.25in"></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates independent
director under Nasdaq Stock Market rules.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="width: 0.25in"></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of our Audit
Committee.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="width: 0.25in"></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of our Compensation,
Nominating and Corporate Governance Committee.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dikla Czaczkes Akselbrad, Chief Executive Officer,
Director </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Ms. Dikla Czaczkes Akselbrad
</i>has served as our Chief Executive Officer since July 2022 and a director since August 2022. From December 2016 to July 2022, Ms.&#160;Czaczkes
Akselbrad served as our Executive Vice President and Chief Financial Officer. Prior to that time, Ms.&#160;Czaczkes Akselbrad served as
our Chief Strategy Officer from July 2014 to December 2016. Ms. Czaczkes Akselbrad has over 20 years of experience in capital markets,
finance and business development. Ms. Czaczkes Akselbrad served as a chief financial officer of Compugen Ltd. (Nasdaq: CGEN) from February
2008 to May 2014. She holds a B.A. in accounting and economics and an M.B.A. in finance, both from Tel Aviv University, and is a certified
public accountant in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 109 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Noam Emanuel, Ph.D., Chief Scientific Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Noam Emanuel, Ph.D.,
</i>our co- founder, served as our Chief Executive Officer from 2008 to 2010 and has served as our Chief Scientific Officer since April
2019. He previously served as a director from October 2008 to May 2020 and was our Chief Technology Officer from October 2010 to April
2019. Dr.&#160;Emanuel has over 25&#160;years of experience in drug development, drug delivery and immunology, including with respect
to local, systemic and transdermal drug delivery systems, as well as in imaging and diagnostics. He holds a Ph.D. in immunology and drug
delivery from the Hebrew University of Jerusalem. Dr. Emanuel will retire from our company during the second quarter of 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dalit Hazan, Executive Vice President, Research
and Development, Clinical and Regulatory Affairs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Ms. Dalit Hazan</i> has
served as our Executive Vice President, Research and Development, Clinical and Regulatory Affairs since March 2022, Senior Vice President,
Research and Development and Regulatory Affairs since June 2021, Vice President, Research and Development and Regulatory Affairs since
April 2019, Vice President, Regulatory Affairs since March 2018 and Regulatory Affairs Director since April 2016. Prior to that time,
Ms.&#160;Hazan was the head of Global Regulatory Affairs at Teva Pharmaceuticals Industries&#160;Ltd. From 2013 to April 2016 as well
as Head of Regulatory Affairs department since 2007. She holds a B.S. in biology and a M.S. in physiology and pharmacology from the Sackler
Faculty of Medicine at Tel Aviv University and an Executive MBA from Bar Ilan University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Ori Warshavsky, <span>Chief
Operating Officer</span> - US</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Ori Warshavsky</i>
has served as our <span>Chief Operating Officer</span> - US since January 2022 and as Vice President of
Marketing since October 2020. Prior to joining the Company, Mr. Warshavsky spent over 10 years at Teva Pharmaceuticals Industries&#160;Ltd.
most recently as Senior Director of Oncology Marketing for the U.S. market from December 2017 to September 2020. Prior to that, he served
as Head of Market Access for Teva Canada from June 2016 to December 2017 and as Chief of Staff to the Chief Executive Officer of Teva&#8217;s
global generics business from June 2014 to June 2016. He holds a B.Sc. in Biotechnology Engineering from The Ben-Gurion University and
an M.B.A from Duke University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Jonny Missulawin, Senior Vice President of
Finance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Jonny Missulawin </i>has
served as our Senior Vice President of Finance since August 2022. From December 2017 to August 2022, Mr. Missulawin served as our Director
of Finance. From May 2014 to December 2017, Mr. Missulawin served as our Financial Controller. Prior to joining the Company, Mr. Missulawin
served as a Senior Auditor at Ernst &amp; Young from 2010 to 2013. Mr. Missulawin holds an MBA from Tel Aviv University in Financial Management
and a BA in Accounting and Economics from Bar-Ilan University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Jacob Harel, Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Jacob Harel</i> has
served as a director since November 2017 and the chairman of our board of directors since December 2017. Mr.&#160;Harel has more than
27 years of experience at Merck &amp; Co. in leadership roles in sales, marketing and in his last position he was the head of the corporate
business development group. Since 2014,&#160;Mr. Harel&#160;serves as the&#160;president of The Harel Group, a&#160;business development
advisory firm that provides business development support to pharmaceutical and medical device companies. He holds a B.S. in economics
from Haifa University and an M.B.A. from Tel Aviv University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Yechezkel Barenholz, Ph.D., Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Yechezkel Barenholz,
Ph.D. </i>has served as a director since April 2008. Prof.&#160;Barenholz&#160;currently serves as head of the Laboratory of Membrane
and Liposome Research at the Department of Biochemistry of the Hadassah Medical School at the Hebrew University of Jerusalem, a position
he has held since 1975.&#160;He has served&#160;as Chief Executive Officer and Chief Scientific Officer of Ayana Pharma Ltd. since 2018
and 2014, respectively. He has served as&#160;a director of Aulos Bioscience since 2019. He is the co-inventor and co-developer of Doxil,
the first nano-delivery system approved by the FDA. He&#160;led the development of generic Doxil at Ayana Pharma Ltd. that was approved
by the FDA on October 2021, and which is now sold in the United States and Israel.&#160; Prof.&#160;Barenholz&#160; has been awarded many
national and international prizes including the prestigious Israel Prime Minister 2020 EMET prize in Nanotechnology. He&#160;holds a B.S.,
M.S. and Ph.D. in biochemistry from the Hebrew University of Jerusalem.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Nir Dror, Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Nir Dror</i> has served
as a director since May 2020. Mr.&#160;Dror currently serves as the Chief Financial Officer of Aurum Ventures M.K.I.&#160;Ltd., a position
he has held since 2013. He holds a B.A. and L.L.M. from Tel Aviv University and an M.B.A. from the University of Michigan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 110 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Chaim Hurvitz, Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. <i>Chaim Hurvitz</i> has
served as a director since February 2016. Mr.&#160;Hurvitz currently serves as Chief Executive Officer of CH Health, a private venture
capital firm, a position he has held since May 2011. He served as chairman of Galmed Pharmaceuticals&#160;Ltd. from 2011 to December 2018
and a director of UroGen Pharma&#160;Ltd. from May 2013 to December 2017. He holds a B.A. in political science and economics from Tel
Aviv University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Itzhak Krinsky, Ph.D., Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Itzhak Krinsky, Ph.D.</i>
has served as a director since January 2019. Dr. Krinsky currently serves as a director and member of the audit committee of Globrands
Ltd., Noramco Inc. and Woodstock Sterile Solutions, positions he has held since July 2018, September 2018 and April 2021, respectively.
Dr.&#160;Krinsky previously worked at Teva Pharmaceuticals Industries&#160;Ltd. as the Chairman of Teva Japan, Chairman of Teva South
Korea and Head of Business Development, Asia Pacific from October 2012 to April 2016. Dr.&#160;Krinsky served as a director of Kamada&#160;Ltd.
from November 2017 to November 2019 and as a member of the nominating and corporate governance committee of Advanz Pharma Corp. (formerly
known as Concordia Healthcare Corp) from May 2017 to September 2018. He holds a B.A. and M.A. in economics from Tel Aviv University and
a Ph.D. in economics from McMaster University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Anat Tsour Segal, Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Ms. Anat Tsour Segal</i>
has served as a director since April 2008. From April 2003 to February 2016, she served as the founder, Chief Executive Officer and a
director of Xenia Venture Capital, a technological incubator and investment firm. Xenia Venture Capital, our first seed investor, also
seeded over 25 companies in the areas of pharma, medical devices and technology. From 2018 to 2021, Ms. Tsour Segal served as Chief Executive
Officer of Capital Nature, a technological incubator and investment firm specializing in areas of sustainability and renewable energy.
She holds a B.A. in economics and management, an M.B.A. in finance and an LL.B. from Tel Aviv University and she is a lecturer at the
Adelson School of Entrepreneurship at Reichman University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Robert B. Stein, M.D., Ph.D., Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr.&#160;<i>Robert B. Stein,
M.D., Ph.D.</i>, has served as a director since June 2020. Dr.&#160;Stein currently serves as an Operating Partner at Samsara BioCapital,
a position he has held since January 2018, and he is the Principal Consultant at RBS Biotech Consulting,&#160;LLC, which he founded in
August 2008. He previously served as the Chief Scientific Officer and Head of Research and Development of Agenus&#160;Inc. from January
2014 to January 2016 and as the President of Research and Development from January 2016 to April 2017. He has served on the boards of
directors of Protagenic Therapeutics,&#160;Inc. since February 2016 and Taro Pharmaceutical Industries&#160;Ltd. since February 2020.
.. He holds a B.S. in biology and chemistry from Indiana University and an M.D. and a Ph.D. in physiology and pharmacology from Duke University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Family Relationships</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
between any members of our executive management and our directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 111 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Arrangements for Election of Directors and
Members of Management</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors consists
of eight directors, each of whom will continue to serve pursuant to their appointment until the next annual general meeting of shareholders.
We are not a party to, and are not aware of, any voting agreements among our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B. Compensation. </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
in the aggregate all compensation we paid to all of our directors and senior management from January 1, 2022 through December 31, 2022.
The table does not include any amounts we paid to reimburse any of such persons for costs incurred in providing us with services during
this period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All amounts reported in the
tables below reflect our cost, in thousands of U.S. dollars. Amounts paid in NIS are translated into U.S. dollars at the rate of NIS 3.36
= U.S. $1.00, based on the average representative rate of exchange between the NIS and the U.S. dollar as reported by the Bank of Israel
during such period of time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Salary&#160;<br/>
and&#160;Related<br/>
Benefits <sup>(1)</sup></b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus<br/> Payments,<br/> Benefits<br/> and<br/> Perquisites</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Share-Based<br/>
Compensation<sup>(2)</sup></b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">All directors and senior management as a group, consisting of 15 persons as of December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,394,858</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">437,904</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,129,958</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the directors and senior management&#8217;s gross salary plus payment of mandatory social benefits made by the company on behalf of such officer. Such benefits may include, to the extent applicable to the executive, payments, contributions and/or allocations for savings funds, education funds (referred to in Hebrew as &#8220;Keren Hishtalmut&#8221;), pension, severance, risk insurances (e.g., life or work disability insurance) and payments for social security.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computed based on Black-Scholes-Merton model.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the Israeli
Companies Law, we are required to disclose the compensation granted to our five most highly compensated officers. The table below reflects
the compensation granted during or with respect to the year ended December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Executive Officer</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary<br/>
 and&#160;Related<br/>
 Benefits</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus<br/>
 Payments,<br/>
 Benefits<br/>
 and<br/>
 Perquisites</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share-Based<br/>
 Compensation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Amir Weisberg</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">429,363</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">223,115</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">237,382</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">889,860</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dikla Czaczkes Akselbrad</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">356,449</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">65,885</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">326,976</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">749,310</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Noam Emanuel, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">334,108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,514</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">459,275</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">893,897</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dalit Hazan</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">287,091</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25,160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">266,717</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">578,968</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ori Warshavsky</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">335,521</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">153,513</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">489,034</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 112 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into written
employment or services agreements with each of our executive officers. All of these agreements contain customary provisions regarding
noncompetition, confidentiality of information and most of them contain also customary provisions regarding assignment of inventions.
However, the enforceability of the noncompetition provisions may be limited under applicable law. In addition, we have entered into agreements
with each executive officer and director pursuant to which we have agreed to indemnify each of them up to a certain amount and to the
extent that these liabilities are not covered by directors and officers insurance. Members of our senior management may be eligible for
bonuses in accordance with our compensation policy and as set forth by our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a description of the terms
of our options and option plans, see &#8220;Item 6. E. Share Ownership&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Directors&#8217; Service Contracts </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than with respect to
our directors that are also executive officers, we do not have written agreements with any director providing for benefits upon the termination
of his or her engagement with our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C. Board Practices.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Board of Directors </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our amended and restated
articles of association, our board of directors must consist of at least five directors and not more than eleven directors. Our board
of directors presently consists of eight members. We believe that Messrs.&#160;Harel, Dror and Hurvitz, Ms.&#160;Segal, Drs. Krinsky and
Stein and Prof. Barenholz are &#8220;independent&#8221; for purposes of the Nasdaq Stock Market rules. Under the Israeli Companies Law,
our board of directors is responsible for setting our general policies and supervising the performance of management. Our board of directors
may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive
officers are responsible for our day-to-day management and have individual responsibilities established by our board of directors. Our
Chief Executive Officer is appointed by, and serves at the discretion of, our board of directors, subject to the terms of the employment
agreement that we have entered into with her.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than vacancies to be
filled through selection by the remaining members of our board, the Israeli Companies Law and our amended and restated articles of association
provide that directors are elected at the annual general meeting of our shareholders by a vote of the majority of the total voting power
of our company voting in person, by proxy or by other voting instrument at that meeting. We have only one class of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, our board of directors is required to employ independent judgment and discretion when voting, and is prohibited from entering into
any voting arrangements with respect to actions taken at meetings of the board. Further, the Israeli Companies Law provides that in the
event a director learns about an alleged breach of law or improper conduct of business relating to a company matter, said director must
promptly take action to summon a meeting of the board of directors to address any such breach.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the exemptions
available to foreign private issuers under Nasdaq Rules, we follow the requirements of the Nasdaq Rules with regard to the process of
nominating directors by means of our compensation, nominating and corporate governance committee, which is comprised of directors who
our board has deemed to be independent under Nasdaq Rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 113 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our amended and
restated articles of association allows our board of directors to appoint directors to fill vacancies on our board of directors, including
filling empty board seats up to the maximum number of directors permitted under our articles of association, for a term of office equal
to the remaining period of the term of office of each director whose office has been vacated. Vacancies on our board of directors may
be filled by a vote of a simple majority of the directors then in office. A director so appointed will hold office until the next annual
general meeting of our shareholders in which the other directors then in office are proposed to be replaced or reappointed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors may be removed from
office by a resolution at a general meeting of shareholders adopted by a vote of 65% of the total voting power of our company in accordance
with the Israeli Companies Law and our amended and restated articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, and except as described below, we would be required to include on our board of directors at least two members, each of whom qualifies
as an external director, and as to whom special qualifications and other provisions would be applicable. We would also be required to
include one such external director on each of our board committees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under regulations promulgated
under the Israeli Companies Law, Israeli companies whose shares are traded on stock exchanges such as The Nasdaq Global Market that do
not have a controlling shareholder (as defined therein) and which comply with the requirements of the jurisdiction where the company&#8217;s
shares are traded with respect to the appointment of independent directors and the composition of an audit committee and compensation
committee, may elect not to follow the Israeli Companies Law requirements with respect to the composition of its audit committee and compensation
committee and the appointment of external directors. As we do not have a controlling shareholder, and we comply with the requirements
of the Nasdaq Stock Market with respect to the composition of our board and such committees, we therefore are exempt from the Israeli
Companies Law requirements with respect thereto, including the appointment of external directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors is
required to elect one director to serve as the chairman of the board of directors to preside at the meetings of the board of directors,
and may also release that director from his or her position as chairman. Pursuant to the Israeli Companies Law, neither the chief executive
officer nor any of his or her relatives is permitted to serve as the chairman of the board of directors, and a company may not (subject
to a certain time-limited exemption, as described below) vest the chairman or any of his or her relatives with the chief executive officer&#8217;s
authorities. In addition, a person who reports, directly or indirectly, to the chief executive officer may not serve as the chairman of
the board of directors; the chairman may not be vested with authorities of a person who reports, directly or indirectly, to the chief
executive officer; and the chairman may not serve in any other position in the company or a controlled company, but he or she may serve
as a director or chairman of a controlled company. However, and notwithstanding the foregoing, the Israeli Companies Law permits the shareholders
of a company to determine, for periods not exceeding three years from each such determination, that the Chairman or his or her relative
may serve as chief executive officer or be vested with the chief executive officer&#8217;s authorities, and that the chief executive officer
or his or her relative may serve as Chairman or be vested with the Chairman&#8217;s authorities. Such determination of a company&#8217;s
shareholders requires either: (1) the approval of at least the majority of the shares of those shareholders present and voting on the
matter (other than controlling shareholders and those having a personal interest in the determination); or (2) that the total number of
shares opposing such determination does not exceed 2% of the total voting power in the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Director Independence
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although not required of foreign
private issuers under Nasdaq Rules, we comply with the requirements thereunder applicable to domestic listed companies that a majority
of the board of directors be deemed to be independent under such rules, as well as the independence requirements that are applicable to
our audit committee and compensation, nominating and corporate governance committee if we were a domestic listed company, as described
below. In light of this obligation, our board of directors has undertaken a review of the independence of our directors under current
rules and regulations of the SEC and Nasdaq Rules and considered whether any of our directors has a material relationship with us that
could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information
requested from and provided by each director concerning such director&#8217;s background, employment and affiliations, including family
relationships, our board of directors determined that Messrs.&#160;Harel, Dror and Hurvitz, Ms.&#160;Segal, Drs. Krinsky and Stein and
Prof. Barenholz, representing seven of our eight directors, are &#8220;independent directors&#8221; as defined under current rules and
regulations of the SEC and Nasdaq Rules. In making these determinations, our board of directors considered the current and prior relationships
that each non-employee director has with our company and all other facts and circumstances that our board of directors deemed relevant
in determining their independence, including the beneficial ownership of our share capital by each non-employee director and the transactions
involving them described in &#8220;Item 7. B. &#8212; Related Party Transactions.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 114 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Alternate Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our articles of association
provide, consistent with the Israeli Companies Law, that any director, and with respect to external directors &#8211; only subject to
certain preconditions, may appoint another person to serve as his or her alternate director, provided such person has the qualifications
prescribed under the Israeli Companies Law to be appointed and to serve as a director and is not already serving as a director or an alternate
director of the company. The term of an alternate director may be terminated at any time by the appointing director and automatically
terminates upon the termination of the term of the appointing director. An alternate director has the same rights and responsibilities
as a director. To date, there are no alternate director appointments in effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Leadership
Structure of the Board </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the Israeli
Companies Law and our amended and restated articles of association, our board of directors is required to appoint one of its members to
serve as chairman of the board of directors. Our board of directors has appointed Jacob Harel to serve as chairman of the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Board Committees
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law and our amended and restated articles of association, our board of directors is permitted to form committees, and to delegate to any
such committee powers allotted to the board of directors, subject to certain exceptions. In general, the board of directors may overturn
a resolution adopted by a committee it has formed; provided, however, that the board&#8217;s decision shall not affect the ability of
third parties, who were not aware of such decision, to rely on the committee&#8217;s resolution prior to the time it is overturned. Only
members of the board of directors can be members of a board committee, unless the committee is solely advisory. Our board of directors
has established two standing committees &#8211; the audit committee and the compensation committee, both of which are mandatory under
the Israeli Companies Law.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Audit Committee
</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Israeli Companies
Law Requirements </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, we are required to appoint an audit committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Nasdaq Listing
Requirements </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Nasdaq Rules, we
are required to maintain an audit committee consisting of at least three independent directors, each of whom is financially literate and
one of whom has accounting or related financial management expertise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The members of our audit committee
include Dr. Krinsky, Ms. Tsour Segal and Prof. Barenholz. Dr. Krinsky serves as the chairman of our audit committee. All members of our
audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and The Nasdaq Global
Market. Our board of directors has determined that each of Dr.&#160;Krinsky and Ms.&#160;Segal is an audit committee financial expert
as such term is defined by the SEC rules and has the requisite financial experience as defined by the Nasdaq Rules. Each of the members
of our audit committee is &#8220;independent&#8221; as such term is defined in Rule&#160;10A-3(b)(1) under the Exchange Act and satisfies
the independent director requirements under the Nasdaq Rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 115 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Audit Committee
Role </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee charter
sets forth the responsibilities of the audit committee consistent with the rules and regulations of the SEC and the Nasdaq Rules, as well
as the requirements for such committee under the Israeli Companies Law, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in accordance with Israeli law; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending the engagement or termination of the person filling the office of our internal auditor, reviewing the services provided by our internal auditor and reviewing effectiveness of our system of internal control over financial reporting;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board of directors; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and monitoring, if applicable, legal matters with significant impact, receiving reports regarding irregularities and legal compliance, acting according to the Company&#8217;s &#8220;whistleblower policy&#8221; and recommending actions to our board of directors if so required.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee provides
assistance to our board of directors in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing,
financial reporting, internal control and legal compliance functions by pre-approving the services performed by our independent accountants
and reviewing their reports regarding our accounting practices and systems of internal control over financial reporting. Our audit committee
also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that
the auditors are independent of management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, our audit committee is responsible, among other things, for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether there are deficiencies in the business management practices of our company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the board of directors to improve such practices; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under the Israeli Companies Law); </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing the approval process for certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under the Israeli Companies Law) and establishing the approval process for certain transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the board of directors approves the working plan of the internal auditor, examining such working plan before its submission to the board of directors and proposing amendments thereto; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining our internal audit controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources and tools to fulfill his responsibilities; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining the scope of our auditor&#8217;s work and compensation and submitting a recommendation with respect thereto to our board of directors, depending on which of them is considering the appointment of our auditor; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures for the handling of employees&#8217; complaints as to the financial management of our business and the protection to be provided to such employees. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Compensation,
Nominating and Corporate Governance Committee and Compensation Policy </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The composition of our compensation,
nominating and corporate governance committee meets the requirements for and guidance under the Nasdaq Rules and current SEC rules and
regulations applicable to domestic issuers. The members of this committee are Mr.&#160;Dror, Dr.&#160;Krinsky and Prof. Barenholz, each
of whom is independent in accordance with the Nasdaq rules. Mr. Dror serves as the chair of the committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Israeli Companies
Law Requirements </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, the board of directors of a public company must appoint a compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 116 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duties of the compensation
committee under the Israeli Companies Law, include the recommendation to the company&#8217;s board of directors of a policy regarding
the terms of engagement of office holders, to which we refer as a compensation policy. That policy must be adopted by the company&#8217;s
board of directors, after considering the recommendations of the compensation, nominating and corporate governance committee, and will
need to be approved by the company&#8217;s shareholders, which approval requires what we refer to as a Special Majority Approval for Compensation.
A Special Majority Approval for Compensation requires shareholder approval by a majority vote of the shares present and voting at a meeting
of shareholders called for such purpose, provided that either: (i)&#160;such majority includes at least a majority of the shares held
by all shareholders who are not controlling shareholders and do not have a personal interest in such compensation arrangement, excluding
abstentions; or (ii)&#160;the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest
in the compensation arrangement and who vote against the arrangement does not exceed 2% of the company&#8217;s aggregate voting rights.
Our board of directors and our shareholders have approved a compensation policy, which will be in effect until the fifth anniversary of
our IPO, which took place in June 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation policy must
(subject to certain exemptions) set the framework and limitation for decisions concerning the financial terms of employment or engagement
of office holders, including exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment
or engagement. The compensation policy must relate to certain factors, including advancement of the company&#8217;s long-term objectives,
business plan and policies, and creation of appropriate incentives for office holders. It must also consider, among other things, the
company&#8217;s risk management, size and the nature of its operations. The compensation policy must furthermore consider the following
additional factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the education, skills, expertise and accomplishments of the relevant office holder; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder&#8217;s roles and responsibilities and prior compensation agreements with him or her; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between the terms offered and the average compensation of the company&#8217;s personnel; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of disparities in salary upon work relationships in the company; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility of reducing variable compensation at the discretion of the board of directors; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as to financial payment upon termination of service, the period of service of the office holder, the terms of his or her compensation during such service period, the company&#8217;s performance during that period of service, the person&#8217;s contribution towards the company&#8217;s achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="padding-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The compensation policy must also include the following principles:</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the link between variable compensation and long-term performance and measurable criteria; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the conditions under which an office holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was restated in the company&#8217;s financial statements; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the minimum holding or vesting period for variable, equity-based compensation; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maximum limits for financial payment upon termination of service. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 117 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><i>Compensation,
Nominating and Corporate Governance Committee Roles </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation, nominating
and corporate governance committee is responsible for (i)&#160;recommending the compensation policy to our board of directors for its
approval (and subsequent approval by our shareholders) and (ii)&#160;duties related to the compensation policy and to the compensation
of our office holders, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than five years from a company&#8217;s initial public offering, or otherwise three years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur five years from a company&#8217;s initial public offering, or otherwise every three years); </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the board of directors periodic updates to the compensation policy; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing implementation of the compensation policy; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether to approve the terms of compensation of certain office holders which, according to the Israeli Companies Law, require the committee&#8217;s approval; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether the limited conditions exist which would allow for the compensation terms of a candidate for the position of the chief executive officer not to be brought for approval by the shareholders. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation, nominating
and corporate governance charter sets forth the responsibilities of the compensation, nominating and corporate committee, which include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the responsibilities set forth in the compensation policy; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving the granting of options and other incentive awards to the extent such authority is delegated by our board of directors; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing, evaluating and making recommendations regarding the compensation and benefits for our non-employee directors. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="padding-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, our compensation, nominating and corporate governance committee is responsible for:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing our corporate governance functions on behalf of the board; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making recommendations to the board regarding corporate governance issues; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying and evaluating candidates to serve as our directors consistent with the criteria approved by the board;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and evaluating the performance of the board; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">serving as a focal point for communication between director candidates, non-committee directors and our management; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting or recommending to the board for selection candidates to the board; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making other recommendations to the board regarding affairs relating to our directors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Disclosure
of Compensation of Executive Officers </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For so long as we qualify
as a foreign private issuer, we are not required to comply with the proxy rules applicable to U.S. domestic companies, including the requirement
applicable to emerging growth companies to disclose the compensation of our Chief Executive Officer, Chief Financial Officer and other
three most highly compensated executive officers on an individual, rather than on an aggregate, basis. Nevertheless, under regulations
promulgated under the Israeli Companies Law, we are required to disclose the annual compensation of our five most highly compensated office
holders (as defined under the Israeli Companies Law) on an individual basis. This disclosure is not as extensive as that required of a
U.S. domestic issuer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 118 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Internal Auditor
</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, the board of directors of an Israeli public company must appoint an internal auditor recommended by the audit committee. An internal
auditor may not, among other things, be:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person (or a relative of a person) who holds 5% or more of the company&#8217;s outstanding shares or voting rights; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person (or a relative of a person) who has the power to appoint a director or the general manager of the company; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an office holder (including a director) of the company (or a relative thereof); or </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a member of the company&#8217;s independent accounting firm, or anyone on its behalf. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The role of the internal auditor
is to examine, among other things, our compliance with applicable law and orderly business procedures, and to report to the chief executive
officer, the chairman of the board and the chairman of the audit committee. The internal auditor is entitled to receive notice of audit
committee meetings and to participate in them. In addition, the internal auditor may request that the chairman of the audit committee
convene a meeting within a reasonable time to discuss an issue raised by the internal auditor. The internal auditor is responsible for
preparing a proposal for an annual or periodical audit plan and submit such plan to the board of directors or the audit committee for
their approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our internal auditor is not
an interested party in the Company and not our employee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Exculpation, Insurance
and Indemnification of Directors and Officers </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate
an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach
of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated
articles of association include such a provision. A company may not exculpate in advance a director from liability arising out of a breach
of the duty of care with respect to a distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, a company may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed by him
or her as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles
of association include a provision authorizing such indemnification:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder (1)&#160;as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i)&#160;no indictment was filed against such office holder as a result of such investigation or proceeding, and (ii)&#160;no financial liability was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2)&#160;in connection with a monetary sanction; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred by an office holder in connection with an administrative procedure instituted against such office holder, or certain compensation payments made to an injured party imposed on an office holder by an administrative proceeding, pursuant to the Securities Law. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 119 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder,
if and to the extent provided in the company&#8217;s articles of association:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed on the office holder in favor of a third party. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, a company may not indemnify or insure an office holder against any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of a duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an act or omission committed with intent to derive illegal personal benefit; or </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a fine, civil fine, monetary sanction or forfeit levied against the office holder. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and
the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by the
Israeli Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We obtained directors and
officers liability insurance for the benefit of our office holders in an amount standard for a company of our size. We intend to maintain
such increased coverage and pay all premiums thereunder to the fullest extent permitted by the Israeli Companies Law. We entered into
agreements with each of our directors and executive officers exculpating them from liability to us for damages caused to us as a result
of a breach of duty of care and undertaking to indemnify them, in each case, to the fullest extent permitted by our amended and restated
articles of association and Israeli law, including with respect to liabilities resulting from our IPO to the extent that these liabilities
are not covered by insurance. In the opinion of the SEC, however, indemnification of directors and office holders for liabilities arising
under the Securities Act is against public policy and therefore unenforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Duties of Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Under
the Companies Law, a shareholder has a duty to refrain from abusing his power in the company and to act in good faith and in an acceptable
manner in exercising his rights and performing his obligations toward the company and other shareholders, including, among other things,
in voting at general meetings of shareholders (and at shareholder class meetings) on the following matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendment of the articles of association;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase in the company&#8217;s authorized share capital;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">merger; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval of related party transactions and acts of office holders that require shareholder approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Employees.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 31, 2020, we had
65 full-time employees and 4 part-time employees. On December 31, 2021, we had 75 full-time employees and 4 part-time employees. On December
31, 2022, we had 57 full-time employees and 3 part-time employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 26, 2023, we had
five full-time senior management employees, including our Chief Executive Officer, Chief Scientific Officer, Executive Vice President,
Research and Development, Clinical and Regulatory Affairs, <span>Chief Operating Officer</span> &#8211;
US and Senior Vice President of Finance. In addition, we currently have 59 full-time employees, 3 part-time employees and 1 full-time
service provider. 61 of our employees are located in Israel and 1 employee located in New Jersey, the United States. None of our employees
are represented by labor unions or covered by collective bargaining agreements. We believe that we maintain good relations with all of
our employees. However, in Israel, we are subject to certain Israeli labor laws, regulations and national labor court precedent rulings,
as well as certain provisions of collective bargaining agreements applicable to us by virtue of extension orders issued in accordance
with relevant labor laws by the Israeli Ministry of Economy and which apply such agreement provisions to our employees even though they
are not part of a union that has signed a collective bargaining agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Noam Emanuel, Ph.D., our
co-founder and Chief Scientific Officer, will retire from our company during the second quarter of 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 120 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our employment and
consulting agreements include employees&#8217; and consultants&#8217; undertakings with respect to non-competition, assignment to us of
intellectual property rights developed in the course of employment, and confidentiality. The enforceability of such provisions is limited
by Israeli law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E. Share Ownership.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 7.A. Major
Shareholders&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Amended and Restated
2012 Share Option Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated 2012
Share Option Plan, or the 2012 Plan, was adopted by our board of directors on August&#160;29, 2012, amended on January&#160;30, 2018,
and extended on August 8, 2022. The 2012 Plan provides for the grant of options to our directors, employees, office holders, service providers
and consultants. A total of 1,116,820 shares are reserved but unissued under our 2012 Plan as of the date of March 26, 2023. As of March
26, 2023, options to purchase 3,388,008 Ordinary Shares were issued and outstanding with an average exercise price of $2.96 per share,
out of which options to purchase 2,093,463 Ordinary Shares were vested as of that date, with an average exercise price of $3.86 per share.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 15, 2022, our
board of directors approved to reduce the exercise price of the outstanding options previously issued to Israeli employees and directors
and U.S. employee, consultant and directors, bearing an exercise price higher than $4.50 to&#160;$0.77, provided however, that the repricing
mechanism does not apply with respect to employees or directors: (i) who did not provide their written consent to such repricing; or (ii)
with respect to whom any process of termination of employment or service, as the case may be, was initiated, whether by the Company or
by the employee/director, before February 1, 2023. In addition, the Board of Directors and the Chief Executive Officer&#8217;s repriced
options are subject to the approval of the shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2012 Plan is administered
by our board of directors, which, on its own or upon the recommendation of a remuneration committee or any other similar committee of
the board of directors, shall determine, subject to applicable law, the identity of grantees of awards and various terms of the grant.
With respect to those grantees subject to Israeli taxation, the 2012 Plan provides for granting options in compliance with Section&#160;102
of the Israeli Income Tax Ordinance, 1961, or the Ordinance, under the capital gains track, and for grants to non-employee Israeli service
providers, consultants and shareholders who hold 10% or more of our total share capital or are otherwise controlling shareholders pursuant
to section&#160;3(i) of the Ordinance, as further detailed below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#160;102 of the Ordinance
allows employees, directors and officers who are not controlling shareholders and are considered Israeli residents to receive favorable
tax treatment for compensation in the form of shares or options. Our non-employee service providers and controlling shareholders may only
be granted options under section&#160;3(i) of the Ordinance, which does not provide for similar tax benefits. Section&#160;102 includes
two alternatives for tax treatment involving the issuance of options or shares to a trustee for the benefit of the grantees and also includes
an additional alternative for the issuance of options or shares directly to the grantee. Section&#160;102(b)(2) of the Ordinance, the
most favorable tax treatment for the grantee, permits the issuance to a trustee under the &#8220;capital gain track.&#8221; However, under
this track we are not allowed to deduct an expense with respect to the issuance of the options or shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, options granted
to our employees will vest over three or four years, as may be determined by the board of directors at the time of the grant, and not
be exercisable before the first anniversary of the date of grant of options. With respect to the remainder of the options, they will become
exercisable in equal amounts of options at the end of each three-month period till the end of the third or fourth year from the date of
grant, as the case may be. Generally, options that are not exercised within ten years from the grant date shall expire.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 121 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than by will or laws
of descent, neither the options nor any right in connection with such options are assignable or transferable. If we terminate a grantee&#8217;s
employment or service for any reason whatsoever, other than for cause, any options granted to such grantee that are not vested shall immediately
expire. All of the grantee&#8217;s vested options shall be deemed expired on the earlier of: (a)&#160;the expiration date of such vested
options as was in effect immediately prior to such termination; or (b)&#160;three months following the date of such termination, or if
such termination is the result of death or disability of the grantee, 12&#160;months from the date of such termination. However, for certain
executives and other senior management, our board of directors (and shareholders where applicable) has resolved that the expiration date
of their vested options shall be between one to four years following the date of such termination. If we terminate a grantee&#8217;s employment
or service for cause, all of the grantee&#8217;s vested and unvested options will expire on the date of termination. Also, and subject
to applicable law, if the grantee&#8217;s employment or services is terminated for cause, then we will have a right of repurchase against
any shares issued pursuant to the exercise of options. In the event that we exercise such right of repurchase, we will pay such grantee
for each such share being repurchased an amount equal to the price originally paid by the grantee for such share. Alternatively, we may
assign such rights of repurchase to our shareholders pro rata to their respective holdings of our issued and outstanding shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are party to a merger
or consolidation, outstanding options and shares acquired under the 2012 Plan will be subject to the agreement of merger or consolidation,
which will provide for one or more of the following: (i)&#160;the assumption of such options by the surviving corporation or its parent,
(ii)&#160;the substitution by the surviving corporation or its parent of new options, or (iii)&#160;in the event that the successor entity
neither assumes nor substitutes all outstanding options, then each respective grantee shall have a period of 15&#160;days to exercise
his or her vested options, after which all remaining options, whether vested or not shall expire. For certain individuals, if their position
is terminated within a certain period after the transaction, their options shall accelerate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of any variation
in our share capital, including a share dividend, share split, combination or exchange of shares, recapitalization, or any other like
event, the number, class and kind of shares subject to the 2012 Plan and outstanding options, and the exercise prices of the options,
will be appropriately and equitably adjusted so as to maintain the proportionate number of shares without changing the aggregate exercise
price of the options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January&#160;30, 2018,
our board of directors adopted an appendix to the 2012 Plan for U.S. residents, which was approved by our shareholders on February&#160;8,
2018. Under this appendix, the 2012 Plan provides for the granting of options to U.S. residents in compliance with the U.S. Internal Revenue
Code of 1986, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 122 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 7.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. Major Shareholders.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding beneficial ownership of our Ordinary Shares as of March 30, 2023 by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person, or group of affiliated persons, known to us to be the beneficial owner of more than 5% of our voting securities.</span></td></tr>
  </table><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our directors and executive officers; and</span></td></tr>
  </table><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all of our directors and executive officers as a group.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as indicated in footnotes
to this table, we believe that the shareholder named in this table has sole voting and investment power with respect to all shares shown
to be beneficially owned by it, based on information provided to us by such shareholder. The shareholders listed below do not have any
different voting rights from any of our other shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.&#160;of&#160;Shares<br/> Beneficially<br/> Owned <sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage<br/> Owned <sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Holders of more than 5% of our voting securities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aurum Ventures M.K.I.&#160;Ltd. <sup>(3)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,891,152</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.7</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Directors and executive officers:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dikla Czaczkes Akselbrad <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210,899</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noam Emanuel <sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">607,629</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dalit Hazan <sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,030</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ori Warshavsky <sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,721</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonny Missulawin <sup>(8)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yechezkel Barenholz <sup>(9)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nir Dror <sup>(10)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,925,914</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob Harel <sup>(11)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86,113</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chaim Hurvitz <sup>(12)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,075,175</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itzhak Krinsky <sup>(13)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,263</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anat Tsour Segal <sup>(14)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,603</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert B. Stein <sup>(15)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,237</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">All directors and executive officers as a group (12&#160;persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,340,213</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.8</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under 1%</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 34px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial ownership is determined in accordance with the rules of the SEC. Under these rules, a person is deemed to be a beneficial owner of a security if that person, even if not the record owner, has or shares the underlying benefits of ownership. These benefits include the power to direct the voting or the disposition of the securities or to receive the economic benefit of ownership of the securities. A person also is considered to be the &#8220;beneficial owner&#8221; of securities that the person has the right to acquire within 60 days by option or other agreement. Beneficial owners include persons who hold their securities through one or more trustees, brokers, agents, legal representatives or other intermediaries, or through companies in which they have a &#8220;controlling interest,&#8221; which means the direct or indirect power to direct the management and policies of the entity.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The percentages shown are based on 21,835,171 Ordinary Shares issued and outstanding as of March 30, 2023. The number of shares issued and outstanding and the percentages above do not give effect to the completion of the Offering on March 31, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The beneficial ownership is based on the latest available filing made with the SEC on Schedule 13G/A on July 15, 2022 and consists of 1,891,152 Ordinary Shares. Morris Kahn, or the Reporting Individual, is the ultimate sole beneficial shareholder of Aurum Ventures M.K.I. Ltd., or the Reporting Entity, as the outstanding shares of the Reporting Entity are held indirectly by a trust for which the Reporting Individual is the settlor and the sole ultimate beneficiary. Consequently, the Reporting Individual may be deemed to share beneficial ownership of the Ordinary Shares held by the Reporting Entity. The Reporting Individual does not make day-to-day voting or investment decisions with respect to the Ordinary Shares held by the Reporting Entity and therefore disclaims beneficial ownership of them except to the extent of his pecuniary interest therein. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 123 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i)&#160;12,443 Ordinary Shares and (ii)&#160;198,456 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. In addition, Ms. Czaczkes Akselbrad holds options to purchase 130,839 Ordinary Shares that are not exercisable within 60 days. Ms. Czaczkes Akselbrad&#8217;s options have expiration dates ranging from July 10, 2024 to May 3, 2032, and a weighted average exercise price of $6.24. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34px">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(5)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i)&#160;203,150 Ordinary Shares and (ii)&#160;404,479 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. In addition, Mr. Emanuel holds options to purchase 95,628 Ordinary Shares that are not exercisable within 60 days. Mr. Emanuel&#8217;s options have expiration dates ranging from March 19, 2023 to May 9, 2032, and a weighted average exercise price of $0.84. &#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 80,030 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. In addition, Ms. Hazan holds options to purchase 81,827 Ordinary Shares that are not exercisable within 60 days. Ms. Hazan&#8217;s options have expiration dates ranging from April 5, 2026 to May 9, 2032, and a weighted average exercise price of $0.82. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 53,721 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. In addition, Ms. Warshavsky holds options to purchase 50,099 Ordinary Shares that are not exercisable within 60 days. Ms. Warshavsky&#8217;s options have expiration dates ranging from November 9, 2020 to May 9, 2032, and a weighted average exercise price of $0.77.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 47,498 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. In addition, Ms. Missulawin holds options to purchase 47,655 Ordinary Shares that are not exercisable within 60 days. Ms. Missulawin&#8217;s options have expiration dates ranging from June 22, 2024 to May 9, 2032, and a weighted average exercise price of $0.79.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i)&#160;82,793 Ordinary Shares and (ii)&#160;18,338 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. Prof. Barenholz&#8217;s options have an expiration date of March 19, 2023 to May 3, 2032, and a weighted average exercise price of $7.23.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of beneficial ownership of the shares set forth in note&#160;(3) above by Aurum Ventures M.K.I.&#160;Ltd.&#160;&#160;In addition, Mr. Dror holds options to purchase 34,862 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. Mr. Dror holds options to purchase 1,501 Ordinary Shares that are not exercisable within 60 days. Mr. Dror&#8217;s options have an expiration date of June 18, 2030 to May 3, 2032, and a weighted average exercise price of $6.93. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 124 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i)&#160;14,000 Ordinary Shares and (ii)&#160;72,113 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. Mr. Jacob&#8217;s options have an expiration date of August 7, 2029 to May 3, 2032, and a weighted average exercise price of $7.82. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i)&#160;873,455 Ordinary Shares held by Shirat Hachaim Ltd. and (ii) 201,720 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. Ms. Hurvitz&#8217;s options have an expiration date of June 1, 2027 to May 3, 2032, and a weighted average exercise price of $4.39. Chaim Hurvitz is the beneficial owner of Shirat Hachaim&#160;Ltd. The address of Shirat Hachaim&#160;Ltd. is 31 Yavne Street, Tel Aviv, Israel 65792. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of (i)&#160;25,000 Ordinary Shares and (ii)&#160;36,263 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. Mr. Krinsky&#8217;s options have an expiration date of August 7, 2029 to May 3, 2032, and a weighted average exercise price of $7.93. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 50,603 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. Ms. Tsour Segal&#8217;s options have expiration dates ranging from June 1, 2027 to May 3, 2032, and a weighted average exercise price of $6.51. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 40,237 Ordinary Shares issuable upon exercise of outstanding options that are exercisable within 60 days. In addition, options to purchase 2,001 Ordinary Shares that are not exercisable within 60 days. Mr. Stein&#8217;s options have an expiration date of June 18, 2030 to May 3, 2032, and a weighted average exercise price of $6.89.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Changes
in Ownership of Major Shareholders</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Over the course of 2022, there
were no material increases in the percentage ownership of our major shareholders. On the other hand, there were decreases in the percentage
ownership of entities affiliated with Shavit Capital Funds (from 6.1% to 2.1%).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Over the course of 2021, we
are not aware of any material increases or decrease in the percentage ownership of our major shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Over the course of 2020, there
were no material increases in the percentage ownership of our major shareholders. On the other hand, there were decreases in the percentage
ownership of entities affiliated with (i) Aurum Ventures M.K.I.&#160;Ltd (from 15.8% to 10.8%) and (ii) Shavit Capital Funds (from 12.5%
to 6.9%), which was due to the dilution of their ownership as a result of the IPO.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Record Holders </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 22, 2023, there
were a total of 63 holders of record of our shares, of which 38 record holders had registered addresses in the United States. This number
is not representative of the number of beneficial holders of our shares nor is it representative of where such beneficial holders reside,
since many of these shares were held of record by brokers or other nominees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not controlled by another
corporation, by any foreign government or by any natural or legal persons except as set forth herein, and there are no arrangements known
to us which would result in a change in control of us at a subsequent date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B. Related Party Transactions. </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 6.B. Compensation&#8221;
for compensation to our directors and officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 125 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Agreements and Arrangements With, and Compensation
of, Directors and Executive Officers </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our executive officers
have employment agreements with us, which contain customary provisions and representations, including confidentiality, non-competition,
non-solicitation and inventions assignment undertakings by the executive officers. Under current applicable Israeli employment laws, we
may not be able to enforce (either in whole or in part) covenants not to compete and therefore may be unable to prevent our competitors
from benefiting from the expertise of some of our former employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b>Indemnification
Agreements </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association permit us to exculpate, indemnify and insure each of our directors and office holders to the fullest extent permitted by
the Israeli Companies Law. We entered into indemnification agreements with each of our directors and executive officers, undertaking to
indemnify them to the fullest extent permitted by Israeli law, including with respect to liabilities resulting from a public offering
of our shares, to the extent that these liabilities are not covered by insurance. We have also obtained directors and officers insurance
for each of our executive officers and directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_033"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C. Interests of Experts and Counsel.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_034"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 8.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>FINANCIAL INFORMATION.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_035"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. Consolidated Statements and Other Financial Information.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 18. Financial
Statements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not currently subject
to any material legal proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash
dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including
our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board
of directors may deem relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
imposes further restrictions on our ability to declare and pay dividends.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payment of dividends may be
subject to Israeli withholding taxes. See &#8220;Item 10. E. Taxation&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_036"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B. Significant Changes.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No significant change, other
than as otherwise described in this annual report on Form 20-F, has occurred in our operations since the date of our consolidated financial
statements included in this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_037"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 9.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>THE OFFER AND LISTING</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_038"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. Offer and Listing Details.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares have been
trading under the symbol &#8220;PYPD&#8221; on the Nasdaq Global Market since June 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_039"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B. Plan of Distribution.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_040"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C. Markets.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares have been
listed for trading on the Nasdaq Global Market since June 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_041"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D. Selling Shareholders.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 126 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_042"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E. Dilution.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_043"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F. Expenses of the Issue.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_044"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 10.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ADDITIONAL INFORMATION</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_045"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. Share Capital.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Not
applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><div><a id="a_046"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B. Memorandum and Articles of Association.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of our articles of
association is attached as Exhibit 1.1 to this annual report on Form 20-F. The information called for by this Item is set forth in Exhibit
2(d) to this annual report on Form 20-F and is incorporated by reference into this annual report on Form 20-F.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_047"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C. Material Contracts. </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of each material contract, other than material contracts entered into in the ordinary course of business, to which we are or have been
a party, for the two years immediately preceding the date of this annual report on Form 20-F:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales Agreement, dated July 2, 2021, by and between PolyPid Ltd. and Cantor Fitzgerald &amp; Co., filed as <span style="text-decoration:underline">Exhibit 10.1</span> to form F-3 (File No. 333-257651) filed on July 2, 2021. See Item 5.B &#8220;Liquidity and Capital Resources &#8212;Cash Flows &#8212; Financing Activities&#8221; for more information about this document.</span></td></tr>
  </table><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Officer Indemnity and Exculpation Agreement, filed as <span style="text-decoration:underline">Exhibit 10.1</span> to Form F-1 (File No. 333-238978) filed on June 22, 2020. See Item 6. C. &#8220;Board Practices &#8212; Exculpation, Insurance and Indemnification of Directors and Officers&#8221; for more information about this document.</span></td></tr>
  </table><div>
</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation Policy, filed as <span style="text-decoration:underline">Exhibit 99.1</span> to Form 6-K (File No. 001-38428) filed on April 13, 2021, and incorporated herein by reference. See Item 6. C. &#8220;Board Practices &#8212; Compensation, Nominating and Corporate Governance Committee and Compensation Policy&#8221; for more information about this document.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement for the Provision of a Loan Facility of up to US$15 million dated April 5, 2022, by and between Kreos Capital VI (Expert Fund) LP and PolyPid Ltd., filed as Exhibit 10.1 to Form 6-K (File No. 001-38428), filed on April 6, 2022. See Item &#8220;Item 5.C- Liquidity and Capital Resources&#8221; for more information about this document.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">License, Distribution and Supply Agreement, dated
    August 2, 2022, by and between PolyPid Ltd. and Mercury Pharma Group Limited, under the trade name Advanz Pharma Holdings, filed as Exhibit
    10.1 to Form 6-K (File No. 001-38428), filed on August 8, 2022. See Item &#8220;Item 4.B &#8211; Business Overview&#8221; for more information
    about this document.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_048"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D. Exchange Controls</b>. </span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently no Israeli
currency control restrictions on remittances of dividends on our Ordinary Shares, proceeds from the sale of the shares or interest or
other payments to non-residents of Israel, except for shareholders who are subjects of countries that are, or have been, in a state of
war with Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 127 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_049"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E. Taxation.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Israeli Tax Considerations and Government Programs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of the material Israeli income tax laws applicable to us. This section also contains a discussion of material Israeli income tax considerations
concerning the ownership and disposition of our Ordinary Shares by holders that purchase Ordinary Shares pursuant to the offering and
hold such Ordinary Shares as capital assets. This summary does not discuss all the aspects of Israeli income tax law that may be relevant
to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment
under Israeli law. Examples of this kind of investor include residents of Israel or traders in securities who are subject to special tax
regimes not covered in this discussion. To the extent that the discussion is based on new tax legislation that has not yet been subject
to judicial or administrative interpretation, we cannot assure you that the appropriate tax authorities or the courts will accept the
views expressed in this discussion. This summary is based on laws and regulations in effect as of the date of this annual report on Form
20-F and does not take into account possible future amendments which may be under consideration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>General Corporate
Tax Structure in Israel </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2023, Israeli resident
companies like us are generally subject to corporate tax at the rate of 23.0%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Capital gains derived by an
Israeli resident company are generally subject to tax at the same rate as the corporate tax rate. Under Israeli tax legislation, a corporation
will be considered as an &#8220;Israeli resident&#8221; for tax purposes if it meets one of the following: (a)&#160;it was incorporated
in Israel; or (b)&#160;the management and control of its business are exercised in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Taxation of
our Israeli Individual Shareholders on Receipt of Dividends </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli residents who are
individuals are generally subject to Israeli income tax for dividends paid on our Ordinary Shares (other than bonus shares or share dividends)
at a rate of 25.0%, or 30.0% if the recipient of such dividend is a &#8220;substantial shareholder&#8221; (as defined below) at the time
of distribution or at any time during the preceding 12-month period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of January&#160;1, 2017,
an additional income tax at a rate of 3.0% is imposed on high earners whose annual taxable income or gain exceeds certain thresholds (NIS&#160;698,280
as of January&#160;1, 2023).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A &#8220;substantial Shareholder&#8221;
is generally a person who alone, or together with his or her relative, as defined under section 88 of the Israeli Income Tax Ordinance
[New Version], 1961, or the Israeli Tax Ordinance, or another person who collaborates with him based on an agreement on substantive matters
of the company on a regular basis, holds, directly or indirectly, at least 10.0% of any of the &#8220;means of control&#8221; of the corporation.
&#8220;Means of control&#8221; generally include the right to vote in a general meeting of shareholders or receive profits, nominate a
director or an officer, receive assets upon liquidation, or instruct someone who holds any of the aforesaid rights regarding the manner
in which he or she is to exercise such right(s), and whether by virtue of shares, rights to shares or other rights, or in any other manner,
including by means of voting or trusteeship agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &#8220;Israeli resident&#8221;
for individuals is generally defined under the Israeli Tax Ordinance, as an individual whose center of life is in Israel. According to
the Israeli Tax Ordinance, in order to determine the center of life of an individual, account will be taken of the individual&#8217;s
family, economic and social connections, including, but not limited to: (a)&#160;the place of the individual&#8217;s permanent home; (b)&#160;the
place of residence of the individual and the individual&#8217;s family; (c)&#160;the place of the individual&#8217;s regular or permanent
place of business or the place of the individual&#8217;s permanent employment; (d)&#160;place of the individual&#8217;s active and substantial
economic interests; (e)&#160;place of the individual&#8217;s activities in organizations, associations and other institutions. The center
of life of an individual will be presumed to be in Israel if: (a)&#160;the individual was present in Israel for 183&#160;days or more
in the tax year; or (b)&#160;the individual was present in Israel for 30&#160;days or more in the tax year, and the total period of the
individual&#8217;s presence in Israel in that tax year and the two previous tax years is 425&#160;days or more. The presumption in this
paragraph may be rebutted either by the individual or by the assessing officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 128 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Taxation of
Israeli Resident Corporations on Receipt of Dividends </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli resident corporations
are generally exempt from Israeli corporate income tax with respect to dividends paid on our Ordinary Shares unless the distribution is
from a Preferred Enterprise, as defined below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Capital Gains
Taxes Applicable to Israeli Resident Shareholders </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The income tax rate applicable
to Real Capital Gain, which is the excess of the total capital gain over inflationary surplus computed generally on the basis of the increase
in the Israeli consumer price index between the date of purchase and the date of disposal, derived by an Israeli individual from the sale
of shares which had been purchased after January&#160;1, 2012, whether listed on a stock exchange or not, is 25.0%. However, if such shareholder
is considered a &#8220;Substantial Shareholder&#8221; (as defined above) at the time of sale or at any time during the preceding 12-month
period, such gain will be taxed at the rate of 30.0%. As of January&#160;1, 2017, an additional income tax at a rate of 3% will be imposed
on high earners whose annual taxable income or gain exceeds certain thresholds (NIS 647,640).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, capital gains derived
by a shareholder who is a dealer or trader in securities, or to whom such income is otherwise taxable as ordinary business income, are
taxed in Israel at ordinary income rates (currently, up to 47.0% +3% for individuals and as of January&#160;1, 2022, the corporate tax
rate is 23.0%).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Taxation of
Non-Israeli Shareholders on Receipt of Dividends </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-Israeli residents (individuals
or corporations) are generally subject to Israeli income tax on the receipt of dividends paid on our Ordinary Shares at the rate of 25.0%
(or 30.0% if such person or entity is a &#8220;substantial shareholder&#8221; at the time receiving the dividend or on any date in the
12&#160;months preceding such date), which tax will be withheld at source, unless a tax certificate is obtained from the Israeli Tax Authority,
or ITA, authorizing withholding-exempt remittances or a reduced rate of tax pursuant to an applicable tax treaty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
a dividend paid by the Company arising from the profits of a preferred enterprise and / or a preferred technological enterprise entitled
to tax benefits under the Capital Investment Encouragement Law shall generally be taxable at 20% for individuals, unless subject to a
lower rate under the relevant double taxation treaties. Corporations will generally be subject to a withholding tax rate of either 20%
(Preferred Enterprise) or a reduced rate of 4% (Preferred Technological Enterprise), subject to fulfillment of certain conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-Israeli resident who
receives dividends from which tax was withheld is generally exempt from the duty to file tax returns in Israel in respect of such income,
provided such income was not derived from a business conducted in Israel by such taxpayer, and such taxpayer has no other taxable sources
of income in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, under the Convention
Between the Government of the United States of America and the Government of Israel with Respect to Taxes on Income, as amended, Israeli
withholding tax on dividends paid to a U.S. resident for treaty purposes may not, in general, exceed 25.0%, or 15.0% in the case of dividends
paid out of the profits of an Approved Enterprise, subject to certain conditions. Where the recipient is a U.S. corporation owning 10.0%
or more of the issued and outstanding voting shares of the paying corporation during the part of the paying corporation&#8217;s taxable
year which precedes the date of payment of the dividend and during the whole of its prior taxable year (if any) and not more than 25.0%
of the gross income of the paying corporation for such prior taxable year (if any) consists of certain interest or dividends and the dividend
is not paid from the profits of an Approved Enterprise, the Israeli tax withheld may not exceed 12.5%, subject to certain conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Capital Gains
Income Taxes Applicable to Non-Israeli Shareholders </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provided certain conditions
are met, non-Israeli resident shareholders are generally exempt from Israeli capital gains tax on any gains derived from the sale, exchange
or disposition of our Ordinary Shares, provided that such gains were not derived from a permanent establishment or business activity of
such shareholders in Israel. However, non-Israeli corporations&#8217; shareholders will not be entitled to the foregoing exemptions if
Israeli residents (i)&#160;have a controlling interest of more than 25.0% in such non-Israeli corporation or (ii)&#160;are the beneficiaries
of or are entitled to 25.0% or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regardless of whether shareholders
may be liable for Israeli income tax on the sale of our Ordinary Shares, the payment of the consideration may be subject to withholding
of Israeli tax at the source. Accordingly, shareholders may be required to demonstrate that they are exempt from tax on their capital
gains in order to avoid withholding at source at the time of sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 129 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Law for the
Encouragement of Capital Investments</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Law for the Encouragement
of Capital Investments, 5719-1959, or the Investment Law, provides certain incentives for capital investments in production facilities
(or other eligible intangible assets) by &#8220;Industrial Enterprises&#8221; (as defined under the Investment Law). Generally, an investment
program that is implemented in accordance with the provisions of the Investment Law, referred to as an Approved Enterprise, a Beneficiary
Enterprise, a Preferred Enterprise, a Preferred Technological Enterprise, or a Special Preferred Technological Enterprise, is entitled
to benefits as discussed below. These benefits may include cash grants from the Israeli government and tax benefits based upon, among
other things, the geographic location in Israel of the facility in which the investment is made.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January&#160;1, 2011, new
legislation amending the Investment Law came into effect, or the 2011 Amendment. The 2011 Amendment introduced a new status of Preferred
Enterprise. Subject to certain conditions, a Preferred Enterprise entitles the company to reduced corporate tax rates, without limitations
on dividends and other distributions, instead of full exemption from corporate tax. These preferred corporate tax rates vary from 7.5%
for Preferred Enterprises residing in a &#8220;development zone,&#8221; or 16.0% for Preferred Enterprises residing in other zones in
Israel. Dividend distributions are subject to 20% tax rate, subject to the provision of the relevant tax treaty. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to gain the status
of Preferred Enterprise, a company must meet the conditions of competitive industrial company that contributes to the GDP or comparative
industrial company in the field of renewable energy. <b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Investment Law was significantly amended effective
as of January 1, 2017, or the 2017 Amendment. The 2017 Amendment was enacted as part of the Economic Efficiency Law that was published
on December 29, 2016 and is effective as of January 1, 2017. The 2017 Amendment provides new tax benefits for two types of &#8220;Technological
Enterprises,&#8221; as described below, and is in addition to the other existing tax beneficial programs under the Investment Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The 2017 Amendment provides that a preferred company,
which is defined as either (i) a company incorporated in Israel which is not wholly owned by a governmental entity, or (ii) a limited
partnership that: (a) was registered under the Israeli Partnerships Ordinance; and (b) all of its limited partners are companies incorporated
in Israel, but not all of them are governmental entities; which has, among other things, Preferred Enterprise status and is controlled
and managed from Israel, or a Preferred Company, satisfying certain conditions will qualify as having a &#8220;Preferred Technological
Enterprise&#8221; and will thereby enjoy a reduced corporate tax rate of 12% on income that qualifies as &#8220;Preferred Technological
Income,&#8221; as defined in the Investment Law. The corporate tax rate may be further reduced to 7.5% with respect to a Preferred Technological
Enterprise located in development zone &#8220;A,&#8221; as defined under the Investment Law. In addition, a Preferred Technological Company
will enjoy a reduced corporate tax rate of 12% on capital gain derived from the sale of certain &#8220;Benefitted Intangible Assets&#8221;
(as defined in the Investment Law) to a related foreign company if the Benefitted Intangible Assets were acquired from a foreign company
on or after January 1, 2017 for at least NIS 200 million, and the sale receives prior approval from the Israel Innovation Authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dividends distributed by a Preferred Technological
Enterprise, paid out of Preferred Technological Income, are generally subject to tax at the rate of 20% or such lower rate as may be provided
in an applicable tax treaty (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The withholding tax rate applicable to distribution
of dividend from such income to non-Israeli residents is 25% (or 30% if distributed to a &#8220;substantial shareholder&#8221; at the
time of the distribution or at any time during the preceding twelve months period), which may be reduced by applying in advance for a
withholding certificate from the ITA. A &#8220;substantial shareholder&#8221; is generally a person who, alone or together with such person&#8217;s
relative or another person who collaborates with such person on a permanent basis, holds, directly or indirectly, at least 10% of any
of the &#8220;Means of Control&#8221; of the corporation. &#8220;Means of control&#8221; generally include the right to vote, receive
profits, nominate a director or an executive officer, receive assets upon liquidation or order someone who holds any of the aforesaid
rights how to act, regardless of the source of such right.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if such dividends
are distributed to a foreign company that holds solely or together with other foreign companies 90% or more in the Israeli company and
other conditions are met (including that less than 25% of the shareholder of the foreign company are Israeli residents), the withholding
tax rate will be 4% (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate). However,
if such dividends are paid to an Israeli company, no tax is required to be withheld.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 130 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Material U.S. Federal Income Tax Considerations
to U.S. Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following discussion describes
the material U.S. federal income tax considerations relating to the ownership and disposition of our Ordinary Shares by U.S. Holders (as
defined below). This discussion applies to U.S. Holders that hold such Ordinary Shares as capital assets within the meaning of Section
1221 of the U.S. Internal Revenue Code of 1986, as amended, or the Code. This discussion is based on the Code, U.S. Treasury regulations
promulgated thereunder and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of which are
subject to change, possibly with retroactive effect. This discussion does not address all of the U.S. federal income tax consequences
that may be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special treatment
under U.S. federal income tax law (such as certain financial institutions, insurance companies, broker-dealers and traders in securities
or other persons that generally mark their securities to market for U.S. federal income tax purposes, tax-exempt entities, retirement
plans, regulated investment companies, real estate investment trusts, certain former citizens or residents of the United States, persons
who hold Ordinary Shares as part of a &#8220;straddle&#8221;, &#8220;hedge&#8221;, &#8220;conversion transaction&#8221;, &#8220;synthetic
security&#8221; or integrated investment, persons who received their Ordinary Shares as compensatory payments, persons that have a &#8220;functional
currency&#8221; other than the U.S. dollar, persons that own directly, indirectly or through attribution 10% or more of our shares by
vote or value, persons subject to special tax accounting rules as a result of any item of gross income with respect to the shares being
taken into account in an applicable financial statement, corporations that accumulate earnings to avoid U.S. federal income tax, partnerships
and other pass-through entities, and investors in such pass-through entities). This discussion does not address any U.S. state or local
or non-U.S. tax consequences or any U.S. federal estate, gift or alternative minimum tax or Medicare tax consequences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this discussion,
the term &#8220;U.S. Holder&#8221; means a beneficial owner of Ordinary Shares that is, for U.S. federal income tax purposes, (1) an individual
who is a citizen or resident of the United States, (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes)
created or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (3) an estate the income
of which is subject to U.S. federal income tax regardless of its source or (4) a trust (x) with respect to which a court within the United
States is able to exercise primary supervision over its administration and one or more United States persons have the authority to control
all of its substantial decisions or (y) that has elected under applicable U.S. Treasury regulations to be treated as a domestic trust
for U.S. federal income tax purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an entity or arrangement
treated as a partnership for U.S. federal income tax purposes holds Ordinary Shares, the U.S. federal income tax consequences relating
to an investment in the ordinary shares will depend in part upon the status and activities of such entity or arrangement and the particular
partner. Any such entity or arrangement should consult its own tax advisor regarding the U.S. federal income tax consequences applicable
to it and its partners of the ownership and disposition of Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THE FOLLOWING SUMMARY IS INCLUDED
HEREIN FOR GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR TAX ADVICE. EACH U.S. HOLDER SHOULD
CONSULT WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND SALE
OF ORDINARY SHARES AND AMERICAN DEPOSITARY SHARES, INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND POSSIBLE
CHANGES IN THE TAX LAWS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Passive Foreign
Investment Company Consequences </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, a corporation
organized outside the United States will be treated as PFIC for any taxable year in which either (1) at least 75% of its gross income
is &#8220;passive income&#8221;, the PFIC income test, or (2) on average at least 50% of its assets, determined on a quarterly basis,
are assets that produce passive income or are held for the production of passive income, the PFIC asset test. Passive income for this
purpose generally includes, among other things, dividends, interest, royalties, rents, and gains from the sale or exchange of property
that gives rise to passive income. Assets that produce or are held for the production of passive income generally include cash, even if
held as working capital or raised in a public offering, marketable securities, and other assets that may produce passive income. Generally,
in determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it
owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 131 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our status as a PFIC will
depend on the nature and composition of our income and the nature, composition and value of our assets (which, generally may be determined
based on the fair market value of each asset, with the value of goodwill and going concern value being determined in large part by reference
to the market value of our Ordinary Shares, which may be volatile). Based upon the estimated value of our assets, including any goodwill,
and the nature and estimated composition of our income and assets, we may be classified as a PFIC for the taxable year ended December
31, 2022 and in future taxable years In particular, so long as we do not generate revenue from operations for any taxable year and do
not receive any research and development grants, or even if we receive a research and development grant, if such grant does not constitute
gross income for U.S. federal income tax purposes, we likely will be classified as a PFIC for such taxable year. Even if we determine
that we are not a PFIC for a taxable year, there can be no assurance that the IRS will agree with our conclusion and that the IRS would
not successfully challenge our position. Our status as a PFIC is a fact-intensive determination made on an annual basis after the end
of each taxable year. Accordingly, our U.S. counsel expresses no opinion with respect to our PFIC status for our taxable year ended December
31, 2022 and also expresses no opinion with regard to our expectations regarding our PFIC status in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are a PFIC in any taxable
year during which a U.S. Holder owns Ordinary Shares, the U.S. Holder could be liable for additional taxes and interest charges under
the &#8220;PFIC excess distribution regime&#8221; upon (1) a distribution paid during a taxable year that is greater than 125% of the
average annual distributions paid in the three preceding taxable years, or, if shorter, the U.S. Holder&#8217;s holding period for the
Ordinary Shares, and (2) any gain recognized on a sale, exchange or other disposition, including a pledge, of the Ordinary Shares, whether
or not we continue to be a PFIC. Under the PFIC excess distribution regime, the tax on such distribution or gain would be determined by
allocating the distribution or gain ratably over the U.S. Holder&#8217;s holding period for Ordinary Shares. The amount allocated to the
current taxable year (i.e., the year in which the distribution occurs or the gain is recognized) and any year prior to the first taxable
year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount allocated to other taxable
years will be taxed at the highest marginal rates in effect for individuals or corporations, as applicable, to ordinary income for each
such taxable year, and an interest charge, generally applicable to underpayments of tax, will be added to the tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are a PFIC for any year
during which a U.S. Holder holds Ordinary Shares, we must generally continue to be treated as a PFIC by that holder for all succeeding
years during which the U.S. Holder holds the Ordinary Shares, unless we cease to meet the requirements for PFIC status and the U.S. Holder
makes a &#8220;deemed sale&#8221; election with respect to the Ordinary Shares. If the election is made, the U.S. Holder will be deemed
to sell the Ordinary Shares it holds at their fair market value on the last day of the last taxable year in which we qualified as a PFIC,
and any gain recognized from such deemed sale would be taxed under the PFIC excess distribution regime. After the deemed sale election,
the U.S. Holder&#8217;s Ordinary Shares would not be treated as shares of a PFIC unless we subsequently become a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are a PFIC for any taxable
year during which a U.S. Holder holds Ordinary Shares and one of our non-U.S. corporate subsidiaries is also a PFIC (i.e., a lower-tier
PFIC), such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC and would be
taxed under the PFIC excess distribution regime on distributions by the lower-tier PFIC and on gain from the disposition of shares of
the lower-tier PFIC even though such U.S. Holder would not receive the proceeds of those distributions or dispositions. Each U.S. Holder
is advised to consult its tax advisors regarding the application of the PFIC rules to our non-U.S. subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are a PFIC, a U.S. Holder
will not be subject to tax under the PFIC excess distribution regime on distributions or gain recognized on Ordinary Shares if such U.S.
Holder makes a valid &#8220;mark-to-market&#8221; election for our Ordinary Shares. A mark-to-market election is available to a U.S. Holder
only for &#8220;marketable stock.&#8221; Our Ordinary Shares will be marketable stock as long as they remain listed on the Nasdaq Global
Market and are regularly traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. If a mark-to-market
election is in effect, a U.S. Holder generally would take into account, as ordinary income for each taxable year of the U.S. holder, the
excess of the fair market value of Ordinary Shares held at the end of such taxable year over the adjusted tax basis of such Ordinary Shares.
The U.S. Holder would also take into account, as an ordinary loss each year, the excess of the adjusted tax basis of such Ordinary Shares
over their fair market value at the end of the taxable year, but only to the extent of the excess of amounts previously included in income
over ordinary losses deducted as a result of the mark-to-market election. The U.S. Holder&#8217;s tax basis in Ordinary Shares would be
adjusted to reflect any income or loss recognized as a result of the mark-to-market election. Any gain from a sale, exchange or other
disposition of Ordinary Shares in any taxable year in which we are a PFIC would be treated as ordinary income and any loss from such sale,
exchange or other disposition would be treated first as ordinary loss (to the extent of any net mark-to-market gains previously included
in income) and thereafter as capital loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A mark-to-market election
will not apply to Ordinary Shares for any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent
taxable year in which we become a PFIC. Such election will not apply to any non-U.S. subsidiaries that we may organize or acquire in the
future. Accordingly, a U.S. Holder may continue to be subject to tax under the PFIC excess distribution regime with respect to any lower-tier
PFICs that we may organize or acquire in the future notwithstanding the U.S. Holder&#8217;s mark-to-market election for the Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax consequences that
would apply if we are a PFIC would also be different from those described above if a U.S. Holder were able to make a valid QEF election.
At this time, we do not expect to provide U.S. Holders with the information necessary for a U.S. Holder to make a QEF election. Prospective
investors should assume that a QEF election will not be available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each U.S. person that is an
investor of a PFIC is generally required to file an annual information return on IRS Form 8621 containing such information as the U.S.
Treasury Department may require. The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the
statute of limitations with respect to U.S. federal income tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 132 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The U.S. federal income tax rules relating
to PFICs are very complex. U.S. Holders are strongly urged to consult their own tax advisors with respect to the impact of PFIC status
on the ownership and disposition of Ordinary Shares, the consequences to them of an investment in a PFIC, any elections available with
respect to the Ordinary Shares and the IRS information reporting obligations with respect to the ownership and disposition of Ordinary
Shares of a PFIC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Distributions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not anticipate declaring
or paying dividends to holders of our ordinary stock in the foreseeable future. However, if we make a distribution contrary to the expectation,
subject to the discussion above under &#8220;&#8212;<i>Passive Foreign Investment Company Consequences</i>,&#8221; a U.S. Holder that
receives a distribution with respect to Ordinary Shares generally will be required to include the gross amount of such distribution in
gross income as a dividend when actually or constructively received to the extent of the U.S. Holder&#8217;s pro rata share of our current
and/or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution received
by a U.S. Holder is not a dividend because it exceeds the U.S. Holder&#8217;s pro rata share of our current and accumulated earnings and
profits, it will be treated first as a tax-free return of capital and reduce (but not below zero) the adjusted tax basis of the U.S. Holder&#8217;s
Ordinary Shares. To the extent the distribution exceeds the adjusted tax basis of the U.S. Holder&#8217;s Ordinary Shares, the remainder
will be taxed as capital gain. Because we may not account for our earnings and profits in accordance with U.S. federal income tax principles,
U.S. Holders should expect all distributions to be reported to them as dividends.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Distributions on Ordinary
Shares that are treated as dividends generally will constitute income from sources outside the United States for foreign tax credit purposes
and generally will constitute passive category income. Subject to certain complex conditions and limitations, Israeli taxes withheld on
any distributions on Ordinary Shares may be eligible for credit against a U.S. Holder&#8217;s federal income tax liability. The rules
relating to the determination of the U.S. foreign tax credit are complex, and U.S. Holders should consult their tax advisors regarding
the availability of a foreign tax credit in their particular circumstances and the possibility of claiming an itemized deduction (in lieu
of the foreign tax credit) for any foreign taxes paid or withheld.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends paid by a &#8220;qualified
foreign corporation&#8221; are eligible for taxation to non-corporate U.S. holders at a reduced capital gains rate rather than the marginal
tax rates generally applicable to ordinary income provided that certain requirements are met. Each U.S. Holder is advised to consult its
tax advisors regarding the availability of the reduced tax rate on dividends with regard to its particular circumstances. Each U.S. Holder
is advised to consult its tax advisors regarding the availability of the reduced tax rate on dividends with regard to its particular circumstances.
Distributions on Ordinary Shares that are treated as dividends generally will not be eligible for the &#8220;dividends received&#8221;
deduction generally allowed to corporate shareholders with respect to dividends received from U.S. corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-United States corporation
(other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year)
generally will be considered to be a qualified foreign corporation (a) if it is eligible for the benefits of a comprehensive tax treaty
with the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision
and which includes an exchange of information provision, or (b) with respect to any dividend it pays on Ordinary Shares that are readily
tradable on an established securities market in the United States. We believe that we qualify as a resident of Israel for purposes of,
and are eligible for the benefits of, the U.S.-Israel Treaty, although there can be no assurance in this regard. Further, the IRS has
determined that the U.S.-Israel Treaty is satisfactory for purposes of the qualified dividend rules and that it includes an exchange of
information provision. Our Ordinary Shares will also generally be considered to be readily tradable on an established securities market
in the United States if they are listed on The Nasdaq Global Market. Therefore, subject to the discussion above under &#8220;&#8212;Passive
Foreign Investment Company Consequences,&#8221; if the U.S.-Israel Treaty is applicable, or if our Ordinary Shares are readily tradable
on an established securities market in the United States, such dividends will generally be &#8220;qualified dividend income&#8221; in
the hands of individual U.S. Holders, provided that certain conditions are met, including holding period and the absence of certain risk
reduction transaction requirements. Each U.S. Holder is advised to consult its tax advisors regarding the availability of the reduced
tax rate on dividends with regard to its particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Sale, Exchange
or Other Disposition of Ordinary Shares </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the discussion
above under &#8220;&#8212;<i>Passive Foreign Investment Company Consequences</i>,&#8221; a U.S. Holder generally will recognize capital
gain or loss for U.S. federal income tax purposes upon the sale, exchange or other disposition of Ordinary Shares in an amount equal to
the difference, if any, between the amount realized (i.e., the amount of cash plus the fair market value of any property received) on
the sale, exchange or other disposition and such U.S. Holder&#8217;s adjusted tax basis in the Ordinary Shares. Such capital gain or loss
generally will be long-term capital gain taxable at a reduced rate for non-corporate U.S. Holders or long-term capital loss if, on the
date of sale, exchange or other disposition, the Ordinary Shares were held by the U.S. Holder for more than one year. Any capital gain
of a non-corporate U.S. Holder that is not long-term capital gain is taxed at ordinary income rates. The deductibility of capital losses
is subject to limitations. Any gain or loss recognized from the sale or other disposition of Ordinary Shares will generally be gain or
loss from sources within the United States for U.S. foreign tax credit purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 133 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><b><i>Information
Reporting and Backup Withholding </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders may be required
to file certain U.S. information reporting returns with the IRS with respect to an investment in Ordinary Shares, including, among others,
IRS Form 8938 (Statement of Specified Foreign Financial Assets). As described above under &#8220;<i>Passive Foreign Investment Company
Consequences</i>&#8221;, each U.S. Holder who is a shareholder of a PFIC must file an annual report containing certain information. U.S.
Holders paying more than US$100,000 for Ordinary Shares may be required to file IRS Form 926 (Return by a U.S. Transferor of Property
to a Foreign Corporation) reporting this payment. Substantial penalties may be imposed upon a U.S. Holder that fails to comply with the
required information reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends on and proceeds
from the sale or other disposition of Ordinary Shares may be reported to the IRS unless the U.S. Holder establishes a basis for exemption.
Backup withholding may apply to amounts subject to reporting if the holder (1) fails to provide an accurate United States taxpayer identification
number or otherwise establish a basis for exemption (usually on IRS Form W-9), or (2) is described in certain other categories of persons.
However, U.S. Holders that are corporations generally are excluded from these information reporting and backup withholding tax rules.
Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund
or a credit against a U.S. Holder&#8217;s U.S. federal income tax liability if the required information is furnished by the U.S. Holder
on a timely basis to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders should consult
their own tax advisors regarding the backup withholding tax and information reporting rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><div><a id="a_050"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F. Dividends and Paying Agents.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_051"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G. Statement by Experts.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_052"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H. Documents on Display.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
reporting requirements of the Exchange Act, applicable to foreign private issuers and under those requirements will file reports with
the SEC. The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically
with the SEC. Our filings with the SEC are also available to the public through the SEC&#8217;s website at www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors
and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange
Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with
the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act. However, we file
with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form
20-F containing financial statements audited by an independent registered public accounting firm, and may submit to the SEC, on a Form
6-K, unaudited quarterly financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
www.polypid.com. Information contained on, or that can be accessed through, our website and the other websites referenced above do not
constitute a part of this annual report on Form 20-F. We have included these website addresses in this annual report on Form 20-F solely
as inactive textual references.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 134 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_053"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I. Subsidiary Information.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_054"></a></div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>J. Annual Report to Security Holders.</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39.35pt">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_055"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 11.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the ordinary course of
our operations, we are exposed to certain market risks, primarily changes in foreign currency exchange rates and interest rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Quantitative and Qualitative
Disclosure About Market Risk </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to market risks
in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse
changes in financial market prices and rates. Our current investment policy is to invest available cash in bank deposits with banks that
have a credit rating of at least A-minus. Accordingly, a substantial majority of our cash and cash equivalents is held in deposits that
bear interest. Given the current low rates of interest we receive, we will not be adversely affected if such rates are reduced. Our market
risk exposure is primarily a result of NIS/U.S. dollar exchange rates, which is discussed in detail in the following paragraph.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Foreign Currency Exchange
Risk </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate primarily in Israel,
and approximately 50% of our expenses are denominated in NIS. We are therefore exposed to market risk, which represents the risk of loss
that may impact our financial position due to adverse changes in financial market prices and rates. We are subject to fluctuations in
foreign currency rates in connection with these arrangements. Changes of 5% and 10% in the U.S. dollar/NIS exchange rate would have increased/decreased
operating expenses by approximately 1.2% and 2.4%, respectively, in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently partially hedge
our foreign currency exchange rate risk to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal
operating currencies. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations. <b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_056"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 12.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_057"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. Debt Securities.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_058"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B. Warrants and rights.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_059"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C. Other Securities.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_060"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D. American Depositary Shares.</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 135 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_060a"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_061"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 13.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_062"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 14.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2020, we sold 4,312,500
Ordinary Shares in the IPO at a public offering price of $16.00 per share, for aggregate gross proceeds to us of $69.0 million. The net
offering proceeds to us, after deducting underwriting discounts and commissions totaling approximately $4.8 million and offering expenses
totaling approximately $1.4 million were approximately $62.8 million. The offering commenced on June 5, 2020 and did not terminate before
all of the securities registered in the registration statement were sold. The effective dates of the registration statements, File Nos.
333-238978 and 333-239442, for the IPO of our Ordinary Shares were June 25, 2020. Barclays Capital Inc. acted as sole book-running manager
and as representative of the underwriters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The net proceeds from IPO
have been used as described in the final prospectus for the IPO filed with the SEC on June 29, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_063"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 15.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>CONTROLS AND PROCEDURES</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our disclosure controls and
procedures are designed to provide reasonable assurance of achieving the desired control objectives. Our management, including our Chief
Executive Officer and Senior Vice President of Finance, recognizes that any control system, no matter how well designed and operated,
is based upon certain judgments and assumptions and cannot provide absolute assurance that its objectives will be met. Similarly, an evaluation
of controls cannot provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances
of fraud, if any, have been detected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with the participation
of our Chief Executive Officer and Senior Vice President of Finance, has evaluated the effectiveness of our disclosure controls and procedures
(as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2022, or the Evaluation Date. Based
on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective
in recording, processing, summarizing and reporting, on a timely basis, information required to be included in periodic filings under
the Exchange Act and that such information is accumulated and communicated to management, including our principal executive and financial
officers, as appropriate to allow timely decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 136 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Management&#8217;s Annual Report on Internal
Control over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the
Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and Senior Vice
President of Finance, we conducted an evaluation of the effectiveness of our internal control over financial reporting based principally
on the framework and criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations
of the Treadway Commission as of the end of the period covered by this report. Based on that evaluation, our management has concluded
that our internal control over financial reporting was effective as of December 31, 2022 at providing reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted
accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(c) Attestation Report of the Registered Public
Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This annual report does not
include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting
due to an exemption for emerging growth companies provided in the JOBS Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(d) Changes in Internal Control over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2022, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_064"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16.</b> [Reserved].</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_065"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
determined that each of Dr.&#160;Krinsky and Ms.&#160;Segal is an audit committee financial expert as such term is defined by the SEC
rules and has the requisite financial experience as defined by the Nasdaq Rules. Each of the members of our audit committee is &#8220;independent&#8221;
as such term is defined in Rule&#160;10A-3(b)(1) under the Exchange Act and satisfies the independent director requirements under the
Nasdaq Rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_066"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16B. CODE OF ETHICS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a Corporate
Code of Ethics and Conduct applicable to all of our directors and employees, including our Chief Executive Officer, Senior Vice President
of Finance, controller or principal accounting officer, or other persons performing similar functions, which is a &#8220;code of ethics&#8221;
as defined in Item&#160;16B of Form&#160;20-F promulgated by the SEC. The full text of the Corporate Code of Ethics and Conduct is posted
on our website at www.polypid.com. Information contained on, or that can be accessed through, our website does not constitute a part of
this annual report and is not incorporated by reference herein. If we make any amendment to the Corporate Code of Ethics and Conduct or
grant any waivers, including any implicit waiver, from a provision of such code, we will disclose the nature of such amendment or waiver
on our website to the extent required by the rules and regulations of the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 137 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_067"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Kost, Forer, Gabbay&#160;&amp;
Kasierer, Certified Public Accountants (Israel), an independent registered public accounting firm and a member firm of Ernst&#160;&amp;
Young Global, has served as our principal independent registered public accounting firm for each of the two years ended December 31, 2021
and 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
information regarding fees paid by us to Kost, Forer, Gabbay&#160;&amp; Kasierer and/or other member firms of Ernst&#160;&amp; Young Global
for all services, including audit services, for the years ended December 31, 2021 and 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees <sup>(1) </sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">240,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">252,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related fees <sup>(2) </sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax fees <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,251</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,900</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">All other fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">285,251</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">373,900</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="width: 97%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes professional services rendered in connection with the audit of our annual financial statements, review of our interim financial statements and tax returns. </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes professional services rendered, such as comfort letters for the Sales Agreement and audit of the IIA programs, in connection with the preparation the Company&#8217;s registration statement on Form F-3. </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes professional services rendered for tax compliance and tax advice other than in connection with the audit.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pre-Approval of Auditors&#8217; Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the regulations
promulgated under the Israeli Companies Law, pre-approval of audit fees is only mandatory for a public company. In addition, under our
audit committee charter our audit committee is responsible for, among other things, pre-approving audit and non-audit services provided
to us by the independent registered public accounting firm. Subject to the board of directors&#8217; and shareholders&#8217; approval,
if and to the extent required by applicable law, the audit committee shall have the authority to approve all audit engagement fees and
terms and all non-audit engagements, as may be permissible, with the independent registered public accounting firm. <span>All
the fees set forth above were pre-approved by the audit committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_068"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_069"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_070"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 138 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_071"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16G. CORPORATE GOVERNANCE</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Sarbanes-Oxley Act, as
well as related rules subsequently implemented by the SEC, require foreign private issuers, such as us, to comply with various corporate
governance practices. In addition, we are required to comply with the Nasdaq Stock Market rules. Under those rules, we may elect to follow
certain corporate governance practices permitted under the Israeli Companies Law in lieu of compliance with corresponding corporate governance
requirements otherwise imposed by the Nasdaq Stock Market rules for U.S. domestic issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Israeli
law and practice and subject to the exemption set forth in Rule 5615 of the Nasdaq Stock Market rules, we have elected to follow the provisions
of the Israeli Companies Law, rather than the Nasdaq Stock Market rules, with respect to the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Proxy Statements.</i>&#160;We will not be required to and, in reliance on home country practice, we do not intend to comply with certain Nasdaq Rules regarding the provision of proxy statements for general meetings of shareholders. Israeli corporate law does not have a regulatory regime for the solicitation of proxies. We intend to provide notice convening an annual general meeting, including an agenda and other relevant documents. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Quorum</i>. As permitted under the Israeli Companies Law and pursuant to our amended and restated articles of association, the quorum required for an ordinary meeting of shareholders will consist of at least two shareholders present in person, by proxy or by other voting instrument in accordance with the Israeli Companies Law, who hold at least 25% of the voting power of our shares. A meeting adjourned for lack of a quorum is generally adjourned to the same day in the following week at the same time and place or to a later time or date if so specified in the summons or notice of the meeting. At the reconvened meeting, in general any shareholder present in person or by proxy shall constitute a lawful quorum, instead of 33&#8531;% of the issued share capital as required under the Nasdaq Rules.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nomination of our directors</i>. The nominations for directors, which are presented to our shareholders by our board of directors, are generally made by the board of directors itself, in accordance with the provisions of our articles of association and the Israeli Companies Law. Nominations need not be made by a nominating committee of our board of directors consisting solely of independent directors or by a vote consisting solely of our independent directors in order to determine which persons shall be nominated for election by our shareholders, as required under the Nasdaq Stock Market rules.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Independent Directors</i>. Under the Israeli Companies Law, we would be required to include on our board of directors at least two members, each of whom qualifies as an external director, and as to whom special qualifications and other provisions would be applicable. We would also be required to include one such external director on each of our board committees. However, as we do not have a controlling shareholder, and we comply with the requirements of the Nasdaq Stock Market with respect to the composition of our board and such committees, we therefore are exempt from the Israeli Companies Law requirements with respect thereto, including the appointment of external directors. We are required, however, to ensure that all members of our audit committee are &#8220;independent&#8221; under the Nasdaq Rules, and we must also ensure that a majority of the members of our audit committee are &#8220;independent directors&#8221; as defined in the Israeli Companies Law. Furthermore, Israeli law does not require, and our independent directors do not conduct regularly scheduled meetings at which only they are present, as otherwise required by the Nasdaq Stock Market rules.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 139 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shareholder Approval.</i>&#160;We will not be required to and, in reliance on home country practice, we do not intend to comply with certain Nasdaq Rules regarding shareholder approval for certain issuances of securities under Nasdaq Rule&#160;5635. In particular, under the Nasdaq Rules, shareholder approval is generally required for: (i)&#160;an acquisition of shares or assets of another company that involves the issuance of 20% or more of the acquirer&#8217;s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest (or such persons collectively have a 10% or greater interest) in the target company or the assets to be acquired or the consideration to be received and the present or potential issuance of Ordinary Shares, or securities convertible into or exercisable for Ordinary Shares, could result in an increase in outstanding Ordinary Shares or voting power of 5% or more; (ii)&#160;the issuance of shares leading to a change of control; (iii)&#160;adoption or amendment of a stock option or purchase plan or other equity compensation arrangements, pursuant to which stock may be acquired by officers, directors, employees or consultants (with certain limited exception); and (iv)&#160;issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales by directors or officers or 5% shareholders) if such equity is issued (or sold) at below a specified minimum price. By contrast, under the Israeli Companies Law, the adoption of, and material changes to, equity-based compensation plans generally require the approval of the board of directors and the compensation committee of the board of directors. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Approval of Related Party Transactions</i>. All related party transactions are approved in accordance with the requirements and procedures for approval of interested party acts and transactions as set forth in the Israeli Companies Law, which requires the approval of the audit committee, or the compensation committee, as the case may be, the board of directors and shareholders, as may be applicable, for specified transactions, rather than approval by the audit committee or other independent body of our board of directors as required under the Nasdaq Stock Market rules.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Annual Shareholders Meeting.</i>&#160;We will not be required to and, in reliance on home country practice, we do not intend to comply with Nasdaq Stock Market Rule 5620(a), which requires a listed company to hold its annual shareholders meeting within one year of the company&#8217;s fiscal year-end. Under the Israeli Companies Law, we are required to hold an annual shareholders meeting each calendar year and within 15 months of the last annual shareholders meeting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to take all actions
necessary for us to maintain compliance as a foreign private issuer under the applicable corporate governance requirements of the Sarbanes-Oxley
Act of 2002, the rules adopted by the SEC and the Nasdaq Stock Market corporate governance rules and listing standards. Because we are
a foreign private issuer, our directors and senior management are not subject to short-swing profit and insider trading reporting obligations
under Section&#160;16 of the Exchange Act. They are, however, subject to the obligations to report changes in share ownership under Section&#160;13
of the Exchange Act and related SEC rules.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_072"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16H. MINE SAFETY DISCLOSURE</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_073"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 140 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_074"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_075"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 17.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>FINANCIAL STATEMENTS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have elected to provide
financial statements and related information pursuant to Item&#160;18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_076"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 18.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>FINANCIAL STATEMENTS</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements and the related notes required by this Item are included in this annual report on Form 20-F beginning on page&#160;F-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_077"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 19.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>EXHIBITS. </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 91%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1611842/000121390022023333/ea159296ex99-1_polypidltd.htm" style="-sec-extract: exhibit">Articles of Association of PolyPid Ltd., filed as Exhibit 99.1 to Form 6-K (File No. 001-38428) filed on May 3, 2022, and incorporated herein by reference.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-4_2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant to purchase Series&#160;E-1 Preferred Shares, filed as Exhibit 4.2 to form F-1 (File No. 333-238978) filed on June 5, 2020, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2022ex2-2_polypidltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities (filed herewith).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000104746920003758/a2241928zex-10_1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Officer Indemnity and Exculpation Agreement, filed as Exhibit 10.1 to Form F-1 (File No. 333-238978) filed on June 22, 2020, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000121390021021249/ea139446ex99-1_polypid.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation Policy, filed as Exhibit 99.1 to Form 6-K (File No. 001-38428) filed on April 13, 2021, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000121390022046074/ea164129ex99-1_polypidltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated PolyPid Ltd. 2012 Share Option Plan, filed as Exhibit 99.1 to Form 6-K (File No. 001-38428) filed on August 10, 2022, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-10_4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease Agreement, dated March 27, 2014, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 10.4 as Exhibit 10.4 to Form F-1 (File No. 333-238978) filed on June 22, 2020, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-10_41.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addendum to Lease Agreement, dated July 1, 2014, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 10.4.1 to Form F-1 (File No. 333-238978) filed on June 22, 2020, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-10_42.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Addendum to Lease Agreement, dated July 23, 2017, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 10.4.2 to Form F-1 (File No.&#160;333-238978) filed on June 22, 2020, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-10_43.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Addendum to Lease Agreement, dated November 28, 2017, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 10.4.3 to Form F-1 (File No. 333-238978) filed on June 22, 2020, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-10_44.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourth Addendum to Lease Agreement, dated January 22, 2018, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 10.4.4 to Form F-1 (File No. 333-238978) filed on June 22, 2020, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-10_45.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fifth Addendum to Lease Agreement, dated November 4, 2018, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 10.4.5 to Form F-1 (File No. 333-238978) filed on June 22, 2020, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000104746920003386/a2241750zex-10_46.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sixth Addendum to Lease Agreement, dated December 15, 2019, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 10.4.6 to Form F-1 (File No. 333-238978) filed on June 22, 2020, and incorporated herein by reference.</span></a></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 141 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 91%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000121390022009722/f20f2021ex4-11_polypidltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seventh Addendum to Lease Agreement, dated April 11, 2021 by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 4.11 to Form 20-F (File No. 001-38428) filed on February 28, 2022, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000121390022009722/f20f2021ex4-12_polypidltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eighth Addendum to Lease Agreement, dated August 9, 2021, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 4.12 to Form 20-F (File No. 001-38428) filed on February 28, 2022, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000121390022009722/f20f2021ex4-13_polypidltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ninth Addendum to Lease Agreement, dated October 26, 2021, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 4.13 to Form 20-F (File No. 001-38428) filed on February 28, 2022, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000121390022009722/f20f2021ex4-14_polypidltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenth Addendum to Lease Agreement, dated January 25, 2022, by and between PolyPid Ltd. and Ogen Yielding Real Estate Ltd. (unofficial English translation from Hebrew original), filed as Exhibit 4.14 to Form 20-F (File No. 001-38428) filed on February 28, 2022, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000121390021035574/ea143509ex10-1_polypidltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales Agreement, dated July 2, 2021, by and between PolyPid Ltd. and Cantor Fitzgerald &amp; Co., filed as Exhibit 10.1 to form F-3 (File No. 333-257651) filed on July 2, 2021, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000121390022018318/ea158121ex10-1_polypidltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement for the Provision of a Loan Facility of up to US$15,000,000 dated April 5, 2022, by and between Kreos Capital VI (Expert Fund) LP and PolyPid Ltd., filed as Exhibit 10.1 to Form 6-K (File No. 001-38428), filed on April 6, 2022, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000121390022045399/ea163911ex10-1_polypidltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License, Distribution and Supply Agreement, dated August 2, 2022, by and between PolyPid Ltd. and Mercury Pharma Group Limited, under the trade name Advanz Pharma Holdings, filed as Exhibit 10.1 to Form 6-K (File No. 001-38428), filed on August 8, 2022, and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1611842/000121390021013722/f20f2020ex8-1_polypid.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries, filed as Exhibit 8.1 to form 20-F (File No. 001-38428) filed on March 5, 2021 and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2022ex12-1_polypidltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Principal Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2022ex12-2_polypidltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Principal Financial Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2022ex13-1_polypidltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Principal Executive Officer pursuant to 18 U.S.C. 1350, furnished herewith.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2022ex13-2_polypidltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Principal Financial Officer pursuant to 18 U.S.C. 1350, furnished herewith.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2022ex15-1_polypidltd.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Kost, Forer, Gabbay&#160;&amp; Kasierer, Certified Public Accountants (Israel), an independent registered public accounting firm and a member firm of Ernst&#160;&amp; Young Global.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following financial
    information from the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2022, formatted in XBRL (eXtensible
    Business Reporting Language): (i) Report of Independent Registered Public Accounting Firm; (ii) Consolidated Balance Sheets; (iii)
    Consolidated Statements of Operations; (iv) Consolidated Statements of Changes in Convertible Preferred Shares and Shareholders&#8217;
    Equity (Deficit); (v) Consolidated Statements of Cash Flows; and (vi) Notes to the Consolidated Financial Statements, tagged as blocks
    of text and in detail.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive
    Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 142 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registrant hereby certifies
that it meets all of the requirements for filing on Form&#160;20-F and that it has duly caused and authorized the undersigned to sign
this annual report on Form 20-F filed on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>POLYPID LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 31, 2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>By:&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dikla Czaczkes Akselbrad</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dikla Czaczkes Akselbrad</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Chief Executive Officer and Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 143 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>POLYPID LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AS OF DECEMBER&#160;31, 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AUDITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 90%; text-align: justify">&#160;</td> <td style="border-bottom: Black 1.5pt solid; width: 10%; padding-right: 0.05in; padding-left: 0.05in; text-align: center"><b>Page</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: 0.7pt; text-align: justify">&#160;</td> <td style="padding-right: 0.05in; padding-left: 0.05in; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0.7pt; text-align: justify"><b><a href="#fin_001">Report of Independent Registered Public Accounting Firm (PCAOB ID: <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId">1281</ix:nonNumeric>)</a></b></td> <td style="padding-right: 0.05in; padding-left: 0.05in; text-align: center"><b>F-2</b></td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0.7pt; text-align: justify">&#160;</td> <td style="padding-right: 0.05in; padding-left: 0.05in; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0.7pt; text-align: justify"><b><a href="#fin_002">Consolidated Balance Sheets</a></b></td> <td style="padding-right: 0.05in; padding-left: 0.05in; text-align: center"><b>F-3 - F-4</b></td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0.7pt; text-align: justify">&#160;</td> <td style="padding-right: 0.05in; padding-left: 0.05in; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0.7pt; text-align: justify"><b><a href="#fin_003">Consolidated Statements of Operations</a></b></td> <td style="padding-right: 0.05in; padding-left: 0.05in; text-align: center"><b>F-5</b></td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0.7pt; text-align: justify">&#160;</td> <td style="padding-right: 0.05in; padding-left: 0.05in; text-align: center">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: 0.7pt; text-align: justify"><b><a href="#fin_004">Consolidated Statements of Changes in Convertible Preferred Shares and Shareholders&#8217; Equity (Deficit)</a></b></td> <td style="vertical-align: bottom; padding-right: 0.05in; padding-left: 0.05in; text-align: center"><b>F-6</b></td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0.7pt; text-align: justify">&#160;</td> <td style="padding-right: 0.05in; padding-left: 0.05in; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0.7pt; text-align: justify"><b><a href="#fin_005">Consolidated Statements of Cash Flows</a></b></td> <td style="padding-right: 0.05in; padding-left: 0.05in; text-align: center"><b>F-7 - F-8</b></td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0.7pt; text-align: justify">&#160;</td> <td style="padding-right: 0.05in; padding-left: 0.05in; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0.7pt; text-align: justify"><b><a href="#fin_007">Notes to Consolidated Financial Statements</a></b></td> <td style="padding-right: 0.05in; padding-left: 0.05in; text-align: center"><b>F-9 - F-34</b></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>- - - - - - - - - - - - - - - - - - -</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 144; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 20%"><img alt="" src="fin_001.jpg"/>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>
                                                                     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>
                                                                     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Kost
                                            Forer Gabbay &amp; Kasierer</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2 Pal-Yam Blvd. Brosh Bldg.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Haifa 3309502, Israel</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
                                                                     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
                                                                     <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel:
                                            +972-4-8654000</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fax: +972-3-5633439</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">ey.com</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="fin_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Report of Independent Registered
Public Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Shareholders and Board of Directors of</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">POLYPID LTD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of PolyPid Ltd. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related consolidated
statements of operations, changes in convertible preferred shares and shareholders&#8217; equity (deficit) and cash flows for each of the three
years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).
In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company
at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December
31, 2022, in conformity with U.S. generally accepted accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The Company&#8217;s Ability to Continue as
a Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1.d to the financial consolidated
statements, the Company has suffered recurring losses from operations and has stated that substantial doubt exists about the Company&#8217;s
ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding
these matters are also described in Note 1.d. The consolidated financial statements do not include any adjustments that might result from
the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal
control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: top; width: 62%; text-align: justify">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName">KOST FORER GABBAY &amp; KASIERER</ix:nonNumeric></td> <td style="vertical-align: bottom; width: 38%; text-align: center">&#160;</td></tr> <tr> <td style="vertical-align: top; text-align: justify">A Member of Ernst &amp; Young Global</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr> <td style="vertical-align: top; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr> <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company&#8217;s auditor since 2010.</p></td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr> <td style="vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation">Haifa, Israel</ix:nonNumeric></td> <td style="vertical-align: bottom">&#160;</td></tr> <tr> <td style="vertical-align: top; text-align: left">March 31, 2023</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><div><a id="fin_002"></a></div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED
BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.25in; font-weight: bold; text-align: justify">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">CURRENT ASSETS:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">8,552</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">9,819</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd">511</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd">397</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Short-term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssets" scale="3" unitRef="usd">4,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssets" scale="3" unitRef="usd">22,384</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd">1,089</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd">2,211</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">14,194</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">34,811</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">LONG-TERM ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">9,247</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">8,761</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="pypd:LongtermDeposits" scale="3" unitRef="usd">2,431</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">Other long-term assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd">99</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd">663</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> long-term assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="3" unitRef="usd">11,777</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="3" unitRef="usd">9,424</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="text-decoration:underline">Total</span> assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">25,971</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">44,235</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><b>CONSOLIDATED
BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.25in; font-weight: bold; text-align: left">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: justify">Current maturities of long-term debt</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtCurrent" scale="3" unitRef="usd">4,024</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" unitRef="usd">2,429</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" unitRef="usd">3,940</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd">1,141</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd">4,136</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">Current maturities of operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">959</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">8,553</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">8,076</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">LONG-TERM LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Long-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" unitRef="usd">7,574</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify">Deferred revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" unitRef="usd">2,548</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Long-term operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">1,173</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">Other liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilities" scale="3" unitRef="usd">294</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilities" scale="3" unitRef="usd">199</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> long-term liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="pypd:TotalLongtermLiabilities" scale="3" unitRef="usd">11,589</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="pypd:TotalLongtermLiabilities" scale="3" unitRef="usd">199</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">COMMITMENTS AND CONTINGENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">SHAREHOLDERS&#8217; EQUITY:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify">Ordinary shares, <span style="-sec-ix-hidden: hidden-fact-5"><span style="-sec-ix-hidden: hidden-fact-6">no</span></span> par value - Authorized: <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">47,800,000</ix:nonFraction></ix:nonFraction> shares at December 31, 2022 and 2021; Issued and outstanding: <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">19,851,833</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">18,756,570</ix:nonFraction></ix:nonFraction> shares at December 31, 2022 and 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">220,273</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">210,847</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">214,444</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">174,887</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">5,829</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">35,960</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="text-decoration:underline">Total</span> liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">25,971</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">44,235</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><div><a id="fin_003"></a></div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year
Ended December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 64%; text-align: left">Research and development, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">27,990</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">30,553</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">16,954</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Marketing and business development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:MarketingAndBusinessDevelopmentExpenses" scale="3" unitRef="usd">2,888</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="pypd:MarketingAndBusinessDevelopmentExpenses" scale="3" unitRef="usd">2,983</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:MarketingAndBusinessDevelopmentExpenses" scale="3" unitRef="usd">1,614</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">8,010</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">9,609</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">7,704</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">38,888</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">43,145</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">26,272</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Financial (income) expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">540</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">544</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">10,597</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss before income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" sign="-" unitRef="usd">39,428</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" sign="-" unitRef="usd">42,601</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" sign="-" unitRef="usd">36,869</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd">129</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">39,557</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">42,601</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">36,869</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deemed dividend</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:DeemedDividends" scale="3" sign="-" unitRef="usd">2,114</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net loss attributable to Ordinary shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:NetLossAttributableToOrdinarySharesinDollarsPerShare" scale="3" sign="-" unitRef="usd">39,557</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="pypd:NetLossAttributableToOrdinarySharesinDollarsPerShare" scale="3" sign="-" unitRef="usd">42,601</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:NetLossAttributableToOrdinarySharesinDollarsPerShare" scale="3" sign="-" unitRef="usd">38,983</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-13; -sec-ix-hidden: hidden-fact-12; -sec-ix-hidden: hidden-fact-11">Basic and diluted net loss per Ordinary share</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">2.04</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">2.28</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">4.48</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><div style="-sec-ix-hidden: hidden-fact-16; -sec-ix-hidden: hidden-fact-15; -sec-ix-hidden: hidden-fact-14">Weighted average number of Ordinary shares used in computing basic and diluted loss per share</div></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">19,426,692</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">18,721,528</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">9,582,405</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><div><a id="fin_004"></a></div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS&#8217; EQUITY (DEFICIT)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Convertible Preferred shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shareholders&#8217; equity (deficit)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/>
 shares</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-right: Black 1.5pt solid; white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/>
 Ordinary<br/>
 shares</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Additional<br/>
 paid-in<br/>
 capital</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<br/>
 deficit</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Total<br/>
 shareholders&#8217; </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>equity (deficit) </b></p></td><td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Balances as of January 1, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">12,520,977</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">106,313</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">106,313</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid; width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">562,748</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">5,671</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">93,303</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">87,632</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd">4,577</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd">4,577</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Issuance of Ordinary shares in connection with the IPO, net (1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">4,312,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" unitRef="usd">62,757</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" unitRef="usd">62,757</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Conversion of convertible Preferred shares to Ordinary shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="pypd:ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" scale="0" sign="-" unitRef="shares">12,520,977</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares" scale="3" sign="-" unitRef="usd">106,313</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares" scale="3" sign="-" unitRef="usd">106,313</ix:nonFraction></td><td style="text-align: left">)</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="pypd:ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" scale="0" unitRef="shares">12,520,977</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares" scale="3" unitRef="usd">106,313</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares" scale="3" unitRef="usd">106,313</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Deemed dividend related to Series E-1 Preferred shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">158,967</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" scale="3" unitRef="usd">2,114</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" scale="3" sign="-" unitRef="usd">2,114</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Reclassification of warrants into equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ReclassificationOfWarrantsIntoEquity" scale="3" unitRef="usd">23,614</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ReclassificationOfWarrantsIntoEquity" scale="3" unitRef="usd">23,614</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="pypd:StockIssuedDuringPeriodExerciseOfWarrantsShares" scale="0" unitRef="shares">939,152</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ExerciseOfWarrants" scale="3" unitRef="usd">13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ExerciseOfWarrants" scale="3" unitRef="usd">13</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">395</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">36,869</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">36,869</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Balances as of December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">18,494,739</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">205,063</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">132,286</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">72,777</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd">4,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd">4,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="pypd:StockIssuedDuringPeriodExerciseOfWarrantsShares" scale="0" unitRef="shares">184,473</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ExerciseOfWarrants" scale="3" unitRef="usd">632</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ExerciseOfWarrants" scale="3" unitRef="usd">632</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">77,358</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">402</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">402</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">42,601</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">42,601</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Balances as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">18,756,570</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">210,847</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">174,887</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">35,960</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd">4,307</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd">4,307</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Issuance of Ordinary shares, net (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" id="ix_3_fact" name="pypd:IssuanceOfOrdinarySharesNetinShares" scale="0" unitRef="shares">1,065,057</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">4,423</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">4,423</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" unitRef="usd">588</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" unitRef="usd">588</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">30,206</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">108</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid; padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">39,557</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">39,557</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Balances as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="border-right: Black 1.5pt solid; padding-bottom: 4pt">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">19,851,833</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">220,273</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">214,444</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">5,829</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span>Net of issuance costs
of $6,243 (see Note&#160;1c).</span></ix:footnote></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span>Net of issuance costs
of $222.</span></ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><div><a id="fin_005"></a></div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year
Ended December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="text-decoration:underline">Cash flows from operating activities:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 64%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">39,557</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">42,601</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">36,869</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify">Adjustments to reconcile net loss to net cash used&#160;in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Depreciation of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">1,721</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">1,118</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">1,012</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Remeasurement of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ReevaluationOfWarrants" scale="3" unitRef="usd">11,373</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Non-cash financial expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" sign="-" unitRef="usd">289</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Share-based compensation expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">4,307</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">4,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">4,577</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-style: italic; text-align: left">Changes in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:DecreaseincreaseInReceivablesAndPrepaidExpenses" scale="3" sign="-" unitRef="usd">1,185</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="pypd:DecreaseincreaseInReceivablesAndPrepaidExpenses" scale="3" sign="-" unitRef="usd">83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:DecreaseincreaseInReceivablesAndPrepaidExpenses" scale="3" unitRef="usd">1,929</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Operating lease liabilities and right-of-use assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">299</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" sign="-" unitRef="usd">3,095</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd">2,221</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" sign="-" unitRef="usd">607</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Deferred revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" unitRef="usd">2,548</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Accrued expenses and other liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitRef="usd">1,416</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd">2,043</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd">847</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">34,317</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">32,386</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">21,596</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Short-term and long-term deposits, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:PaymentsForProceedsFromShorttermAndLongtermDepositsNet" scale="3" sign="-" unitRef="usd">18,342</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="pypd:PaymentsForProceedsFromShorttermAndLongtermDepositsNet" scale="3" sign="-" unitRef="usd">39,893</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:PaymentsForProceedsFromShorttermAndLongtermDepositsNet" scale="3" unitRef="usd">39,592</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Pre-payments for equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="pypd:PrepaymentForEquipments" scale="3" unitRef="usd">340</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:PrepaymentForEquipments" scale="3" unitRef="usd">395</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Purchase of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">1,767</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">2,653</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">781</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd">16,575</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd">36,900</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">40,768</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" unitRef="usd">632</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" unitRef="usd">13</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd">108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd">402</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from issuance of Ordinary shares in connection with the IPO, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" unitRef="usd">62,757</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from issuance of Ordinary shares, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd">4,423</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from long-term debt, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" unitRef="usd">11,711</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Repayment of long-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" unitRef="usd">402</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Proceeds from issuance of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:IssuanceOfWarrants" scale="3" sign="-" unitRef="usd">588</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:IssuanceOfWarrants" scale="3" sign="-" unitRef="usd">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">16,428</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">1,034</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">62,774</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Increase (decrease) in cash, cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">1,314</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd">5,548</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd">410</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cash, cash equivalents and restricted cash at the beginning of the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">10,456</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">4,908</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">4,498</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Cash, cash equivalents and restricted cash at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">9,142</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">10,456</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">4,908</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-decoration: underline; text-align: left">Supplemental disclosures of cash flows:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Interest paid</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd">734</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Cash paid during the year for income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="3" unitRef="usd">8</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES</b></p><div>

</div><div><a id="fin_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="text-decoration:underline">Supplemental disclosures of cash flow information:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">8,552</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">9,819</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">4,319</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">511</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">397</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">390</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash included in other long-term assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:RestrictedCashIncludedInOtherLongtermAssets" scale="3" unitRef="usd">79</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="pypd:RestrictedCashIncludedInOtherLongtermAssets" scale="3" unitRef="usd">240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:RestrictedCashIncludedInOtherLongtermAssets" scale="3" unitRef="usd">199</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Cash, cash equivalents and restricted cash at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">9,142</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">10,456</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">4,908</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-decoration: underline; text-align: left; text-indent: -9pt; padding-left: 9pt">Supplemental disclosures of non-cash investing and financing information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment acquired by credit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:PurchaseOfPropertyAndEquipmentIncludedInTradePayable" scale="3" unitRef="usd">100</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="pypd:PurchaseOfPropertyAndEquipmentIncludedInTradePayable" scale="3" unitRef="usd">941</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment paid for in prior periods</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:PropertyAndEquipmentPaidForInPriorPeriods" scale="3" unitRef="usd">340</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="pypd:PropertyAndEquipmentPaidForInPriorPeriods" scale="3" unitRef="usd">395</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Right-of-use asset recognized with corresponding lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">3,528</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Cash paid for amounts included in measurement of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="3" unitRef="usd">1,259</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><div><a id="fin_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccounting-c0_cont_1" escape="true" name="us-gaap:BasisOfAccounting"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left">NOTE 1:-</td><td style="text-align: justify">GENERAL</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_BasisOfAccounting-c0_cont_2" id="_BasisOfAccounting-c0_cont_1"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">a.</td><td style="text-align: justify">PolyPid Ltd. (the &#8220;Company&#8221;) was incorporated under the laws of Israel and commenced operations
on February&#160;28, 2008. The Company is a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and
prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. The Company&#8217;s product candidates
are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release
rates and durations over extended periods ranging from days to several months. The Company is initially focused on the development of
its lead product candidate, D-PLEX, which incorporates an antibiotic for the prevention of surgical site infection in bone and soft tissue.
Through December 31, 2022, the Company has been primarily engaged in research and development.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BasisOfAccounting-c0_cont_3" id="_BasisOfAccounting-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">The Company&#8217;s wholly owned subsidiaries
include a subsidiary in the United States of America (the &#8220;US Subsidiary&#8221;) and a subsidiary in Romania. The US Subsidiary&#8217;s
operation focuses on marketing and business development of the Company&#8217;s operation in the United States of America.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BasisOfAccounting-c0_cont_4" id="_BasisOfAccounting-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">On June 21, 2020, <ix:nonNumeric contextRef="c43" name="pypd:DescriptionOfReverseShareSplit">the Company&#8217;s Board of Directors resolved to consolidate the Company&#8217;s share
capital by applying a reverse share split at a ratio of 1.046:1 (the &#8220;Reverse Split Ratio&#8221;) and to cancel the shares&#8217;
par value such that every 1.046 Ordinary shares of NIS 0.8 par value, were substituted by 1 Ordinary share with no par value (the &#8220;Split&#8221;).
The Split was applied in the same proportion and manner to all of the Company&#8217;s authorized, issued and outstanding securities, including
preferred shares, options and warrants (See Note 10.a).</ix:nonNumeric></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BasisOfAccounting-c0_cont_5" id="_BasisOfAccounting-c0_cont_4"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">c.</td><td style="text-align: justify">On June 30, 2020, the Company closed its initial public offering (&#8220;IPO&#8221;) whereby <ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="pypd:StockIssuedDuringPeriodSharesNewIssue" scale="0" unitRef="shares">4,312,500</ix:nonFraction> Ordinary
shares were sold by the Company to the public (inclusive of <ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="pypd:StockIssuedDuringPeriodSharesNewIssue" scale="0" unitRef="shares">562,500</ix:nonFraction> Ordinary shares pursuant to the full exercise of an overallotment
option granted to the underwriters). The aggregate net proceeds received by the Company from the offering were $<ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="pypd:AggregateNetProceeds" scale="3" unitRef="usd">62,757</ix:nonFraction>, net of underwriting
discounts and other offering costs.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BasisOfAccounting-c0_cont_6" id="_BasisOfAccounting-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">d.</td><td style="text-align: justify">The Company&#8217;s activities since inception have consisted of performing research and development activities.
Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations is dependent on future
events, including, among other things, its ability to secure financing; obtain marketing approval from regulatory authorities; access
potential markets; build a sustainable customer base; attract, retain and motivate qualified personnel; and develop strategic alliances.
The Company&#8217;s operations are funded by its shareholders and research and development grants and the Company intends to seek further private
or public financing as well as make applications for further research and development grants for continuing its operations. Although management
believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to
do so or that the Company will ever operate profitably.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BasisOfAccounting-c0_cont_7" id="_BasisOfAccounting-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">In September 2022,
<ix:nonNumeric contextRef="c47" continuedAt="pypd_DescriptionAdministration-c47_cont_1" name="pypd:DescriptionAdministration">the Company announced top-line results from the Surgical site Hospital acquired Infection prEvention with Local D-PLEX<sub>100</sub> (&#8220;SHIELD&#8221;)
I Phase&#160;3 trial. SHIELD I did not achieve its primary endpoint of reduction in Surgical Site Infections (&#8220;SSIs&#8221;), re-interventions
due to SSIs and mortality: in the Intent to Treat (&#8220;ITT&#8221;) population, the local administration of D-PLEX<sub>100</sub> and standard
of care (&#8220;SoC&#8221;), (n=485) resulted in a decrease in the primary endpoint of 23 percent compared to SoC alone (n=489) (p=0.1520).</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left">NOTE 1:-</td><td style="text-align: justify">GENERAL (CONT.)</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><ix:continuation continuedAt="_BasisOfAccounting-c0_cont_8" id="_BasisOfAccounting-c0_cont_7"><ix:continuation id="pypd_DescriptionAdministration-c47_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">That said, in a
pre-specified subgroup ITT analysis requested by the United States (&#8220;U.S.&#8221;) Food and Drug Administration of a total of 423 subjects
with large incisions (&gt;20 centimeters), the local administration of D-PLEX<sub>100 </sub>resulted in a significant reduction of 54
percent in the primary endpoint, compared to SoC alone (p=0.0032). Within the first 30 days post-surgery, SSIs decreased from 9.7% in
the SoC treatment arm (n=211), as compared to 4.4% in the D-PLEX<sub>100</sub> treatment arm (n=212).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BasisOfAccounting-c0_cont_9" id="_BasisOfAccounting-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company expects
to continue to incur substantial losses over the next several years during its clinical development phase. To fully execute its business
plan, the Company will need to complete phase 3 clinical studies and certain development activities as well as manufacture the required
clinical and commercial production batches in the pilot manufacturing plant. Further, the Company&#8217;s product candidates will require regulatory
approval prior to commercialization and the Company will need to establish sales, marketing and logistic infrastructures. These activities
may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these
activities could adversely impact the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BasisOfAccounting-c0_cont_10" id="_BasisOfAccounting-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As of December 31,
2022, the Company had cash, cash equivalents and short-term deposits in the total amount of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" unitRef="usd">12,594</ix:nonFraction>. During the year ended December&#160;31,
2022, the Company incurred a net loss of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:IncurredLoss" scale="3" unitRef="usd">39,557</ix:nonFraction> and had negative cash flows from operating activities of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:CashFlowsFromOperatingActivities" scale="3" unitRef="usd">34,317</ix:nonFraction>. In addition, the Company
had an accumulated deficit of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CumulativeEarningsDeficit" scale="3" unitRef="usd">214,444</ix:nonFraction> at December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BasisOfAccounting-c0_cont_11" id="_BasisOfAccounting-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company&#8217;s future
operations are highly dependent on a combination of factors, including (i) completion of all required clinical studies; (ii) the success
of its research and development activities; (iii) manufacture of all required clinical and commercial production batches; (iv) marketing
approval by the relevant regulatory authorities; and (v) market acceptance of the Company&#8217;s product candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BasisOfAccounting-c0_cont_12" id="_BasisOfAccounting-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">There can be no
assurance that the Company will succeed in achieving the clinical, scientific and commercial milestones as detailed above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BasisOfAccounting-c0_cont_13" id="_BasisOfAccounting-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Based on the
abovementioned, as of the approval date of these consolidated financial statements, the Company has not raised the necessary funding in
order to continue its activity for a period of at least <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric> after the date of the filing of this annual report on Form 20-F. Therefore,
these factors raise a substantial doubt about the Company&#8217;s ability to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_BasisOfAccounting-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The consolidated
financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that might result
should the Company be unable to continue as a going concern.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>


</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left">NOTE 2:-</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES</td>
</tr></table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The consolidated financial statements
are prepared according to United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">a.</td><td style="text-align: justify">Use of estimates:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company&#8217;s management
believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made.
These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting
periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="pypd_ConsolidatedFinancialStatementsPolicyTextBlock-c0_cont_1" escape="true" name="pypd:ConsolidatedFinancialStatementsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">Consolidated financial statements in U.S.&#160;dollars:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation continuedAt="pypd_ConsolidatedFinancialStatementsPolicyTextBlock-c0_cont_2" id="pypd_ConsolidatedFinancialStatementsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accompanying consolidated financial
statements have been prepared in United States of America dollars (&#8220;USD&#8221;, &#8220;$&#8221; or &#8220;U.S. dollars&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation continuedAt="pypd_ConsolidatedFinancialStatementsPolicyTextBlock-c0_cont_3" id="pypd_ConsolidatedFinancialStatementsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A substantial portion of the Company&#8217;s
expenses are incurred in New Israeli Shekels (&#8220;NIS&#8221;). However, the Company finances its operations mainly in U.S. dollars,
a substantial portion of its expenses are incurred in U.S. dollars and potential revenues from its primary markets are anticipated to
be generated in U.S. dollars. As such, the Company&#8217;s management believes that the U.S. dollar is the currency of the primary economic
environment in which the Company and its subsidiaries operate. Thus, the functional and reporting currency of the Company is the U.S.
dollar.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation id="pypd_ConsolidatedFinancialStatementsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the dollar are re-measured
into U.S. dollars in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) No. 830, &#8220;<i>Foreign Currency Matters</i>&#8221;.
All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the statements of operations as
financial income or expenses, as appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">c.</td><td style="text-align: justify">Principles of consolidation:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The consolidated
financial statements include the accounts of the Company and its subsidiaries. Intercompany balances have been eliminated upon consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">d.</td><td style="text-align: justify">Cash equivalents:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Cash equivalents
are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or less, at
the date acquired.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" continuedAt="pypd_RestrictedCashPolicyTextBlock-c0_cont_1" escape="true" name="pypd:RestrictedCashPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">e.</td><td style="text-align: justify">Restricted cash:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:continuation id="pypd_RestrictedCashPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Restricted cash
is primarily invested in a bank deposit and is used as security for the Company&#8217;s lease commitments and for its forward and options transactions
activities (see Note 2q).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.75in; text-align: left">NOTE 2:-</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES (CONT.)</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">f.</td><td style="text-align: justify">Segment reporting:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company
identifies operating segments in accordance with ASC No. 280, &#8220;<i>Segment Reporting</i>&#8221;, as components of an entity for which
discrete financial information is available and is regularly reviewed by the chief operating decision maker, or decision-making group,
in making decisions regarding resource allocation and evaluating financial performance. The Company&#8217;s chief operating decision maker is
its chief executive officer. The Company determined it operates in one operating segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:nonNumeric contextRef="c0" continuedAt="pypd_ShorttermDepositsPolicyTextBlock-c0_cont_1" escape="true" name="pypd:ShorttermDepositsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">g.</td><td style="text-align: justify">Short-term deposits:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation id="pypd_ShorttermDepositsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A short-term bank deposit is a deposit
with a maturity of more than three months, but less than one year. Deposits in U.S. dollars bear interest at rates ranging from <ix:nonFraction contextRef="c48" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure">4.55</ix:nonFraction>%-<ix:nonFraction contextRef="c49" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure">5.90</ix:nonFraction>%,
per annum, as of December 31, 2022. Short-term deposits are presented at cost, which approximates market value due to their short maturities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.75pt; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">h.</td><td style="text-align: justify">Property and equipment, net:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Property and equipment
are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful
lives of the assets at the following rates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 77%; text-align: justify">Computers and software</td><td style="width: 1%">&#160;</td>
    <td style="width: 22%; text-align: center; padding-left: 0.05in"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="pypd:ComputersandSoftware" scale="-2" unitRef="pure">33</ix:nonFraction></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0.05in"><ix:nonFraction contextRef="c52" decimals="2" format="ixt:num-dot-decimal" name="pypd:LaboratoryAndManufacturingEquipment" scale="-2" unitRef="pure">10</ix:nonFraction>&#160;-&#160;<ix:nonFraction contextRef="c53" decimals="2" format="ixt:num-dot-decimal" name="pypd:LaboratoryAndManufacturingEquipment" scale="-2" unitRef="pure">15</ix:nonFraction></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0.05in"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="pypd:PropertyPlantAndEquipmentPercent" scale="-2" unitRef="pure">15</ix:nonFraction></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in">Leasehold improvements</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: center; padding-left: 0.05in"><ix:nonNumeric contextRef="c0" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives">Over the shorter of the term of the lease or its useful life</ix:nonNumeric></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">i.</td><td style="text-align: justify">Leases:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">On January 1, 2022,
the Company adopted ASC No. 842, &#8220;<i>Leases</i>&#8221; (&#8220;ASC 842&#8221;), using the modified retrospective method&#160;by applying
the new standard to all leases existing at the date of initial application. Results and disclosure requirements for reporting periods
beginning after January 1, 2022, are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported
in accordance with the Company&#8217;s historical accounting under ASC No. 840, &#8220;<i>Leases</i>&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company has
elected the package of practical expedients permitted under the transition guidance, which allows the Company not to reassess: (1) whether
any existing contracts as of the adoption date are or contain a lease under ASC 842, (2) lease classification for any existing leases
as of the adoption date, and (3) initial direct costs for any existing leases as of the adoption date. Lastly, the Company also elected
the practical expedient to not separate lease and non-lease components for its leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_4" id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As a result of the
adoption of ASC 842 on January 1, 2022, the Company recorded both operating leases right-of-use (&#8220;ROU&#8221;) assets and operating
lease liabilities of $<ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="pypd:RighttouseAssetsAndLeaseLiabilities" scale="3" unitRef="usd">3,388</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_5" id="_LesseeLeasesPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The ROU assets include
adjustments for lease prepayments in the amount of $<ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="pypd:LeasePrepayments" scale="3" unitRef="usd">36</ix:nonFraction>. The adoption did not impact the Company&#8217;s beginning accumulated deficit,
or its prior year consolidated statements of operations and statements of cash flows. The adoption did not have a material impact on the
Company&#8217;s current year consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.75in; text-align: left">NOTE 2:-</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES (CONT.)</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">i.</td><td style="text-align: justify">Leases: (Cont.)</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_6" id="_LesseeLeasesPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Leases are classified
as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the
lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably
certain to be exercised, the lease term is for a major part of the remaining useful life of the asset, the present value of the lease
payments equals or exceeds substantially all of the fair value of the asset, or the underlying asset is of such a specialized nature that
it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does
not meet any one of these criteria. Since all of the Company&#8217;s lease contracts do not meet any of the criteria above, the Company
concluded that all of its lease contracts should be classified as operating leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">ROU assets
and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For
this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company&#8217;s
leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available on the commencement
date in determining the present value of lease payments. All ROU assets are reviewed for impairment. The lease terms may include options
to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">j.</td><td style="text-align: justify">Impairment of long-lived assets:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company&#8217;s long-lived
assets are reviewed for impairment in accordance with ASC No. 360, &#8220;<i>Property, Plant and Equipment</i>&#8221;, whenever events or
changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held
and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated
by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying
amount of the asset exceeds its fair value. As of December 31, 2022 and 2021, no impairment losses have been identified.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">k.</td><td style="text-align: justify">Research and development, net expenses:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Research and development
expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments
to subcontractors, chemical, manufacturing and control activities, costs associated with obtaining regulatory approvals, executing pre-clinical
and clinical studies and maintenance and prosecution of the Company&#8217;s intellectual property rights. In addition, research and development
expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research
and development expenses as expenses when incurred and are presented net of government grants (see Note 2.l).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.75in; text-align: left">NOTE 2:-</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES (CONT.)</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">l.</td><td style="text-align: justify">Grants and participations:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Royalty-bearing grants from the Israeli
Innovation Authority (&#8220;IIA&#8221;) of the Ministry of Economy and Industry in Israel for funding of approved research and development
projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a
deduction from research and development expenses. Non-royalty-bearing grants from the IIA MAGNET program and from European Commission&#8217;s
Seventh Framework Programme for Research (&#8220;FP7&#8221;) for funding approved research and development projects are recognized at
the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and
development expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Since the payment
of royalties is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until
the related revenues are recognized.&#160;In the event of failure of a project that was partly financed by IIA, the Company will not be
obligated to pay any royalties or repay the amounts received.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_4" id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company recognizes
participations in research and development, as a reduction from research and development expenses in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd">738</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd">542</ix:nonFraction> for the
years ended December 31, 2022, and 2021, respectively (no grants were received for the year ended December 31, 2020).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">From inception up
until December 31, 2022, the Company received a total of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ReceivedTotalAmount" scale="3" unitRef="usd">7,193</ix:nonFraction> in grants, out of which royalty-bearing grants in the amount of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" scale="3" unitRef="usd">4,888</ix:nonFraction>
from the IIA, non-royalty bearing grants in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:NonroyaltyBearingGrantsAmount" scale="3" unitRef="usd">1,578</ix:nonFraction> from the IIA (out of which $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:OutOfReceivedAmount" scale="3" unitRef="usd">521</ix:nonFraction> were received during the year ended December
31, 2022) and non-royalty bearing grants in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:NonroyaltyBearingGrants" scale="3" unitRef="usd">727</ix:nonFraction> from the FP7.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">m.</td><td style="text-align: justify">Accounting for share-based compensation:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Share-based compensation
expense related to share-based awards is recognized based on the fair value of the awards granted and recognized as an expense on a straight-line
basis over the requisite service period for share options. The fair value of each option award is estimated on the grant date using the
Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including
the expected term of the award, the expected volatility of the price of the Company&#8217;s Ordinary shares, risk-free interest rates,
and the expected dividend yield of Ordinary shares. The assumptions used to determine the fair value of the share awards represent management&#8217;s
best estimates. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. Forfeitures are accounted
for as they occur instead of estimating the number of awards expected to be forfeited.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:nonNumeric contextRef="c0" continuedAt="pypd_BasicAndDilutedLossPerSharePolicyTextBlock-c0_cont_1" escape="true" name="pypd:BasicAndDilutedLossPerSharePolicyTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">n.</td><td style="text-align: justify">Basic and diluted net loss per share:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:continuation continuedAt="pypd_BasicAndDilutedLossPerSharePolicyTextBlock-c0_cont_2" id="pypd_BasicAndDilutedLossPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Prior to the Company&#8217;s
IPO, the Company computed its net loss per share using the two-class method required for participating securities. The two-class method
requires income available to Ordinary shareholders for the period to be allocated between Ordinary shares and participating securities
based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considered its
convertible preferred shares to be participating securities as the holders of the convertible preferred shares would be entitled to dividends
that would be distributed to the holders of Ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities
did not contractually require the holders of such shares to participate in the Company&#8217;s losses.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.75in; text-align: left">NOTE 2:-</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES (CONT.)</td>
</tr></table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">n.</td><td style="text-align: justify">Basic and diluted net loss per share: (Cont.)</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:continuation continuedAt="pypd_BasicAndDilutedLossPerSharePolicyTextBlock-c0_cont_3" id="pypd_BasicAndDilutedLossPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As such,&#160;during
the periods when the Company is in a loss position, the loss attributable to Ordinary shareholders was not allocated to the convertible
preferred shares under the two-class method as these securities did not have a contractual obligation to share in the Company&#8217;s
losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:continuation id="pypd_BasicAndDilutedLossPerSharePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Following the Company&#8217;s
IPO, the Company&#8217;s basic net loss per share is calculated by dividing the net loss attributable to Ordinary shareholders by the
weighted-average number of shares of Ordinary shares outstanding for the period, without consideration of potentially dilutive securities.
The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using
the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as
basic net loss per share in periods when the effects of potentially dilutive shares of Ordinary shares are anti-dilutive.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:nonNumeric contextRef="c0" continuedAt="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock-c0_cont_1" escape="true" name="pypd:ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">o.</td><td style="text-align: justify">Convertible preferred shares and convertible preferred shares warrant liability:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:continuation continuedAt="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock-c0_cont_2" id="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The terms of the
convertible preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1&#160;shares allowed the holders to redeem shares, under certain circumstances,
outside of the Company&#8217;s control. Therefore, these shares were classified as mezzanine equity on the balance sheet and not included as
a component of shareholders&#8217; deficit before the IPO. The Company did not adjust the preferred shares&#8217; carrying value to the redemption
value since redemption was not probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><ix:continuation continuedAt="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock-c0_cont_3" id="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Following the Company&#8217;s
IPO, the convertible preferred shares were converted into Ordinary shares and were reclassified into permanent equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><ix:continuation continuedAt="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock-c0_cont_4" id="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Warrants to purchase the Company&#8217;s
convertible preferred shares were classified as a liability on the balance sheet, and measured at fair value, as the underlying shares
are contingently redeemable (upon a deemed liquidation event) and, therefore, may obligate the Company to transfer assets at some point
in the future. The warrants were subject to re-measurement to fair value at each balance sheet date and any change in fair value was recognized
as a component of financial expenses, net, in the statements of operation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><ix:continuation id="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Following the Company&#8217;s IPO,
the warrants can only be exercised into the Company&#8217;s ordinary equity shares. Consequently, as of the IPO date, the Company reclassified
the warrants as equity since the warrants are not an ASC No. 480, &#8220;<i>Distinguishing Liabilities from Equity</i>&#8221; (&#8220;ASC
480&#8221;), liability, are indexed to the Company&#8217;s own stock and can be classified as equity pursuant to ASC No. 815-40, &#8220;<i>Derivatives
and Hedging</i>&#8221; (&#8220;ASC 815&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">p.</td><td style="text-align: justify">Fair value of financial instruments:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company applies
ASC No. 820, &#8220;<i>Fair Value Measurements and Disclosures</i>&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined
as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly
transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches.
ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the
use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market
participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.75in; text-align: left">NOTE 2:-</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES (CONT.)</td>
</tr></table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">p.</td><td style="text-align: justify">Fair value of financial instruments: (Cont.)</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Unobservable inputs
are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability
developed based on the best information available in the circumstances.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Fair value is an
exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction
between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market
participants would use in pricing an asset or a liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">A three-tier fair
value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring
fair value:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1.25in">&#160;</td>
    <td style="width: 0.6in; text-align: justify; text-indent: 0in;">Level 1 -</td>
    <td style="padding-left: 0in; text-align: justify; text-indent: 0in;">Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; text-indent: 0in;">Level 2 -</td>
    <td style="text-align: justify; text-indent: 0in;">Include other inputs that are directly or indirectly observable in the marketplace.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; text-indent: 0in;">Level 3 -</td>
    <td style="text-align: justify; text-indent: 0in;">Unobservable inputs which are supported by little or no market activity</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value hierarchy also requires
an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value<span style="font-size: 10pt">.</span></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The carrying amounts of cash and cash
equivalents, restricted cash, short-term deposits, long-term deposits, prepaid expenses and other current assets, trade payables, accrued
expenses and other current and non-current liabilities approximate their fair value due to the short-term maturity of such instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_9" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>The
fair value measurement of the FCA (as defined in Note 7) is measured using unobservable inputs that require a high level of judgment to
determine fair value, and thus is classified as a Level&#160;3 financial instrument. The Company estimates the fair value of the abovementioned
instrument using the Monte-Carlo simulation and the Black-Scholes option pricing model.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Fair
value estimates are made at a specific point in time, based on relevant market information and information about the financial instruments.
These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined
with precision. Changes in assumptions could significantly affect these estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_59" id="_SignificantAccountingPoliciesTextBlock-c0_cont_58"><ix:nonNumeric contextRef="c0" continuedAt="_DerivativesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DerivativesPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">q.</td><td style="text-align: justify">Derivative financial instruments:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_60" id="_SignificantAccountingPoliciesTextBlock-c0_cont_59"><ix:continuation continuedAt="_DerivativesPolicyTextBlock-c0_cont_2" id="_DerivativesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company accounts
for derivatives based on ASC 815. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The Company
enters into option and forward contracts in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred
in NIS. Since the derivative instruments that the Company holds were not designated as hedging instruments under ASC 815, any gain or
loss derived from such instruments is recognized immediately as &#8220;financial (income) expense, net&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.6pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_61" id="_SignificantAccountingPoliciesTextBlock-c0_cont_60"><ix:continuation id="_DerivativesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company measured the fair value
of the contracts in accordance with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs
are based on quoted prices and market observable data of similar instruments. As of December 31, 2022 and 2021, the fair value of the
options and forward contracts was ($<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="3" sign="-" unitRef="usd">12</ix:nonFraction>) and $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="3" unitRef="usd">28</ix:nonFraction>, respectively, which were
presented as Accrued expenses and other current liabilities and Prepaid expenses and other current assets, respectively. Financial expense
(income) for the years ended December 31, 2022, 2021 and 2020, amounted to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:FinancialExpenseIncome" scale="3" unitRef="usd">273</ix:nonFraction>, ($<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="pypd:FinancialExpenseIncome" scale="3" sign="-" unitRef="usd">58</ix:nonFraction>) and&#160;($<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:FinancialExpenseIncome" scale="3" sign="-" unitRef="usd">81</ix:nonFraction>), respectively.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.75in; text-align: left">NOTE 2:-</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES (CONT.)</td>
</tr></table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_62" id="_SignificantAccountingPoliciesTextBlock-c0_cont_61"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">r.</td><td style="text-align: justify">Income taxes:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_63" id="_SignificantAccountingPoliciesTextBlock-c0_cont_62"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company accounts
for income taxes in accordance with ASC No. 740, &#8220;<i>Income Taxes</i>&#8221; (&#8220;ASC 740&#8221;). ASC 740 prescribes the use of
the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial
reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the
differences are expected to reverse. The Company provides a valuation allowance to reduce deferred tax assets to their estimated realizable
value, if needed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_64" id="_SignificantAccountingPoliciesTextBlock-c0_cont_63"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_3" id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">ASC 740 contains
a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position
taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than
not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals
or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="pypd:TaxBenefitPercentage" scale="-2" unitRef="pure">50</ix:nonFraction>% likely to be realized
upon ultimate settlement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_65" id="_SignificantAccountingPoliciesTextBlock-c0_cont_64"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As of December&#160;31,
2022 and 2021, the Company&#8217;s uncertain tax position liability was immaterial.	The Company&#8217;s policy is to accrue interest and penalties
related to unrecognized tax benefits in its taxes on income.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_66" id="_SignificantAccountingPoliciesTextBlock-c0_cont_65"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionAllowances-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionAllowances"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">s.</td><td style="text-align: justify">Revenue recognition:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_67" id="_SignificantAccountingPoliciesTextBlock-c0_cont_66"><ix:continuation continuedAt="_RevenueRecognitionAllowances-c0_cont_2" id="_RevenueRecognitionAllowances-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company recognizes
revenue from contracts with customers under ASC No. 606, &#8220;<i>Revenue from Contracts with Customers</i>&#8221;. Accordingly, the Company
recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it
expects to be entitled in exchange for those goods or services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_68" id="_SignificantAccountingPoliciesTextBlock-c0_cont_67"><ix:continuation continuedAt="_RevenueRecognitionAllowances-c0_cont_3" id="_RevenueRecognitionAllowances-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">To determine revenue
recognition for contracts with customers, the Company performs the following five steps:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_69" id="_SignificantAccountingPoliciesTextBlock-c0_cont_68"><ix:continuation continuedAt="_RevenueRecognitionAllowances-c0_cont_4" id="_RevenueRecognitionAllowances-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(i) identify the
contract(s) with a customer;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_70" id="_SignificantAccountingPoliciesTextBlock-c0_cont_69"><ix:continuation continuedAt="_RevenueRecognitionAllowances-c0_cont_5" id="_RevenueRecognitionAllowances-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(ii) identify the
performance obligations in the contract;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_71" id="_SignificantAccountingPoliciesTextBlock-c0_cont_70"><ix:continuation continuedAt="_RevenueRecognitionAllowances-c0_cont_6" id="_RevenueRecognitionAllowances-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(iii) determine
the transaction price;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_72" id="_SignificantAccountingPoliciesTextBlock-c0_cont_71"><ix:continuation continuedAt="_RevenueRecognitionAllowances-c0_cont_7" id="_RevenueRecognitionAllowances-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(iv) allocate the
transaction price to the performance obligations in the contract; and</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_73" id="_SignificantAccountingPoliciesTextBlock-c0_cont_72"><ix:continuation continuedAt="_RevenueRecognitionAllowances-c0_cont_8" id="_RevenueRecognitionAllowances-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(v) recognize revenue
when (or as) the Company satisfies its performance obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_74" id="_SignificantAccountingPoliciesTextBlock-c0_cont_73"><ix:continuation continuedAt="_RevenueRecognitionAllowances-c0_cont_9" id="_RevenueRecognitionAllowances-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">At contract inception,
the Company assesses the goods or services agreed upon within each contract and assesses whether each good or service is distinct to determine
the performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_75" id="_SignificantAccountingPoliciesTextBlock-c0_cont_74"><ix:continuation continuedAt="_RevenueRecognitionAllowances-c0_cont_10" id="_RevenueRecognitionAllowances-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">On August 2, 2022,
the Company entered into a license, distribution and supply agreement (the &#8220;Agreement&#8221;) with Mercury Pharma Group Limited, under
the trade name Advanz Pharma Holdings
(the &#8220;Customer&#8221;), with respect to the Company&#8217;s product, the D-PLEX<sub>100</sub> (the &#8220;Product&#8221;), for the prevention
of (i) post abdominal surgery incisional infection; and/or (ii) post cardiac surgery sternal infection.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.75in; text-align: left">NOTE 2:-</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES (CONT.)</td>
</tr></table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">s.</td><td style="text-align: justify">Revenue recognition: (Cont.)</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_76" id="_SignificantAccountingPoliciesTextBlock-c0_cont_75"><ix:continuation continuedAt="_RevenueRecognitionAllowances-c0_cont_11" id="_RevenueRecognitionAllowances-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The term of the
Agreement is until the later of December 31, 2035, or <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="pypd:AgreementTerm">10</ix:nonNumeric> years after the first commercial sale of the Product. The Agreement can also
be terminated by either party under certain limited circumstances. Pursuant to the Agreement, the Customer was granted an exclusive license
to market, commercialize, and distribute the Product in the European Economic Area and in the United Kingdom. Under the Agreement, the
Company will carry out all activities required to obtain marketing authorization in each territory, approving the commercial sale of the
Product in that territory. Once marketing authorization will be granted in a territory, the Customer will be required to achieve minimum
sales requirements for that territory.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_77" id="_SignificantAccountingPoliciesTextBlock-c0_cont_76"><ix:continuation continuedAt="_RevenueRecognitionAllowances-c0_cont_12" id="_RevenueRecognitionAllowances-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Under the terms
of the Agreement, the Company received a non-refundable, one-time payment of &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="pypd:NonRefundableAmount" scale="6" unitRef="eur">2.5</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:NonRefundableAmount" scale="3" unitRef="usd">2,548</ix:nonFraction>). The Company is
also entitled to receive additional development-related milestones payments for a total of up to &#8364;<ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="pypd:AdditionalDevelopmentrelatedMilestonesPayments" scale="6" unitRef="eur">23</ix:nonFraction> million.
In addition, the Company will be entitled to receive up to additional &#8364;<ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="pypd:AdditionalAmountOfCommercialSaleMilestones" scale="6" unitRef="eur">87</ix:nonFraction> million upon achievement of certain
commercial sale milestones.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_78" id="_SignificantAccountingPoliciesTextBlock-c0_cont_77"><ix:continuation continuedAt="_RevenueRecognitionAllowances-c0_cont_13" id="_RevenueRecognitionAllowances-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company has
concluded that the Agreement includes a single performance obligation. The Company has concluded that the license and development are
not distinct from the manufacturing since the Customer could not use, consume, or sell the license and development services on their own
or with resources readily available to the Customer because of the Company&#8217;s specialized knowledge and the associated manufacturing know-how
and because currently, and in the foreseeable future, there are no other parties that could manufacture the Product. As such, the transaction
price was fully allocated to the single performance obligation. Since it is not probable that a significant reversal in the amount of
cumulative revenue recognized will not occur when the uncertainty associated with the milestone payments is resolved, the Company estimated
the transaction price at &#8364;<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" unitRef="eur">2.5</ix:nonFraction> million (approximately $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" unitRef="usd">2,548</ix:nonFraction>).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_79" id="_SignificantAccountingPoliciesTextBlock-c0_cont_78"><ix:continuation id="_RevenueRecognitionAllowances-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As of December 31,
2022, the Company has yet to satisfy its performance obligation under the Agreement and, therefore, no revenues were recognized. Accordingly,
the upfront payment amount was classified as a long-term deferred revenue in the Company&#8217;s consolidated balance sheet as of December 31,
2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_80" id="_SignificantAccountingPoliciesTextBlock-c0_cont_79"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.5in; text-align: left">t.</td><td style="text-align: justify">Concentration of credit risks:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_81" id="_SignificantAccountingPoliciesTextBlock-c0_cont_80"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Financial instruments
that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and short-term deposits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_82" id="_SignificantAccountingPoliciesTextBlock-c0_cont_81"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_3" id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Cash, cash equivalents,
restricted cash and short-term deposits are deposited in major banks in Israel and in the United States of America. Such investments may
be in excess of insured limits or not insured. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal
risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.75in; text-align: left">NOTE 2:-</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES (CONT.)</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.5in; text-align: left">t.</td><td style="text-align: justify">Concentration of credit risks: (Cont.)</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_83" id="_SignificantAccountingPoliciesTextBlock-c0_cont_82"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company utilizes
option and forward contracts to protect against the risk of overall changes in exchange rates. The derivative instruments hedge a portion
of the Company&#8217;s non-dollar currency exposure. Counterparties to the Company&#8217;s derivative instruments are all major financial institutions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_84" id="_SignificantAccountingPoliciesTextBlock-c0_cont_83"><ix:nonNumeric contextRef="c0" continuedAt="pypd_SeverancePayPolicyTextBlock-c0_cont_1" escape="true" name="pypd:SeverancePayPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">u.</td><td style="text-align: justify">Severance pay:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_85" id="_SignificantAccountingPoliciesTextBlock-c0_cont_84"><ix:continuation continuedAt="pypd_SeverancePayPolicyTextBlock-c0_cont_2" id="pypd_SeverancePayPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">All the Company&#8217;s
employees who are Israeli citizens have subscribed to Section&#160;14 of Israel&#8217;s Severance Pay Law, 5723-1963 (&#8220;Section&#160;14&#8221;).
Pursuant to Section&#160;14, employees covered by this section are entitled to monthly deposits at a rate of <ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="pypd:monthlyDepositsAtARate" scale="-2" unitRef="pure">8.33</ix:nonFraction>% of their monthly salary,
made on their behalf by the Company. Payments in accordance with Section&#160;14 release the Company from any future severance liabilities
in respect of those employees. Neither severance pay liability nor severance pay fund under Section&#160;14 for such employees is recorded
on the Company&#8217;s consolidated balance sheets. Severance pay expense for the years ended December 31, 2022, 2021 and 2020, amounted to
$<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:SeverancePayExpenseAmount" scale="3" unitRef="usd">537</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="pypd:SeverancePayExpenseAmount" scale="3" unitRef="usd">547</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:SeverancePayExpenseAmount" scale="3" unitRef="usd">394</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_86" id="_SignificantAccountingPoliciesTextBlock-c0_cont_85"><ix:continuation id="pypd_SeverancePayPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The US Subsidiary
has a Safe Harbor 401(k) plan covering all the US Subsidiary employees. <ix:nonNumeric contextRef="c2" name="pypd:SeverancePay">All eligible employees may elect to contribute up to 100% of their
payroll compensation (minus mandatory payroll deductions) to the plan, for 2022, up to a maximum of $20,500 per year (for employees over
50 years of age the maximum contribution was $28,000 per year), as determined by the U.S. Internal Revenue Service (&#8220;IRS&#8221;).
The US Subsidiary matches at 100%, on each payroll, up to 5% of the employee compensation to the plan within the IRS limits (which was
set at $300 in 2022 for purposes of the plan).</ix:nonNumeric> During the year ended December 31, 2022, the Company recorded expenses for matching contributions
in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:MatchingContributionsAmounts" scale="3" unitRef="usd">30</ix:nonFraction>, as compared to $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="pypd:MatchingContributionsAmounts" scale="3" unitRef="usd">28</ix:nonFraction> in 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_87" id="_SignificantAccountingPoliciesTextBlock-c0_cont_86"><ix:nonNumeric contextRef="c0" continuedAt="_ContingentLiabilityReserveEstimatePolicy-c0_cont_1" escape="true" name="us-gaap:ContingentLiabilityReserveEstimatePolicy"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">v.</td><td style="text-align: justify">Contingent liabilities:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_88" id="_SignificantAccountingPoliciesTextBlock-c0_cont_87"><ix:continuation continuedAt="_ContingentLiabilityReserveEstimatePolicy-c0_cont_2" id="_ContingentLiabilityReserveEstimatePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company accounts
for its contingent liabilities in accordance with ASC No. 450, &#8220;<i>Contingencies</i>&#8221;. A provision is recorded when it is both
probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_89" id="_SignificantAccountingPoliciesTextBlock-c0_cont_88"><ix:continuation continuedAt="_ContingentLiabilityReserveEstimatePolicy-c0_cont_3" id="_ContingentLiabilityReserveEstimatePolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">With respect to
legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice
of legal counsel and other information and events pertaining to a particular matter. The Company is occasionally a party to routine claims
or litigation incidental to its business. The Company does not believe that it is a party to any pending legal proceeding that is likely
to have a material adverse effect on its business, financial condition or results of operations. The Company recorded an accrual in the
consolidated statement of operations, which it deems appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_90" id="_SignificantAccountingPoliciesTextBlock-c0_cont_89"><ix:continuation id="_ContingentLiabilityReserveEstimatePolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As of December 31,
2022 and 2021, no liability due to legal matters has been accrued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_91" id="_SignificantAccountingPoliciesTextBlock-c0_cont_90"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">w.</td><td style="text-align: justify">Recently adopted accounting pronouncements:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_92" id="_SignificantAccountingPoliciesTextBlock-c0_cont_91"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As an &#8220;Emerging
Growth Company&#8221;, the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;) allows the Company to delay adoption of new or
revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The
Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election<span style="font-family: Times New Roman, Times, Serif">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.75in; text-align: left">NOTE 2:-</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES (CONT.)</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">w.</td><td style="text-align: justify">Recently adopted accounting pronouncements: (Cont.)</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_93" id="_SignificantAccountingPoliciesTextBlock-c0_cont_92"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">On January 1, 2022,
the Company adopted ASC 842. Upon adoption, we recognized total ROU assets and corresponding liabilities of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount" scale="0" unitRef="usd">3,388</ix:nonFraction>&#160;on our consolidated
balance sheets. The ROU assets include adjustments for prepayments and accrued lease payments. The adoption did not impact the beginning
balance of retained earnings, or prior year consolidated statements of operations and statements of cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_94" id="_SignificantAccountingPoliciesTextBlock-c0_cont_93"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">For information
regarding the impact of ASC 842 adoption, see Note 2.i and Note 5 - Leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_95" id="_SignificantAccountingPoliciesTextBlock-c0_cont_94"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.3pt">In December 2019,
the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, &#8220;<i>Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>&#8221; (ASU 2019-12), which simplifies the accounting for income taxes.
The guidance is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted. The Company
has adopted ASU 2019-12 as of January 1, 2022. The impact of adoption of this standard on the Company&#8217;s consolidated financial statements
was immaterial.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.3pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_96" id="_SignificantAccountingPoliciesTextBlock-c0_cont_95"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In August 2020, the FASB issued ASU
No. 2020-06, &#8220;<i>Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s
Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>&#8221; (&#8220;ASU
2020-06&#8221;), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP.
The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception,
and it simplifies the diluted earnings per share calculation in certain areas. The Company adopted ASU 2020-06 on January 1, 2022. The
adoption of the standard did not result in a material impact to the Company&#8217;s consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_97" id="_SignificantAccountingPoliciesTextBlock-c0_cont_96"><ix:nonNumeric contextRef="c0" continuedAt="pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted-c0_cont_1" escape="true" name="pypd:RecentlyIssuedAccountingPronouncementsNotYetAdopted"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">x.</td><td style="text-align: justify">Recently issued accounting pronouncements, not yet adopted:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_97"><ix:continuation id="pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In June 2016, the FASB issued ASU No.
2016-13, &#8220;<i>Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>,&#8221;
which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured
at amortized cost to be presented at the net amount expected to be collected. The guidance will be effective for the Company beginning
January 1, 2023, and interim periods thereafter. The Company adopted ASU 2016-13 on January 1, 2023. The adoption of the standard did
not result in a material impact to the Company&#8217;s consolidated financial statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 163; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="pypd_PrepaidExpensesAndOtherReceivablesTextBlock-c0_cont_1" escape="true" name="pypd:PrepaidExpensesAndOtherReceivablesTextBlock"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.75in; text-align: left">NOTE 3:-</td><td style="text-align: justify">PREPAID EXPENSES AND OTHER CURRENT ASSETS</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="pypd_PrepaidExpensesAndOtherReceivablesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="3" unitRef="usd">552</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="3" unitRef="usd">1,453</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="pypd:GovernmentAuthorities" scale="3" unitRef="usd">239</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="pypd:GovernmentAuthorities" scale="3" unitRef="usd">596</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Lease deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseDepositLiability" scale="3" unitRef="usd">44</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd">298</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd">118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 2.85pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 2.85pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" unitRef="usd">1,089</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" unitRef="usd">2,211</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.75in; text-align: left">NOTE 4:-</td><td style="text-align: justify">PROPERTY AND EQUIPMENT, NET</td>
</tr></table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Computers and software</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">613</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">577</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">7,933</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">6,247</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">173</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">167</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">6,503</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">6,024</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">15,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">13,015</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">5,975</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">4,254</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Depreciated cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">9,247</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">8,761</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Depreciation expenses amounted to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">1,721</ix:nonFraction>,
$<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">1,118</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">1,012</ix:nonFraction> for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The majority of the Company&#8217;s
property and equipment is located in Israel.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OperatingLeasesOfLessorDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.75in; text-align: left">NOTE 5:-</td><td style="text-align: justify">LEASES</td>
</tr></table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLessorDisclosureTextBlock-c0_cont_2" id="_OperatingLeasesOfLessorDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">a.</td><td style="text-align: justify">The Company&#8217;s facilities are leased under operating lease agreements for periods ending no later than
2027. The Company has bank guarantees in connection with the facilities lease agreements in the total amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalLeasesIndemnificationAgreementsPayments" scale="3" unitRef="usd">213</ix:nonFraction>. Accordingly, cash,
in the same amount, was restricted in bank deposits. The Company also leases motor vehicles under various operating leases, the latest
of which expires in 2025.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -21.3pt">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -21.3pt"></p><div>

</div><!-- Field: Page; Sequence: 164; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"></td><td style="width: 0.75in; text-align: left">NOTE 5:-</td><td style="text-align: justify">LEASES (CONT.)</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -21.3pt">&#160;</p><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLessorDisclosureTextBlock-c0_cont_3" id="_OperatingLeasesOfLessorDisclosureTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">The following table summarizes the Company&#8217;s lease-related assets and liabilities recorded on the
balance sheets:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLessorDisclosureTextBlock-c0_cont_4" id="_OperatingLeasesOfLessorDisclosureTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="pypd:ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Classification</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 67%; font-style: italic; text-align: left">Lease assets:</td><td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: left; padding-left: 5.4pt">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Operating lease assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt; padding-left: 5.4pt">Operating lease ROU assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="pypd:OperatingLeaseAssets" scale="3" unitRef="usd">2,431</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Lease liabilities:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; width: 67%; text-align: left">Current lease liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: center; padding-left: 5.4pt">Short-term operating lease liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">959</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Long-term lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt">Long-term lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="3" unitRef="usd">1,173</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="pypd:LeaseLiabilities" scale="3" unitRef="usd">2,132</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted Average Remaining lease term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">3.37</ix:nonNumeric> years</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Weighted Average Discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">9.95</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLessorDisclosureTextBlock-c0_cont_5" id="_OperatingLeasesOfLessorDisclosureTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">c.</td><td style="text-align: justify">The components of operating lease expense for the year ended December 31, 2022, were $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd">1,344</ix:nonFraction>.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -21.3pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLessorDisclosureTextBlock-c0_cont_6" id="_OperatingLeasesOfLessorDisclosureTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">d.</td><td style="text-align: justify">Lease liability as of December 31, 2022, is as follows:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLessorDisclosureTextBlock-c0_cont_7" id="_OperatingLeasesOfLessorDisclosureTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="pypd:ScheduleOfLeaseLiabilityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="3" unitRef="usd">1,047</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="3" unitRef="usd">439</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" unitRef="usd">385</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" unitRef="usd">367</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" unitRef="usd">186</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="3" unitRef="usd">2,424</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less - imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReceivableWithImputedInterestNetAmount" scale="3" unitRef="usd">292</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="3" unitRef="usd">2,132</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLessorDisclosureTextBlock-c0_cont_8" id="_OperatingLeasesOfLessorDisclosureTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">e.</td><td style="text-align: justify">The following table presents supplemental cash flow information related to the lease costs for operating
leases as of December 31, 2022:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OperatingLeasesOfLessorDisclosureTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left">Cash paid for amounts included in measurement of lease liability:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 4pt">Operating cash flows for operating leases</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" unitRef="usd">1,259</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Right-of-use asset recognized with corresponding lease liability:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Operating leases</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd">3,528</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><!-- Field: Page; Sequence: 165; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 6:- </td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</td></tr>
</table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:nonNumeric><div>


</div><div>

</div><ix:continuation id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd">1,246</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd">1,787</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Employees and payroll accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd">1,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd">1,879</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">IIA deferred grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="pypd:IsraelInnovationAuthorityGrantReceived" scale="3" unitRef="usd">269</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" unitRef="usd">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" unitRef="usd">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 2.85pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 2.85pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd">2,429</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd">3,940</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="pypd_LineOfCreditArrangementTextBlock-c0_cont_1" escape="true" name="pypd:LineOfCreditArrangementTextBlock"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 7:- </td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt">LINE OF CREDIT ARRANGEMENT</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p></ix:nonNumeric><div>


</div><div>

</div><ix:continuation continuedAt="pypd_LineOfCreditArrangementTextBlock-c0_cont_2" id="pypd_LineOfCreditArrangementTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">On
April 5, 2022, the Company entered into a secured line of credit agreement for up to $<ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LinesOfCreditCurrent" scale="3" unitRef="usd">15,000</ix:nonFraction> (the &#8220;Credit Line&#8221;) with Kreos
Capital VI (Expert Fund) LP (&#8220;Kreos&#8221;). The Credit Line is comprised of three tranches in the amount of $<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" unitRef="usd">10,000</ix:nonFraction>, $<ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ProceedsFromLinesOfCreditOne" scale="3" unitRef="usd">2,500</ix:nonFraction> and
$<ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ProceedsFromLinesOfCreditTwo" scale="3" unitRef="usd">2,500</ix:nonFraction>, respectively, in which the first tranche and in the amount of $<ix:nonFraction contextRef="c68" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount" scale="3" unitRef="usd">10,000</ix:nonFraction> (the &#8220;First Tranche&#8221;) and the second tranche in
the amount of $<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount" scale="3" unitRef="usd">2,500</ix:nonFraction> (the &#8220;Second Tranche) were drawn on April 26, 2022 and July 19, 2022, respectively. In addition, in accordance
with the Credit Line agreement, the Company will issue to Kreos warrants to purchase the Company&#8217;s Ordinary shares equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" unitRef="pure">8</ix:nonFraction>% of
the amount of each tranche, when and if borrowed, with an exercise price of $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">5.14</ix:nonFraction> per share. The expiration date for each warrant issued
will be seven years from the agreement date. Accordingly, as a result of the First Tranche and Second Tranche withdrawal, the Company
issued to Kreos a warrant in the total amount of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" unitRef="usd">1,000</ix:nonFraction>. The total number of shares issuable upon exercise is equal to the total amount
divided by the exercise price.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="pypd_LineOfCreditArrangementTextBlock-c0_cont_3" id="pypd_LineOfCreditArrangementTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">The
Credit Line is denominated in USD and bears interest at an annual rate equal to <ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" unitRef="pure">9.25</ix:nonFraction>%. The interest paid due to the Credit Line for the
year ended December 31, 2022 amounted to $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="3" unitRef="usd">734</ix:nonFraction>. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="pypd_LineOfCreditArrangementTextBlock-c0_cont_4" id="pypd_LineOfCreditArrangementTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">On
each drawdown date, the Company shall pay to Kreos on the drawdown date the last period payment for such drawdown. For the First Tranche
and Second Tranche, the amount the Company paid was $<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityPeriodicPayment" scale="3" unitRef="usd">317</ix:nonFraction> and $<ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityPeriodicPayment" scale="3" unitRef="usd">85</ix:nonFraction>, respectively.</span></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 56.7pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="pypd_LineOfCreditArrangementTextBlock-c0_cont_5" id="pypd_LineOfCreditArrangementTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">The
third and final tranche of $<ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="pypd:LineOfCreditFacilityPeriodicPaymentOne" scale="3" unitRef="usd">2,500</ix:nonFraction> will never be drawn since the third tranche milestone has not been met. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="pypd_LineOfCreditArrangementTextBlock-c0_cont_6" id="pypd_LineOfCreditArrangementTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">The
Company has concluded that the Credit Line includes several legally detachable and separately exercisable freestanding financial instruments:
The First Tranche term loan, the warrants, and the right to receive additional loan tranches (the &#8220;FCA&#8221;). </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="pypd_LineOfCreditArrangementTextBlock-c0_cont_7" id="pypd_LineOfCreditArrangementTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">The
Company has concluded that the warrants should be classified as equity since the warrants are not an ASC 480 liability, are indexed to
the Company&#8217;s own Ordinary stock and meet all the equity classification conditions pursuant to ASC 815-40. The Company has also concluded
that the FCA is not indexed to the Company&#8217;s own Ordinary stock and should be measured at fair value, with changes in fair value recognized
in earnings. In addition, the First Tranche and the Second Tranche term loan were accounted for using the effective interest method. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="pypd_LineOfCreditArrangementTextBlock-c0_cont_8" id="pypd_LineOfCreditArrangementTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">The
Company allocated the proceeds received to the FCA at fair value. The remaining proceeds were allocated between the warrants and the First
Tranche term loan using the relative fair value method. The proceeds allocation resulted in $<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" unitRef="usd">9,532</ix:nonFraction> allocated to the First Tranche and
$<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" unitRef="usd">468</ix:nonFraction> allocated to the warrants, net of issuance costs. The proceeds allocated to the FCA were immaterial. </span></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><!-- Field: Page; Sequence: 166; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 7:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> LINE OF CREDIT ARRANGEMENT (CONT.)</td></tr>
</table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p><div>

</div><ix:continuation continuedAt="pypd_LineOfCreditArrangementTextBlock-c0_cont_9" id="pypd_LineOfCreditArrangementTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">The
Company allocated the proceeds received under the Credit Line between the warrants and the Second Tranche term loan using the relative
fair value method. <ix:nonNumeric contextRef="c0" name="us-gaap:LineOfCreditFacilityDescription">The proceeds allocation resulted in $2,380 allocated to the Second Tranche and $120 allocated to the warrants.</ix:nonNumeric> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="pypd_LineOfCreditArrangementTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">During
the year ended December 31, 2022, the Company recognized $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseShortTermBorrowings" scale="3" unitRef="usd">1,023</ix:nonFraction> of interest expenses related to the First Tranche and the Second Tranche,
which were included as part of financial expenses in the Company&#8217;s statements of operation. </span></p></ix:continuation><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 8:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> COMMITMENTS AND CONTINGENT LIABILITIES</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:nonNumeric><div>


</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">a.</td><td style="text-align: justify">In connection with its research and development programs, through December 31, 2022, the Company received
participation payments from the IIA in the aggregate amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ProceedsFromParticipationPayments" scale="3" unitRef="usd">4,888</ix:nonFraction>. In return for the IIA&#8217;s participation, <ix:nonNumeric contextRef="c0" name="pypd:CommitmentsAndContingentLiabilitiesDescription">the Company is committed
to pay royalties at a rate of 3% of sales of the developed products, up to 100% of the amount of grants received plus interest at LIBOR
rate. Through December 31, 2022, no royalties have been paid or accrued.</ix:nonNumeric></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.2pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">On December 22, 2016, the Company received a written demand for a finder&#8217;s fee in an amount of $<ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="pypd:FindersFee" scale="3" unitRef="usd">250</ix:nonFraction>, in
connection with the second financing round that occurred in 2016. In September 2017, a suit was filed against the Company in the Tel-Aviv
Magistrates Court in an amount of $<ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="pypd:SuitFillingExpense" scale="3" unitRef="usd">250</ix:nonFraction>. On April 30, 2020, the Company received the court ruling, which ruled in favor of the Company,
discharging the entire claim, and accordingly reversed the related provision. </td></tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 9:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> INCOME TAXES</td></tr>
</table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:nonNumeric><div>


</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">a.</td><td style="text-align: justify">Corporate tax rates:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The corporate tax
rate in Israel in 2022, 2021 and 2020 was <ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" unitRef="pure">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The United States of America federal
rate was <ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:FederalHomeLoanBankAdvancesInterestRate" scale="-2" unitRef="pure">21</ix:nonFraction>% and the state corporate income tax rates range from <ix:nonFraction contextRef="c76" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c77" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c78" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" unitRef="pure">6.5</ix:nonFraction></ix:nonFraction></ix:nonFraction>% to <ix:nonFraction contextRef="c79" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c80" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c81" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" unitRef="pure">11.5</ix:nonFraction></ix:nonFraction></ix:nonFraction>%, for the years ended December 31, 2022, 2021 and 2020.
The Company didn&#8217;t account for any federal, state and foreign income tax expenses for the years ended December 31, 2022, 2021 and
2020. The Company is subject to United States of America income tax laws. There are no provisions for United States of America federal,
state or other taxes for any period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_5" id="_IncomeTaxDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">Loss before taxes is comprised as
follows<span style="font-size: 10pt">:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_6" id="_IncomeTaxDisclosureTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year
Ended <br/>
December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Domestic (Israel)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitRef="usd">38,403</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitRef="usd">41,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitRef="usd">35,983</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitRef="usd">1,154</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitRef="usd">1,404</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitRef="usd">886</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitRef="usd">39,557</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitRef="usd">42,601</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitRef="usd">36,869</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 167; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 9:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> INCOME TAXES (CONT.)</td></tr>
</table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_7" id="_IncomeTaxDisclosureTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">Net operating losses carryforward:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_8" id="_IncomeTaxDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The Company has
accumulated losses for tax purposes as of December 31, 2022, in the amount of approximately $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxBasisOfInvestmentsCostForIncomeTaxPurposes" scale="3" unitRef="usd">152,107</ix:nonFraction> which may be carried forward and
offset against taxable income in the future for an indefinite period.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_9" id="_IncomeTaxDisclosureTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">c.</td><td style="text-align: justify">Tax assessment:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_10" id="_IncomeTaxDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The Company has
net operating losses from prior tax periods which may be subjected to examination in future periods. As of December 31, 2022, the Company&#8217;s
tax years until December 31, 2017, are subject to the statute of limitation in Israel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_11" id="_IncomeTaxDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The US Subsidiary has yet to receive
final tax assessments since its incorporation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_12" id="_IncomeTaxDisclosureTextBlock-c0_cont_11"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">d.</td><td style="text-align: justify">Deferred taxes:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_13" id="_IncomeTaxDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts used for income tax purposes. The Company&#8217;s deferred tax assets are comprised of
operating loss carryforwards and other temporary differences. Significant components of the Company&#8217;s deferred tax assets are as
follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_14" id="_IncomeTaxDisclosureTextBlock-c0_cont_13"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Carryforward losses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd">34,984</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd">31,289</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd">5,376</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd">5,203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" unitRef="usd">490</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Reserves and allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="3" unitRef="usd">157</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="3" unitRef="usd">239</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitRef="usd">479</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" unitRef="usd">41,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" unitRef="usd">37,210</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">40,448</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">37,210</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd">559</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease ROU assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd">559</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" unitRef="usd">559</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_15" id="_IncomeTaxDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">Management
currently believes that since the Company has a history of losses, and there is uncertainty with respect to future taxable income of
the Company, it is more likely than not that the deferred tax assets will not be utilized in the foreseeable future. Thus, a full
valuation allowance was provided to reduce deferred tax assets to their realizable value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 168; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 9:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> INCOME TAXES (CONT.)</td></tr>
</table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_16" id="_IncomeTaxDisclosureTextBlock-c0_cont_15"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">d.</td><td style="text-align: justify">Deferred taxes: (Cont.)</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_17" id="_IncomeTaxDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">In 2022 and 2021,
the main reconciling items of the Company&#8217;s statutory tax rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">23</ix:nonFraction>% and the effective tax rate of (<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" sign="-" unitRef="pure">0.3</ix:nonFraction>)% and <ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure">0</ix:nonFraction>%, respectively, is tax
carryforward losses and other temporary differences, such as research and development expenses, for which a full valuation allowance was
provided.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_18" id="_IncomeTaxDisclosureTextBlock-c0_cont_17"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">e.</td><td style="text-align: justify">Income taxes are comprised as follows:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_19" id="_IncomeTaxDisclosureTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year
Ended <br/>
December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Current</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" unitRef="usd">129</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 2.85pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" unitRef="usd">129</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_19"><ix:continuation id="_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended <br/>
December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Domestic (Israel)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Foreign</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" unitRef="usd">129</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 2.85pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" unitRef="usd">129</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 10:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> SHAREHOLDERS&#8217; EQUITY</td></tr>
</table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:nonNumeric><div>


</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">a.</td><td style="text-align: justify">Reverse Share Split:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">On June 21, 2020,
the Company&#8217;s Board of Directors resolved to consolidate the Company&#8217;s share capital by applying an additional reverse share
split and cancelling the shares&#8217; par value (See Note 1.b).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">Following the reverse
share split and the cancellation of the par value, all Ordinary shares, Convertible Preferred shares, options, convertible loans, warrants,
exercise prices and per share data have been adjusted retroactively for all periods presented in these consolidated financial statements.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">Ordinary share capital is composed as follows:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCapitalLeasedAsssetsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/>
 outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/>
 outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 52%; text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">&#160;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">&#160;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">&#160;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">&#160;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt">Ordinary shares with no par value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesAuthorized" scale="0" unitRef="shares">47,800,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesOutstanding" scale="0" unitRef="shares">19,851,833</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesAuthorized" scale="0" unitRef="shares">47,800,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesOutstanding" scale="0" unitRef="shares">18,756,570</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify; text-indent: 56.7pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify; text-indent: 56.7pt"></p><div>

</div><!-- Field: Page; Sequence: 169; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify; text-indent: 56.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify; text-indent: 56.7pt">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 10:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> SHAREHOLDERS&#8217; EQUITY (CONT.)</td></tr>
</table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify; text-indent: -28.35pt">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">c.</td><td style="text-align: justify">Controlled Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221;):</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">In July 2021, the
Company entered into a Sales Agreement with Cantor Fitzgerald &amp; Co. (the &#8220;Agent&#8221;), pursuant to which the Company may offer
and sell, from time to time, its Ordinary shares, through the Agent in an at the market offering (&#8220;ATM&#8217;&#8221;), as defined in Rule
415(a)(4) promulgated under the Securities Act of 1933, as amended, for an aggregate offering price of up to $<ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="pypd:AggregateOfferingPrice" scale="3" unitRef="usd">45,000</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.25pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">During the year
ended December 31, 2022, the Company sold <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" unitRef="shares">1,065,057</ix:nonFraction> Ordinary shares under the ATM for a total amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" unitRef="usd">4,423</ix:nonFraction>, net of issuance cost in
the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" unitRef="usd">222</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.25pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">d.</td><td style="text-align: justify">Ordinary shares rights:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The Ordinary shares confer upon their
holders the right to participate in the general meetings of the Company, to vote at such meetings (each share represents one vote), and
to participate in any distribution of dividends or any other distribution of the Company&#8217;s property, including the distribution of surplus
assets upon liquidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">e.</td><td style="text-align: justify">Share option plan:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The Company has
authorized through its 2012 Share Option Plan, the grant of options to officers, directors, advisors, management and other key employees
of up to <ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">4,672,094</ix:nonFraction> Ordinary shares. <ix:nonNumeric contextRef="c90" name="pypd:StockOptionVestingPeriodDescription">The options granted generally have a four-year vesting period and expire ten years after the date
of grant.</ix:nonNumeric> Options granted under the Company&#8217;s option plan that are canceled or forfeited before expiration become available for future
grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c91" name="pypd:ShareOptionPlanDescription"><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">On May 3, 2022, the annual and extraordinary
general meeting of shareholders of the Company approved a new grant of 76,120 options to the then current Chief Executive Officer of the
Company, Mr. Amir Weisberg. In addition, it was approved to accelerate the vesting of 12,906 options from an outstanding grant; in both
cases the vesting of all options will occur on June 30, 2022. As a result, the Company recognized a total share-based compensation expense
in the amount of $76.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">On May 9, 2022,
the Company&#8217;s Board of Directors approved to increase the Company&#8217;s options pool by an additional <ix:nonFraction contextRef="c92" decimals="-6" format="ixt-sec:numwordsen" name="pypd:NumberOfOptions" scale="6" unitRef="shares">one</ix:nonFraction> million options from <ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="pypd:StockOptionShares" scale="0" unitRef="shares">3,672,094</ix:nonFraction>
to <ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="pypd:StockOptionShares" scale="0" unitRef="shares">4,672,094</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">As of December 31,
2022, <ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="pypd:StockOptionsAvailableForFutureGrants" scale="0" unitRef="shares">700,965</ix:nonFraction> of the Company&#8217;s options were available for future grants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 170; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 10:- </td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt">SHAREHOLDERS&#8217; EQUITY (CONT.)</td></tr>
</table><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">e.</td><td style="text-align: justify">Share option plan: (Cont.)</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">A summary of the
status of options to employees under the Company&#8217;s option plan as of December&#160;31, 2022, and changes during the relevant period ended
on that date is presented below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of options</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> intrinsic<br/> value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b>&#160;<b><br/> average</b>&#160;<b><br/> remaining</b>&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>contractual<br/> life (years)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">2,726,911</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c96" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.25</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd">2,323</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c97" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">6.44</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">1,124,520</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.51</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" scale="0" sign="-" unitRef="shares">30,206</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="pypd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">21</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Forfeited and expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" scale="0" sign="-" unitRef="shares">517,879</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" scale="0" unitRef="usdPershares">6.57</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Outstanding at end of year</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">3,303,346</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">$</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.97</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">$</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd">115</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: right"><ix:nonNumeric contextRef="c97" format="ixt-sec:duryear" name="pypd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding">6.14</ix:nonNumeric></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable options</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">2,016,737</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.81</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c98" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" unitRef="usd">115</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c97" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.34</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares">3,303,346</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" scale="0" unitRef="usdPershares">5.97</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" unitRef="usd">115</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c97" format="ixt-sec:duryear" name="pypd:WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest">6.14</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">&#160;</p></ix:nonNumeric></ix:continuation><div>




</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The weighted average
grant date fair value of options granted during the year ended December 31, 2022, was $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="pypd:WeightedAverageGrantDateFairValueOfOptionsGranted" scale="0" unitRef="usdPershares">3.46</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The Black-Scholes
assumptions used to value the employee share options at the grant dates are presented in the following table by years:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; text-indent: 0in">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0in">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">70.45</ix:nonFraction>-<ix:nonFraction contextRef="c53" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">92.67</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c99" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">72.97</ix:nonFraction>-<ix:nonFraction contextRef="c100" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">78.69</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c101" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">74.35</ix:nonFraction>-<ix:nonFraction contextRef="c102" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">84.77</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0in">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.81</ix:nonFraction>-<ix:nonFraction contextRef="c53" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">4.30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c99" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.62</ix:nonFraction>-<ix:nonFraction contextRef="c100" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.32</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c101" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.23</ix:nonFraction>-<ix:nonFraction contextRef="c102" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0in">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c52" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">1.2</ix:nonNumeric>-<ix:nonNumeric contextRef="c53" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c99" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric>-<ix:nonNumeric contextRef="c100" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c101" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric>-<ix:nonNumeric contextRef="c102" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">These assumptions
and estimates were determined as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1.25in">&#160;</td>
    <td style="width: 38px; text-align: justify">o</td>
    <td style="text-align: justify">Fair Value of Ordinary Shares - Prior to the IPO, the fair value was determined by the Company&#8217;s Board of Directors, with input from management and third-party valuation specialists. After the IPO, the fair value of each Ordinary share was based on the closing price of the Company&#8217;s publicly traded Ordinary shares as reported on the date of the grant.</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1.25in">&#160;</td> <td style="width: 38px; text-align: justify">o</td> <td style="text-align: justify">Dividend Yield - The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. As a result, an expected dividend yield of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:fixed-zero" name="pypd:ExpectedDividendYield" scale="-2" unitRef="pure">zero</ix:nonFraction> percent was used.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">o</td> <td style="text-align: justify">Expected Volatility - As the Company has a short trading history for its Ordinary shares, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</td></tr> </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 171; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 10:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> SHAREHOLDERS&#8217; EQUITY (CONT.)</td></tr>
</table><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_25" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.5in; text-align: left">e.</td><td style="text-align: justify">Share option plan: (Cont.)</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_26" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_25"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1.25in; text-align: justify">&#160;</td>
    <td style="width: 38px">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">o</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">Risk-Free&#160;Interest Rate - The risk-free rate for the expected term of the options is based on the Black-Scholes option pricing model on the yields of United States of America Treasury securities with maturities appropriate for the expected term of employee share option awards.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">o</td>
    <td style="text-align: justify">Expected term - The expected term represents the period that options are expected to be outstanding. For option grants that are considered to be &#8220;plain vanilla,&#8221; the Company determines the expected term using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the options.</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_27" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The total share-based
compensation expense recognized by the Company&#8217;s departments for the three years ended December&#160;31, 2022, 2021 and 2020, was comprised
as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_28" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_27"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year Ended <br/>
</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c103" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">2,081</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c104" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">2,203</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c105" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">1,806</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Marketing and business development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">383</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c107" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">317</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">140</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">1,843</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">2,230</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c111" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">2,631</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -11.35pt; padding-left: 14.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="text-decoration:underline">Total</span> share-based compensation expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">4,307</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">4,750</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">4,577</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_29" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">As of December 31,
2022, there were unrecognized compensation costs of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="pypd:UnrecognizedCompensationCosts" scale="3" unitRef="usd">6,379</ix:nonFraction>, which are expected to be recognized over a weighted average period of approximately
<ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="pypd:RecognizedOverWeightedAveragePeriod">2.5</ix:nonNumeric> years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 172; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 10:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> SHAREHOLDERS&#8217; EQUITY (CONT.)</td></tr>
</table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_30" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_29"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">f.</td><td style="text-align: justify">Options issued to non-employees (including directors and consultants):</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_31" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_30"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">Outstanding options
granted to non-employees as of December&#160;31, 2022, were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_32" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_31"><ix:nonNumeric contextRef="c0" continuedAt="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock-c0_cont_1" escape="true" name="pypd:ScheduleOfOutstandingOptionGrantedTablesTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Grant date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Options<br/> outstanding </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,<br/> 2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Average<br/> Exercise </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>per share ($)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercisable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,<br/> 2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable through</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: center; text-indent: -12pt; padding-left: 12pt">October 2013</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">5,719</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">5.06</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">5,719</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 30%; text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"><ix:nonNumeric contextRef="c113" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">October 2023</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">September 2014</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">5,719</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">5.06</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">5,719</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"><ix:nonNumeric contextRef="c115" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">September 2024</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">April 2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">5,975</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">3.10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">5,975</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"><ix:nonNumeric contextRef="c117" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">April 2026</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">December 2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">7,170</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">3.93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">7,170</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"><ix:nonNumeric contextRef="c119" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">December 2026</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">June 2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">197,722</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">4.10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">197,722</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"><ix:nonNumeric contextRef="c121" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">June 2027</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">November 2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">17,925</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">7.70</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">17,925</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"><ix:nonNumeric contextRef="c123" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">November 2027</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">August 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">71,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c124" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">8.18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">71,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"><ix:nonNumeric contextRef="c125" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">August 2029</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">June 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">64,530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c126" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">6.62</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">53,724</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"><ix:nonNumeric contextRef="c127" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">June 2030</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">April 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">62,741</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c128" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">9.57</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">62,741</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"><ix:nonNumeric contextRef="c129" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">April 2031</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">August 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">15,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c130" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">8.13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">6,206</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"><ix:nonNumeric contextRef="c131" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">August 2031</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">December 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c132" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">6.80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">3,300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"><ix:nonNumeric contextRef="c133" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">December 2031</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">May 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">65,625</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">5.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">32,809</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"><ix:nonNumeric contextRef="c135" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">May 2032</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt">November 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">5,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c136" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">1.05</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; text-indent: -5.6pt; padding-left: 5.6pt"><ix:nonNumeric contextRef="c137" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">November 2032</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -12pt; padding-left: 12pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-indent: -5.6pt; padding-left: 5.6pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">534,826</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">470,710</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-indent: -5.6pt; padding-left: 5.6pt">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:nonNumeric></ix:continuation><div>




</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_33" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_32"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">No options were exercised by non-employees
during the year ended December&#160;31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_34" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_33"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">g.</td><td style="text-align: justify">Warrants:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_35" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_34"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal"><ix:nonNumeric contextRef="c95" name="pypd:WarrantsDescription">During
the year ended December 31, 2020, 2,106,879 D-2 warrants were exercised into 885,377 Ordinary shares on a cashless basis. As of December
31, 2020, 648,519 D-2 warrants were outstanding. In addition, 53,775 A warrants were exercised into 53,775 Ordinary shares for a total
consideration of $13.</ix:nonNumeric> As of December 31, 2022, <span style="-sec-ix-hidden: hidden-fact-127">no</span> A warrants were outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_36" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_35"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">Further
to the discussion in Note 7, as of April 26, 2022 and July 19, 2022, the Company measured the fair value of the warrants to purchase Ordinary
shares (a Level 3 valuation) using the Black-Scholes option pricing model. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 173; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"><i>&#160;</i></p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 10:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> SHAREHOLDERS&#8217; EQUITY (CONT.)</td></tr>
</table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_37" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_36"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">g.</td><td style="text-align: justify">Warrants: (Cont.)</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_38" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_37"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">As of April 26, 2022 and July 19,
2022, the relative fair value of the warrants to purchase Ordinary shares issued to Kreos was $<ix:nonFraction contextRef="c68" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="3" unitRef="usd">468</ix:nonFraction> and $<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="3" unitRef="usd">120</ix:nonFraction>, respectively, which was calculated
using the following assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_39" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_38"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">July 19,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">April 26,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Share price ($)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">5.12</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c149" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">4.96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">5.14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c149" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">5.14</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c150" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">60.57</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c151" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">60.81</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Adjustment to risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c150" decimals="4" format="ixt:num-dot-decimal" name="pypd:AdjustmentToRiskfreeInterestRate" scale="-2" unitRef="pure">3.07</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c151" decimals="4" format="ixt:num-dot-decimal" name="pypd:AdjustmentToRiskfreeInterestRate" scale="-2" unitRef="pure">2.84</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c150" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">3.11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c151" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">2.88</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c150" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.72</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c151" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.94</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.6pt; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_40" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_39"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal"><ix:nonNumeric contextRef="c0" name="pypd:WarrantsDescription">During
the year ended December 31, 2021, 580,028 D-2 warrants were exercised into 115,982 Ordinary shares on a cashless basis. In addition, 68,491
D-2 warrants were exercised into 68,491 Ordinary shares for a total consideration of $632. As of December 31, 2022, no D-2 warrants are
outstanding.</ix:nonNumeric> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_41" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_40"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">Since
the IPO and as of December 31, 2022, all warrants are exercisable into Ordinary shares, in which the outstanding issued warrants to purchase
Ordinary shares as of December&#160;31, 2022, were as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -56.7pt"><span style="font-weight: normal">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_41"><ix:continuation id="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Grant date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrants<br/>
 outstanding </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31, <br/>
2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Average<br/>
 Exercise </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>per share ($)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrants<br/>
 exercisable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,<br/>
 2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable through</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: center">August 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">200,596</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction contextRef="c139" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">15.95</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">200,596</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 30%; text-align: center"><ix:nonNumeric contextRef="c140" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">August 2023</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">September 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">17,925</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c141" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">16.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">17,925</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c142" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">September 2024</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">April 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">155,794</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c143" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">5.14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">155,794</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c144" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">April 2029</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt">July 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">38,948</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">5.14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">38,948</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; text-indent: -5.6pt; padding-left: 5.6pt"><ix:nonNumeric contextRef="c146" name="pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">April 2029</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">413,263</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="pypd:OptionsExercisable" scale="0" unitRef="shares">413,263</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 4pt">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-weight: normal"><i>&#160;</i></span></p><div>

</div><!-- Field: Page; Sequence: 174; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-weight: normal"><i>&#160;</i></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FinancialInstrumentsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:FinancialInstrumentsDisclosureTextBlock"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 11:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> FINANCIAL (INCOME) EXPENSES, NET</td></tr>
</table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:nonNumeric><div>


</div><div>

</div><ix:continuation id="_FinancialInstrumentsDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year Ended<br/>
</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; font-style: italic; text-align: justify">Financial expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; width: 64%; text-align: justify">Financial expenses from loan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireLoansReceivable" scale="3" unitRef="usd">1,023</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify">Other financial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd">316</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd">26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd">17</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify">Remeasurement of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:RemeasurementOfWarrants" scale="3" unitRef="usd">11,373</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="text-decoration:underline">Total</span> financial expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="3" unitRef="usd">1,339</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="3" unitRef="usd">26</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInvestmentExpense" scale="3" unitRef="usd">11,390</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; font-style: italic; text-align: justify">Financial income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify">Foreign currency transaction gains, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainBeforeTax" scale="3" unitRef="usd">532</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainBeforeTax" scale="3" unitRef="usd">44</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainBeforeTax" scale="3" unitRef="usd">243</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify">Interest from bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd">267</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd">468</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd">474</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify">Other financial income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" unitRef="usd">58</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" unitRef="usd">76</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="text-decoration:underline">Total</span> financial income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNonoperating" scale="3" unitRef="usd">799</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNonoperating" scale="3" unitRef="usd">570</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNonoperating" scale="3" unitRef="usd">793</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-align: justify"><span style="text-decoration:underline">Total</span> financial (income) expense, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNet" scale="3" unitRef="usd">540</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNet" scale="3" sign="-" unitRef="usd">544</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNet" scale="3" unitRef="usd">10,597</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerShareTextBlock"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 12:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> BASIC AND DILUTED NET LOSS PER SHARE</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p></ix:nonNumeric><div>


</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_2" id="_EarningsPerShareTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in">The following table
sets forth the computation of the Company&#8217;s basic and diluted loss per Ordinary share:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_3" id="_EarningsPerShareTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year Ended <br/>
</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; font-style: italic; text-align: left; text-indent: 0pt">Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; width: 64%; text-align: left; text-indent: 0pt">Allocation of net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" scale="3" unitRef="usd">39,557</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" scale="3" unitRef="usd">42,601</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" scale="3" unitRef="usd">36,869</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt">Preferred share preference</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:PreferredSharePreference" scale="3" unitRef="usd">3,933</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt">Deemed dividend</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="pypd:DeemedDividend" scale="3" unitRef="usd">2,114</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">Allocation of net loss attributable to Ordinary shareholders</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" unitRef="usd">39,557</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" unitRef="usd">42,601</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" unitRef="usd">42,916</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; font-style: italic; text-align: left; text-indent: 0pt">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt">Weighted average Ordinary shares outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">19,426,692</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">18,721,528</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">9,582,405</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-139; -sec-ix-hidden: hidden-fact-138; -sec-ix-hidden: hidden-fact-137">Basic and diluted net loss per share</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">2.04</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">2.28</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">4.48</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 175; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: Black 1.5pt solid"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 12:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> BASIC AND DILUTED NET LOSS PER SHARE (CONT.)</td></tr>
</table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_4" id="_EarningsPerShareTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in">The potential ordinary
shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented
because including them would have been anti-dilutive are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_EarningsPerShareTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Ordinary shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Ordinary share options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" unitRef="shares">2,487,447</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" unitRef="shares">1,995,749</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" unitRef="shares">1,583,210</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="pypd:WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" scale="0" unitRef="shares">413,263</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="pypd:WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" scale="0" unitRef="shares">218,521</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="pypd:WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" scale="0" unitRef="shares">867,040</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="pypd:WeightedAverageNumberOfSharesIssued" scale="0" unitRef="shares">2,900,710</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="pypd:WeightedAverageNumberOfSharesIssued" scale="0" unitRef="shares">2,214,270</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="pypd:WeightedAverageNumberOfSharesIssued" scale="0" unitRef="shares">2,450,250</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 13:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> RELATED PARTIES</td></tr>
</table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:nonNumeric><div>


</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">a.</td><td style="text-align: justify">Through February 2016, several management members also provided services to the Company as service providers.
As of December 31, 2022 and 2021, the Company has recorded a provision for severance pay liability for such service providers in the amounts
of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ServiceProvidersInAmount" scale="3" unitRef="usd">174</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="pypd:ServiceProvidersInAmount" scale="3" unitRef="usd">199</ix:nonFraction>, respectively. These amounts are included in &#8220;Other liabilities&#8221;.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">In July 2019, the Company entered into a master service agreement with a third-party provider (the &#8220;Provider&#8221;)
to conduct a portion of a phase 3 clinical trial in Eastern Europe. One of the Company&#8217;s directors serves as a director and shareholder
in the Provider.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_4" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0in">During the
years ended December 31, 2022 and 2021, and following the agreement with the Provider, the Company recognized research and development
expenses in the total amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" unitRef="usd">1,422</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" unitRef="usd">3,748</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_5" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0in">In May 2022,
the Provider was acquired by a non-related third party. As a result, the Provider no longer exists<span style="font-family: Times New Roman, Times, Serif">.</span>
Accordingly, the director is no longer an officer nor a shareholder of the third party or has any other connection to the third party.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">c.</td><td style="text-align: justify">On December 30, 2021, the Company&#8217;s Board of Directors appointed Dikla Czaczkes Akselbrad, the then
current Company&#8217;s Executive Vice President and Chief Financial Officer, as the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;),
effective July 1, 2022, replacing Amir Weisberg after <ix:nonNumeric contextRef="c152" format="ixt-sec:duryear" name="pypd:RelatedPartiesTerm">11</ix:nonNumeric> years.</td></tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.25pt; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 176; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.25pt; text-align: justify"></p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>POLYPID LTD. AND ITS SUBSIDIARIES </b></p><div>

</div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S.&#160;dollars in thousands (except share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: left; padding-left: 0pt; text-indent: 0pt; width: 0.75in"><b>NOTE</b> 14:- </td>
  <td style="text-align: left; padding-left: 0pt; text-indent: 0pt">SUBSEQUENT EVENTS</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:nonNumeric><div>


</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">a.</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Further to the disclosed in Note 10c, During January 2023, the Company
sold <ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyCommittedCapital" scale="0" unitRef="usd">1,949,029</ix:nonFraction> Ordinary shares under the ATM for a total amount of $<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" scale="0" unitRef="usd">2,190</ix:nonFraction>, net of issuance costs in the amount of $<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" scale="0" unitRef="usd">90</ix:nonFraction>. </span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_3" id="_SubsequentEventsTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">b.</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During the first quarter of 2023, the Company
decreased the exercise price of <ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="pypd:ExercisePriceDecrease" scale="0" unitRef="shares">2,021,599</ix:nonFraction> options granted to all employees and a consultant under the 2012 Share Option Plan. As of the
modification date, the options can be exercised for $<ix:nonFraction contextRef="c155" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.77</ix:nonFraction>. </span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_4" id="_SubsequentEventsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt 1in; text-align: justify">The Company's Board of Directors also approved
a similar exercise price decrease of <ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="pypd:ExercisePriceDecrease" scale="0" unitRef="shares">522,507</ix:nonFraction> options previously granted to the Company's CEO and Board members, subject to shareholders
approval<b>.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_5" id="_SubsequentEventsTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">c.</span></td> <td> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further to the disclosed in Note 7, on March 29, 2023, the Company
entered into an amendment to the Credit Line (the "Amendment"). Pursuant to this Amendment, <ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" name="pypd:InterestRepayments" scale="-2" unitRef="pure">70</ix:nonFraction>% of the remaining principal and
interest repayments will be delayed and repaid on a monthly equal basis from August 2024 to May 2026. The amended secured credit line
now bears an interest at the rate of <ix:nonFraction contextRef="c158" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">10</ix:nonFraction>%. In addition, the Company will pay to Kreos a restructuring fee consisting of <ix:nonFraction contextRef="c158" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" scale="-2" unitRef="pure">1</ix:nonFraction>% on the closing
date of the Amendment and an incremental <ix:nonFraction contextRef="c158" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" scale="-2" unitRef="pure">3</ix:nonFraction>% at the maturity of the Amendment. In return for this additional deferral of repayment, Kreos
has the right to receive a potential Claw-Back payment on account of the then outstanding principal amount (the "Claw-Back").
This Claw-Back mechanism will be triggered by additional incoming funds from future collaboration and partnership agreements or additional
funding. If triggered, the minimum Claw-Back to be paid will be $<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="pypd:MinimumPaidAmount" scale="0" unitRef="usd">1,500</ix:nonFraction>, but will not exceed $<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="pypd:ExceedAmount" scale="0" unitRef="usd">3,000</ix:nonFraction>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Further to the above and to Note 10g, the outstanding warrants issued to Kreos were repriced and as a result bear an exercise price of $<ix:nonFraction contextRef="c158" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.42</ix:nonFraction> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_6" id="_SubsequentEventsTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">d.</td><td style="text-align: justify">On March 29, 2023, the Company entered into a concurrent private placement of unregistered pre-funded
warrants to purchase up to <ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares">10,357,139</ix:nonFraction> Ordinary shares, (the &#8220;Private Warrants&#8221;), at a price of $<ix:nonFraction contextRef="c161" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">0.4199</ix:nonFraction> per Private Warrant
with certain of the Company&#8217;s existing shareholders. The Private Warrants have an exercise price of $<ix:nonFraction contextRef="c162" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.0001</ix:nonFraction> per Ordinary share.
The gross proceeds from the concurrent private placement, before deducting private placement fees and other estimated offering expenses
payable by the Company, are approximately $<ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="pypd:OfferingExpensesPayable" scale="0" unitRef="usd">4,350</ix:nonFraction>.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">e.</td><td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On March 31, 2023, the Company closed a public offering which was comprised
of <ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">16,859,000</ix:nonFraction> Ordinary shares, with no par value (inclusive of <ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">2,199,000</ix:nonFraction> Ordinary shares pursuant to the full exercise of an overallotment
option granted to the underwriters), at a public offering price of $<ix:nonFraction contextRef="c165" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">0.42</ix:nonFraction> per share (the &#8220;Public Offering&#8221;). The gross proceeds
to the Company from the Public Offering, before deducting underwriting commissions and other estimated offering expenses payable by the
Company, are approximately $<ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="pypd:OfferingExpensesPayable" scale="0" unitRef="usd">7,081</ix:nonFraction>.</p></td></tr></table></ix:continuation><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;- - - - - - - - - - - - - - - - - - - -</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 177; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&#160;</p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:EntityRegistrantName">PolyPid Ltd.</ix:nonNumeric>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-5" name="us-gaap:CommonStockNoParValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-6" name="us-gaap:CommonStockNoParValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-7" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-8" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-9" name="pypd:DeemedDividends" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-10" name="pypd:DeemedDividends" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-11" name="us-gaap:EarningsPerShareDiluted" unitRef="usdPershares">2.04</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="2" id="hidden-fact-12" name="us-gaap:EarningsPerShareDiluted" unitRef="usdPershares">2.28</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-13" name="us-gaap:EarningsPerShareDiluted" unitRef="usdPershares">4.48</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="INF" id="hidden-fact-14" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">18721528</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="INF" id="hidden-fact-15" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">19426692</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="INF" id="hidden-fact-16" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">9582405</ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-17" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-18" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-19" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-21" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-23" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-24" name="pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-25" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-26" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-27" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-28" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-29" name="pypd:ReclassificationOfWarrantsIntoEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-30" name="pypd:ReclassificationOfWarrantsIntoEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-31" name="pypd:ReclassificationOfWarrantsIntoEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-32" name="pypd:StockIssuedDuringPeriodExerciseOfWarrantsShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-33" name="pypd:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-34" name="pypd:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-35" name="pypd:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-36" name="us-gaap:StockIssuedDuringPeriodSharesOther" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-37" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-38" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-39" name="us-gaap:StockIssuedDuringPeriodSharesOther" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-40" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-41" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-42" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-43" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-44" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-45" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-46" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-47" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-48" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-49" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-50" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-51" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-52" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-53" name="pypd:StockIssuedDuringPeriodExerciseOfWarrantsShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-54" name="pypd:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-55" name="pypd:ExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-56" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-57" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-58" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-59" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-60" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-61" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-62" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-63" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-64" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-65" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-66" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-67" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-68" name="pypd:IssuanceOfOrdinarySharesNetinShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-69" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-70" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-71" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-72" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-73" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-74" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-75" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-76" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-77" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-78" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-79" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-80" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-81" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-82" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-83" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-84" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-85" name="pypd:ReevaluationOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-86" name="pypd:ReevaluationOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-87" name="us-gaap:OtherNoncashIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-88" name="us-gaap:OtherNoncashIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-89" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-90" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-91" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-92" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-93" name="pypd:PrepaymentForEquipments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-94" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-95" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-96" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-97" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-98" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-99" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-100" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-101" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-102" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-103" name="pypd:IssuanceOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-104" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-105" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-106" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-107" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-108" name="pypd:PurchaseOfPropertyAndEquipmentIncludedInTradePayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-109" name="pypd:PropertyAndEquipmentPaidForInPriorPeriods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-110" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-111" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-112" name="us-gaap:StockIssued1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-113" name="us-gaap:StockIssued1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-114" name="pypd:IsraelInnovationAuthorityGrantReceived" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-115" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-116" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-117" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-118" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-119" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-120" name="pypd:DomesticIsrael" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-121" name="pypd:DomesticIsrael" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-122" name="pypd:DomesticIsrael" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-123" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-124" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c150" id="hidden-fact-125" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c151" id="hidden-fact-126" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-127" name="pypd:WarrantsOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-128" name="us-gaap:PaymentsToAcquireLoansReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-129" name="us-gaap:PaymentsToAcquireLoansReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-130" name="pypd:RemeasurementOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-131" name="pypd:RemeasurementOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-132" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-133" name="pypd:PreferredSharePreference" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-134" name="pypd:PreferredSharePreference" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-135" name="pypd:DeemedDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-136" name="pypd:DeemedDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-137" name="us-gaap:EarningsPerShareDiluted" unitRef="usdPershares">2.04</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="2" id="hidden-fact-138" name="us-gaap:EarningsPerShareDiluted" unitRef="usdPershares">2.28</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-139" name="us-gaap:EarningsPerShareDiluted" unitRef="usdPershares">4.48</ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001611842</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="pypd-20221231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><ix:relationship fromRefs="hidden-fact-20 hidden-fact-21 hidden-fact-22 ix_0_fact ix_1_fact hidden-fact-23 ix_2_fact" toRefs="ix_0_footnote"></ix:relationship>
<ix:relationship fromRefs="hidden-fact-68 hidden-fact-69 hidden-fact-70 ix_3_fact ix_4_fact hidden-fact-71 ix_5_fact" toRefs="ix_1_footnote"></ix:relationship>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-02</xbrli:startDate>
    <xbrli:endDate>2020-06-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-25</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-25</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-25</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-09-01</xbrli:startDate>
    <xbrli:endDate>2022-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pypd:ShortTermDepositsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pypd:ShortTermDepositsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pypd:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pypd:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pypd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pypd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pypd:FirstTrancheMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pypd:SecondTrancheMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pypd:ThiredTrancheMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-04-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2022-07-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-12-22</xbrli:startDate>
    <xbrli:endDate>2016-12-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-09-30</xbrli:startDate>
    <xbrli:endDate>2017-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYyn91pOe7VtKs04Jlb3SPvCuMaehdfSUhtJg7vOyFoOF/AztNXIUhzx+P+epY4WtCBWdIE9zpOkAYuuw4yh598SS/DDR25UhB1vr3InT0Iv/WeMwUMCDO+Y4l9K2x3Xs422PVBz1J7zYQwrV5v8agZB4PYMfGJUC77vg+ip4C7gULXDfwlRwrIX/tFVfrhaz0=] CSR-->
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-15</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pypd:TwoThousandTwelveShareOptionPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pypd:TwoThousandTwelveShareOptionPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pypd:MarketingAndBusinessDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pypd:MarketingAndBusinessDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pypd:MarketingAndBusinessDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:OctoberTwoThousandThirteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:OctoberTwoThousandThirteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:SeptemberTwoThousandFourteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:SeptemberTwoThousandFourteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:AprilTwoThousandSixteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:AprilTwoThousandSixteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:DecemberTwoThousandSixteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:DecemberTwoThousandSixteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:JuneTwoThousandSeventeenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:JuneTwoThousandSeventeenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:NovemberTwoThousandSeventeenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:NovemberTwoThousandSeventeenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:August2019Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:August2019Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:JuneTwoThousandTwentyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:JuneTwoThousandTwentyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:April2021Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:April2021Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:August2021Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:August2021Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:December2021Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:December2021Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:May2022Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:May2022Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:November2022Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:November2022Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:August2019Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:August2019Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:September2020Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:September2020Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:April2022Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:April2022Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:July2022Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:July2022Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-07-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-01</xbrli:startDate>
    <xbrli:endDate>2022-07-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-04-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-07-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-30</xbrli:startDate>
    <xbrli:endDate>2023-03-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-31</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-29</xbrli:startDate>
    <xbrli:endDate>2023-03-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-29</xbrli:startDate>
    <xbrli:endDate>2023-03-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pypd:ConsultAndDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001611842</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="eur">
  <xbrli:measure>iso4217:EUR</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.3
<SEQUENCE>2
<FILENAME>f20f2022ex2-2_polypidltd.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 2.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Description of Rights of Each Class of Securities</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Type and Class of Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">PolyPid Ltd.&rsquo;s (the
&ldquo;Company&rdquo;) authorized share capital consists of 47,800,000 ordinary shares, no par value per share (&ldquo;Ordinary Shares&rdquo;).
The Company will ask its shareholders to approve the increase of the authorized share capital to 107,800,000 Ordinary Shares at its upcoming
annual shareholders meeting on May 5, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registration Number and Purposes and Objects
of the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s registration
number with the Israeli Registrar of Companies is 51-410592-3. The Company&rsquo;s purpose is set forth in section 3 of the Company&rsquo;s
amended and restated articles of association and includes every lawful purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Powers of the Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s board
of directors (&ldquo;Board&rdquo;) may exercise all powers that are not required under the Israeli Companies Law of 1999 (the &ldquo;Companies
Law&rdquo;) or under the Company&rsquo;s amended and restated articles of association, other than the powers which are to be exercised
or taken by the Company&rsquo;s shareholders.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preemptive Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s Ordinary
Shares are not redeemable and are not subject to any preemptive right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Voting Rights of Directors </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Companies Law and the Company&rsquo;s amended and restated articles of association, no director shall be disqualified by virtue
of his or her office from holding any office or place of profit in the Company or in any company in which the Company shall be a shareholder
or otherwise interested, or from contracting with the Company as vendor, purchaser or otherwise, nor shall any such contract, or any contract
or arrangement entered into by or on behalf of the Company in which any director shall be in any way interested, be avoided, nor, other
than as required under the Companies Law, shall any director be liable to account to the Company for any profit arising from any such
office or place of profit or realized by any such contract or arrangement by reason only of such director&rsquo;s holding that office
or of the fiduciary relations thereby established, but the nature of his or her interest, as well as any material fact or document, must
be disclosed by him at the meeting of the Board at which the contract or arrangement is first considered, if his or her interest then
exists, or, in any other case, at no later than the first meeting of the Board after the acquisition of his or her interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitations or Qualifications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rights of the Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s Ordinary
Shares shall confer upon the holders thereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">equal right to attend and to vote at all of the Company&rsquo;s general meetings, whether regular or special, with each Ordinary Share entitling the holder thereof, which attends the meeting and participates in the voting, either in person or by a proxy or by a written ballot, to one vote;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">equal right to participate in distribution of dividends, if any, whether payable in cash or in bonus shares, in distribution of assets or in any other distribution, on a per share pro rata basis; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">equal right to participate, upon the Company&rsquo;s dissolution, in the distribution of the Company&rsquo;s assets legally available for distribution, on a per share pro rata basis.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Election of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the Company&rsquo;s amended and restated articles of association, the Company&rsquo;s directors are elected solely at an annual general
meeting of the Company&rsquo;s shareholders and serve on the Board until the next annual general meeting of the Company&rsquo;s shareholders
following his or her appointment, or until they cease to act as Board members pursuant to the provisions of the Company&rsquo;s amended
and restated articles of association or any applicable law. The Board may at any time and from time to time appoint any person as a director
to fill a vacancy (whether such vacancy is due to a director no longer serving or due to the number of directors serving being less than
the maximum number of eleven, as stated in the Company&rsquo;s amended and restated articles of association). In the event of one or more
such vacancies in the Board, the continuing directors may continue to act in every matter, provided, however, that if they number less
than the minimum number of five, as provided in the Company&rsquo;s amended and restated articles of association, they may only act in
an emergency or to fill the office of director which has become vacant up to a number equal to the minimum number of five. The office
of a director that was appointed by the Board to fill any vacancy shall only be for the remaining period of time during which the director
whose service has ended was filled would have held office, or in case of a vacancy due to the number of directors serving being less than
the maximum number of eleven. The Company is not currently required to have external directors serving on Board, based on an exemption
that the Company has elected to be governed by under the Companies Law regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Annual and Special Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
Israeli law, the Company is required to hold an annual general meeting of&nbsp;the Company&rsquo;s shareholders once every calendar year,
at such time and place which shall be determined by&nbsp;the Board, which must be no later than 15 months after the date of the previous
annual general meeting. All meetings other than the annual general meeting of shareholders are referred to as special general meetings.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Subject
to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general
meetings are the shareholders of record on a date to be decided by the Board, that will be in any event not more than the maximum period
and not less than the minimum period permitted by the Companies Law. Resolutions regarding the following matters must be passed at a general
meeting of the Company&rsquo;s shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">amendments to&nbsp;the Company&rsquo;s amended and restated articles of association;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the exercise of&nbsp;the Board&rsquo;s powers by a general meeting if&nbsp;the Board&rsquo;s is unable to exercise its powers and the exercise of any of its powers is required for the Company&rsquo;s proper management;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">appointment or termination of&nbsp;the Company&rsquo;s auditors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">appointment of directors (other than in the cases specified in the Company&rsquo;s amended and restated articles of association);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">approval of acts and transactions requiring general meeting approval pursuant to the provisions of the Companies Law and any other applicable law;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">increases or reductions of&nbsp;the Company&rsquo;s authorized share capital; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a merger (as such term is defined in the Companies Law).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Notices</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law and our
articles of association require that a notice of any annual or special shareholders meeting be provided at least 14 or 21 days prior to
the meeting, as the case may be, and if the agenda of the meeting includes the appointment or removal of directors, the approval of transactions
with office holders or interested or related parties, approval of the company&rsquo;s general manager to serve as the chairman of the
board of directors or an approval of a merger, notice must be provided at least 35 days prior to the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Quorum</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
permitted under the Companies Law, the quorum required for the Company&rsquo;s general meetings consists of at least two shareholders
present in person, by proxy, written ballot or voting by means of electronic voting system, who hold or represent between them in the
aggregate at least twenty five percent (25%)&nbsp; of the voting power of the Company. If within half an hour of the time set forth for
the general meeting a quorum is not present, the general meeting shall stand adjourned either (i) to the same day of the following week,
at the same hour and in the same place (ii) to such other date, time and place as prescribed in the notice to the shareholders and in
such adjourned meeting or (iii) to such day and at such time and place as the chairperson of the general meeting shall determine (which
may be earlier or later than the date pursuant to clause (i) above). If no quorum is present within half an hour of the time arranged,
any number of shareholders participating in the meeting, shall constitute a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Access to Corporate Records</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, shareholders
are provided access to: minutes of the Company&rsquo;s general meetings; the Company&rsquo;s shareholders register and principal shareholders
register, articles of association and annual audited financial statements; and any document that the Company is required by law to file
publicly with the Israeli Companies Registrar or the Israel Securities Authority. These documents are publicly available and may be found
and inspected at the Israeli Registrar of Companies. In addition, shareholders may request to be provided with any document related to
an action or transaction requiring shareholder approval under the related party transaction provisions of the Companies Law. The Company
may deny this request if the Company believes it has not been made in good faith or if such denial is necessary to protect the Company&rsquo;s
interest or protect a trade secret or patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Adoption of Resolutions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as required by the
Companies Law or the Company&rsquo;s amended and restated articles of association, a resolution of the shareholders shall be adopted if
approved by the holders of a simple majority of the voting power represented at the general meeting in person or by proxy and voting thereon,
as one class, and disregarding abstentions from the count of the voting power present and voting. Without limiting the generality of the
foregoing, a resolution with respect to a matter or action for which the Companies Law prescribes a higher majority or pursuant to which
a provision requiring a higher majority would have been deemed to have been incorporated into the Company&rsquo;s amended and restated
articles of association, but resolutions with respect to which the Companies Law allows the Company&rsquo;s amended and restated articles
of association to provide otherwise, shall be adopted by a simple majority of the voting power represented at the General Meeting in person
or by proxy and voting thereon, as one class, and disregarding abstentions from the count of the voting power present and voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changing Rights Attached to Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time the share capital
of the Company is divided into different classes of shares, the rights attached to any class, unless otherwise provided by the Companies
Law or the Company&rsquo;s amended and restated articles of association, may be modified or cancelled by the Company by a resolution of
the general meeting of the holders of all shares as one class, without any required separate resolution of any class of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
enlargement of an existing class of shares or the issuance of additional shares thereof, shall not be deemed to modify the rights attached
to the previously issued shares of such class or of any other class, unless otherwise provided by the terms of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitations on the Rights to Own Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">There
are no limitations on the right to own&nbsp;</FONT>the Company&rsquo;s&nbsp;<FONT STYLE="background-color: white">securities</FONT><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Provisions Restricting Change in Control of
the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
are no specific provisions of the Company&rsquo;s amended and restated articles of association that would have an effect of delaying,
deferring or preventing a change in control of the Company or that would operate only with respect to a merger, acquisition or corporate
restructuring involving the Company (or the Company&rsquo;s subsidiaries). However, as described below, certain provisions of the Companies
Law may have such effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Companies Law includes provisions that allow a merger transaction and requires that each company that is a party to the merger have the
transaction approved by its board of directors and, unless certain requirements described under the Companies Law are met, a vote of the
majority of its shareholders, and, in the case of the target company, also a majority vote of each class of its shares. For purposes of
the shareholder vote of each party, unless a court rules otherwise, the merger will not be deemed approved if shares representing a majority
of the voting power present at the shareholders meeting and which are not held by the other party to the merger (or by any person or group
of persons acting in concert who holds 25% or more of the voting power or the right to appoint 25% or more of the directors of the other
party) vote against the merger. If, however, the merger involves a merger with a company&rsquo;s own controlling shareholder or if the
controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same Special Majority (as defined
below) approval that governs all extraordinary transactions with controlling shareholders. Upon the request of a creditor of either party
to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result
of the merger, the surviving company will be unable to satisfy the obligations of any of the parties to the merger, and may further give
instructions to secure the rights of creditors. In addition, a merger may not be completed unless at least (1) 50 days have passed from
the time that the requisite proposals for approval of the merger were filed with the Israeli Registrar of Companies by each merging company
and (2) 30 days have passed since the merger was approved by the shareholders of each merging company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &ldquo;Special Majority&rdquo;
is defined in the Companies Law as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">at least a majority of the shares held by shareholders who are not controlling shareholders and do not have personal interest in the merger (excluding a personal interest that did not result from the shareholder&rsquo;s relationship with the controlling shareholder) have voted in favor of the proposal (shares held by abstaining shareholders shall not be considered); or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the total number of shares voted against the merger, does not exceed 2% of the aggregate voting rights of the company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Companies Law also provides that an acquisition of shares in an Israeli public company must be made by means of a &ldquo;special&rdquo;
tender offer if as a result of the acquisition (1) the purchaser would become a holder of 25% or more of the voting rights in the company,
unless there is already another holder of at least 25% or more of the voting rights in the company, or (2) the purchaser would become
a holder of 45% or more of the voting rights in the company, unless there is already a holder of more than 45% of the voting rights in
the company. These requirements do not apply if, in general, the acquisition (1) was made in a private placement that received shareholders&rsquo;
approval, subject to certain conditions, (2) was from a holder of 25% or more of the voting rights in the company which resulted in the
acquirer becoming a holder of 25% or more of the voting rights in the company, or (3) was from a holder of more than 45% of the voting
rights in the company which resulted in the acquirer becoming a holder of more than 45% of the voting rights in the company. A &ldquo;special&rdquo;
tender offer must be extended to all shareholders. In general, a &ldquo;special&rdquo; tender offer may be consummated only if (1) at
least 5% of the voting power attached to the company&rsquo;s outstanding shares will be acquired by the offeror and (2) the offer is accepted
by a majority of the offerees who notified the company of their position in connection with such offer (excluding the offeror, controlling
shareholders, holders of 25% or more of the voting rights in the company or anyone on their behalf, or any person having a personal interest
in the acceptance of the tender offer). If a special tender offer is accepted, then the purchaser or any person or entity controlling
it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase
of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the
offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If,
as a result of an acquisition of shares, the acquirer will hold more than 90% of an Israeli public company&rsquo;s outstanding shares,
the acquisition must be made by means of a tender offer for all of the outstanding shares. In general, if less than 5% of the outstanding
shares are not tendered in the tender offer and more than half of the offerees who have no personal interest in the offer tendered their
shares, all the shares that the acquirer offered to purchase will be transferred to it by operation of law. However, a tender offer will
also be accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the
company or of the applicable class of shares. Shareholders may request appraisal rights in connection with a full tender offer for a period
of six months following the consummation of the tender offer, but the acquirer is entitled to stipulate, under certain conditions, that
tendering shareholders will forfeit such appraisal rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Differences Between Law of Different Jurisdictions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Borrowing Powers&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law and the Company&rsquo;s amended and restated articles of association, the Board may exercise all powers and take all actions that
are not required under law or under the Company&rsquo;s amended and restated articles to be exercised or taken by the shareholders, including
the power to borrow money for company purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in the Company&rsquo;s Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The general meeting may, by
a simple majority vote of the shareholders attending the general meeting and subject to the provisions of the Companies Law:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">increase the Company&rsquo;s registered share capital by the creation of new shares from the existing class or a new class, as determined by the general meeting;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">cancel any registered share capital which has not been taken or agreed to be taken by any person;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">consolidate and divide all or any of the Company&rsquo;s share capital into shares of larger nominal value than the Company&rsquo;s existing shares;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">subdivide the Company&rsquo;s existing shares or any of them, the Company&rsquo;s share capital or any of it, into shares of smaller nominal value than is fixed; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reduce the Company&rsquo;s share capital and any fund reserved for capital redemption in any manner, and with and subject to any incident authorized, and consent required, by the Companies Law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company does not have
any debt securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants and Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company does not have
any warrants or rights that are registered under Section 12 of the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company does not have
any other securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>3
<FILENAME>f20f2022ex12-1_polypidltd.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO EXCHANGE ACT RULE
13a-14(a) or 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Dikla Czaczkes Akselbrad, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this annual report on Form 20&ndash;F of PolyPid Ltd.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by
the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over
financial reporting.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 60%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 31, 2023</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 40%; border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dikla Czaczkes Akselbrad</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dikla Czaczkes Akselbrad</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>4
<FILENAME>f20f2022ex12-2_polypidltd.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO EXCHANGE ACT RULE
13a-14(a) or 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Jonny Missulawin, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this annual report on Form 20&ndash;F of PolyPid Ltd.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the Company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 61%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 31, 2023</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 39%; border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jonny Missulawin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonny Missulawin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Vice President of Finance</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>5
<FILENAME>f20f2022ex13-1_polypidltd.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C.&nbsp;Section 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the filing
of the Annual Report on Form 20-F for the period ended December 31, 2022 (the &ldquo;Report&rdquo;) by PolyPid Ltd. (the &ldquo;Company&rdquo;),
the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) the Report fully complies
with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) the information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 31, 2023</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dikla Czaczkes Akselbrad </FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dikla Czaczkes Akselbrad</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>6
<FILENAME>f20f2022ex13-2_polypidltd.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C.&nbsp;Section 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the filing
of the Annual Report on Form 20-F for the period ended December 31, 2022 (the &ldquo;Report&rdquo;) by PolyPid Ltd. (the &ldquo;Company&rdquo;),
the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) the Report fully complies
with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) the information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 31, 2023</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jonny Missulawin</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonny Missulawin</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Vice President of Finance</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>7
<FILENAME>f20f2022ex15-1_polypidltd.htm
<DESCRIPTION>CONSENT OF KOST, FORER, GABBAY & KASIERER, CERTIFIED PUBLIC ACCOUNTANTS (ISRAEL), AN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM AND A MEMBER FIRM OF ERNST & YOUNG GLOBAL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white">We consent to the incorporation
by reference in the following Registration Statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Registration Statement (Form F-3 No. 333-257651) of PolyPid Ltd., and</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Registration Statement (Form S-8 No. 333-239517) pertaining to the equity incentive plan of PolyPid Ltd.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">of our report dated March
31, 2023, with respect to the consolidated financial statements of PolyPid Ltd. included in this Annual Report (Form 20-F) of PolyPid
Ltd. for the year ended December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>

    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>/s/ Kost Forer Gabbay &amp; Kasierer</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 31, 2023</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Haifa, Israel</P></TD>
    <TD STYLE="width: 40%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Kost Forer Gabbay &amp; Kasierer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">A Member of Ernst &amp; Young Global</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>fin_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !> % # 2(  A$! Q$!_\0
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !7 *L# 2(  A$! Q$!_\0
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M$'UI)U:QTV2-\&YN?W:(.^>/ZUTMWX-AL4EN+;6+BSMD!=D8;PH[XR:K^#=
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M/_7L_P#(U9T__D&VO_7%/Y"JWB#_ )%[4?\ KV?^1JSI_P#R#;7_ *XI_(4
M9L7_ ".EQ_UXI_Z&:VZPED2+QG<&1U4&Q3ECC^,UISZG8VT32S7<"(HR27%
M&5XA!;4M#2/_ %QO-P_W IW?I6_7.:89=;UW^V61X[*",Q6H<8,A/WGQV':N
MCH K7UA:ZE;?9[N$2Q9#;22.1]*?:VL-E;1VUO&(X8QM11V%1WMT]OY*0QAY
MIGV(&. ."22?3 JNVHRPPWHGB036T?F#:QVNI!P?;D$'Z4 :5%92ZG/)974T
M:02-;D_,LA*. N>#CKVJ1+^81V+2Q1AKJ3;\C$A04+=Q[4 &H:#I>J-NN[..
M1_[X^5OS'-48?!>@PR;Q9;B.SR,P_+-78M64B]\Y-AMV;: <[U!(!'N2",4E
MIJDD]M;R26_E/+<-"R%LE,;OU^6@#0BAC@B6**-8XU&%51@#\*9=VD%]:R6U
MS&)(9!AE/>JT=U='4_LS1PE I=W1CE1_"#QU//Y5!IVKM>V\LQ$ V(6\M)"6
M&"?O<<=* (?^$/T'_H'1_P#?3?XU+;>&-&L[F.X@L426,[D8,>#^=6;:]E>:
M*.XB1?.B\R-D8D<8R#D<'D4EY=7<-U!%#'"RS,54NQ!!"D]A[4 7ZH6&C:?I
MDLLEG;+$\OWR">><]_K3+G6;>TDN8II(TDB0,JL^"_!/]*2YU1H;VWM_W">;
M'OS*Y'<# XY/- &G4$]I!<R0R31AG@??&2?NMC&:HW>K-;ZDMJ!"22@",Y#O
MN)^Z,<XQFIK[4OL<\2"/>O#3-G_5H3M!]^3^0/I0!?HK,U35#82P(OD#S%=M
MTTFT?+C@<'DYI)-59;JVAQ#%YL:R8F<AN3C &.M &A/!'<V\D$R!XI%*LI[@
M]13D18XUC0850 !Z 56>]*M>#8#]G0-UZ_*344UW=_Z*88H"L^!\[D$':6[#
MVH ;?^']+U2X$][:+-*%VAB3T_ U%;^%M#MI!)%IL&X<@LN['YU8EU+R/MF^
M(G[,B'"')<L.@_&I8GO%C=[B*+(7*I$Q)SZ<@4 6@,# HJCIEY)?0&5_)'8H
MC$E#W5LC@BKU %>ZM%NA&=[1R1/O1UZJ<$?R)%1?V:C1W0DD=Y+E=KN<9"XX
M ] ,G\Z** +$\*SVTD!RJR(4..P(Q41L8RMF-S?Z*P9??"E>?SHHH B?2H7E
MB=G?]W*TF.,-EMV#[ X(^@J1=/C4( [_ "3M./JV[CZ?,:** &6NGO:S22"Z
MD<2.7<,J_,3[XSQP!]*+33OLMJUJ+B1X=I558#Y<Y[@>]%% #X+$12QR/*TC
M1Q^6F0 %'&>G<X'Y5++;+--!*Q(,+%E [Y!'/YT44 -:S1S<Y9A]H7:WMQCB
MHY+$FXCGBN)(G2/R^ #D9![CVHHH 6?3XYS*Q=E=]A##&5*G((_.HY=(L[B6
M>6YC$S3?*2_9<8VCVZGZDT44 .BTV*%K0AW;[+&T:;CG(..OTP*?+:,]V+B.
MX>-M@0@ $$9SW%%% #+C3_/DE99Y(A,@215QR!]1P<'%3M;(Q@QE1"V5 _W2
MO]:** (I-/AF-UYFYEN%57&<8QTQ4D,$L2E7NGEXP"RJ"/?@<FBB@!EM9""X
6EN&E:2:555F( X7..!]35JBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #P ?@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W34+^/3X4
M=T>1Y'$<<<8^9V/0#/%1?VJ(X8'N+6>!YIQ;A' R&/0\'&/>FZV+%K)4U#S!
M"7&V2,-F-AR&RO*_6L!OM=]86T4DUQ- NIHL%SM*2-'@_-T['(W8YKLI4HSB
MF_ZWV_7J>=B,1.G4:B[Z:+[M^OH]OF=-+J$45Z;1E?S! 9\@<;0<?G51M=C*
MV?D6EQ.UW"9D1 N0O'7)'J*H_8&M->EQ+=3JVG/\\S%\'<. ?Z50VI$N@M=3
M75M&M@5,D(8,&^3@X!]_RJXT*;MU_P"&?S,JF*K*_37R[I;[;,Z=-14W-M;R
M0RQ37$;R!6Q\H7&0<'W%0W.KBWOGM([*YN)$C61_)"G )('4CT-9US>6UOJN
MDW;22M;"WE42LC,2<IC/&<G!H_M.UMO$,]U(T@AGM(O*80N=V&?L!UY%0J*W
MY;Z?C<N6)>W,EJE?3:U[]M^IMV5[!J%JMQ;L2C9&",%2."".Q%)8WL=_;M-$
M&"B1X_F'.5)!_E5+0894M[J>6)H?M5T\ZQN,,JG &1V)QG\:3PZK1Z7('1E/
MVF<X(P<>8U9SIQ7-;HT=%.K.7)S=4[_+;T[_ #);+6%OG5HK2X%J^[9<L%V-
MCOUR!QQD59M+^VOK=9[>4-&Q(!Z<YQ_,5SUH]NNJP0:2\[VL[/\ :[.6-O+B
M!!R?F'RG/&.AS52VC@@\-HL<&R>UO$>Z5(B&"K*3D\<X'Z5O+#Q>VFWZ[_=Z
M''#&5%\5GO?Y6VMY-[ZJVNQVFY<D9''7GI5)-3BDU0V:[2H@$WFAP0<L5Q^E
M<Y?2&^;69[:.9X'2VR0C#S(PQW[?7C-.2RL=3U2_BL(?+MIK *)%B*(9 W!'
M';C\J4</%)N;Z?=M_F7/&3E)*FNOW_%MIMHKOS1UV1G&1GKBLNZUV.UNKF'[
M)=2K;*KS21J"$!&<]<G@=A53P]+-J=Q-JEPA1U1;55/8KS(?Q;_T&F/I]Q?:
M]J\8NI;>WD2%7V(,R#:<@,>GX>M1&E",W&?1?JNQ<\14G3C.DOB>GI9]]M5]
MQO+=0-'%()DVR@&,EL;@>F*<\L<8)D=4 ZECBN4N8=/M;W4H-1MBX,2)9 Q%
M\QA,;4XX.[/OTJ,"VM]3LAKD?F,FEH'\Q"X#[CG.,\]LU7U9/5-_YZ7T_)^9
M+QLEHTNV[TUMKIY77D=CN7(&1DC(YJK<7ZP7MG;!-_VEG4,#]W:I/]*YO3V;
M33HMQ>I+'$+>:,%D)*98%%..0=H_2G::LI?29/(E7_2KMRK(00#OQGTH^K*-
MVW=?\/\ Y!]=E)))6>GW>[Y=;O[ONZD3Q,S*LJ%D^\ PX^M58]4AN;2*YM%:
MXCD<)\F 5!.,G..!7,Z;MNM7TYQ;01AEE6>"*V9?+!7[LC'[QS2V$4*:%901
M0;;F*_B%RJQD,")#C/'/%4\-&.[UT_7_ "(6.G/5+37_ -MV^3U]#L#+&)!&
M9$$AY"EN3^%#2QH0&D523@ G&3Z5QES'";34+>2!VUQ[IFA;RR7/S?(RMCA0
MN.^!@U:OM/CG/B2:6V\R947RF*$D$1 Y7WSZ5/U:/5_UI^&OX%_79N]H_B^T
MG9Z;Z?BOGUE%16I8VD)?.XQKG/7.*EKC:L['I)W5PHHHI#"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!DDJ1 %]W/HI/\JC^V0_]-/\ OVW^%3T4
MU8EJ71D'VR'_ *:?]^V_PH^V0_\ 33_OVW^%3T4[KL*TN_X$'VR'_II_W[;_
M  H^V0_]-/\ OVW^%3T4778+2[_@0?;(?^FG_?MO\*/MD/\ TT_[]M_A4]%%
MUV"TN_X$'VR'_II_W[;_  H^V0_]-/\ OVW^%3T4778+2[_@0?;(?^FG_?MO
M\*0WD)'63_OVW^%6**+KL%I=_P "A9_8["T2V@$HC3.,HQ)).22<=<FK'VR'
M_II_W[;_  J>BFY)N[%&+BDELO(@^V0_]-/^_;?X57S:?;S>XE\XQ>5G8V-N
M<],>M7Z*%)+8'%O?\B#[9#_TT_[]M_A1]LA_Z:?]^V_PJ>BE==AVEW_ @^V0
M_P#33_OVW^%'VR'_ *:?]^V_PJ>BBZ[!:7?\"#[9#_TT_P"_;?X4?;(?^FG_
M '[;_"IZ*+KL%I=_P(/MD/\ TT_[]M_A1]LA_P"FG_?MO\*GHHNNP6EW_ @^
MV0_]-/\ OVW^%'VR'_II_P!^V_PJ>BBZ[!:7?\"#[9#_ --/^_;?X4?;(?\
MII_W[;_"IZ*+KL%I=_P(/MD/_33_ +]M_A1]LA_Z:?\ ?MO\*GHHNNP6EW_
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M=.%^$\R4L4\T*N#N;O@<')Z<5G2ZGX0M=@1]+>0I)>Q1P!'9]@^9U ZGGZT
M.A\6QW6E:IJ$%C/]GLX6ECDE^19\!N 3T^[^1%.T[Q.;O4;?3Y[%XIW#1R,L
MBLJRJ@9UZY(&X#=C&>*LK=>'H+:\B\W388L_Z7$S(H4L.D@[$C/!]Z73;G0)
M=3NH=->P:]ACC\\0;=ZHPRF2.V!Q^% &1<>(-235YK:&YL3:F8V\=Q)$P$;J
MK229^?Y@J+@]/F/L:JVOC#4FN+5+Z""W6ZCA9652XC#8))P<\YX!QC@\CKOR
MW/ANXMX[:2;2YH2S21PEHV#,N2Q5>Y')./>JPUSPL]@NI2W-A$BQK?GS]JR1
MAE!#E3R#MQ[]* &ZKXMCTZXNH4LY)O(#J9-Z@>:L1EVXSG&W&6Q@%@*9)XEG
MTFWT^#4K9YKZ6%9;GRBJB++JF,9Y^9\ #).TU8O1X:U(3R2W=B&,227$B3(K
MF+@C>W78>/J,4EO<^'=3DC\0F2V;+&V@N;@@#*.P_=D^K;N1UP* *2^-&NKJ
M""RT_>)98L/).BCRG$C;^"2#MC+;3S@CUIMOXZBD@D<6%W.(X@SO'&%&]MI2
M/DXR0ZCKUJQ_:/A2WTX7 M[.,,Z2_9U@7S=SOY:/L'/); /H:FOM4\.Z5<V!
M:.U:?4I%B@,*(2X3YMV?[J!<Y[8'M0!3_P"$TE#W4ATMQ;6L&^9O.4LK^:T>
M,#^$;&8MV JSJGB9].U6SB^SF2T> 2W#HRGR]\B(ASGD<OTSG'M5AY?"TT4<
MSRZ.\<I\N-RT9#D'=@'OC)./?WJ2UU?P]JBV\UO>Z?.;B,2PG>I9T0DY /.%
M.[Z<T 8TOC^!;6XE33Y2\<?G(IEC :/RS)N)S\IV[>#S\XJ]/XF;3Q86UU;-
M->2QP&<HRH$:1M@P&.3\P;@9P%)J:SM]"O9&M;72;66TC F6=((V@9SE2%(Z
ML,8/IQ6K+86<]U'<S6D$EQ&,)*\8++]#U% '.2^*YX?#6G:O=6Z6WVF3>Z!O
M-Q"%9R1CJ2B_F:<OC1"8%;2[I)))$1DD95*AY-B$ D%LD,<#LI_'H%TZR6W2
MW6S@$,8(2,1C:H/! ';.3^=1C1],#0M_9]KF%=L1\E<H/0<<=Z ,G3/$\FK:
MM;VL%CLA>*629GE&^(JX4*5['.[([8J]I5_=7FHZM%,(/(M;A886BSD_(K'=
MGO\ ,.E6X--L;5HVM[.WB:-2B%(PI52<D#'8GFEM-.LK#S?L=I#;^:V^3RD"
M[V]3CJ: +-%%% !6+KGA\:U+&[7 B"VT]N<Q!CB4*"0<\$!<?B:VJ* .3O\
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M18I8R #(Y!=B!P ,8!ZMM_$GB[4?$\=C$ES J3I)) ;-2(X7G?Y9G_@(@0$
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M@_D010!)144-S#<*6AD5U#,N0>X."/P/%,EOK6&YAMI+B-9YL^7&6Y;'7 H
ML44A8#J0/QHW*.XX&>M "T5%<7,-I T\\@2)<98^YP/UJLNLZ:\?F+>1,F<9
M!S_$%_F0/QH O4444 %%%% !1110 4THA<.54NH(#8Y /6G5176-.>Z:U2\A
M:=9/*,8;)#<\8_ _E0!>I@BC65I0BB1@ S <D#IDTX,IQ@CGIS1N7U'(SUH
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M!CPEJ!AMCIN'S<9W[B.Y R:["B@#E9?!@DEW+?"->JJD(_=$8V^7S\HX4'U
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MMR  _*IWOP/4>E!\#1B5W%[GY0(U:,[8_G+%0H8#802"OH>M==10!S3>$O\
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M/YQB6DJ,>NK_ $/?R?#IMUI=-%^H $D  DGH!7H?AGPVNG1+=W:!KQAD _\
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MM_=H191-E01_K6']!W_*O4*9%%'!$L42*D:#"JHP *?7RV*Q,L1/F>W1'WN
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FKK:* ,W33?\ VF[6\WLFX&)V"@'U  [#CG/.:TJ** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $# @T# 2(  A$! Q$!_\0
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M:/-D_P">C_\ ?1IE%%D%WW'^;)_ST?\ [Z-'FR?\]'_[Z-,HHL@N^X_S9/\
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M[PQ/[UNBKC&(P!_O"O0_M'$?S?@CR/[%P7\GXLF_X5[)_P!!-/\ OR?\:/\
MA7LG_033_OR?\:;:^-=>O]7>PM] \L&XCB26?>JA65R2V!V* ?\  A4K^--4
M?PE/K-MHAEF2[%L(-Y&,':[D_P!T,#CVQ1_:.(_F_!!_8N"_D_%C/^%>R?\
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MT$\:0SMJ5O%9R+=V%J]S*CL"H 4,O(ZAL\8]#Z4_:>2_$/9/^9_A_D:6^_\
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M^(>R?\S_  _R,=3?(,+I94>@F04N^_\ ^@8W_?\ 2M>BG[3R7XA[)_S/\/\
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MCDCC20 GS"ZJPP.O\6/PJ1_$6FQM$AF<O+)Y:*L;$EMQ7ICU!_*BT.WX_P#
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M>EQ_X#2?_$TM%'+#M^/_   O4_F7W?\ !$_MFT]+C_P&D_\ B:/[9M/2X_\
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M>EQ_X#2?_$TM%'+#M^/_   O4_F7W?\ !$_MFT]+C_P&D_\ B:/[9M/2X_\
M :3_ .)I:P;OQ1%:2WL;6TC-:LJD;U!8'^+'91GK1:';\?\ @!^\_F7W?\$W
M?[9M/2X_\!I/_B:/[9M/2X_\!I/_ (FL>#Q):W&I"Q5&$C%=K%AM92N=P/<<
M@>];-%H=OQ_X ?O/YOP_X)#=:Q:-:3@"XR8V_P"7>3T^E7;'_D'VW_7)?Y"J
M=S_QZ3_]<V_D:NV/_(/MO^N2_P A1-)0T[_H*'-[3WG?3]2>BBBL#I"BBB@
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M6Y//7FM\I9#&5M^0".%Z'I_(U2;5-#24Q--:APX0J0 022!GVRIY]J.:'G^
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M6W_YX1?]\"CGAY_@'+5\OQ,[[;:?\_4'_?Q?\:/MMI_S]0?]_%_QK1^RV_\
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M;;3_ )^H/^_B_P"-'VVT_P"?J#_OXO\ C6C]EM_^>$7_ 'P*/LMO_P \(O\
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MNJ^'O[5GCE>[:-EB\L[4^\=P8$\XQD=/UJL?",,EV9Y[IGS(LNP1@#?E"?\
M@)\L8';)JW_9UMZ2?]_G_P :/[.MO23_ +_/_C1[./?\/^"'M*G\J^__ (!5
MA\(VT%OJ4"W$A6]S\QR60%BV,DX(R3Q@<<5=TG0HM+N);@2F2:5<.=H49W,Q
MP!T&6Z>U,_LZV])/^_S_ .-']G6WI)_W^?\ QH]G'O\ A_P0]I4_E7W_ / *
M<_@^&07#)>2"6Y#><TB!PQ+[@0.Q!)P1TS3U\)P%&BGN9)8&N%N",;79A_><
M')!S5G^SK;TD_P"_S_XT?V=;>DG_ '^?_&CV<>_X?\$/:5/Y5]__  "M+X3A
MDNVG%P(U\P/'"D($8PK*-R]&.&QGT %6(_#<!TB+3KFXFFA20NP!VAN<A1W5
M1V /;K2_V=;>DG_?Y_\ &C^SK;TD_P"_S_XT>SCW_#_@A[2I_*OO_P" 5)O"
MKW$TT\VI,T[R,PD\D9",I0IUZ;3@>G7FNAAB2W@CACSLC4(N?0#%9/\ 9UMZ
M2?\ ?Y_\:/[.MO23_O\ /_C1[./?\/\ @A[2I_*OO_X!LT5C?V=;>DG_ '^?
M_&C^SK;TD_[_ #_XT>SCW_#_ ((>TJ?RK[_^ ;-%8W]G6WI)_P!_G_QH_LZV
M])/^_P _^-'LX]_P_P""'M*G\J^__@&S16-_9UMZ2?\ ?Y_\:/[.MO23_O\
M/_C1[./?\/\ @A[2I_*OO_X!LT5C?V=;>DG_ '^?_&C^SK;TD_[_ #_XT>SC
MW_#_ ((>TJ?RK[_^ ;-%8W]G6WI)_P!_G_QH_LZV])/^_P _^-'LX]_P_P""
M'M*G\J^__@&S16-_9UMZ2?\ ?Y_\:/[.MO23_O\ /_C1[./?\/\ @A[2I_*O
MO_X!LUC/HDLLVJ/->F3[="85!C ,2X( !ST&2?J:/[.MO23_ +_/_C1_9UMZ
M2?\ ?Y_\:/9Q[_A_P0]I4_E7W_\  &0Z!*LDK2W@:.:UBM9(EB_A4$'#9SSN
M/Z57?PC#-"!<71EF'2;R@&&U0J#Z#&?<U;_LZV])/^_S_P"-']G6WI)_W^?_
M !H]G'O^'_!#VE3^5??_ , FTC2Y-.,[2W!G>38N]LY(50H)]SS6G6-_9UMZ
M2?\ ?Y_\:/[.MO23_O\ /_C1[./?\/\ @A[2I_*OO_X!LT5C?V=;>DG_ '^?
M_&C^SK;TD_[_ #_XT>SCW_#_ ((>TJ?RK[_^ ;-9KZ2'UQ-2\Q5*)MVI& S<
M8^9NI'M4']G6WI)_W^?_ !H_LZV])/\ O\_^-'LX]_P_X(>TJ?RK[_\ @$%K
MX>N+>>W<:@#';>9Y49B# %V8[^OWL-CZ?4U&?!]J\UV\LN]+F3>R^4H(RV3S
MW/. >H'%6_[.MO23_O\ /_C1_9UMZ2?]_G_QH]G'O^'_  0]I4_E7W_\ 32M
M"?3;M)7NVG$<+1(6ZX9]Q'T& !^-;58W]G6WI)_W^?\ QH_LZV])/^_S_P"-
M'LX]_P /^"'M*G\J^_\ X!LT5C?V=;>DG_?Y_P#&C^SK;TD_[_/_ (T>SCW_
M  _X(>TJ?RK[_P#@&S7-S^$@UU?W%K?R6KWF=Q2,$_,06R>^<<>F3BK?]G6W
MI)_W^?\ QH_LZV])/^_S_P"-'LX]_P /^"'M*G\J^_\ X!"?"\7V^WO8[@PS
M1;0?)0('4 9! ]<>_'%;]8W]G6WI)_W^?_&C^SK;TD_[_/\ XT>SCW_#_@A[
M2I_*OO\ ^ :=W_QY3_\ 7-OY4EC_ ,@^V_ZY+_(5D7.GVXM9CB3B-O\ EL_H
M?>M:Q_Y!]M_UR7^0HE%*&CZ_H*$I.IJK:?J6****Q.@**** "BBB@ JEJ_\
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M_?*?X4?V9+_T$;C_ +Y3_"B\>_YA>?\ +^*'44W^S)?^@C<?]\I_A1_9DO\
MT$;C_OE/\*+Q[_F%Y_R_BAU%-_LR7_H(W'_?*?X4?V9+_P!!&X_[Y3_"B\>_
MYA>?\OXH=13?[,E_Z"-Q_P!\I_A1_9DO_01N/^^4_P *+Q[_ )A>?\OXH=13
M?[,E_P"@C<?]\I_A1_9DO_01N/\ OE/\*+Q[_F%Y_P OXH=13?[,E_Z"-Q_W
MRG^%']F2_P#01N/^^4_PHO'O^87G_+^*'44W^S)?^@C<?]\I_A1_9DO_ $$;
MC_OE/\*+Q[_F%Y_R_BAU%-_LR7_H(W'_ 'RG^%']F2_]!&X_[Y3_  HO'O\
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M_9DO_01N/^^4_P *+Q[_ )A>?\OXH=13?[,E_P"@C<?]\I_A1_9DO_01N/\
MOE/\*+Q[_F%Y_P OXH=13?[,E_Z"-Q_WRG^%']F2_P#01N/^^4_PHO'O^87G
M_+^*&7/_ !Z3_P#7-OY&KMC_ ,@^V_ZY+_(50NM-E6TG/]H7!Q&W&U/3Z5>L
M?^0?;?\ 7)?Y"E.W)H^OZ!"_M-5;3]2Q1116!TA1110 4444 %4M6_Y!<_\
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M_M&I_P#3G^3T?:-3_P"G/\GH]D^Z#VR[/[O^":E%9?VC4_\ IS_)Z/M&I_\
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MD_[^I_C1OO?^@;)_W]3_ !HY?ZN@]HO/[G_D3T5!OO?^@;)_W]3_ !HWWO\
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M-6Q(,,,CO[TGF7W_ $#I?^_J?XT;[W_H'2?]_4_QHY7W_%![1>?W/_(=<_\
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M #TD_P"_+_X4>RGV#V]+^9&A16?_ &U8_P#/23_OR_\ A1_;5C_STD_[\O\
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M<\>YM65ZM[$[H"ICE:)U)Y#*?_U'\:LY/J:H6*6EC#(BW,;&25I78N.68_\
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MYJ&H+IMN)Y(Y7CW ,8\?+D@9.2/7M5"\TC1]1DN3>&"9+@HS*6'RLHQD'W
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MGEW#V<.R^Y?Y%B:[T. W D%JIM\></+!\O(R,\<<4^:;1;<VXF%HAN 3"&0
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MU6H]*U632]1@FNI/.><+;,92O[M3D$D<\Y(([@>]'/(/90[&U]@B_OW/_?\
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M\:P+SP_JCRSI;:BZV8<&"+SGWA3RP+9SD-@K[<4K>&[QYHY9+QYML_G,C3N
MQ#Y7'/&%...M'/(/90[&ZME"ZAEDN"IZ$7#D']:7[!%_?N/^_P"_^-<T?#6L
ML$0ZF0HV!V65UW(#'E !T^Z_S=3OK2TG2M0L=1,MQ=F:#R3'AI&8\,2N >!\
MN 2<D^M'/(/90[&G]AB_YZ7'_@0_^-'V&+_GI<?^!#_XU9HHYY=P]E#L5OL,
M7_/2X_\  A_\:/L,7_/2X_\  A_\:LT4<\NX>RAV*WV&+_GI<?\ @0_^-'V&
M+_GI<?\ @0_^-6:*.>7</90[%;[#%_STN/\ P(?_ !H^PQ?\]+C_ ,"'_P :
MLT4<\NX>RAV*WV&+_GI<?^!#_P"-'V&+_GI<?^!#_P"-6:*.>7</90[%;[#%
M_P ]+C_P(?\ QH^PQ?\ /2X_\"'_ ,:LT4<\NX>RAV*WV&+_ )Z7'_@0_P#C
M1]AB_P">EQ_X$/\ XU9HHYY=P]E#L5OL,7_/2X_\"'_QIHM+<LRB:8LOWA]I
M?(^O-6ZYP>'9X[S5[B&8H+J"6.--P.7?G<3CUZ YQDT<\NX>RAV-A;2W?&V>
M9LC<,7+G(]>M)]EMLX\^;/(Q]I;MU[UD:?H5]::FNHBY4M)9K;M&\8!BQMQ@
MCJ!@GW)]ZHCP7.D4B_:UED,[RB8C82"J\$="68')_P :7/(?LH=CIDM;>0$I
M/,P!P=MRYP?SIWV&+_GI<?\ @0_^-4]&M+RV:[>\V[Y&3[HPK%4 9@.V3_*M
M6GSR[B]E#L5OL,7_ #TN/_ A_P#&C[#%_P ]+C_P(?\ QJS11SR[A[*'8K?8
M8O\ GI<?^!#_ .-,-M:J"3<2@ [>;ENOIUZU<KD;WPK<7D5]&!%!Y]W)-&R/
MD*KJ%)(QUXS^-'/+N'LH=CHFM[5&*O<2JP )#7+#@G [^M(\%I'((WN9$=NB
MM=,"?PS6+K/AZXU.ZN@K$;DC\F8L,)A61@00<_>+?4U<ET0W1L%NA'+'9QLH
M)^_(P7:A)[=R??%+GD'LH=B\+>T+*HN926^Z/M3<_3FI/L,7_/2X_P# A_\
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M0>QAY_>_\S._LZY_Z"#_ /?I?\*/[.N?^@@__?I?\*T:*/:2_I(/8P\_O?\
MF9W]G7/_ $$'_P"_2_X4?V=<_P#00?\ []+_ (5HT4>TE_20>QAY_>_\S._L
MZY_Z"#_]^E_PH_LZY_Z"#_\ ?I?\*T:*/:2_I(/8P\_O?^9G?V=<_P#00?\
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4 !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $" G # 2(  A$! Q$!_\0
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M8U#:Z_I-]J3:?:W\,UTL2R[$;.5/0@]_Z9% '1?VYJ?_ #^/^0_PH_MS4_\
MG\?\A_A6%)K.EQ/.DFI6B-;X\X&908\]-W/%(^M:5$(3)J=F@F :(M,HW@G
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M)/5<8Q@BK:I)V:1G&5>2YDW]Y%_PL;Q?_P!!R?\ []I_\31_PL;Q?_T')_\
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M_9OG^9][*[A@64].,'I5>+P (]+DLVOT<M8O:*Y@^[NF,NX9/;.,9_&O2/\
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M[(A8]NXHQ;?U[YZ5OUJ?\([JG_/NO_?Q?\:/^$=U3_GW7_OXO^- &76I>_\
M).KS_KH/_0UH_P"$=U3_ )]U_P"_B_XU?N=&OY/!ESIZP@W3N"J;QR-P/7IT
M%;X=I5HM]T<N,BY8>I&*NVG^1Y;6I)K=Q_85OI<+20I&7\PJ_$H8YP1[5=_X
M0CQ!_P ^:_\ ?Y/\:/\ A"/$'_/FO_?Y/\:^LE7PTK<TEIYGYY#"8VG?EIR5
MU;9[$L7BYH[R[F-O($N!%@)(-R%!@8)4C!^E1CQ.C36=Q+:2M/;2;@1/A67>
M6Y&.3SU_2D_X0CQ!_P ^:_\ ?Y/\:/\ A"/$'_/FO_?Y/\:P_P!C_F7W_(ZO
M^%+;DE_X#YW_ #!O$Y-MY2VS*?+BCW"3^Y(7].^<4]O%2/))OLV\J7[0'"RX
M;$K!N#C@C'XTS_A"/$'_ #YK_P!_D_QH_P"$(\0?\^:_]_D_QI_['_,OO"V9
M?R2_\!)(_%,,6FO9I8, P(W&4'/S[@22N2>W7'M6'J-W]OU*YNPFP32M)MSG
M&3G&:V/^$(\0?\^:_P#?Y/\ &C_A"/$'_/FO_?Y/\:NG4PM-N49*[\S*K1Q]
M6*C.#LO[I:^'O_(R/_U[M_-:\_U;_D-7_P#U\R?^A&O5?!_AO5=)UIKF]MUC
MB,+)D2*W)(]#[5R&H?#[Q+/J=W-'8(8Y)G=3YZ#(+$CO7'.O2^LRES*UEU]3
MTJ>%KK!0AR._-+2WH<;6S'XCNK?PTNCVKRP?OGDDECDQO5@!M(_#UK1_X5SX
MH_Z!Z?\ @0G^-'_"N?%'_0/3_P "$_QJI5:,MY+[R(8?%0ORP:OIL*GC(*QW
MV)DCV6B"-I?E'D?AW_3WJX_CV%[A';396C6$Q&,SJ _S%AN 0# SQ@ CUJE_
MPKGQ1_T#T_\  A/\:/\ A7/BC_H'I_X$)_C63^K/JOO.A/'+[+^XCU7Q>^IZ
M&NG_ &=XCY<<;;9!Y9"=#C;NS]6JBVJV1\+KI*V<XF$_VCSC,"N_ 4_+MZ8]
M^M:7_"N?%'_0/3_P(3_&C_A7/BC_ *!Z?^!"?XU2EATK*2[[F<J>,D[R@]K;
M=#E:?#_Q\1?[Z_SKI_\ A7/BC_H'I_X$)_C3HOAUXG65&.GI@,"?](3U^M:.
MO2_F7WF"PF(O\#^X/C;_ ,C-IW_7G_[.:\RKVOXH>#==\2:Y97.E6BS116WE
MNQF1,-N)Q@D=C7#_ /"JO&/_ $#(_P#P)C_^*KS:-2"II-GN8JC4E6DU%F+X
M:U]_#FH3WD<3/));20(5?:4+# ;..W6M#2O&MU8QQFZ$]W<#4XK^29IR&D"*
M5V'COG].E6O^%5>,?^@9'_X$Q_\ Q5'_  JKQC_T#(__  )C_P#BJMRI/=HS
MC#$15DG]Q9A^(D,.CK8QZ5)&V4)>*X"\K+YFX?+N#'IUP.PJ6/XEI%<W+QZ9
M)%',8GW13()#(F<LQ*%><_PJ,=15'_A57C'_ *!D?_@3'_\ %4?\*J\8_P#0
M,C_\"8__ (JIM1[_ (FE\5V?W%#0/$EII-SJ5U<6,\MW=AECN(9PCP!B=VTE
M3R<XSVYKG9"AE<QAEC+':&.2!VR>YKL?^%5>,?\ H&1_^!,?_P 51_PJKQC_
M - R/_P)C_\ BJM3IIWN8NE7:2<7]QQE>O:#_P D$U/_ +;?^ABN4_X55XQ_
MZ!D?_@3'_P#%5Z+I/A36;7X2WVA36JKJ,OF;(O-4@Y;(^;.*RK5(-*SZHZ,+
M1J1<KQ>S/#Z0C((KL?\ A5WB_P#Z!D?_ ($Q_P"-'_"KO%__ $#(_P#P)C_Q
MKH]K3_F1R_5ZO\K^X27Q]=S>*H-6=)VM(!^ZL3/\J'RMA(.,9SSTJ?2?'R:<
M+3SM,>>2WM(K<2^<-Q*2,^?F4\'=@]^.#4/_  J[Q?\ ] R/_P "8_\ &C_A
M5WB__H&1_P#@3'_C63]BU:Z^\W7UE.]G]Q:A^(JP-!(FE%Y8KIIU,L^0BLS$
MJF%!'WNY(!&0*Q-7\1QZOK-E>307+06R!!&TZB0C)/#(JA>3Q@=JT?\ A5WB
M_P#Z!D?_ ($Q_P"-'_"KO%__ $#(_P#P)C_QIIT4[IK[Q26(DK-/[C)\1:\-
M=EL]D$D:6L A5YY?-EDYSEWP,^W%8M=A_P *N\7_ /0,C_\  F/_ !H_X5=X
MO_Z!D?\ X$Q_XU:J4TK)HSE1K2=W%_<:7P<_Y'*X_P"O)_\ T-*[+4CC5KL_
M]-F_G67\-O!>O>'O$LUYJ=FL,#6K1AA,C?,64XP#[&NEOM!U&;4+B6. %'D9
ME.\<@GZUYN)DI5+H]G!1E&E:2MJSRY/A\(]/N;./4BD=Y&Z706+B1O,WQOC/
M!7[I]1Z5!?\ @F2.QL+:VP9I;TBZEMT95%NZ@2!MS,<$*O?K7J'_  CNJ?\
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MG^#SIVIV%U!=PQ1VR;7CB@*F7[W!)8_+EL\@D>M=36I_PCNJ?\^Z_P#?Q?\
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M_?Y_\:,-_P ]9O\ O\_^-+11RQ[![2?<3#?\]9O^_P _^-&&_P">LW_?Y_\
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M:,-_SUF_[_/_ (T[!]#1@^AHY8]@]I/N-PW_ #UF_P"_S_XT8;_GK-_W^?\
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MS(I.)9-N6/ )&/PZ5(OACP\90YOX3;[A&2MZN=_VC:<#KCR^<XQWI.K!;K\
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M-%V2!&B.[,;G*@Q\CYCZ9J6V^)5A_:%XUVDRZ4?):TO$A^4!X/-VR'.=QPV
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MY;*1;D0F<QY!.P DGKV /'7BE["F_M?D-XJJMX?F>X?\)1H'_0:L/^_ZT?\
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M1-=:/J%F]O\ :+6:WEVQLBN,-OR%''<X(_ U#6I:>FQS[>+M0^UK;0VUE/\
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MY( SG(]JK3>+=0EUJRU7R;9)K1/+1%0[67G(;)).02.O2NL_X5-)_P!!I/\
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M>RA2?O9[>OZ<4+X^U02!VMK!V3RS%NA.(70,%=0#P<,?;IQ5'Q1X=?PWKO\
M9?VC[4_EHX98]N=W;&371^&OA?J&I[+G5F:QM3R(\?O7'T_A_'GVH:II78E*
MLWRIE'3/%WB"^U0+9V,%W=221R;%C;)9(O*!X88XY//7\JZ[1OAD+B]DU3Q(
M\;S32&4V=O\ +&I)S@D=O8?G7<:1HFFZ%:_9]-M4@3^)ARS^[-U-:%8.?\JL
M=<:3M[[N1V]O#:6Z6]O$D,,8PD:+A5'L*DHHK,V"BBL_6;/4+VQ6+3-3.G7
ME1S.(A)E ?F7!]1QF@!^K6 U/3VM3.8,NCB0*&P5<,.#P>5K(M_#)AU^SOQ<
M>9'$)I;@\#SIV8E3M'0+ODQSWK5URT6_T._MO(6=GMY!'&R@Y?:=N,]\XKGC
M%K&GI##:0S6\4,$!C2*-! !M/G&3ONST]\8SS4/<N.QHW6@2F7;;ZF(H'O1>
MBVEB#!I 0Q&[(.W(W8]>^.*LV&CW-AI]W -3+W-P6<W?D .)#_&1DAB.,#@
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M"3^-/F%RG:!E+,H92RXR >1Z9I:Y7PW;:LFH7MU<+.HG6W\Q[Y '<JA#A=N
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M:0 'K@L21G/:M)5"J%4 *!@ =A0D^H.W06@@'J :**HD**** "BBB@   &
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M  LB7_H%1_\ ?\_X4 =_6?J^L6VBV\5Q=A_*DE$99!G;D$YQZ<5R'_"R)?\
MH%1_]_S_ (5E>(/%KZ]8):M9+ %D$FX2%LX!&.GO0!Z=:W=O?6ZSVLR31-T9
M#G_]535XC8:E>:7<>?97#Q/WQT;ZCH:[[1?'MK=;8=346TQX\U>8V^O=?Y4
M=A12*RN@=&#*PR&4Y!%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4448H ***.M !1110
M4444 %%%% !1110 4444 %6M._Y"$/U/\C56K6G?\A"'ZG^1H ?JO_(0?Z#^
M54JNZK_R$'^@_E5*@ KRN35+34O%NKSZYI.M:LFG7S6]G;VMN9+:((!\Q (!
M<DYYSVKU2N2\#$BZ\6<_\Q^X_P#04H /^$^A_P"A;\2_^"X_XUS7BK5].U*"
M;5+?0?$VGZS;0EH-0BLVC*[1D"0YPR>N>U>IY/J:S/$9/_"+:OR?^/*;_P!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_9Y_^?V7_OE/_B: ,/\ L^[_ .>#?F*/[/N_^>#?F*W/L\W_ #^R_P#?*?\
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MP;\Q1_9]W_SP;\Q6Y]GF_P"?V7_OE/\ XFC[/-_S^R_]\I_\30!A_P!GW?\
MSP;\Q1_9]W_SP;\Q6Y]GF_Y_9?\ OE/_ (FC[/-_S^R_]\I_\30!A_V?=_\
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M\7?]"]??]\C_ !HYH]PY9=CG:*Z+_A ?%W_0O7W_ 'R/\:/^$!\7?]"]??\
M?(_QHYH]PY9=CG:*Z+_A ?%W_0O7W_?(_P :/^$!\7?]"]??]\C_ !HYH]PY
M9=CG:*Z+_A ?%W_0O7W_ 'R/\:/^$!\7?]"]??\ ?(_QHYH]PY9=CG:*Z+_A
M ?%W_0O7W_?(_P :/^$!\7?]"]??]\C_ !HYH]PY9=CG:*Z+_A ?%W_0O7W_
M 'R/\:/^$!\7?]"]??\ ?(_QHYH]PY9=CG:*Z+_A ?%W_0O7W_?(_P :/^$!
M\7?]"]??]\C_ !HYH]PY9=CG:*Z+_A ?%W_0O7W_ 'R/\:/^$!\7?]"]??\
M?(_QHYH]PY9=CG:*Z+_A ?%W_0O7W_?(_P :5?A_XN9@H\/7HSZA0/YT<T>X
M<LNQSE>]?!/1I;'PS=:E,I7[?,#&".J(" ?Q):N<\*_!B^GN8[GQ(R6]LIR;
M6)]SR>S,.%'TR?I7MT,,5M!'!#&L<4:A411@*!T KGK5$URHZ:-)I\S'T445
MRG6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !] A8# 2(  A$! Q$!_\0
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M;I?[@_[Z_P#K4;I?[@_[Z_\ K5+10!%NE_N#_OK_ .M1NE_N#_OK_P"M4M%
M$6Z7^X/^^O\ ZU&Z7^X/^^O_ *U2T4 1;I?[@_[Z_P#K4;I?[@_[Z_\ K5+1
M0!%NE_N#_OK_ .M1NE_N#_OK_P"M4M% $6Z7_GF/^^J-\O\ SS'_ 'U_]:I*
MH:J\J6+F$N) 1C:,D\T(4G97++3.B[FC&,@<'U.*1IW$S1I%NV@$G('7/^%-
ME;=;*<=63^8IZ?\ 'W-_NK_6D,/-G_Y]_P#QX4>;/_S[_P#CPJ>BF!!YL_\
MS[_^/"CS9_\ GW_\>%3T4 0>;/\ \^__ (\*/-G_ .??_P >%3T4 0>;/_S[
M_P#CPH\V?_GW_P#'A4]% $'FS_\ /O\ ^/"CS9_^??\ \>%3T4 0>;/_ ,^_
M_CPH\V?_ )]__'A4]% $'FS_ //O_P"/"CS9_P#GW_\ 'A4]% $'FS_\^_\
MX\*/-G_Y]_\ QX5/10!!YL__ #[_ /CPH\V?_GW_ /'A4])0!#YLW_/O_P"/
M"CS9O^??_P >%39K-\V0ZP5!D$03D%?E)[8HM<3E8N13-([HR;"N.^<YI5F#
M,P56.UMI/'6F1_\ 'W-]%_D:=;_>G_ZZ'^0I#)-[?\\V_2C>W_/-OTI^:*8#
M-[?\\V_2C>W_ #S;]*?10 S>W_/-OTHWM_SS;]*?10 S>W_/-OTHWM_SS;]*
M?10 S>W_ #S;]*-[?\\V_2GT4 ,WM_SS;]*-[?\ /-OTI]% #-[?\\V_2C>W
M_/-OTI]% #-[?\\V_2C>W_/-OTI]% #-[?\ /-OTI-[?\\V_2I** (M[?\\V
M_2C>W]QOTJ0\5G65X\]W<PL5*QD;2!C@T6)<DFD7XI!)&'7.#ZT5%:_\>J_4
M_P S104-G_X_;;_@7\J\O^(GBY+G4GT"WD=K:W4->K#DM*W7R^.P')_*O3;M
MQ%<12'HJN3^ KQFQ\5>&-$TC^T[FZ%YK<KRW)6)",22?\LWD]/:IEL5%I.[)
MM/T/7=6,2I$+.V7RRJ( 7DA<YR,<< =#BK;V/A'PNLAU74[:2[$<J-&2))95
M)XW 9",,8R,=37-:_J'B77_#[:M87,NFZ&FU'MD4PX;'; ^=>G)K*\"P:5=Z
MZ$U"P^WQR1DF ':F5!.]L\'I^9J(I):'3>I.-UL:NN?$74KV"W'AZ:*QBF4)
M,P!,Z$<<N<Y&/[M:VB?#_1=1LCJ^L>(GU$>27FB@)+,!RQ.[+ \C.,5D^+[;
MP]=ZD9[:5HG$<86WLE&U<#D'/ (X&16/)K<]O916ELQMK:-6VJAR[ACELMC/
M.!^52YJ*L]2UAU**L=-XFT[P[9S6W]EW0TJ6P91%]F(>208W>86'<9Q@UZ5X
M#\5CQ-HA,W%_:D1W QC=Z./]X?KFOGF2:5_G VY&X.YR2#UY_7FN\^%TMWIG
MBU86CD\O4;5_+,@*AROS+@]P,$9'K2A-MBK4DH+78]XS2US>DZ_=75S=QW]B
MUFENP3<3N!/4\XZ8QS[UT"2)(@=&#*>ZG-;1DI*Z.247%V9)13=PI0<U1(M%
M%% !1110 4444 %(:6D- %*6^V-C:*9]O_V5J*XL+B1LJ4_$FH?[,NO5/S-:
MI1.64JE]$6'O!(FT@#D'CV.:47@65Y,#+ #'TS_C5233[F,;BR8R!U/<XH&G
MW)D*!DRH!/)[_P#ZJ=H$\]7L7O[1']T4D5Z WS'Y3^E5#IEUZI^9J.RMI+F4
M[N(U."?4TK1L'/4NDT;P8, 1R#2TB*$4*!@"EK(ZT+1110,**** "BBB@ HH
MHH **** "BBB@!*9(^Q"WI3ZBG1I(65<9/K0A/;0K-?A6(VCBF_V@/[HJM)I
MMTTC,#'@^YIO]F77JGYFMDH'*Y5.Q86\"RNX R^./I2I>JA<@ [FS51;"Y,C
MH&3*XSR>]":?<N6 9/E.T\FBT!<]7L76O]PQ@"I;>\61MC'#=O>LN:RN((S(
MY0@>A.:M:;:-@33#_=7T]Z34;#A*HY69K4445D=84444 %%%% !1110 4444
M %%%% !1110 4444 )BFK&JYPH&>N!3Z* *]K_QZK]3_ #-%%K_QZK_O'^9H
MH BNT$DT*'HZN#^5?-OA^"71O%D@FM8F2VNFBG-TN85QG)8>N!QCFOI6?_C\
MMO\ @7\J\G^*7A*XCF?7]-A,MO*N+V(#[K#I+@>W!^@-2]M#6DU>S*FN^/XK
M^TDM4B^T(T:HT>,1H^<DKT..@YK@[O5'N69%\N 2$@Q6Z;5!//;KT_*H+>QO
M-08K$'DR0C>6.%R<*<] /<UUNE_#^YEC-Q?O]EM\ND^P@-"RC"L7;Y2"?2N;
MWI'=>G35CCXHY[N5((E*R2\1H@RQ8GICZ>E=)I'@?4[_ .?R_)9D:2(.-SEE
M."F!]TG_ &JW9/$O@SPP)(K(+?W0V/)#9\('0??\UN1SUQUQ65-X]UOQ!J]C
MI^GP6FGP3L<IYA"3AATE;K^(]:M4S*6(;^!&VMOX-\(W:_;KL7%Y#*94A11-
M-MVX:-@/E SD^HK2\(:W!XJ\4VLFFZ6UM8:-;2R0YD#,_F?*%(_AZ$XJ%O ?
M@WPE8M?:E&^HWTG^K@$G!<C)5/;KR>W6M_X=>'S9^$KFY5/L5QJTC3 0]8$/
M" 'O@<_C6T58Y')O5LTM$\2:KJ6HZC;7GAVXLTMROEAL%G!SSGH>G:M*ZG6&
MVGG-A<V^V-B9$P<<>@/)K*T+PEJ6E2WS7'B*\N?M$@97/WL 8YSW^E;7]G7L
M<$WE:C/+*T96/S@-JD]&P/2FX):)DKU.<;54,KK)K%S"-HROD']V2 ,'W)-;
M-GXFTM$M[7[3*\NT(-T39;&!G]:;I]AJ-O=^;JNI03QD<Q;0 " ,$$]^":U_
MM5@'!^T6H8?[:YJ.3E>C'*3>Y<%+4"7=NWW+B)L],.#4PP1GJ*T)%HHHS0 4
M444 %%%% !1110!!=?ZG_@2_S%"?\?DW^ZO]:+K_ %/_  )?YBA/^/R;_=7^
MM("8TU45!P,?2GT4P"BBC- !BDJK=7L-FL;3N4#N$& 3R?I3[>YCNK=)X6+1
MN,JV",C\: LR>EJHE];N@<R! 20-_P N<'!X/:JLNO:;#=-;/>1+,HSL+C.,
M$_C@#-*Z&HR>R-3.* P-<9J>N0:B]G=Z3XC6W1"2T2PF19LC.#QGL>E<M#\2
M==@U&>&[T^*2VWGRI8P5PO;BIE-(UC1E)71ZY1FO*]/^)U_'YS:I:0%G?,,4
M#8*KWR3U-;D'Q'L)1!OMI(O,;$A=QB(?WC[4*<6$J$T=QFEKF-#\5)J]]=0O
M'##%$X6%_/#&7/?;VKHDECD#%'#!6*G'8CJ*I-,SE"479DM%,9U1=S,% [DX
M%.R/6F2+129STI: "BC-% %>'_C[G_X#_*EM_O3_ /70_P A20_\?<__  '^
M5+;_ 'I_^NA_D* )64,,$ CWI0*6B@ HHI"0!G.!0 M%-W+V(S]>U-9T7 9@
M"3@9.,GTH DI,TA( ))X'-0FYA$8?S!L(!!P3P>E $^11FN>NKW6K*XN)GM[
M6:T S$B.5D;V]"3Q4&C^,!JFG7-T=(U&!X%):%HLE^<84]S2N5R.USJ:2L;3
M=<-]IL5W<6-S9F1B!#*F6 '<XZ5H"[B(@^8CSON J<GC/^<T7$TT6:6LZWU>
MPN;M[:&YC>5"0Z*>A':KX8<X(/K3!IK<=129%&10(6BDR/6C(H 6BBB@"O:_
M\>J_[Q_F:*+7_CU7_>/\S10 V;_C\MO^!?RJPRAE((!!&"#5>;_C\MO^!?RJ
MU0!Q-QX'%A>37GAYH8%GYN+"=2;>8YSGCD<_A7G7B*S^($^I@ZO;JEA$CHOV
M6 RP%3V*#KGL3TKWO%-)P,_C2:3'<^=/ @TO3-2G2^T=+W>P\M'ML21$=-N[
M''M7?2>'+S7-3>]M?#\=@7_Y;WQ7 '8B-?;WJ[XS\;>$=.1K>Z@@U2]Y_<1@
M$J?]INU>/:EXOU2^ED^P22:7:,NW[/:RMMQGN3_2AR2-8N3?NH])\0S:!H#6
M]KJ.J_;=0N_DN[PX9H85Y*(HX3=]W'US4-]\:K2VB$&CZ,[1H-L;3OM7 Z8
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MKC"/4AXB70\"^UV@7'FH3S_&*0W]F4&9H\\9^<5[]_PI_P $_P#0('_?UO\
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M_P#?NK4%U(>(ET/FLZG9 G-Q$/\ @51'5;'!'G1[C]:^F?\ A7OA'_H 6/\
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M.-HQV@<$\/5D[\Q\J?9X?[HI/L\/]U:^K/\ A ?"O_0"L_\ OBD_X0#PI_T
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M(=44HI7/0$Y_#%8DMEX@T6>QT>$:AL9PB16+*LC6\,"@X8] TCY_"O9$C2-
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G8M_$Z^*3)JTE\]FEC&A,K*J"; #  $[@3DYX(KOZ** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #, EH# 2(  A$! Q$!_\0
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MB[,$40M_,D$A&-F\[G/X\DT <EH'B^ZO?$<T-Y*/LL\C1V4:Q8\T!B!(AZE
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M &%=>+[FUU>[LH;)KR1)I%53(L818XD<\X.<[OS]JKQ>,;R[U*U%A LEK<W
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M'@;3&1D:XNW@PRP1&0;8 SAV"<=R.^>.* "3QSIPN[2%(;IEF:=96,14VYB
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M;75T\D)CSM,8#-&^Y<@+QSUQC/>FM\/],>7[09[DW?GM/YY$9.64*PV[=N"
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M0':?[G]35Z;_ %+_ .Z:H^'_ /D!VG^Y_4U70S^VO0TZ***DT"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"";_CX@_WC_*IZ@F_X^(/]X_RJ>@ K(U[_ (]K;_KYB_\
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MM[4 6)O^/B#_ 'C_ "J>H)O^/B#_ 'C_ "J>@! *YKQ9<W4,-L+:W:4>:')
M)P5Y X]:Z7-4VGD<EHD5HU]>K?2LJJYE:]C2E+EDI-7)[=WDMHW=-CLH)7T/
MI4QJ*&594#+^(]*E-7'8A[A1115""BBB@ HHHH **** "BBB@ HHHH ****
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MW6I=@NHIX8I =HD&55^"?PJ02QEBH=2P[ UC7.G7,\KMY48,JH Q;F''I_\
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M_P ZW4)/9',ZL%HV7*6J7]JV'_/W'^=+_:UA_P _<?YT_9R["]M3[ERBJ?\
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M;W&KRZ1/=RZ*T5W&<1VAG4F3ISNZ#O\ E1SR[A[*'8D_LNP_Y\X/^^*4:98
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M2.?[.3OCE?:'_N'&/QJ:+4YY/M43P+'/%")D&_<&!!QGTY%0:GI5E'I]U-'
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M+UH1%Y:[ Z%SAG! .0.A'/K6K5./3[6WN%ECB ?&P$DG:,=!Z=!5R@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %< E,# 2(  A$! Q$!_\0
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M2^3;0,$ED3[[M@$J#V !&3U^E:U8&OM?Z997-]I)M_M$C*-ET<0AB0N]B.0
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M["#E\CMQQ]2*B\/RW,C7$<DLCP08C0O@ELC<#]-I4?7-6M.L?*:2YE0"9UV
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MU^^A;'\1(.!Q4UYIFDS($ODC=>H$TG^)K.N;>R2U%KI%W/#-D-&EI(6'7OU
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M35=.\A[QHO*#L?E;!Z-CD$=*R;]K_597M[FRN[(H D-S"=Z^8>"& /S)G!Y
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M,U?HH 0# P.E+110 4444 %!Z44'I0!#!_J$^E%$'^H3Z44R"O=7-O:2 S7
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M\BY.#@=J@M([U9K2:9)_.$4L:LP_BW?+N_"FZSTT#V*UU.IVO_SU/Y"C:_\
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MBT445J0%%%% !1110 4444 %%%% !1129'J* %HI,CUHR/6@!:*3(]:,CUH
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M** L1^3'_=%'DQ_W14E% 6(_)C_NBCR8_P"Z*DHH"Q'Y,?\ =%'DQ_W14E%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_C_WC4E1Q?Q_[QH$24444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $[
M5'!_J5J3M4<'^I6@74EHHHH&%%%% !1110 5B:YXCM-$ 1]TURX^2",98^Y]
M!4E_+JDUP;33XEA7&7NY>0N>RKW/Z5S.JVUA:226EL\EUJCD&>[D)8QCTX[^
MBBD-&1J>HW>K7"F[WO,Q_<6D62$/&.!U;G//I6GIWAD.P%U$MQ==6AW?NX_9
MV'7Z#K4\*:;H%J%GE-JK#YAC-S-GM@?<'MUK+O/&-[.K6NF0)86P'RXYE;^@
MS^= _0[:WM['3IHQ<7$376WY <+M'HB_PBI-1O+=-B[][J<E$&XX(([?6O*
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M% !1110 4444 %%%% !1110 4444 %%%% !VJ&*1%B + 'ZU-2<9H$-\V/\
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M%&!0&IR?@F.065[>W:F.>[NF8AQ@E1P#@^^:ZKS8_P"^OYT[BC H'J-\V/\
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M["BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
..*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $H G # 2(  A$! Q$!_\0
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MQRS1O'.T\<JGYE8YS^'-">'[=8KU7GGE:\0),[MDG QD>E9O_":Z;_T$(?\
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M)_C4O#XE[I_C_D:+%X%;273JNBLNO8ZFBN6_X373?^@A#_X#R?XT?\)KIO\
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M_EZ]=>M_P*9\.6:7+POJ+@PVWVB9A#G:, X'/)YIK^'(5TP7)O"LCQ&:-64
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M?]]"E_X0_7?^?%O^^A7H?6:/\Z^\\CZEB?\ GV_N9A45N_\ "'Z[_P ^+?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **JZCJ%OI=D]W=,5B3&<#)YJI>Z];6FAC5E5Y8&"[<<8W'&6)^Z!GD]
MJKEER\UM"/:1Y^2^N]O(U:*R/^$ETR.W\RYN4A9<!TY;:2N[J!R,<Y'%1#Q9
MI?VFXA=KB/R8XY"[V[@$/]T#C)/MUJ2S<HK$D\7:'&T:F\8F15==D$C<'. <
M+P3@C!YXI5\4Z69 //+*XC,7EQN[/O!(^4+D< _3OB@#:HJA>:S8:?<QV]U,
MT3R E28VVG )QNQC. >,YJB/%^DR36L<+SRFXE\E2MN_RL5W MD< C!!Z4 ;
MM%<U:^--/N!.'!C=%#1Y#%),Q"3AMN <$\'GC.*EOO&>CV%I<3R2R2&WCWLD
M4+MNQC(4XPQ&>0#QWH Z"BLB'Q%82W'V<NPE,K1HBQNQX Y8!?E'S <\>]+=
M>)=(L[V:TN+O9-",R QOM7Y"^"V,9V@G&<\4 :U%9">)](DDBC%RP:4 KOA=
M0,],DKA2<< X)[53D\:Z0#:O%))+#,Q#.(G!1?+9U;;MR5(4\@8_*@#HZ*PK
MWQ7IMO9&>WD%RQ<(L:Y7<<KGDCL'!]ZE?Q3HT7F^;=F(Q/Y;B2)T(;!('(YR
M <8Z]J -BBLRRUZRO;G[,CGSRT@"*K' 5BN2<87E3U_6J%WXM@LI)A):RLD<
MTD6Y#G(159FQZ?-C\#0!T5%4['48[^:[6%3LMY?*,G9FP"<?3(K*_P"$NMD=
M99[:>+3Y))(X[QL%69 S'@<@$*V#WQ0!T-%8D_BG38H%='E9Y(FEA1X7C\P*
M"< LN,X!-+'KS26%]<+9LTEJX7RE?E@55@<_\"_2@#:HJAI^JP:BL\D)'DQ/
ML#[A\V.IQV&:35-533(8)C!+-'+,D6Z/&$WL%#')Z9(Z9H T**R-4\0V>D75
MM'<[O+FWYD12^S: >0H)[_A1)XGT>*6:-[P P@EF\MMIQC.UL88C(R 3B@#7
MHK-37M-EU(:='<%[K+ HL;G&TX.3C YXY-4[?Q=ICM=I<2-;R6TTD15D8[]C
M[,J<8;DC@9(R* -ZBN<'C+3FU%H$W&V2!97N-C]6<HJ!=O+;@1CKGC!JU_PE
M>BX!^V'!B,I_<O\ *H..>.#GC!YSVH V:*R)_$NG06=I=!I98;JX%LACA8E7
M.?O+C(QCG(JO9^+]+N+:62:1H'B;#1M&Y)^8J-O'S<C^'.* -^BH;6Z@OK6.
MYMI!)#(,JPXS4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !110>E #)H8KB)HIHTDC;JCC(/X5!=60GL3:PS26@P KP!<J!V ((
MQ[8J>.1)HPZ,"IZ$5F^(FO$T69K!IEN 5*^3'O8\C('!QGIG!QUIZ["23]Y&
M=!X-M;:_66&5TA2R-LHX8[BQ)<Y!&<$CIC!IQ\%:<;,6IFN3&(T3!*GYD.5?
M!7&1DC'3':LR6Z\4.[P1P7D;E99 ^U655,2[%W8Y8/NK/N=2UZ/Q!<:?:W]W
M(\$'EPJZJ1-)Y8)W87@@[CG@=!2&=='X9LHRAW2%E\KD;5R8R2#@ #^(]!4"
M^$K&"6&>WN;JWGBVA)4=<X (V\@CD,:R((?$ES:QLVHWD&RVGD#/$J'S 1L6
M3<N2/O= ,U;BFU;4_#-A?[)5GN;N.X\O8"882W Q[+@GODF@"_J7A2PU75$O
M[AYO,4 ;5(QP"!U&1PQZ$ ]ZD'ANT2:.:*:>.2-XW#*P_@38!R.A7K_2N?N]
M4UJS\&0R2_:TO'NU@,CX6212?O %?DSZ$<54L[OQ1<Q"2"[NI838[K>4P?ZY
MO*;[WRC:_F8QG'3IS0!T">"M.C7RQ<7?D8'[DN-NX1^4&Z9SM]\>U.D\&Z=+
M%-"\UR;=U<)%O&V$O]YEXSD^^1R:QKU?%=LX@AN;I[<2\7!C#R9,<9&0J\H&
M,@/ Z#FG:K_PE$%HTEHU]+<RW;E NW;&@/RC 4\$=R?QH W8?#EK#J(O8+RX
M6Z+,975E_>@XRK#' RH/&*K7/A"*_P!7U&[O+J9K>Z966W0@*I$/E;CQG."W
M?'M7/WD6KZ'/<ZO!;R#R5?"8!$VZ?A/QR#^%;FL2Z[8V5FMJ+FYE-G,DC1(K
M'SRJ^6QXX .[GI0!?NO#5K<7+3>=. P0M#N'ENZ#".>,Y''0@<"J>E^#K6QM
MK07-U/<7<4*P^:S 9 B:/: !T 9B._/)-9%W<>*0TZ0_;3"+D;IQ'A@A5OE1
M-I) .W)YR#VYJQ:6^M3^+;"6_%W(MO(Y+>6%@"&# 8=]Q8MD9XH OQ>#+07M
MW(\DAAEM[>W15;E1$0<GMDD#GVIJ^ ])$<L9DNF61Q(1O PRY*G(')4G()SR
M!G.*R9H?$%G%=16\NK-F[G97"JY+$ Q 9'^JSG/IZBKVM7FM+J=E:VS77GM:
MI(4MD4Q^;O .\D<)C- &M#X:M8=0M[P3SEH)))54E<%I"Q8DXS_$>,XZ<4V/
MPW!]KGEG<NK32RQJ.,"1 K*?7H3^-8,R>*HEL/\ 2KK]\\K3.(P_EON 1=H7
M[FW/^-)>2>+UBG ,ZQP3^3YD2 O(GS,)% !SU1>G9J .ETO1!H\-E:6=S(+.
MVC92CX9I2>A9O:JDGA*P</'+<7)M"9#';%QY<3."K,O&<X9L9) SP*R+VT\3
M7$-T!=WA\R)H56,*BX,/WQQD-O\ ?C-2ZM;WC>'M&DBAO[F\AC&(9HRPD?:!
MB;!&WG^+MR: -.\\):;?:FM[+)-YJ1^7M#+@?(4],CACQG&><59MM#$4&HQ/
M.X%W(/FCX9$"JH7/X'\ZYE++5%U&=+>UNO)-['.\\J%74^9EE!S^\0 G!XP,
M"ND\,2:A)I)_M)9_/65E#SC:TB\?-MP-HZ\>W>@">UT2TM9+I@&D2Y"JT4@!
M1548"@8Z?7-)J>BQ:C8PV:7$UI#$Z.HMP@^Z0RCE3P"!6G10!F7&@V-Q(7,?
MENRR*QC 7<7&&)XY/%4'\&:=)')"TMR8"K".+>,0E@-S+QG)QW)'6NBHH R-
M,\/6NEWDEVDT\UQ(&#O*P.[<VXG@#O5*X\$Z;=O<&>6YD61WD1&92(6=P[%>
M.[*IP<CBNDHH PSX6LC;F/S9E?;%MD3:I5HW+JP 7;G<Q/3!]*8WA#37LKBU
MD::07";979@68[B^[IC.XY]/:M^B@#*_L& :;;V8FE7[/*LR2HJ*V\'K@+M[
MGM52Z\':9=P)%(9OW8.QL@E3OW9P1@\^HQ7044 06=JEE9Q6T9RL:[0=H&?P
M  _(5/110 4444 %%%% !1110 4444 %%%% !1110 4444 <Q9^-;.XU6]LK
MB%K7[/=+:H9'&^1V. =G4*3T/0T[_A/?#OG)%]N.YDW@^6VW!#$9., D(V![
M4MUX'T>]NKBZN/MDES,RL)C=/OBVMO C.?E&[G K/7X;:4DURR37 C:!(K>$
MRL4B*HZAR,_.WSD@GI0!,WQ%T,SVQAGW6KB1IYG5D\D*BN"01DA@PQ3S\1_"
M_D0S#42R2C(*1.V/FV<X''S<?C3+3X<:!#I\=M<QSW;B/RWEFG9F?Y GKP %
M&!V[5+_PAWAS3;6-9O,2,&*-7FN6R2)0Z DGD[\?RH D'C_PR9K:'^TT$EQ&
M9(T*D' )&#QP<JPQ[&H4^(>@SRV:6\EQ,+J0Q@K WR?)O!8$9 *\@TRZ\&^%
M;.\AN;@FWE82(-UTRB3)=SG)YQN<^U6SX+T*XBC9$EVX3:\=PPRJQ>6.0>04
MX/K0 S3?&^EZUJEE:Z5(MU%<>>LDJG'E-$$.TCWWUTU<]HW@G1-!N(I[&&82
MQERK23,_WE53U/HB_E70T %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 44C,J*68@*.22>E0-= L4B0N=NX-_![<_X4TFR7)+<L5 UW&"@3,NYM
MN8^0/7-1A)7:-Y9#N4<I&<*3_6G(BQJ%10JCL!BKY4MR'.3VT%B:=W/F[%&X
M[0G/'O5BHD^]4M3+<J&Q!9@K:H&B$1Y^0=N:GJM8F,62%&8ISR_7K4[ND<;2
M.RJBC)8G  ]:)?$PI_"AU,\F(3&;RT\TC;OVC./3-$4L<\*2PR+)&ZAD=#D,
M#T(/<5#+J-G H:2ZA4'H2XYY"_S('XU)99(!&",@T    # '84P31F8PAU\T
M*&*9Y .0#CTX/Y4U[F")MKS1JVY5P6&<MPH_'M0 ^2..:,QRHKHW56&0?PI0
M H    X %+10 444U9$9F574E3A@#T/O0 K*&&& (]"*6FO(D>W>ZKN;:NXX
MR?0>])#-%<1++#(LD;<JRG(- #Z*:[K&A=V"JHR68X %.SGI0 4FT;MV!GIF
MHOM=OYR0^='YCL550W)(&2/J!4U !1110 44R.:*;?Y<BOL8HVTYVL.Q]Z22
MXBBDBC>15>4D(I/+$#)Q0!)1110 445 ;VV'FYGC'DL$DRV-I., _F/SH GH
MHIBS1O(\:R*SIC>H/*YZ9H ?13)9HX(S)+(L: @%F.!R<#]34-MJ%G>2/';W
M,<KH2&"MDC!P?UH LT45#/=V]JK-//'&%7<=S8P,XS],T 344R25(8GED8+&
MBEF8] !U--@N(;E"T$J2*#@E3G!H EHJ)[F".58GFC61AD*S $\X_F0*EH *
M*C@GBN81+!(LD9SAE/!P<&I* "BBB@ JIJ<5Y/ITT5A.D%TXPDK+D)SR<>N,
MU;K(N/%.A6EQ=6]QJEM%-:A3.CO@H&(49^I('XT <O=:CK^@ZPXO=3DO8;?2
MY+^6WBMT'F.K*-BG&0.3[U2E^*D\4: Z?8N^YQO2\)CE"[3B)MF6;YL8P.17
M33^.O#D<VV.]CGF^SB=?+'WHRVWANG4=,]J?)K'A,W%O>O>6/F0RM:0R;N%<
MGYE';J* .=M?B'<133Q7$,:B-;B;==2E'949@J1JJ'<1MY[@>M0:+XMUOQG>
M11V+IIA,$A<#$J;DE3D$CNI(]LUU%[XT\*V,<TLVIVI^SNJ2;!O*%VV] ,]>
MOTJ6'Q1H$>=]W;6K+)-&H<@9$9(8^PX[T ;%E%-!8V\-S.;B=(U628J!YC <
MM@=,GFIZQCXCM);K28;'_2UU(N4DC/"QHI)<^V<#ZD5LT %8GBG3]1U+1O(T
MV4I*)HW=!,T)EC#99-Z\KD=Q6W2!@6*@C(ZC/2@#S>+PGXK656N]7F-J+-XG
MCBNG9Q+ARC@]21E4QWQGK6*+#QI/JVA&\_M7S+B!IKEX7=8H9WS@$9P%7"DJ
M>?2MSQK\0-3T36VT?3[&(2;%<3S'((/HM>8:[XG\4:CJ'ES:Q<B+LD+^6O\
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M>H3>4A*36\$WFQPR3-R!,C@9_P!T,/QH'AG6U:Z=[N65WF#,IN=L<\?F;MF
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M,]\&J%I\36MYK]M1M"UG'<2-'<1R+B.W641$N <C!R>>M%P.Z_LF#_GM>?\
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M--71SRBXZ,O5S,WCKPZ6O+66>9W@D6WF@^RR,S%\@ +CY@<$<5TPSGBN<M/
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MSXWM+)M'&26Q3L(W(='@4QFYAE4&:<$9P2J+D8_&L_3HK:[OW#Q,L94[%&2
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ME]I(D*/W*?E2>4!_$?PXJF\>JF0H+VW!QD?N>M0O;ZUVO8/^_>*?L(]U^/\
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M9V0SUQ !FE8=S2@MH+>XTUDLTD@9HF:Y=N"2>01T_"JUJ"GB.0-$(2!+\@X
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MDP=1-N*.SHHHKUCB.&^(OW=/^LG_ ++7"UW7Q%^[I_UD_P#9:X6MH[&4MPH
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M,1+&=BIN,B\CWXZU2L]B7=;DE%-1UD0.C!E/((/!IU(84444 %%%% !1110
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M &__ *U \%Z2K1L!."F0").QZBI_^$OT#_H)1_\ ?+?X4?\ "7Z!_P!!*/\
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M^@E'_P!\M_A1_P )?H'_ $$H_P#OEO\ "E]3G_(_N9#S*DVVZJU\T"^%[%0
M'GP/5Z</#5B!C,I'H6IO_"7Z!_T$H_\ OEO\*/\ A+] _P"@E'_WRW^%5]5J
M_P C^YD?7Z'_ #\7WH:_A/3Y$9'>X*MU ? ^G2HCX+TDNK?OLKT^?_ZU3_\
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M/^?VV_)JZG_A+] _Z"4?_?+?X4?\)?H'_02C_P"^6_PH]C7_ )']S#ZUAO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5'/<0VT9DGE2)!U9VP***:
$!G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $L G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^HS/$)Q
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M )6*6)G[946E??Y6_._3MJ;U%(2 ,DC'K074+N+#;ZYXKF.ZXM%%% !1110
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M4>3;(=_\*C')%='U2KM8Y'F&'2OS?@^IT]%<]-XED@U!X3:J85GC@)\SY\N
M0=N.@S70UC.E*%N;J=-*O"JVH/8****S-@HHHH **** "BBB@ HHHH ****
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M']EF8V5I;/+$\T+SS%5V!<D=,[LD# ZU)IOB:^,B6I:)YPNZ5[J7:-J!=^T
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M)]31+X/U*34)I8UM(X\R^40S;E5HPBICH%7YOSH Z5].TG685F6--LVR9S&
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MU?29?.1K4REHQM.3MSC/XU>BC$,*1+]U%"C\*[86F@DX&G\^TQ_QI?L6A_\
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MW&0N[ S]X@9('O0!E6-D]G;B'<[@'@D'BK.UO[K?E5]]6AB,AD9DBCVAY">
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MI[Y_Q/YU2HH OB/3!"80L8B)#%-IP2,8/Z#\J'CTR15#*A"DE>",$]>E4**
M-"-=-AD#Q+&C#H57'_Z^M66N;?RD/FC!SVK&J5_^/>+ZM0!H23VLL;1O+\K
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M@8!2Q*S \#J>O04^1=/B&9&B0;=V6EQQZ]>E8T_A&&>*6+[9*B2H0Y51N+$
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MO\JO5=7^)+U?YLSP_P#!AZ+\D%%%%9FP5Y5J_P#R'M3_ .OJ3^=>JUY5J_\
MR'M3_P"OJ3^=7#<F14HHHK4S+45_+#;^0FT+AQG'/S  _H*D?5)983%)%$Z_
M+MROW<+MX_ 51HH T1K5R%<;(BS%\.5Y3< #C\A2OK5RP&(XE;=N+*N"S;=N
M3^%9M%*P7-*VU>6.Z$CX"$KNVKG@# 'TJ.]OHY[N%XH5$,*!$C8<$#V]ZI(A
MD=8U^\Q"CZFNANM.L[F>26'S0L1961<9<(H^Z,>I]Z!F=_;$Q!0Q1&':$$6.
M  <]>O4FJ4\SW,\D\IS)(Q9CC'-;#Z+#B7RA,7 3",P&S=@$$XPQ!.,<4^;2
MK:U=Y$\Y1'YN1, 2P  #8QP"QQ^%%T&IF#47\F*-H87,0PCLO(&<XJ3^VKS"
M#<OR2-(..K'_  R<?6M5M%M9;TH(+E$5UA(5AP0N6<G'3^=5VT^"2T4%),PV
M_F?+QNR222<8R%V\<470:F9)?,]K]G2*.*,D,VP?>(& 31)?NUOY$<<<*$AF
M\L8+$="32W]RERT(CW%8XPF6&">3SU-5*8B_!JT]ND2QI'B-MYR,[CC'/YTJ
M:O,D2QK%"-H5=VWG:IR%^E9]%%@'22-+*\C?>=BQ^IIM%% !0>A^E%!Z'Z4
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M*Q8H_L6'.?W.<YSY7>JY;Q  <BV/[M> O);C//0=Q^1J%6\0+"EN-@<H?WI
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M^9%M3))V]AW]Z<-68J&\R'!&<X'3UH AO;;6Y9(S;W"H&@,<N&QAL\.H]?\
M&F[?$3I*C&!5VX3D9/RXY/UYS4S:SL8!I8 6.!D#KZ4'62&9?,BRN,X7.,T
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MK_(R_P#A'?D1&M)&5&9E#+D9( _I4!\* \"&X QC _'_ !-;?]GR?]!/4?\
MO_\ _6H_L^3_ *">H_\ ?_\ ^M1R0_F_!A[6K_)^*_R,4>%=JX\BXS@Y..O
M']*O6VE7%K;QP1P2[$&%R,G%7/[/D_Z">H_]_P#_ .M1_9\G_03U'_O_ /\
MUJ.2'\WX,/:U?Y/Q7^1!]ANO^?>3_OFC[#=?\^\G_?-3_P!GR?\ 03U'_O\
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M1_[_ /\ ]:D.F.RE6U+4"",$>?\ _6IJ$$_B_!B=2JTUR?BO\B71?^0)9?\
M7%?Y5>J*V@2UMHH(\[(U"KGK@5+6<VI3;75FU*+C3C%]$OR04445!H%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $/ 4X# 2(  A$! Q$!_\0
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M2GU"\BTZ:QE<PJ[BT:W88W$ DPPI[]2>^!UH ]!HHHH **** "BBB@ HHHH
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M055@#AP" <-GGGK0!T=%%% !1110 4444 %%%% !1110 4444 %(<45SNO\
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M:Y;5_P#D*3?A_(5U-<MJ_P#R%)OP_D* *5%%% !1110 4444 %%%% !1110
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M8K*2!LPV0002>Q&.>HH [NN6U?\ Y"DWX?R%=37+:O\ \A2;\/Y"@"E1110
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M;7,=U& Y7$B'*GCK]* /)+;4?$EGJEBOVO7X]%N/$-G;VIUC*7,JF.3SE8$
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $> 6(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WF=I$@D:)
M!)(%)5<[0QQP,]OK7-6GCO2I-0_LS4=^G:AP#%,0R@DX'SJ2HR>@)!/I5WQ2
MUV=#EALI1%/.K(':W:90-I)R%((SC /J1Q7->%HS<7"Z;+#"FGB$EK5-$>VC
MD/RX+,Y(..>."<^U 'H=% Z44 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 )116-?Z\+:[:VM[6:YDC3?+Y>/D'X]
M3[4TF]B9245=FS16-=:\D(MU@MI9YYTWI$/E(7N3GI3?^$ABDT^.XB@=I))1
M"(B=I#^A/:GR2W)]K"]KFW16/'KB2VUJZ0L99Y3&(L\J02&)/H,&M<L ,D@#
MWI--;E1DI:H=142S1L6"NI*\D ]*5)8Y5W1NK#U4YI68[H?16;?ZO%8B':HE
M,DRQ$*P^7/<U?#JQ(W#(ZC/2G9B4XMV3'_A13#+&J;RZA?7/%5[K4;>TL7NY
M&W1(,DKSGZ468.26[+=%9ZZ@SW-O'';L\,R%S+D83T!%6Q/$9#&)%+_W<\T-
M- IQ?4FS1FHGFB0$O(J@=<G&*>&# $'(/>D.Z'4444#,7Q+86]]H5SY]BEZT
M"--% X)#.H.!@>M</X( M_%OD^58;C S?Z+9/$VPA&5R2QPIW$8P#E3[UV_B
MJRN-0\-7\-K-<PW'DL8S;/M=F .%R/7I7.^#S!/J22,_B%[J.#:RWYS'&>,K
MQ_%]?>@#O:*** "BBB@ HHHH *XCQ-X]G\/WUW'#X>OKVTL(EEO;M6$:1*W]
MW/WR!R0.E=O7E7CP^(M9\1Q:6WAW4+OPQ;[9)DM9$0WLG!"L21A >W<B@#9U
MKXARV.MV^F:3H<NK336:79*7"1;58D*,-U)QT'/M5A/'G_%5)H\VF-#$9%MI
M+AI@2DQA\W;LQT"\;L]>U<MXWT&;4KR]$?@=KF[O;".*QOX91FWD Z/E@$V]
M01UQCG-;6N>&6FM='LTL%FUJ]CCM;[55C^:.%5_>MO[,PRH[_-[4 =7X>UEM
M?TH:B+9H+>61_L^XY,D8)"OC QNQD#G@BMBO.O!:>)8?%E];7T=Y'ID,<B;)
ME A0B3$ AQV\KK[]>:]%H **** "BBB@ HHHH **** "BBB@ HHHH **** $
M-</J*0V^MZD;NXEM]\:R0,C%0Y QVZD'M7<5%)!%*09(U8@Y&1G%7"7*958<
MZ1R$TK)'I5[=71M+TQ%3(\>Y"/1NF#4^@:<MYI=PUP799+EI8Y/N-QT8>AZU
MU,D,<J[9$5AZ$9I^T;=H QZ4W4TL9+#^]=LXX2?9=MS:8C@\W[);N_S! 22\
MG)YR1C\*OR7LM]X1N9Y<;_+D4LHP&P2,CZXK;DAMDM3')'&(%'*E1M 'M59=
M0L5/D [54A,>60JDXP"<8'44<U];#]GRZ7W.9GLQ;>$(Y[2,J\ZQFX<9RR]\
M^W/Y4_3D'GWK:?-#N^RD>5;*VW=_"<]-WZUV#-%%"Q<JL:CG/  JO:S6ODLU
MOM5 3N^7;M^H.*?/IL3[%76IQ"#3OL.EF#!O?/3SO[V<\[OQZ9K6>[AM-<UA
M9G"-+"FP$<M\N./6MM;S3_+>=0F-P!_=\DGI@8R<]J5KVPWQ.[(68?*VTG /
M')QP,\<TW._02I6V9RB[1HNA?:L_8-[>?Z9YVY]LU8NX].FT#4SIT;F)&#\C
MY-P[I^%=1--9PYAD* ;"Y3&?E'4X]*L)%&L>Q44)Z <4N?J-4KW5SCD,?V[3
M/[/*X^RR^7LZ;\<_K5!/L9TNV^S%O[:\T$XSOWY^;/MBO0$MXHP L:C;TP.E
M MXA(9!&H<_Q8YI^T787U=]SEGLX+SQ+J2W""0);H0IY ..OUK3\*L6\/6I)
M)^\/_'C6OY:;BVT9/4XIR(J#"@ >@J)2NK&T*?+*XZBBBH-BAJR"31;Y/M/V
M;=;N//SCR\@_-^'6N#\%/:7&NVS6EI86+0V;*XLEE_TK.WDEHU  QD<DY/6N
MZUN)Y]"OX8HQ+(]NZHA7<&)4X&._/:N8\("^2ZABN6\1D+;[2NHPPK$",=TY
MSZ=J .XJK/?6]LX2:0*Q&<')XJU7.Z]_Q_)_US'\S0!J_P!JV7_/P/R/^%']
MJV7_ #\#\C_A7+44 =3_ &K9?\_ _(_X4?VK9?\ /P/R/^%<M10!U/\ :ME_
MS\#\C_A2?VM9?\]Q^1_PKEZ* .H_M6R_Y[K^1_PI?[5LO^?@?D?\*Y:B@#J/
M[5LO^>X_(_X4O]JV7_/P/R/^%<M10!U/]JV7_/P/R/\ A1_:ME_S\#\C_A7+
M44 =3_:ME_S\#\C_ (4?VK9?\_ _(_X5RU% '5Q:A;3R"..4,YZ#!JW7,:/_
M ,A./Z-_*NGH **** "BBB@ HHHH **** "BBB@ HHHH S]5#/;Q*!E3,@?Z
M9']<57M=)."]S(Y+2&1H@WRYSD<>W%:_%+3N[6(<$W=F"^CR1Q2,AC<DJ=JI
MM+ ,"1GWQBI)+2YEM+I2N)+G+D9X7@ +^('6MJBGS,7LT8+6EV+A;SR-S%\^
M3N&5&W:/;N30+.Y1H;5[?? H4R.K ;VSDY[X!YQWK>HHYF+V:.:GTZZCFN&D
MD65IXS$A"X8ECU//0 #\*Z)%VQA?08IU+2;N5&"CL%%%%(L**** "BBB@"EJ
M9N%TJ[-FZ)<B%C$SXVJ^#M)SVSBN=\+>+I]?NOLDMO9J\46Z22"\\S<>!D+M
M&5)SR"172W]FFH:?<V4I81SQM$Q7@@$8XK"TCP]J%MJ5O=:EJ%O<_9(6B@6"
MU$77 );GG@#@8'7B@#IZYW7O^/Y/^N8_F:Z*N=U[_C^3_KF/YF@#+HHHH **
M** "IFM;A4,C0N$ R3BH3T-:GVR,W<K&4>6;?8.O7'3\Z ,S!]&_*KBV&Z/(
MF3SBGF>7CM]?6IH[Z)(E4W%R"% P%7'X4*;:.U(ANHUE=?G9E);Z#T% $'V#
M,#,LZ-*B>8T8'0?7UJG6E%);PVLJB8-%)'_JR/G#_7TK-H **** "BBB@"_I
M'_(2C^C?RKIJ\_U'Q+:>$K7^UKZ.:6!&"%81ELG@=P*R?^%]^&O^?'4O^_:_
MXU<:<I*Z1+G%:-GJ]%>4?\+[\-?\^.I?]^U_QH_X7WX:_P"?'4O^_:_XT_95
M.Q/M(=SU>BO*/^%]^&O^?'4O^_:_XT?\+[\-?\^.I?\ ?M?\:/95.P>TAW/5
MZ*\H_P"%]^&O^?'4O^_:_P"-'_"^_#7_ #XZE_W[7_&CV53L'M(=SU>BO*/^
M%]^&O^?'4O\ OVO^-*/CUX:R,V.I8_ZYK_C1[&IV#VD.YZM25YI#\<O"$D@5
MCJ$0_O/;\?H374Z/XY\-:\0FGZQ;22-TB9MCY] &QG\*EPDMT-3B]F='1114
MEA1110 4444 %%%% !1110 4444 %%%% !1110!A^)=2M--T.X-U=R6GGHT,
M<R1/(4=@<'" GCK7%>!W@N/$L4T=ZK7)@<3(D4X&P!%CC!=0"%"EB>I+'WKK
M/%UY<6-I8R+-<06GVM?MDUO&7=(MK'@ $@%@H) Z$UB>&KK5I-?LWN;B^>6[
MMY;F^M90?*M59AY*KV5MO&!UY)H ] KG=>_X_D_ZYC^9KHJYW7O^/Y/^N8_F
M: ,NBBB@ HHHH **** "BBB@ HHHH **** "BBB@#C/BD&;P1* I8_:(^ #G
MJ?2O#?)F_P">4G_?!_PKZSTI%?48U=588;@C(Z5T7V6W_P">$?\ WP*Z*==P
M5K&%2ESN]SXJ\F7_ )Y2?]\'_"CR9?\ GE)_WP?\*^U?LMO_ ,\(O^^!1]EM
M_P#GA%_WP*T^MOL1]67<^*O)E_YY2?\ ?!_PH\F7_GE)_P!\'_"OM7[+;_\
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MW3K'Y,I[[D.W)]SC/XUMBH;21G0E]DZVBBBN,ZPHHHH **** "BBB@ HHHH
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MU_:36]LZPFYTR)4D0;0RY5_O8 _G7?ZNYBT:]D$+S%8'/E(2&?@\ CH:\_\
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MPO;Q7_S[Z;_W[;_&O,**KV%/L3[6?<]/_P"%[>*_^??3?^_;?XT?\+U\5_\
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M44 %%%% !1110 4444 %%%% %_1O^0E']&_E73US&C?\A*/Z-_*NGH ****
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M.5BT4FX>M&X>M',NX<K%HQ2;AZT;AZT<R#E8N*,4FX>M&X>M',@Y6=3\._\
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1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>20
<FILENAME>pypd-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 19:22:17 UTC 2023 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://Polypid.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:pypd="http://Polypid.com/20221231" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="pypd-20221231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="pypd-20221231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="pypd-20221231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="pypd-20221231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://Polypid.com/role/ConsolidatedBalanceSheet" id="pypd_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals" id="pypd_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ConsolidatedIncomeStatement" id="pypd_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ConsolidatedIncomeStatement_Parentheticals" id="pypd_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Consolidated Statements of Operations (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ShareholdersEquityType2or3" id="pypd_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Consolidated Statements of Changes in Convertible Preferred Shares and Shareholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ConsolidatedCashFlow" id="pypd_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/General" id="pypd_r_General">
        <link:definition>007 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/SignificantAccountingPolicies" id="pypd_r_SignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssets" id="pypd_r_PrepaidExpensesandOtherCurrentAssets">
        <link:definition>009 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/PropertyandEquipmentNet" id="pypd_r_PropertyandEquipmentNet">
        <link:definition>010 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/Leases" id="pypd_r_Leases">
        <link:definition>011 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilities" id="pypd_r_AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>012 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/LineofCreditArrangement" id="pypd_r_LineofCreditArrangement">
        <link:definition>013 - Disclosure - Line of Credit Arrangement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/CommitmentsandContingentLiabilities" id="pypd_r_CommitmentsandContingentLiabilities">
        <link:definition>014 - Disclosure - Commitments and Contingent Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/IncomeTaxes" id="pypd_r_IncomeTaxes">
        <link:definition>015 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ShareholdersEquity" id="pypd_r_ShareholdersEquity">
        <link:definition>016 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/FinancialIncomeExpensesNet" id="pypd_r_FinancialIncomeExpensesNet">
        <link:definition>017 - Disclosure - Financial (Income) Expenses, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/BasicandDilutedNetLossPerShare" id="pypd_r_BasicandDilutedNetLossPerShare">
        <link:definition>018 - Disclosure - Basic and Diluted Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/RelatedParties" id="pypd_r_RelatedParties">
        <link:definition>019 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/SubsequentEvents" id="pypd_r_SubsequentEvents">
        <link:definition>020 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/AccountingPoliciesByPolicy" id="pypd_r_AccountingPoliciesByPolicy">
        <link:definition>021 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/SignificantAccountingPoliciesTables" id="pypd_r_SignificantAccountingPoliciesTables">
        <link:definition>022 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssetsTables" id="pypd_r_PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>023 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/PropertyandEquipmentNetTables" id="pypd_r_PropertyandEquipmentNetTables">
        <link:definition>024 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/LeasesTables" id="pypd_r_LeasesTables">
        <link:definition>025 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" id="pypd_r_AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>026 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/IncomeTaxesTables" id="pypd_r_IncomeTaxesTables">
        <link:definition>027 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ShareholdersEquityTables" id="pypd_r_ShareholdersEquityTables">
        <link:definition>028 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/FinancialIncomeExpensesNetTables" id="pypd_r_FinancialIncomeExpensesNetTables">
        <link:definition>029 - Disclosure - Financial (Income) Expenses, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/BasicandDilutedNetLossPerShareTables" id="pypd_r_BasicandDilutedNetLossPerShareTables">
        <link:definition>030 - Disclosure - Basic and Diluted Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/GeneralDetails" id="pypd_r_GeneralDetails">
        <link:definition>031 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/SignificantAccountingPoliciesDetails" id="pypd_r_SignificantAccountingPoliciesDetails">
        <link:definition>032 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable" id="pypd_r_ScheduleofpropertyandequipmentusefullifeTable">
        <link:definition>033 - Disclosure - Significant Accounting Policies (Details) - Schedule of property and equipment useful life</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable" id="pypd_r_ScheduleofprepaidexpensesandothercurrentassetsTable">
        <link:definition>034 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/PropertyandEquipmentNetDetails" id="pypd_r_PropertyandEquipmentNetDetails">
        <link:definition>035 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofpropertyandequipmentTable" id="pypd_r_ScheduleofpropertyandequipmentTable">
        <link:definition>036 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/LeasesDetails" id="pypd_r_LeasesDetails">
        <link:definition>037 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofleaserelatedassetsandliabilitiesTable" id="pypd_r_ScheduleofleaserelatedassetsandliabilitiesTable">
        <link:definition>038 - Disclosure - Leases (Details) - Schedule of lease-related assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofleaseliabilityTable" id="pypd_r_ScheduleofleaseliabilityTable">
        <link:definition>039 - Disclosure - Leases (Details) - Schedule of lease liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheleasecostsTable" id="pypd_r_ScheduleofsupplementalcashflowinformationrelatedtotheleasecostsTable">
        <link:definition>040 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to the lease costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable" id="pypd_r_ScheduleofaccruedexpensesandothercurrentliabilitiesTable">
        <link:definition>041 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - Schedule of accrued expenses and other current liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/LineofCreditArrangementDetails" id="pypd_r_LineofCreditArrangementDetails">
        <link:definition>042 - Disclosure - Line of Credit Arrangement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails" id="pypd_r_CommitmentsandContingentLiabilitiesDetails">
        <link:definition>043 - Disclosure - Commitments and Contingent Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/IncomeTaxesDetails" id="pypd_r_IncomeTaxesDetails">
        <link:definition>044 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofdeferredtaxassetsTable" id="pypd_r_ScheduleofdeferredtaxassetsTable">
        <link:definition>045 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable" id="pypd_r_ScheduleofdeferredincometaxesreflectthenettaxeffectsTable">
        <link:definition>046 - Disclosure - Income Taxes (Details) - Schedule of deferred income taxes reflect the net tax effects</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofincometaxesTable" id="pypd_r_ScheduleofincometaxesTable">
        <link:definition>047 - Disclosure - Income Taxes (Details) - Schedule of income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ShareholdersEquityDetails" id="pypd_r_ShareholdersEquityDetails">
        <link:definition>048 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofordinarysharecapitalTable" id="pypd_r_ScheduleofordinarysharecapitalTable">
        <link:definition>049 - Disclosure - Shareholders' Equity (Details) - Schedule of ordinary share capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable" id="pypd_r_ScheduleofstatusofoptionstoemployeesTable">
        <link:definition>050 - Disclosure - Shareholders' Equity (Details) - Schedule of status of options to employees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable" id="pypd_r_ScheduleofshareoptionsatthegrantdateTable">
        <link:definition>051 - Disclosure - Shareholders' Equity (Details) - Schedule of share options at the grant date</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofsharebasedcompensationexpenserecognizedTable" id="pypd_r_ScheduleofsharebasedcompensationexpenserecognizedTable">
        <link:definition>052 - Disclosure - Shareholders' Equity (Details) - Schedule of share-based compensation expense recognized</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable" id="pypd_r_ScheduleofoutstandingoptionsgrantedTable">
        <link:definition>053 - Disclosure - Shareholders' Equity (Details) - Schedule of outstanding options granted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYyn91pOe7VtKs04Jlb3SPvCuMaehdfSUhtJg7vOyFoOF/AztNXIUhzx+P+epY4WtCBWdIE9zpOkAYuuw4yh598SS/DDR25UhB1vr3InT0Iv/WeMwUMCDO+Y4l9K2x3Xs422PVBz1J7zYQwrV5v8agZB4PYMfGJUC4Mjgm9z9+jJcHkWA/VMdgTvB77jxF4Vxs=] CSR-->
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable" id="pypd_r_ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable">
        <link:definition>054 - Disclosure - Shareholders' Equity (Details) - Schedule of relative fair value of the warrants to purchase Ordinary shares issued</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable" id="pypd_r_ScheduleoffinancialincomeexpensesnetTable">
        <link:definition>055 - Disclosure - Financial (Income) Expenses, Net (Details) - Schedule of financial (income) expenses, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable" id="pypd_r_ScheduleofbasicanddilutedlossperordinaryshareTable">
        <link:definition>056 - Disclosure - Basic and Diluted Net Loss Per Share (Details) - Schedule of basic and diluted loss per ordinary share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable_Parentheticals" id="pypd_r_ScheduleofbasicanddilutedlossperordinaryshareTable_Parentheticals">
        <link:definition>057 - Disclosure - Basic and Diluted Net Loss Per Share (Details) - Schedule of basic and diluted loss per ordinary share (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable" id="pypd_r_ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable">
        <link:definition>058 - Disclosure - Basic and Diluted Net Loss Per Share (Details) - Schedule of diluted loss per share attributable to ordinary shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/RelatedPartiesDetails" id="pypd_r_RelatedPartiesDetails">
        <link:definition>059 - Disclosure - Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/SubsequentEventsDetails" id="pypd_r_SubsequentEventsDetails">
        <link:definition>060 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://Polypid.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentUsefulLifeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfPropertyAndEquipmentUsefulLifeAbstract"/>
  <xs:element name="PrepaidExpensesAndOtherReceivablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_PrepaidExpensesAndOtherReceivablesAbstract"/>
  <xs:element name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfLeaseLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfLeaseLiabilityAbstract"/>
  <xs:element name="ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract"/>
  <xs:element name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
  <xs:element name="LineOfCreditArrangementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_LineOfCreditArrangementAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfDeferredTaxAssetsAbstract"/>
  <xs:element name="ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract"/>
  <xs:element name="ScheduleOfIncomeTaxesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfIncomeTaxesAbstract"/>
  <xs:element name="ScheduleOfOrdinaryShareCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfOrdinaryShareCapitalAbstract"/>
  <xs:element name="ScheduleOfStatusOfOptionsToEmployeesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract"/>
  <xs:element name="ScheduleOfShareOptionsAtTheGrantDateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfShareOptionsAtTheGrantDateAbstract"/>
  <xs:element name="ScheduleOfShareBasedCompensationExpenseRecognizedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfShareBasedCompensationExpenseRecognizedAbstract"/>
  <xs:element name="ScheduleOfOutstandingOptionsGrantedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfOutstandingOptionsGrantedAbstract"/>
  <xs:element name="ScheduleOfRelativeFairValueOfTheWarrantsToPurchaseOrdinarySharesIssuedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfRelativeFairValueOfTheWarrantsToPurchaseOrdinarySharesIssuedAbstract"/>
  <xs:element name="ScheduleOfFinancialIncomeExpensesNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfFinancialIncomeExpensesNetAbstract"/>
  <xs:element name="ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract"/>
  <xs:element name="ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract16"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract17"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract19"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract20"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract22"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract24"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract25"/>
  <xs:element name="UnlabeledAbstract26" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract26"/>
  <xs:element name="UnlabeledAbstract27" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract27"/>
  <xs:element name="UnlabeledAbstract28" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract28"/>
  <xs:element name="UnlabeledAbstract29" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract29"/>
  <xs:element name="UnlabeledAbstract30" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract30"/>
  <xs:element name="UnlabeledAbstract31" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract31"/>
  <xs:element name="UnlabeledAbstract32" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract32"/>
  <xs:element name="UnlabeledAbstract33" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract33"/>
  <xs:element name="UnlabeledAbstract34" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract34"/>
  <xs:element name="UnlabeledAbstract35" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract35"/>
  <xs:element name="UnlabeledAbstract36" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract36"/>
  <xs:element name="UnlabeledAbstract37" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract37"/>
  <xs:element name="UnlabeledAbstract38" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract38"/>
  <xs:element name="UnlabeledAbstract39" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract39"/>
  <xs:element name="CostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_CostAbstract"/>
  <xs:element name="UnlabeledAbstract40" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract40"/>
  <xs:element name="UnlabeledAbstract41" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract41"/>
  <xs:element name="LeaseAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_LeaseAssetsAbstract"/>
  <xs:element name="UnlabeledAbstract42" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract42"/>
  <xs:element name="LeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_LeaseLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract43" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract43"/>
  <xs:element name="UnlabeledAbstract44" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract44"/>
  <xs:element name="UnlabeledAbstract45" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract45"/>
  <xs:element name="UnlabeledAbstract46" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract46"/>
  <xs:element name="UnlabeledAbstract47" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract47"/>
  <xs:element name="UnlabeledAbstract48" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract48"/>
  <xs:element name="UnlabeledAbstract49" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract49"/>
  <xs:element name="UnlabeledAbstract50" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract50"/>
  <xs:element name="UnlabeledAbstract51" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract51"/>
  <xs:element name="UnlabeledAbstract52" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract52"/>
  <xs:element name="UnlabeledAbstract53" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract53"/>
  <xs:element name="UnlabeledAbstract54" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract54"/>
  <xs:element name="UnlabeledAbstract55" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract55"/>
  <xs:element name="UnlabeledAbstract56" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract56"/>
  <xs:element name="NumberOfSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_NumberOfSharesAbstract"/>
  <xs:element name="UnlabeledAbstract57" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract57"/>
  <xs:element name="UnlabeledAbstract58" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract58"/>
  <xs:element name="UnlabeledAbstract59" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract59"/>
  <xs:element name="UnlabeledAbstract60" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract60"/>
  <xs:element name="UnlabeledAbstract61" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract61"/>
  <xs:element name="UnlabeledAbstract62" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract62"/>
  <xs:element name="UnlabeledAbstract63" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract63"/>
  <xs:element name="FinancialExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_FinancialExpensesAbstract"/>
  <xs:element name="UnlabeledAbstract64" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract64"/>
  <xs:element name="UnlabeledAbstract65" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract65"/>
  <xs:element name="FinancialIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_FinancialIncomeAbstract"/>
  <xs:element name="UnlabeledAbstract66" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract66"/>
  <xs:element name="UnlabeledAbstract67" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract67"/>
  <xs:element name="NumeratorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_NumeratorAbstract"/>
  <xs:element name="UnlabeledAbstract68" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract68"/>
  <xs:element name="UnlabeledAbstract69" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract69"/>
  <xs:element name="DenominatorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_DenominatorAbstract"/>
  <xs:element name="UnlabeledAbstract70" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract70"/>
  <xs:element name="NumberOfOrdinarySharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_NumberOfOrdinarySharesAbstract"/>
  <xs:element name="UnlabeledAbstract71" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract71"/>
  <xs:element name="UnlabeledAbstract72" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnlabeledAbstract72"/>
  <xs:element name="LongtermDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_LongtermDeposits"/>
  <xs:element name="TotalLongtermLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_TotalLongtermLiabilities"/>
  <xs:element name="MarketingAndBusinessDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_MarketingAndBusinessDevelopmentExpenses"/>
  <xs:element name="DeemedDividends" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_DeemedDividends"/>
  <xs:element name="NetLossAttributableToOrdinarySharesinDollarsPerShare" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare"/>
  <xs:element name="ConversionOfConvertiblePreferredSharesToOrdinaryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares"/>
  <xs:element name="ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares"/>
  <xs:element name="ReclassificationOfWarrantsIntoEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ReclassificationOfWarrantsIntoEquity"/>
  <xs:element name="ExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExerciseOfWarrants"/>
  <xs:element name="StockIssuedDuringPeriodExerciseOfWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares"/>
  <xs:element name="IssuanceOfOrdinarySharesNetinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_IssuanceOfOrdinarySharesNetinShares"/>
  <xs:element name="ReevaluationOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ReevaluationOfWarrants"/>
  <xs:element name="DecreaseincreaseInReceivablesAndPrepaidExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses"/>
  <xs:element name="PaymentsForProceedsFromShorttermAndLongtermDepositsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet"/>
  <xs:element name="PrepaymentForEquipments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_PrepaymentForEquipments"/>
  <xs:element name="IssuanceOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_IssuanceOfWarrants"/>
  <xs:element name="RestrictedCashIncludedInOtherLongtermAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_RestrictedCashIncludedInOtherLongtermAssets"/>
  <xs:element name="PurchaseOfPropertyAndEquipmentIncludedInTradePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable"/>
  <xs:element name="PropertyAndEquipmentPaidForInPriorPeriods" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_PropertyAndEquipmentPaidForInPriorPeriods"/>
  <xs:element name="PrepaidExpensesAndOtherReceivablesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_PrepaidExpensesAndOtherReceivablesTextBlock"/>
  <xs:element name="LineOfCreditArrangementTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_LineOfCreditArrangementTextBlock"/>
  <xs:element name="FinancialIncomeExpensesNetTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_FinancialIncomeExpensesNetTable"/>
  <xs:element name="FinancialIncomeExpensesNetLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_FinancialIncomeExpensesNetLineItems"/>
  <xs:element name="ConsolidatedFinancialStatementsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConsolidatedFinancialStatementsPolicyTextBlock"/>
  <xs:element name="RestrictedCashPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_RestrictedCashPolicyTextBlock"/>
  <xs:element name="ShorttermDepositsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShorttermDepositsPolicyTextBlock"/>
  <xs:element name="BasicAndDilutedLossPerSharePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_BasicAndDilutedLossPerSharePolicyTextBlock"/>
  <xs:element name="ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock"/>
  <xs:element name="SeverancePayPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeverancePayPolicyTextBlock"/>
  <xs:element name="RecentlyIssuedAccountingPronouncementsNotYetAdopted" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted"/>
  <xs:element name="ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock"/>
  <xs:element name="ScheduleOfLeaseLiabilityTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfLeaseLiabilityTableTextBlock"/>
  <xs:element name="AccruedExpensesandOtherCurrentLiabilitiesTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesTable"/>
  <xs:element name="AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems"/>
  <xs:element name="ScheduleOfOutstandingOptionGrantedTablesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock"/>
  <xs:element name="FinancialIncomeExpensesNetTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_FinancialIncomeExpensesNetTablesTable"/>
  <xs:element name="FinancialIncomeExpensesNetTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_FinancialIncomeExpensesNetTablesLineItems"/>
  <xs:element name="ComputersandSoftware" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ComputersandSoftware"/>
  <xs:element name="LaboratoryAndManufacturingEquipment" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_LaboratoryAndManufacturingEquipment"/>
  <xs:element name="PropertyPlantAndEquipmentPercent" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_PropertyPlantAndEquipmentPercent"/>
  <xs:element name="PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <xs:element name="PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems"/>
  <xs:element name="GovernmentAuthorities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_GovernmentAuthorities"/>
  <xs:element name="OperatingLeaseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_OperatingLeaseAssets"/>
  <xs:element name="LeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_LeaseLiabilities"/>
  <xs:element name="AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable"/>
  <xs:element name="AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems"/>
  <xs:element name="IsraelInnovationAuthorityGrantReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_IsraelInnovationAuthorityGrantReceived"/>
  <xs:element name="IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable"/>
  <xs:element name="IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems"/>
  <xs:element name="DomesticIsrael" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_DomesticIsrael"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofordinarysharecapitalTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices"/>
  <xs:element name="WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems"/>
  <xs:element name="OptionsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="pypd_OptionsExercisable"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration"/>
  <xs:element name="AdjustmentToRiskfreeInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_AdjustmentToRiskfreeInterestRate"/>
  <xs:element name="RemeasurementOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_RemeasurementOfWarrants"/>
  <xs:element name="PreferredSharePreference" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_PreferredSharePreference"/>
  <xs:element name="DeemedDividend" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_DeemedDividend"/>
  <xs:element name="WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares"/>
  <xs:element name="WeightedAverageNumberOfSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_WeightedAverageNumberOfSharesIssued"/>
  <xs:element name="GeneralDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_GeneralDetailsTable"/>
  <xs:element name="GeneralDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_GeneralDetailsLineItems"/>
  <xs:element name="DescriptionOfReverseShareSplit" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_DescriptionOfReverseShareSplit"/>
  <xs:element name="StockIssuedDuringPeriodSharesNewIssue" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_StockIssuedDuringPeriodSharesNewIssue"/>
  <xs:element name="AggregateNetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_AggregateNetProceeds"/>
  <xs:element name="DescriptionAdministration" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_DescriptionAdministration"/>
  <xs:element name="IncurredLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_IncurredLoss"/>
  <xs:element name="CashFlowsFromOperatingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_CashFlowsFromOperatingActivities"/>
  <xs:element name="SignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_SignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="RighttouseAssetsAndLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_RighttouseAssetsAndLeaseLiabilities"/>
  <xs:element name="LeasePrepayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_LeasePrepayments"/>
  <xs:element name="ReceivedTotalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ReceivedTotalAmount"/>
  <xs:element name="NonroyaltyBearingGrantsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_NonroyaltyBearingGrantsAmount"/>
  <xs:element name="OutOfReceivedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_OutOfReceivedAmount"/>
  <xs:element name="NonroyaltyBearingGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_NonroyaltyBearingGrants"/>
  <xs:element name="FinancialExpenseIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_FinancialExpenseIncome"/>
  <xs:element name="TaxBenefitPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="pypd_TaxBenefitPercentage"/>
  <xs:element name="AgreementTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_AgreementTerm"/>
  <xs:element name="NonRefundableAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_NonRefundableAmount"/>
  <xs:element name="AdditionalDevelopmentrelatedMilestonesPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_AdditionalDevelopmentrelatedMilestonesPayments"/>
  <xs:element name="AdditionalAmountOfCommercialSaleMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_AdditionalAmountOfCommercialSaleMilestones"/>
  <xs:element name="monthlyDepositsAtARate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="pypd_monthlyDepositsAtARate"/>
  <xs:element name="SeverancePayExpenseAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeverancePayExpenseAmount"/>
  <xs:element name="SeverancePay" type="xbrli:stringItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeverancePay"/>
  <xs:element name="MatchingContributionsAmounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_MatchingContributionsAmounts"/>
  <xs:element name="LineofCreditArrangementDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_LineofCreditArrangementDetailsTable"/>
  <xs:element name="LineofCreditArrangementDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_LineofCreditArrangementDetailsLineItems"/>
  <xs:element name="ProceedsFromLinesOfCreditOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ProceedsFromLinesOfCreditOne"/>
  <xs:element name="ProceedsFromLinesOfCreditTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ProceedsFromLinesOfCreditTwo"/>
  <xs:element name="LineOfCreditFacilityPeriodicPaymentOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_LineOfCreditFacilityPeriodicPaymentOne"/>
  <xs:element name="ProceedsFromParticipationPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ProceedsFromParticipationPayments"/>
  <xs:element name="CommitmentsAndContingentLiabilitiesDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_CommitmentsAndContingentLiabilitiesDescription"/>
  <xs:element name="FindersFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_FindersFee"/>
  <xs:element name="SuitFillingExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_SuitFillingExpense"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_IncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_IncomeTaxesDetailsLineItems"/>
  <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_ShareholdersEquityDetailsTable"/>
  <xs:element name="ShareholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareholdersEquityDetailsLineItems"/>
  <xs:element name="AggregateOfferingPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_AggregateOfferingPrice"/>
  <xs:element name="StockOptionVestingPeriodDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_StockOptionVestingPeriodDescription"/>
  <xs:element name="ShareOptionPlanDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShareOptionPlanDescription"/>
  <xs:element name="NumberOfOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_NumberOfOptions"/>
  <xs:element name="StockOptionShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_StockOptionShares"/>
  <xs:element name="StockOptionsAvailableForFutureGrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_StockOptionsAvailableForFutureGrants"/>
  <xs:element name="WeightedAverageGrantDateFairValueOfOptionsGranted" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_WeightedAverageGrantDateFairValueOfOptionsGranted"/>
  <xs:element name="ExpectedDividendYield" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExpectedDividendYield"/>
  <xs:element name="UnrecognizedCompensationCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_UnrecognizedCompensationCosts"/>
  <xs:element name="RecognizedOverWeightedAveragePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_RecognizedOverWeightedAveragePeriod"/>
  <xs:element name="WarrantsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_WarrantsDescription"/>
  <xs:element name="WarrantsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_WarrantsOutstanding"/>
  <xs:element name="RelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_RelatedPartiesDetailsTable"/>
  <xs:element name="RelatedPartiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_RelatedPartiesDetailsLineItems"/>
  <xs:element name="ServiceProvidersInAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ServiceProvidersInAmount"/>
  <xs:element name="RelatedPartiesTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="pypd_RelatedPartiesTerm"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="pypd_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SubsequentEventsDetailsLineItems"/>
  <xs:element name="ExercisePriceDecrease" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExercisePriceDecrease"/>
  <xs:element name="InterestRepayments" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="pypd_InterestRepayments"/>
  <xs:element name="MinimumPaidAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_MinimumPaidAmount"/>
  <xs:element name="ExceedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_ExceedAmount"/>
  <xs:element name="OfferingExpensesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="pypd_OfferingExpensesPayable"/>
  <xs:element name="April2021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_April2021Member"/>
  <xs:element name="April2022Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_April2022Member"/>
  <xs:element name="AprilTwoThousandSixteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_AprilTwoThousandSixteenMember"/>
  <xs:element name="August2019Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_August2019Member"/>
  <xs:element name="August2021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_August2021Member"/>
  <xs:element name="ConsultAndDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConsultAndDirectorsMember"/>
  <xs:element name="ConvertiblePreferredSharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ConvertiblePreferredSharesMember"/>
  <xs:element name="December2021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_December2021Member"/>
  <xs:element name="DecemberTwoThousandSixteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_DecemberTwoThousandSixteenMember"/>
  <xs:element name="FirstTrancheMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_FirstTrancheMember"/>
  <xs:element name="FurnitureAndOfficeEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_FurnitureAndOfficeEquipmentMember"/>
  <xs:element name="July2022Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_July2022Member"/>
  <xs:element name="JuneTwoThousandSeventeenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_JuneTwoThousandSeventeenMember"/>
  <xs:element name="JuneTwoThousandTwentyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_JuneTwoThousandTwentyMember"/>
  <xs:element name="LaboratoryEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_LaboratoryEquipmentMember"/>
  <xs:element name="MarketingAndBusinessDevelopmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_MarketingAndBusinessDevelopmentMember"/>
  <xs:element name="May2022Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_May2022Member"/>
  <xs:element name="November2022Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_November2022Member"/>
  <xs:element name="NovemberTwoThousandSeventeenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_NovemberTwoThousandSeventeenMember"/>
  <xs:element name="OctoberTwoThousandThirteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_OctoberTwoThousandThirteenMember"/>
  <xs:element name="SecondTrancheMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SecondTrancheMember"/>
  <xs:element name="September2020Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_September2020Member"/>
  <xs:element name="SeptemberTwoThousandFourteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_SeptemberTwoThousandFourteenMember"/>
  <xs:element name="ShortTermDepositsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ShortTermDepositsMember"/>
  <xs:element name="ThiredTrancheMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_ThiredTrancheMember"/>
  <xs:element name="TwoThousandTwelveShareOptionPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_TwoThousandTwelveShareOptionPlanMember"/>
  <xs:element name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract"/>
  <xs:element name="RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="pypd_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>21
<FILENAME>pypd-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 19:22:17 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ConsolidatedBalanceSheet" roleURI="http://Polypid.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ConsolidatedIncomeStatement" roleURI="http://Polypid.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ConsolidatedCashFlow" roleURI="http://Polypid.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofaccruedexpensesandothercurrentliabilitiesTable" roleURI="http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable" roleURI="http://Polypid.com/role/ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_LongtermDeposits" xlink:href="pypd-20221231.xsd#pypd_LongtermDeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermInvestments" xlink:to="pypd_LongtermDeposits" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_TotalLongtermLiabilities" xlink:href="pypd-20221231.xsd#pypd_TotalLongtermLiabilities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pypd_TotalLongtermLiabilities" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pypd_TotalLongtermLiabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pypd_TotalLongtermLiabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pypd_TotalLongtermLiabilities" xlink:to="us-gaap_OtherLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="pypd_TotalLongtermLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="pypd_MarketingAndBusinessDevelopmentExpenses" xlink:href="pypd-20221231.xsd#pypd_MarketingAndBusinessDevelopmentExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="pypd_MarketingAndBusinessDevelopmentExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossAttributableToParent" order="1" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYyn91pOe7VtKs04Jlb3SPvCuMaehdfSUhtJg7vOyFoOF/AztNXIUhzx+P+epY4WtCBWdIE9zpOkAYuuw4yh598SS/DDR25UhB1vr3InT0Iv/WeMwUMCDO+Y4l9K2x3Xs422PVBz1J7zYQwrV5v8agZB4PYMfGJUC4Mjgm9z9+jJRlU04ZfM/kV6G5C/2Q60pM=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare" xlink:href="pypd-20221231.xsd#pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_DeemedDividends" xlink:href="pypd-20221231.xsd#pypd_DeemedDividends"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare" xlink:to="pypd_DeemedDividends" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_ReevaluationOfWarrants" xlink:href="pypd-20221231.xsd#pypd_ReevaluationOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pypd_ReevaluationOfWarrants" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses" xlink:href="pypd-20221231.xsd#pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet" xlink:href="pypd-20221231.xsd#pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaymentForEquipments" xlink:href="pypd-20221231.xsd#pypd_PrepaymentForEquipments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="pypd_PrepaymentForEquipments" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="pypd_IssuanceOfWarrants" xlink:href="pypd-20221231.xsd#pypd_IssuanceOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pypd_IssuanceOfWarrants" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_IsraelInnovationAuthorityGrantReceived" xlink:href="pypd-20221231.xsd#pypd_IsraelInnovationAuthorityGrantReceived"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="pypd_IsraelInnovationAuthorityGrantReceived" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable">
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageNumberOfSharesIssued" xlink:href="pypd-20221231.xsd#pypd_WeightedAverageNumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pypd_WeightedAverageNumberOfSharesIssued" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" xlink:href="pypd-20221231.xsd#pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pypd_WeightedAverageNumberOfSharesIssued" xlink:to="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>22
<FILENAME>pypd-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 19:22:17 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ConsolidatedBalanceSheet" roleURI="http://Polypid.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ConsolidatedIncomeStatement" roleURI="http://Polypid.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://Polypid.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ShareholdersEquityType2or3" roleURI="http://Polypid.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ConsolidatedCashFlow" roleURI="http://Polypid.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_General" roleURI="http://Polypid.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_SignificantAccountingPolicies" roleURI="http://Polypid.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_PropertyandEquipmentNet" roleURI="http://Polypid.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_Leases" roleURI="http://Polypid.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_AccruedExpensesandOtherCurrentLiabilities" roleURI="http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_LineofCreditArrangement" roleURI="http://Polypid.com/role/LineofCreditArrangement"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_CommitmentsandContingentLiabilities" roleURI="http://Polypid.com/role/CommitmentsandContingentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_IncomeTaxes" roleURI="http://Polypid.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ShareholdersEquity" roleURI="http://Polypid.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_FinancialIncomeExpensesNet" roleURI="http://Polypid.com/role/FinancialIncomeExpensesNet"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_BasicandDilutedNetLossPerShare" roleURI="http://Polypid.com/role/BasicandDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_RelatedParties" roleURI="http://Polypid.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_SubsequentEvents" roleURI="http://Polypid.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_AccountingPoliciesByPolicy" roleURI="http://Polypid.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_SignificantAccountingPoliciesTables" roleURI="http://Polypid.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_PropertyandEquipmentNetTables" roleURI="http://Polypid.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_LeasesTables" roleURI="http://Polypid.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_IncomeTaxesTables" roleURI="http://Polypid.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ShareholdersEquityTables" roleURI="http://Polypid.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_FinancialIncomeExpensesNetTables" roleURI="http://Polypid.com/role/FinancialIncomeExpensesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_BasicandDilutedNetLossPerShareTables" roleURI="http://Polypid.com/role/BasicandDilutedNetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofpropertyandequipmentusefullifeTable" roleURI="http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://Polypid.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofpropertyandequipmentTable" roleURI="http://Polypid.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofleaserelatedassetsandliabilitiesTable" roleURI="http://Polypid.com/role/ScheduleofleaserelatedassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofleaseliabilityTable" roleURI="http://Polypid.com/role/ScheduleofleaseliabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofsupplementalcashflowinformationrelatedtotheleasecostsTable" roleURI="http://Polypid.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofaccruedexpensesandothercurrentliabilitiesTable" roleURI="http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofdeferredtaxassetsTable" roleURI="http://Polypid.com/role/ScheduleofdeferredtaxassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofdeferredincometaxesreflectthenettaxeffectsTable" roleURI="http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofincometaxesTable" roleURI="http://Polypid.com/role/ScheduleofincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofordinarysharecapitalTable" roleURI="http://Polypid.com/role/ScheduleofordinarysharecapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofstatusofoptionstoemployeesTable" roleURI="http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofshareoptionsatthegrantdateTable" roleURI="http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofsharebasedcompensationexpenserecognizedTable" roleURI="http://Polypid.com/role/ScheduleofsharebasedcompensationexpenserecognizedTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofoutstandingoptionsgrantedTable" roleURI="http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable" roleURI="http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleoffinancialincomeexpensesnetTable" roleURI="http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofbasicanddilutedlossperordinaryshareTable" roleURI="http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofbasicanddilutedlossperordinaryshareTable_Parentheticals" roleURI="http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable" roleURI="http://Polypid.com/role/ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_GeneralDetails" roleURI="http://Polypid.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_SignificantAccountingPoliciesDetails" roleURI="http://Polypid.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_PropertyandEquipmentNetDetails" roleURI="http://Polypid.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_LeasesDetails" roleURI="http://Polypid.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_LineofCreditArrangementDetails" roleURI="http://Polypid.com/role/LineofCreditArrangementDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_CommitmentsandContingentLiabilitiesDetails" roleURI="http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_IncomeTaxesDetails" roleURI="http://Polypid.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ShareholdersEquityDetails" roleURI="http://Polypid.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_RelatedPartiesDetails" roleURI="http://Polypid.com/role/RelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_SubsequentEventsDetails" roleURI="http://Polypid.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#DocumentAndEntityInformation" roleURI="http://Polypid.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermInvestmentsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_LongtermDeposits" xlink:href="pypd-20221231.xsd#pypd_LongtermDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="pypd_LongtermDeposits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_LongTermInvestments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_Assets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_OtherLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_TotalLongtermLiabilities" xlink:href="pypd-20221231.xsd#pypd_TotalLongtermLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="pypd_TotalLongtermLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockNoParValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_MarketingAndBusinessDevelopmentExpenses" xlink:href="pypd-20221231.xsd#pypd_MarketingAndBusinessDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="pypd_MarketingAndBusinessDevelopmentExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossAttributableToParent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_DeemedDividends" xlink:href="pypd-20221231.xsd#pypd_DeemedDividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="pypd_DeemedDividends" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare" xlink:href="pypd-20221231.xsd#pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesMember" xlink:href="pypd-20221231.xsd#pypd_ConvertiblePreferredSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pypd_ConvertiblePreferredSharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_IssuanceOfOrdinarySharesNetinShares" xlink:href="pypd-20221231.xsd#pypd_IssuanceOfOrdinarySharesNetinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pypd_IssuanceOfOrdinarySharesNetinShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares" xlink:href="pypd-20221231.xsd#pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" xlink:href="pypd-20221231.xsd#pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ReclassificationOfWarrantsIntoEquity" xlink:href="pypd-20221231.xsd#pypd_ReclassificationOfWarrantsIntoEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pypd_ReclassificationOfWarrantsIntoEquity" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExerciseOfWarrants" xlink:href="pypd-20221231.xsd#pypd_ExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pypd_ExerciseOfWarrants" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares" xlink:href="pypd-20221231.xsd#pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ReevaluationOfWarrants" xlink:href="pypd-20221231.xsd#pypd_ReevaluationOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pypd_ReevaluationOfWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses" xlink:href="pypd-20221231.xsd#pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet" xlink:href="pypd-20221231.xsd#pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaymentForEquipments" xlink:href="pypd-20221231.xsd#pypd_PrepaymentForEquipments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="pypd_PrepaymentForEquipments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_IssuanceOfWarrants" xlink:href="pypd-20221231.xsd#pypd_IssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pypd_IssuanceOfWarrants" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_RestrictedCashIncludedInOtherLongtermAssets" xlink:href="pypd-20221231.xsd#pypd_RestrictedCashIncludedInOtherLongtermAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="pypd_RestrictedCashIncludedInOtherLongtermAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable" xlink:href="pypd-20221231.xsd#pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_PropertyAndEquipmentPaidForInPriorPeriods" xlink:href="pypd-20221231.xsd#pypd_PropertyAndEquipmentPaidForInPriorPeriods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pypd_PropertyAndEquipmentPaidForInPriorPeriods" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/General">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfAccounting" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesAbstract" xlink:href="pypd-20221231.xsd#pypd_PrepaidExpensesAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesTextBlock" xlink:href="pypd-20221231.xsd#pypd_PrepaidExpensesAndOtherReceivablesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_PrepaidExpensesAndOtherReceivablesAbstract" xlink:to="pypd_PrepaidExpensesAndOtherReceivablesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/LineofCreditArrangement">
    <loc xlink:type="locator" xlink:label="pypd_LineOfCreditArrangementAbstract" xlink:href="pypd-20221231.xsd#pypd_LineOfCreditArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="pypd_LineOfCreditArrangementTextBlock" xlink:href="pypd-20221231.xsd#pypd_LineOfCreditArrangementTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LineOfCreditArrangementAbstract" xlink:to="pypd_LineOfCreditArrangementTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/CommitmentsandContingentLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/FinancialIncomeExpensesNet">
    <loc xlink:type="locator" xlink:label="pypd_FinancialIncomeExpensesNetLineItems" xlink:href="pypd-20221231.xsd#pypd_FinancialIncomeExpensesNetLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_FinancialIncomeExpensesNetTable" xlink:href="pypd-20221231.xsd#pypd_FinancialIncomeExpensesNetTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_FinancialIncomeExpensesNetLineItems" xlink:to="pypd_FinancialIncomeExpensesNetTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FinancialIncomeExpensesNetLineItems" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/BasicandDilutedNetLossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/RelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ConsolidatedFinancialStatementsPolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_ConsolidatedFinancialStatementsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pypd_ConsolidatedFinancialStatementsPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_RestrictedCashPolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_RestrictedCashPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pypd_RestrictedCashPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShorttermDepositsPolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_ShorttermDepositsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pypd_ShorttermDepositsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_BasicAndDilutedLossPerSharePolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_BasicAndDilutedLossPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pypd_BasicAndDilutedLossPerSharePolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionAllowances" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAllowances"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionAllowances" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeverancePayPolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_SeverancePayPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pypd_SeverancePayPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ContingentLiabilityReserveEstimatePolicy" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted" xlink:href="pypd-20221231.xsd#pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted" order="23" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesAbstract" xlink:href="pypd-20221231.xsd#pypd_PrepaidExpensesAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_PrepaidExpensesAndOtherReceivablesAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfLeaseLiabilityTableTextBlock" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfLeaseLiabilityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="pypd_ScheduleOfLeaseLiabilityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems" xlink:href="pypd-20221231.xsd#pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesTable" xlink:href="pypd-20221231.xsd#pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems" xlink:to="pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/FinancialIncomeExpensesNetTables">
    <loc xlink:type="locator" xlink:label="pypd_FinancialIncomeExpensesNetTablesLineItems" xlink:href="pypd-20221231.xsd#pypd_FinancialIncomeExpensesNetTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_FinancialIncomeExpensesNetTablesTable" xlink:href="pypd-20221231.xsd#pypd_FinancialIncomeExpensesNetTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_FinancialIncomeExpensesNetTablesLineItems" xlink:to="pypd_FinancialIncomeExpensesNetTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FinancialIncomeExpensesNetTablesLineItems" xlink:to="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/BasicandDilutedNetLossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ComputersandSoftware" xlink:href="pypd-20221231.xsd#pypd_ComputersandSoftware"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="pypd_ComputersandSoftware" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_LaboratoryAndManufacturingEquipment" xlink:href="pypd-20221231.xsd#pypd_LaboratoryAndManufacturingEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="pypd_LaboratoryAndManufacturingEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_PropertyPlantAndEquipmentPercent" xlink:href="pypd-20221231.xsd#pypd_PropertyPlantAndEquipmentPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="pypd_PropertyPlantAndEquipmentPercent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" xlink:href="pypd-20221231.xsd#pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable" xlink:href="pypd-20221231.xsd#pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" xlink:to="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_GovernmentAuthorities" xlink:href="pypd-20221231.xsd#pypd_GovernmentAuthorities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" xlink:to="pypd_GovernmentAuthorities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseDepositLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" xlink:to="us-gaap_LeaseDepositLiability" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_LaboratoryEquipmentMember" xlink:href="pypd-20221231.xsd#pypd_LaboratoryEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pypd_LaboratoryEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_FurnitureAndOfficeEquipmentMember" xlink:href="pypd-20221231.xsd#pypd_FurnitureAndOfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pypd_FurnitureAndOfficeEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofleaserelatedassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="pypd_LeaseAssetsAbstract" xlink:href="pypd-20221231.xsd#pypd_LeaseAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract" xlink:to="pypd_LeaseAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_OperatingLeaseAssets" xlink:href="pypd-20221231.xsd#pypd_OperatingLeaseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LeaseAssetsAbstract" xlink:to="pypd_OperatingLeaseAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_LeaseLiabilitiesAbstract" xlink:href="pypd-20221231.xsd#pypd_LeaseLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract" xlink:to="pypd_LeaseLiabilitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LeaseLiabilitiesAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_LeaseLiabilities" xlink:href="pypd-20221231.xsd#pypd_LeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LeaseLiabilitiesAbstract" xlink:to="pypd_LeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofleaseliabilityTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfLeaseLiabilityAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfLeaseLiabilityAbstract" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheleasecostsTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract" xlink:href="pypd-20221231.xsd#pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract" xlink:to="pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract" xlink:href="pypd-20221231.xsd#pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract" xlink:to="pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable">
    <loc xlink:type="locator" xlink:label="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" xlink:href="pypd-20221231.xsd#pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable" xlink:href="pypd-20221231.xsd#pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" xlink:to="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_IsraelInnovationAuthorityGrantReceived" xlink:href="pypd-20221231.xsd#pypd_IsraelInnovationAuthorityGrantReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" xlink:to="pypd_IsraelInnovationAuthorityGrantReceived" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofdeferredtaxassetsTable">
    <loc xlink:type="locator" xlink:label="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:href="pypd-20221231.xsd#pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" xlink:href="pypd-20221231.xsd#pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:to="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofincometaxesTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfIncomeTaxesAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_DomesticIsrael" xlink:href="pypd-20221231.xsd#pypd_DomesticIsrael"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfIncomeTaxesAbstract" xlink:to="pypd_DomesticIsrael" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofordinarysharecapitalTable">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYyn91pOe7VtKs04Jlb3SPvCuMaehdfSUhtJg7vOyFoOF/AztNXIUhzx+P+epY4WtCBWdIE9zpOkAYuuw4yh598SS/DDR25UhB1vr3InT0Iv/WeMwUMCDO+Y4l9K2x3Xs422PVBz1J7zYQwrV5v8agZB4PYMfGJUC5OPir95Yrkl1OIYmvadz9wpw12KwAtdf4=] CSR-->
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems" xlink:to="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems" xlink:to="us-gaap_ExcessStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems" xlink:to="us-gaap_ExcessStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable">
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding" xlink:href="pypd-20221231.xsd#pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest" xlink:href="pypd-20221231.xsd#pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable">
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems" xlink:to="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofsharebasedcompensationexpenserecognizedTable">
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems" xlink:to="pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_MarketingAndBusinessDevelopmentMember" xlink:href="pypd-20221231.xsd#pypd_MarketingAndBusinessDevelopmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="pypd_MarketingAndBusinessDevelopmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable">
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable" xlink:to="us-gaap_AwardDateAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_OctoberTwoThousandThirteenMember" xlink:href="pypd-20221231.xsd#pypd_OctoberTwoThousandThirteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_OctoberTwoThousandThirteenMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeptemberTwoThousandFourteenMember" xlink:href="pypd-20221231.xsd#pypd_SeptemberTwoThousandFourteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_SeptemberTwoThousandFourteenMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_AprilTwoThousandSixteenMember" xlink:href="pypd-20221231.xsd#pypd_AprilTwoThousandSixteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_AprilTwoThousandSixteenMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_DecemberTwoThousandSixteenMember" xlink:href="pypd-20221231.xsd#pypd_DecemberTwoThousandSixteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_DecemberTwoThousandSixteenMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_JuneTwoThousandSeventeenMember" xlink:href="pypd-20221231.xsd#pypd_JuneTwoThousandSeventeenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_JuneTwoThousandSeventeenMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_NovemberTwoThousandSeventeenMember" xlink:href="pypd-20221231.xsd#pypd_NovemberTwoThousandSeventeenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_NovemberTwoThousandSeventeenMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_August2019Member" xlink:href="pypd-20221231.xsd#pypd_August2019Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_August2019Member" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_JuneTwoThousandTwentyMember" xlink:href="pypd-20221231.xsd#pypd_JuneTwoThousandTwentyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_JuneTwoThousandTwentyMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_April2021Member" xlink:href="pypd-20221231.xsd#pypd_April2021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_April2021Member" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_August2021Member" xlink:href="pypd-20221231.xsd#pypd_August2021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_August2021Member" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_December2021Member" xlink:href="pypd-20221231.xsd#pypd_December2021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_December2021Member" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_May2022Member" xlink:href="pypd-20221231.xsd#pypd_May2022Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_May2022Member" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_November2022Member" xlink:href="pypd-20221231.xsd#pypd_November2022Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_November2022Member" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_September2020Member" xlink:href="pypd-20221231.xsd#pypd_September2020Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_September2020Member" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_April2022Member" xlink:href="pypd-20221231.xsd#pypd_April2022Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_April2022Member" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_July2022Member" xlink:href="pypd-20221231.xsd#pypd_July2022Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="pypd_July2022Member" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_OptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_OptionsExercisable" xlink:href="pypd-20221231.xsd#pypd_OptionsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="pypd_OptionsExercisable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_AdjustmentToRiskfreeInterestRate" xlink:href="pypd-20221231.xsd#pypd_AdjustmentToRiskfreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="pypd_AdjustmentToRiskfreeInterestRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfFinancialIncomeExpensesNetAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfFinancialIncomeExpensesNetAbstract"/>
    <loc xlink:type="locator" xlink:label="pypd_FinancialExpensesAbstract" xlink:href="pypd-20221231.xsd#pypd_FinancialExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFinancialIncomeExpensesNetAbstract" xlink:to="pypd_FinancialExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLoansReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FinancialExpensesAbstract" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FinancialExpensesAbstract" xlink:to="us-gaap_OtherExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_RemeasurementOfWarrants" xlink:href="pypd-20221231.xsd#pypd_RemeasurementOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FinancialExpensesAbstract" xlink:to="pypd_RemeasurementOfWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FinancialExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_FinancialIncomeAbstract" xlink:href="pypd-20221231.xsd#pypd_FinancialIncomeAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFinancialIncomeExpensesNetAbstract" xlink:to="pypd_FinancialIncomeAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FinancialIncomeAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FinancialIncomeAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FinancialIncomeAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_FinancialIncomeAbstract" xlink:to="us-gaap_InvestmentIncomeNonoperating" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfFinancialIncomeExpensesNetAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract"/>
    <loc xlink:type="locator" xlink:label="pypd_NumeratorAbstract" xlink:href="pypd-20221231.xsd#pypd_NumeratorAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" xlink:to="pypd_NumeratorAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_NumeratorAbstract" xlink:to="us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_PreferredSharePreference" xlink:href="pypd-20221231.xsd#pypd_PreferredSharePreference"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_NumeratorAbstract" xlink:to="pypd_PreferredSharePreference" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_DeemedDividend" xlink:href="pypd-20221231.xsd#pypd_DeemedDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_NumeratorAbstract" xlink:to="pypd_DeemedDividend" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_DenominatorAbstract" xlink:href="pypd-20221231.xsd#pypd_DenominatorAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" xlink:to="pypd_DenominatorAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable">
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" xlink:href="pypd-20221231.xsd#pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract" xlink:to="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageNumberOfSharesIssued" xlink:href="pypd-20221231.xsd#pypd_WeightedAverageNumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract" xlink:to="pypd_WeightedAverageNumberOfSharesIssued" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="pypd_GeneralDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_GeneralDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_GeneralDetailsTable" xlink:href="pypd-20221231.xsd#pypd_GeneralDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="pypd_GeneralDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_GeneralDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_DescriptionOfReverseShareSplit" xlink:href="pypd-20221231.xsd#pypd_DescriptionOfReverseShareSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="pypd_DescriptionOfReverseShareSplit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_StockIssuedDuringPeriodSharesNewIssue" xlink:href="pypd-20221231.xsd#pypd_StockIssuedDuringPeriodSharesNewIssue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="pypd_StockIssuedDuringPeriodSharesNewIssue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_AggregateNetProceeds" xlink:href="pypd-20221231.xsd#pypd_AggregateNetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="pypd_AggregateNetProceeds" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_DescriptionAdministration" xlink:href="pypd-20221231.xsd#pypd_DescriptionAdministration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="pypd_DescriptionAdministration" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_IncurredLoss" xlink:href="pypd-20221231.xsd#pypd_IncurredLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="pypd_IncurredLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_CashFlowsFromOperatingActivities" xlink:href="pypd-20221231.xsd#pypd_CashFlowsFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="pypd_CashFlowsFromOperatingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeEarningsDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeEarningsDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="us-gaap_CumulativeEarningsDeficit" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_SignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_SignificantAccountingPoliciesDetailsTable" xlink:href="pypd-20221231.xsd#pypd_SignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_SignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_SignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShortTermDepositsMember" xlink:href="pypd-20221231.xsd#pypd_ShortTermDepositsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="pypd_ShortTermDepositsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_RighttouseAssetsAndLeaseLiabilities" xlink:href="pypd-20221231.xsd#pypd_RighttouseAssetsAndLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_RighttouseAssetsAndLeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_LeasePrepayments" xlink:href="pypd-20221231.xsd#pypd_LeasePrepayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_LeasePrepayments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ReceivedTotalAmount" xlink:href="pypd-20221231.xsd#pypd_ReceivedTotalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_ReceivedTotalAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_NonroyaltyBearingGrantsAmount" xlink:href="pypd-20221231.xsd#pypd_NonroyaltyBearingGrantsAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_NonroyaltyBearingGrantsAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_OutOfReceivedAmount" xlink:href="pypd-20221231.xsd#pypd_OutOfReceivedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_OutOfReceivedAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_NonroyaltyBearingGrants" xlink:href="pypd-20221231.xsd#pypd_NonroyaltyBearingGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_NonroyaltyBearingGrants" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_FinancialExpenseIncome" xlink:href="pypd-20221231.xsd#pypd_FinancialExpenseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_FinancialExpenseIncome" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_TaxBenefitPercentage" xlink:href="pypd-20221231.xsd#pypd_TaxBenefitPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_TaxBenefitPercentage" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_AgreementTerm" xlink:href="pypd-20221231.xsd#pypd_AgreementTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_AgreementTerm" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_NonRefundableAmount" xlink:href="pypd-20221231.xsd#pypd_NonRefundableAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_NonRefundableAmount" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_AdditionalDevelopmentrelatedMilestonesPayments" xlink:href="pypd-20221231.xsd#pypd_AdditionalDevelopmentrelatedMilestonesPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_AdditionalDevelopmentrelatedMilestonesPayments" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_AdditionalAmountOfCommercialSaleMilestones" xlink:href="pypd-20221231.xsd#pypd_AdditionalAmountOfCommercialSaleMilestones"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_AdditionalAmountOfCommercialSaleMilestones" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_monthlyDepositsAtARate" xlink:href="pypd-20221231.xsd#pypd_monthlyDepositsAtARate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_monthlyDepositsAtARate" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeverancePayExpenseAmount" xlink:href="pypd-20221231.xsd#pypd_SeverancePayExpenseAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_SeverancePayExpenseAmount" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SeverancePay" xlink:href="pypd-20221231.xsd#pypd_SeverancePay"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_SeverancePay" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_MatchingContributionsAmounts" xlink:href="pypd-20221231.xsd#pypd_MatchingContributionsAmounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_MatchingContributionsAmounts" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesIndemnificationAgreementsPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeasesIndemnificationAgreementsPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CapitalLeasesIndemnificationAgreementsPayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/LineofCreditArrangementDetails">
    <loc xlink:type="locator" xlink:label="pypd_LineofCreditArrangementDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_LineofCreditArrangementDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_LineofCreditArrangementDetailsTable" xlink:href="pypd-20221231.xsd#pypd_LineofCreditArrangementDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="pypd_LineofCreditArrangementDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_LineofCreditArrangementDetailsTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_FirstTrancheMember" xlink:href="pypd-20221231.xsd#pypd_FirstTrancheMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="pypd_FirstTrancheMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SecondTrancheMember" xlink:href="pypd-20221231.xsd#pypd_SecondTrancheMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="pypd_SecondTrancheMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ThiredTrancheMember" xlink:href="pypd-20221231.xsd#pypd_ThiredTrancheMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="pypd_ThiredTrancheMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LinesOfCreditCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_LinesOfCreditCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ProceedsFromLinesOfCreditOne" xlink:href="pypd-20221231.xsd#pypd_ProceedsFromLinesOfCreditOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="pypd_ProceedsFromLinesOfCreditOne" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ProceedsFromLinesOfCreditTwo" xlink:href="pypd-20221231.xsd#pypd_ProceedsFromLinesOfCreditTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="pypd_ProceedsFromLinesOfCreditTwo" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_LineOfCredit" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityPeriodicPayment" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_LineOfCreditFacilityPeriodicPaymentOne" xlink:href="pypd-20221231.xsd#pypd_LineOfCreditFacilityPeriodicPaymentOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="pypd_LineOfCreditFacilityPeriodicPaymentOne" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityDescription" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_InterestExpenseShortTermBorrowings" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="pypd_ProceedsFromParticipationPayments" xlink:href="pypd-20221231.xsd#pypd_ProceedsFromParticipationPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pypd_ProceedsFromParticipationPayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_CommitmentsAndContingentLiabilitiesDescription" xlink:href="pypd-20221231.xsd#pypd_CommitmentsAndContingentLiabilitiesDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pypd_CommitmentsAndContingentLiabilitiesDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_FindersFee" xlink:href="pypd-20221231.xsd#pypd_FindersFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pypd_FindersFee" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_SuitFillingExpense" xlink:href="pypd-20221231.xsd#pypd_SuitFillingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pypd_SuitFillingExpense" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="pypd_IncomeTaxesDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_IncomeTaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_IncomeTaxesDetailsTable" xlink:href="pypd-20221231.xsd#pypd_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_IncomeTaxesDetailsLineItems" xlink:to="pypd_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_IncomeTaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_IncomeTaxesDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalHomeLoanBankAdvancesInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_FederalHomeLoanBankAdvancesInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="pypd_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_TwoThousandTwelveShareOptionPlanMember" xlink:href="pypd-20221231.xsd#pypd_TwoThousandTwelveShareOptionPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pypd_TwoThousandTwelveShareOptionPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_OfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_AggregateOfferingPrice" xlink:href="pypd-20221231.xsd#pypd_AggregateOfferingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="pypd_AggregateOfferingPrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_StockOptionVestingPeriodDescription" xlink:href="pypd-20221231.xsd#pypd_StockOptionVestingPeriodDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="pypd_StockOptionVestingPeriodDescription" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareOptionPlanDescription" xlink:href="pypd-20221231.xsd#pypd_ShareOptionPlanDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="pypd_ShareOptionPlanDescription" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_NumberOfOptions" xlink:href="pypd-20221231.xsd#pypd_NumberOfOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="pypd_NumberOfOptions" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_StockOptionShares" xlink:href="pypd-20221231.xsd#pypd_StockOptionShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="pypd_StockOptionShares" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_StockOptionsAvailableForFutureGrants" xlink:href="pypd-20221231.xsd#pypd_StockOptionsAvailableForFutureGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="pypd_StockOptionsAvailableForFutureGrants" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageGrantDateFairValueOfOptionsGranted" xlink:href="pypd-20221231.xsd#pypd_WeightedAverageGrantDateFairValueOfOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="pypd_WeightedAverageGrantDateFairValueOfOptionsGranted" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExpectedDividendYield" xlink:href="pypd-20221231.xsd#pypd_ExpectedDividendYield"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="pypd_ExpectedDividendYield" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_UnrecognizedCompensationCosts" xlink:href="pypd-20221231.xsd#pypd_UnrecognizedCompensationCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="pypd_UnrecognizedCompensationCosts" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_RecognizedOverWeightedAveragePeriod" xlink:href="pypd-20221231.xsd#pypd_RecognizedOverWeightedAveragePeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="pypd_RecognizedOverWeightedAveragePeriod" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_WarrantsDescription" xlink:href="pypd-20221231.xsd#pypd_WarrantsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="pypd_WarrantsDescription" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_WarrantsOutstanding" xlink:href="pypd-20221231.xsd#pypd_WarrantsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="pypd_WarrantsOutstanding" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/RelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="pypd_RelatedPartiesDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_RelatedPartiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_RelatedPartiesDetailsTable" xlink:href="pypd-20221231.xsd#pypd_RelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_RelatedPartiesDetailsLineItems" xlink:to="pypd_RelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_RelatedPartiesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ServiceProvidersInAmount" xlink:href="pypd-20221231.xsd#pypd_ServiceProvidersInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_RelatedPartiesDetailsLineItems" xlink:to="pypd_ServiceProvidersInAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_RelatedPartiesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_RelatedPartiesTerm" xlink:href="pypd-20221231.xsd#pypd_RelatedPartiesTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_RelatedPartiesDetailsLineItems" xlink:to="pypd_RelatedPartiesTerm" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="pypd_SubsequentEventsDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="pypd_SubsequentEventsDetailsTable" xlink:href="pypd-20221231.xsd#pypd_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="pypd_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_SubsequentEventsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pypd_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ConsultAndDirectorsMember" xlink:href="pypd-20221231.xsd#pypd_ConsultAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="pypd_ConsultAndDirectorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyCommittedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_InvestmentCompanyCommittedCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceDecrease" xlink:href="pypd-20221231.xsd#pypd_ExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="pypd_ExercisePriceDecrease" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_InterestRepayments" xlink:href="pypd-20221231.xsd#pypd_InterestRepayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="pypd_InterestRepayments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_MinimumPaidAmount" xlink:href="pypd-20221231.xsd#pypd_MinimumPaidAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="pypd_MinimumPaidAmount" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_ExceedAmount" xlink:href="pypd-20221231.xsd#pypd_ExceedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="pypd_ExceedAmount" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="pypd_OfferingExpensesPayable" xlink:href="pypd-20221231.xsd#pypd_OfferingExpensesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="pypd_OfferingExpensesPayable" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://Polypid.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="40" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>23
<FILENAME>pypd-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 19:22:17 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US">Total long-term assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_TotalLongtermLiabilities" xlink:href="pypd-20221231.xsd#pypd_TotalLongtermLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="pypd_TotalLongtermLiabilities_lbl" xml:lang="en-US">Total long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_TotalLongtermLiabilities" xlink:to="pypd_TotalLongtermLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeLossAttributableToParent_lbl" xml:lang="en-US">Loss before income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare" xlink:href="pypd-20221231.xsd#pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare_lbl" xml:lang="en-US">Net loss attributable to Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare" xlink:to="pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Increase (decrease) in cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">General [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Balance Sheet Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Beginning balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Options, Ending balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Beginning balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Aggregate intrinsic value, Ending balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract_lbl" xml:lang="en-US">Number of Ordinary Shares [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract" xlink:to="pypd_ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageNumberOfSharesIssued" xlink:href="pypd-20221231.xsd#pypd_WeightedAverageNumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="pypd_WeightedAverageNumberOfSharesIssued_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageNumberOfSharesIssued" xlink:to="pypd_WeightedAverageNumberOfSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract" xlink:to="pypd_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssets_lbl" xml:lang="en-US">Short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract0" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract0" xlink:to="pypd_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract1" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract1" xlink:to="pypd_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermInvestmentsAbstract_lbl" xml:lang="en-US">LONG-TERM ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_LongTermInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Depreciated cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_LongtermDeposits" xlink:href="pypd-20221231.xsd#pypd_LongtermDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_LongtermDeposits_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LongtermDeposits" xlink:to="pypd_LongtermDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other long-term assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract2" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract2" xlink:to="pypd_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract3" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract3" xlink:to="pypd_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract4" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract4" xlink:to="pypd_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Current maturities of long-term debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current maturities of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract5" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract5" xlink:to="pypd_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract6" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract6" xlink:to="pypd_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_lbl" xml:lang="en-US">LONG-TERM LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US">Long-term debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract7" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract7" xlink:to="pypd_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract8" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract8" xlink:to="pypd_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract9" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract9" xlink:to="pypd_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares, no par value - Authorized: 47,800,000 shares at December 31, 2022 and 2021; Issued and outstanding: 19,851,833 and 18,756,570 shares at December 31, 2022 and 2021, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US">Ordinary shares, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract10" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract10" xlink:to="pypd_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract11" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract11" xlink:to="pypd_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_MarketingAndBusinessDevelopmentExpenses" xlink:href="pypd-20221231.xsd#pypd_MarketingAndBusinessDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_MarketingAndBusinessDevelopmentExpenses_lbl" xml:lang="en-US">Marketing and business development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MarketingAndBusinessDevelopmentExpenses" xlink:to="pypd_MarketingAndBusinessDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract12" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract12" xlink:to="pypd_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract13" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract13" xlink:to="pypd_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract14" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract14" xlink:to="pypd_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract15" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract15" xlink:to="pypd_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract16" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract16" xlink:to="pypd_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract17" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract17" xlink:to="pypd_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic and diluted net loss per Ordinary share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Basic and diluted net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Basic and diluted net loss per Ordinary share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Diluted net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract18" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract18" xlink:to="pypd_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of Ordinary shares used in computing basic and diluted loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted average Ordinary shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract19" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract19" xlink:to="pypd_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of Ordinary shares in connection with the IPO, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Ordinary shares in connection with the IPO, net (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares" xlink:href="pypd-20221231.xsd#pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares_lbl" xml:lang="en-US">Conversion of convertible Preferred shares to Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares" xlink:to="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" xlink:href="pypd-20221231.xsd#pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares_lbl" xml:lang="en-US">Conversion of convertible Preferred shares to Ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" xlink:to="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_lbl" xml:lang="en-US">Deemed dividend related to Series E-1 Preferred shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Deemed dividend related to Series E-1 Preferred shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ReclassificationOfWarrantsIntoEquity" xlink:href="pypd-20221231.xsd#pypd_ReclassificationOfWarrantsIntoEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ReclassificationOfWarrantsIntoEquity_lbl" xml:lang="en-US">Reclassification of warrants into equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReclassificationOfWarrantsIntoEquity" xlink:to="pypd_ReclassificationOfWarrantsIntoEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExerciseOfWarrants" xlink:href="pypd-20221231.xsd#pypd_ExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExerciseOfWarrants" xlink:to="pypd_ExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares" xlink:href="pypd-20221231.xsd#pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares_lbl" xml:lang="en-US">Exercise of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares" xlink:to="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Issuance of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract20" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract20" xlink:to="pypd_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract21" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract21" xlink:to="pypd_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract22" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract22" xlink:to="pypd_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract23" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract23" xlink:to="pypd_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Ordinary shares, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_IssuanceOfOrdinarySharesNetinShares" xlink:href="pypd-20221231.xsd#pypd_IssuanceOfOrdinarySharesNetinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_IssuanceOfOrdinarySharesNetinShares_lbl" xml:lang="en-US">Issuance of Ordinary shares, net (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IssuanceOfOrdinarySharesNetinShares" xlink:to="pypd_IssuanceOfOrdinarySharesNetinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract24" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract24" xlink:to="pypd_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ReevaluationOfWarrants" xlink:href="pypd-20221231.xsd#pypd_ReevaluationOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ReevaluationOfWarrants_lbl" xml:lang="en-US">Remeasurement of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReevaluationOfWarrants" xlink:to="pypd_ReevaluationOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Operating lease liabilities and right-of-use assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract25" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract25" xlink:to="pypd_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract26" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract26"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract26_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract26" xlink:to="pypd_UnlabeledAbstract26_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract27" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract27"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract27_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract27" xlink:to="pypd_UnlabeledAbstract27_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract28" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract28"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract28_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract28" xlink:to="pypd_UnlabeledAbstract28_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from issuance of Ordinary shares in connection with the IPO, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of Ordinary shares, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Proceeds from long-term debt, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract29" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract29"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract29_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract29" xlink:to="pypd_UnlabeledAbstract29_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract30" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract30"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract30_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract30" xlink:to="pypd_UnlabeledAbstract30_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract31" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract31"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract31_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract31" xlink:to="pypd_UnlabeledAbstract31_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract32" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract32"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract32_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract32" xlink:to="pypd_UnlabeledAbstract32_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flows:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract33" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract33"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract33_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract33" xlink:to="pypd_UnlabeledAbstract33_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid during the year for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RestrictedCashIncludedInOtherLongtermAssets" xlink:href="pypd-20221231.xsd#pypd_RestrictedCashIncludedInOtherLongtermAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_RestrictedCashIncludedInOtherLongtermAssets_lbl" xml:lang="en-US">Restricted cash included in other long-term assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RestrictedCashIncludedInOtherLongtermAssets" xlink:to="pypd_RestrictedCashIncludedInOtherLongtermAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract34" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract34"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract34_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract34" xlink:to="pypd_UnlabeledAbstract34_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract35" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract35"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract35_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract35" xlink:to="pypd_UnlabeledAbstract35_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable" xlink:href="pypd-20221231.xsd#pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable_lbl" xml:lang="en-US">Property and equipment acquired by credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable" xlink:to="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract36" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract36"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract36_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract36" xlink:to="pypd_UnlabeledAbstract36_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PropertyAndEquipmentPaidForInPriorPeriods" xlink:href="pypd-20221231.xsd#pypd_PropertyAndEquipmentPaidForInPriorPeriods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_PropertyAndEquipmentPaidForInPriorPeriods_lbl" xml:lang="en-US">Property and equipment paid for in prior periods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PropertyAndEquipmentPaidForInPriorPeriods" xlink:to="pypd_PropertyAndEquipmentPaidForInPriorPeriods_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract37" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract37"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract37_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract37" xlink:to="pypd_UnlabeledAbstract37_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract38" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract38"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract38_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract38" xlink:to="pypd_UnlabeledAbstract38_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Cash paid for amounts included in measurement of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Financial (income) expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DeemedDividends" xlink:href="pypd-20221231.xsd#pypd_DeemedDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pypd_DeemedDividends_lbl" xml:lang="en-US">Deemed dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DeemedDividends" xlink:to="pypd_DeemedDividends_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Non-cash financial expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses" xlink:href="pypd-20221231.xsd#pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses" xlink:to="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet" xlink:href="pypd-20221231.xsd#pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet_lbl" xml:lang="en-US">Short-term and long-term deposits, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet" xlink:to="pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaymentForEquipments" xlink:href="pypd-20221231.xsd#pypd_PrepaymentForEquipments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pypd_PrepaymentForEquipments_lbl" xml:lang="en-US">Pre-payments for equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaymentForEquipments" xlink:to="pypd_PrepaymentForEquipments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Repayment of long-term debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_IssuanceOfWarrants" xlink:href="pypd-20221231.xsd#pypd_IssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pypd_IssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IssuanceOfWarrants" xlink:to="pypd_IssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesMember" xlink:href="pypd-20221231.xsd#pypd_ConvertiblePreferredSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ConvertiblePreferredSharesMember_lbl" xml:lang="en-US">Convertible Preferred Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesMember" xlink:to="pypd_ConvertiblePreferredSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Number of Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ComputersandSoftware" xlink:href="pypd-20221231.xsd#pypd_ComputersandSoftware"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ComputersandSoftware_lbl" xml:lang="en-US">Computers and software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ComputersandSoftware" xlink:to="pypd_ComputersandSoftware_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LaboratoryAndManufacturingEquipment" xlink:href="pypd-20221231.xsd#pypd_LaboratoryAndManufacturingEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_LaboratoryAndManufacturingEquipment_lbl" xml:lang="en-US">Laboratory equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LaboratoryAndManufacturingEquipment" xlink:to="pypd_LaboratoryAndManufacturingEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PropertyPlantAndEquipmentPercent" xlink:href="pypd-20221231.xsd#pypd_PropertyPlantAndEquipmentPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_PropertyPlantAndEquipmentPercent_lbl" xml:lang="en-US">Furniture and office equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PropertyPlantAndEquipmentPercent" xlink:to="pypd_PropertyPlantAndEquipmentPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US">Leasehold improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesTextBlock" xlink:href="pypd-20221231.xsd#pypd_PrepaidExpensesAndOtherReceivablesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaidExpensesAndOtherReceivablesTextBlock" xlink:to="pypd_PrepaidExpensesAndOtherReceivablesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_GovernmentAuthorities" xlink:href="pypd-20221231.xsd#pypd_GovernmentAuthorities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_GovernmentAuthorities_lbl" xml:lang="en-US">Government authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_GovernmentAuthorities" xlink:to="pypd_GovernmentAuthorities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseDepositLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseDepositLiability_lbl" xml:lang="en-US">Lease deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseDepositLiability" xlink:to="us-gaap_LeaseDepositLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract39" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract39"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract39_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract39" xlink:to="pypd_UnlabeledAbstract39_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_CostAbstract" xlink:href="pypd-20221231.xsd#pypd_CostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_CostAbstract_lbl" xml:lang="en-US">Cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_CostAbstract" xlink:to="pypd_CostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract40" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract40"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract40_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract40" xlink:to="pypd_UnlabeledAbstract40_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract41" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract41"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract41_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract41" xlink:to="pypd_UnlabeledAbstract41_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of lease-related assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" xlink:to="pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LeaseAssetsAbstract" xlink:href="pypd-20221231.xsd#pypd_LeaseAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_LeaseAssetsAbstract_lbl" xml:lang="en-US">Lease assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LeaseAssetsAbstract" xlink:to="pypd_LeaseAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_OperatingLeaseAssets" xlink:href="pypd-20221231.xsd#pypd_OperatingLeaseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_OperatingLeaseAssets_lbl" xml:lang="en-US">Operating lease assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OperatingLeaseAssets" xlink:to="pypd_OperatingLeaseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract42" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract42"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract42_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract42" xlink:to="pypd_UnlabeledAbstract42_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LeaseLiabilitiesAbstract" xlink:href="pypd-20221231.xsd#pypd_LeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_LeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Lease liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LeaseLiabilitiesAbstract" xlink:to="pypd_LeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Long-term lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract43" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract43"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract43_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract43" xlink:to="pypd_UnlabeledAbstract43_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LeaseLiabilities" xlink:href="pypd-20221231.xsd#pypd_LeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_LeaseLiabilities_lbl" xml:lang="en-US">Total lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LeaseLiabilities" xlink:to="pypd_LeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract44" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract44"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract44_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract44" xlink:to="pypd_UnlabeledAbstract44_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted Average Remaining lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted Average Discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfLeaseLiabilityTableTextBlock" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfLeaseLiabilityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ScheduleOfLeaseLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfLeaseLiabilityTableTextBlock" xlink:to="pypd_ScheduleOfLeaseLiabilityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract45" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract45"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract45_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract45" xlink:to="pypd_UnlabeledAbstract45_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US">Total undiscounted lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract46" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract46"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract46_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract46" xlink:to="pypd_UnlabeledAbstract46_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Present value of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental cash flow information related to the lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract" xlink:href="pypd-20221231.xsd#pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in measurement of lease liability:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract" xlink:to="pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xml:lang="en-US">Operating cash flows for operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract47" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract47"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract47_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract47" xlink:to="pypd_UnlabeledAbstract47_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract" xlink:href="pypd-20221231.xsd#pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract_lbl" xml:lang="en-US">Right-of-use asset recognized with corresponding lease liability:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract" xlink:to="pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employees and payroll accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_IsraelInnovationAuthorityGrantReceived" xlink:href="pypd-20221231.xsd#pypd_IsraelInnovationAuthorityGrantReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_IsraelInnovationAuthorityGrantReceived_lbl" xml:lang="en-US">IIA deferred grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IsraelInnovationAuthorityGrantReceived" xlink:to="pypd_IsraelInnovationAuthorityGrantReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract48" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract48"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract48_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract48" xlink:to="pypd_UnlabeledAbstract48_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LineOfCreditArrangementTextBlock" xlink:href="pypd-20221231.xsd#pypd_LineOfCreditArrangementTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_LineOfCreditArrangementTextBlock_lbl" xml:lang="en-US">LINE OF CREDIT ARRANGEMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LineOfCreditArrangementTextBlock" xlink:to="pypd_LineOfCreditArrangementTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred income taxes reflect the net tax effects</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract49" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract49"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract49_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract49" xlink:to="pypd_UnlabeledAbstract49_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred income taxes reflect the net tax effects</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Carryforward losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Reserves and allowances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract50" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract50"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract50_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract50" xlink:to="pypd_UnlabeledAbstract50_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Deferred tax assets before valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract51" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract51"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract51_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract51" xlink:to="pypd_UnlabeledAbstract51_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract52" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract52"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract52_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract52" xlink:to="pypd_UnlabeledAbstract52_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract53" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract53"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract53_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract53" xlink:to="pypd_UnlabeledAbstract53_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract54" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract54"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract54_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract54" xlink:to="pypd_UnlabeledAbstract54_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract55" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract55"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract55_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract55" xlink:to="pypd_UnlabeledAbstract55_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DomesticIsrael" xlink:href="pypd-20221231.xsd#pypd_DomesticIsrael"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_DomesticIsrael_lbl" xml:lang="en-US">Domestic (Israel)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DomesticIsrael" xlink:to="pypd_DomesticIsrael_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract56" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract56"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract56_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract56" xlink:to="pypd_UnlabeledAbstract56_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of ordinary share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NumberOfSharesAbstract" xlink:href="pypd-20221231.xsd#pypd_NumberOfSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_NumberOfSharesAbstract_lbl" xml:lang="en-US">Number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumberOfSharesAbstract" xlink:to="pypd_NumberOfSharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract57" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract57"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract57_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract57" xlink:to="pypd_UnlabeledAbstract57_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesAuthorized" xlink:to="us-gaap_ExcessStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesOutstanding" xlink:to="us-gaap_ExcessStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of status of options to employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life (years), Beginning Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share option plan grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Exercised options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised_lbl" xml:lang="en-US">Number of Options, Exercised (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Aggregate intrinsic value, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1_lbl" xml:lang="en-US">Number of Options, Forfeited and cancelled (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract58" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract58"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract58_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract58" xlink:to="pypd_UnlabeledAbstract58_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding" xlink:href="pypd-20221231.xsd#pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding_lbl" xml:lang="en-US">Weighted average remaining contractual life (years), Ending Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding" xlink:to="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract59" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract59"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract59_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract59" xlink:to="pypd_UnlabeledAbstract59_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, Exercisable options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, Exercisable options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life (years), Exercisable options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract60" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract60"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract60_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract60" xlink:to="pypd_UnlabeledAbstract60_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Vested and expected to vest (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices_lbl" xml:lang="en-US">Weighted average exercise price, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, Vested and expected to vest (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest" xlink:href="pypd-20221231.xsd#pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest_lbl" xml:lang="en-US">Weighted average remaining contractual life (years), Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest" xlink:to="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of relative fair value of the warrants to purchase Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Expected life (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_lbl" xml:lang="en-US">Schedule of share-based compensation expense recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract61" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract61"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract61_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract61" xlink:to="pypd_UnlabeledAbstract61_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock_lbl" xml:lang="en-US">Schedule of outstanding options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock" xlink:to="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Average Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_OptionsExercisable" xlink:href="pypd-20221231.xsd#pypd_OptionsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_OptionsExercisable_lbl" xml:lang="en-US">Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OptionsExercisable" xlink:to="pypd_OptionsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration_lbl" xml:lang="en-US">Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract62" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract62"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract62_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract62" xlink:to="pypd_UnlabeledAbstract62_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract63" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract63"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract63_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract63" xlink:to="pypd_UnlabeledAbstract63_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of relative fair value of the warrants to purchase Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price ($) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price ($) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_AdjustmentToRiskfreeInterestRate" xlink:href="pypd-20221231.xsd#pypd_AdjustmentToRiskfreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_AdjustmentToRiskfreeInterestRate_lbl" xml:lang="en-US">Adjustment to risk-free interest rate (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AdjustmentToRiskfreeInterestRate" xlink:to="pypd_AdjustmentToRiskfreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US">FINANCIAL (INCOME) EXPENSES, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_lbl" xml:lang="en-US">Schedule of financial (income) expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FinancialExpensesAbstract" xlink:href="pypd-20221231.xsd#pypd_FinancialExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_FinancialExpensesAbstract_lbl" xml:lang="en-US">Financial expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialExpensesAbstract" xlink:to="pypd_FinancialExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLoansReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable_lbl" xml:lang="en-US">Financial expenses from loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLoansReceivable" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Other financial expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RemeasurementOfWarrants" xlink:href="pypd-20221231.xsd#pypd_RemeasurementOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_RemeasurementOfWarrants_lbl" xml:lang="en-US">Remeasurement of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RemeasurementOfWarrants" xlink:to="pypd_RemeasurementOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract64" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract64"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract64_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract64" xlink:to="pypd_UnlabeledAbstract64_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl" xml:lang="en-US">Total financial expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract65" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract65"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract65_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract65" xlink:to="pypd_UnlabeledAbstract65_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FinancialIncomeAbstract" xlink:href="pypd-20221231.xsd#pypd_FinancialIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_FinancialIncomeAbstract_lbl" xml:lang="en-US">Financial income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialIncomeAbstract" xlink:to="pypd_FinancialIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract66" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract66"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract66_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract66" xlink:to="pypd_UnlabeledAbstract66_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract67" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract67"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract67_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract67" xlink:to="pypd_UnlabeledAbstract67_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US">Total financial (income) expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">BASIC AND DILUTED NET LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of basic and diluted loss per ordinary share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NumeratorAbstract" xlink:href="pypd-20221231.xsd#pypd_NumeratorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_NumeratorAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumeratorAbstract" xlink:to="pypd_NumeratorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic_lbl" xml:lang="en-US">Allocation of net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:to="us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PreferredSharePreference" xlink:href="pypd-20221231.xsd#pypd_PreferredSharePreference"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_PreferredSharePreference_lbl" xml:lang="en-US">Preferred share preference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PreferredSharePreference" xlink:to="pypd_PreferredSharePreference_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DeemedDividend" xlink:href="pypd-20221231.xsd#pypd_DeemedDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_DeemedDividend_lbl" xml:lang="en-US">Deemed dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DeemedDividend" xlink:to="pypd_DeemedDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract68" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract68"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract68_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract68" xlink:to="pypd_UnlabeledAbstract68_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Allocation of net loss attributable to Ordinary shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract69" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract69"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract69_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract69" xlink:to="pypd_UnlabeledAbstract69_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DenominatorAbstract" xlink:href="pypd-20221231.xsd#pypd_DenominatorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_DenominatorAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DenominatorAbstract" xlink:to="pypd_DenominatorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract70" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract70"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract70_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract70" xlink:to="pypd_UnlabeledAbstract70_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of diluted loss per share attributable to ordinary shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NumberOfOrdinarySharesAbstract" xlink:href="pypd-20221231.xsd#pypd_NumberOfOrdinarySharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_NumberOfOrdinarySharesAbstract_lbl" xml:lang="en-US">Number of Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumberOfOrdinarySharesAbstract" xlink:to="pypd_NumberOfOrdinarySharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract71" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract71"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract71_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract71" xlink:to="pypd_UnlabeledAbstract71_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xml:lang="en-US">Ordinary share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" xlink:href="pypd-20221231.xsd#pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" xlink:to="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnlabeledAbstract72" xlink:href="pypd-20221231.xsd#pypd_UnlabeledAbstract72"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnlabeledAbstract72_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract72" xlink:to="pypd_UnlabeledAbstract72_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount_lbl" xml:lang="en-US">Less - imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Operating lease ROU assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl" xml:lang="en-US">Foreign currency transaction gains, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest from bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Other financial income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xml:lang="en-US">Total financial income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers and software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LaboratoryEquipmentMember" xlink:href="pypd-20221231.xsd#pypd_LaboratoryEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LaboratoryEquipmentMember" xlink:to="pypd_LaboratoryEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FurnitureAndOfficeEquipmentMember" xlink:href="pypd-20221231.xsd#pypd_FurnitureAndOfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_FurnitureAndOfficeEquipmentMember_lbl" xml:lang="en-US">Furniture and office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FurnitureAndOfficeEquipmentMember" xlink:to="pypd_FurnitureAndOfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic (Israel) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Share Option Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_MarketingAndBusinessDevelopmentMember" xlink:href="pypd-20221231.xsd#pypd_MarketingAndBusinessDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_MarketingAndBusinessDevelopmentMember_lbl" xml:lang="en-US">Marketing and business development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MarketingAndBusinessDevelopmentMember" xlink:to="pypd_MarketingAndBusinessDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_OctoberTwoThousandThirteenMember" xlink:href="pypd-20221231.xsd#pypd_OctoberTwoThousandThirteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_OctoberTwoThousandThirteenMember_lbl" xml:lang="en-US">October 2013 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OctoberTwoThousandThirteenMember" xlink:to="pypd_OctoberTwoThousandThirteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeptemberTwoThousandFourteenMember" xlink:href="pypd-20221231.xsd#pypd_SeptemberTwoThousandFourteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeptemberTwoThousandFourteenMember_lbl" xml:lang="en-US">September 2014 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeptemberTwoThousandFourteenMember" xlink:to="pypd_SeptemberTwoThousandFourteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_AprilTwoThousandSixteenMember" xlink:href="pypd-20221231.xsd#pypd_AprilTwoThousandSixteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_AprilTwoThousandSixteenMember_lbl" xml:lang="en-US">April 2016 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AprilTwoThousandSixteenMember" xlink:to="pypd_AprilTwoThousandSixteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DecemberTwoThousandSixteenMember" xlink:href="pypd-20221231.xsd#pypd_DecemberTwoThousandSixteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_DecemberTwoThousandSixteenMember_lbl" xml:lang="en-US">December 2016 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DecemberTwoThousandSixteenMember" xlink:to="pypd_DecemberTwoThousandSixteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_JuneTwoThousandSeventeenMember" xlink:href="pypd-20221231.xsd#pypd_JuneTwoThousandSeventeenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_JuneTwoThousandSeventeenMember_lbl" xml:lang="en-US">June 2017 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_JuneTwoThousandSeventeenMember" xlink:to="pypd_JuneTwoThousandSeventeenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NovemberTwoThousandSeventeenMember" xlink:href="pypd-20221231.xsd#pypd_NovemberTwoThousandSeventeenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_NovemberTwoThousandSeventeenMember_lbl" xml:lang="en-US">November 2017 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NovemberTwoThousandSeventeenMember" xlink:to="pypd_NovemberTwoThousandSeventeenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_August2019Member" xlink:href="pypd-20221231.xsd#pypd_August2019Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_August2019Member_lbl" xml:lang="en-US">August 2019 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_August2019Member" xlink:to="pypd_August2019Member_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_JuneTwoThousandTwentyMember" xlink:href="pypd-20221231.xsd#pypd_JuneTwoThousandTwentyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_JuneTwoThousandTwentyMember_lbl" xml:lang="en-US">June 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_JuneTwoThousandTwentyMember" xlink:to="pypd_JuneTwoThousandTwentyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_April2021Member" xlink:href="pypd-20221231.xsd#pypd_April2021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_April2021Member_lbl" xml:lang="en-US">April 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_April2021Member" xlink:to="pypd_April2021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_August2021Member" xlink:href="pypd-20221231.xsd#pypd_August2021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_August2021Member_lbl" xml:lang="en-US">August 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_August2021Member" xlink:to="pypd_August2021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_December2021Member" xlink:href="pypd-20221231.xsd#pypd_December2021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_December2021Member_lbl" xml:lang="en-US">December 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_December2021Member" xlink:to="pypd_December2021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_May2022Member" xlink:href="pypd-20221231.xsd#pypd_May2022Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_May2022Member_lbl" xml:lang="en-US">May 2022 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_May2022Member" xlink:to="pypd_May2022Member_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_November2022Member" xlink:href="pypd-20221231.xsd#pypd_November2022Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_November2022Member_lbl" xml:lang="en-US">November 2022 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_November2022Member" xlink:to="pypd_November2022Member_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_September2020Member" xlink:href="pypd-20221231.xsd#pypd_September2020Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_September2020Member_lbl" xml:lang="en-US">September 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_September2020Member" xlink:to="pypd_September2020Member_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_April2022Member" xlink:href="pypd-20221231.xsd#pypd_April2022Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_April2022Member_lbl" xml:lang="en-US">April 2022 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_April2022Member" xlink:to="pypd_April2022Member_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_July2022Member" xlink:href="pypd-20221231.xsd#pypd_July2022Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_July2022Member_lbl" xml:lang="en-US">July 2022 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_July2022Member" xlink:to="pypd_July2022Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US">Lender Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DescriptionOfReverseShareSplit" xlink:href="pypd-20221231.xsd#pypd_DescriptionOfReverseShareSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_DescriptionOfReverseShareSplit_lbl" xml:lang="en-US">Description of reverse share split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DescriptionOfReverseShareSplit" xlink:to="pypd_DescriptionOfReverseShareSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_StockIssuedDuringPeriodSharesNewIssue" xlink:href="pypd-20221231.xsd#pypd_StockIssuedDuringPeriodSharesNewIssue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_StockIssuedDuringPeriodSharesNewIssue_lbl" xml:lang="en-US">Sale of ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockIssuedDuringPeriodSharesNewIssue" xlink:to="pypd_StockIssuedDuringPeriodSharesNewIssue_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_AggregateNetProceeds" xlink:href="pypd-20221231.xsd#pypd_AggregateNetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_AggregateNetProceeds_lbl" xml:lang="en-US">Aggregate net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AggregateNetProceeds" xlink:to="pypd_AggregateNetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_DescriptionAdministration" xlink:href="pypd-20221231.xsd#pypd_DescriptionAdministration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_DescriptionAdministration_lbl" xml:lang="en-US">Description administration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DescriptionAdministration" xlink:to="pypd_DescriptionAdministration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Cash equivalents and short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_IncurredLoss" xlink:href="pypd-20221231.xsd#pypd_IncurredLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_IncurredLoss_lbl" xml:lang="en-US">Incurred loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IncurredLoss" xlink:to="pypd_IncurredLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_CashFlowsFromOperatingActivities" xlink:href="pypd-20221231.xsd#pypd_CashFlowsFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_CashFlowsFromOperatingActivities_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_CashFlowsFromOperatingActivities" xlink:to="pypd_CashFlowsFromOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeEarningsDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeEarningsDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CumulativeEarningsDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEarningsDeficit" xlink:to="us-gaap_CumulativeEarningsDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Date of filing term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Short-term deposit bearing interest percentage rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RighttouseAssetsAndLeaseLiabilities" xlink:href="pypd-20221231.xsd#pypd_RighttouseAssetsAndLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_RighttouseAssetsAndLeaseLiabilities_lbl" xml:lang="en-US">Right-to-use assets and lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RighttouseAssetsAndLeaseLiabilities" xlink:to="pypd_RighttouseAssetsAndLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LeasePrepayments" xlink:href="pypd-20221231.xsd#pypd_LeasePrepayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_LeasePrepayments_lbl" xml:lang="en-US">Adjustments for lease repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LeasePrepayments" xlink:to="pypd_LeasePrepayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ReceivedTotalAmount" xlink:href="pypd-20221231.xsd#pypd_ReceivedTotalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ReceivedTotalAmount_lbl" xml:lang="en-US">Received total amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReceivedTotalAmount" xlink:to="pypd_ReceivedTotalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xml:lang="en-US">Royalty bearing grants amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NonroyaltyBearingGrantsAmount" xlink:href="pypd-20221231.xsd#pypd_NonroyaltyBearingGrantsAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_NonroyaltyBearingGrantsAmount_lbl" xml:lang="en-US">Non-royalty bearing grants amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NonroyaltyBearingGrantsAmount" xlink:to="pypd_NonroyaltyBearingGrantsAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_OutOfReceivedAmount" xlink:href="pypd-20221231.xsd#pypd_OutOfReceivedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_OutOfReceivedAmount_lbl" xml:lang="en-US">Out of received amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OutOfReceivedAmount" xlink:to="pypd_OutOfReceivedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NonroyaltyBearingGrants" xlink:href="pypd-20221231.xsd#pypd_NonroyaltyBearingGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_NonroyaltyBearingGrants_lbl" xml:lang="en-US">Non-royalty bearing grants amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NonroyaltyBearingGrants" xlink:to="pypd_NonroyaltyBearingGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FinancialExpenseIncome" xlink:href="pypd-20221231.xsd#pypd_FinancialExpenseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_FinancialExpenseIncome_lbl" xml:lang="en-US">Financial expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialExpenseIncome" xlink:to="pypd_FinancialExpenseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_TaxBenefitPercentage" xlink:href="pypd-20221231.xsd#pypd_TaxBenefitPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_TaxBenefitPercentage_lbl" xml:lang="en-US">Tax benefit, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_TaxBenefitPercentage" xlink:to="pypd_TaxBenefitPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_AgreementTerm" xlink:href="pypd-20221231.xsd#pypd_AgreementTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_AgreementTerm_lbl" xml:lang="en-US">Agreement term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AgreementTerm" xlink:to="pypd_AgreementTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NonRefundableAmount" xlink:href="pypd-20221231.xsd#pypd_NonRefundableAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_NonRefundableAmount_lbl" xml:lang="en-US">Non-refundable amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NonRefundableAmount" xlink:to="pypd_NonRefundableAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_AdditionalDevelopmentrelatedMilestonesPayments" xlink:href="pypd-20221231.xsd#pypd_AdditionalDevelopmentrelatedMilestonesPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_AdditionalDevelopmentrelatedMilestonesPayments_lbl" xml:lang="en-US">Additional development-related milestones payments (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AdditionalDevelopmentrelatedMilestonesPayments" xlink:to="pypd_AdditionalDevelopmentrelatedMilestonesPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_AdditionalAmountOfCommercialSaleMilestones" xlink:href="pypd-20221231.xsd#pypd_AdditionalAmountOfCommercialSaleMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_AdditionalAmountOfCommercialSaleMilestones_lbl" xml:lang="en-US">Additional amount of commercial sale milestones (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AdditionalAmountOfCommercialSaleMilestones" xlink:to="pypd_AdditionalAmountOfCommercialSaleMilestones_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US">Transaction price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_monthlyDepositsAtARate" xlink:href="pypd-20221231.xsd#pypd_monthlyDepositsAtARate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_monthlyDepositsAtARate_lbl" xml:lang="en-US">Monthly deposits percentage rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_monthlyDepositsAtARate" xlink:to="pypd_monthlyDepositsAtARate_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeverancePayExpenseAmount" xlink:href="pypd-20221231.xsd#pypd_SeverancePayExpenseAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeverancePayExpenseAmount_lbl" xml:lang="en-US">Severance pay expense amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeverancePayExpenseAmount" xlink:to="pypd_SeverancePayExpenseAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeverancePay" xlink:href="pypd-20221231.xsd#pypd_SeverancePay"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeverancePay_lbl" xml:lang="en-US">Severance pay, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeverancePay" xlink:to="pypd_SeverancePay_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_MatchingContributionsAmounts" xlink:href="pypd-20221231.xsd#pypd_MatchingContributionsAmounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_MatchingContributionsAmounts_lbl" xml:lang="en-US">Matching in contributions amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MatchingContributionsAmounts" xlink:to="pypd_MatchingContributionsAmounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount_lbl" xml:lang="en-US">Corresponding liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount" xlink:to="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesIndemnificationAgreementsPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeasesIndemnificationAgreementsPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesIndemnificationAgreementsPayments_lbl" xml:lang="en-US">Bank guarantees lease agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesIndemnificationAgreementsPayments" xlink:to="us-gaap_CapitalLeasesIndemnificationAgreementsPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LinesOfCreditCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xml:lang="en-US">Line credit agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">First tranche amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ProceedsFromLinesOfCreditOne" xlink:href="pypd-20221231.xsd#pypd_ProceedsFromLinesOfCreditOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ProceedsFromLinesOfCreditOne_lbl" xml:lang="en-US">Second tranche amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ProceedsFromLinesOfCreditOne" xlink:to="pypd_ProceedsFromLinesOfCreditOne_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ProceedsFromLinesOfCreditTwo" xlink:href="pypd-20221231.xsd#pypd_ProceedsFromLinesOfCreditTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ProceedsFromLinesOfCreditTwo_lbl" xml:lang="en-US">Third tranche amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ProceedsFromLinesOfCreditTwo" xlink:to="pypd_ProceedsFromLinesOfCreditTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_lbl" xml:lang="en-US">Line of credit borrowing price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:to="us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" xml:lang="en-US">Warrants percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Warrants exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants total amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl" xml:lang="en-US">Bears interest an annual rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Credit line fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPayment_lbl" xml:lang="en-US">Line of credit payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:to="us-gaap_LineOfCreditFacilityPeriodicPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LineOfCreditFacilityPeriodicPaymentOne" xlink:href="pypd-20221231.xsd#pypd_LineOfCreditFacilityPeriodicPaymentOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_LineOfCreditFacilityPeriodicPaymentOne_lbl" xml:lang="en-US">Third tranche not withdrawn</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LineOfCreditFacilityPeriodicPaymentOne" xlink:to="pypd_LineOfCreditFacilityPeriodicPaymentOne_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityDescription_lbl" xml:lang="en-US">Line of credit arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityDescription" xlink:to="us-gaap_LineOfCreditFacilityDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseShortTermBorrowings_lbl" xml:lang="en-US">Interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseShortTermBorrowings" xlink:to="us-gaap_InterestExpenseShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ProceedsFromParticipationPayments" xlink:href="pypd-20221231.xsd#pypd_ProceedsFromParticipationPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ProceedsFromParticipationPayments_lbl" xml:lang="en-US">Participation payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ProceedsFromParticipationPayments" xlink:to="pypd_ProceedsFromParticipationPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_CommitmentsAndContingentLiabilitiesDescription" xlink:href="pypd-20221231.xsd#pypd_CommitmentsAndContingentLiabilitiesDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_CommitmentsAndContingentLiabilitiesDescription_lbl" xml:lang="en-US">Commitments and Contingent liabilities, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_CommitmentsAndContingentLiabilitiesDescription" xlink:to="pypd_CommitmentsAndContingentLiabilitiesDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FindersFee" xlink:href="pypd-20221231.xsd#pypd_FindersFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_FindersFee_lbl" xml:lang="en-US">Finder&apos;s fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FindersFee" xlink:to="pypd_FindersFee_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SuitFillingExpense" xlink:href="pypd-20221231.xsd#pypd_SuitFillingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SuitFillingExpense_lbl" xml:lang="en-US">Suit filling expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SuitFillingExpense" xlink:to="pypd_SuitFillingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">State corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalHomeLoanBankAdvancesInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalHomeLoanBankAdvancesInterestRate_lbl" xml:lang="en-US">Federal tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalHomeLoanBankAdvancesInterestRate" xlink:to="us-gaap_FederalHomeLoanBankAdvancesInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_lbl" xml:lang="en-US">Accumulated losses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:to="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_AggregateOfferingPrice" xlink:href="pypd-20221231.xsd#pypd_AggregateOfferingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_AggregateOfferingPrice_lbl" xml:lang="en-US">Aggregate offering price (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AggregateOfferingPrice" xlink:to="pypd_AggregateOfferingPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US">Sale of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US">Total amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Net of issuance cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_StockOptionVestingPeriodDescription" xlink:href="pypd-20221231.xsd#pypd_StockOptionVestingPeriodDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_StockOptionVestingPeriodDescription_lbl" xml:lang="en-US">Stock option vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockOptionVestingPeriodDescription" xlink:to="pypd_StockOptionVestingPeriodDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareOptionPlanDescription" xlink:href="pypd-20221231.xsd#pypd_ShareOptionPlanDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShareOptionPlanDescription_lbl" xml:lang="en-US">Share option plan description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareOptionPlanDescription" xlink:to="pypd_ShareOptionPlanDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_NumberOfOptions" xlink:href="pypd-20221231.xsd#pypd_NumberOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_NumberOfOptions_lbl" xml:lang="en-US">Number of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumberOfOptions" xlink:to="pypd_NumberOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_StockOptionShares" xlink:href="pypd-20221231.xsd#pypd_StockOptionShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_StockOptionShares_lbl" xml:lang="en-US">Stock option shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockOptionShares" xlink:to="pypd_StockOptionShares_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_StockOptionsAvailableForFutureGrants" xlink:href="pypd-20221231.xsd#pypd_StockOptionsAvailableForFutureGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_StockOptionsAvailableForFutureGrants_lbl" xml:lang="en-US">Stock options available for future grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockOptionsAvailableForFutureGrants" xlink:to="pypd_StockOptionsAvailableForFutureGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_WeightedAverageGrantDateFairValueOfOptionsGranted" xlink:href="pypd-20221231.xsd#pypd_WeightedAverageGrantDateFairValueOfOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_WeightedAverageGrantDateFairValueOfOptionsGranted_lbl" xml:lang="en-US">Weighted average grant date fair value of options granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageGrantDateFairValueOfOptionsGranted" xlink:to="pypd_WeightedAverageGrantDateFairValueOfOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExpectedDividendYield" xlink:href="pypd-20221231.xsd#pypd_ExpectedDividendYield"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExpectedDividendYield_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExpectedDividendYield" xlink:to="pypd_ExpectedDividendYield_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_UnrecognizedCompensationCosts" xlink:href="pypd-20221231.xsd#pypd_UnrecognizedCompensationCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_UnrecognizedCompensationCosts_lbl" xml:lang="en-US">Unrecognized compensation costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnrecognizedCompensationCosts" xlink:to="pypd_UnrecognizedCompensationCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RecognizedOverWeightedAveragePeriod" xlink:href="pypd-20221231.xsd#pypd_RecognizedOverWeightedAveragePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_RecognizedOverWeightedAveragePeriod_lbl" xml:lang="en-US">Recognized over weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RecognizedOverWeightedAveragePeriod" xlink:to="pypd_RecognizedOverWeightedAveragePeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_WarrantsDescription" xlink:href="pypd-20221231.xsd#pypd_WarrantsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_WarrantsDescription_lbl" xml:lang="en-US">Warrants, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WarrantsDescription" xlink:to="pypd_WarrantsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_WarrantsOutstanding" xlink:href="pypd-20221231.xsd#pypd_WarrantsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_WarrantsOutstanding_lbl" xml:lang="en-US">Warrants outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WarrantsOutstanding" xlink:to="pypd_WarrantsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl" xml:lang="en-US">Warrant to purchase ordinary shares (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ServiceProvidersInAmount" xlink:href="pypd-20221231.xsd#pypd_ServiceProvidersInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ServiceProvidersInAmount_lbl" xml:lang="en-US">Service providers in amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ServiceProvidersInAmount" xlink:to="pypd_ServiceProvidersInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RelatedPartiesTerm" xlink:href="pypd-20221231.xsd#pypd_RelatedPartiesTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_RelatedPartiesTerm_lbl" xml:lang="en-US">Amir weisberg term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RelatedPartiesTerm" xlink:to="pypd_RelatedPartiesTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyCommittedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentCompanyCommittedCapital_lbl" xml:lang="en-US">Sale of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyCommittedCapital" xlink:to="us-gaap_InvestmentCompanyCommittedCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_lbl" xml:lang="en-US">Total amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:to="us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_lbl" xml:lang="en-US">Net issuance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExercisePriceDecrease" xlink:href="pypd-20221231.xsd#pypd_ExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExercisePriceDecrease_lbl" xml:lang="en-US">Exercise price decreased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceDecrease" xlink:to="pypd_ExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_InterestRepayments" xlink:href="pypd-20221231.xsd#pypd_InterestRepayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_InterestRepayments_lbl" xml:lang="en-US">Interest repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_InterestRepayments" xlink:to="pypd_InterestRepayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_lbl" xml:lang="en-US">Restructuring percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US">Percentage incremental</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_MinimumPaidAmount" xlink:href="pypd-20221231.xsd#pypd_MinimumPaidAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_MinimumPaidAmount_lbl" xml:lang="en-US">Minimum paid amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MinimumPaidAmount" xlink:to="pypd_MinimumPaidAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ExceedAmount" xlink:href="pypd-20221231.xsd#pypd_ExceedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ExceedAmount_lbl" xml:lang="en-US">Exceed amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExceedAmount" xlink:to="pypd_ExceedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Pre funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Private Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_OfferingExpensesPayable" xlink:href="pypd-20221231.xsd#pypd_OfferingExpensesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_OfferingExpensesPayable_lbl" xml:lang="en-US">Offering expenses payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OfferingExpensesPayable" xlink:to="pypd_OfferingExpensesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConsolidatedFinancialStatementsPolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_ConsolidatedFinancialStatementsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ConsolidatedFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US">Consolidated financial statements in U.S. dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConsolidatedFinancialStatementsPolicyTextBlock" xlink:to="pypd_ConsolidatedFinancialStatementsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RestrictedCashPolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_RestrictedCashPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_RestrictedCashPolicyTextBlock_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RestrictedCashPolicyTextBlock" xlink:to="pypd_RestrictedCashPolicyTextBlock_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYyn91pOe7VtKs04Jlb3SPvCuMaehdfSUhtJg7vOyFoOF/AztNXIUhzx+P+epY4WtCBWdIE9zpOkAYuuw4yh598SS/DDR25UhB1vr3InT0Iv/WeMwUMCDO+Y4l9K2x3Xs422PVBz1J7zYQwrV5v8agZB4PYMfGJUC77vg+ip4C7gf3USrQzneAX+J4iGbbvfy0=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShorttermDepositsPolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_ShorttermDepositsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShorttermDepositsPolicyTextBlock_lbl" xml:lang="en-US">Short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShorttermDepositsPolicyTextBlock" xlink:to="pypd_ShorttermDepositsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development, net expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Grants and participations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Accounting for share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_BasicAndDilutedLossPerSharePolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_BasicAndDilutedLossPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_BasicAndDilutedLossPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_BasicAndDilutedLossPerSharePolicyTextBlock" xlink:to="pypd_BasicAndDilutedLossPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US">Convertible preferred shares and convertible preferred shares warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" xlink:to="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value of financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivative financial instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionAllowances" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAllowances"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionAllowances_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAllowances" xlink:to="us-gaap_RevenueRecognitionAllowances_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of credit risks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SeverancePayPolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_SeverancePayPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SeverancePayPolicyTextBlock_lbl" xml:lang="en-US">Severance pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeverancePayPolicyTextBlock" xlink:to="pypd_SeverancePayPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy_lbl" xml:lang="en-US">Contingent liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:to="us-gaap_ContingentLiabilityReserveEstimatePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted accounting pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted" xlink:href="pypd-20221231.xsd#pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted_lbl" xml:lang="en-US">Recently issued accounting pronouncements, not yet adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted" xlink:to="pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Overallotment option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl0" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ShortTermDepositsMember" xlink:href="pypd-20221231.xsd#pypd_ShortTermDepositsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ShortTermDepositsMember_lbl" xml:lang="en-US">Short-Term Deposits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShortTermDepositsMember" xlink:to="pypd_ShortTermDepositsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FirstTrancheMember" xlink:href="pypd-20221231.xsd#pypd_FirstTrancheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_FirstTrancheMember_lbl" xml:lang="en-US">First tranche [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FirstTrancheMember" xlink:to="pypd_FirstTrancheMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SecondTrancheMember" xlink:href="pypd-20221231.xsd#pypd_SecondTrancheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_SecondTrancheMember_lbl" xml:lang="en-US">Second Tranche [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SecondTrancheMember" xlink:to="pypd_SecondTrancheMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ThiredTrancheMember" xlink:href="pypd-20221231.xsd#pypd_ThiredTrancheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ThiredTrancheMember_lbl" xml:lang="en-US">Third tranches [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ThiredTrancheMember" xlink:to="pypd_ThiredTrancheMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_IL_lbl" xml:lang="en-US">Israel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">United States of America [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_OfficerMember_lbl" xml:lang="en-US">Officers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_TwoThousandTwelveShareOptionPlanMember" xlink:href="pypd-20221231.xsd#pypd_TwoThousandTwelveShareOptionPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_TwoThousandTwelveShareOptionPlanMember_lbl" xml:lang="en-US">2012 Share Option Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_TwoThousandTwelveShareOptionPlanMember" xlink:to="pypd_TwoThousandTwelveShareOptionPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ConsultAndDirectorsMember" xlink:href="pypd-20221231.xsd#pypd_ConsultAndDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_ConsultAndDirectorsMember_lbl" xml:lang="en-US">Consultant and Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConsultAndDirectorsMember" xlink:to="pypd_ConsultAndDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FinancialIncomeExpensesNetTable" xlink:href="pypd-20221231.xsd#pypd_FinancialIncomeExpensesNetTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FinancialIncomeExpensesNetTable_lbl" xml:lang="en-US">Financial (Income) Expenses, Net [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialIncomeExpensesNetTable" xlink:to="pypd_FinancialIncomeExpensesNetTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FinancialIncomeExpensesNetLineItems" xlink:href="pypd-20221231.xsd#pypd_FinancialIncomeExpensesNetLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FinancialIncomeExpensesNetLineItems_lbl" xml:lang="en-US">Financial (Income) Expenses, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialIncomeExpensesNetLineItems" xlink:to="pypd_FinancialIncomeExpensesNetLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesTable" xlink:href="pypd-20221231.xsd#pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesTable_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesTable" xlink:to="pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems" xlink:href="pypd-20221231.xsd#pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems_lbl" xml:lang="en-US">Schedule of Accrued Expenses And Other Current Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems" xlink:to="pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FinancialIncomeExpensesNetTablesTable" xlink:href="pypd-20221231.xsd#pypd_FinancialIncomeExpensesNetTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FinancialIncomeExpensesNetTablesTable_lbl" xml:lang="en-US">Financial (Income) Expenses, Net (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialIncomeExpensesNetTablesTable" xlink:to="pypd_FinancialIncomeExpensesNetTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_FinancialIncomeExpensesNetTablesLineItems" xlink:href="pypd-20221231.xsd#pypd_FinancialIncomeExpensesNetTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_FinancialIncomeExpensesNetTablesLineItems_lbl" xml:lang="en-US">Financial (Income) Expenses, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialIncomeExpensesNetTablesLineItems" xlink:to="pypd_FinancialIncomeExpensesNetTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Public Utility, Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Public Utility, Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US">Balance Sheet Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable" xlink:href="pypd-20221231.xsd#pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable" xlink:to="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" xlink:href="pypd-20221231.xsd#pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" xlink:to="pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable" xlink:href="pypd-20221231.xsd#pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities (Details) - Schedule of accrued expenses and other current liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable" xlink:to="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" xlink:href="pypd-20221231.xsd#pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems_lbl" xml:lang="en-US">Schedule of Accrued Expenses And Other Current Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" xlink:to="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" xlink:href="pypd-20221231.xsd#pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable_lbl" xml:lang="en-US">Income Taxes (Details) - Schedule of deferred tax assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" xlink:to="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:href="pypd-20221231.xsd#pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) - Schedule of deferred tax assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:to="pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of ordinary share capital [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalTable" xlink:to="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems_lbl" xml:lang="en-US">Schedule of ordinary share capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems" xlink:to="pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of status of options to employees [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable" xlink:to="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of status of options to employees [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of share options at the grant date [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable" xlink:to="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of share options at the grant date [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems" xlink:to="pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of share-based compensation expense recognized [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable" xlink:to="pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of share-based compensation expense recognized [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems" xlink:to="pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US">Award Date [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of outstanding options granted [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable" xlink:to="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of outstanding options granted [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_GeneralDetailsTable" xlink:href="pypd-20221231.xsd#pypd_GeneralDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_GeneralDetailsTable_lbl" xml:lang="en-US">General (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_GeneralDetailsTable" xlink:to="pypd_GeneralDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_GeneralDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_GeneralDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_GeneralDetailsLineItems_lbl" xml:lang="en-US">General (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_GeneralDetailsLineItems" xlink:to="pypd_GeneralDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SignificantAccountingPoliciesDetailsTable" xlink:href="pypd-20221231.xsd#pypd_SignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SignificantAccountingPoliciesDetailsTable" xlink:to="pypd_SignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_SignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SignificantAccountingPoliciesDetailsLineItems" xlink:to="pypd_SignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LineofCreditArrangementDetailsTable" xlink:href="pypd-20221231.xsd#pypd_LineofCreditArrangementDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LineofCreditArrangementDetailsTable_lbl" xml:lang="en-US">Line of Credit Arrangement (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LineofCreditArrangementDetailsTable" xlink:to="pypd_LineofCreditArrangementDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LineofCreditArrangementDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_LineofCreditArrangementDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LineofCreditArrangementDetailsLineItems_lbl" xml:lang="en-US">Line of Credit Arrangement (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LineofCreditArrangementDetailsLineItems" xlink:to="pypd_LineofCreditArrangementDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_IncomeTaxesDetailsTable" xlink:href="pypd-20221231.xsd#pypd_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IncomeTaxesDetailsTable" xlink:to="pypd_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_IncomeTaxesDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_IncomeTaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_IncomeTaxesDetailsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IncomeTaxesDetailsLineItems" xlink:to="pypd_IncomeTaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDetailsTable" xlink:to="pypd_ShareholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_ShareholdersEquityDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareholdersEquityDetailsLineItems" xlink:to="pypd_ShareholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RelatedPartiesDetailsTable" xlink:href="pypd-20221231.xsd#pypd_RelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RelatedPartiesDetailsTable_lbl" xml:lang="en-US">Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RelatedPartiesDetailsTable" xlink:to="pypd_RelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_RelatedPartiesDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_RelatedPartiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RelatedPartiesDetailsLineItems_lbl" xml:lang="en-US">Related Parties (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RelatedPartiesDetailsLineItems" xlink:to="pypd_RelatedPartiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SubsequentEventsDetailsTable" xlink:href="pypd-20221231.xsd#pypd_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SubsequentEventsDetailsTable" xlink:to="pypd_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_SubsequentEventsDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SubsequentEventsDetailsLineItems" xlink:to="pypd_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_AdditionalAmountOfCommercialSaleMilestones_lbl0" xml:lang="en-US">Additional amount of commercial sale milestones.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AdditionalAmountOfCommercialSaleMilestones" xlink:to="pypd_AdditionalAmountOfCommercialSaleMilestones_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_AdditionalDevelopmentrelatedMilestonesPayments_lbl0" xml:lang="en-US">Additional development-related milestones payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AdditionalDevelopmentrelatedMilestonesPayments" xlink:to="pypd_AdditionalDevelopmentrelatedMilestonesPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_AdjustmentToRiskfreeInterestRate_lbl0" xml:lang="en-US">Adjustment to risk-free interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AdjustmentToRiskfreeInterestRate" xlink:to="pypd_AdjustmentToRiskfreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_AggregateNetProceeds_lbl0" xml:lang="en-US">Amount related to net proceeds from initial public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AggregateNetProceeds" xlink:to="pypd_AggregateNetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_AggregateOfferingPrice_lbl0" xml:lang="en-US">Aggregate offering price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AggregateOfferingPrice" xlink:to="pypd_AggregateOfferingPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_AgreementTerm_lbl0" xml:lang="en-US">Agreement term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AgreementTerm" xlink:to="pypd_AgreementTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ComputersandSoftware_lbl0" xml:lang="en-US">Computers and software.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ComputersandSoftware" xlink:to="pypd_ComputersandSoftware_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ConsolidatedFinancialStatementsPolicyTextBlock_lbl0" xml:lang="en-US">Consolidated financial statements in U.S. dollars policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConsolidatedFinancialStatementsPolicyTextBlock" xlink:to="pypd_ConsolidatedFinancialStatementsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares_lbl0" xml:lang="en-US">Amount related to conversion of Convertible Preferred shares to ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares" xlink:to="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares_lbl0" xml:lang="en-US">Conversion of Convertible Preferred shares to ordinary shares, shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" xlink:to="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_lbl0" xml:lang="en-US">Convertible preferred shares and convertible preferred shares warrant liability policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" xlink:to="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses_lbl0" xml:lang="en-US">Decrease (increase) in receivables and prepaid expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses" xlink:to="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_DeemedDividend_lbl0" xml:lang="en-US">Amount declared as dividend.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DeemedDividend" xlink:to="pypd_DeemedDividend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_DeemedDividends_lbl0" xml:lang="en-US">The amount of deemed dividend.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DeemedDividends" xlink:to="pypd_DeemedDividends_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_DescriptionAdministration_lbl0" xml:lang="en-US">Description of administration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DescriptionAdministration" xlink:to="pypd_DescriptionAdministration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_DomesticIsrael_lbl0" xml:lang="en-US">The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DomesticIsrael" xlink:to="pypd_DomesticIsrael_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ExerciseOfWarrants_lbl0" xml:lang="en-US">Exercise of Warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExerciseOfWarrants" xlink:to="pypd_ExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ExercisePriceDecrease_lbl0" xml:lang="en-US">Share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceDecrease" xlink:to="pypd_ExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_FinancialExpenseIncome_lbl0" xml:lang="en-US">Amount of financial expense (income).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialExpenseIncome" xlink:to="pypd_FinancialExpenseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_FindersFee_lbl0" xml:lang="en-US">Finder&apos;s fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FindersFee" xlink:to="pypd_FindersFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_GovernmentAuthorities_lbl0" xml:lang="en-US">Guarantee by US government authority for government insured loans.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_GovernmentAuthorities" xlink:to="pypd_GovernmentAuthorities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_InterestRepayments_lbl0" xml:lang="en-US">Percentage of interest repayments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_InterestRepayments" xlink:to="pypd_InterestRepayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_IsraelInnovationAuthorityGrantReceived_lbl0" xml:lang="en-US">Israel Innovation Authority grant received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IsraelInnovationAuthorityGrantReceived" xlink:to="pypd_IsraelInnovationAuthorityGrantReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_IssuanceOfOrdinarySharesNetinShares_lbl0" xml:lang="en-US">Number of issuance of Ordinary shares, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IssuanceOfOrdinarySharesNetinShares" xlink:to="pypd_IssuanceOfOrdinarySharesNetinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_IssuanceOfWarrants_lbl0" xml:lang="en-US">Issuance of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IssuanceOfWarrants" xlink:to="pypd_IssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_LaboratoryAndManufacturingEquipment_lbl0" xml:lang="en-US">Laboratory and manufacturing equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LaboratoryAndManufacturingEquipment" xlink:to="pypd_LaboratoryAndManufacturingEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_LeaseLiabilities_lbl0" xml:lang="en-US">Amount of lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LeaseLiabilities" xlink:to="pypd_LeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_LeasePrepayments_lbl0" xml:lang="en-US">Lease prepayments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LeasePrepayments" xlink:to="pypd_LeasePrepayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_LineOfCreditArrangementTextBlock_lbl0" xml:lang="en-US">The entire disclosure of line of credit arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LineOfCreditArrangementTextBlock" xlink:to="pypd_LineOfCreditArrangementTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_LineOfCreditFacilityPeriodicPaymentOne_lbl0" xml:lang="en-US">Amount of the required periodic payments of both interest and principal.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LineOfCreditFacilityPeriodicPaymentOne" xlink:to="pypd_LineOfCreditFacilityPeriodicPaymentOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_LongtermDeposits_lbl0" xml:lang="en-US">Amount available in long term deposits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LongtermDeposits" xlink:to="pypd_LongtermDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_MarketingAndBusinessDevelopmentExpenses_lbl0" xml:lang="en-US">Amount related to Marketing and business development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MarketingAndBusinessDevelopmentExpenses" xlink:to="pypd_MarketingAndBusinessDevelopmentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_MatchingContributionsAmounts_lbl0" xml:lang="en-US">Matching Contributions Amounts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MatchingContributionsAmounts" xlink:to="pypd_MatchingContributionsAmounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare_lbl0" xml:lang="en-US">Net loss attributable to Ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare" xlink:to="pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_NonRefundableAmount_lbl0" xml:lang="en-US">Non refundable amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NonRefundableAmount" xlink:to="pypd_NonRefundableAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_NonroyaltyBearingGrants_lbl0" xml:lang="en-US">Non-royalty bearing grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NonroyaltyBearingGrants" xlink:to="pypd_NonroyaltyBearingGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_NonroyaltyBearingGrantsAmount_lbl0" xml:lang="en-US">Non-royalty Bearing Grants Amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NonroyaltyBearingGrantsAmount" xlink:to="pypd_NonroyaltyBearingGrantsAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_NumberOfOptions_lbl0" xml:lang="en-US">Number of options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumberOfOptions" xlink:to="pypd_NumberOfOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_OfferingExpensesPayable_lbl0" xml:lang="en-US">Amount of offering expenses payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OfferingExpensesPayable" xlink:to="pypd_OfferingExpensesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_OperatingLeaseAssets_lbl0" xml:lang="en-US">Operating lease assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OperatingLeaseAssets" xlink:to="pypd_OperatingLeaseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_OptionsExercisable_lbl0" xml:lang="en-US">Options exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OptionsExercisable" xlink:to="pypd_OptionsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_OutOfReceivedAmount_lbl0" xml:lang="en-US">Out of Received Amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OutOfReceivedAmount" xlink:to="pypd_OutOfReceivedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet_lbl0" xml:lang="en-US">The amount of Short term and long term deposits, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet" xlink:to="pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_PrepaymentForEquipments_lbl0" xml:lang="en-US">Pre-payment for equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaymentForEquipments" xlink:to="pypd_PrepaymentForEquipments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ProceedsFromLinesOfCreditOne_lbl0" xml:lang="en-US">Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ProceedsFromLinesOfCreditOne" xlink:to="pypd_ProceedsFromLinesOfCreditOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ProceedsFromLinesOfCreditTwo_lbl0" xml:lang="en-US">Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ProceedsFromLinesOfCreditTwo" xlink:to="pypd_ProceedsFromLinesOfCreditTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ProceedsFromParticipationPayments_lbl0" xml:lang="en-US">Participation payments received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ProceedsFromParticipationPayments" xlink:to="pypd_ProceedsFromParticipationPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_PropertyAndEquipmentPaidForInPriorPeriods_lbl0" xml:lang="en-US">The amount of property and equipment paid for in prior periods.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PropertyAndEquipmentPaidForInPriorPeriods" xlink:to="pypd_PropertyAndEquipmentPaidForInPriorPeriods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_PropertyPlantAndEquipmentPercent_lbl0" xml:lang="en-US">Property, plant and equipment percent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PropertyPlantAndEquipmentPercent" xlink:to="pypd_PropertyPlantAndEquipmentPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable_lbl0" xml:lang="en-US">Purchase of property and equipment included in trade payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable" xlink:to="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ReceivedTotalAmount_lbl0" xml:lang="en-US">Received Total Amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReceivedTotalAmount" xlink:to="pypd_ReceivedTotalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted_lbl0" xml:lang="en-US">Recently Issued Accounting Pronouncements and not yet adopted policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted" xlink:to="pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ReclassificationOfWarrantsIntoEquity_lbl0" xml:lang="en-US">Reclassification of Warrants into equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReclassificationOfWarrantsIntoEquity" xlink:to="pypd_ReclassificationOfWarrantsIntoEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_RecognizedOverWeightedAveragePeriod_lbl0" xml:lang="en-US">Recognized over a weighted average period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RecognizedOverWeightedAveragePeriod" xlink:to="pypd_RecognizedOverWeightedAveragePeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ReevaluationOfWarrants_lbl0" xml:lang="en-US">Re-evaluation of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReevaluationOfWarrants" xlink:to="pypd_ReevaluationOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_RelatedPartiesTerm_lbl0" xml:lang="en-US">Related parties term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RelatedPartiesTerm" xlink:to="pypd_RelatedPartiesTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_RestrictedCashIncludedInOtherLongtermAssets_lbl0" xml:lang="en-US">The amount of restricted cash included in other long term assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RestrictedCashIncludedInOtherLongtermAssets" xlink:to="pypd_RestrictedCashIncludedInOtherLongtermAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_RestrictedCashPolicyTextBlock_lbl0" xml:lang="en-US">Restricted cash policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RestrictedCashPolicyTextBlock" xlink:to="pypd_RestrictedCashPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_RighttouseAssetsAndLeaseLiabilities_lbl0" xml:lang="en-US">Right-to-use assets and lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RighttouseAssetsAndLeaseLiabilities" xlink:to="pypd_RighttouseAssetsAndLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">The entire disclosure of lease related assets and liabilities table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" xlink:to="pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_SeverancePay_lbl0" xml:lang="en-US">Severance pay.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeverancePay" xlink:to="pypd_SeverancePay_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_SeverancePayExpenseAmount_lbl0" xml:lang="en-US">Severance Pay Expense Amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeverancePayExpenseAmount" xlink:to="pypd_SeverancePayExpenseAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_SeverancePayPolicyTextBlock_lbl0" xml:lang="en-US">Severance pay policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeverancePayPolicyTextBlock" xlink:to="pypd_SeverancePayPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ShareOptionPlanDescription_lbl0" xml:lang="en-US">Share option plan description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareOptionPlanDescription" xlink:to="pypd_ShareOptionPlanDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_ShorttermDepositsPolicyTextBlock_lbl0" xml:lang="en-US">Short-term deposits policy text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShorttermDepositsPolicyTextBlock" xlink:to="pypd_ShorttermDepositsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares_lbl0" xml:lang="en-US">Exercise of Warrants, shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares" xlink:to="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_StockOptionShares_lbl0" xml:lang="en-US">Stock option shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockOptionShares" xlink:to="pypd_StockOptionShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_StockOptionsAvailableForFutureGrants_lbl0" xml:lang="en-US">Stock options available for future grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockOptionsAvailableForFutureGrants" xlink:to="pypd_StockOptionsAvailableForFutureGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_SuitFillingExpense_lbl0" xml:lang="en-US">Suit filling expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SuitFillingExpense" xlink:to="pypd_SuitFillingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_TaxBenefitPercentage_lbl0" xml:lang="en-US">Tax Benefit Percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_TaxBenefitPercentage" xlink:to="pypd_TaxBenefitPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_UnrecognizedCompensationCosts_lbl0" xml:lang="en-US">Amount of unrecognized compensation costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnrecognizedCompensationCosts" xlink:to="pypd_UnrecognizedCompensationCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_WarrantsDescription_lbl0" xml:lang="en-US">Warrants, Description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WarrantsDescription" xlink:to="pypd_WarrantsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares_lbl0" xml:lang="en-US">Weighted average effect of dilutive securities Warrants to convertible preferred shares (in Shares).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" xlink:to="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_WeightedAverageGrantDateFairValueOfOptionsGranted_lbl0" xml:lang="en-US">Weighted average grant date fair value of options granted .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageGrantDateFairValueOfOptionsGranted" xlink:to="pypd_WeightedAverageGrantDateFairValueOfOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pypd_monthlyDepositsAtARate_lbl0" xml:lang="en-US">Monthly deposits percentage rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_monthlyDepositsAtARate" xlink:to="pypd_monthlyDepositsAtARate_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding_lbl0" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding" xlink:to="pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted_lbl1" xml:lang="en-US">Recently Issued Accounting Pronouncements Not Yet Adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted" xlink:to="pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_MarketingAndBusinessDevelopmentExpenses_lbl1" xml:lang="en-US">Marketing And Business Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MarketingAndBusinessDevelopmentExpenses" xlink:to="pypd_MarketingAndBusinessDevelopmentExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AgreementTerm_lbl1" xml:lang="en-US">Agreement Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AgreementTerm" xlink:to="pypd_AgreementTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract61_lbl0" xml:lang="en-US">Unlabeled Abstract61</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract61" xlink:to="pypd_UnlabeledAbstract61_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract62_lbl0" xml:lang="en-US">Unlabeled Abstract62</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract62" xlink:to="pypd_UnlabeledAbstract62_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract60_lbl0" xml:lang="en-US">Unlabeled Abstract60</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract60" xlink:to="pypd_UnlabeledAbstract60_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract65_lbl0" xml:lang="en-US">Unlabeled Abstract65</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract65" xlink:to="pypd_UnlabeledAbstract65_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy_lbl0" xml:lang="en-US">Contingent Liability Reserve Estimate, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:to="us-gaap_ContingentLiabilityReserveEstimatePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract66_lbl0" xml:lang="en-US">Unlabeled Abstract66</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract66" xlink:to="pypd_UnlabeledAbstract66_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract63_lbl0" xml:lang="en-US">Unlabeled Abstract63</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract63" xlink:to="pypd_UnlabeledAbstract63_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract_lbl0" xml:lang="en-US">Rightofuse Asset Recognized With Corresponding Lease Liability Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract" xlink:to="pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract64_lbl0" xml:lang="en-US">Unlabeled Abstract64</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract64" xlink:to="pypd_UnlabeledAbstract64_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract69_lbl0" xml:lang="en-US">Unlabeled Abstract69</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract69" xlink:to="pypd_UnlabeledAbstract69_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LineOfCreditFacilityPeriodicPaymentOne_lbl1" xml:lang="en-US">Line Of Credit Facility Periodic Payment One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LineOfCreditFacilityPeriodicPaymentOne" xlink:to="pypd_LineOfCreditFacilityPeriodicPaymentOne_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_lbl0" xml:lang="en-US">Line of Credit Facility, Maximum Month-end Outstanding Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:to="us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract67_lbl0" xml:lang="en-US">Unlabeled Abstract67</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract67" xlink:to="pypd_UnlabeledAbstract67_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract68_lbl0" xml:lang="en-US">Unlabeled Abstract68</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract68" xlink:to="pypd_UnlabeledAbstract68_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl0" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare_lbl1" xml:lang="en-US">Net Loss Attributable To Ordinary Sharesin Dollars Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare" xlink:to="pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_WarrantsDescription_lbl1" xml:lang="en-US">Warrants Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WarrantsDescription" xlink:to="pypd_WarrantsDescription_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DomesticIsrael_lbl1" xml:lang="en-US">Domestic Israel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DomesticIsrael" xlink:to="pypd_DomesticIsrael_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract72_lbl0" xml:lang="en-US">Unlabeled Abstract72</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract72" xlink:to="pypd_UnlabeledAbstract72_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract70_lbl0" xml:lang="en-US">Unlabeled Abstract70</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract70" xlink:to="pypd_UnlabeledAbstract70_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract71_lbl0" xml:lang="en-US">Unlabeled Abstract71</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract71" xlink:to="pypd_UnlabeledAbstract71_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl0" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PropertyAndEquipmentPaidForInPriorPeriods_lbl1" xml:lang="en-US">Property And Equipment Paid For In Prior Periods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PropertyAndEquipmentPaidForInPriorPeriods" xlink:to="pypd_PropertyAndEquipmentPaidForInPriorPeriods_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl0" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract38_lbl0" xml:lang="en-US">Unlabeled Abstract38</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract38" xlink:to="pypd_UnlabeledAbstract38_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract39_lbl0" xml:lang="en-US">Unlabeled Abstract39</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract39" xlink:to="pypd_UnlabeledAbstract39_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_August2021Member_lbl0" xml:lang="en-US">August2021 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_August2021Member" xlink:to="pypd_August2021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExerciseOfWarrants_lbl1" xml:lang="en-US">Exercise Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExerciseOfWarrants" xlink:to="pypd_ExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract40_lbl0" xml:lang="en-US">Unlabeled Abstract40</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract40" xlink:to="pypd_UnlabeledAbstract40_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_StockOptionShares_lbl1" xml:lang="en-US">Stock Option Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockOptionShares" xlink:to="pypd_StockOptionShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract43_lbl0" xml:lang="en-US">Unlabeled Abstract43</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract43" xlink:to="pypd_UnlabeledAbstract43_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestmentsAbstract_lbl0" xml:lang="en-US">Long-Term Investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_LongTermInvestmentsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract44_lbl0" xml:lang="en-US">Unlabeled Abstract44</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract44" xlink:to="pypd_UnlabeledAbstract44_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract41_lbl0" xml:lang="en-US">Unlabeled Abstract41</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract41" xlink:to="pypd_UnlabeledAbstract41_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract42_lbl0" xml:lang="en-US">Unlabeled Abstract42</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract42" xlink:to="pypd_UnlabeledAbstract42_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl1" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract47_lbl0" xml:lang="en-US">Unlabeled Abstract47</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract47" xlink:to="pypd_UnlabeledAbstract47_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract48_lbl0" xml:lang="en-US">Unlabeled Abstract48</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract48" xlink:to="pypd_UnlabeledAbstract48_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract45_lbl0" xml:lang="en-US">Unlabeled Abstract45</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract45" xlink:to="pypd_UnlabeledAbstract45_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract46_lbl0" xml:lang="en-US">Unlabeled Abstract46</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract46" xlink:to="pypd_UnlabeledAbstract46_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RecognizedOverWeightedAveragePeriod_lbl1" xml:lang="en-US">Recognized Over Weighted Average Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RecognizedOverWeightedAveragePeriod" xlink:to="pypd_RecognizedOverWeightedAveragePeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract49_lbl0" xml:lang="en-US">Unlabeled Abstract49</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract49" xlink:to="pypd_UnlabeledAbstract49_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl0" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Lease Related Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract" xlink:to="pypd_ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_StockOptionVestingPeriodDescription_lbl0" xml:lang="en-US">Stock Option Vesting Period Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockOptionVestingPeriodDescription" xlink:to="pypd_StockOptionVestingPeriodDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseShortTermBorrowings_lbl0" xml:lang="en-US">Interest Expense, Short-Term Borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseShortTermBorrowings" xlink:to="us-gaap_InterestExpenseShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="pypd_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract50_lbl0" xml:lang="en-US">Unlabeled Abstract50</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract50" xlink:to="pypd_UnlabeledAbstract50_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssets_lbl0" xml:lang="en-US">Deposits Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract51_lbl0" xml:lang="en-US">Unlabeled Abstract51</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract51" xlink:to="pypd_UnlabeledAbstract51_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FinancialExpenseIncome_lbl1" xml:lang="en-US">Financial Expense Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialExpenseIncome" xlink:to="pypd_FinancialExpenseIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract54_lbl0" xml:lang="en-US">Unlabeled Abstract54</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract54" xlink:to="pypd_UnlabeledAbstract54_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract55_lbl0" xml:lang="en-US">Unlabeled Abstract55</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract55" xlink:to="pypd_UnlabeledAbstract55_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic_lbl0" xml:lang="en-US">Undistributed Continuing Operation Earnings (Loss), Allocation to Participating Securities, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:to="us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract52_lbl0" xml:lang="en-US">Unlabeled Abstract52</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract52" xlink:to="pypd_UnlabeledAbstract52_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract53_lbl0" xml:lang="en-US">Unlabeled Abstract53</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract53" xlink:to="pypd_UnlabeledAbstract53_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract58_lbl0" xml:lang="en-US">Unlabeled Abstract58</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract58" xlink:to="pypd_UnlabeledAbstract58_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract59_lbl0" xml:lang="en-US">Unlabeled Abstract59</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract59" xlink:to="pypd_UnlabeledAbstract59_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract56_lbl0" xml:lang="en-US">Unlabeled Abstract56</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract56" xlink:to="pypd_UnlabeledAbstract56_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract57_lbl0" xml:lang="en-US">Unlabeled Abstract57</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract57" xlink:to="pypd_UnlabeledAbstract57_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract18" xlink:to="pypd_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract19" xlink:to="pypd_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract16" xlink:to="pypd_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract17" xlink:to="pypd_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DenominatorAbstract_lbl0" xml:lang="en-US">Denominator Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DenominatorAbstract" xlink:to="pypd_DenominatorAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalHomeLoanBankAdvancesInterestRate_lbl0" xml:lang="en-US">Federal Home Loan Bank, Advances, Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalHomeLoanBankAdvancesInterestRate" xlink:to="us-gaap_FederalHomeLoanBankAdvancesInterestRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract_lbl" xml:lang="en-US">Schedule Of Deferred Income Taxes Reflect The Net Tax Effects Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" xlink:to="pypd_ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfShareBasedCompensationExpenseRecognizedAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfShareBasedCompensationExpenseRecognizedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfShareBasedCompensationExpenseRecognizedAbstract_lbl" xml:lang="en-US">Schedule Of Share Based Compensation Expense Recognized Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfShareBasedCompensationExpenseRecognizedAbstract" xlink:to="pypd_ScheduleOfShareBasedCompensationExpenseRecognizedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestments_lbl0" xml:lang="en-US">Long-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract21" xlink:to="pypd_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract22" xlink:to="pypd_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract20" xlink:to="pypd_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract25" xlink:to="pypd_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LineOfCreditArrangementTextBlock_lbl1" xml:lang="en-US">Line Of Credit Arrangement Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LineOfCreditArrangementTextBlock" xlink:to="pypd_LineOfCreditArrangementTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0" xml:lang="en-US">Short-Term Debt, Percentage Bearing Fixed Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract26_lbl0" xml:lang="en-US">Unlabeled Abstract26</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract26" xlink:to="pypd_UnlabeledAbstract26_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract23" xlink:to="pypd_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeverancePayPolicyTextBlock_lbl1" xml:lang="en-US">Severance Pay Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeverancePayPolicyTextBlock" xlink:to="pypd_SeverancePayPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract24" xlink:to="pypd_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract29_lbl0" xml:lang="en-US">Unlabeled Abstract29</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract29" xlink:to="pypd_UnlabeledAbstract29_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract27_lbl0" xml:lang="en-US">Unlabeled Abstract27</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract27" xlink:to="pypd_UnlabeledAbstract27_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract28_lbl0" xml:lang="en-US">Unlabeled Abstract28</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract28" xlink:to="pypd_UnlabeledAbstract28_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesOutstanding_lbl0" xml:lang="en-US">Excess Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesOutstanding" xlink:to="us-gaap_ExcessStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_CashFlowsFromOperatingActivities_lbl0" xml:lang="en-US">Cash Flows From Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_CashFlowsFromOperatingActivities" xlink:to="pypd_CashFlowsFromOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl1" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl0" xml:lang="en-US">Other Operating Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_JuneTwoThousandSeventeenMember_lbl0" xml:lang="en-US">June Two Thousand Seventeen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_JuneTwoThousandSeventeenMember" xlink:to="pypd_JuneTwoThousandSeventeenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract32_lbl0" xml:lang="en-US">Unlabeled Abstract32</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract32" xlink:to="pypd_UnlabeledAbstract32_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract33_lbl0" xml:lang="en-US">Unlabeled Abstract33</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract33" xlink:to="pypd_UnlabeledAbstract33_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract30_lbl0" xml:lang="en-US">Unlabeled Abstract30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract30" xlink:to="pypd_UnlabeledAbstract30_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract31_lbl0" xml:lang="en-US">Unlabeled Abstract31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract31" xlink:to="pypd_UnlabeledAbstract31_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FinancialIncomeAbstract_lbl0" xml:lang="en-US">Financial Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialIncomeAbstract" xlink:to="pypd_FinancialIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract36_lbl0" xml:lang="en-US">Unlabeled Abstract36</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract36" xlink:to="pypd_UnlabeledAbstract36_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract37_lbl0" xml:lang="en-US">Unlabeled Abstract37</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract37" xlink:to="pypd_UnlabeledAbstract37_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract34_lbl0" xml:lang="en-US">Unlabeled Abstract34</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract34" xlink:to="pypd_UnlabeledAbstract34_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract35_lbl0" xml:lang="en-US">Unlabeled Abstract35</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract35" xlink:to="pypd_UnlabeledAbstract35_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LongtermDeposits_lbl1" xml:lang="en-US">Longterm Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LongtermDeposits" xlink:to="pypd_LongtermDeposits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FindersFee_lbl1" xml:lang="en-US">Finders Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FindersFee" xlink:to="pypd_FindersFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RemeasurementOfWarrants_lbl0" xml:lang="en-US">Remeasurement Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RemeasurementOfWarrants" xlink:to="pypd_RemeasurementOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfIncomeTaxesAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfIncomeTaxesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfIncomeTaxesAbstract_lbl" xml:lang="en-US">Schedule Of Income Taxes Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfIncomeTaxesAbstract" xlink:to="pypd_ScheduleOfIncomeTaxesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesAuthorized_lbl0" xml:lang="en-US">Excess Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesAuthorized" xlink:to="us-gaap_ExcessStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativeEarningsDeficit_lbl0" xml:lang="en-US">Cumulative Earnings (Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEarningsDeficit" xlink:to="us-gaap_CumulativeEarningsDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LaboratoryAndManufacturingEquipment_lbl1" xml:lang="en-US">Laboratory And Manufacturing Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LaboratoryAndManufacturingEquipment" xlink:to="pypd_LaboratoryAndManufacturingEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl0" xml:lang="en-US">Options Held [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl0" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl0" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_lbl0" xml:lang="en-US">Lessor, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl0" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_lbl0" xml:lang="en-US">Long-Term Debt and Lease Obligation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl0" xml:lang="en-US">Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract10" xlink:to="pypd_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract11" xlink:to="pypd_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NumberOfOptions_lbl1" xml:lang="en-US">Number Of Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumberOfOptions" xlink:to="pypd_NumberOfOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract14" xlink:to="pypd_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract15" xlink:to="pypd_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract12" xlink:to="pypd_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPayment_lbl0" xml:lang="en-US">Line of Credit Facility, Periodic Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:to="us-gaap_LineOfCreditFacilityPeriodicPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract13" xlink:to="pypd_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_OptionsExercisable_lbl1" xml:lang="en-US">Options Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OptionsExercisable" xlink:to="pypd_OptionsExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExceedAmount_lbl0" xml:lang="en-US">Exceed Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExceedAmount" xlink:to="pypd_ExceedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FinancialIncomeExpensesNetTablesLineItems_lbl0" xml:lang="en-US">Financial Income Expenses Net Tables Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialIncomeExpensesNetTablesLineItems" xlink:to="pypd_FinancialIncomeExpensesNetTablesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl0" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossAttributableToParent_lbl0" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConsultAndDirectorsMember_lbl0" xml:lang="en-US">Consult And Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConsultAndDirectorsMember" xlink:to="pypd_ConsultAndDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest_lbl0" xml:lang="en-US">Weighted Average Remaining Contractual Lifeyears Vested And Expected To Vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest" xlink:to="pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeptemberTwoThousandFourteenMember_lbl0" xml:lang="en-US">September Two Thousand Fourteen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeptemberTwoThousandFourteenMember" xlink:to="pypd_SeptemberTwoThousandFourteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ProceedsFromParticipationPayments_lbl1" xml:lang="en-US">Proceeds From Participation Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ProceedsFromParticipationPayments" xlink:to="pypd_ProceedsFromParticipationPayments_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_IssuanceOfOrdinarySharesNetinShares_lbl1" xml:lang="en-US">Issuance Of Ordinary Shares Netin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IssuanceOfOrdinarySharesNetinShares" xlink:to="pypd_IssuanceOfOrdinarySharesNetinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract2" xlink:to="pypd_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract1" xlink:to="pypd_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract4" xlink:to="pypd_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract3" xlink:to="pypd_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract0" xlink:to="pypd_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract9" xlink:to="pypd_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract6" xlink:to="pypd_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FirstTrancheMember_lbl0" xml:lang="en-US">First Tranche Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FirstTrancheMember" xlink:to="pypd_FirstTrancheMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract5" xlink:to="pypd_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract8" xlink:to="pypd_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract7" xlink:to="pypd_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl0" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl1" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl0" xml:lang="en-US">Investment Income, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ReceivedTotalAmount_lbl1" xml:lang="en-US">Received Total Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReceivedTotalAmount" xlink:to="pypd_ReceivedTotalAmount_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LeaseLiabilities_lbl1" xml:lang="en-US">Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LeaseLiabilities" xlink:to="pypd_LeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LeaseAssetsAbstract_lbl0" xml:lang="en-US">Lease Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LeaseAssetsAbstract" xlink:to="pypd_LeaseAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnlabeledAbstract" xlink:to="pypd_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LinesOfCreditCurrent_lbl0" xml:lang="en-US">Line of Credit, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_OutOfReceivedAmount_lbl1" xml:lang="en-US">Out Of Received Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OutOfReceivedAmount" xlink:to="pypd_OutOfReceivedAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PreferredSharePreference_lbl0" xml:lang="en-US">Preferred Share Preference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PreferredSharePreference" xlink:to="pypd_PreferredSharePreference_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl0" xml:lang="en-US">Long-Term Debt and Lease Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_WeightedAverageNumberOfSharesIssued_lbl0" xml:lang="en-US">Weighted Average Number Of Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageNumberOfSharesIssued" xlink:to="pypd_WeightedAverageNumberOfSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_lbl0" xml:lang="en-US">Investment Owned, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:to="us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesAbstract" xlink:href="pypd-20221231.xsd#pypd_PrepaidExpensesAndOtherReceivablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesAbstract_lbl" xml:lang="en-US">Prepaid Expenses And Other Receivables Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaidExpensesAndOtherReceivablesAbstract" xlink:to="pypd_PrepaidExpensesAndOtherReceivablesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DeemedDividends_lbl1" xml:lang="en-US">Deemed Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DeemedDividends" xlink:to="pypd_DeemedDividends_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AdditionalAmountOfCommercialSaleMilestones_lbl1" xml:lang="en-US">Additional Amount Of Commercial Sale Milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AdditionalAmountOfCommercialSaleMilestones" xlink:to="pypd_AdditionalAmountOfCommercialSaleMilestones_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PrepaidExpensesAndOtherReceivablesTextBlock_lbl0" xml:lang="en-US">Prepaid Expenses And Other Receivables Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaidExpensesAndOtherReceivablesTextBlock" xlink:to="pypd_PrepaidExpensesAndOtherReceivablesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_OctoberTwoThousandThirteenMember_lbl0" xml:lang="en-US">October Two Thousand Thirteen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OctoberTwoThousandThirteenMember" xlink:to="pypd_OctoberTwoThousandThirteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_InterestRepayments_lbl1" xml:lang="en-US">Interest Repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_InterestRepayments" xlink:to="pypd_InterestRepayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RestrictedCashIncludedInOtherLongtermAssets_lbl1" xml:lang="en-US">Restricted Cash Included In Other Longterm Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RestrictedCashIncludedInOtherLongtermAssets" xlink:to="pypd_RestrictedCashIncludedInOtherLongtermAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ReclassificationOfWarrantsIntoEquity_lbl1" xml:lang="en-US">Reclassification Of Warrants Into Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReclassificationOfWarrantsIntoEquity" xlink:to="pypd_ReclassificationOfWarrantsIntoEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConvertiblePreferredSharesMember_lbl0" xml:lang="en-US">Convertible Preferred Shares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesMember" xlink:to="pypd_ConvertiblePreferredSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next 12 Months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl0" xml:lang="en-US">Investment Income, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount_lbl0" xml:lang="en-US">Receivable with Imputed Interest, Net Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AggregateOfferingPrice_lbl1" xml:lang="en-US">Aggregate Offering Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AggregateOfferingPrice" xlink:to="pypd_AggregateOfferingPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AggregateNetProceeds_lbl1" xml:lang="en-US">Aggregate Net Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AggregateNetProceeds" xlink:to="pypd_AggregateNetProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeverancePayExpenseAmount_lbl1" xml:lang="en-US">Severance Pay Expense Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeverancePayExpenseAmount" xlink:to="pypd_SeverancePayExpenseAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AdjustmentToRiskfreeInterestRate_lbl1" xml:lang="en-US">Adjustment To Riskfree Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AdjustmentToRiskfreeInterestRate" xlink:to="pypd_AdjustmentToRiskfreeInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems_lbl0" xml:lang="en-US">Accrued Expensesand Other Current Liabilities Details Scheduleofaccruedexpensesandothercurrentliabilities Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" xlink:to="pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNoParValue_lbl0" xml:lang="en-US">Common Stock, No Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_July2022Member_lbl0" xml:lang="en-US">July2022 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_July2022Member" xlink:to="pypd_July2022Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfLeaseLiabilityAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfLeaseLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfLeaseLiabilityAbstract_lbl" xml:lang="en-US">Schedule Of Lease Liability Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfLeaseLiabilityAbstract" xlink:to="pypd_ScheduleOfLeaseLiabilityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl0" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="pypd_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl0" xml:lang="en-US">Long-Term Debt, Current Maturities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NumeratorAbstract_lbl0" xml:lang="en-US">Numerator Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumeratorAbstract" xlink:to="pypd_NumeratorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FurnitureAndOfficeEquipmentMember_lbl0" xml:lang="en-US">Furniture And Office Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FurnitureAndOfficeEquipmentMember" xlink:to="pypd_FurnitureAndOfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RestrictedCashPolicyTextBlock_lbl1" xml:lang="en-US">Restricted Cash Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RestrictedCashPolicyTextBlock" xlink:to="pypd_RestrictedCashPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesIndemnificationAgreementsPayments_lbl0" xml:lang="en-US">Capital Leases, Indemnification Agreements, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesIndemnificationAgreementsPayments" xlink:to="us-gaap_CapitalLeasesIndemnificationAgreementsPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_CommitmentsAndContingentLiabilitiesDescription_lbl0" xml:lang="en-US">Commitments And Contingent Liabilities Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_CommitmentsAndContingentLiabilitiesDescription" xlink:to="pypd_CommitmentsAndContingentLiabilitiesDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareOptionPlanDescription_lbl1" xml:lang="en-US">Share Option Plan Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareOptionPlanDescription" xlink:to="pypd_ShareOptionPlanDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares_lbl1" xml:lang="en-US">Conversion Of Convertible Preferred Shares To Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares" xlink:to="pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl0" xml:lang="en-US">Foreign Currency Transaction Gain, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract_lbl" xml:lang="en-US">Schedule Of Status Of Options To Employees Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl0" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_StockIssuedDuringPeriodSharesNewIssue_lbl0" xml:lang="en-US">Stock Issued During Period Shares New Issue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockIssuedDuringPeriodSharesNewIssue" xlink:to="pypd_StockIssuedDuringPeriodSharesNewIssue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount_lbl0" xml:lang="en-US">Obligation with Joint and Several Liability Arrangement, Corresponding Entry, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount" xlink:to="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet_lbl1" xml:lang="en-US">Payments For Proceeds From Shortterm And Longterm Deposits Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet" xlink:to="pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_BasicAndDilutedLossPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Basic And Diluted Loss Per Share Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_BasicAndDilutedLossPerSharePolicyTextBlock" xlink:to="pypd_BasicAndDilutedLossPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Cancelled1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_MinimumPaidAmount_lbl0" xml:lang="en-US">Minimum Paid Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MinimumPaidAmount" xlink:to="pypd_MinimumPaidAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityDescription_lbl0" xml:lang="en-US">Line of Credit Facility, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityDescription" xlink:to="us-gaap_LineOfCreditFacilityDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExercisePriceDecrease_lbl1" xml:lang="en-US">Exercise Price Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExercisePriceDecrease" xlink:to="pypd_ExercisePriceDecrease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_August2019Member_lbl0" xml:lang="en-US">August2019 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_August2019Member" xlink:to="pypd_August2019Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares_lbl1" xml:lang="en-US">Stock Issued During Period Exercise Of Warrants Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares" xlink:to="pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LaboratoryEquipmentMember_lbl0" xml:lang="en-US">Laboratory Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LaboratoryEquipmentMember" xlink:to="pypd_LaboratoryEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_April2021Member_lbl0" xml:lang="en-US">April2021 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_April2021Member" xlink:to="pypd_April2021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_IssuanceOfWarrants_lbl1" xml:lang="en-US">Issuance Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IssuanceOfWarrants" xlink:to="pypd_IssuanceOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_monthlyDepositsAtARate_lbl1" xml:lang="en-US">monthly Deposits At ARate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_monthlyDepositsAtARate" xlink:to="pypd_monthlyDepositsAtARate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_UnrecognizedCompensationCosts_lbl1" xml:lang="en-US">Unrecognized Compensation Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_UnrecognizedCompensationCosts" xlink:to="pypd_UnrecognizedCompensationCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficerMember_lbl0" xml:lang="en-US">Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited And Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfRelativeFairValueOfTheWarrantsToPurchaseOrdinarySharesIssuedAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfRelativeFairValueOfTheWarrantsToPurchaseOrdinarySharesIssuedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfRelativeFairValueOfTheWarrantsToPurchaseOrdinarySharesIssuedAbstract_lbl" xml:lang="en-US">Schedule Of Relative Fair Value Of The Warrants To Purchase Ordinary Shares Issued Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfRelativeFairValueOfTheWarrantsToPurchaseOrdinarySharesIssuedAbstract" xlink:to="pypd_ScheduleOfRelativeFairValueOfTheWarrantsToPurchaseOrdinarySharesIssuedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl0" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DecemberTwoThousandSixteenMember_lbl0" xml:lang="en-US">December Two Thousand Sixteen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DecemberTwoThousandSixteenMember" xlink:to="pypd_DecemberTwoThousandSixteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants_lbl0" xml:lang="en-US">Payments for Repurchase of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable_lbl1" xml:lang="en-US">Purchase Of Property And Equipment Included In Trade Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable" xlink:to="pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_GovernmentAuthorities_lbl1" xml:lang="en-US">Government Authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_GovernmentAuthorities" xlink:to="pypd_GovernmentAuthorities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_IncurredLoss_lbl0" xml:lang="en-US">Incurred Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IncurredLoss" xlink:to="pypd_IncurredLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl0" xml:lang="en-US">Restricted Cash, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_WeightedAverageGrantDateFairValueOfOptionsGranted_lbl1" xml:lang="en-US">Weighted Average Grant Date Fair Value Of Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageGrantDateFairValueOfOptionsGranted" xlink:to="pypd_WeightedAverageGrantDateFairValueOfOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NumberOfOrdinarySharesAbstract_lbl0" xml:lang="en-US">Number Of Ordinary Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumberOfOrdinarySharesAbstract" xlink:to="pypd_NumberOfOrdinarySharesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl0" xml:lang="en-US">Investment Income, Investment Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AprilTwoThousandSixteenMember_lbl0" xml:lang="en-US">April Two Thousand Sixteen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AprilTwoThousandSixteenMember" xlink:to="pypd_AprilTwoThousandSixteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseDepositLiability_lbl0" xml:lang="en-US">Lease Deposit Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseDepositLiability" xlink:to="us-gaap_LeaseDepositLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_AdditionalDevelopmentrelatedMilestonesPayments_lbl1" xml:lang="en-US">Additional Developmentrelated Milestones Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_AdditionalDevelopmentrelatedMilestonesPayments" xlink:to="pypd_AdditionalDevelopmentrelatedMilestonesPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl0" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl0" xml:lang="en-US">Repayments of Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_CostAbstract_lbl0" xml:lang="en-US">Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_CostAbstract" xlink:to="pypd_CostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl0" xml:lang="en-US">Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RighttouseAssetsAndLeaseLiabilities_lbl1" xml:lang="en-US">Righttouse Assets And Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RighttouseAssetsAndLeaseLiabilities" xlink:to="pypd_RighttouseAssetsAndLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ProceedsFromLinesOfCreditOne_lbl1" xml:lang="en-US">Proceeds From Lines Of Credit One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ProceedsFromLinesOfCreditOne" xlink:to="pypd_ProceedsFromLinesOfCreditOne_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_JuneTwoThousandTwentyMember_lbl0" xml:lang="en-US">June Two Thousand Twenty Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_JuneTwoThousandTwentyMember" xlink:to="pypd_JuneTwoThousandTwentyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl0" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_IsraelInnovationAuthorityGrantReceived_lbl1" xml:lang="en-US">Israel Innovation Authority Grant Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_IsraelInnovationAuthorityGrantReceived" xlink:to="pypd_IsraelInnovationAuthorityGrantReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="pypd_LineOfCreditArrangementAbstract" xlink:href="pypd-20221231.xsd#pypd_LineOfCreditArrangementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LineOfCreditArrangementAbstract_lbl" xml:lang="en-US">Line Of Credit Arrangement Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LineOfCreditArrangementAbstract" xlink:to="pypd_LineOfCreditArrangementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_November2022Member_lbl0" xml:lang="en-US">November2022 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_November2022Member" xlink:to="pypd_November2022Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SecondTrancheMember_lbl0" xml:lang="en-US">Second Tranche Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SecondTrancheMember" xlink:to="pypd_SecondTrancheMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Exercised In Period Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares_lbl1" xml:lang="en-US">Weighted Average Effect Of Dilutive Securities Warrants To Convertible Preferred Sharesin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" xlink:to="pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl0" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PrepaymentForEquipments_lbl1" xml:lang="en-US">Prepayment For Equipments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PrepaymentForEquipments" xlink:to="pypd_PrepaymentForEquipments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl0" xml:lang="en-US">Proceeds from Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ReevaluationOfWarrants_lbl1" xml:lang="en-US">Reevaluation Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ReevaluationOfWarrants" xlink:to="pypd_ReevaluationOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_lbl0" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ServiceProvidersInAmount_lbl0" xml:lang="en-US">Service Providers In Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ServiceProvidersInAmount" xlink:to="pypd_ServiceProvidersInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl0" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DescriptionOfReverseShareSplit_lbl0" xml:lang="en-US">Description Of Reverse Share Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DescriptionOfReverseShareSplit" xlink:to="pypd_DescriptionOfReverseShareSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShortTermDepositsMember_lbl0" xml:lang="en-US">Short Term Deposits Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShortTermDepositsMember" xlink:to="pypd_ShortTermDepositsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfOrdinaryShareCapitalAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfOrdinaryShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfOrdinaryShareCapitalAbstract_lbl" xml:lang="en-US">Schedule Of Ordinary Share Capital Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfOrdinaryShareCapitalAbstract" xlink:to="pypd_ScheduleOfOrdinaryShareCapitalAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NovemberTwoThousandSeventeenMember_lbl0" xml:lang="en-US">November Two Thousand Seventeen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NovemberTwoThousandSeventeenMember" xlink:to="pypd_NovemberTwoThousandSeventeenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares_lbl1" xml:lang="en-US">Conversion Of Convertible Preferred Shares To Ordinary Shares Sharesin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" xlink:to="pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Public Utility Property, Plant, and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_OperatingLeaseAssets_lbl1" xml:lang="en-US">Operating Lease Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OperatingLeaseAssets" xlink:to="pypd_OperatingLeaseAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Capital Leased Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ProceedsFromLinesOfCreditTwo_lbl1" xml:lang="en-US">Proceeds From Lines Of Credit Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ProceedsFromLinesOfCreditTwo" xlink:to="pypd_ProceedsFromLinesOfCreditTwo_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl0" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_PropertyPlantAndEquipmentPercent_lbl1" xml:lang="en-US">Property Plant And Equipment Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_PropertyPlantAndEquipmentPercent" xlink:to="pypd_PropertyPlantAndEquipmentPercent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_WarrantsOutstanding_lbl0" xml:lang="en-US">Warrants Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_WarrantsOutstanding" xlink:to="pypd_WarrantsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl0" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl0" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConsolidatedFinancialStatementsPolicyTextBlock_lbl1" xml:lang="en-US">Consolidated Financial Statements Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConsolidatedFinancialStatementsPolicyTextBlock" xlink:to="pypd_ConsolidatedFinancialStatementsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl0" xml:lang="en-US">Research and Development in Process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LeasePrepayments_lbl1" xml:lang="en-US">Lease Prepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LeasePrepayments" xlink:to="pypd_LeasePrepayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock_lbl0" xml:lang="en-US">Schedule Of Outstanding Option Granted Tables Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock" xlink:to="pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NonroyaltyBearingGrants_lbl1" xml:lang="en-US">Nonroyalty Bearing Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NonroyaltyBearingGrants" xlink:to="pypd_NonroyaltyBearingGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_lbl1" xml:lang="en-US">Convertible Preferred Shares And Convertible Preferred Shares Warrant Liability Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" xlink:to="pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfLeaseLiabilityTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Lease Liability Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfLeaseLiabilityTableTextBlock" xlink:to="pypd_ScheduleOfLeaseLiabilityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses_lbl1" xml:lang="en-US">Decreaseincrease In Receivables And Prepaid Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses" xlink:to="pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentCompanyCommittedCapital_lbl0" xml:lang="en-US">Investment Company, Committed Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyCommittedCapital" xlink:to="us-gaap_InvestmentCompanyCommittedCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_TwoThousandTwelveShareOptionPlanMember_lbl0" xml:lang="en-US">Two Thousand Twelve Share Option Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_TwoThousandTwelveShareOptionPlanMember" xlink:to="pypd_TwoThousandTwelveShareOptionPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_May2022Member_lbl0" xml:lang="en-US">May2022 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_May2022Member" xlink:to="pypd_May2022Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract_lbl" xml:lang="en-US">Schedule Of Supplemental Cash Flow Information Related To The Lease Costs Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract" xlink:to="pypd_ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SeverancePay_lbl1" xml:lang="en-US">Severance Pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SeverancePay" xlink:to="pypd_SeverancePay_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_lbl0" xml:lang="en-US">Tax Basis of Investments, Cost for Income Tax Purposes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:to="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl0" xml:lang="en-US">Long-Term Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_LeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_LeaseLiabilitiesAbstract" xlink:to="pypd_LeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfDeferredTaxAssetsAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfDeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="pypd_ScheduleOfDeferredTaxAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Accrued Expenses And Other Current Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="pypd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl0" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_OfferingExpensesPayable_lbl1" xml:lang="en-US">Offering Expenses Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_OfferingExpensesPayable" xlink:to="pypd_OfferingExpensesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_September2020Member_lbl0" xml:lang="en-US">September2020 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_September2020Member" xlink:to="pypd_September2020Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NumberOfSharesAbstract_lbl0" xml:lang="en-US">Number Of Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NumberOfSharesAbstract" xlink:to="pypd_NumberOfSharesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_April2022Member_lbl0" xml:lang="en-US">April2022 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_April2022Member" xlink:to="pypd_April2022Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Leaserelated Assets And Liabilities Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" xlink:to="pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ExpectedDividendYield_lbl0" xml:lang="en-US">Expected Dividend Yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ExpectedDividendYield" xlink:to="pypd_ExpectedDividendYield_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_TotalLongtermLiabilities_lbl0" xml:lang="en-US">Total Longterm Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_TotalLongtermLiabilities" xlink:to="pypd_TotalLongtermLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Prices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract_lbl" xml:lang="en-US">Schedule Of Basic And Diluted Loss Per Ordinary Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" xlink:to="pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl0" xml:lang="en-US">Stock Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DescriptionAdministration_lbl1" xml:lang="en-US">Description Administration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DescriptionAdministration" xlink:to="pypd_DescriptionAdministration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfShareOptionsAtTheGrantDateAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfShareOptionsAtTheGrantDateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfShareOptionsAtTheGrantDateAbstract_lbl" xml:lang="en-US">Schedule Of Share Options At The Grant Date Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfShareOptionsAtTheGrantDateAbstract" xlink:to="pypd_ScheduleOfShareOptionsAtTheGrantDateAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfOutstandingOptionsGrantedAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfOutstandingOptionsGrantedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfOutstandingOptionsGrantedAbstract_lbl" xml:lang="en-US">Schedule Of Outstanding Options Granted Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfOutstandingOptionsGrantedAbstract" xlink:to="pypd_ScheduleOfOutstandingOptionsGrantedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable_lbl0" xml:lang="en-US">Payments to Acquire Loans Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLoansReceivable" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_RelatedPartiesTerm_lbl1" xml:lang="en-US">Related Parties Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_RelatedPartiesTerm" xlink:to="pypd_RelatedPartiesTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_December2021Member_lbl0" xml:lang="en-US">December2021 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_December2021Member" xlink:to="pypd_December2021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_MatchingContributionsAmounts_lbl1" xml:lang="en-US">Matching Contributions Amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MatchingContributionsAmounts" xlink:to="pypd_MatchingContributionsAmounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_DeemedDividend_lbl1" xml:lang="en-US">Deemed Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_DeemedDividend" xlink:to="pypd_DeemedDividend_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_FinancialExpensesAbstract_lbl0" xml:lang="en-US">Financial Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_FinancialExpensesAbstract" xlink:to="pypd_FinancialExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl0" xml:lang="en-US">Basis of Accounting [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_SuitFillingExpense_lbl1" xml:lang="en-US">Suit Filling Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_SuitFillingExpense" xlink:to="pypd_SuitFillingExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl0" xml:lang="en-US">Foreign Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ThiredTrancheMember_lbl0" xml:lang="en-US">Thired Tranche Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ThiredTrancheMember" xlink:to="pypd_ThiredTrancheMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract_lbl0" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Of Lease Liability Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract" xlink:to="pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_TaxBenefitPercentage_lbl1" xml:lang="en-US">Tax Benefit Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_TaxBenefitPercentage" xlink:to="pypd_TaxBenefitPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl0"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfFinancialIncomeExpensesNetAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfFinancialIncomeExpensesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfFinancialIncomeExpensesNetAbstract_lbl" xml:lang="en-US">Schedule Of Financial Income Expenses Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfFinancialIncomeExpensesNetAbstract" xlink:to="pypd_ScheduleOfFinancialIncomeExpensesNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl0" xml:lang="en-US">Excess Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShorttermDepositsPolicyTextBlock_lbl1" xml:lang="en-US">Shortterm Deposits Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShorttermDepositsPolicyTextBlock" xlink:to="pypd_ShorttermDepositsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NonRefundableAmount_lbl1" xml:lang="en-US">Non Refundable Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NonRefundableAmount" xlink:to="pypd_NonRefundableAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl0" xml:lang="en-US">ISRAEL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_MarketingAndBusinessDevelopmentMember_lbl0" xml:lang="en-US">Marketing And Business Development Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_MarketingAndBusinessDevelopmentMember" xlink:to="pypd_MarketingAndBusinessDevelopmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl0" xml:lang="en-US">Debt Instrument, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_StockOptionsAvailableForFutureGrants_lbl1" xml:lang="en-US">Stock Options Available For Future Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_StockOptionsAvailableForFutureGrants" xlink:to="pypd_StockOptionsAvailableForFutureGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" xlink:to="pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAllowances_lbl0" xml:lang="en-US">Revenue Recognition, Allowances [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAllowances" xlink:to="us-gaap_RevenueRecognitionAllowances_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ComputersandSoftware_lbl1" xml:lang="en-US">Computersand Software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ComputersandSoftware" xlink:to="pypd_ComputersandSoftware_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_lbl0" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_NonroyaltyBearingGrantsAmount_lbl1" xml:lang="en-US">Nonroyalty Bearing Grants Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_NonroyaltyBearingGrantsAmount" xlink:to="pypd_NonroyaltyBearingGrantsAmount_lbl1"/>
    <loc xlink:type="locator" xlink:label="pypd_ScheduleOfPropertyAndEquipmentUsefulLifeAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfPropertyAndEquipmentUsefulLifeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pypd_ScheduleOfPropertyAndEquipmentUsefulLifeAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Useful Life Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pypd_ScheduleOfPropertyAndEquipmentUsefulLifeAbstract" xlink:to="pypd_ScheduleOfPropertyAndEquipmentUsefulLifeAbstract_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>24
<FILENAME>pypd-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Mar 31 19:22:17 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ConsolidatedBalanceSheet" roleURI="http://Polypid.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ConsolidatedIncomeStatement" roleURI="http://Polypid.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://Polypid.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ShareholdersEquityType2or3" roleURI="http://Polypid.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ConsolidatedCashFlow" roleURI="http://Polypid.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_General" roleURI="http://Polypid.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_SignificantAccountingPolicies" roleURI="http://Polypid.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_PropertyandEquipmentNet" roleURI="http://Polypid.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_Leases" roleURI="http://Polypid.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_AccruedExpensesandOtherCurrentLiabilities" roleURI="http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_LineofCreditArrangement" roleURI="http://Polypid.com/role/LineofCreditArrangement"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_CommitmentsandContingentLiabilities" roleURI="http://Polypid.com/role/CommitmentsandContingentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_IncomeTaxes" roleURI="http://Polypid.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ShareholdersEquity" roleURI="http://Polypid.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_FinancialIncomeExpensesNet" roleURI="http://Polypid.com/role/FinancialIncomeExpensesNet"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_BasicandDilutedNetLossPerShare" roleURI="http://Polypid.com/role/BasicandDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_RelatedParties" roleURI="http://Polypid.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_SubsequentEvents" roleURI="http://Polypid.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_AccountingPoliciesByPolicy" roleURI="http://Polypid.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_SignificantAccountingPoliciesTables" roleURI="http://Polypid.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_PropertyandEquipmentNetTables" roleURI="http://Polypid.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_LeasesTables" roleURI="http://Polypid.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_IncomeTaxesTables" roleURI="http://Polypid.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ShareholdersEquityTables" roleURI="http://Polypid.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_FinancialIncomeExpensesNetTables" roleURI="http://Polypid.com/role/FinancialIncomeExpensesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_BasicandDilutedNetLossPerShareTables" roleURI="http://Polypid.com/role/BasicandDilutedNetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofpropertyandequipmentusefullifeTable" roleURI="http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://Polypid.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofpropertyandequipmentTable" roleURI="http://Polypid.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofleaserelatedassetsandliabilitiesTable" roleURI="http://Polypid.com/role/ScheduleofleaserelatedassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofleaseliabilityTable" roleURI="http://Polypid.com/role/ScheduleofleaseliabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofsupplementalcashflowinformationrelatedtotheleasecostsTable" roleURI="http://Polypid.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofaccruedexpensesandothercurrentliabilitiesTable" roleURI="http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofdeferredtaxassetsTable" roleURI="http://Polypid.com/role/ScheduleofdeferredtaxassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofdeferredincometaxesreflectthenettaxeffectsTable" roleURI="http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofincometaxesTable" roleURI="http://Polypid.com/role/ScheduleofincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofordinarysharecapitalTable" roleURI="http://Polypid.com/role/ScheduleofordinarysharecapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofstatusofoptionstoemployeesTable" roleURI="http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofshareoptionsatthegrantdateTable" roleURI="http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofsharebasedcompensationexpenserecognizedTable" roleURI="http://Polypid.com/role/ScheduleofsharebasedcompensationexpenserecognizedTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofoutstandingoptionsgrantedTable" roleURI="http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable" roleURI="http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleoffinancialincomeexpensesnetTable" roleURI="http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofbasicanddilutedlossperordinaryshareTable" roleURI="http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofbasicanddilutedlossperordinaryshareTable_Parentheticals" roleURI="http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable" roleURI="http://Polypid.com/role/ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_GeneralDetails" roleURI="http://Polypid.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_SignificantAccountingPoliciesDetails" roleURI="http://Polypid.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_PropertyandEquipmentNetDetails" roleURI="http://Polypid.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_LeasesDetails" roleURI="http://Polypid.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_LineofCreditArrangementDetails" roleURI="http://Polypid.com/role/LineofCreditArrangementDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_CommitmentsandContingentLiabilitiesDetails" roleURI="http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_IncomeTaxesDetails" roleURI="http://Polypid.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_ShareholdersEquityDetails" roleURI="http://Polypid.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_RelatedPartiesDetails" roleURI="http://Polypid.com/role/RelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#pypd_r_SubsequentEventsDetails" roleURI="http://Polypid.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="pypd-20221231.xsd#DocumentAndEntityInformation" roleURI="http://Polypid.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermInvestmentsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongtermDeposits" xlink:href="pypd-20221231.xsd#pypd_LongtermDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="LongtermDeposits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_LongTermInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermInvestmentsAbstract" xlink:to="us-gaap_Assets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_OtherLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalLongtermLiabilities" xlink:href="pypd-20221231.xsd#pypd_TotalLongtermLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="TotalLongtermLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockNoParValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketingAndBusinessDevelopmentExpenses" xlink:href="pypd-20221231.xsd#pypd_MarketingAndBusinessDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="MarketingAndBusinessDevelopmentExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossAttributableToParent" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="DeemedDividends" xlink:href="pypd-20221231.xsd#pypd_DeemedDividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="DeemedDividends" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="NetLossAttributableToOrdinarySharesinDollarsPerShare" xlink:href="pypd-20221231.xsd#pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="NetLossAttributableToOrdinarySharesinDollarsPerShare" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredSharesMember" xlink:href="pypd-20221231.xsd#pypd_ConvertiblePreferredSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="ConvertiblePreferredSharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ParentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="5.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesNetinShares" xlink:href="pypd-20221231.xsd#pypd_IssuanceOfOrdinarySharesNetinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesNetinShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfConvertiblePreferredSharesToOrdinaryShares" xlink:href="pypd-20221231.xsd#pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ConversionOfConvertiblePreferredSharesToOrdinaryShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" xlink:href="pypd-20221231.xsd#pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassificationOfWarrantsIntoEquity" xlink:href="pypd-20221231.xsd#pypd_ReclassificationOfWarrantsIntoEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ReclassificationOfWarrantsIntoEquity" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfWarrants" xlink:href="pypd-20221231.xsd#pypd_ExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfWarrants" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodExerciseOfWarrantsShares" xlink:href="pypd-20221231.xsd#pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodExerciseOfWarrantsShares" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReevaluationOfWarrants" xlink:href="pypd-20221231.xsd#pypd_ReevaluationOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ReevaluationOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecreaseincreaseInReceivablesAndPrepaidExpenses" xlink:href="pypd-20221231.xsd#pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="DecreaseincreaseInReceivablesAndPrepaidExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentsForProceedsFromShorttermAndLongtermDepositsNet" xlink:href="pypd-20221231.xsd#pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsForProceedsFromShorttermAndLongtermDepositsNet" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForEquipments" xlink:href="pypd-20221231.xsd#pypd_PrepaymentForEquipments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PrepaymentForEquipments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfWarrants" xlink:href="pypd-20221231.xsd#pypd_IssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="IssuanceOfWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedCashIncludedInOtherLongtermAssets" xlink:href="pypd-20221231.xsd#pypd_RestrictedCashIncludedInOtherLongtermAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="RestrictedCashIncludedInOtherLongtermAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfPropertyAndEquipmentIncludedInTradePayable" xlink:href="pypd-20221231.xsd#pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="PurchaseOfPropertyAndEquipmentIncludedInTradePayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyAndEquipmentPaidForInPriorPeriods" xlink:href="pypd-20221231.xsd#pypd_PropertyAndEquipmentPaidForInPriorPeriods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="PropertyAndEquipmentPaidForInPriorPeriods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/General">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfAccounting" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherReceivablesAbstract" xlink:href="pypd-20221231.xsd#pypd_PrepaidExpensesAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherReceivablesTextBlock" xlink:href="pypd-20221231.xsd#pypd_PrepaidExpensesAndOtherReceivablesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndOtherReceivablesAbstract" xlink:to="PrepaidExpensesAndOtherReceivablesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/LineofCreditArrangement">
    <loc xlink:type="locator" xlink:label="LineOfCreditArrangementAbstract" xlink:href="pypd-20221231.xsd#pypd_LineOfCreditArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="LineOfCreditArrangementTextBlock" xlink:href="pypd-20221231.xsd#pypd_LineOfCreditArrangementTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditArrangementAbstract" xlink:to="LineOfCreditArrangementTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/CommitmentsandContingentLiabilities">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/FinancialIncomeExpensesNet">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialIncomeExpensesNetTable" xlink:href="pypd-20221231.xsd#pypd_FinancialIncomeExpensesNetTable"/>
    <loc xlink:type="locator" xlink:label="FinancialIncomeExpensesNetLineItems" xlink:href="pypd-20221231.xsd#pypd_FinancialIncomeExpensesNetLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="FinancialIncomeExpensesNetTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeExpensesNetTable" xlink:to="FinancialIncomeExpensesNetLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeExpensesNetLineItems" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/BasicandDilutedNetLossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/RelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedFinancialStatementsPolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_ConsolidatedFinancialStatementsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ConsolidatedFinancialStatementsPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedCashPolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_RestrictedCashPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RestrictedCashPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShorttermDepositsPolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_ShorttermDepositsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ShorttermDepositsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BasicAndDilutedLossPerSharePolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_BasicAndDilutedLossPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="BasicAndDilutedLossPerSharePolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionAllowances" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAllowances"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionAllowances" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeverancePayPolicyTextBlock" xlink:href="pypd-20221231.xsd#pypd_SeverancePayPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SeverancePayPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ContingentLiabilityReserveEstimatePolicy" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecentlyIssuedAccountingPronouncementsNotYetAdopted" xlink:href="pypd-20221231.xsd#pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RecentlyIssuedAccountingPronouncementsNotYetAdopted" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherReceivablesAbstract" xlink:href="pypd-20221231.xsd#pypd_PrepaidExpensesAndOtherReceivablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndOtherReceivablesAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseLiabilityTableTextBlock" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfLeaseLiabilityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="ScheduleOfLeaseLiabilityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedExpensesandOtherCurrentLiabilitiesTablesTable" xlink:href="pypd-20221231.xsd#pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesTable"/>
    <loc xlink:type="locator" xlink:label="AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems" xlink:href="pypd-20221231.xsd#pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="AccruedExpensesandOtherCurrentLiabilitiesTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedExpensesandOtherCurrentLiabilitiesTablesTable" xlink:to="AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingOptionGrantedTablesTextBlock" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ScheduleOfOutstandingOptionGrantedTablesTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/FinancialIncomeExpensesNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialIncomeExpensesNetTablesTable" xlink:href="pypd-20221231.xsd#pypd_FinancialIncomeExpensesNetTablesTable"/>
    <loc xlink:type="locator" xlink:label="FinancialIncomeExpensesNetTablesLineItems" xlink:href="pypd-20221231.xsd#pypd_FinancialIncomeExpensesNetTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="FinancialIncomeExpensesNetTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeExpensesNetTablesTable" xlink:to="FinancialIncomeExpensesNetTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeExpensesNetTablesLineItems" xlink:to="us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/BasicandDilutedNetLossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentUsefulLifeAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfPropertyAndEquipmentUsefulLifeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentUsefulLifeAbstract" xlink:to="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ComputersandSoftware" xlink:href="pypd-20221231.xsd#pypd_ComputersandSoftware"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="ComputersandSoftware" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LaboratoryAndManufacturingEquipment" xlink:href="pypd-20221231.xsd#pypd_LaboratoryAndManufacturingEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="LaboratoryAndManufacturingEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentPercent" xlink:href="pypd-20221231.xsd#pypd_PropertyPlantAndEquipmentPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentPercent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable" xlink:href="pypd-20221231.xsd#pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" xlink:href="pypd-20221231.xsd#pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable" xlink:to="PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GovernmentAuthorities" xlink:href="pypd-20221231.xsd#pypd_GovernmentAuthorities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" xlink:to="GovernmentAuthorities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseDepositLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" xlink:to="us-gaap_LeaseDepositLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LaboratoryEquipmentMember" xlink:href="pypd-20221231.xsd#pypd_LaboratoryEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LaboratoryEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FurnitureAndOfficeEquipmentMember" xlink:href="pypd-20221231.xsd#pypd_FurnitureAndOfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="FurnitureAndOfficeEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofleaserelatedassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeaseAssetsAbstract" xlink:href="pypd-20221231.xsd#pypd_LeaseAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract" xlink:to="LeaseAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseAssets" xlink:href="pypd-20221231.xsd#pypd_OperatingLeaseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseAssetsAbstract" xlink:to="OperatingLeaseAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseLiabilitiesAbstract" xlink:href="pypd-20221231.xsd#pypd_LeaseLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract" xlink:to="LeaseLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseLiabilitiesAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseLiabilities" xlink:href="pypd-20221231.xsd#pypd_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseLiabilitiesAbstract" xlink:to="LeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofleaseliabilityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseLiabilityAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseLiabilityAbstract" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheleasecostsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract" xlink:href="pypd-20221231.xsd#pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract" xlink:to="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract" xlink:href="pypd-20221231.xsd#pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract" xlink:to="RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable" xlink:href="pypd-20221231.xsd#pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" xlink:href="pypd-20221231.xsd#pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable" xlink:to="AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IsraelInnovationAuthorityGrantReceived" xlink:href="pypd-20221231.xsd#pypd_IsraelInnovationAuthorityGrantReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" xlink:to="IsraelInnovationAuthorityGrantReceived" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofdeferredtaxassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" xlink:href="pypd-20221231.xsd#pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:href="pypd-20221231.xsd#pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAbstract" xlink:to="IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofdeferredtaxassetsTable" xlink:to="IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofincometaxesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxesAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYyn91pOe7VtKs04Jlb3SPvCuMaehdfSUhtJg7vOyFoOF/AztNXIUhzx+P+epY4WtCBWdIE9zpOkAYuuw4yh598SS/DDR25UhB1vr3InT0Iv/WeMwUMCDO+Y4l9K2x3Xs422PVBz1J7zYQwrV5v8agZB4PYMfGJUC77vg+ip4C7gQFr1/2PR0WGy4GICqvPJmA=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DomesticIsrael" xlink:href="pypd-20221231.xsd#pypd_DomesticIsrael"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="DomesticIsrael" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxesAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofordinarysharecapitalTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOrdinaryShareCapitalAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfOrdinaryShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofordinarysharecapitalTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOrdinaryShareCapitalAbstract" xlink:to="ShareholdersEquityDetailsScheduleofordinarysharecapitalTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofordinarysharecapitalTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofordinarysharecapitalTable" xlink:to="ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems" xlink:to="us-gaap_ExcessStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems" xlink:to="us-gaap_ExcessStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatusOfOptionsToEmployeesAbstract" xlink:to="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable" xlink:to="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding" xlink:href="pypd-20221231.xsd#pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest" xlink:href="pypd-20221231.xsd#pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems" xlink:to="WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareOptionsAtTheGrantDateAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfShareOptionsAtTheGrantDateAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionsAtTheGrantDateAbstract" xlink:to="ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable" xlink:to="ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofsharebasedcompensationexpenserecognizedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareBasedCompensationExpenseRecognizedAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfShareBasedCompensationExpenseRecognizedAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationExpenseRecognizedAbstract" xlink:to="ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketingAndBusinessDevelopmentMember" xlink:href="pypd-20221231.xsd#pypd_MarketingAndBusinessDevelopmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="MarketingAndBusinessDevelopmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable" xlink:to="ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingOptionsGrantedAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfOutstandingOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingOptionsGrantedAbstract" xlink:to="ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_OptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable" xlink:to="us-gaap_AwardDateAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OctoberTwoThousandThirteenMember" xlink:href="pypd-20221231.xsd#pypd_OctoberTwoThousandThirteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="OctoberTwoThousandThirteenMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeptemberTwoThousandFourteenMember" xlink:href="pypd-20221231.xsd#pypd_SeptemberTwoThousandFourteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="SeptemberTwoThousandFourteenMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AprilTwoThousandSixteenMember" xlink:href="pypd-20221231.xsd#pypd_AprilTwoThousandSixteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="AprilTwoThousandSixteenMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecemberTwoThousandSixteenMember" xlink:href="pypd-20221231.xsd#pypd_DecemberTwoThousandSixteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="DecemberTwoThousandSixteenMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JuneTwoThousandSeventeenMember" xlink:href="pypd-20221231.xsd#pypd_JuneTwoThousandSeventeenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="JuneTwoThousandSeventeenMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NovemberTwoThousandSeventeenMember" xlink:href="pypd-20221231.xsd#pypd_NovemberTwoThousandSeventeenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="NovemberTwoThousandSeventeenMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="August2019Member" xlink:href="pypd-20221231.xsd#pypd_August2019Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="August2019Member" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JuneTwoThousandTwentyMember" xlink:href="pypd-20221231.xsd#pypd_JuneTwoThousandTwentyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="JuneTwoThousandTwentyMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="April2021Member" xlink:href="pypd-20221231.xsd#pypd_April2021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="April2021Member" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="August2021Member" xlink:href="pypd-20221231.xsd#pypd_August2021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="August2021Member" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="December2021Member" xlink:href="pypd-20221231.xsd#pypd_December2021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="December2021Member" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="May2022Member" xlink:href="pypd-20221231.xsd#pypd_May2022Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="May2022Member" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="November2022Member" xlink:href="pypd-20221231.xsd#pypd_November2022Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="November2022Member" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="September2020Member" xlink:href="pypd-20221231.xsd#pypd_September2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="September2020Member" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="April2022Member" xlink:href="pypd-20221231.xsd#pypd_April2022Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="April2022Member" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="July2022Member" xlink:href="pypd-20221231.xsd#pypd_July2022Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="July2022Member" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable" xlink:to="ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsExercisable" xlink:href="pypd-20221231.xsd#pypd_OptionsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="OptionsExercisable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" xlink:href="pypd-20221231.xsd#pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRelativeFairValueOfTheWarrantsToPurchaseOrdinarySharesIssuedAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfRelativeFairValueOfTheWarrantsToPurchaseOrdinarySharesIssuedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelativeFairValueOfTheWarrantsToPurchaseOrdinarySharesIssuedAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentToRiskfreeInterestRate" xlink:href="pypd-20221231.xsd#pypd_AdjustmentToRiskfreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="AdjustmentToRiskfreeInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialIncomeExpensesNetAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfFinancialIncomeExpensesNetAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialExpensesAbstract" xlink:href="pypd-20221231.xsd#pypd_FinancialExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialIncomeExpensesNetAbstract" xlink:to="FinancialExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLoansReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialExpensesAbstract" xlink:to="us-gaap_PaymentsToAcquireLoansReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialExpensesAbstract" xlink:to="us-gaap_OtherExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RemeasurementOfWarrants" xlink:href="pypd-20221231.xsd#pypd_RemeasurementOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialExpensesAbstract" xlink:to="RemeasurementOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialIncomeAbstract" xlink:href="pypd-20221231.xsd#pypd_FinancialIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialIncomeExpensesNetAbstract" xlink:to="FinancialIncomeAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeAbstract" xlink:to="us-gaap_InvestmentIncomeNonoperating" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialIncomeExpensesNetAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract"/>
    <loc xlink:type="locator" xlink:label="NumeratorAbstract" xlink:href="pypd-20221231.xsd#pypd_NumeratorAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" xlink:to="NumeratorAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumeratorAbstract" xlink:to="us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredSharePreference" xlink:href="pypd-20221231.xsd#pypd_PreferredSharePreference"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumeratorAbstract" xlink:to="PreferredSharePreference" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeemedDividend" xlink:href="pypd-20221231.xsd#pypd_DeemedDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumeratorAbstract" xlink:to="DeemedDividend" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DenominatorAbstract" xlink:href="pypd-20221231.xsd#pypd_DenominatorAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" xlink:to="DenominatorAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract" xlink:href="pypd-20221231.xsd#pypd_ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" xlink:href="pypd-20221231.xsd#pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract" xlink:to="WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageNumberOfSharesIssued" xlink:href="pypd-20221231.xsd#pypd_WeightedAverageNumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract" xlink:to="WeightedAverageNumberOfSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralDetailsTable" xlink:href="pypd-20221231.xsd#pypd_GeneralDetailsTable"/>
    <loc xlink:type="locator" xlink:label="GeneralDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_GeneralDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="GeneralDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="GeneralDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfReverseShareSplit" xlink:href="pypd-20221231.xsd#pypd_DescriptionOfReverseShareSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="DescriptionOfReverseShareSplit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesNewIssue" xlink:href="pypd-20221231.xsd#pypd_StockIssuedDuringPeriodSharesNewIssue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateNetProceeds" xlink:href="pypd-20221231.xsd#pypd_AggregateNetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="AggregateNetProceeds" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionAdministration" xlink:href="pypd-20221231.xsd#pypd_DescriptionAdministration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="DescriptionAdministration" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncurredLoss" xlink:href="pypd-20221231.xsd#pypd_IncurredLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="IncurredLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromOperatingActivities" xlink:href="pypd-20221231.xsd#pypd_CashFlowsFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="CashFlowsFromOperatingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CumulativeEarningsDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CumulativeEarningsDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="us-gaap_CumulativeEarningsDeficit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsTable" xlink:href="pypd-20221231.xsd#pypd_SignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_SignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ShortTermDepositsMember" xlink:href="pypd-20221231.xsd#pypd_ShortTermDepositsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="ShortTermDepositsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="SignificantAccountingPoliciesDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RighttouseAssetsAndLeaseLiabilities" xlink:href="pypd-20221231.xsd#pypd_RighttouseAssetsAndLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="RighttouseAssetsAndLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeasePrepayments" xlink:href="pypd-20221231.xsd#pypd_LeasePrepayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="LeasePrepayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceivedTotalAmount" xlink:href="pypd-20221231.xsd#pypd_ReceivedTotalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="ReceivedTotalAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonroyaltyBearingGrantsAmount" xlink:href="pypd-20221231.xsd#pypd_NonroyaltyBearingGrantsAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="NonroyaltyBearingGrantsAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutOfReceivedAmount" xlink:href="pypd-20221231.xsd#pypd_OutOfReceivedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="OutOfReceivedAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonroyaltyBearingGrants" xlink:href="pypd-20221231.xsd#pypd_NonroyaltyBearingGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="NonroyaltyBearingGrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialExpenseIncome" xlink:href="pypd-20221231.xsd#pypd_FinancialExpenseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="FinancialExpenseIncome" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxBenefitPercentage" xlink:href="pypd-20221231.xsd#pypd_TaxBenefitPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="TaxBenefitPercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementTerm" xlink:href="pypd-20221231.xsd#pypd_AgreementTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="AgreementTerm" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonRefundableAmount" xlink:href="pypd-20221231.xsd#pypd_NonRefundableAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="NonRefundableAmount" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalDevelopmentrelatedMilestonesPayments" xlink:href="pypd-20221231.xsd#pypd_AdditionalDevelopmentrelatedMilestonesPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="AdditionalDevelopmentrelatedMilestonesPayments" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalAmountOfCommercialSaleMilestones" xlink:href="pypd-20221231.xsd#pypd_AdditionalAmountOfCommercialSaleMilestones"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="AdditionalAmountOfCommercialSaleMilestones" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="monthlyDepositsAtARate" xlink:href="pypd-20221231.xsd#pypd_monthlyDepositsAtARate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="monthlyDepositsAtARate" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeverancePayExpenseAmount" xlink:href="pypd-20221231.xsd#pypd_SeverancePayExpenseAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="SeverancePayExpenseAmount" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeverancePay" xlink:href="pypd-20221231.xsd#pypd_SeverancePay"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="SeverancePay" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MatchingContributionsAmounts" xlink:href="pypd-20221231.xsd#pypd_MatchingContributionsAmounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="MatchingContributionsAmounts" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalLeasesIndemnificationAgreementsPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeasesIndemnificationAgreementsPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CapitalLeasesIndemnificationAgreementsPayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/LineofCreditArrangementDetails">
    <loc xlink:type="locator" xlink:label="LineOfCreditArrangementAbstract" xlink:href="pypd-20221231.xsd#pypd_LineOfCreditArrangementAbstract"/>
    <loc xlink:type="locator" xlink:label="LineofCreditArrangementDetailsTable" xlink:href="pypd-20221231.xsd#pypd_LineofCreditArrangementDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LineofCreditArrangementDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_LineofCreditArrangementDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditArrangementAbstract" xlink:to="LineofCreditArrangementDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstTrancheMember" xlink:href="pypd-20221231.xsd#pypd_FirstTrancheMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="FirstTrancheMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecondTrancheMember" xlink:href="pypd-20221231.xsd#pypd_SecondTrancheMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="SecondTrancheMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThiredTrancheMember" xlink:href="pypd-20221231.xsd#pypd_ThiredTrancheMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="ThiredTrancheMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsTable" xlink:to="LineofCreditArrangementDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LinesOfCreditCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_LinesOfCreditCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromLinesOfCreditOne" xlink:href="pypd-20221231.xsd#pypd_ProceedsFromLinesOfCreditOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsLineItems" xlink:to="ProceedsFromLinesOfCreditOne" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromLinesOfCreditTwo" xlink:href="pypd-20221231.xsd#pypd_ProceedsFromLinesOfCreditTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsLineItems" xlink:to="ProceedsFromLinesOfCreditTwo" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_LineOfCredit" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityPeriodicPayment" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LineOfCreditFacilityPeriodicPaymentOne" xlink:href="pypd-20221231.xsd#pypd_LineOfCreditFacilityPeriodicPaymentOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsLineItems" xlink:to="LineOfCreditFacilityPeriodicPaymentOne" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityDescription" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineofCreditArrangementDetailsLineItems" xlink:to="us-gaap_InterestExpenseShortTermBorrowings" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromParticipationPayments" xlink:href="pypd-20221231.xsd#pypd_ProceedsFromParticipationPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ProceedsFromParticipationPayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommitmentsAndContingentLiabilitiesDescription" xlink:href="pypd-20221231.xsd#pypd_CommitmentsAndContingentLiabilitiesDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingentLiabilitiesDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FindersFee" xlink:href="pypd-20221231.xsd#pypd_FindersFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="FindersFee" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SuitFillingExpense" xlink:href="pypd-20221231.xsd#pypd_SuitFillingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="SuitFillingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="pypd-20221231.xsd#pypd_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_IncomeTaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_IL" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="IncomeTaxesDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalHomeLoanBankAdvancesInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalHomeLoanBankAdvancesInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_FederalHomeLoanBankAdvancesInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_ShareholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_OfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwelveShareOptionPlanMember" xlink:href="pypd-20221231.xsd#pypd_TwoThousandTwelveShareOptionPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwelveShareOptionPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="ShareholdersEquityDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AggregateOfferingPrice" xlink:href="pypd-20221231.xsd#pypd_AggregateOfferingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="AggregateOfferingPrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionVestingPeriodDescription" xlink:href="pypd-20221231.xsd#pypd_StockOptionVestingPeriodDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="StockOptionVestingPeriodDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareOptionPlanDescription" xlink:href="pypd-20221231.xsd#pypd_ShareOptionPlanDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ShareOptionPlanDescription" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOptions" xlink:href="pypd-20221231.xsd#pypd_NumberOfOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="NumberOfOptions" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionShares" xlink:href="pypd-20221231.xsd#pypd_StockOptionShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="StockOptionShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionsAvailableForFutureGrants" xlink:href="pypd-20221231.xsd#pypd_StockOptionsAvailableForFutureGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="StockOptionsAvailableForFutureGrants" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageGrantDateFairValueOfOptionsGranted" xlink:href="pypd-20221231.xsd#pypd_WeightedAverageGrantDateFairValueOfOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="WeightedAverageGrantDateFairValueOfOptionsGranted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpectedDividendYield" xlink:href="pypd-20221231.xsd#pypd_ExpectedDividendYield"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ExpectedDividendYield" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrecognizedCompensationCosts" xlink:href="pypd-20221231.xsd#pypd_UnrecognizedCompensationCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="UnrecognizedCompensationCosts" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecognizedOverWeightedAveragePeriod" xlink:href="pypd-20221231.xsd#pypd_RecognizedOverWeightedAveragePeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="RecognizedOverWeightedAveragePeriod" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsDescription" xlink:href="pypd-20221231.xsd#pypd_WarrantsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="WarrantsDescription" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstanding" xlink:href="pypd-20221231.xsd#pypd_WarrantsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="WarrantsOutstanding" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfWarrants" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/RelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesDetailsTable" xlink:href="pypd-20221231.xsd#pypd_RelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_RelatedPartiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="RelatedPartiesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ServiceProvidersInAmount" xlink:href="pypd-20221231.xsd#pypd_ServiceProvidersInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="ServiceProvidersInAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTerm" xlink:href="pypd-20221231.xsd#pypd_RelatedPartiesTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="RelatedPartiesTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="pypd-20221231.xsd#pypd_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="pypd-20221231.xsd#pypd_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultAndDirectorsMember" xlink:href="pypd-20221231.xsd#pypd_ConsultAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="ConsultAndDirectorsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyCommittedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_InvestmentCompanyCommittedCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceDecrease" xlink:href="pypd-20221231.xsd#pypd_ExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ExercisePriceDecrease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRepayments" xlink:href="pypd-20221231.xsd#pypd_InterestRepayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="InterestRepayments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumPaidAmount" xlink:href="pypd-20221231.xsd#pypd_MinimumPaidAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="MinimumPaidAmount" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExceedAmount" xlink:href="pypd-20221231.xsd#pypd_ExceedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ExceedAmount" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfferingExpensesPayable" xlink:href="pypd-20221231.xsd#pypd_OfferingExpensesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="OfferingExpensesPayable" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://Polypid.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="pypd-20221231.xsd#pypd_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127134219600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PolyPid Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PYPD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">19,851,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001611842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">18 Hasivim Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Petach Tikva<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">495376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KOST FORER GABBAY & KASIERER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Haifa, Israel<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">372 Franklin Ave.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nutley<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Dikla Czaczkes Akselbrad<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">P.O. Box 558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">858-5995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127135063072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,552<span></span>
</td>
<td class="nump">$ 9,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Short-term deposits</a></td>
<td class="nump">4,042<span></span>
</td>
<td class="nump">22,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,089<span></span>
</td>
<td class="nump">2,211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">14,194<span></span>
</td>
<td class="nump">34,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>LONG-TERM ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,247<span></span>
</td>
<td class="nump">8,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_LongtermDeposits', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">663<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Total long-term assets</a></td>
<td class="nump">11,777<span></span>
</td>
<td class="nump">9,424<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">25,971<span></span>
</td>
<td class="nump">44,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities of long-term debt</a></td>
<td class="nump">4,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,429<span></span>
</td>
<td class="nump">3,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">1,141<span></span>
</td>
<td class="nump">4,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating lease liabilities</a></td>
<td class="nump">959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,553<span></span>
</td>
<td class="nump">8,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>LONG-TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="nump">7,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues</a></td>
<td class="nump">2,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">1,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_TotalLongtermLiabilities', window );">Total long-term liabilities</a></td>
<td class="nump">11,589<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, no par value - Authorized: 47,800,000 shares at December 31, 2022 and 2021; Issued and outstanding: 19,851,833 and 18,756,570 shares at December 31, 2022 and 2021, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">220,273<span></span>
</td>
<td class="nump">210,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(214,444)<span></span>
</td>
<td class="num">(174,887)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">5,829<span></span>
</td>
<td class="nump">35,960<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 25,971<span></span>
</td>
<td class="nump">$ 44,235<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_LongtermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount available in long term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_LongtermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_TotalLongtermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_TotalLongtermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127135049296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized</a></td>
<td class="nump">47,800,000<span></span>
</td>
<td class="nump">47,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">19,851,833<span></span>
</td>
<td class="nump">18,756,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding</a></td>
<td class="nump">19,851,833<span></span>
</td>
<td class="nump">18,756,570<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127134110704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net</a></td>
<td class="nump">$ 27,990<span></span>
</td>
<td class="nump">$ 30,553<span></span>
</td>
<td class="nump">$ 16,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_MarketingAndBusinessDevelopmentExpenses', window );">Marketing and business development</a></td>
<td class="nump">2,888<span></span>
</td>
<td class="nump">2,983<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,010<span></span>
</td>
<td class="nump">9,609<span></span>
</td>
<td class="nump">7,704<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="nump">38,888<span></span>
</td>
<td class="nump">43,145<span></span>
</td>
<td class="nump">26,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financial (income) expense, net</a></td>
<td class="nump">540<span></span>
</td>
<td class="num">(544)<span></span>
</td>
<td class="nump">10,597<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income tax</a></td>
<td class="nump">39,428<span></span>
</td>
<td class="nump">42,601<span></span>
</td>
<td class="nump">36,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">129<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">39,557<span></span>
</td>
<td class="nump">42,601<span></span>
</td>
<td class="nump">36,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_DeemedDividends', window );">Deemed dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,114<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare', window );">Net loss attributable to Ordinary shares</a></td>
<td class="nump">$ 39,557<span></span>
</td>
<td class="nump">$ 42,601<span></span>
</td>
<td class="nump">$ 38,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per Ordinary share (in Dollars per share)</a></td>
<td class="nump">$ 2.04<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="nump">$ 4.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of Ordinary shares used in computing basic and diluted loss per share (in Shares)</a></td>
<td class="nump">19,426,692<span></span>
</td>
<td class="nump">18,721,528<span></span>
</td>
<td class="nump">9,582,405<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_DeemedDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_DeemedDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_MarketingAndBusinessDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount related to Marketing and business development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_MarketingAndBusinessDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net loss attributable to Ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127134134928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted net loss per Ordinary share</a></td>
<td class="nump">$ 2.04<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="nump">$ 4.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of Ordinary shares</a></td>
<td class="nump">19,426,692<span></span>
</td>
<td class="nump">18,721,528<span></span>
</td>
<td class="nump">9,582,405<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127131849376">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Convertible Preferred Shares and Shareholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Convertible Preferred Shares</div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Number of Ordinary shares</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 106,313<span></span>
</td>
<td class="nump">$ 106,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,671<span></span>
</td>
<td class="num">$ (93,303)<span></span>
</td>
<td class="num">$ (87,632)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,520,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">562,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,577<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of Ordinary shares in connection with the IPO, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,757<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">62,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Ordinary shares in connection with the IPO, net (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares', window );">Conversion of convertible Preferred shares to Ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (106,313)<span></span>
</td>
<td class="num">(106,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,313<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">106,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares', window );">Conversion of convertible Preferred shares to Ordinary shares (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,520,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,520,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Deemed dividend related to Series E-1 Preferred shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,114<span></span>
</td>
<td class="num">(2,114)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Deemed dividend related to Series E-1 Preferred shares (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ReclassificationOfWarrantsIntoEquity', window );">Reclassification of warrants into equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,614<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares', window );">Exercise of warrants (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">939,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Issuance of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of warrants (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(36,869)<span></span>
</td>
<td class="num">(36,869)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,063<span></span>
</td>
<td class="num">(132,286)<span></span>
</td>
<td class="nump">72,777<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,494,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,750<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares', window );">Exercise of warrants (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(42,601)<span></span>
</td>
<td class="num">(42,601)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,847<span></span>
</td>
<td class="num">(174,887)<span></span>
</td>
<td class="nump">35,960<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,756,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,307<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Ordinary shares, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,423<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_IssuanceOfOrdinarySharesNetinShares', window );">Issuance of Ordinary shares, net (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,065,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Issuance of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(39,557)<span></span>
</td>
<td class="num">(39,557)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,273<span></span>
</td>
<td class="num">$ (214,444)<span></span>
</td>
<td class="nump">$ 5,829<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,851,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span>Net of issuance costs
of $6,243 (see Note&#160;1c).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span>Net of issuance costs
of $222.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount related to conversion of Convertible Preferred shares to ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Convertible Preferred shares to ordinary shares, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_IssuanceOfOrdinarySharesNetinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of issuance of Ordinary shares, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_IssuanceOfOrdinarySharesNetinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ReclassificationOfWarrantsIntoEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of Warrants into equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ReclassificationOfWarrantsIntoEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of Warrants, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127135061472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (39,557)<span></span>
</td>
<td class="num">$ (42,601)<span></span>
</td>
<td class="num">$ (36,869)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">1,721<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ReevaluationOfWarrants', window );">Remeasurement of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Non-cash financial expenses, net</a></td>
<td class="nump">289<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expenses</a></td>
<td class="nump">4,307<span></span>
</td>
<td class="nump">4,750<span></span>
</td>
<td class="nump">4,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,185<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="num">(1,929)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Operating lease liabilities and right-of-use assets, net</a></td>
<td class="num">(299)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade payables</a></td>
<td class="num">(3,095)<span></span>
</td>
<td class="nump">2,221<span></span>
</td>
<td class="num">(607)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenues</a></td>
<td class="nump">2,548<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(1,416)<span></span>
</td>
<td class="nump">2,043<span></span>
</td>
<td class="nump">847<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(34,317)<span></span>
</td>
<td class="num">(32,386)<span></span>
</td>
<td class="num">(21,596)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet', window );">Short-term and long-term deposits, net</a></td>
<td class="nump">18,342<span></span>
</td>
<td class="nump">39,893<span></span>
</td>
<td class="num">(39,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_PrepaymentForEquipments', window );">Pre-payments for equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(340)<span></span>
</td>
<td class="num">(395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,767)<span></span>
</td>
<td class="num">(2,653)<span></span>
</td>
<td class="num">(781)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">16,575<span></span>
</td>
<td class="nump">36,900<span></span>
</td>
<td class="num">(40,768)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">632<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of Ordinary shares in connection with the IPO, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">62,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of Ordinary shares, net</a></td>
<td class="nump">4,423<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net</a></td>
<td class="nump">11,711<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(402)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_IssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="nump">588<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">16,428<span></span>
</td>
<td class="nump">1,034<span></span>
</td>
<td class="nump">62,774<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(1,314)<span></span>
</td>
<td class="nump">5,548<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the year</a></td>
<td class="nump">10,456<span></span>
</td>
<td class="nump">4,908<span></span>
</td>
<td class="nump">4,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the year</a></td>
<td class="nump">9,142<span></span>
</td>
<td class="nump">10,456<span></span>
</td>
<td class="nump">4,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosures of cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">734<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the year for income taxes</a></td>
<td class="nump">8<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">8,552<span></span>
</td>
<td class="nump">9,819<span></span>
</td>
<td class="nump">4,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_RestrictedCashIncludedInOtherLongtermAssets', window );">Restricted cash included in other long-term assets</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at the end of the year</a></td>
<td class="nump">9,142<span></span>
</td>
<td class="nump">10,456<span></span>
</td>
<td class="nump">4,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable', window );">Property and equipment acquired by credit</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_PropertyAndEquipmentPaidForInPriorPeriods', window );">Property and equipment paid for in prior periods</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset recognized with corresponding lease liability</a></td>
<td class="nump">3,528<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Cash paid for amounts included in measurement of lease liability</a></td>
<td class="nump">$ 1,259<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease (increase) in receivables and prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_IssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_IssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of Short term and long term deposits, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PrepaymentForEquipments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-payment for equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PrepaymentForEquipments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PropertyAndEquipmentPaidForInPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property and equipment paid for in prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PropertyAndEquipmentPaidForInPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of property and equipment included in trade payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ReevaluationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Re-evaluation of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ReevaluationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_RestrictedCashIncludedInOtherLongtermAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of restricted cash included in other long term assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_RestrictedCashIncludedInOtherLongtermAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127136563632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">GENERAL</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left">NOTE 1:-</td><td style="text-align: justify">GENERAL</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">a.</td><td style="text-align: justify">PolyPid Ltd. (the &#8220;Company&#8221;) was incorporated under the laws of Israel and commenced operations
on February&#160;28, 2008. The Company is a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and
prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. The Company&#8217;s product candidates
are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release
rates and durations over extended periods ranging from days to several months. The Company is initially focused on the development of
its lead product candidate, D-PLEX, which incorporates an antibiotic for the prevention of surgical site infection in bone and soft tissue.
Through December 31, 2022, the Company has been primarily engaged in research and development.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">The Company&#8217;s wholly owned subsidiaries
include a subsidiary in the United States of America (the &#8220;US Subsidiary&#8221;) and a subsidiary in Romania. The US Subsidiary&#8217;s
operation focuses on marketing and business development of the Company&#8217;s operation in the United States of America.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">b.</td><td style="text-align: justify">On June 21, 2020, the Company&#8217;s Board of Directors resolved to consolidate the Company&#8217;s share
capital by applying a reverse share split at a ratio of 1.046:1 (the &#8220;Reverse Split Ratio&#8221;) and to cancel the shares&#8217;
par value such that every 1.046 Ordinary shares of NIS 0.8 par value, were substituted by 1 Ordinary share with no par value (the &#8220;Split&#8221;).
The Split was applied in the same proportion and manner to all of the Company&#8217;s authorized, issued and outstanding securities, including
preferred shares, options and warrants (See Note 10.a).</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">c.</td><td style="text-align: justify">On June 30, 2020, the Company closed its initial public offering (&#8220;IPO&#8221;) whereby 4,312,500 Ordinary
shares were sold by the Company to the public (inclusive of 562,500 Ordinary shares pursuant to the full exercise of an overallotment
option granted to the underwriters). The aggregate net proceeds received by the Company from the offering were $62,757, net of underwriting
discounts and other offering costs.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">d.</td><td style="text-align: justify">The Company&#8217;s activities since inception have consisted of performing research and development activities.
Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations is dependent on future
events, including, among other things, its ability to secure financing; obtain marketing approval from regulatory authorities; access
potential markets; build a sustainable customer base; attract, retain and motivate qualified personnel; and develop strategic alliances.
The Company&#8217;s operations are funded by its shareholders and research and development grants and the Company intends to seek further private
or public financing as well as make applications for further research and development grants for continuing its operations. Although management
believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to
do so or that the Company will ever operate profitably.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">In September 2022,
the Company announced top-line results from the Surgical site Hospital acquired Infection prEvention with Local D-PLEX<sub>100</sub> (&#8220;SHIELD&#8221;)
I Phase&#160;3 trial. SHIELD I did not achieve its primary endpoint of reduction in Surgical Site Infections (&#8220;SSIs&#8221;), re-interventions
due to SSIs and mortality: in the Intent to Treat (&#8220;ITT&#8221;) population, the local administration of D-PLEX<sub>100</sub> and standard
of care (&#8220;SoC&#8221;), (n=485) resulted in a decrease in the primary endpoint of 23 percent compared to SoC alone (n=489) (p=0.1520).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">That said, in a
pre-specified subgroup ITT analysis requested by the United States (&#8220;U.S.&#8221;) Food and Drug Administration of a total of 423 subjects
with large incisions (&gt;20 centimeters), the local administration of D-PLEX<sub>100 </sub>resulted in a significant reduction of 54
percent in the primary endpoint, compared to SoC alone (p=0.0032). Within the first 30 days post-surgery, SSIs decreased from 9.7% in
the SoC treatment arm (n=211), as compared to 4.4% in the D-PLEX<sub>100</sub> treatment arm (n=212).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company expects
to continue to incur substantial losses over the next several years during its clinical development phase. To fully execute its business
plan, the Company will need to complete phase 3 clinical studies and certain development activities as well as manufacture the required
clinical and commercial production batches in the pilot manufacturing plant. Further, the Company&#8217;s product candidates will require regulatory
approval prior to commercialization and the Company will need to establish sales, marketing and logistic infrastructures. These activities
may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these
activities could adversely impact the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As of December 31,
2022, the Company had cash, cash equivalents and short-term deposits in the total amount of $12,594. During the year ended December&#160;31,
2022, the Company incurred a net loss of $39,557 and had negative cash flows from operating activities of $34,317. In addition, the Company
had an accumulated deficit of $214,444 at December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company&#8217;s future
operations are highly dependent on a combination of factors, including (i) completion of all required clinical studies; (ii) the success
of its research and development activities; (iii) manufacture of all required clinical and commercial production batches; (iv) marketing
approval by the relevant regulatory authorities; and (v) market acceptance of the Company&#8217;s product candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">There can be no
assurance that the Company will succeed in achieving the clinical, scientific and commercial milestones as detailed above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Based on the
abovementioned, as of the approval date of these consolidated financial statements, the Company has not raised the necessary funding in
order to continue its activity for a period of at least one year after the date of the filing of this annual report on Form 20-F. Therefore,
these factors raise a substantial doubt about the Company&#8217;s ability to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The consolidated
financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that might result
should the Company be unable to continue as a going concern.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127141487600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left">NOTE 2:-</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES</td>
</tr></table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The consolidated financial statements
are prepared according to United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">a.</td><td style="text-align: justify">Use of estimates:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company&#8217;s management
believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made.
These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting
periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">b.</td><td style="text-align: justify">Consolidated financial statements in U.S.&#160;dollars:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accompanying consolidated financial
statements have been prepared in United States of America dollars (&#8220;USD&#8221;, &#8220;$&#8221; or &#8220;U.S. dollars&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A substantial portion of the Company&#8217;s
expenses are incurred in New Israeli Shekels (&#8220;NIS&#8221;). However, the Company finances its operations mainly in U.S. dollars,
a substantial portion of its expenses are incurred in U.S. dollars and potential revenues from its primary markets are anticipated to
be generated in U.S. dollars. As such, the Company&#8217;s management believes that the U.S. dollar is the currency of the primary economic
environment in which the Company and its subsidiaries operate. Thus, the functional and reporting currency of the Company is the U.S.
dollar.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the dollar are re-measured
into U.S. dollars in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) No. 830, &#8220;<i>Foreign Currency Matters</i>&#8221;.
All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the statements of operations as
financial income or expenses, as appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">c.</td><td style="text-align: justify">Principles of consolidation:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The consolidated
financial statements include the accounts of the Company and its subsidiaries. Intercompany balances have been eliminated upon consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">d.</td><td style="text-align: justify">Cash equivalents:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Cash equivalents
are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or less, at
the date acquired.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">e.</td><td style="text-align: justify">Restricted cash:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Restricted cash
is primarily invested in a bank deposit and is used as security for the Company&#8217;s lease commitments and for its forward and options transactions
activities (see Note 2q).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">f.</td><td style="text-align: justify">Segment reporting:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company
identifies operating segments in accordance with ASC No. 280, &#8220;<i>Segment Reporting</i>&#8221;, as components of an entity for which
discrete financial information is available and is regularly reviewed by the chief operating decision maker, or decision-making group,
in making decisions regarding resource allocation and evaluating financial performance. The Company&#8217;s chief operating decision maker is
its chief executive officer. The Company determined it operates in one operating segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">g.</td><td style="text-align: justify">Short-term deposits:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A short-term bank deposit is a deposit
with a maturity of more than three months, but less than one year. Deposits in U.S. dollars bear interest at rates ranging from 4.55%-5.90%,
per annum, as of December 31, 2022. Short-term deposits are presented at cost, which approximates market value due to their short maturities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.75pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">h.</td><td style="text-align: justify">Property and equipment, net:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Property and equipment
are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful
lives of the assets at the following rates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 77%; text-align: justify">Computers and software</td><td style="width: 1%">&#160;</td>
    <td style="width: 22%; text-align: center; padding-left: 0.05in">33</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0.05in">10&#160;-&#160;15</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0.05in">15</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in">Leasehold improvements</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: center; padding-left: 0.05in">Over the shorter of the term of the lease or its useful life</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">i.</td><td style="text-align: justify">Leases:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">On January 1, 2022,
the Company adopted ASC No. 842, &#8220;<i>Leases</i>&#8221; (&#8220;ASC 842&#8221;), using the modified retrospective method&#160;by applying
the new standard to all leases existing at the date of initial application. Results and disclosure requirements for reporting periods
beginning after January 1, 2022, are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported
in accordance with the Company&#8217;s historical accounting under ASC No. 840, &#8220;<i>Leases</i>&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company has
elected the package of practical expedients permitted under the transition guidance, which allows the Company not to reassess: (1) whether
any existing contracts as of the adoption date are or contain a lease under ASC 842, (2) lease classification for any existing leases
as of the adoption date, and (3) initial direct costs for any existing leases as of the adoption date. Lastly, the Company also elected
the practical expedient to not separate lease and non-lease components for its leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As a result of the
adoption of ASC 842 on January 1, 2022, the Company recorded both operating leases right-of-use (&#8220;ROU&#8221;) assets and operating
lease liabilities of $3,388.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The ROU assets include
adjustments for lease prepayments in the amount of $36. The adoption did not impact the Company&#8217;s beginning accumulated deficit,
or its prior year consolidated statements of operations and statements of cash flows. The adoption did not have a material impact on the
Company&#8217;s current year consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Leases are classified
as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the
lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably
certain to be exercised, the lease term is for a major part of the remaining useful life of the asset, the present value of the lease
payments equals or exceeds substantially all of the fair value of the asset, or the underlying asset is of such a specialized nature that
it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does
not meet any one of these criteria. Since all of the Company&#8217;s lease contracts do not meet any of the criteria above, the Company
concluded that all of its lease contracts should be classified as operating leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">ROU assets
and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For
this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company&#8217;s
leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available on the commencement
date in determining the present value of lease payments. All ROU assets are reviewed for impairment. The lease terms may include options
to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">j.</td><td style="text-align: justify">Impairment of long-lived assets:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company&#8217;s long-lived
assets are reviewed for impairment in accordance with ASC No. 360, &#8220;<i>Property, Plant and Equipment</i>&#8221;, whenever events or
changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held
and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated
by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying
amount of the asset exceeds its fair value. As of December 31, 2022 and 2021, no impairment losses have been identified.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">k.</td><td style="text-align: justify">Research and development, net expenses:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Research and development
expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments
to subcontractors, chemical, manufacturing and control activities, costs associated with obtaining regulatory approvals, executing pre-clinical
and clinical studies and maintenance and prosecution of the Company&#8217;s intellectual property rights. In addition, research and development
expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research
and development expenses as expenses when incurred and are presented net of government grants (see Note 2.l).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">l.</td><td style="text-align: justify">Grants and participations:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Royalty-bearing grants from the Israeli
Innovation Authority (&#8220;IIA&#8221;) of the Ministry of Economy and Industry in Israel for funding of approved research and development
projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a
deduction from research and development expenses. Non-royalty-bearing grants from the IIA MAGNET program and from European Commission&#8217;s
Seventh Framework Programme for Research (&#8220;FP7&#8221;) for funding approved research and development projects are recognized at
the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and
development expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Since the payment
of royalties is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until
the related revenues are recognized.&#160;In the event of failure of a project that was partly financed by IIA, the Company will not be
obligated to pay any royalties or repay the amounts received.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company recognizes
participations in research and development, as a reduction from research and development expenses in the amount of $738 and $542 for the
years ended December 31, 2022, and 2021, respectively (no grants were received for the year ended December 31, 2020).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">From inception up
until December 31, 2022, the Company received a total of $7,193 in grants, out of which royalty-bearing grants in the amount of $4,888
from the IIA, non-royalty bearing grants in the amount of $1,578 from the IIA (out of which $521 were received during the year ended December
31, 2022) and non-royalty bearing grants in the amount of $727 from the FP7.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">m.</td><td style="text-align: justify">Accounting for share-based compensation:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Share-based compensation
expense related to share-based awards is recognized based on the fair value of the awards granted and recognized as an expense on a straight-line
basis over the requisite service period for share options. The fair value of each option award is estimated on the grant date using the
Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including
the expected term of the award, the expected volatility of the price of the Company&#8217;s Ordinary shares, risk-free interest rates,
and the expected dividend yield of Ordinary shares. The assumptions used to determine the fair value of the share awards represent management&#8217;s
best estimates. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. Forfeitures are accounted
for as they occur instead of estimating the number of awards expected to be forfeited.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">n.</td><td style="text-align: justify">Basic and diluted net loss per share:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Prior to the Company&#8217;s
IPO, the Company computed its net loss per share using the two-class method required for participating securities. The two-class method
requires income available to Ordinary shareholders for the period to be allocated between Ordinary shares and participating securities
based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considered its
convertible preferred shares to be participating securities as the holders of the convertible preferred shares would be entitled to dividends
that would be distributed to the holders of Ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities
did not contractually require the holders of such shares to participate in the Company&#8217;s losses.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As such,&#160;during
the periods when the Company is in a loss position, the loss attributable to Ordinary shareholders was not allocated to the convertible
preferred shares under the two-class method as these securities did not have a contractual obligation to share in the Company&#8217;s
losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Following the Company&#8217;s
IPO, the Company&#8217;s basic net loss per share is calculated by dividing the net loss attributable to Ordinary shareholders by the
weighted-average number of shares of Ordinary shares outstanding for the period, without consideration of potentially dilutive securities.
The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using
the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as
basic net loss per share in periods when the effects of potentially dilutive shares of Ordinary shares are anti-dilutive.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">o.</td><td style="text-align: justify">Convertible preferred shares and convertible preferred shares warrant liability:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The terms of the
convertible preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1&#160;shares allowed the holders to redeem shares, under certain circumstances,
outside of the Company&#8217;s control. Therefore, these shares were classified as mezzanine equity on the balance sheet and not included as
a component of shareholders&#8217; deficit before the IPO. The Company did not adjust the preferred shares&#8217; carrying value to the redemption
value since redemption was not probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Following the Company&#8217;s
IPO, the convertible preferred shares were converted into Ordinary shares and were reclassified into permanent equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Warrants to purchase the Company&#8217;s
convertible preferred shares were classified as a liability on the balance sheet, and measured at fair value, as the underlying shares
are contingently redeemable (upon a deemed liquidation event) and, therefore, may obligate the Company to transfer assets at some point
in the future. The warrants were subject to re-measurement to fair value at each balance sheet date and any change in fair value was recognized
as a component of financial expenses, net, in the statements of operation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Following the Company&#8217;s IPO,
the warrants can only be exercised into the Company&#8217;s ordinary equity shares. Consequently, as of the IPO date, the Company reclassified
the warrants as equity since the warrants are not an ASC No. 480, &#8220;<i>Distinguishing Liabilities from Equity</i>&#8221; (&#8220;ASC
480&#8221;), liability, are indexed to the Company&#8217;s own stock and can be classified as equity pursuant to ASC No. 815-40, &#8220;<i>Derivatives
and Hedging</i>&#8221; (&#8220;ASC 815&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">p.</td><td style="text-align: justify">Fair value of financial instruments:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company applies
ASC No. 820, &#8220;<i>Fair Value Measurements and Disclosures</i>&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined
as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly
transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches.
ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the
use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market
participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Unobservable inputs
are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability
developed based on the best information available in the circumstances.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Fair value is an
exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction
between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market
participants would use in pricing an asset or a liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">A three-tier fair
value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring
fair value:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1.25in">&#160;</td>
    <td style="width: 0.6in; text-align: justify; text-indent: 0in;">Level 1 -</td>
    <td style="padding-left: 0in; text-align: justify; text-indent: 0in;">Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; text-indent: 0in;">Level 2 -</td>
    <td style="text-align: justify; text-indent: 0in;">Include other inputs that are directly or indirectly observable in the marketplace.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; text-indent: 0in;">Level 3 -</td>
    <td style="text-align: justify; text-indent: 0in;">Unobservable inputs which are supported by little or no market activity</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value hierarchy also requires
an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value<span style="font-size: 10pt">.</span></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The carrying amounts of cash and cash
equivalents, restricted cash, short-term deposits, long-term deposits, prepaid expenses and other current assets, trade payables, accrued
expenses and other current and non-current liabilities approximate their fair value due to the short-term maturity of such instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>The
fair value measurement of the FCA (as defined in Note 7) is measured using unobservable inputs that require a high level of judgment to
determine fair value, and thus is classified as a Level&#160;3 financial instrument. The Company estimates the fair value of the abovementioned
instrument using the Monte-Carlo simulation and the Black-Scholes option pricing model.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Fair
value estimates are made at a specific point in time, based on relevant market information and information about the financial instruments.
These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined
with precision. Changes in assumptions could significantly affect these estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">q.</td><td style="text-align: justify">Derivative financial instruments:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company accounts
for derivatives based on ASC 815. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The Company
enters into option and forward contracts in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred
in NIS. Since the derivative instruments that the Company holds were not designated as hedging instruments under ASC 815, any gain or
loss derived from such instruments is recognized immediately as &#8220;financial (income) expense, net&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.6pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company measured the fair value
of the contracts in accordance with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs
are based on quoted prices and market observable data of similar instruments. As of December 31, 2022 and 2021, the fair value of the
options and forward contracts was ($12) and $28, respectively, which were
presented as Accrued expenses and other current liabilities and Prepaid expenses and other current assets, respectively. Financial expense
(income) for the years ended December 31, 2022, 2021 and 2020, amounted to $273, ($58) and&#160;($81), respectively.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">r.</td><td style="text-align: justify">Income taxes:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company accounts
for income taxes in accordance with ASC No. 740, &#8220;<i>Income Taxes</i>&#8221; (&#8220;ASC 740&#8221;). ASC 740 prescribes the use of
the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial
reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the
differences are expected to reverse. The Company provides a valuation allowance to reduce deferred tax assets to their estimated realizable
value, if needed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">ASC 740 contains
a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position
taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than
not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals
or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized
upon ultimate settlement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As of December&#160;31,
2022 and 2021, the Company&#8217;s uncertain tax position liability was immaterial.	The Company&#8217;s policy is to accrue interest and penalties
related to unrecognized tax benefits in its taxes on income.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">s.</td><td style="text-align: justify">Revenue recognition:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company recognizes
revenue from contracts with customers under ASC No. 606, &#8220;<i>Revenue from Contracts with Customers</i>&#8221;. Accordingly, the Company
recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it
expects to be entitled in exchange for those goods or services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">To determine revenue
recognition for contracts with customers, the Company performs the following five steps:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(i) identify the
contract(s) with a customer;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(ii) identify the
performance obligations in the contract;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(iii) determine
the transaction price;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(iv) allocate the
transaction price to the performance obligations in the contract; and</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(v) recognize revenue
when (or as) the Company satisfies its performance obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">At contract inception,
the Company assesses the goods or services agreed upon within each contract and assesses whether each good or service is distinct to determine
the performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">On August 2, 2022,
the Company entered into a license, distribution and supply agreement (the &#8220;Agreement&#8221;) with Mercury Pharma Group Limited, under
the trade name Advanz Pharma Holdings
(the &#8220;Customer&#8221;), with respect to the Company&#8217;s product, the D-PLEX<sub>100</sub> (the &#8220;Product&#8221;), for the prevention
of (i) post abdominal surgery incisional infection; and/or (ii) post cardiac surgery sternal infection.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The term of the
Agreement is until the later of December 31, 2035, or 10 years after the first commercial sale of the Product. The Agreement can also
be terminated by either party under certain limited circumstances. Pursuant to the Agreement, the Customer was granted an exclusive license
to market, commercialize, and distribute the Product in the European Economic Area and in the United Kingdom. Under the Agreement, the
Company will carry out all activities required to obtain marketing authorization in each territory, approving the commercial sale of the
Product in that territory. Once marketing authorization will be granted in a territory, the Customer will be required to achieve minimum
sales requirements for that territory.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Under the terms
of the Agreement, the Company received a non-refundable, one-time payment of &#8364;2.5 million (approximately $2,548). The Company is
also entitled to receive additional development-related milestones payments for a total of up to &#8364;23 million.
In addition, the Company will be entitled to receive up to additional &#8364;87 million upon achievement of certain
commercial sale milestones.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company has
concluded that the Agreement includes a single performance obligation. The Company has concluded that the license and development are
not distinct from the manufacturing since the Customer could not use, consume, or sell the license and development services on their own
or with resources readily available to the Customer because of the Company&#8217;s specialized knowledge and the associated manufacturing know-how
and because currently, and in the foreseeable future, there are no other parties that could manufacture the Product. As such, the transaction
price was fully allocated to the single performance obligation. Since it is not probable that a significant reversal in the amount of
cumulative revenue recognized will not occur when the uncertainty associated with the milestone payments is resolved, the Company estimated
the transaction price at &#8364;2.5 million (approximately $2,548).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As of December 31,
2022, the Company has yet to satisfy its performance obligation under the Agreement and, therefore, no revenues were recognized. Accordingly,
the upfront payment amount was classified as a long-term deferred revenue in the Company&#8217;s consolidated balance sheet as of December 31,
2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.5in; text-align: left">t.</td><td style="text-align: justify">Concentration of credit risks:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Financial instruments
that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and short-term deposits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Cash, cash equivalents,
restricted cash and short-term deposits are deposited in major banks in Israel and in the United States of America. Such investments may
be in excess of insured limits or not insured. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal
risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company utilizes
option and forward contracts to protect against the risk of overall changes in exchange rates. The derivative instruments hedge a portion
of the Company&#8217;s non-dollar currency exposure. Counterparties to the Company&#8217;s derivative instruments are all major financial institutions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">u.</td><td style="text-align: justify">Severance pay:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">All the Company&#8217;s
employees who are Israeli citizens have subscribed to Section&#160;14 of Israel&#8217;s Severance Pay Law, 5723-1963 (&#8220;Section&#160;14&#8221;).
Pursuant to Section&#160;14, employees covered by this section are entitled to monthly deposits at a rate of 8.33% of their monthly salary,
made on their behalf by the Company. Payments in accordance with Section&#160;14 release the Company from any future severance liabilities
in respect of those employees. Neither severance pay liability nor severance pay fund under Section&#160;14 for such employees is recorded
on the Company&#8217;s consolidated balance sheets. Severance pay expense for the years ended December 31, 2022, 2021 and 2020, amounted to
$537, $547 and $394, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The US Subsidiary
has a Safe Harbor 401(k) plan covering all the US Subsidiary employees. All eligible employees may elect to contribute up to 100% of their
payroll compensation (minus mandatory payroll deductions) to the plan, for 2022, up to a maximum of $20,500 per year (for employees over
50 years of age the maximum contribution was $28,000 per year), as determined by the U.S. Internal Revenue Service (&#8220;IRS&#8221;).
The US Subsidiary matches at 100%, on each payroll, up to 5% of the employee compensation to the plan within the IRS limits (which was
set at $300 in 2022 for purposes of the plan). During the year ended December 31, 2022, the Company recorded expenses for matching contributions
in the amount of $30, as compared to $28 in 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">v.</td><td style="text-align: justify">Contingent liabilities:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company accounts
for its contingent liabilities in accordance with ASC No. 450, &#8220;<i>Contingencies</i>&#8221;. A provision is recorded when it is both
probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">With respect to
legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice
of legal counsel and other information and events pertaining to a particular matter. The Company is occasionally a party to routine claims
or litigation incidental to its business. The Company does not believe that it is a party to any pending legal proceeding that is likely
to have a material adverse effect on its business, financial condition or results of operations. The Company recorded an accrual in the
consolidated statement of operations, which it deems appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As of December 31,
2022 and 2021, no liability due to legal matters has been accrued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">w.</td><td style="text-align: justify">Recently adopted accounting pronouncements:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As an &#8220;Emerging
Growth Company&#8221;, the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;) allows the Company to delay adoption of new or
revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The
Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election<span style="font-family: Times New Roman, Times, Serif">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">On January 1, 2022,
the Company adopted ASC 842. Upon adoption, we recognized total ROU assets and corresponding liabilities of $3,388&#160;on our consolidated
balance sheets. The ROU assets include adjustments for prepayments and accrued lease payments. The adoption did not impact the beginning
balance of retained earnings, or prior year consolidated statements of operations and statements of cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">For information
regarding the impact of ASC 842 adoption, see Note 2.i and Note 5 - Leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.3pt">In December 2019,
the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, &#8220;<i>Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>&#8221; (ASU 2019-12), which simplifies the accounting for income taxes.
The guidance is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted. The Company
has adopted ASU 2019-12 as of January 1, 2022. The impact of adoption of this standard on the Company&#8217;s consolidated financial statements
was immaterial.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.3pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In August 2020, the FASB issued ASU
No. 2020-06, &#8220;<i>Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s
Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>&#8221; (&#8220;ASU
2020-06&#8221;), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP.
The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception,
and it simplifies the diluted earnings per share calculation in certain areas. The Company adopted ASU 2020-06 on January 1, 2022. The
adoption of the standard did not result in a material impact to the Company&#8217;s consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">x.</td><td style="text-align: justify">Recently issued accounting pronouncements, not yet adopted:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In June 2016, the FASB issued ASU No.
2016-13, &#8220;<i>Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>,&#8221;
which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured
at amortized cost to be presented at the net amount expected to be collected. The guidance will be effective for the Company beginning
January 1, 2023, and interim periods thereafter. The Company adopted ASU 2016-13 on January 1, 2023. The adoption of the standard did
not result in a material impact to the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127222946176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_PrepaidExpensesAndOtherReceivablesAbstract', window );"><strong>Prepaid Expenses And Other Receivables Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_PrepaidExpensesAndOtherReceivablesTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"/><td style="width: 0.75in; text-align: left">NOTE 3:-</td><td style="text-align: justify">PREPAID EXPENSES AND OTHER CURRENT ASSETS</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">552</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,453</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">596</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Lease deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">298</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 2.85pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 2.85pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,089</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,211</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PrepaidExpensesAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PrepaidExpensesAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PrepaidExpensesAndOtherReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PrepaidExpensesAndOtherReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127137392000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"/><td style="width: 0.75in; text-align: left">NOTE 4:-</td><td style="text-align: justify">PROPERTY AND EQUIPMENT, NET</td>
</tr></table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Computers and software</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">613</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">577</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,933</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,247</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">173</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">167</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,503</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,024</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,015</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,975</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,254</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Depreciated cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,247</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,761</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Depreciation expenses amounted to $1,721,
$1,118 and $1,012 for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The majority of the Company&#8217;s
property and equipment is located in Israel.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127137392000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt"/><td style="width: 0.75in; text-align: left">NOTE 5:-</td><td style="text-align: justify">LEASES</td>
</tr></table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">a.</td><td style="text-align: justify">The Company&#8217;s facilities are leased under operating lease agreements for periods ending no later than
2027. The Company has bank guarantees in connection with the facilities lease agreements in the total amount of $213. Accordingly, cash,
in the same amount, was restricted in bank deposits. The Company also leases motor vehicles under various operating leases, the latest
of which expires in 2025.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -21.3pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">b.</td><td style="text-align: justify">The following table summarizes the Company&#8217;s lease-related assets and liabilities recorded on the
balance sheets:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Classification</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 67%; font-style: italic; text-align: left">Lease assets:</td><td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: left; padding-left: 5.4pt">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Operating lease assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt; padding-left: 5.4pt">Operating lease ROU assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,431</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Lease liabilities:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; width: 67%; text-align: left">Current lease liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: center; padding-left: 5.4pt">Short-term operating lease liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">959</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Long-term lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt">Long-term lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,173</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,132</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted Average Remaining lease term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.37 years</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Weighted Average Discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.95</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">c.</td><td style="text-align: justify">The components of operating lease expense for the year ended December 31, 2022, were $1,344.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -21.3pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">d.</td><td style="text-align: justify">Lease liability as of December 31, 2022, is as follows:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,047</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">439</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">385</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">367</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">186</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,424</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less - imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(292</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,132</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">e.</td><td style="text-align: justify">The following table presents supplemental cash flow information related to the lease costs for operating
leases as of December 31, 2022:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left">Cash paid for amounts included in measurement of lease liability:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 4pt">Operating cash flows for operating leases</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">1,259</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Right-of-use asset recognized with corresponding lease liability:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Operating leases</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,528</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888252<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127222861696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 6:- </td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</td></tr>
</table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,246</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,787</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Employees and payroll accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,879</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">IIA deferred grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">269</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 2.85pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 2.85pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,429</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,940</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127136693584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Line of Credit Arrangement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_LineOfCreditArrangementAbstract', window );"><strong>Line Of Credit Arrangement Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_LineOfCreditArrangementTextBlock', window );">LINE OF CREDIT ARRANGEMENT</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 7:- </td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt">LINE OF CREDIT ARRANGEMENT</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">On
April 5, 2022, the Company entered into a secured line of credit agreement for up to $15,000 (the &#8220;Credit Line&#8221;) with Kreos
Capital VI (Expert Fund) LP (&#8220;Kreos&#8221;). The Credit Line is comprised of three tranches in the amount of $10,000, $2,500 and
$2,500, respectively, in which the first tranche and in the amount of $10,000 (the &#8220;First Tranche&#8221;) and the second tranche in
the amount of $2,500 (the &#8220;Second Tranche) were drawn on April 26, 2022 and July 19, 2022, respectively. In addition, in accordance
with the Credit Line agreement, the Company will issue to Kreos warrants to purchase the Company&#8217;s Ordinary shares equal to 8% of
the amount of each tranche, when and if borrowed, with an exercise price of $5.14 per share. The expiration date for each warrant issued
will be seven years from the agreement date. Accordingly, as a result of the First Tranche and Second Tranche withdrawal, the Company
issued to Kreos a warrant in the total amount of $1,000. The total number of shares issuable upon exercise is equal to the total amount
divided by the exercise price.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">The
Credit Line is denominated in USD and bears interest at an annual rate equal to 9.25%. The interest paid due to the Credit Line for the
year ended December 31, 2022 amounted to $734. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">On
each drawdown date, the Company shall pay to Kreos on the drawdown date the last period payment for such drawdown. For the First Tranche
and Second Tranche, the amount the Company paid was $317 and $85, respectively.</span></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 56.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">The
third and final tranche of $2,500 will never be drawn since the third tranche milestone has not been met. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">The
Company has concluded that the Credit Line includes several legally detachable and separately exercisable freestanding financial instruments:
The First Tranche term loan, the warrants, and the right to receive additional loan tranches (the &#8220;FCA&#8221;). </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">The
Company has concluded that the warrants should be classified as equity since the warrants are not an ASC 480 liability, are indexed to
the Company&#8217;s own Ordinary stock and meet all the equity classification conditions pursuant to ASC 815-40. The Company has also concluded
that the FCA is not indexed to the Company&#8217;s own Ordinary stock and should be measured at fair value, with changes in fair value recognized
in earnings. In addition, the First Tranche and the Second Tranche term loan were accounted for using the effective interest method. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">The
Company allocated the proceeds received to the FCA at fair value. The remaining proceeds were allocated between the warrants and the First
Tranche term loan using the relative fair value method. The proceeds allocation resulted in $9,532 allocated to the First Tranche and
$468 allocated to the warrants, net of issuance costs. The proceeds allocated to the FCA were immaterial. </span></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">The
Company allocated the proceeds received under the Credit Line between the warrants and the Second Tranche term loan using the relative
fair value method. The proceeds allocation resulted in $2,380 allocated to the Second Tranche and $120 allocated to the warrants. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">During
the year ended December 31, 2022, the Company recognized $1,023 of interest expenses related to the First Tranche and the Second Tranche,
which were included as part of financial expenses in the Company&#8217;s statements of operation. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_LineOfCreditArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_LineOfCreditArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_LineOfCreditArrangementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of line of credit arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_LineOfCreditArrangementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127251104448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 8:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> COMMITMENTS AND CONTINGENT LIABILITIES</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">a.</td><td style="text-align: justify">In connection with its research and development programs, through December 31, 2022, the Company received
participation payments from the IIA in the aggregate amount of $4,888. In return for the IIA&#8217;s participation, the Company is committed
to pay royalties at a rate of 3% of sales of the developed products, up to 100% of the amount of grants received plus interest at LIBOR
rate. Through December 31, 2022, no royalties have been paid or accrued.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.2pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">b.</td><td style="text-align: justify">On December 22, 2016, the Company received a written demand for a finder&#8217;s fee in an amount of $250, in
connection with the second financing round that occurred in 2016. In September 2017, a suit was filed against the Company in the Tel-Aviv
Magistrates Court in an amount of $250. On April 30, 2020, the Company received the court ruling, which ruled in favor of the Company,
discharging the entire claim, and accordingly reversed the related provision. </td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127137913776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 9:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> INCOME TAXES</td></tr>
</table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">a.</td><td style="text-align: justify">Corporate tax rates:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The corporate tax
rate in Israel in 2022, 2021 and 2020 was 23%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The United States of America federal
rate was 21% and the state corporate income tax rates range from 6.5% to 11.5%, for the years ended December 31, 2022, 2021 and 2020.
The Company didn&#8217;t account for any federal, state and foreign income tax expenses for the years ended December 31, 2022, 2021 and
2020. The Company is subject to United States of America income tax laws. There are no provisions for United States of America federal,
state or other taxes for any period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">Loss before taxes is comprised as
follows<span style="font-size: 10pt">:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year
Ended <br/>
December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Domestic (Israel)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">38,403</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">41,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">35,983</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,154</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,404</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">886</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">39,557</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">42,601</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">36,869</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">b.</td><td style="text-align: justify">Net operating losses carryforward:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The Company has
accumulated losses for tax purposes as of December 31, 2022, in the amount of approximately $152,107 which may be carried forward and
offset against taxable income in the future for an indefinite period.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">c.</td><td style="text-align: justify">Tax assessment:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The Company has
net operating losses from prior tax periods which may be subjected to examination in future periods. As of December 31, 2022, the Company&#8217;s
tax years until December 31, 2017, are subject to the statute of limitation in Israel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The US Subsidiary has yet to receive
final tax assessments since its incorporation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">d.</td><td style="text-align: justify">Deferred taxes:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts used for income tax purposes. The Company&#8217;s deferred tax assets are comprised of
operating loss carryforwards and other temporary differences. Significant components of the Company&#8217;s deferred tax assets are as
follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Carryforward losses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">34,984</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">31,289</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,376</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">490</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Reserves and allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">157</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">479</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(40,448</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37,210</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">559</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease ROU assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(559</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(559</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">Management
currently believes that since the Company has a history of losses, and there is uncertainty with respect to future taxable income of
the Company, it is more likely than not that the deferred tax assets will not be utilized in the foreseeable future. Thus, a full
valuation allowance was provided to reduce deferred tax assets to their realizable value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">d.</td><td style="text-align: justify">Deferred taxes: (Cont.)</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">In 2022 and 2021,
the main reconciling items of the Company&#8217;s statutory tax rate of 23% and the effective tax rate of (0.3)% and 0%, respectively, is tax
carryforward losses and other temporary differences, such as research and development expenses, for which a full valuation allowance was
provided.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">e.</td><td style="text-align: justify">Income taxes are comprised as follows:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year
Ended <br/>
December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Current</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">129</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 2.85pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">129</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended <br/>
December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Domestic (Israel)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Foreign</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">129</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 2.85pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">129</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127140472672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 10:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> SHAREHOLDERS&#8217; EQUITY</td></tr>
</table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">a.</td><td style="text-align: justify">Reverse Share Split:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">On June 21, 2020,
the Company&#8217;s Board of Directors resolved to consolidate the Company&#8217;s share capital by applying an additional reverse share
split and cancelling the shares&#8217; par value (See Note 1.b).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">Following the reverse
share split and the cancellation of the par value, all Ordinary shares, Convertible Preferred shares, options, convertible loans, warrants,
exercise prices and per share data have been adjusted retroactively for all periods presented in these consolidated financial statements.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">b.</td><td style="text-align: justify">Ordinary share capital is composed as follows:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/>
 outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/>
 outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 52%; text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">&#160;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">&#160;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">&#160;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">&#160;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt">Ordinary shares with no par value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">47,800,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">19,851,833</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">47,800,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,756,570</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify; text-indent: 56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">c.</td><td style="text-align: justify">Controlled Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221;):</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">In July 2021, the
Company entered into a Sales Agreement with Cantor Fitzgerald &amp; Co. (the &#8220;Agent&#8221;), pursuant to which the Company may offer
and sell, from time to time, its Ordinary shares, through the Agent in an at the market offering (&#8220;ATM&#8217;&#8221;), as defined in Rule
415(a)(4) promulgated under the Securities Act of 1933, as amended, for an aggregate offering price of up to $45,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.25pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">During the year
ended December 31, 2022, the Company sold 1,065,057 Ordinary shares under the ATM for a total amount of $4,423, net of issuance cost in
the amount of $222.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.25pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">d.</td><td style="text-align: justify">Ordinary shares rights:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The Ordinary shares confer upon their
holders the right to participate in the general meetings of the Company, to vote at such meetings (each share represents one vote), and
to participate in any distribution of dividends or any other distribution of the Company&#8217;s property, including the distribution of surplus
assets upon liquidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">e.</td><td style="text-align: justify">Share option plan:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The Company has
authorized through its 2012 Share Option Plan, the grant of options to officers, directors, advisors, management and other key employees
of up to 4,672,094 Ordinary shares. The options granted generally have a four-year vesting period and expire ten years after the date
of grant. Options granted under the Company&#8217;s option plan that are canceled or forfeited before expiration become available for future
grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">On May 3, 2022, the annual and extraordinary
general meeting of shareholders of the Company approved a new grant of 76,120 options to the then current Chief Executive Officer of the
Company, Mr. Amir Weisberg. In addition, it was approved to accelerate the vesting of 12,906 options from an outstanding grant; in both
cases the vesting of all options will occur on June 30, 2022. As a result, the Company recognized a total share-based compensation expense
in the amount of $76.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">On May 9, 2022,
the Company&#8217;s Board of Directors approved to increase the Company&#8217;s options pool by an additional one million options from 3,672,094
to 4,672,094.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">As of December 31,
2022, 700,965 of the Company&#8217;s options were available for future grants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">A summary of the
status of options to employees under the Company&#8217;s option plan as of December&#160;31, 2022, and changes during the relevant period ended
on that date is presented below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of options</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> intrinsic<br/> value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b>&#160;<b><br/> average</b>&#160;<b><br/> remaining</b>&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>contractual<br/> life (years)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,726,911</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.25</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,323</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.44</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,124,520</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,206</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Forfeited and expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(517,879</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">6.57</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Outstanding at end of year</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,303,346</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">$</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: right">5.97</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">$</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: right">115</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: right">6.14</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable options</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,016,737</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.81</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">115</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.34</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,303,346</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.97</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">115</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The weighted average
grant date fair value of options granted during the year ended December 31, 2022, was $3.46.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The Black-Scholes
assumptions used to value the employee share options at the grant dates are presented in the following table by years:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; text-indent: 0in">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0in">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70.45-92.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72.97-78.69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74.35-84.77</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0in">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.81-4.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.62-1.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.23-1.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0in">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.2-6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5-6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5-6</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">These assumptions
and estimates were determined as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1.25in">&#160;</td>
    <td style="width: 38px; text-align: justify">o</td>
    <td style="text-align: justify">Fair Value of Ordinary Shares - Prior to the IPO, the fair value was determined by the Company&#8217;s Board of Directors, with input from management and third-party valuation specialists. After the IPO, the fair value of each Ordinary share was based on the closing price of the Company&#8217;s publicly traded Ordinary shares as reported on the date of the grant.</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1.25in">&#160;</td> <td style="width: 38px; text-align: justify">o</td> <td style="text-align: justify">Dividend Yield - The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. As a result, an expected dividend yield of zero percent was used.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">o</td> <td style="text-align: justify">Expected Volatility - As the Company has a short trading history for its Ordinary shares, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#8217;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#8217;s expected term.</td></tr> </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.5in; text-align: left">e.</td><td style="text-align: justify">Share option plan: (Cont.)</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1.25in; text-align: justify">&#160;</td>
    <td style="width: 38px">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">o</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td>
    <td style="text-align: justify">Risk-Free&#160;Interest Rate - The risk-free rate for the expected term of the options is based on the Black-Scholes option pricing model on the yields of United States of America Treasury securities with maturities appropriate for the expected term of employee share option awards.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">o</td>
    <td style="text-align: justify">Expected term - The expected term represents the period that options are expected to be outstanding. For option grants that are considered to be &#8220;plain vanilla,&#8221; the Company determines the expected term using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the options.</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">The total share-based
compensation expense recognized by the Company&#8217;s departments for the three years ended December&#160;31, 2022, 2021 and 2020, was comprised
as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year Ended <br/>
</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,081</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,203</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,806</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Marketing and business development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">383</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">317</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,843</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,230</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,631</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -11.35pt; padding-left: 14.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="text-decoration:underline">Total</span> share-based compensation expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,307</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,750</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,577</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">As of December 31,
2022, there were unrecognized compensation costs of $6,379, which are expected to be recognized over a weighted average period of approximately
2.5 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">f.</td><td style="text-align: justify">Options issued to non-employees (including directors and consultants):</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">Outstanding options
granted to non-employees as of December&#160;31, 2022, were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Grant date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Options<br/> outstanding </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,<br/> 2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Average<br/> Exercise </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>per share ($)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercisable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,<br/> 2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable through</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: center; text-indent: -12pt; padding-left: 12pt">October 2013</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">5,719</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5.06</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">5,719</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 30%; text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">October 2023</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">September 2014</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,719</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.06</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,719</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">September 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">April 2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">April 2026</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">December 2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,170</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,170</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">December 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">June 2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197,722</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197,722</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">June 2027</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">November 2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,925</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,925</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">November 2027</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">August 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">August 2029</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">June 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">June 2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">April 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">April 2031</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">August 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,206</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">August 2031</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">December 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">December 2031</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">May 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,625</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">May 2032</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt">November 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">1.05</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; text-indent: -5.6pt; padding-left: 5.6pt">November 2032</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -12pt; padding-left: 12pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-indent: -5.6pt; padding-left: 5.6pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">534,826</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">470,710</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-indent: -5.6pt; padding-left: 5.6pt">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">No options were exercised by non-employees
during the year ended December&#160;31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">g.</td><td style="text-align: justify">Warrants:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">During
the year ended December 31, 2020, 2,106,879 D-2 warrants were exercised into 885,377 Ordinary shares on a cashless basis. As of December
31, 2020, 648,519 D-2 warrants were outstanding. In addition, 53,775 A warrants were exercised into 53,775 Ordinary shares for a total
consideration of $13. As of December 31, 2022, <span style="-sec-ix-hidden: hidden-fact-127">no</span> A warrants were outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">Further
to the discussion in Note 7, as of April 26, 2022 and July 19, 2022, the Company measured the fair value of the warrants to purchase Ordinary
shares (a Level 3 valuation) using the Black-Scholes option pricing model. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">g.</td><td style="text-align: justify">Warrants: (Cont.)</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">As of April 26, 2022 and July 19,
2022, the relative fair value of the warrants to purchase Ordinary shares issued to Kreos was $468 and $120, respectively, which was calculated
using the following assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">July 19,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">April 26,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Share price ($)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.96</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.14</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60.81</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Adjustment to risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.84</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.88</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.94</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.6pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">During
the year ended December 31, 2021, 580,028 D-2 warrants were exercised into 115,982 Ordinary shares on a cashless basis. In addition, 68,491
D-2 warrants were exercised into 68,491 Ordinary shares for a total consideration of $632. As of December 31, 2022, no D-2 warrants are
outstanding. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><span style="font-weight: normal">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"><span style="font-weight: normal">Since
the IPO and as of December 31, 2022, all warrants are exercisable into Ordinary shares, in which the outstanding issued warrants to purchase
Ordinary shares as of December&#160;31, 2022, were as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -56.7pt"><span style="font-weight: normal">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Grant date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrants<br/>
 outstanding </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31, <br/>
2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Average<br/>
 Exercise </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>per share ($)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrants<br/>
 exercisable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,<br/>
 2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable through</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: center">August 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">200,596</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">15.95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">200,596</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 30%; text-align: center">August 2023</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">September 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,925</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,925</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">September 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">April 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,794</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,794</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">April 2029</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt">July 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,948</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">5.14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,948</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; text-indent: -5.6pt; padding-left: 5.6pt">April 2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">413,263</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">413,263</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 4pt">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127130870288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial (Income) Expenses, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_FinancialIncomeExpensesNetLineItems', window );"><strong>Financial (Income) Expenses, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL (INCOME) EXPENSES, NET</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 11:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> FINANCIAL (INCOME) EXPENSES, NET</td></tr>
</table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year Ended<br/>
</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; font-style: italic; text-align: justify">Financial expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; width: 64%; text-align: justify">Financial expenses from loan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,023</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify">Other financial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">316</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify">Remeasurement of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,373</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="text-decoration:underline">Total</span> financial expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,339</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,390</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; font-style: italic; text-align: justify">Financial income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify">Foreign currency transaction gains, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(532</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(243</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify">Interest from bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(267</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(468</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(474</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify">Other financial income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(58</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(76</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="text-decoration:underline">Total</span> financial income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(799</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(570</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(793</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-align: justify"><span style="text-decoration:underline">Total</span> financial (income) expense, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">540</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(544</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,597</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_FinancialIncomeExpensesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_FinancialIncomeExpensesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127134270864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">BASIC AND DILUTED NET LOSS PER SHARE</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 12:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> BASIC AND DILUTED NET LOSS PER SHARE</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in">The following table
sets forth the computation of the Company&#8217;s basic and diluted loss per Ordinary share:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year Ended <br/>
</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; font-style: italic; text-align: left; text-indent: 0pt">Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; width: 64%; text-align: left; text-indent: 0pt">Allocation of net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">39,557</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">42,601</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,869</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt">Preferred share preference</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,933</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt">Deemed dividend</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,114</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">Allocation of net loss attributable to Ordinary shareholders</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">39,557</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">42,601</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">42,916</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; font-style: italic; text-align: left; text-indent: 0pt">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt">Weighted average Ordinary shares outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,426,692</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,721,528</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,582,405</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-139; -sec-ix-hidden: hidden-fact-138; -sec-ix-hidden: hidden-fact-137">Basic and diluted net loss per share</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.04</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.28</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4.48</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in">The potential ordinary
shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented
because including them would have been anti-dilutive are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Ordinary shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Ordinary share options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,487,447</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,995,749</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,583,210</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">413,263</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">218,521</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">867,040</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,900,710</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,214,270</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,450,250</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127140557072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in">NOTE 13:-</td>
  <td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"> RELATED PARTIES</td></tr>
</table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">a.</td><td style="text-align: justify">Through February 2016, several management members also provided services to the Company as service providers.
As of December 31, 2022 and 2021, the Company has recorded a provision for severance pay liability for such service providers in the amounts
of $174 and $199, respectively. These amounts are included in &#8220;Other liabilities&#8221;.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">b.</td><td style="text-align: justify">In July 2019, the Company entered into a master service agreement with a third-party provider (the &#8220;Provider&#8221;)
to conduct a portion of a phase 3 clinical trial in Eastern Europe. One of the Company&#8217;s directors serves as a director and shareholder
in the Provider.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0in">During the
years ended December 31, 2022 and 2021, and following the agreement with the Provider, the Company recognized research and development
expenses in the total amount of $1,422 and $3,748, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0in">In May 2022,
the Provider was acquired by a non-related third party. As a result, the Provider no longer exists<span style="font-family: Times New Roman, Times, Serif">.</span>
Accordingly, the director is no longer an officer nor a shareholder of the third party or has any other connection to the third party.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><i>&#160;</i></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">c.</td><td style="text-align: justify">On December 30, 2021, the Company&#8217;s Board of Directors appointed Dikla Czaczkes Akselbrad, the then
current Company&#8217;s Executive Vice President and Chief Financial Officer, as the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;),
effective July 1, 2022, replacing Amir Weisberg after 11 years.</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127137913776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
  <td style="text-align: left; padding-left: 0pt; text-indent: 0pt; width: 0.75in"><b>NOTE</b> 14:- </td>
  <td style="text-align: left; padding-left: 0pt; text-indent: 0pt">SUBSEQUENT EVENTS</td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">a.</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Further to the disclosed in Note 10c, During January 2023, the Company
sold 1,949,029 Ordinary shares under the ATM for a total amount of $2,190, net of issuance costs in the amount of $90. </span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">b.</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During the first quarter of 2023, the Company
decreased the exercise price of 2,021,599 options granted to all employees and a consultant under the 2012 Share Option Plan. As of the
modification date, the options can be exercised for $0.77. </span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt 1in; text-align: justify">The Company's Board of Directors also approved
a similar exercise price decrease of 522,507 options previously granted to the Company's CEO and Board members, subject to shareholders
approval<b>.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">c.</span></td> <td> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further to the disclosed in Note 7, on March 29, 2023, the Company
entered into an amendment to the Credit Line (the "Amendment"). Pursuant to this Amendment, 70% of the remaining principal and
interest repayments will be delayed and repaid on a monthly equal basis from August 2024 to May 2026. The amended secured credit line
now bears an interest at the rate of 10%. In addition, the Company will pay to Kreos a restructuring fee consisting of 1% on the closing
date of the Amendment and an incremental 3% at the maturity of the Amendment. In return for this additional deferral of repayment, Kreos
has the right to receive a potential Claw-Back payment on account of the then outstanding principal amount (the "Claw-Back").
This Claw-Back mechanism will be triggered by additional incoming funds from future collaboration and partnership agreements or additional
funding. If triggered, the minimum Claw-Back to be paid will be $1,500, but will not exceed $3,000.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Further to the above and to Note 10g, the outstanding warrants issued to Kreos were repriced and as a result bear an exercise price of $0.42 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">d.</td><td style="text-align: justify">On March 29, 2023, the Company entered into a concurrent private placement of unregistered pre-funded
warrants to purchase up to 10,357,139 Ordinary shares, (the &#8220;Private Warrants&#8221;), at a price of $0.4199 per Private Warrant
with certain of the Company&#8217;s existing shareholders. The Private Warrants have an exercise price of $0.0001 per Ordinary share.
The gross proceeds from the concurrent private placement, before deducting private placement fees and other estimated offering expenses
payable by the Company, are approximately $4,350.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">e.</td><td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On March 31, 2023, the Company closed a public offering which was comprised
of 16,859,000 Ordinary shares, with no par value (inclusive of 2,199,000 Ordinary shares pursuant to the full exercise of an overallotment
option granted to the underwriters), at a public offering price of $0.42 per share (the &#8220;Public Offering&#8221;). The gross proceeds
to the Company from the Public Offering, before deducting underwriting commissions and other estimated offering expenses payable by the
Company, are approximately $7,081.</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127135042112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">a.</td><td style="text-align: justify">Use of estimates:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company&#8217;s management
believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made.
These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting
periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ConsolidatedFinancialStatementsPolicyTextBlock', window );">Consolidated financial statements in U.S. dollars</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">b.</td><td style="text-align: justify">Consolidated financial statements in U.S.&#160;dollars:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accompanying consolidated financial
statements have been prepared in United States of America dollars (&#8220;USD&#8221;, &#8220;$&#8221; or &#8220;U.S. dollars&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A substantial portion of the Company&#8217;s
expenses are incurred in New Israeli Shekels (&#8220;NIS&#8221;). However, the Company finances its operations mainly in U.S. dollars,
a substantial portion of its expenses are incurred in U.S. dollars and potential revenues from its primary markets are anticipated to
be generated in U.S. dollars. As such, the Company&#8217;s management believes that the U.S. dollar is the currency of the primary economic
environment in which the Company and its subsidiaries operate. Thus, the functional and reporting currency of the Company is the U.S.
dollar.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the dollar are re-measured
into U.S. dollars in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) No. 830, &#8220;<i>Foreign Currency Matters</i>&#8221;.
All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the statements of operations as
financial income or expenses, as appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">c.</td><td style="text-align: justify">Principles of consolidation:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The consolidated
financial statements include the accounts of the Company and its subsidiaries. Intercompany balances have been eliminated upon consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">d.</td><td style="text-align: justify">Cash equivalents:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Cash equivalents
are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or less, at
the date acquired.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_RestrictedCashPolicyTextBlock', window );">Restricted cash</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">e.</td><td style="text-align: justify">Restricted cash:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Restricted cash
is primarily invested in a bank deposit and is used as security for the Company&#8217;s lease commitments and for its forward and options transactions
activities (see Note 2q).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment reporting</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">f.</td><td style="text-align: justify">Segment reporting:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company
identifies operating segments in accordance with ASC No. 280, &#8220;<i>Segment Reporting</i>&#8221;, as components of an entity for which
discrete financial information is available and is regularly reviewed by the chief operating decision maker, or decision-making group,
in making decisions regarding resource allocation and evaluating financial performance. The Company&#8217;s chief operating decision maker is
its chief executive officer. The Company determined it operates in one operating segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShorttermDepositsPolicyTextBlock', window );">Short-term deposits</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">g.</td><td style="text-align: justify">Short-term deposits:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">A short-term bank deposit is a deposit
with a maturity of more than three months, but less than one year. Deposits in U.S. dollars bear interest at rates ranging from 4.55%-5.90%,
per annum, as of December 31, 2022. Short-term deposits are presented at cost, which approximates market value due to their short maturities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.75pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">h.</td><td style="text-align: justify">Property and equipment, net:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Property and equipment
are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful
lives of the assets at the following rates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 77%; text-align: justify">Computers and software</td><td style="width: 1%">&#160;</td>
    <td style="width: 22%; text-align: center; padding-left: 0.05in">33</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0.05in">10&#160;-&#160;15</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0.05in">15</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in">Leasehold improvements</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: center; padding-left: 0.05in">Over the shorter of the term of the lease or its useful life</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">i.</td><td style="text-align: justify">Leases:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">On January 1, 2022,
the Company adopted ASC No. 842, &#8220;<i>Leases</i>&#8221; (&#8220;ASC 842&#8221;), using the modified retrospective method&#160;by applying
the new standard to all leases existing at the date of initial application. Results and disclosure requirements for reporting periods
beginning after January 1, 2022, are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported
in accordance with the Company&#8217;s historical accounting under ASC No. 840, &#8220;<i>Leases</i>&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company has
elected the package of practical expedients permitted under the transition guidance, which allows the Company not to reassess: (1) whether
any existing contracts as of the adoption date are or contain a lease under ASC 842, (2) lease classification for any existing leases
as of the adoption date, and (3) initial direct costs for any existing leases as of the adoption date. Lastly, the Company also elected
the practical expedient to not separate lease and non-lease components for its leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As a result of the
adoption of ASC 842 on January 1, 2022, the Company recorded both operating leases right-of-use (&#8220;ROU&#8221;) assets and operating
lease liabilities of $3,388.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The ROU assets include
adjustments for lease prepayments in the amount of $36. The adoption did not impact the Company&#8217;s beginning accumulated deficit,
or its prior year consolidated statements of operations and statements of cash flows. The adoption did not have a material impact on the
Company&#8217;s current year consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Leases are classified
as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the
lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably
certain to be exercised, the lease term is for a major part of the remaining useful life of the asset, the present value of the lease
payments equals or exceeds substantially all of the fair value of the asset, or the underlying asset is of such a specialized nature that
it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does
not meet any one of these criteria. Since all of the Company&#8217;s lease contracts do not meet any of the criteria above, the Company
concluded that all of its lease contracts should be classified as operating leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">ROU assets
and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For
this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company&#8217;s
leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available on the commencement
date in determining the present value of lease payments. All ROU assets are reviewed for impairment. The lease terms may include options
to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">j.</td><td style="text-align: justify">Impairment of long-lived assets:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company&#8217;s long-lived
assets are reviewed for impairment in accordance with ASC No. 360, &#8220;<i>Property, Plant and Equipment</i>&#8221;, whenever events or
changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held
and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated
by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying
amount of the asset exceeds its fair value. As of December 31, 2022 and 2021, no impairment losses have been identified.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development, net expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">k.</td><td style="text-align: justify">Research and development, net expenses:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Research and development
expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments
to subcontractors, chemical, manufacturing and control activities, costs associated with obtaining regulatory approvals, executing pre-clinical
and clinical studies and maintenance and prosecution of the Company&#8217;s intellectual property rights. In addition, research and development
expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research
and development expenses as expenses when incurred and are presented net of government grants (see Note 2.l).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Grants and participations</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">l.</td><td style="text-align: justify">Grants and participations:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Royalty-bearing grants from the Israeli
Innovation Authority (&#8220;IIA&#8221;) of the Ministry of Economy and Industry in Israel for funding of approved research and development
projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a
deduction from research and development expenses. Non-royalty-bearing grants from the IIA MAGNET program and from European Commission&#8217;s
Seventh Framework Programme for Research (&#8220;FP7&#8221;) for funding approved research and development projects are recognized at
the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and
development expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Since the payment
of royalties is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until
the related revenues are recognized.&#160;In the event of failure of a project that was partly financed by IIA, the Company will not be
obligated to pay any royalties or repay the amounts received.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company recognizes
participations in research and development, as a reduction from research and development expenses in the amount of $738 and $542 for the
years ended December 31, 2022, and 2021, respectively (no grants were received for the year ended December 31, 2020).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">From inception up
until December 31, 2022, the Company received a total of $7,193 in grants, out of which royalty-bearing grants in the amount of $4,888
from the IIA, non-royalty bearing grants in the amount of $1,578 from the IIA (out of which $521 were received during the year ended December
31, 2022) and non-royalty bearing grants in the amount of $727 from the FP7.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Accounting for share-based compensation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">m.</td><td style="text-align: justify">Accounting for share-based compensation:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Share-based compensation
expense related to share-based awards is recognized based on the fair value of the awards granted and recognized as an expense on a straight-line
basis over the requisite service period for share options. The fair value of each option award is estimated on the grant date using the
Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including
the expected term of the award, the expected volatility of the price of the Company&#8217;s Ordinary shares, risk-free interest rates,
and the expected dividend yield of Ordinary shares. The assumptions used to determine the fair value of the share awards represent management&#8217;s
best estimates. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. Forfeitures are accounted
for as they occur instead of estimating the number of awards expected to be forfeited.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_BasicAndDilutedLossPerSharePolicyTextBlock', window );">Basic and diluted net loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">n.</td><td style="text-align: justify">Basic and diluted net loss per share:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Prior to the Company&#8217;s
IPO, the Company computed its net loss per share using the two-class method required for participating securities. The two-class method
requires income available to Ordinary shareholders for the period to be allocated between Ordinary shares and participating securities
based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considered its
convertible preferred shares to be participating securities as the holders of the convertible preferred shares would be entitled to dividends
that would be distributed to the holders of Ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities
did not contractually require the holders of such shares to participate in the Company&#8217;s losses.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As such,&#160;during
the periods when the Company is in a loss position, the loss attributable to Ordinary shareholders was not allocated to the convertible
preferred shares under the two-class method as these securities did not have a contractual obligation to share in the Company&#8217;s
losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Following the Company&#8217;s
IPO, the Company&#8217;s basic net loss per share is calculated by dividing the net loss attributable to Ordinary shareholders by the
weighted-average number of shares of Ordinary shares outstanding for the period, without consideration of potentially dilutive securities.
The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using
the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as
basic net loss per share in periods when the effects of potentially dilutive shares of Ordinary shares are anti-dilutive.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock', window );">Convertible preferred shares and convertible preferred shares warrant liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">o.</td><td style="text-align: justify">Convertible preferred shares and convertible preferred shares warrant liability:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The terms of the
convertible preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1&#160;shares allowed the holders to redeem shares, under certain circumstances,
outside of the Company&#8217;s control. Therefore, these shares were classified as mezzanine equity on the balance sheet and not included as
a component of shareholders&#8217; deficit before the IPO. The Company did not adjust the preferred shares&#8217; carrying value to the redemption
value since redemption was not probable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Following the Company&#8217;s
IPO, the convertible preferred shares were converted into Ordinary shares and were reclassified into permanent equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Warrants to purchase the Company&#8217;s
convertible preferred shares were classified as a liability on the balance sheet, and measured at fair value, as the underlying shares
are contingently redeemable (upon a deemed liquidation event) and, therefore, may obligate the Company to transfer assets at some point
in the future. The warrants were subject to re-measurement to fair value at each balance sheet date and any change in fair value was recognized
as a component of financial expenses, net, in the statements of operation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Following the Company&#8217;s IPO,
the warrants can only be exercised into the Company&#8217;s ordinary equity shares. Consequently, as of the IPO date, the Company reclassified
the warrants as equity since the warrants are not an ASC No. 480, &#8220;<i>Distinguishing Liabilities from Equity</i>&#8221; (&#8220;ASC
480&#8221;), liability, are indexed to the Company&#8217;s own stock and can be classified as equity pursuant to ASC No. 815-40, &#8220;<i>Derivatives
and Hedging</i>&#8221; (&#8220;ASC 815&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value of financial instruments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">p.</td><td style="text-align: justify">Fair value of financial instruments:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company applies
ASC No. 820, &#8220;<i>Fair Value Measurements and Disclosures</i>&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined
as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly
transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches.
ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the
use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market
participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Unobservable inputs
are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability
developed based on the best information available in the circumstances.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Fair value is an
exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction
between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market
participants would use in pricing an asset or a liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">A three-tier fair
value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring
fair value:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 1.25in">&#160;</td>
    <td style="width: 0.6in; text-align: justify; text-indent: 0in;">Level 1 -</td>
    <td style="padding-left: 0in; text-align: justify; text-indent: 0in;">Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; text-indent: 0in;">Level 2 -</td>
    <td style="text-align: justify; text-indent: 0in;">Include other inputs that are directly or indirectly observable in the marketplace.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify; text-indent: 0in;">Level 3 -</td>
    <td style="text-align: justify; text-indent: 0in;">Unobservable inputs which are supported by little or no market activity</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The fair value hierarchy also requires
an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value<span style="font-size: 10pt">.</span></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The carrying amounts of cash and cash
equivalents, restricted cash, short-term deposits, long-term deposits, prepaid expenses and other current assets, trade payables, accrued
expenses and other current and non-current liabilities approximate their fair value due to the short-term maturity of such instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>The
fair value measurement of the FCA (as defined in Note 7) is measured using unobservable inputs that require a high level of judgment to
determine fair value, and thus is classified as a Level&#160;3 financial instrument. The Company estimates the fair value of the abovementioned
instrument using the Monte-Carlo simulation and the Black-Scholes option pricing model.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span>Fair
value estimates are made at a specific point in time, based on relevant market information and information about the financial instruments.
These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined
with precision. Changes in assumptions could significantly affect these estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative financial instruments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">q.</td><td style="text-align: justify">Derivative financial instruments:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company accounts
for derivatives based on ASC 815. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The Company
enters into option and forward contracts in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred
in NIS. Since the derivative instruments that the Company holds were not designated as hedging instruments under ASC 815, any gain or
loss derived from such instruments is recognized immediately as &#8220;financial (income) expense, net&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.6pt; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company measured the fair value
of the contracts in accordance with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs
are based on quoted prices and market observable data of similar instruments. As of December 31, 2022 and 2021, the fair value of the
options and forward contracts was ($12) and $28, respectively, which were
presented as Accrued expenses and other current liabilities and Prepaid expenses and other current assets, respectively. Financial expense
(income) for the years ended December 31, 2022, 2021 and 2020, amounted to $273, ($58) and&#160;($81), respectively.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">r.</td><td style="text-align: justify">Income taxes:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company accounts
for income taxes in accordance with ASC No. 740, &#8220;<i>Income Taxes</i>&#8221; (&#8220;ASC 740&#8221;). ASC 740 prescribes the use of
the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial
reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the
differences are expected to reverse. The Company provides a valuation allowance to reduce deferred tax assets to their estimated realizable
value, if needed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">ASC 740 contains
a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position
taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than
not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals
or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized
upon ultimate settlement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As of December&#160;31,
2022 and 2021, the Company&#8217;s uncertain tax position liability was immaterial.	The Company&#8217;s policy is to accrue interest and penalties
related to unrecognized tax benefits in its taxes on income.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAllowances', window );">Revenue recognition</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">s.</td><td style="text-align: justify">Revenue recognition:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company recognizes
revenue from contracts with customers under ASC No. 606, &#8220;<i>Revenue from Contracts with Customers</i>&#8221;. Accordingly, the Company
recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it
expects to be entitled in exchange for those goods or services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">To determine revenue
recognition for contracts with customers, the Company performs the following five steps:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(i) identify the
contract(s) with a customer;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(ii) identify the
performance obligations in the contract;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(iii) determine
the transaction price;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(iv) allocate the
transaction price to the performance obligations in the contract; and</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(v) recognize revenue
when (or as) the Company satisfies its performance obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">At contract inception,
the Company assesses the goods or services agreed upon within each contract and assesses whether each good or service is distinct to determine
the performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">On August 2, 2022,
the Company entered into a license, distribution and supply agreement (the &#8220;Agreement&#8221;) with Mercury Pharma Group Limited, under
the trade name Advanz Pharma Holdings
(the &#8220;Customer&#8221;), with respect to the Company&#8217;s product, the D-PLEX<sub>100</sub> (the &#8220;Product&#8221;), for the prevention
of (i) post abdominal surgery incisional infection; and/or (ii) post cardiac surgery sternal infection.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The term of the
Agreement is until the later of December 31, 2035, or 10 years after the first commercial sale of the Product. The Agreement can also
be terminated by either party under certain limited circumstances. Pursuant to the Agreement, the Customer was granted an exclusive license
to market, commercialize, and distribute the Product in the European Economic Area and in the United Kingdom. Under the Agreement, the
Company will carry out all activities required to obtain marketing authorization in each territory, approving the commercial sale of the
Product in that territory. Once marketing authorization will be granted in a territory, the Customer will be required to achieve minimum
sales requirements for that territory.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Under the terms
of the Agreement, the Company received a non-refundable, one-time payment of &#8364;2.5 million (approximately $2,548). The Company is
also entitled to receive additional development-related milestones payments for a total of up to &#8364;23 million.
In addition, the Company will be entitled to receive up to additional &#8364;87 million upon achievement of certain
commercial sale milestones.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company has
concluded that the Agreement includes a single performance obligation. The Company has concluded that the license and development are
not distinct from the manufacturing since the Customer could not use, consume, or sell the license and development services on their own
or with resources readily available to the Customer because of the Company&#8217;s specialized knowledge and the associated manufacturing know-how
and because currently, and in the foreseeable future, there are no other parties that could manufacture the Product. As such, the transaction
price was fully allocated to the single performance obligation. Since it is not probable that a significant reversal in the amount of
cumulative revenue recognized will not occur when the uncertainty associated with the milestone payments is resolved, the Company estimated
the transaction price at &#8364;2.5 million (approximately $2,548).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As of December 31,
2022, the Company has yet to satisfy its performance obligation under the Agreement and, therefore, no revenues were recognized. Accordingly,
the upfront payment amount was classified as a long-term deferred revenue in the Company&#8217;s consolidated balance sheet as of December 31,
2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.5in; text-align: left">t.</td><td style="text-align: justify">Concentration of credit risks:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Financial instruments
that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and short-term deposits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Cash, cash equivalents,
restricted cash and short-term deposits are deposited in major banks in Israel and in the United States of America. Such investments may
be in excess of insured limits or not insured. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal
risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company utilizes
option and forward contracts to protect against the risk of overall changes in exchange rates. The derivative instruments hedge a portion
of the Company&#8217;s non-dollar currency exposure. Counterparties to the Company&#8217;s derivative instruments are all major financial institutions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84pt; text-align: justify; text-indent: 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_SeverancePayPolicyTextBlock', window );">Severance pay</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">u.</td><td style="text-align: justify">Severance pay:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">All the Company&#8217;s
employees who are Israeli citizens have subscribed to Section&#160;14 of Israel&#8217;s Severance Pay Law, 5723-1963 (&#8220;Section&#160;14&#8221;).
Pursuant to Section&#160;14, employees covered by this section are entitled to monthly deposits at a rate of 8.33% of their monthly salary,
made on their behalf by the Company. Payments in accordance with Section&#160;14 release the Company from any future severance liabilities
in respect of those employees. Neither severance pay liability nor severance pay fund under Section&#160;14 for such employees is recorded
on the Company&#8217;s consolidated balance sheets. Severance pay expense for the years ended December 31, 2022, 2021 and 2020, amounted to
$537, $547 and $394, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The US Subsidiary
has a Safe Harbor 401(k) plan covering all the US Subsidiary employees. All eligible employees may elect to contribute up to 100% of their
payroll compensation (minus mandatory payroll deductions) to the plan, for 2022, up to a maximum of $20,500 per year (for employees over
50 years of age the maximum contribution was $28,000 per year), as determined by the U.S. Internal Revenue Service (&#8220;IRS&#8221;).
The US Subsidiary matches at 100%, on each payroll, up to 5% of the employee compensation to the plan within the IRS limits (which was
set at $300 in 2022 for purposes of the plan). During the year ended December 31, 2022, the Company recorded expenses for matching contributions
in the amount of $30, as compared to $28 in 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentLiabilityReserveEstimatePolicy', window );">Contingent liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">v.</td><td style="text-align: justify">Contingent liabilities:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company accounts
for its contingent liabilities in accordance with ASC No. 450, &#8220;<i>Contingencies</i>&#8221;. A provision is recorded when it is both
probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">With respect to
legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice
of legal counsel and other information and events pertaining to a particular matter. The Company is occasionally a party to routine claims
or litigation incidental to its business. The Company does not believe that it is a party to any pending legal proceeding that is likely
to have a material adverse effect on its business, financial condition or results of operations. The Company recorded an accrual in the
consolidated statement of operations, which it deems appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As of December 31,
2022 and 2021, no liability due to legal matters has been accrued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">w.</td><td style="text-align: justify">Recently adopted accounting pronouncements:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As an &#8220;Emerging
Growth Company&#8221;, the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;) allows the Company to delay adoption of new or
revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The
Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election<span style="font-family: Times New Roman, Times, Serif">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">On January 1, 2022,
the Company adopted ASC 842. Upon adoption, we recognized total ROU assets and corresponding liabilities of $3,388&#160;on our consolidated
balance sheets. The ROU assets include adjustments for prepayments and accrued lease payments. The adoption did not impact the beginning
balance of retained earnings, or prior year consolidated statements of operations and statements of cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">For information
regarding the impact of ASC 842 adoption, see Note 2.i and Note 5 - Leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.3pt">In December 2019,
the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, &#8220;<i>Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>&#8221; (ASU 2019-12), which simplifies the accounting for income taxes.
The guidance is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted. The Company
has adopted ASU 2019-12 as of January 1, 2022. The impact of adoption of this standard on the Company&#8217;s consolidated financial statements
was immaterial.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.3pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In August 2020, the FASB issued ASU
No. 2020-06, &#8220;<i>Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s
Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>&#8221; (&#8220;ASU
2020-06&#8221;), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP.
The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception,
and it simplifies the diluted earnings per share calculation in certain areas. The Company adopted ASU 2020-06 on January 1, 2022. The
adoption of the standard did not result in a material impact to the Company&#8217;s consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted', window );">Recently issued accounting pronouncements, not yet adopted</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">x.</td><td style="text-align: justify">Recently issued accounting pronouncements, not yet adopted:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In June 2016, the FASB issued ASU No.
2016-13, &#8220;<i>Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>,&#8221;
which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured
at amortized cost to be presented at the net amount expected to be collected. The guidance will be effective for the Company beginning
January 1, 2023, and interim periods thereafter. The Company adopted ASU 2016-13 on January 1, 2023. The adoption of the standard did
not result in a material impact to the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_BasicAndDilutedLossPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_BasicAndDilutedLossPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ConsolidatedFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated financial statements in U.S. dollars policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ConsolidatedFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred shares and convertible preferred shares warrant liability policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently Issued Accounting Pronouncements and not yet adopted policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_RestrictedCashPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted cash policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_RestrictedCashPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_SeverancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance pay policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_SeverancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShorttermDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term deposits policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShorttermDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentLiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentLiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition for sales allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127140472672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment useful life</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 77%; text-align: justify">Computers and software</td><td style="width: 1%">&#160;</td>
    <td style="width: 22%; text-align: center; padding-left: 0.05in">33</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0.05in">10&#160;-&#160;15</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0.05in">15</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in">Leasehold improvements</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: center; padding-left: 0.05in">Over the shorter of the term of the lease or its useful life</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 980<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84167750&amp;loc=d3e42232-110370<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127136627472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_PrepaidExpensesAndOtherReceivablesAbstract', window );"><strong>Prepaid Expenses And Other Receivables Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">552</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,453</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Government authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">596</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Lease deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">298</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 2.85pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 2.85pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,089</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,211</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PrepaidExpensesAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PrepaidExpensesAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127137369216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Computers and software</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">613</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">577</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,933</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,247</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">173</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">167</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,503</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,024</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,015</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,975</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,254</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Depreciated cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,247</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,761</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127140553744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock', window );">Schedule of lease-related assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Classification</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 67%; font-style: italic; text-align: left">Lease assets:</td><td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: left; padding-left: 5.4pt">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Operating lease assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt; padding-left: 5.4pt">Operating lease ROU assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,431</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Lease liabilities:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; width: 67%; text-align: left">Current lease liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: center; padding-left: 5.4pt">Short-term operating lease liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">959</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Long-term lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt">Long-term lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,173</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,132</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted Average Remaining lease term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.37 years</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Weighted Average Discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.95</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ScheduleOfLeaseLiabilityTableTextBlock', window );">Schedule of lease liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,047</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">439</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">385</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">367</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">186</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,424</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less - imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(292</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,132</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of supplemental cash flow information related to the lease costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left">Cash paid for amounts included in measurement of lease liability:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 4pt">Operating cash flows for operating leases</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">1,259</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Right-of-use asset recognized with corresponding lease liability:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Operating leases</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,528</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfLeaseLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfLeaseLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of lease related assets and liabilities table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127136640032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems', window );"><strong>Schedule of Accrued Expenses And Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,246</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,787</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Employees and payroll accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,879</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">IIA deferred grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">269</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 2.85pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt; padding-left: 2.85pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,429</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,940</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127140520512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred income taxes reflect the net tax effects</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year
Ended <br/>
December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Domestic (Israel)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">38,403</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">41,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">35,983</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,154</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,404</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">886</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">39,557</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">42,601</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">36,869</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of deferred income taxes reflect the net tax effects</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Carryforward losses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">34,984</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">31,289</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,376</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,203</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">490</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Reserves and allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">157</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">479</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,210</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(40,448</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37,210</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">559</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease ROU assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(559</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(559</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of income taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year
Ended <br/>
December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Current</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">129</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 2.85pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">129</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended <br/>
December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Domestic (Israel)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Foreign</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">129</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 2.85pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">129</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127131822048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock', window );">Schedule of ordinary share capital</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/>
 outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/>
 outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 52%; text-align: left; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">&#160;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">&#160;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">&#160;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">&#160;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt">Ordinary shares with no par value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">47,800,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">19,851,833</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">47,800,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,756,570</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify; text-indent: 56.7pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of status of options to employees</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of options</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> intrinsic<br/> value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b>&#160;<b><br/> average</b>&#160;<b><br/> remaining</b>&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>contractual<br/> life (years)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,726,911</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.25</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,323</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.44</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,124,520</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,206</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Forfeited and expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(517,879</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">6.57</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Outstanding at end of year</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,303,346</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">$</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: right">5.97</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">$</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: right">115</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: right">6.14</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable options</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,016,737</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.81</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">115</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.34</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,303,346</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.97</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">115</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6.14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of relative fair value of the warrants to purchase Ordinary shares issued</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; text-indent: 0in">Dividend yield (%)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0in">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70.45-92.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72.97-78.69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74.35-84.77</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: 0in">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.81-4.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.62-1.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.23-1.38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 0in">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.2-6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5-6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5-6</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of share-based compensation expense recognized</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year Ended <br/>
</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,081</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,203</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,806</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Marketing and business development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">383</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">317</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,843</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,230</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,631</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: -11.35pt; padding-left: 14.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="text-decoration:underline">Total</span> share-based compensation expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,307</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,750</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,577</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock', window );">Schedule of outstanding options granted</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Grant date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Options<br/> outstanding </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,<br/> 2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Average<br/> Exercise </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>per share ($)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercisable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,<br/> 2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable through</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: center; text-indent: -12pt; padding-left: 12pt">October 2013</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">5,719</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5.06</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">5,719</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 30%; text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">October 2023</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">September 2014</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,719</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.06</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,719</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">September 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">April 2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">April 2026</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">December 2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,170</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,170</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">December 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">June 2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197,722</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197,722</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">June 2027</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">November 2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,925</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,925</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">November 2027</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">August 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">August 2029</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">June 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">June 2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">April 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">April 2031</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">August 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,206</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">August 2031</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">December 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">December 2031</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">May 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,625</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">May 2032</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt">November 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">1.05</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; text-indent: -5.6pt; padding-left: 5.6pt">November 2032</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -12pt; padding-left: 12pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-indent: -5.6pt; padding-left: 5.6pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">534,826</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">470,710</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-indent: -5.6pt; padding-left: 5.6pt">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Grant date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrants<br/>
 outstanding </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31, <br/>
2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Average<br/>
 Exercise </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>per share ($)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrants<br/>
 exercisable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,<br/>
 2022</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable through</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: center">August 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">200,596</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">15.95</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">200,596</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 30%; text-align: center">August 2023</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">September 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,925</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,925</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">September 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">April 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,794</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,794</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">April 2029</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt">July 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,948</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">5.14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,948</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; text-indent: -5.6pt; padding-left: 5.6pt">April 2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: -12pt; padding-left: 12pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">413,263</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">413,263</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 4pt">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of relative fair value of the warrants to purchase Ordinary shares issued</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">July 19,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">April 26,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Share price ($)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.96</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Exercise price ($)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.14</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60.81</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Adjustment to risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.07</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.84</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.88</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.94</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.6pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived, depreciable assets that are subject to a lease meeting the criteria for capitalization and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127137362544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial (Income) Expenses, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_FinancialIncomeExpensesNetTablesLineItems', window );"><strong>Financial (Income) Expenses, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of financial (income) expenses, net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year Ended<br/>
</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; font-style: italic; text-align: justify">Financial expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; width: 64%; text-align: justify">Financial expenses from loan</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,023</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify">Other financial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">316</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify">Remeasurement of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,373</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="text-decoration:underline">Total</span> financial expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,339</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,390</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; font-style: italic; text-align: justify">Financial income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify">Foreign currency transaction gains, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(532</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(243</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify">Interest from bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(267</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(468</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(474</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify">Other financial income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(58</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(76</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="text-decoration:underline">Total</span> financial income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(799</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(570</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(793</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-align: justify"><span style="text-decoration:underline">Total</span> financial (income) expense, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">540</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(544</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,597</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_FinancialIncomeExpensesNetTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_FinancialIncomeExpensesNetTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127137487360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted loss per ordinary share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year Ended <br/>
</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; font-style: italic; text-align: left; text-indent: 0pt">Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; width: 64%; text-align: left; text-indent: 0pt">Allocation of net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">39,557</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">42,601</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,869</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt">Preferred share preference</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,933</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt">Deemed dividend</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,114</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">Allocation of net loss attributable to Ordinary shareholders</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">39,557</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">42,601</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">42,916</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; font-style: italic; text-align: left; text-indent: 0pt">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt">Weighted average Ordinary shares outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,426,692</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,721,528</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,582,405</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-139; -sec-ix-hidden: hidden-fact-138; -sec-ix-hidden: hidden-fact-137">Basic and diluted net loss per share</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.04</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.28</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4.48</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Schedule of diluted loss per share attributable to ordinary shareholders</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Ordinary shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Ordinary share options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,487,447</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,995,749</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,583,210</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">413,263</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">218,521</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">867,040</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,900,710</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,214,270</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,450,250</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127134135392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 21, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_GeneralDetailsLineItems', window );"><strong>General (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_DescriptionOfReverseShareSplit', window );">Description of reverse share split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company&#8217;s Board of Directors resolved to consolidate the Company&#8217;s share
capital by applying a reverse share split at a ratio of 1.046:1 (the &#8220;Reverse Split Ratio&#8221;) and to cancel the shares&#8217;
par value such that every 1.046 Ordinary shares of NIS 0.8 par value, were substituted by 1 Ordinary share with no par value (the &#8220;Split&#8221;).
The Split was applied in the same proportion and manner to all of the Company&#8217;s authorized, issued and outstanding securities, including
preferred shares, options and warrants (See Note 10.a).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_AggregateNetProceeds', window );">Aggregate net proceeds</a></td>
<td class="nump">$ 62,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_DescriptionAdministration', window );">Description administration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company announced top-line results from the Surgical site Hospital acquired Infection prEvention with Local D-PLEX100 (&#8220;SHIELD&#8221;)
I Phase&#160;3 trial. SHIELD I did not achieve its primary endpoint of reduction in Surgical Site Infections (&#8220;SSIs&#8221;), re-interventions
due to SSIs and mortality: in the Intent to Treat (&#8220;ITT&#8221;) population, the local administration of D-PLEX100 and standard
of care (&#8220;SoC&#8221;), (n=485) resulted in a decrease in the primary endpoint of 23 percent compared to SoC alone (n=489) (p=0.1520).That said, in a
pre-specified subgroup ITT analysis requested by the United States (&#8220;U.S.&#8221;) Food and Drug Administration of a total of 423 subjects
with large incisions (>20 centimeters), the local administration of D-PLEX100 resulted in a significant reduction of 54
percent in the primary endpoint, compared to SoC alone (p=0.0032). Within the first 30 days post-surgery, SSIs decreased from 9.7% in
the SoC treatment arm (n=211), as compared to 4.4% in the D-PLEX100 treatment arm (n=212).&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash equivalents and short-term deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_IncurredLoss', window );">Incurred loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_CashFlowsFromOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CumulativeEarningsDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Date of filing term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_GeneralDetailsLineItems', window );"><strong>General (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_StockIssuedDuringPeriodSharesNewIssue', window );">Sale of ordinary shares (in Shares)</a></td>
<td class="nump">4,312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Overallotment option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_GeneralDetailsLineItems', window );"><strong>General (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_StockIssuedDuringPeriodSharesNewIssue', window );">Sale of ordinary shares (in Shares)</a></td>
<td class="nump">562,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_AggregateNetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount related to net proceeds from initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_AggregateNetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_CashFlowsFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_CashFlowsFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_DescriptionAdministration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of administration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_DescriptionAdministration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_DescriptionOfReverseShareSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_DescriptionOfReverseShareSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_GeneralDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_GeneralDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_IncurredLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_IncurredLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_StockIssuedDuringPeriodSharesNewIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_StockIssuedDuringPeriodSharesNewIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEarningsDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative earnings (deficits) for relevant time periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEarningsDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127135725728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_RighttouseAssetsAndLeaseLiabilities', window );">Right-to-use assets and lease liabilities</a></td>
<td class="nump">$ 3,388,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_LeasePrepayments', window );">Adjustments for lease repayments</a></td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 542,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ReceivedTotalAmount', window );">Received total amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Royalty bearing grants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,888,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_NonroyaltyBearingGrantsAmount', window );">Non-royalty bearing grants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,578,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OutOfReceivedAmount', window );">Out of received amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_NonroyaltyBearingGrants', window );">Non-royalty bearing grants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">727,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_FinancialExpenseIncome', window );">Financial expense (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 273,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,000)<span></span>
</td>
<td class="num">$ (81,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_TaxBenefitPercentage', window );">Tax benefit, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_AgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_NonRefundableAmount', window );">Non-refundable amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,548,000<span></span>
</td>
<td class="nump">&#8364; 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_AdditionalDevelopmentrelatedMilestonesPayments', window );">Additional development-related milestones payments (in Euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_AdditionalAmountOfCommercialSaleMilestones', window );">Additional amount of commercial sale milestones (in Euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 87.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,548,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_monthlyDepositsAtARate', window );">Monthly deposits percentage rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.33%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_SeverancePayExpenseAmount', window );">Severance pay expense amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547,000<span></span>
</td>
<td class="nump">$ 394,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_SeverancePay', window );">Severance pay, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">All eligible employees may elect to contribute up to 100% of their
payroll compensation (minus mandatory payroll deductions) to the plan, for 2022, up to a maximum of $20,500 per year (for employees over
50 years of age the maximum contribution was $28,000 per year), as determined by the U.S. Internal Revenue Service (&#8220;IRS&#8221;).
The US Subsidiary matches at 100%, on each payroll, up to 5% of the employee compensation to the plan within the IRS limits (which was
set at $300 in 2022 for purposes of the plan).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">All eligible employees may elect to contribute up to 100% of their
payroll compensation (minus mandatory payroll deductions) to the plan, for 2022, up to a maximum of $20,500 per year (for employees over
50 years of age the maximum contribution was $28,000 per year), as determined by the U.S. Internal Revenue Service (&#8220;IRS&#8221;).
The US Subsidiary matches at 100%, on each payroll, up to 5% of the employee compensation to the plan within the IRS limits (which was
set at $300 in 2022 for purposes of the plan).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_MatchingContributionsAmounts', window );">Matching in contributions amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount', window );">Corresponding liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pypd_ShortTermDepositsMember', window );">Short-Term Deposits [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Short-term deposit bearing interest percentage rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.55%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pypd_ShortTermDepositsMember', window );">Short-Term Deposits [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_SignificantAccountingPoliciesDetailsLineItems', window );"><strong>Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Short-term deposit bearing interest percentage rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_AdditionalAmountOfCommercialSaleMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional amount of commercial sale milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_AdditionalAmountOfCommercialSaleMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_AdditionalDevelopmentrelatedMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional development-related milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_AdditionalDevelopmentrelatedMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_AgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_AgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_FinancialExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of financial expense (income).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_FinancialExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_LeasePrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease prepayments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_LeasePrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_MatchingContributionsAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Matching Contributions Amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_MatchingContributionsAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_NonRefundableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non refundable amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_NonRefundableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_NonroyaltyBearingGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-royalty bearing grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_NonroyaltyBearingGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_NonroyaltyBearingGrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-royalty Bearing Grants Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_NonroyaltyBearingGrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_OutOfReceivedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Out of Received Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_OutOfReceivedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ReceivedTotalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Received Total Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ReceivedTotalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_RighttouseAssetsAndLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-to-use assets and lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_RighttouseAssetsAndLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_SeverancePay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance pay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_SeverancePay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_SeverancePayExpenseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance Pay Expense Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_SeverancePayExpenseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_SignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_SignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_TaxBenefitPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Benefit Percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_TaxBenefitPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_monthlyDepositsAtARate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly deposits percentage rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_monthlyDepositsAtARate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of corresponding entry for the joint and several liability arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 405<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=84228828&amp;loc=SL34748401-199205<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pypd_ShortTermDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pypd_ShortTermDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127134112480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment useful life<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems', window );"><strong>Public Utility, Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ComputersandSoftware', window );">Computers and software</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_PropertyPlantAndEquipmentPercent', window );">Furniture and office equipment</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Leasehold improvements</a></td>
<td class="text">Over the shorter of the term of the lease or its useful life<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems', window );"><strong>Public Utility, Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_LaboratoryAndManufacturingEquipment', window );">Laboratory equipment</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems', window );"><strong>Public Utility, Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_LaboratoryAndManufacturingEquipment', window );">Laboratory equipment</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ComputersandSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Computers and software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ComputersandSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_LaboratoryAndManufacturingEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Laboratory and manufacturing equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_LaboratoryAndManufacturingEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PropertyPlantAndEquipmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, plant and equipment percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PropertyPlantAndEquipmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127135829264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets - Prepaid Expenses and Other Current Assets [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems', window );"><strong>Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 552<span></span>
</td>
<td class="nump">$ 1,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseDepositLiability', window );">Lease deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Total</a></td>
<td class="nump">$ 1,089<span></span>
</td>
<td class="nump">$ 2,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Guarantee by US government authority for government insured loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919106-209958<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127138306832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">$ 1,721<span></span>
</td>
<td class="nump">$ 1,118<span></span>
</td>
<td class="nump">$ 1,012<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127135590656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - Schedule of property and equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 15,222<span></span>
</td>
<td class="nump">$ 13,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(5,975)<span></span>
</td>
<td class="num">(4,254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Depreciated cost</a></td>
<td class="nump">9,247<span></span>
</td>
<td class="nump">8,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pypd_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,933<span></span>
</td>
<td class="nump">6,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pypd_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 6,503<span></span>
</td>
<td class="nump">$ 6,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pypd_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pypd_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pypd_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pypd_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127134367104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalLeasesIndemnificationAgreementsPayments', window );">Bank guarantees lease agreement</a></td>
<td class="nump">$ 213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 1,344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesIndemnificationAgreementsPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payments made under the terms of an indemnification agreement contained in a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 25<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=126933198&amp;loc=d3e35680-112684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesIndemnificationAgreementsPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127134154448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of lease-related assets and liabilities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_LeaseAssetsAbstract', window );"><strong>Lease assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">$ 2,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_LeaseLiabilitiesAbstract', window );"><strong>Lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current lease liabilities</a></td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">1,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_LeaseLiabilities', window );">Total lease liabilities</a></td>
<td class="nump">$ 2,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted Average Remaining lease term</a></td>
<td class="text">3 years 4 months 13 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average Discount rate</a></td>
<td class="nump">9.95%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_LeaseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_LeaseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_OperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_OperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127138755264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of lease liability<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ScheduleOfLeaseLiabilityAbstract', window );"><strong>Schedule Of Lease Liability Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2023</a></td>
<td class="nump">$ 1,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2024</a></td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2025</a></td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2026</a></td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2027</a></td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Total undiscounted lease payments</a></td>
<td class="nump">2,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestNetAmount', window );">Less - imputed interest</a></td>
<td class="num">(292)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 2,132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestNetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The receivable or note face amount less the unamortized discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestNetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127135905648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of supplemental cash flow information related to the lease costs<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract', window );"><strong>Cash paid for amounts included in measurement of lease liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Operating cash flows for operating leases</a></td>
<td class="nump">$ 1,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract', window );"><strong>Right-of-use asset recognized with corresponding lease liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">$ 3,528<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127131791712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - Schedule of accrued expenses and other current liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems', window );"><strong>Schedule of Accrued Expenses And Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 1,246<span></span>
</td>
<td class="nump">$ 1,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees and payroll accruals</a></td>
<td class="nump">1,167<span></span>
</td>
<td class="nump">1,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_IsraelInnovationAuthorityGrantReceived', window );">IIA deferred grants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,429<span></span>
</td>
<td class="nump">$ 3,940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_IsraelInnovationAuthorityGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Israel Innovation Authority grant received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_IsraelInnovationAuthorityGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127138240384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Line of Credit Arrangement (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 19, 2022</div></th>
<th class="th"><div>Apr. 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 05, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_LineofCreditArrangementDetailsLineItems', window );"><strong>Line of Credit Arrangement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Line credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount', window );">Line of credit borrowing price</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Warrants percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Warrants exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants total amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Bears interest an annual rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Credit line fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDescription', window );">Line of credit arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The proceeds allocation resulted in $2,380 allocated to the Second Tranche and $120 allocated to the warrants.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseShortTermBorrowings', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=pypd_FirstTrancheMember', window );">First tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_LineofCreditArrangementDetailsLineItems', window );"><strong>Line of Credit Arrangement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">First tranche amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPayment', window );">Line of credit payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=pypd_SecondTrancheMember', window );">Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_LineofCreditArrangementDetailsLineItems', window );"><strong>Line of Credit Arrangement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ProceedsFromLinesOfCreditOne', window );">Second tranche amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPayment', window );">Line of credit payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=pypd_ThiredTrancheMember', window );">Third tranches [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_LineofCreditArrangementDetailsLineItems', window );"><strong>Line of Credit Arrangement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ProceedsFromLinesOfCreditTwo', window );">Third tranche amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_LineOfCreditFacilityPeriodicPaymentOne', window );">Third tranche not withdrawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_LineOfCreditFacilityPeriodicPaymentOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments of both interest and principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_LineOfCreditFacilityPeriodicPaymentOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_LineofCreditArrangementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_LineofCreditArrangementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ProceedsFromLinesOfCreditOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ProceedsFromLinesOfCreditOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ProceedsFromLinesOfCreditTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ProceedsFromLinesOfCreditTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate interest expense incurred on short-term borrowings including commercial paper and Federal funds purchased and securities sold under agreements to repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum month-end amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments of both interest and principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=pypd_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=pypd_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=pypd_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=pypd_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=pypd_ThiredTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=pypd_ThiredTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127134128144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 22, 2016</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ProceedsFromParticipationPayments', window );">Participation payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_CommitmentsAndContingentLiabilitiesDescription', window );">Commitments and Contingent liabilities, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company is committed
to pay royalties at a rate of 3% of sales of the developed products, up to 100% of the amount of grants received plus interest at LIBOR
rate. Through December 31, 2022, no royalties have been paid or accrued.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_FindersFee', window );">Finder's fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_SuitFillingExpense', window );">Suit filling expense</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_CommitmentsAndContingentLiabilitiesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_CommitmentsAndContingentLiabilitiesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_FindersFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finder's fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_FindersFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ProceedsFromParticipationPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Participation payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ProceedsFromParticipationPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_SuitFillingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Suit filling expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_SuitFillingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127131901776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes', window );">Accumulated losses (in Dollars)</a></td>
<td class="nump">$ 152,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Effective tax rate</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">State corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBankAdvancesInterestRate', window );">Federal tax</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">State corporate tax rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">State corporate tax rate</a></td>
<td class="nump">11.50%<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_IncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_IncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalHomeLoanBankAdvancesInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate of advances made and reported by Federal Home Loan Bank (FHLBank).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalHomeLoanBankAdvancesInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of investments for Federal income tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(2)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126898976&amp;loc=d3e600178-122990<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127131821760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of deferred tax assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems', window );"><strong>Income Taxes (Details) - Schedule of deferred tax assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Total</a></td>
<td class="nump">$ 39,557<span></span>
</td>
<td class="nump">$ 42,601<span></span>
</td>
<td class="nump">$ 36,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic (Israel) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems', window );"><strong>Income Taxes (Details) - Schedule of deferred tax assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Total</a></td>
<td class="nump">38,403<span></span>
</td>
<td class="nump">41,197<span></span>
</td>
<td class="nump">35,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems', window );"><strong>Income Taxes (Details) - Schedule of deferred tax assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Total</a></td>
<td class="nump">$ 1,154<span></span>
</td>
<td class="nump">$ 1,404<span></span>
</td>
<td class="nump">$ 886<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127134143696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of deferred income taxes reflect the net tax effects - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Carryforward losses</a></td>
<td class="nump">$ 34,984<span></span>
</td>
<td class="nump">$ 31,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development expenses</a></td>
<td class="nump">5,376<span></span>
</td>
<td class="nump">5,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Reserves and allowances</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">41,007<span></span>
</td>
<td class="nump">37,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(40,448)<span></span>
</td>
<td class="num">(37,210)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating lease ROU assets</a></td>
<td class="num">(559)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(559)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127134119632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of income taxes - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ScheduleOfIncomeTaxesAbstract', window );"><strong>Schedule Of Income Taxes Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_DomesticIsrael', window );">Domestic (Israel)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">129<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_DomesticIsrael">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_DomesticIsrael</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127138677408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 09, 2022</div></th>
<th class="th"><div>May 03, 2022</div></th>
<th class="th"><div>Jul. 19, 2022</div></th>
<th class="th"><div>Apr. 26, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_AggregateOfferingPrice', window );">Aggregate offering price (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Sale of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,065,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Total amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance cost (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareOptionPlanDescription', window );">Share option plan description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On May 3, 2022, the annual and extraordinary
general meeting of shareholders of the Company approved a new grant of 76,120 options to the then current Chief Executive Officer of the
Company, Mr. Amir Weisberg. In addition, it was approved to accelerate the vesting of 12,906 options from an outstanding grant; in both
cases the vesting of all options will occur on June 30, 2022. As a result, the Company recognized a total share-based compensation expense
in the amount of $76.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_NumberOfOptions', window );">Number of options</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_WeightedAverageGrantDateFairValueOfOptionsGranted', window );">Weighted average grant date fair value of options granted (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ExpectedDividendYield', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_UnrecognizedCompensationCosts', window );">Unrecognized compensation costs (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_RecognizedOverWeightedAveragePeriod', window );">Recognized over weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_WarrantsDescription', window );">Warrants, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">During
the year ended December 31, 2021, 580,028 D-2 warrants were exercised into 115,982 Ordinary shares on a cashless basis. In addition, 68,491
D-2 warrants were exercised into 68,491 Ordinary shares for a total consideration of $632. As of December 31, 2022, no D-2 warrants are
outstanding.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_WarrantsOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Warrant to purchase ordinary shares (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_WarrantsDescription', window );">Warrants, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">During
the year ended December 31, 2020, 2,106,879 D-2 warrants were exercised into 885,377 Ordinary shares on a cashless basis. As of December
31, 2020, 648,519 D-2 warrants were outstanding. In addition, 53,775 A warrants were exercised into 53,775 Ordinary shares for a total
consideration of $13.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pypd_TwoThousandTwelveShareOptionPlanMember', window );">2012 Share Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_StockOptionVestingPeriodDescription', window );">Stock option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The options granted generally have a four-year vesting period and expire ten years after the date
of grant.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_StockOptionsAvailableForFutureGrants', window );">Stock options available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_StockOptionShares', window );">Stock option shares</a></td>
<td class="nump">3,672,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_StockOptionShares', window );">Stock option shares</a></td>
<td class="nump">4,672,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_OfficerMember', window );">Officers [Member] | 2012 Share Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share option plan grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,672,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_AggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_AggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ExpectedDividendYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ExpectedDividendYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_NumberOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_NumberOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_RecognizedOverWeightedAveragePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognized over a weighted average period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_RecognizedOverWeightedAveragePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareOptionPlanDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share option plan description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareOptionPlanDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_StockOptionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_StockOptionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_StockOptionVestingPeriodDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_StockOptionVestingPeriodDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_StockOptionsAvailableForFutureGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock options available for future grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_StockOptionsAvailableForFutureGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_UnrecognizedCompensationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized compensation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_UnrecognizedCompensationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_WarrantsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_WarrantsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_WarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_WarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_WeightedAverageGrantDateFairValueOfOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value of options granted .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_WeightedAverageGrantDateFairValueOfOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pypd_TwoThousandTwelveShareOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pypd_TwoThousandTwelveShareOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127140398512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of ordinary share capital - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems', window );"><strong>Schedule of ordinary share capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesAuthorized', window );">Ordinary shares Authorized</a></td>
<td class="nump">47,800,000<span></span>
</td>
<td class="nump">47,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Ordinary shares Issued</a></td>
<td class="nump">19,851,833<span></span>
</td>
<td class="nump">18,756,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesOutstanding', window );">Ordinary shares outstanding</a></td>
<td class="nump">19,851,833<span></span>
</td>
<td class="nump">18,756,570<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of excess stock shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of excess stock held by shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127138374736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of status of options to employees - Share Option Plan [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of status of options to employees [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Beginning balance (in Shares) | shares</a></td>
<td class="nump">2,726,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance</a></td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Beginning balance (in Dollars) | $</a></td>
<td class="nump">$ 2,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (years), Beginning Outstanding</a></td>
<td class="text">6 years 5 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted (in Shares) | shares</a></td>
<td class="nump">1,124,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 5.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised', window );">Number of Options, Exercised (in Shares) | shares</a></td>
<td class="num">(30,206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Aggregate intrinsic value, Exercised</a></td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1', window );">Number of Options, Forfeited and cancelled (in Shares) | shares</a></td>
<td class="num">(517,879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled', window );">Weighted average exercise price, Forfeited and cancelled</a></td>
<td class="nump">$ 6.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Ending balance (in Shares) | shares</a></td>
<td class="nump">3,303,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance</a></td>
<td class="nump">$ 5.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Ending balance (in Dollars) | $</a></td>
<td class="nump">$ 115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding', window );">Weighted average remaining contractual life (years), Ending Outstanding</a></td>
<td class="text">6 years 1 month 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable options (in Shares) | shares</a></td>
<td class="nump">2,016,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable options</a></td>
<td class="nump">$ 5.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable options (in Dollars) | $</a></td>
<td class="nump">$ 115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (years), Exercisable options</a></td>
<td class="text">4 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest (in Shares) | shares</a></td>
<td class="nump">3,303,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices', window );">Weighted average exercise price, Vested and expected to vest</a></td>
<td class="nump">$ 5.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Aggregate intrinsic value, Vested and expected to vest (in Dollars) | $</a></td>
<td class="nump">$ 115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest', window );">Weighted average remaining contractual life (years), Vested and expected to vest</a></td>
<td class="text">6 years 1 month 20 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127130733472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of share options at the grant date<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of share options at the grant date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (%)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of share options at the grant date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (%)</a></td>
<td class="nump">70.45%<span></span>
</td>
<td class="nump">72.97%<span></span>
</td>
<td class="nump">74.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (%)</a></td>
<td class="nump">1.81%<span></span>
</td>
<td class="nump">0.62%<span></span>
</td>
<td class="nump">0.23%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of share options at the grant date [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (%)</a></td>
<td class="nump">92.67%<span></span>
</td>
<td class="nump">78.69%<span></span>
</td>
<td class="nump">84.77%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (%)</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">1.32%<span></span>
</td>
<td class="nump">1.38%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127135782928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of share-based compensation expense recognized - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of share-based compensation expense recognized [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 4,307<span></span>
</td>
<td class="nump">$ 4,750<span></span>
</td>
<td class="nump">$ 4,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of share-based compensation expense recognized [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">2,081<span></span>
</td>
<td class="nump">2,203<span></span>
</td>
<td class="nump">1,806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pypd_MarketingAndBusinessDevelopmentMember', window );">Marketing and business development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of share-based compensation expense recognized [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of share-based compensation expense recognized [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 1,843<span></span>
</td>
<td class="nump">$ 2,230<span></span>
</td>
<td class="nump">$ 2,631<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pypd_MarketingAndBusinessDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pypd_MarketingAndBusinessDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127137858112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">534,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">470,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member] | October 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">5,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">5,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">October 2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member] | September 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">5,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">5,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">September 2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member] | April 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">5,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">5,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">April 2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member] | December 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">7,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">7,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">December 2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member] | June 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">197,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">197,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">June 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member] | November 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">17,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">17,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">November 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member] | August 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">71,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">71,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">August 2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member] | June 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">64,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">53,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">June 2030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member] | April 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">62,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">62,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">April 2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member] | August 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">6,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">August 2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member] | December 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">3,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">December 2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member] | May 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">65,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">32,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">May 2032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Option [Member] | November 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">November 2032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">413,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">413,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member] | August 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">200,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">200,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">August 2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member] | September 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">17,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">17,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">September 2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member] | April 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">155,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">155,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">April 2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member] | July 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options outstanding</a></td>
<td class="nump">38,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OptionsExercisable', window );">Options exercisable</a></td>
<td class="nump">38,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration', window );">Exercisable</a></td>
<td class="text">April 2029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_OptionsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_OptionsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_OctoberTwoThousandThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_OctoberTwoThousandThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_SeptemberTwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_SeptemberTwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_AprilTwoThousandSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_AprilTwoThousandSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_DecemberTwoThousandSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_DecemberTwoThousandSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_JuneTwoThousandSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_JuneTwoThousandSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_NovemberTwoThousandSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_NovemberTwoThousandSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_August2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_August2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_JuneTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_JuneTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_April2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_April2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_August2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_August2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_December2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_December2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_May2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_May2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_November2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_November2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_September2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_September2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_April2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_April2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=pypd_July2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=pypd_July2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127135671152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of relative fair value of the warrants to purchase Ordinary shares issued - Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 19, 2022</div></th>
<th class="th"><div>Apr. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price ($) (in Dollars per share)</a></td>
<td class="nump">$ 5.12<span></span>
</td>
<td class="nump">$ 4.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price ($) (in Dollars per share)</a></td>
<td class="nump">$ 5.14<span></span>
</td>
<td class="nump">$ 5.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (%)</a></td>
<td class="nump">60.57%<span></span>
</td>
<td class="nump">60.81%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_AdjustmentToRiskfreeInterestRate', window );">Adjustment to risk-free interest rate (%)</a></td>
<td class="nump">3.07%<span></span>
</td>
<td class="nump">2.84%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (%)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (%)</a></td>
<td class="nump">3.11%<span></span>
</td>
<td class="nump">2.88%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 8 months 19 days<span></span>
</td>
<td class="text">6 years 11 months 8 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_AdjustmentToRiskfreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to risk-free interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_AdjustmentToRiskfreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127135614000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial (Income) Expenses, Net (Details) - Schedule of financial (income) expenses, net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_FinancialExpensesAbstract', window );"><strong>Financial expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLoansReceivable', window );">Financial expenses from loan</a></td>
<td class="nump">$ 1,023<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other financial expenses</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_RemeasurementOfWarrants', window );">Remeasurement of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInvestmentExpense', window );">Total financial expenses</a></td>
<td class="nump">1,339<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">11,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_FinancialIncomeAbstract', window );"><strong>Financial income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax', window );">Foreign currency transaction gains, net</a></td>
<td class="num">(532)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="num">(243)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest from bank deposits</a></td>
<td class="num">(267)<span></span>
</td>
<td class="num">(468)<span></span>
</td>
<td class="num">(474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other financial income</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Total financial income</a></td>
<td class="num">(799)<span></span>
</td>
<td class="num">(570)<span></span>
</td>
<td class="num">(793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Total financial (income) expense, net</a></td>
<td class="nump">$ 540<span></span>
</td>
<td class="num">$ (544)<span></span>
</td>
<td class="nump">$ 10,597<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_FinancialExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_FinancialExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_FinancialIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_FinancialIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_RemeasurementOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_RemeasurementOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInvestmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the generation of investment income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInvestmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of loan receivable arising from the financing of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127140483808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share (Details) - Schedule of basic and diluted loss per ordinary share - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic', window );">Allocation of net loss</a></td>
<td class="nump">$ 39,557<span></span>
</td>
<td class="nump">$ 42,601<span></span>
</td>
<td class="nump">$ 36,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_PreferredSharePreference', window );">Preferred share preference</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_DeemedDividend', window );">Deemed dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Allocation of net loss attributable to Ordinary shareholders</a></td>
<td class="nump">$ 39,557<span></span>
</td>
<td class="nump">$ 42,601<span></span>
</td>
<td class="nump">$ 42,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average Ordinary shares outstanding (in Shares)</a></td>
<td class="nump">19,426,692<span></span>
</td>
<td class="nump">18,721,528<span></span>
</td>
<td class="nump">9,582,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per share (in Dollars per share)</a></td>
<td class="nump">$ 2.04<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="nump">$ 4.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount declared as dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_PreferredSharePreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_PreferredSharePreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) from continuing operations allocated to participating securities for basic earnings (loss) per share or per unit calculation under two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2793-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127135581408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share (Details) - Schedule of basic and diluted loss per ordinary share (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract', window );"><strong>Schedule Of Basic And Diluted Loss Per Ordinary Share Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in Dollars per share)</a></td>
<td class="nump">$ 2.04<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="nump">$ 4.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127131875392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share (Details) - Schedule of diluted loss per share attributable to ordinary shareholders - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract', window );"><strong>Number of Ordinary Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Ordinary share options</a></td>
<td class="nump">2,487,447<span></span>
</td>
<td class="nump">1,995,749<span></span>
</td>
<td class="nump">1,583,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares', window );">Warrants</a></td>
<td class="nump">413,263<span></span>
</td>
<td class="nump">218,521<span></span>
</td>
<td class="nump">867,040<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_WeightedAverageNumberOfSharesIssued', window );">Total</a></td>
<td class="nump">2,900,710<span></span>
</td>
<td class="nump">2,214,270<span></span>
</td>
<td class="nump">2,450,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average effect of dilutive securities Warrants to convertible preferred shares (in Shares).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_WeightedAverageNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_WeightedAverageNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127135771184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_RelatedPartiesDetailsLineItems', window );"><strong>Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ServiceProvidersInAmount', window );">Service providers in amount</a></td>
<td class="nump">$ 174<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development expenses</a></td>
<td class="nump">$ 1,422<span></span>
</td>
<td class="nump">$ 3,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_RelatedPartiesDetailsLineItems', window );"><strong>Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_RelatedPartiesTerm', window );">Amir weisberg term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_RelatedPartiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_RelatedPartiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_RelatedPartiesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related parties term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_RelatedPartiesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ServiceProvidersInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ServiceProvidersInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140127134301280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 30, 2023</div></th>
<th class="th"><div>Mar. 29, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ExercisePriceDecrease', window );">Exercise price decreased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,021,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercised options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_MinimumPaidAmount', window );">Minimum paid amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ExceedAmount', window );">Exceed amount</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Pre funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,357,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OfferingExpensesPayable', window );">Offering expenses payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">Sale of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,949,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue', window );">Total amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Net issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,199,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_InterestRepayments', window );">Interest repayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges', window );">Restructuring percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Percentage incremental</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Private Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_OfferingExpensesPayable', window );">Offering expenses payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_ExercisePriceDecrease', window );">Exercise price decreased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">522,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=pypd_ConsultAndDirectorsMember', window );">Consultant and Directors [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pypd_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,859,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ExceedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ExceedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_ExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_ExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_InterestRepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of interest repayments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_InterestRepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_MinimumPaidAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_MinimumPaidAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_OfferingExpensesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of offering expenses payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_OfferingExpensesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pypd_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pypd_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pypd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section S45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=68176171&amp;loc=SL68176184-208336<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyCommittedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funds committed to investment company from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 205<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=25866437&amp;loc=d3e10491-115837<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyCommittedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount on the investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 10<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6438156&amp;loc=d3e57880-113973<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 10<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6431724&amp;loc=d3e32938-113948<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=pypd_ConsultAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=pypd_ConsultAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>f20f2022_polypidltd_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pypd="http://Polypid.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pypd-20221231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pypd:ConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2020-06-02</startDate>
            <endDate>2020-06-21</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-25</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-25</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2020-06-25</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pypd:ShortTermDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pypd:ShortTermDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pypd:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pypd:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pypd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pypd:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <instant>2022-04-05</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pypd:FirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pypd:SecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">pypd:ThiredTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-26</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-19</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2016-12-22</startDate>
            <endDate>2016-12-22</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2017-09-30</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2021-07-15</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pypd:TwoThousandTwelveShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pypd:TwoThousandTwelveShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-03</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-09</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-09</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-09</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pypd:MarketingAndBusinessDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pypd:MarketingAndBusinessDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pypd:MarketingAndBusinessDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:OctoberTwoThousandThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:OctoberTwoThousandThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:SeptemberTwoThousandFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:SeptemberTwoThousandFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:AprilTwoThousandSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:AprilTwoThousandSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:DecemberTwoThousandSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:DecemberTwoThousandSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:JuneTwoThousandSeventeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:JuneTwoThousandSeventeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:NovemberTwoThousandSeventeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:NovemberTwoThousandSeventeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:August2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:August2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:JuneTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:JuneTwoThousandTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:April2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:April2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:August2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:August2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:December2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:December2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:May2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:May2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:November2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:November2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:August2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:August2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:September2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:September2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:April2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:April2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:July2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">pypd:July2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-19</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-26</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-19</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-26</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-30</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-30</startDate>
            <endDate>2023-03-30</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <startDate>2023-03-29</startDate>
            <endDate>2023-03-29</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-29</startDate>
            <endDate>2023-03-29</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pypd:ConsultAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001611842</identifier>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:DocumentType contextRef="c0">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0">001-38428</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0">18 Hasivim Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0">Petach Tikva</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0">495376</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c1">Dikla Czaczkes Akselbrad</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1">372 Franklin Ave.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1">P.O. Box 558</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c1">Nutley</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c1">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c1">07110</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c1">(908)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1">858-5995</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0">Ordinary Shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">PYPD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">19851833</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c0">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard contextRef="c0">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="c0">1281</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c0">KOST FORER GABBAY &amp; KASIERER</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0">Haifa, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">8552000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">9819000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c2" decimals="-3" unitRef="usd">511000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c3" decimals="-3" unitRef="usd">397000</us-gaap:RestrictedCashCurrent>
    <us-gaap:DepositsAssets contextRef="c2" decimals="-3" unitRef="usd">4042000</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets contextRef="c3" decimals="-3" unitRef="usd">22384000</us-gaap:DepositsAssets>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c2" decimals="-3" unitRef="usd">1089000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c3" decimals="-3" unitRef="usd">2211000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">14194000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">34811000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">9247000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">8761000</us-gaap:PropertyPlantAndEquipmentNet>
    <pypd:LongtermDeposits contextRef="c2" decimals="-3" unitRef="usd">2431000</pypd:LongtermDeposits>
    <us-gaap:OtherAssetsNoncurrent contextRef="c2" decimals="-3" unitRef="usd">99000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="-3" unitRef="usd">663000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:LongTermInvestments contextRef="c2" decimals="-3" unitRef="usd">11777000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c3" decimals="-3" unitRef="usd">9424000</us-gaap:LongTermInvestments>
    <us-gaap:Assets contextRef="c2" decimals="-3" unitRef="usd">25971000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" unitRef="usd">44235000</us-gaap:Assets>
    <us-gaap:LongTermDebtCurrent contextRef="c2" decimals="-3" unitRef="usd">4024000</us-gaap:LongTermDebtCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c2" decimals="-3" unitRef="usd">2429000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c3" decimals="-3" unitRef="usd">3940000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c2" decimals="-3" unitRef="usd">1141000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c3" decimals="-3" unitRef="usd">4136000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" unitRef="usd">959000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">8553000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">8076000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c2" decimals="-3" unitRef="usd">7574000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c2" decimals="-3" unitRef="usd">2548000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" unitRef="usd">1173000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilities contextRef="c2" decimals="-3" unitRef="usd">294000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities contextRef="c3" decimals="-3" unitRef="usd">199000</us-gaap:OtherLiabilities>
    <pypd:TotalLongtermLiabilities contextRef="c2" decimals="-3" unitRef="usd">11589000</pypd:TotalLongtermLiabilities>
    <pypd:TotalLongtermLiabilities contextRef="c3" decimals="-3" unitRef="usd">199000</pypd:TotalLongtermLiabilities>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">47800000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">47800000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">19851833</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">19851833</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">18756570</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">18756570</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" unitRef="usd">220273000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" unitRef="usd">210847000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" unitRef="usd">-214444000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" unitRef="usd">-174887000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">5829000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">35960000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">25971000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">44235000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">27990000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" unitRef="usd">30553000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" unitRef="usd">16954000</us-gaap:ResearchAndDevelopmentExpense>
    <pypd:MarketingAndBusinessDevelopmentExpenses contextRef="c0" decimals="-3" unitRef="usd">2888000</pypd:MarketingAndBusinessDevelopmentExpenses>
    <pypd:MarketingAndBusinessDevelopmentExpenses contextRef="c4" decimals="-3" unitRef="usd">2983000</pypd:MarketingAndBusinessDevelopmentExpenses>
    <pypd:MarketingAndBusinessDevelopmentExpenses contextRef="c5" decimals="-3" unitRef="usd">1614000</pypd:MarketingAndBusinessDevelopmentExpenses>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">8010000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="-3" unitRef="usd">9609000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" unitRef="usd">7704000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-38888000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-43145000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-26272000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">-540000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c4" decimals="-3" unitRef="usd">544000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="-3" unitRef="usd">-10597000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent contextRef="c0" decimals="-3" unitRef="usd">-39428000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c4" decimals="-3" unitRef="usd">-42601000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c5" decimals="-3" unitRef="usd">-36869000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="-3" unitRef="usd">129000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c0" decimals="-3" unitRef="usd">-39557000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c4" decimals="-3" unitRef="usd">-42601000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c5" decimals="-3" unitRef="usd">-36869000</us-gaap:ProfitLoss>
    <pypd:DeemedDividends contextRef="c5" decimals="-3" unitRef="usd">-2114000</pypd:DeemedDividends>
    <pypd:NetLossAttributableToOrdinarySharesinDollarsPerShare contextRef="c0" decimals="-3" unitRef="usd">-39557000</pypd:NetLossAttributableToOrdinarySharesinDollarsPerShare>
    <pypd:NetLossAttributableToOrdinarySharesinDollarsPerShare contextRef="c4" decimals="-3" unitRef="usd">-42601000</pypd:NetLossAttributableToOrdinarySharesinDollarsPerShare>
    <pypd:NetLossAttributableToOrdinarySharesinDollarsPerShare contextRef="c5" decimals="-3" unitRef="usd">-38983000</pypd:NetLossAttributableToOrdinarySharesinDollarsPerShare>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">2.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c4" decimals="2" unitRef="usdPershares">2.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">4.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="INF" unitRef="shares">19426692</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c4" decimals="INF" unitRef="shares">18721528</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c5" decimals="INF" unitRef="shares">9582405</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c6" decimals="0" unitRef="shares">12520977</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="-3" unitRef="usd">106313000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="-3" unitRef="usd">106313000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c8" decimals="0" unitRef="shares">562748</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" unitRef="usd">5671000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" unitRef="usd">-93303000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="-3" unitRef="usd">-87632000</us-gaap:StockholdersEquity>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c14" decimals="-3" unitRef="usd">4577000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c5" decimals="-3" unitRef="usd">4577000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c16"
      decimals="0"
      id="ix_0_fact"
      unitRef="shares">4312500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c14" decimals="-3" id="ix_1_fact" unitRef="usd">62757000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c5" decimals="-3" id="ix_2_fact" unitRef="usd">62757000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <pypd:ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares contextRef="c12" decimals="0" unitRef="shares">-12520977</pypd:ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares>
    <pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares contextRef="c12" decimals="-3" unitRef="usd">-106313000</pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares>
    <pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares contextRef="c13" decimals="-3" unitRef="usd">-106313000</pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares>
    <pypd:ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares contextRef="c16" decimals="0" unitRef="shares">12520977</pypd:ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares>
    <pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares contextRef="c14" decimals="-3" unitRef="usd">106313000</pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares>
    <pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares contextRef="c5" decimals="-3" unitRef="usd">106313000</pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c16" decimals="0" unitRef="shares">158967</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings contextRef="c14" decimals="-3" unitRef="usd">2114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings contextRef="c15" decimals="-3" unitRef="usd">-2114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <pypd:ReclassificationOfWarrantsIntoEquity contextRef="c14" decimals="-3" unitRef="usd">23614000</pypd:ReclassificationOfWarrantsIntoEquity>
    <pypd:ReclassificationOfWarrantsIntoEquity contextRef="c5" decimals="-3" unitRef="usd">23614000</pypd:ReclassificationOfWarrantsIntoEquity>
    <pypd:StockIssuedDuringPeriodExerciseOfWarrantsShares contextRef="c16" decimals="0" unitRef="shares">939152</pypd:StockIssuedDuringPeriodExerciseOfWarrantsShares>
    <pypd:ExerciseOfWarrants contextRef="c14" decimals="-3" unitRef="usd">13000</pypd:ExerciseOfWarrants>
    <pypd:ExerciseOfWarrants contextRef="c5" decimals="-3" unitRef="usd">13000</pypd:ExerciseOfWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c14" decimals="-3" unitRef="usd">1000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c5" decimals="-3" unitRef="usd">1000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c16" decimals="0" unitRef="shares">395</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c14" decimals="-3" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c5" decimals="-3" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c15" decimals="-3" unitRef="usd">-36869000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-36869000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c19" decimals="0" unitRef="shares">18494739</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" unitRef="usd">205063000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" unitRef="usd">-132286000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" unitRef="usd">72777000</us-gaap:StockholdersEquity>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c25" decimals="-3" unitRef="usd">4750000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c4" decimals="-3" unitRef="usd">4750000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <pypd:StockIssuedDuringPeriodExerciseOfWarrantsShares contextRef="c27" decimals="0" unitRef="shares">184473</pypd:StockIssuedDuringPeriodExerciseOfWarrantsShares>
    <pypd:ExerciseOfWarrants contextRef="c25" decimals="-3" unitRef="usd">632000</pypd:ExerciseOfWarrants>
    <pypd:ExerciseOfWarrants contextRef="c4" decimals="-3" unitRef="usd">632000</pypd:ExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c27" decimals="0" unitRef="shares">77358</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c25" decimals="-3" unitRef="usd">402000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c4" decimals="-3" unitRef="usd">402000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c26" decimals="-3" unitRef="usd">-42601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-42601000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c30" decimals="0" unitRef="shares">18756570</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c31" decimals="-3" unitRef="usd">210847000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="-3" unitRef="usd">-174887000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">35960000</us-gaap:StockholdersEquity>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c35" decimals="-3" unitRef="usd">4307000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">4307000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <pypd:IssuanceOfOrdinarySharesNetinShares
      contextRef="c37"
      decimals="0"
      id="ix_3_fact"
      unitRef="shares">1065057</pypd:IssuanceOfOrdinarySharesNetinShares>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c35" decimals="-3" id="ix_4_fact" unitRef="usd">4423000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="-3" id="ix_5_fact" unitRef="usd">4423000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c35" decimals="-3" unitRef="usd">588000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c0" decimals="-3" unitRef="usd">588000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c37" decimals="0" unitRef="shares">30206</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c35" decimals="-3" unitRef="usd">108000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="-3" unitRef="usd">108000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c36" decimals="-3" unitRef="usd">-39557000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-39557000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c40" decimals="0" unitRef="shares">19851833</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="-3" unitRef="usd">220273000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="-3" unitRef="usd">-214444000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">5829000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-39557000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-42601000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-36869000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" unitRef="usd">1721000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c4" decimals="-3" unitRef="usd">1118000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="-3" unitRef="usd">1012000</us-gaap:Depreciation>
    <pypd:ReevaluationOfWarrants contextRef="c5" decimals="-3" unitRef="usd">11373000</pypd:ReevaluationOfWarrants>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">-289000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">4307000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c4" decimals="-3" unitRef="usd">4750000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c5" decimals="-3" unitRef="usd">4577000</us-gaap:ShareBasedCompensation>
    <pypd:DecreaseincreaseInReceivablesAndPrepaidExpenses contextRef="c0" decimals="-3" unitRef="usd">-1185000</pypd:DecreaseincreaseInReceivablesAndPrepaidExpenses>
    <pypd:DecreaseincreaseInReceivablesAndPrepaidExpenses contextRef="c4" decimals="-3" unitRef="usd">-83000</pypd:DecreaseincreaseInReceivablesAndPrepaidExpenses>
    <pypd:DecreaseincreaseInReceivablesAndPrepaidExpenses contextRef="c5" decimals="-3" unitRef="usd">1929000</pypd:DecreaseincreaseInReceivablesAndPrepaidExpenses>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c0" decimals="-3" unitRef="usd">-299000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c0" decimals="-3" unitRef="usd">-3095000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c4" decimals="-3" unitRef="usd">2221000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c5" decimals="-3" unitRef="usd">-607000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c0" decimals="-3" unitRef="usd">2548000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="-3" unitRef="usd">-1416000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c4" decimals="-3" unitRef="usd">2043000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c5" decimals="-3" unitRef="usd">847000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">-34317000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c4" decimals="-3" unitRef="usd">-32386000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="-3" unitRef="usd">-21596000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <pypd:PaymentsForProceedsFromShorttermAndLongtermDepositsNet contextRef="c0" decimals="-3" unitRef="usd">-18342000</pypd:PaymentsForProceedsFromShorttermAndLongtermDepositsNet>
    <pypd:PaymentsForProceedsFromShorttermAndLongtermDepositsNet contextRef="c4" decimals="-3" unitRef="usd">-39893000</pypd:PaymentsForProceedsFromShorttermAndLongtermDepositsNet>
    <pypd:PaymentsForProceedsFromShorttermAndLongtermDepositsNet contextRef="c5" decimals="-3" unitRef="usd">39592000</pypd:PaymentsForProceedsFromShorttermAndLongtermDepositsNet>
    <pypd:PrepaymentForEquipments contextRef="c4" decimals="-3" unitRef="usd">340000</pypd:PrepaymentForEquipments>
    <pypd:PrepaymentForEquipments contextRef="c5" decimals="-3" unitRef="usd">395000</pypd:PrepaymentForEquipments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" unitRef="usd">1767000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c4" decimals="-3" unitRef="usd">2653000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="-3" unitRef="usd">781000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" unitRef="usd">16575000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c4" decimals="-3" unitRef="usd">36900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="-3" unitRef="usd">-40768000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c4" decimals="-3" unitRef="usd">632000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c5" decimals="-3" unitRef="usd">13000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="-3" unitRef="usd">108000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c4" decimals="-3" unitRef="usd">402000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c5" decimals="-3" unitRef="usd">3000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c5" decimals="-3" unitRef="usd">62757000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="-3" unitRef="usd">4423000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c0" decimals="-3" unitRef="usd">11711000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c0" decimals="-3" unitRef="usd">402000</us-gaap:RepaymentsOfLongTermDebt>
    <pypd:IssuanceOfWarrants contextRef="c0" decimals="-3" unitRef="usd">-588000</pypd:IssuanceOfWarrants>
    <pypd:IssuanceOfWarrants contextRef="c5" decimals="-3" unitRef="usd">-1000</pypd:IssuanceOfWarrants>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" unitRef="usd">16428000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c4" decimals="-3" unitRef="usd">1034000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="-3" unitRef="usd">62774000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" unitRef="usd">-1314000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c4" decimals="-3" unitRef="usd">5548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c5" decimals="-3" unitRef="usd">410000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">10456000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c22" decimals="-3" unitRef="usd">4908000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c11" decimals="-3" unitRef="usd">4498000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" unitRef="usd">9142000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">10456000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c22" decimals="-3" unitRef="usd">4908000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="-3" unitRef="usd">734000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c0" decimals="-3" unitRef="usd">8000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">8552000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">9819000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c22" decimals="-3" unitRef="usd">4319000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">511000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">397000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c22" decimals="-3" unitRef="usd">390000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <pypd:RestrictedCashIncludedInOtherLongtermAssets contextRef="c0" decimals="-3" unitRef="usd">79000</pypd:RestrictedCashIncludedInOtherLongtermAssets>
    <pypd:RestrictedCashIncludedInOtherLongtermAssets contextRef="c4" decimals="-3" unitRef="usd">240000</pypd:RestrictedCashIncludedInOtherLongtermAssets>
    <pypd:RestrictedCashIncludedInOtherLongtermAssets contextRef="c5" decimals="-3" unitRef="usd">199000</pypd:RestrictedCashIncludedInOtherLongtermAssets>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c2" decimals="-3" unitRef="usd">9142000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c3" decimals="-3" unitRef="usd">10456000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c22" decimals="-3" unitRef="usd">4908000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <pypd:PurchaseOfPropertyAndEquipmentIncludedInTradePayable contextRef="c0" decimals="-3" unitRef="usd">100000</pypd:PurchaseOfPropertyAndEquipmentIncludedInTradePayable>
    <pypd:PurchaseOfPropertyAndEquipmentIncludedInTradePayable contextRef="c4" decimals="-3" unitRef="usd">941000</pypd:PurchaseOfPropertyAndEquipmentIncludedInTradePayable>
    <pypd:PropertyAndEquipmentPaidForInPriorPeriods contextRef="c0" decimals="-3" unitRef="usd">340000</pypd:PropertyAndEquipmentPaidForInPriorPeriods>
    <pypd:PropertyAndEquipmentPaidForInPriorPeriods contextRef="c4" decimals="-3" unitRef="usd">395000</pypd:PropertyAndEquipmentPaidForInPriorPeriods>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" unitRef="usd">3528000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1 contextRef="c0" decimals="-3" unitRef="usd">1259000</us-gaap:StockIssued1>
    <us-gaap:BasisOfAccounting contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;NOTE 1:-&lt;/td&gt;&lt;td style="text-align: justify"&gt;GENERAL&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;a.&lt;/td&gt;&lt;td style="text-align: justify"&gt;PolyPid Ltd. (the &#x201c;Company&#x201d;) was incorporated under the laws of Israel and commenced operations
on February&#160;28, 2008. The Company is a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and
prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. The Company&#x2019;s product candidates
are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release
rates and durations over extended periods ranging from days to several months. The Company is initially focused on the development of
its lead product candidate, D-PLEX, which incorporates an antibiotic for the prevention of surgical site infection in bone and soft tissue.
Through December 31, 2022, the Company has been primarily engaged in research and development.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s wholly owned subsidiaries
include a subsidiary in the United States of America (the &#x201c;US Subsidiary&#x201d;) and a subsidiary in Romania. The US Subsidiary&#x2019;s
operation focuses on marketing and business development of the Company&#x2019;s operation in the United States of America.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;b.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On June 21, 2020, the Company&#x2019;s Board of Directors resolved to consolidate the Company&#x2019;s share
capital by applying a reverse share split at a ratio of 1.046:1 (the &#x201c;Reverse Split Ratio&#x201d;) and to cancel the shares&#x2019;
par value such that every 1.046 Ordinary shares of NIS 0.8 par value, were substituted by 1 Ordinary share with no par value (the &#x201c;Split&#x201d;).
The Split was applied in the same proportion and manner to all of the Company&#x2019;s authorized, issued and outstanding securities, including
preferred shares, options and warrants (See Note 10.a).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;c.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On June 30, 2020, the Company closed its initial public offering (&#x201c;IPO&#x201d;) whereby 4,312,500 Ordinary
shares were sold by the Company to the public (inclusive of 562,500 Ordinary shares pursuant to the full exercise of an overallotment
option granted to the underwriters). The aggregate net proceeds received by the Company from the offering were $62,757, net of underwriting
discounts and other offering costs.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;d.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The Company&#x2019;s activities since inception have consisted of performing research and development activities.
Successful completion of the Company&#x2019;s development programs and, ultimately, the attainment of profitable operations is dependent on future
events, including, among other things, its ability to secure financing; obtain marketing approval from regulatory authorities; access
potential markets; build a sustainable customer base; attract, retain and motivate qualified personnel; and develop strategic alliances.
The Company&#x2019;s operations are funded by its shareholders and research and development grants and the Company intends to seek further private
or public financing as well as make applications for further research and development grants for continuing its operations. Although management
believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to
do so or that the Company will ever operate profitably.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;In September 2022,
the Company announced top-line results from the Surgical site Hospital acquired Infection prEvention with Local D-PLEX&lt;sub&gt;100&lt;/sub&gt; (&#x201c;SHIELD&#x201d;)
I Phase&#160;3 trial. SHIELD I did not achieve its primary endpoint of reduction in Surgical Site Infections (&#x201c;SSIs&#x201d;), re-interventions
due to SSIs and mortality: in the Intent to Treat (&#x201c;ITT&#x201d;) population, the local administration of D-PLEX&lt;sub&gt;100&lt;/sub&gt; and standard
of care (&#x201c;SoC&#x201d;), (n=485) resulted in a decrease in the primary endpoint of 23 percent compared to SoC alone (n=489) (p=0.1520).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;That said, in a
pre-specified subgroup ITT analysis requested by the United States (&#x201c;U.S.&#x201d;) Food and Drug Administration of a total of 423 subjects
with large incisions (&amp;gt;20 centimeters), the local administration of D-PLEX&lt;sub&gt;100 &lt;/sub&gt;resulted in a significant reduction of 54
percent in the primary endpoint, compared to SoC alone (p=0.0032). Within the first 30 days post-surgery, SSIs decreased from 9.7% in
the SoC treatment arm (n=211), as compared to 4.4% in the D-PLEX&lt;sub&gt;100&lt;/sub&gt; treatment arm (n=212).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company expects
to continue to incur substantial losses over the next several years during its clinical development phase. To fully execute its business
plan, the Company will need to complete phase 3 clinical studies and certain development activities as well as manufacture the required
clinical and commercial production batches in the pilot manufacturing plant. Further, the Company&#x2019;s product candidates will require regulatory
approval prior to commercialization and the Company will need to establish sales, marketing and logistic infrastructures. These activities
may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these
activities could adversely impact the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;As of December 31,
2022, the Company had cash, cash equivalents and short-term deposits in the total amount of $12,594. During the year ended December&#160;31,
2022, the Company incurred a net loss of $39,557 and had negative cash flows from operating activities of $34,317. In addition, the Company
had an accumulated deficit of $214,444 at December 31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company&#x2019;s future
operations are highly dependent on a combination of factors, including (i) completion of all required clinical studies; (ii) the success
of its research and development activities; (iii) manufacture of all required clinical and commercial production batches; (iv) marketing
approval by the relevant regulatory authorities; and (v) market acceptance of the Company&#x2019;s product candidates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;There can be no
assurance that the Company will succeed in achieving the clinical, scientific and commercial milestones as detailed above.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Based on the
abovementioned, as of the approval date of these consolidated financial statements, the Company has not raised the necessary funding in
order to continue its activity for a period of at least one year after the date of the filing of this annual report on Form 20-F. Therefore,
these factors raise a substantial doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The consolidated
financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that might result
should the Company be unable to continue as a going concern.&lt;/p&gt;</us-gaap:BasisOfAccounting>
    <pypd:DescriptionOfReverseShareSplit contextRef="c43">the Company&#x2019;s Board of Directors resolved to consolidate the Company&#x2019;s share
capital by applying a reverse share split at a ratio of 1.046:1 (the &#x201c;Reverse Split Ratio&#x201d;) and to cancel the shares&#x2019;
par value such that every 1.046 Ordinary shares of NIS 0.8 par value, were substituted by 1 Ordinary share with no par value (the &#x201c;Split&#x201d;).
The Split was applied in the same proportion and manner to all of the Company&#x2019;s authorized, issued and outstanding securities, including
preferred shares, options and warrants (See Note 10.a).</pypd:DescriptionOfReverseShareSplit>
    <pypd:StockIssuedDuringPeriodSharesNewIssue contextRef="c44" decimals="0" unitRef="shares">4312500</pypd:StockIssuedDuringPeriodSharesNewIssue>
    <pypd:StockIssuedDuringPeriodSharesNewIssue contextRef="c45" decimals="0" unitRef="shares">562500</pypd:StockIssuedDuringPeriodSharesNewIssue>
    <pypd:AggregateNetProceeds contextRef="c46" decimals="-3" unitRef="usd">62757000</pypd:AggregateNetProceeds>
    <pypd:DescriptionAdministration contextRef="c47">the Company announced top-line results from the Surgical site Hospital acquired Infection prEvention with Local D-PLEX100 (&#x201c;SHIELD&#x201d;)
I Phase&#160;3 trial. SHIELD I did not achieve its primary endpoint of reduction in Surgical Site Infections (&#x201c;SSIs&#x201d;), re-interventions
due to SSIs and mortality: in the Intent to Treat (&#x201c;ITT&#x201d;) population, the local administration of D-PLEX100 and standard
of care (&#x201c;SoC&#x201d;), (n=485) resulted in a decrease in the primary endpoint of 23 percent compared to SoC alone (n=489) (p=0.1520).That said, in a
pre-specified subgroup ITT analysis requested by the United States (&#x201c;U.S.&#x201d;) Food and Drug Administration of a total of 423 subjects
with large incisions (&gt;20 centimeters), the local administration of D-PLEX100 resulted in a significant reduction of 54
percent in the primary endpoint, compared to SoC alone (p=0.0032). Within the first 30 days post-surgery, SSIs decreased from 9.7% in
the SoC treatment arm (n=211), as compared to 4.4% in the D-PLEX100 treatment arm (n=212).&#160;</pypd:DescriptionAdministration>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c2" decimals="-3" unitRef="usd">12594000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <pypd:IncurredLoss contextRef="c0" decimals="-3" unitRef="usd">39557000</pypd:IncurredLoss>
    <pypd:CashFlowsFromOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">34317000</pypd:CashFlowsFromOperatingActivities>
    <us-gaap:CumulativeEarningsDeficit contextRef="c2" decimals="-3" unitRef="usd">214444000</us-gaap:CumulativeEarningsDeficit>
    <us-gaap:DebtInstrumentTerm contextRef="c0">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in; text-align: left"&gt;NOTE 2:-&lt;/td&gt;&lt;td style="text-align: justify"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;The consolidated financial statements
are prepared according to United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;a.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Use of estimates:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company&#x2019;s management
believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made.
These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting
periods. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;b.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Consolidated financial statements in U.S.&#160;dollars:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The accompanying consolidated financial
statements have been prepared in United States of America dollars (&#x201c;USD&#x201d;, &#x201c;$&#x201d; or &#x201c;U.S. dollars&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A substantial portion of the Company&#x2019;s
expenses are incurred in New Israeli Shekels (&#x201c;NIS&#x201d;). However, the Company finances its operations mainly in U.S. dollars,
a substantial portion of its expenses are incurred in U.S. dollars and potential revenues from its primary markets are anticipated to
be generated in U.S. dollars. As such, the Company&#x2019;s management believes that the U.S. dollar is the currency of the primary economic
environment in which the Company and its subsidiaries operate. Thus, the functional and reporting currency of the Company is the U.S.
dollar.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the dollar are re-measured
into U.S. dollars in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) No. 830, &#x201c;&lt;i&gt;Foreign Currency Matters&lt;/i&gt;&#x201d;.
All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the statements of operations as
financial income or expenses, as appropriate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;c.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Principles of consolidation:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The consolidated
financial statements include the accounts of the Company and its subsidiaries. Intercompany balances have been eliminated upon consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;d.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Cash equivalents:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Cash equivalents
are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or less, at
the date acquired.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;e.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Restricted cash:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Restricted cash
is primarily invested in a bank deposit and is used as security for the Company&#x2019;s lease commitments and for its forward and options transactions
activities (see Note 2q).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;f.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Segment reporting:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company
identifies operating segments in accordance with ASC No. 280, &#x201c;&lt;i&gt;Segment Reporting&lt;/i&gt;&#x201d;, as components of an entity for which
discrete financial information is available and is regularly reviewed by the chief operating decision maker, or decision-making group,
in making decisions regarding resource allocation and evaluating financial performance. The Company&#x2019;s chief operating decision maker is
its chief executive officer. The Company determined it operates in one operating segment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;g.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Short-term deposits:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A short-term bank deposit is a deposit
with a maturity of more than three months, but less than one year. Deposits in U.S. dollars bear interest at rates ranging from 4.55%-5.90%,
per annum, as of December 31, 2022. Short-term deposits are presented at cost, which approximates market value due to their short maturities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.75pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;h.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Property and equipment, net:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Property and equipment
are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful
lives of the assets at the following rates:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 77%; text-align: justify"&gt;Computers and software&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: center; padding-left: 0.05in"&gt;33&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0.05in"&gt;10&#160;-&#160;15&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0.05in"&gt;15&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: center; padding-left: 0.05in"&gt;Over the shorter of the term of the lease or its useful life&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;i.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Leases:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;On January 1, 2022,
the Company adopted ASC No. 842, &#x201c;&lt;i&gt;Leases&lt;/i&gt;&#x201d; (&#x201c;ASC 842&#x201d;), using the modified retrospective method&#160;by applying
the new standard to all leases existing at the date of initial application. Results and disclosure requirements for reporting periods
beginning after January 1, 2022, are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported
in accordance with the Company&#x2019;s historical accounting under ASC No. 840, &#x201c;&lt;i&gt;Leases&lt;/i&gt;&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company has
elected the package of practical expedients permitted under the transition guidance, which allows the Company not to reassess: (1) whether
any existing contracts as of the adoption date are or contain a lease under ASC 842, (2) lease classification for any existing leases
as of the adoption date, and (3) initial direct costs for any existing leases as of the adoption date. Lastly, the Company also elected
the practical expedient to not separate lease and non-lease components for its leases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;As a result of the
adoption of ASC 842 on January 1, 2022, the Company recorded both operating leases right-of-use (&#x201c;ROU&#x201d;) assets and operating
lease liabilities of $3,388.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The ROU assets include
adjustments for lease prepayments in the amount of $36. The adoption did not impact the Company&#x2019;s beginning accumulated deficit,
or its prior year consolidated statements of operations and statements of cash flows. The adoption did not have a material impact on the
Company&#x2019;s current year consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Leases are classified
as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the
lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably
certain to be exercised, the lease term is for a major part of the remaining useful life of the asset, the present value of the lease
payments equals or exceeds substantially all of the fair value of the asset, or the underlying asset is of such a specialized nature that
it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does
not meet any one of these criteria. Since all of the Company&#x2019;s lease contracts do not meet any of the criteria above, the Company
concluded that all of its lease contracts should be classified as operating leases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;ROU assets
and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For
this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company&#x2019;s
leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available on the commencement
date in determining the present value of lease payments. All ROU assets are reviewed for impairment. The lease terms may include options
to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;j.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Impairment of long-lived assets:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company&#x2019;s long-lived
assets are reviewed for impairment in accordance with ASC No. 360, &#x201c;&lt;i&gt;Property, Plant and Equipment&lt;/i&gt;&#x201d;, whenever events or
changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held
and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated
by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying
amount of the asset exceeds its fair value. As of December 31, 2022 and 2021, no impairment losses have been identified.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;k.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Research and development, net expenses:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Research and development
expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments
to subcontractors, chemical, manufacturing and control activities, costs associated with obtaining regulatory approvals, executing pre-clinical
and clinical studies and maintenance and prosecution of the Company&#x2019;s intellectual property rights. In addition, research and development
expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research
and development expenses as expenses when incurred and are presented net of government grants (see Note 2.l).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;l.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Grants and participations:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Royalty-bearing grants from the Israeli
Innovation Authority (&#x201c;IIA&#x201d;) of the Ministry of Economy and Industry in Israel for funding of approved research and development
projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a
deduction from research and development expenses. Non-royalty-bearing grants from the IIA MAGNET program and from European Commission&#x2019;s
Seventh Framework Programme for Research (&#x201c;FP7&#x201d;) for funding approved research and development projects are recognized at
the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and
development expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Since the payment
of royalties is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until
the related revenues are recognized.&#160;In the event of failure of a project that was partly financed by IIA, the Company will not be
obligated to pay any royalties or repay the amounts received.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company recognizes
participations in research and development, as a reduction from research and development expenses in the amount of $738 and $542 for the
years ended December 31, 2022, and 2021, respectively (no grants were received for the year ended December 31, 2020).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;From inception up
until December 31, 2022, the Company received a total of $7,193 in grants, out of which royalty-bearing grants in the amount of $4,888
from the IIA, non-royalty bearing grants in the amount of $1,578 from the IIA (out of which $521 were received during the year ended December
31, 2022) and non-royalty bearing grants in the amount of $727 from the FP7.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;m.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Accounting for share-based compensation:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Share-based compensation
expense related to share-based awards is recognized based on the fair value of the awards granted and recognized as an expense on a straight-line
basis over the requisite service period for share options. The fair value of each option award is estimated on the grant date using the
Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including
the expected term of the award, the expected volatility of the price of the Company&#x2019;s Ordinary shares, risk-free interest rates,
and the expected dividend yield of Ordinary shares. The assumptions used to determine the fair value of the share awards represent management&#x2019;s
best estimates. These estimates involve inherent uncertainties and the application of management&#x2019;s judgment. Forfeitures are accounted
for as they occur instead of estimating the number of awards expected to be forfeited.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;n.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Basic and diluted net loss per share:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Prior to the Company&#x2019;s
IPO, the Company computed its net loss per share using the two-class method required for participating securities. The two-class method
requires income available to Ordinary shareholders for the period to be allocated between Ordinary shares and participating securities
based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considered its
convertible preferred shares to be participating securities as the holders of the convertible preferred shares would be entitled to dividends
that would be distributed to the holders of Ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities
did not contractually require the holders of such shares to participate in the Company&#x2019;s losses.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;As such,&#160;during
the periods when the Company is in a loss position, the loss attributable to Ordinary shareholders was not allocated to the convertible
preferred shares under the two-class method as these securities did not have a contractual obligation to share in the Company&#x2019;s
losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Following the Company&#x2019;s
IPO, the Company&#x2019;s basic net loss per share is calculated by dividing the net loss attributable to Ordinary shareholders by the
weighted-average number of shares of Ordinary shares outstanding for the period, without consideration of potentially dilutive securities.
The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using
the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as
basic net loss per share in periods when the effects of potentially dilutive shares of Ordinary shares are anti-dilutive.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;o.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Convertible preferred shares and convertible preferred shares warrant liability:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The terms of the
convertible preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1&#160;shares allowed the holders to redeem shares, under certain circumstances,
outside of the Company&#x2019;s control. Therefore, these shares were classified as mezzanine equity on the balance sheet and not included as
a component of shareholders&#x2019; deficit before the IPO. The Company did not adjust the preferred shares&#x2019; carrying value to the redemption
value since redemption was not probable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Following the Company&#x2019;s
IPO, the convertible preferred shares were converted into Ordinary shares and were reclassified into permanent equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Warrants to purchase the Company&#x2019;s
convertible preferred shares were classified as a liability on the balance sheet, and measured at fair value, as the underlying shares
are contingently redeemable (upon a deemed liquidation event) and, therefore, may obligate the Company to transfer assets at some point
in the future. The warrants were subject to re-measurement to fair value at each balance sheet date and any change in fair value was recognized
as a component of financial expenses, net, in the statements of operation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Following the Company&#x2019;s IPO,
the warrants can only be exercised into the Company&#x2019;s ordinary equity shares. Consequently, as of the IPO date, the Company reclassified
the warrants as equity since the warrants are not an ASC No. 480, &#x201c;&lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;&#x201d; (&#x201c;ASC
480&#x201d;), liability, are indexed to the Company&#x2019;s own stock and can be classified as equity pursuant to ASC No. 815-40, &#x201c;&lt;i&gt;Derivatives
and Hedging&lt;/i&gt;&#x201d; (&#x201c;ASC 815&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;p.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Fair value of financial instruments:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company applies
ASC No. 820, &#x201c;&lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;&#x201d; (&#x201c;ASC 820&#x201d;), pursuant to which fair value is defined
as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly
transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches.
ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the
use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market
participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Unobservable inputs
are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset or liability
developed based on the best information available in the circumstances.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Fair value is an
exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction
between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market
participants would use in pricing an asset or a liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;A three-tier fair
value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring
fair value:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 1.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.6in; text-align: justify; text-indent: 0in;"&gt;Level 1 -&lt;/td&gt;
    &lt;td style="padding-left: 0in; text-align: justify; text-indent: 0in;"&gt;Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; text-indent: 0in;"&gt;Level 2 -&lt;/td&gt;
    &lt;td style="text-align: justify; text-indent: 0in;"&gt;Include other inputs that are directly or indirectly observable in the marketplace.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; text-indent: 0in;"&gt;Level 3 -&lt;/td&gt;
    &lt;td style="text-align: justify; text-indent: 0in;"&gt;Unobservable inputs which are supported by little or no market activity&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The fair value hierarchy also requires
an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value&lt;span style="font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The carrying amounts of cash and cash
equivalents, restricted cash, short-term deposits, long-term deposits, prepaid expenses and other current assets, trade payables, accrued
expenses and other current and non-current liabilities approximate their fair value due to the short-term maturity of such instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;The
fair value measurement of the FCA (as defined in Note 7) is measured using unobservable inputs that require a high level of judgment to
determine fair value, and thus is classified as a Level&#160;3 financial instrument. The Company estimates the fair value of the abovementioned
instrument using the Monte-Carlo simulation and the Black-Scholes option pricing model.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;Fair
value estimates are made at a specific point in time, based on relevant market information and information about the financial instruments.
These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined
with precision. Changes in assumptions could significantly affect these estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;q.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Derivative financial instruments:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company accounts
for derivatives based on ASC 815. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The Company
enters into option and forward contracts in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred
in NIS. Since the derivative instruments that the Company holds were not designated as hedging instruments under ASC 815, any gain or
loss derived from such instruments is recognized immediately as &#x201c;financial (income) expense, net&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.6pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company measured the fair value
of the contracts in accordance with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs
are based on quoted prices and market observable data of similar instruments. As of December 31, 2022 and 2021, the fair value of the
options and forward contracts was ($12) and $28, respectively, which were
presented as Accrued expenses and other current liabilities and Prepaid expenses and other current assets, respectively. Financial expense
(income) for the years ended December 31, 2022, 2021 and 2020, amounted to $273, ($58) and&#160;($81), respectively.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;r.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Income taxes:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company accounts
for income taxes in accordance with ASC No. 740, &#x201c;&lt;i&gt;Income Taxes&lt;/i&gt;&#x201d; (&#x201c;ASC 740&#x201d;). ASC 740 prescribes the use of
the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial
reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the
differences are expected to reverse. The Company provides a valuation allowance to reduce deferred tax assets to their estimated realizable
value, if needed.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;ASC 740 contains
a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position
taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than
not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals
or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized
upon ultimate settlement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;As of December&#160;31,
2022 and 2021, the Company&#x2019;s uncertain tax position liability was immaterial.	The Company&#x2019;s policy is to accrue interest and penalties
related to unrecognized tax benefits in its taxes on income.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;s.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Revenue recognition:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company recognizes
revenue from contracts with customers under ASC No. 606, &#x201c;&lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;&#x201d;. Accordingly, the Company
recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it
expects to be entitled in exchange for those goods or services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;To determine revenue
recognition for contracts with customers, the Company performs the following five steps:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;(i) identify the
contract(s) with a customer;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;(ii) identify the
performance obligations in the contract;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;(iii) determine
the transaction price;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;(iv) allocate the
transaction price to the performance obligations in the contract; and&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;(v) recognize revenue
when (or as) the Company satisfies its performance obligations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;At contract inception,
the Company assesses the goods or services agreed upon within each contract and assesses whether each good or service is distinct to determine
the performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;On August 2, 2022,
the Company entered into a license, distribution and supply agreement (the &#x201c;Agreement&#x201d;) with Mercury Pharma Group Limited, under
the trade name Advanz Pharma Holdings
(the &#x201c;Customer&#x201d;), with respect to the Company&#x2019;s product, the D-PLEX&lt;sub&gt;100&lt;/sub&gt; (the &#x201c;Product&#x201d;), for the prevention
of (i) post abdominal surgery incisional infection; and/or (ii) post cardiac surgery sternal infection.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The term of the
Agreement is until the later of December 31, 2035, or 10 years after the first commercial sale of the Product. The Agreement can also
be terminated by either party under certain limited circumstances. Pursuant to the Agreement, the Customer was granted an exclusive license
to market, commercialize, and distribute the Product in the European Economic Area and in the United Kingdom. Under the Agreement, the
Company will carry out all activities required to obtain marketing authorization in each territory, approving the commercial sale of the
Product in that territory. Once marketing authorization will be granted in a territory, the Customer will be required to achieve minimum
sales requirements for that territory.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Under the terms
of the Agreement, the Company received a non-refundable, one-time payment of &#x20ac;2.5 million (approximately $2,548). The Company is
also entitled to receive additional development-related milestones payments for a total of up to &#x20ac;23 million.
In addition, the Company will be entitled to receive up to additional &#x20ac;87 million upon achievement of certain
commercial sale milestones.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company has
concluded that the Agreement includes a single performance obligation. The Company has concluded that the license and development are
not distinct from the manufacturing since the Customer could not use, consume, or sell the license and development services on their own
or with resources readily available to the Customer because of the Company&#x2019;s specialized knowledge and the associated manufacturing know-how
and because currently, and in the foreseeable future, there are no other parties that could manufacture the Product. As such, the transaction
price was fully allocated to the single performance obligation. Since it is not probable that a significant reversal in the amount of
cumulative revenue recognized will not occur when the uncertainty associated with the milestone payments is resolved, the Company estimated
the transaction price at &#x20ac;2.5 million (approximately $2,548).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;As of December 31,
2022, the Company has yet to satisfy its performance obligation under the Agreement and, therefore, no revenues were recognized. Accordingly,
the upfront payment amount was classified as a long-term deferred revenue in the Company&#x2019;s consolidated balance sheet as of December 31,
2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in; text-align: left"&gt;t.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Concentration of credit risks:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Financial instruments
that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and short-term deposits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Cash, cash equivalents,
restricted cash and short-term deposits are deposited in major banks in Israel and in the United States of America. Such investments may
be in excess of insured limits or not insured. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal
risk.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company utilizes
option and forward contracts to protect against the risk of overall changes in exchange rates. The derivative instruments hedge a portion
of the Company&#x2019;s non-dollar currency exposure. Counterparties to the Company&#x2019;s derivative instruments are all major financial institutions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;u.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Severance pay:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;All the Company&#x2019;s
employees who are Israeli citizens have subscribed to Section&#160;14 of Israel&#x2019;s Severance Pay Law, 5723-1963 (&#x201c;Section&#160;14&#x201d;).
Pursuant to Section&#160;14, employees covered by this section are entitled to monthly deposits at a rate of 8.33% of their monthly salary,
made on their behalf by the Company. Payments in accordance with Section&#160;14 release the Company from any future severance liabilities
in respect of those employees. Neither severance pay liability nor severance pay fund under Section&#160;14 for such employees is recorded
on the Company&#x2019;s consolidated balance sheets. Severance pay expense for the years ended December 31, 2022, 2021 and 2020, amounted to
$537, $547 and $394, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The US Subsidiary
has a Safe Harbor 401(k) plan covering all the US Subsidiary employees. All eligible employees may elect to contribute up to 100% of their
payroll compensation (minus mandatory payroll deductions) to the plan, for 2022, up to a maximum of $20,500 per year (for employees over
50 years of age the maximum contribution was $28,000 per year), as determined by the U.S. Internal Revenue Service (&#x201c;IRS&#x201d;).
The US Subsidiary matches at 100%, on each payroll, up to 5% of the employee compensation to the plan within the IRS limits (which was
set at $300 in 2022 for purposes of the plan). During the year ended December 31, 2022, the Company recorded expenses for matching contributions
in the amount of $30, as compared to $28 in 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;v.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Contingent liabilities:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company accounts
for its contingent liabilities in accordance with ASC No. 450, &#x201c;&lt;i&gt;Contingencies&lt;/i&gt;&#x201d;. A provision is recorded when it is both
probable that a liability has been incurred and the amount of the loss can be reasonably estimated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;With respect to
legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice
of legal counsel and other information and events pertaining to a particular matter. The Company is occasionally a party to routine claims
or litigation incidental to its business. The Company does not believe that it is a party to any pending legal proceeding that is likely
to have a material adverse effect on its business, financial condition or results of operations. The Company recorded an accrual in the
consolidated statement of operations, which it deems appropriate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;As of December 31,
2022 and 2021, no liability due to legal matters has been accrued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;w.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Recently adopted accounting pronouncements:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;As an &#x201c;Emerging
Growth Company&#x201d;, the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;) allows the Company to delay adoption of new or
revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The
Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election&lt;span style="font-family: Times New Roman, Times, Serif"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;On January 1, 2022,
the Company adopted ASC 842. Upon adoption, we recognized total ROU assets and corresponding liabilities of $3,388&#160;on our consolidated
balance sheets. The ROU assets include adjustments for prepayments and accrued lease payments. The adoption did not impact the beginning
balance of retained earnings, or prior year consolidated statements of operations and statements of cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;For information
regarding the impact of ASC 842 adoption, see Note 2.i and Note 5 - Leases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.3pt"&gt;In December 2019,
the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2019-12, &#x201c;&lt;i&gt;Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/i&gt;&#x201d; (ASU 2019-12), which simplifies the accounting for income taxes.
The guidance is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted. The Company
has adopted ASU 2019-12 as of January 1, 2022. The impact of adoption of this standard on the Company&#x2019;s consolidated financial statements
was immaterial.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.3pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In August 2020, the FASB issued ASU
No. 2020-06, &#x201c;&lt;i&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s
Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;&#x201d; (&#x201c;ASU
2020-06&#x201d;), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP.
The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception,
and it simplifies the diluted earnings per share calculation in certain areas. The Company adopted ASU 2020-06 on January 1, 2022. The
adoption of the standard did not result in a material impact to the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;x.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Recently issued accounting pronouncements, not yet adopted:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In June 2016, the FASB issued ASU No.
2016-13, &#x201c;&lt;i&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;,&#x201d;
which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured
at amortized cost to be presented at the net amount expected to be collected. The guidance will be effective for the Company beginning
January 1, 2023, and interim periods thereafter. The Company adopted ASU 2016-13 on January 1, 2023. The adoption of the standard did
not result in a material impact to the Company&#x2019;s consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;a.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Use of estimates:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company&#x2019;s management
believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made.
These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting
periods. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <pypd:ConsolidatedFinancialStatementsPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;b.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Consolidated financial statements in U.S.&#160;dollars:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The accompanying consolidated financial
statements have been prepared in United States of America dollars (&#x201c;USD&#x201d;, &#x201c;$&#x201d; or &#x201c;U.S. dollars&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A substantial portion of the Company&#x2019;s
expenses are incurred in New Israeli Shekels (&#x201c;NIS&#x201d;). However, the Company finances its operations mainly in U.S. dollars,
a substantial portion of its expenses are incurred in U.S. dollars and potential revenues from its primary markets are anticipated to
be generated in U.S. dollars. As such, the Company&#x2019;s management believes that the U.S. dollar is the currency of the primary economic
environment in which the Company and its subsidiaries operate. Thus, the functional and reporting currency of the Company is the U.S.
dollar.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the dollar are re-measured
into U.S. dollars in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) No. 830, &#x201c;&lt;i&gt;Foreign Currency Matters&lt;/i&gt;&#x201d;.
All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the statements of operations as
financial income or expenses, as appropriate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;</pypd:ConsolidatedFinancialStatementsPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;c.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Principles of consolidation:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The consolidated
financial statements include the accounts of the Company and its subsidiaries. Intercompany balances have been eliminated upon consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;d.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Cash equivalents:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Cash equivalents
are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or less, at
the date acquired.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <pypd:RestrictedCashPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;e.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Restricted cash:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Restricted cash
is primarily invested in a bank deposit and is used as security for the Company&#x2019;s lease commitments and for its forward and options transactions
activities (see Note 2q).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;</pypd:RestrictedCashPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;f.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Segment reporting:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company
identifies operating segments in accordance with ASC No. 280, &#x201c;&lt;i&gt;Segment Reporting&lt;/i&gt;&#x201d;, as components of an entity for which
discrete financial information is available and is regularly reviewed by the chief operating decision maker, or decision-making group,
in making decisions regarding resource allocation and evaluating financial performance. The Company&#x2019;s chief operating decision maker is
its chief executive officer. The Company determined it operates in one operating segment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <pypd:ShorttermDepositsPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;g.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Short-term deposits:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;A short-term bank deposit is a deposit
with a maturity of more than three months, but less than one year. Deposits in U.S. dollars bear interest at rates ranging from 4.55%-5.90%,
per annum, as of December 31, 2022. Short-term deposits are presented at cost, which approximates market value due to their short maturities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.75pt; text-align: justify"&gt;&#160;&lt;/p&gt;</pypd:ShorttermDepositsPolicyTextBlock>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate contextRef="c48" decimals="4" unitRef="pure">0.0455</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate contextRef="c49" decimals="4" unitRef="pure">0.059</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;h.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Property and equipment, net:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Property and equipment
are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful
lives of the assets at the following rates:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 77%; text-align: justify"&gt;Computers and software&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: center; padding-left: 0.05in"&gt;33&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0.05in"&gt;10&#160;-&#160;15&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0.05in"&gt;15&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: center; padding-left: 0.05in"&gt;Over the shorter of the term of the lease or its useful life&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 77%; text-align: justify"&gt;Computers and software&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 22%; text-align: center; padding-left: 0.05in"&gt;33&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0.05in"&gt;10&#160;-&#160;15&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 0.05in"&gt;15&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -0.1in; padding-left: 0.1in"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: center; padding-left: 0.05in"&gt;Over the shorter of the term of the lease or its useful life&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock>
    <pypd:ComputersandSoftware contextRef="c0" decimals="2" unitRef="pure">0.33</pypd:ComputersandSoftware>
    <pypd:LaboratoryAndManufacturingEquipment contextRef="c52" decimals="2" unitRef="pure">0.10</pypd:LaboratoryAndManufacturingEquipment>
    <pypd:LaboratoryAndManufacturingEquipment contextRef="c53" decimals="2" unitRef="pure">0.15</pypd:LaboratoryAndManufacturingEquipment>
    <pypd:PropertyPlantAndEquipmentPercent contextRef="c0" decimals="2" unitRef="pure">0.15</pypd:PropertyPlantAndEquipmentPercent>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="c0">Over the shorter of the term of the lease or its useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;i.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Leases:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;On January 1, 2022,
the Company adopted ASC No. 842, &#x201c;&lt;i&gt;Leases&lt;/i&gt;&#x201d; (&#x201c;ASC 842&#x201d;), using the modified retrospective method&#160;by applying
the new standard to all leases existing at the date of initial application. Results and disclosure requirements for reporting periods
beginning after January 1, 2022, are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported
in accordance with the Company&#x2019;s historical accounting under ASC No. 840, &#x201c;&lt;i&gt;Leases&lt;/i&gt;&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company has
elected the package of practical expedients permitted under the transition guidance, which allows the Company not to reassess: (1) whether
any existing contracts as of the adoption date are or contain a lease under ASC 842, (2) lease classification for any existing leases
as of the adoption date, and (3) initial direct costs for any existing leases as of the adoption date. Lastly, the Company also elected
the practical expedient to not separate lease and non-lease components for its leases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;As a result of the
adoption of ASC 842 on January 1, 2022, the Company recorded both operating leases right-of-use (&#x201c;ROU&#x201d;) assets and operating
lease liabilities of $3,388.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The ROU assets include
adjustments for lease prepayments in the amount of $36. The adoption did not impact the Company&#x2019;s beginning accumulated deficit,
or its prior year consolidated statements of operations and statements of cash flows. The adoption did not have a material impact on the
Company&#x2019;s current year consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Leases are classified
as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the
lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably
certain to be exercised, the lease term is for a major part of the remaining useful life of the asset, the present value of the lease
payments equals or exceeds substantially all of the fair value of the asset, or the underlying asset is of such a specialized nature that
it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does
not meet any one of these criteria. Since all of the Company&#x2019;s lease contracts do not meet any of the criteria above, the Company
concluded that all of its lease contracts should be classified as operating leases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;ROU assets
and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For
this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company&#x2019;s
leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available on the commencement
date in determining the present value of lease payments. All ROU assets are reviewed for impairment. The lease terms may include options
to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <pypd:RighttouseAssetsAndLeaseLiabilities contextRef="c50" decimals="-3" unitRef="usd">3388000</pypd:RighttouseAssetsAndLeaseLiabilities>
    <pypd:LeasePrepayments contextRef="c51" decimals="-3" unitRef="usd">36000</pypd:LeasePrepayments>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;j.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Impairment of long-lived assets:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company&#x2019;s long-lived
assets are reviewed for impairment in accordance with ASC No. 360, &#x201c;&lt;i&gt;Property, Plant and Equipment&lt;/i&gt;&#x201d;, whenever events or
changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held
and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated
by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying
amount of the asset exceeds its fair value. As of December 31, 2022 and 2021, no impairment losses have been identified.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;k.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Research and development, net expenses:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Research and development
expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments
to subcontractors, chemical, manufacturing and control activities, costs associated with obtaining regulatory approvals, executing pre-clinical
and clinical studies and maintenance and prosecution of the Company&#x2019;s intellectual property rights. In addition, research and development
expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research
and development expenses as expenses when incurred and are presented net of government grants (see Note 2.l).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;l.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Grants and participations:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Royalty-bearing grants from the Israeli
Innovation Authority (&#x201c;IIA&#x201d;) of the Ministry of Economy and Industry in Israel for funding of approved research and development
projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a
deduction from research and development expenses. Non-royalty-bearing grants from the IIA MAGNET program and from European Commission&#x2019;s
Seventh Framework Programme for Research (&#x201c;FP7&#x201d;) for funding approved research and development projects are recognized at
the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and
development expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Since the payment
of royalties is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until
the related revenues are recognized.&#160;In the event of failure of a project that was partly financed by IIA, the Company will not be
obligated to pay any royalties or repay the amounts received.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company recognizes
participations in research and development, as a reduction from research and development expenses in the amount of $738 and $542 for the
years ended December 31, 2022, and 2021, respectively (no grants were received for the year ended December 31, 2020).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;From inception up
until December 31, 2022, the Company received a total of $7,193 in grants, out of which royalty-bearing grants in the amount of $4,888
from the IIA, non-royalty bearing grants in the amount of $1,578 from the IIA (out of which $521 were received during the year ended December
31, 2022) and non-royalty bearing grants in the amount of $727 from the FP7.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">738000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c4" decimals="-3" unitRef="usd">542000</us-gaap:OtherResearchAndDevelopmentExpense>
    <pypd:ReceivedTotalAmount contextRef="c0" decimals="-3" unitRef="usd">7193000</pypd:ReceivedTotalAmount>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="c2" decimals="-3" unitRef="usd">4888000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <pypd:NonroyaltyBearingGrantsAmount contextRef="c0" decimals="-3" unitRef="usd">1578000</pypd:NonroyaltyBearingGrantsAmount>
    <pypd:OutOfReceivedAmount contextRef="c0" decimals="-3" unitRef="usd">521000</pypd:OutOfReceivedAmount>
    <pypd:NonroyaltyBearingGrants contextRef="c0" decimals="-3" unitRef="usd">727000</pypd:NonroyaltyBearingGrants>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;m.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Accounting for share-based compensation:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Share-based compensation
expense related to share-based awards is recognized based on the fair value of the awards granted and recognized as an expense on a straight-line
basis over the requisite service period for share options. The fair value of each option award is estimated on the grant date using the
Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including
the expected term of the award, the expected volatility of the price of the Company&#x2019;s Ordinary shares, risk-free interest rates,
and the expected dividend yield of Ordinary shares. The assumptions used to determine the fair value of the share awards represent management&#x2019;s
best estimates. These estimates involve inherent uncertainties and the application of management&#x2019;s judgment. Forfeitures are accounted
for as they occur instead of estimating the number of awards expected to be forfeited.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <pypd:BasicAndDilutedLossPerSharePolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;n.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Basic and diluted net loss per share:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Prior to the Company&#x2019;s
IPO, the Company computed its net loss per share using the two-class method required for participating securities. The two-class method
requires income available to Ordinary shareholders for the period to be allocated between Ordinary shares and participating securities
based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considered its
convertible preferred shares to be participating securities as the holders of the convertible preferred shares would be entitled to dividends
that would be distributed to the holders of Ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities
did not contractually require the holders of such shares to participate in the Company&#x2019;s losses.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;As such,&#160;during
the periods when the Company is in a loss position, the loss attributable to Ordinary shareholders was not allocated to the convertible
preferred shares under the two-class method as these securities did not have a contractual obligation to share in the Company&#x2019;s
losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Following the Company&#x2019;s
IPO, the Company&#x2019;s basic net loss per share is calculated by dividing the net loss attributable to Ordinary shareholders by the
weighted-average number of shares of Ordinary shares outstanding for the period, without consideration of potentially dilutive securities.
The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using
the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as
basic net loss per share in periods when the effects of potentially dilutive shares of Ordinary shares are anti-dilutive.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;</pypd:BasicAndDilutedLossPerSharePolicyTextBlock>
    <pypd:ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;o.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Convertible preferred shares and convertible preferred shares warrant liability:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The terms of the
convertible preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1&#160;shares allowed the holders to redeem shares, under certain circumstances,
outside of the Company&#x2019;s control. Therefore, these shares were classified as mezzanine equity on the balance sheet and not included as
a component of shareholders&#x2019; deficit before the IPO. The Company did not adjust the preferred shares&#x2019; carrying value to the redemption
value since redemption was not probable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Following the Company&#x2019;s
IPO, the convertible preferred shares were converted into Ordinary shares and were reclassified into permanent equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Warrants to purchase the Company&#x2019;s
convertible preferred shares were classified as a liability on the balance sheet, and measured at fair value, as the underlying shares
are contingently redeemable (upon a deemed liquidation event) and, therefore, may obligate the Company to transfer assets at some point
in the future. The warrants were subject to re-measurement to fair value at each balance sheet date and any change in fair value was recognized
as a component of financial expenses, net, in the statements of operation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Following the Company&#x2019;s IPO,
the warrants can only be exercised into the Company&#x2019;s ordinary equity shares. Consequently, as of the IPO date, the Company reclassified
the warrants as equity since the warrants are not an ASC No. 480, &#x201c;&lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;&#x201d; (&#x201c;ASC
480&#x201d;), liability, are indexed to the Company&#x2019;s own stock and can be classified as equity pursuant to ASC No. 815-40, &#x201c;&lt;i&gt;Derivatives
and Hedging&lt;/i&gt;&#x201d; (&#x201c;ASC 815&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;</pypd:ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;p.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Fair value of financial instruments:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company applies
ASC No. 820, &#x201c;&lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;&#x201d; (&#x201c;ASC 820&#x201d;), pursuant to which fair value is defined
as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly
transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches.
ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the
use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market
participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Unobservable inputs
are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset or liability
developed based on the best information available in the circumstances.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Fair value is an
exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction
between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market
participants would use in pricing an asset or a liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;A three-tier fair
value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring
fair value:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 1.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.6in; text-align: justify; text-indent: 0in;"&gt;Level 1 -&lt;/td&gt;
    &lt;td style="padding-left: 0in; text-align: justify; text-indent: 0in;"&gt;Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; text-indent: 0in;"&gt;Level 2 -&lt;/td&gt;
    &lt;td style="text-align: justify; text-indent: 0in;"&gt;Include other inputs that are directly or indirectly observable in the marketplace.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify; text-indent: 0in;"&gt;Level 3 -&lt;/td&gt;
    &lt;td style="text-align: justify; text-indent: 0in;"&gt;Unobservable inputs which are supported by little or no market activity&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The fair value hierarchy also requires
an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value&lt;span style="font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The carrying amounts of cash and cash
equivalents, restricted cash, short-term deposits, long-term deposits, prepaid expenses and other current assets, trade payables, accrued
expenses and other current and non-current liabilities approximate their fair value due to the short-term maturity of such instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;The
fair value measurement of the FCA (as defined in Note 7) is measured using unobservable inputs that require a high level of judgment to
determine fair value, and thus is classified as a Level&#160;3 financial instrument. The Company estimates the fair value of the abovementioned
instrument using the Monte-Carlo simulation and the Black-Scholes option pricing model.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span&gt;Fair
value estimates are made at a specific point in time, based on relevant market information and information about the financial instruments.
These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined
with precision. Changes in assumptions could significantly affect these estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;q.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Derivative financial instruments:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company accounts
for derivatives based on ASC 815. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The Company
enters into option and forward contracts in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred
in NIS. Since the derivative instruments that the Company holds were not designated as hedging instruments under ASC 815, any gain or
loss derived from such instruments is recognized immediately as &#x201c;financial (income) expense, net&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.6pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company measured the fair value
of the contracts in accordance with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs
are based on quoted prices and market observable data of similar instruments. As of December 31, 2022 and 2021, the fair value of the
options and forward contracts was ($12) and $28, respectively, which were
presented as Accrued expenses and other current liabilities and Prepaid expenses and other current assets, respectively. Financial expense
(income) for the years ended December 31, 2022, 2021 and 2020, amounted to $273, ($58) and&#160;($81), respectively.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="c0" decimals="-3" unitRef="usd">-12000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="c4" decimals="-3" unitRef="usd">28000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <pypd:FinancialExpenseIncome contextRef="c0" decimals="-3" unitRef="usd">273000</pypd:FinancialExpenseIncome>
    <pypd:FinancialExpenseIncome contextRef="c4" decimals="-3" unitRef="usd">-58000</pypd:FinancialExpenseIncome>
    <pypd:FinancialExpenseIncome contextRef="c5" decimals="-3" unitRef="usd">-81000</pypd:FinancialExpenseIncome>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;r.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Income taxes:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company accounts
for income taxes in accordance with ASC No. 740, &#x201c;&lt;i&gt;Income Taxes&lt;/i&gt;&#x201d; (&#x201c;ASC 740&#x201d;). ASC 740 prescribes the use of
the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial
reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the
differences are expected to reverse. The Company provides a valuation allowance to reduce deferred tax assets to their estimated realizable
value, if needed.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;ASC 740 contains
a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position
taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than
not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals
or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized
upon ultimate settlement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;As of December&#160;31,
2022 and 2021, the Company&#x2019;s uncertain tax position liability was immaterial.	The Company&#x2019;s policy is to accrue interest and penalties
related to unrecognized tax benefits in its taxes on income.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <pypd:TaxBenefitPercentage contextRef="c2" decimals="2" unitRef="pure">0.50</pypd:TaxBenefitPercentage>
    <us-gaap:RevenueRecognitionAllowances contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;s.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Revenue recognition:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company recognizes
revenue from contracts with customers under ASC No. 606, &#x201c;&lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;&#x201d;. Accordingly, the Company
recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it
expects to be entitled in exchange for those goods or services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;To determine revenue
recognition for contracts with customers, the Company performs the following five steps:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;(i) identify the
contract(s) with a customer;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;(ii) identify the
performance obligations in the contract;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;(iii) determine
the transaction price;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;(iv) allocate the
transaction price to the performance obligations in the contract; and&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;(v) recognize revenue
when (or as) the Company satisfies its performance obligations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;At contract inception,
the Company assesses the goods or services agreed upon within each contract and assesses whether each good or service is distinct to determine
the performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;On August 2, 2022,
the Company entered into a license, distribution and supply agreement (the &#x201c;Agreement&#x201d;) with Mercury Pharma Group Limited, under
the trade name Advanz Pharma Holdings
(the &#x201c;Customer&#x201d;), with respect to the Company&#x2019;s product, the D-PLEX&lt;sub&gt;100&lt;/sub&gt; (the &#x201c;Product&#x201d;), for the prevention
of (i) post abdominal surgery incisional infection; and/or (ii) post cardiac surgery sternal infection.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The term of the
Agreement is until the later of December 31, 2035, or 10 years after the first commercial sale of the Product. The Agreement can also
be terminated by either party under certain limited circumstances. Pursuant to the Agreement, the Customer was granted an exclusive license
to market, commercialize, and distribute the Product in the European Economic Area and in the United Kingdom. Under the Agreement, the
Company will carry out all activities required to obtain marketing authorization in each territory, approving the commercial sale of the
Product in that territory. Once marketing authorization will be granted in a territory, the Customer will be required to achieve minimum
sales requirements for that territory.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Under the terms
of the Agreement, the Company received a non-refundable, one-time payment of &#x20ac;2.5 million (approximately $2,548). The Company is
also entitled to receive additional development-related milestones payments for a total of up to &#x20ac;23 million.
In addition, the Company will be entitled to receive up to additional &#x20ac;87 million upon achievement of certain
commercial sale milestones.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company has
concluded that the Agreement includes a single performance obligation. The Company has concluded that the license and development are
not distinct from the manufacturing since the Customer could not use, consume, or sell the license and development services on their own
or with resources readily available to the Customer because of the Company&#x2019;s specialized knowledge and the associated manufacturing know-how
and because currently, and in the foreseeable future, there are no other parties that could manufacture the Product. As such, the transaction
price was fully allocated to the single performance obligation. Since it is not probable that a significant reversal in the amount of
cumulative revenue recognized will not occur when the uncertainty associated with the milestone payments is resolved, the Company estimated
the transaction price at &#x20ac;2.5 million (approximately $2,548).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;As of December 31,
2022, the Company has yet to satisfy its performance obligation under the Agreement and, therefore, no revenues were recognized. Accordingly,
the upfront payment amount was classified as a long-term deferred revenue in the Company&#x2019;s consolidated balance sheet as of December 31,
2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionAllowances>
    <pypd:AgreementTerm contextRef="c0">P10Y</pypd:AgreementTerm>
    <pypd:NonRefundableAmount contextRef="c0" decimals="-5" unitRef="eur">2500000</pypd:NonRefundableAmount>
    <pypd:NonRefundableAmount contextRef="c0" decimals="-3" unitRef="usd">2548000</pypd:NonRefundableAmount>
    <pypd:AdditionalDevelopmentrelatedMilestonesPayments contextRef="c0" decimals="-6" unitRef="eur">23000000</pypd:AdditionalDevelopmentrelatedMilestonesPayments>
    <pypd:AdditionalAmountOfCommercialSaleMilestones contextRef="c0" decimals="-6" unitRef="eur">87000000</pypd:AdditionalAmountOfCommercialSaleMilestones>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c2" decimals="-5" unitRef="eur">2500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c2" decimals="-3" unitRef="usd">2548000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in; text-align: left"&gt;t.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Concentration of credit risks:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Financial instruments
that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and short-term deposits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Cash, cash equivalents,
restricted cash and short-term deposits are deposited in major banks in Israel and in the United States of America. Such investments may
be in excess of insured limits or not insured. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal
risk.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company utilizes
option and forward contracts to protect against the risk of overall changes in exchange rates. The derivative instruments hedge a portion
of the Company&#x2019;s non-dollar currency exposure. Counterparties to the Company&#x2019;s derivative instruments are all major financial institutions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <pypd:SeverancePayPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;u.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Severance pay:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;All the Company&#x2019;s
employees who are Israeli citizens have subscribed to Section&#160;14 of Israel&#x2019;s Severance Pay Law, 5723-1963 (&#x201c;Section&#160;14&#x201d;).
Pursuant to Section&#160;14, employees covered by this section are entitled to monthly deposits at a rate of 8.33% of their monthly salary,
made on their behalf by the Company. Payments in accordance with Section&#160;14 release the Company from any future severance liabilities
in respect of those employees. Neither severance pay liability nor severance pay fund under Section&#160;14 for such employees is recorded
on the Company&#x2019;s consolidated balance sheets. Severance pay expense for the years ended December 31, 2022, 2021 and 2020, amounted to
$537, $547 and $394, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The US Subsidiary
has a Safe Harbor 401(k) plan covering all the US Subsidiary employees. All eligible employees may elect to contribute up to 100% of their
payroll compensation (minus mandatory payroll deductions) to the plan, for 2022, up to a maximum of $20,500 per year (for employees over
50 years of age the maximum contribution was $28,000 per year), as determined by the U.S. Internal Revenue Service (&#x201c;IRS&#x201d;).
The US Subsidiary matches at 100%, on each payroll, up to 5% of the employee compensation to the plan within the IRS limits (which was
set at $300 in 2022 for purposes of the plan). During the year ended December 31, 2022, the Company recorded expenses for matching contributions
in the amount of $30, as compared to $28 in 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;</pypd:SeverancePayPolicyTextBlock>
    <pypd:monthlyDepositsAtARate contextRef="c2" decimals="4" unitRef="pure">0.0833</pypd:monthlyDepositsAtARate>
    <pypd:SeverancePayExpenseAmount contextRef="c0" decimals="-3" unitRef="usd">537000</pypd:SeverancePayExpenseAmount>
    <pypd:SeverancePayExpenseAmount contextRef="c4" decimals="-3" unitRef="usd">547000</pypd:SeverancePayExpenseAmount>
    <pypd:SeverancePayExpenseAmount contextRef="c5" decimals="-3" unitRef="usd">394000</pypd:SeverancePayExpenseAmount>
    <pypd:SeverancePay contextRef="c2">All eligible employees may elect to contribute up to 100% of their
payroll compensation (minus mandatory payroll deductions) to the plan, for 2022, up to a maximum of $20,500 per year (for employees over
50 years of age the maximum contribution was $28,000 per year), as determined by the U.S. Internal Revenue Service (&#x201c;IRS&#x201d;).
The US Subsidiary matches at 100%, on each payroll, up to 5% of the employee compensation to the plan within the IRS limits (which was
set at $300 in 2022 for purposes of the plan).</pypd:SeverancePay>
    <pypd:MatchingContributionsAmounts contextRef="c0" decimals="-3" unitRef="usd">30000</pypd:MatchingContributionsAmounts>
    <pypd:MatchingContributionsAmounts contextRef="c4" decimals="-3" unitRef="usd">28000</pypd:MatchingContributionsAmounts>
    <us-gaap:ContingentLiabilityReserveEstimatePolicy contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;v.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Contingent liabilities:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Company accounts
for its contingent liabilities in accordance with ASC No. 450, &#x201c;&lt;i&gt;Contingencies&lt;/i&gt;&#x201d;. A provision is recorded when it is both
probable that a liability has been incurred and the amount of the loss can be reasonably estimated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;With respect to
legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice
of legal counsel and other information and events pertaining to a particular matter. The Company is occasionally a party to routine claims
or litigation incidental to its business. The Company does not believe that it is a party to any pending legal proceeding that is likely
to have a material adverse effect on its business, financial condition or results of operations. The Company recorded an accrual in the
consolidated statement of operations, which it deems appropriate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;As of December 31,
2022 and 2021, no liability due to legal matters has been accrued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;</us-gaap:ContingentLiabilityReserveEstimatePolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;w.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Recently adopted accounting pronouncements:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;As an &#x201c;Emerging
Growth Company&#x201d;, the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;) allows the Company to delay adoption of new or
revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The
Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election&lt;span style="font-family: Times New Roman, Times, Serif"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;On January 1, 2022,
the Company adopted ASC 842. Upon adoption, we recognized total ROU assets and corresponding liabilities of $3,388&#160;on our consolidated
balance sheets. The ROU assets include adjustments for prepayments and accrued lease payments. The adoption did not impact the beginning
balance of retained earnings, or prior year consolidated statements of operations and statements of cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;For information
regarding the impact of ASC 842 adoption, see Note 2.i and Note 5 - Leases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.3pt"&gt;In December 2019,
the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2019-12, &#x201c;&lt;i&gt;Income
Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/i&gt;&#x201d; (ASU 2019-12), which simplifies the accounting for income taxes.
The guidance is effective for interim and annual periods beginning after December 15, 2021, with early adoption permitted. The Company
has adopted ASU 2019-12 as of January 1, 2022. The impact of adoption of this standard on the Company&#x2019;s consolidated financial statements
was immaterial.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.3pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In August 2020, the FASB issued ASU
No. 2020-06, &#x201c;&lt;i&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s
Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;&#x201d; (&#x201c;ASU
2020-06&#x201d;), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP.
The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception,
and it simplifies the diluted earnings per share calculation in certain areas. The Company adopted ASU 2020-06 on January 1, 2022. The
adoption of the standard did not result in a material impact to the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount contextRef="c2" decimals="0" unitRef="usd">3388</us-gaap:ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount>
    <pypd:RecentlyIssuedAccountingPronouncementsNotYetAdopted contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;x.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Recently issued accounting pronouncements, not yet adopted:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In June 2016, the FASB issued ASU No.
2016-13, &#x201c;&lt;i&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;,&#x201d;
which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured
at amortized cost to be presented at the net amount expected to be collected. The guidance will be effective for the Company beginning
January 1, 2023, and interim periods thereafter. The Company adopted ASU 2016-13 on January 1, 2023. The adoption of the standard did
not result in a material impact to the Company&#x2019;s consolidated financial statements.&lt;/p&gt;</pypd:RecentlyIssuedAccountingPronouncementsNotYetAdopted>
    <pypd:PrepaidExpensesAndOtherReceivablesTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0pt"/&gt;&lt;td style="width: 0.75in; text-align: left"&gt;NOTE 3:-&lt;/td&gt;&lt;td style="text-align: justify"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;552&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,453&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;596&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Lease deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;298&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 2.85pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 2.85pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,089&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,211&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</pypd:PrepaidExpensesAndOtherReceivablesTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;552&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,453&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Government authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;596&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Lease deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;298&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 2.85pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 2.85pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,089&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,211&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="c54" decimals="-3" unitRef="usd">552000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="c55" decimals="-3" unitRef="usd">1453000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <pypd:GovernmentAuthorities contextRef="c54" decimals="-3" unitRef="usd">239000</pypd:GovernmentAuthorities>
    <pypd:GovernmentAuthorities contextRef="c55" decimals="-3" unitRef="usd">596000</pypd:GovernmentAuthorities>
    <us-gaap:LeaseDepositLiability contextRef="c55" decimals="-3" unitRef="usd">44000</us-gaap:LeaseDepositLiability>
    <us-gaap:OtherAssetsCurrent contextRef="c54" decimals="-3" unitRef="usd">298000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c55" decimals="-3" unitRef="usd">118000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c54" decimals="-3" unitRef="usd">1089000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c55" decimals="-3" unitRef="usd">2211000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0pt"/&gt;&lt;td style="width: 0.75in; text-align: left"&gt;NOTE 4:-&lt;/td&gt;&lt;td style="text-align: justify"&gt;PROPERTY AND EQUIPMENT, NET&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Computers and software&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;613&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;577&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,933&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;173&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,503&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,015&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,975&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,254&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Depreciated cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,247&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,761&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Depreciation expenses amounted to $1,721,
$1,118 and $1,012 for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The majority of the Company&#x2019;s
property and equipment is located in Israel.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Computers and software&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;613&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;577&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,933&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;173&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,503&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,015&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,975&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,254&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Depreciated cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,247&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,761&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c56" decimals="-3" unitRef="usd">613000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c57" decimals="-3" unitRef="usd">577000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c58" decimals="-3" unitRef="usd">7933000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c59" decimals="-3" unitRef="usd">6247000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c60" decimals="-3" unitRef="usd">173000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c61" decimals="-3" unitRef="usd">167000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c62" decimals="-3" unitRef="usd">6503000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c63" decimals="-3" unitRef="usd">6024000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="-3" unitRef="usd">15222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="-3" unitRef="usd">13015000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" unitRef="usd">5975000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" unitRef="usd">4254000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">9247000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">8761000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" unitRef="usd">1721000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c4" decimals="-3" unitRef="usd">1118000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="-3" unitRef="usd">1012000</us-gaap:Depreciation>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0pt"/&gt;&lt;td style="width: 0.75in; text-align: left"&gt;NOTE 5:-&lt;/td&gt;&lt;td style="text-align: justify"&gt;LEASES&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;a.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The Company&#x2019;s facilities are leased under operating lease agreements for periods ending no later than
2027. The Company has bank guarantees in connection with the facilities lease agreements in the total amount of $213. Accordingly, cash,
in the same amount, was restricted in bank deposits. The Company also leases motor vehicles under various operating leases, the latest
of which expires in 2025.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -21.3pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;b.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The following table summarizes the Company&#x2019;s lease-related assets and liabilities recorded on the
balance sheets:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Classification&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 67%; font-style: italic; text-align: left"&gt;Lease assets:&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Operating lease assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 4pt; padding-left: 5.4pt"&gt;Operating lease ROU assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,431&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; width: 67%; text-align: left"&gt;Current lease liabilities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: center; padding-left: 5.4pt"&gt;Short-term operating lease liabilities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Long-term lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Long-term lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,173&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,132&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted Average Remaining lease term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.37 years&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Weighted Average Discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.95&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;c.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The components of operating lease expense for the year ended December 31, 2022, were $1,344.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -21.3pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;d.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Lease liability as of December 31, 2022, is as follows:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;439&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;385&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;186&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total undiscounted lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less - imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(292&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,132&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;e.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The following table presents supplemental cash flow information related to the lease costs for operating
leases as of December 31, 2022:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Cash paid for amounts included in measurement of lease liability:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 4pt"&gt;Operating cash flows for operating leases&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;1,259&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Right-of-use asset recognized with corresponding lease liability:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Operating leases&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,528&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <us-gaap:CapitalLeasesIndemnificationAgreementsPayments contextRef="c0" decimals="-3" unitRef="usd">213000</us-gaap:CapitalLeasesIndemnificationAgreementsPayments>
    <pypd:ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Classification&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 67%; font-style: italic; text-align: left"&gt;Lease assets:&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Operating lease assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 4pt; padding-left: 5.4pt"&gt;Operating lease ROU assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,431&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; width: 67%; text-align: left"&gt;Current lease liabilities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: center; padding-left: 5.4pt"&gt;Short-term operating lease liabilities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Long-term lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Long-term lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,173&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,132&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted Average Remaining lease term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.37 years&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Weighted Average Discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.95&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;</pypd:ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock>
    <pypd:OperatingLeaseAssets contextRef="c2" decimals="-3" unitRef="usd">2431000</pypd:OperatingLeaseAssets>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" unitRef="usd">959000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c2" decimals="-3" unitRef="usd">1173000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <pypd:LeaseLiabilities contextRef="c2" decimals="-3" unitRef="usd">2132000</pypd:LeaseLiabilities>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2">P3Y4M13D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="4" unitRef="pure">0.0995</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="-3" unitRef="usd">1344000</us-gaap:OperatingLeaseExpense>
    <pypd:ScheduleOfLeaseLiabilityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;439&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;385&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;186&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total undiscounted lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less - imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(292&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,132&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;</pypd:ScheduleOfLeaseLiabilityTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="c2" decimals="-3" unitRef="usd">1047000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="c2" decimals="-3" unitRef="usd">439000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="c2" decimals="-3" unitRef="usd">385000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="c2" decimals="-3" unitRef="usd">367000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="c2" decimals="-3" unitRef="usd">186000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="c2" decimals="-3" unitRef="usd">2424000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:ReceivableWithImputedInterestNetAmount contextRef="c2" decimals="-3" unitRef="usd">292000</us-gaap:ReceivableWithImputedInterestNetAmount>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="c2" decimals="-3" unitRef="usd">2132000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Cash paid for amounts included in measurement of lease liability:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 88%; text-align: left; padding-bottom: 4pt"&gt;Operating cash flows for operating leases&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;1,259&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Right-of-use asset recognized with corresponding lease liability:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Operating leases&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,528&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c0" decimals="-3" unitRef="usd">1259000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="-3" unitRef="usd">3528000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0">&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in"&gt;NOTE 6:- &lt;/td&gt;
  &lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"&gt;ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,246&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,787&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;IIA deferred grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;269&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 2.85pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 2.85pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,429&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,940&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,246&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,787&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;IIA deferred grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;269&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 2.85pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 2.85pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,429&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,940&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">1246000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">1787000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">1167000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">1879000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <pypd:IsraelInnovationAuthorityGrantReceived contextRef="c3" decimals="-3" unitRef="usd">269000</pypd:IsraelInnovationAuthorityGrantReceived>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c2" decimals="-3" unitRef="usd">16000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c3" decimals="-3" unitRef="usd">5000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">2429000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">3940000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <pypd:LineOfCreditArrangementTextBlock contextRef="c0">&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in"&gt;NOTE 7:- &lt;/td&gt;
  &lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"&gt;LINE OF CREDIT ARRANGEMENT&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"&gt;&lt;span style="font-weight: normal"&gt;On
April 5, 2022, the Company entered into a secured line of credit agreement for up to $15,000 (the &#x201c;Credit Line&#x201d;) with Kreos
Capital VI (Expert Fund) LP (&#x201c;Kreos&#x201d;). The Credit Line is comprised of three tranches in the amount of $10,000, $2,500 and
$2,500, respectively, in which the first tranche and in the amount of $10,000 (the &#x201c;First Tranche&#x201d;) and the second tranche in
the amount of $2,500 (the &#x201c;Second Tranche) were drawn on April 26, 2022 and July 19, 2022, respectively. In addition, in accordance
with the Credit Line agreement, the Company will issue to Kreos warrants to purchase the Company&#x2019;s Ordinary shares equal to 8% of
the amount of each tranche, when and if borrowed, with an exercise price of $5.14 per share. The expiration date for each warrant issued
will be seven years from the agreement date. Accordingly, as a result of the First Tranche and Second Tranche withdrawal, the Company
issued to Kreos a warrant in the total amount of $1,000. The total number of shares issuable upon exercise is equal to the total amount
divided by the exercise price.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"&gt;&lt;span style="font-weight: normal"&gt;The
Credit Line is denominated in USD and bears interest at an annual rate equal to 9.25%. The interest paid due to the Credit Line for the
year ended December 31, 2022 amounted to $734. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"&gt;&lt;span style="font-weight: normal"&gt;On
each drawdown date, the Company shall pay to Kreos on the drawdown date the last period payment for such drawdown. For the First Tranche
and Second Tranche, the amount the Company paid was $317 and $85, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 56.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"&gt;&lt;span style="font-weight: normal"&gt;The
third and final tranche of $2,500 will never be drawn since the third tranche milestone has not been met. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"&gt;&lt;span style="font-weight: normal"&gt;The
Company has concluded that the Credit Line includes several legally detachable and separately exercisable freestanding financial instruments:
The First Tranche term loan, the warrants, and the right to receive additional loan tranches (the &#x201c;FCA&#x201d;). &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"&gt;&lt;span style="font-weight: normal"&gt;The
Company has concluded that the warrants should be classified as equity since the warrants are not an ASC 480 liability, are indexed to
the Company&#x2019;s own Ordinary stock and meet all the equity classification conditions pursuant to ASC 815-40. The Company has also concluded
that the FCA is not indexed to the Company&#x2019;s own Ordinary stock and should be measured at fair value, with changes in fair value recognized
in earnings. In addition, the First Tranche and the Second Tranche term loan were accounted for using the effective interest method. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"&gt;&lt;span style="font-weight: normal"&gt;The
Company allocated the proceeds received to the FCA at fair value. The remaining proceeds were allocated between the warrants and the First
Tranche term loan using the relative fair value method. The proceeds allocation resulted in $9,532 allocated to the First Tranche and
$468 allocated to the warrants, net of issuance costs. The proceeds allocated to the FCA were immaterial. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"&gt;&lt;span style="font-weight: normal"&gt;The
Company allocated the proceeds received under the Credit Line between the warrants and the Second Tranche term loan using the relative
fair value method. The proceeds allocation resulted in $2,380 allocated to the Second Tranche and $120 allocated to the warrants. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.75"&gt;&lt;span style="font-weight: normal"&gt;During
the year ended December 31, 2022, the Company recognized $1,023 of interest expenses related to the First Tranche and the Second Tranche,
which were included as part of financial expenses in the Company&#x2019;s statements of operation. &lt;/span&gt;&lt;/p&gt;</pypd:LineOfCreditArrangementTextBlock>
    <us-gaap:LinesOfCreditCurrent contextRef="c64" decimals="-3" unitRef="usd">15000000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c65" decimals="-3" unitRef="usd">10000000</us-gaap:ProceedsFromLinesOfCredit>
    <pypd:ProceedsFromLinesOfCreditOne contextRef="c66" decimals="-3" unitRef="usd">2500000</pypd:ProceedsFromLinesOfCreditOne>
    <pypd:ProceedsFromLinesOfCreditTwo contextRef="c67" decimals="-3" unitRef="usd">2500000</pypd:ProceedsFromLinesOfCreditTwo>
    <us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount contextRef="c68" decimals="-3" unitRef="usd">10000000</us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount>
    <us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount contextRef="c69" decimals="-3" unitRef="usd">2500000</us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage contextRef="c0" decimals="2" unitRef="pure">0.08</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:SharesIssuedPricePerShare contextRef="c2" decimals="2" unitRef="usdPershares">5.14</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c2" decimals="-3" unitRef="usd">1000000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="c2" decimals="4" unitRef="pure">0.0925</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCredit contextRef="c2" decimals="-3" unitRef="usd">734000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityPeriodicPayment contextRef="c65" decimals="-3" unitRef="usd">317000</us-gaap:LineOfCreditFacilityPeriodicPayment>
    <us-gaap:LineOfCreditFacilityPeriodicPayment contextRef="c66" decimals="-3" unitRef="usd">85000</us-gaap:LineOfCreditFacilityPeriodicPayment>
    <pypd:LineOfCreditFacilityPeriodicPaymentOne contextRef="c67" decimals="-3" unitRef="usd">2500000</pypd:LineOfCreditFacilityPeriodicPaymentOne>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c65" decimals="-3" unitRef="usd">9532000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c0" decimals="-3" unitRef="usd">468000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:LineOfCreditFacilityDescription contextRef="c0">The proceeds allocation resulted in $2,380 allocated to the Second Tranche and $120 allocated to the warrants.</us-gaap:LineOfCreditFacilityDescription>
    <us-gaap:InterestExpenseShortTermBorrowings contextRef="c0" decimals="-3" unitRef="usd">1023000</us-gaap:InterestExpenseShortTermBorrowings>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in"&gt;NOTE 8:-&lt;/td&gt;
  &lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"&gt; COMMITMENTS AND CONTINGENT LIABILITIES&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;a.&lt;/td&gt;&lt;td style="text-align: justify"&gt;In connection with its research and development programs, through December 31, 2022, the Company received
participation payments from the IIA in the aggregate amount of $4,888. In return for the IIA&#x2019;s participation, the Company is committed
to pay royalties at a rate of 3% of sales of the developed products, up to 100% of the amount of grants received plus interest at LIBOR
rate. Through December 31, 2022, no royalties have been paid or accrued.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.2pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;b.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On December 22, 2016, the Company received a written demand for a finder&#x2019;s fee in an amount of $250, in
connection with the second financing round that occurred in 2016. In September 2017, a suit was filed against the Company in the Tel-Aviv
Magistrates Court in an amount of $250. On April 30, 2020, the Company received the court ruling, which ruled in favor of the Company,
discharging the entire claim, and accordingly reversed the related provision. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pypd:ProceedsFromParticipationPayments contextRef="c0" decimals="-3" unitRef="usd">4888000</pypd:ProceedsFromParticipationPayments>
    <pypd:CommitmentsAndContingentLiabilitiesDescription contextRef="c0">the Company is committed
to pay royalties at a rate of 3% of sales of the developed products, up to 100% of the amount of grants received plus interest at LIBOR
rate. Through December 31, 2022, no royalties have been paid or accrued.</pypd:CommitmentsAndContingentLiabilitiesDescription>
    <pypd:FindersFee contextRef="c70" decimals="-3" unitRef="usd">250000</pypd:FindersFee>
    <pypd:SuitFillingExpense contextRef="c71" decimals="-3" unitRef="usd">250000</pypd:SuitFillingExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in"&gt;NOTE 9:-&lt;/td&gt;
  &lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"&gt; INCOME TAXES&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;a.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Corporate tax rates:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;The corporate tax
rate in Israel in 2022, 2021 and 2020 was 23%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;The United States of America federal
rate was 21% and the state corporate income tax rates range from 6.5% to 11.5%, for the years ended December 31, 2022, 2021 and 2020.
The Company didn&#x2019;t account for any federal, state and foreign income tax expenses for the years ended December 31, 2022, 2021 and
2020. The Company is subject to United States of America income tax laws. There are no provisions for United States of America federal,
state or other taxes for any period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;Loss before taxes is comprised as
follows&lt;span style="font-size: 10pt"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year
Ended &lt;br/&gt;
December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Domestic (Israel)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;38,403&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35,983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,404&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;39,557&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;42,601&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;36,869&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;b.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Net operating losses carryforward:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;The Company has
accumulated losses for tax purposes as of December 31, 2022, in the amount of approximately $152,107 which may be carried forward and
offset against taxable income in the future for an indefinite period.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;c.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Tax assessment:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;The Company has
net operating losses from prior tax periods which may be subjected to examination in future periods. As of December 31, 2022, the Company&#x2019;s
tax years until December 31, 2017, are subject to the statute of limitation in Israel.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;The US Subsidiary has yet to receive
final tax assessments since its incorporation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;d.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Deferred taxes:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts used for income tax purposes. The Company&#x2019;s deferred tax assets are comprised of
operating loss carryforwards and other temporary differences. Significant components of the Company&#x2019;s deferred tax assets are as
follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 76%; text-align: left"&gt;Carryforward losses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;34,984&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;31,289&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,376&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Reserves and allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;157&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;479&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(40,448&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(37,210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;559&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Operating lease ROU assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(559&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(559&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;Management
currently believes that since the Company has a history of losses, and there is uncertainty with respect to future taxable income of
the Company, it is more likely than not that the deferred tax assets will not be utilized in the foreseeable future. Thus, a full
valuation allowance was provided to reduce deferred tax assets to their realizable value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;d.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Deferred taxes: (Cont.)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;In 2022 and 2021,
the main reconciling items of the Company&#x2019;s statutory tax rate of 23% and the effective tax rate of (0.3)% and 0%, respectively, is tax
carryforward losses and other temporary differences, such as research and development expenses, for which a full valuation allowance was
provided.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;e.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Income taxes are comprised as follows:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year
Ended &lt;br/&gt;
December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Current&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;129&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deferred&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 2.85pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;129&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended &lt;br/&gt;
December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Domestic (Israel)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;129&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 2.85pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;129&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c72" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c73" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c74" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:FederalHomeLoanBankAdvancesInterestRate contextRef="c75" decimals="2" unitRef="pure">0.21</us-gaap:FederalHomeLoanBankAdvancesInterestRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c76" decimals="3" unitRef="pure">0.065</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c77" decimals="3" unitRef="pure">0.065</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c78" decimals="3" unitRef="pure">0.065</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c79" decimals="3" unitRef="pure">0.115</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c80" decimals="3" unitRef="pure">0.115</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c81" decimals="3" unitRef="pure">0.115</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year
Ended &lt;br/&gt;
December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Domestic (Israel)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;38,403&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35,983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,404&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;39,557&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;42,601&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;36,869&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c82" decimals="-3" unitRef="usd">38403000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c83" decimals="-3" unitRef="usd">41197000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c84" decimals="-3" unitRef="usd">35983000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c85" decimals="-3" unitRef="usd">1154000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c86" decimals="-3" unitRef="usd">1404000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c87" decimals="-3" unitRef="usd">886000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c0" decimals="-3" unitRef="usd">39557000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c4" decimals="-3" unitRef="usd">42601000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c5" decimals="-3" unitRef="usd">36869000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:TaxBasisOfInvestmentsCostForIncomeTaxPurposes contextRef="c2" decimals="-3" unitRef="usd">152107000</us-gaap:TaxBasisOfInvestmentsCostForIncomeTaxPurposes>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 76%; text-align: left"&gt;Carryforward losses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;34,984&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;31,289&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,376&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Reserves and allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;157&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;479&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(40,448&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(37,210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;559&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Operating lease ROU assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(559&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(559&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c2" decimals="-3" unitRef="usd">34984000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="-3" unitRef="usd">31289000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c2" decimals="-3" unitRef="usd">5376000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c3" decimals="-3" unitRef="usd">5203000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" unitRef="usd">490000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c2" decimals="-3" unitRef="usd">157000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c3" decimals="-3" unitRef="usd">239000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c3" decimals="-3" unitRef="usd">479000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c0" decimals="-3" unitRef="usd">41007000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c4" decimals="-3" unitRef="usd">37210000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="-3" unitRef="usd">40448000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-3" unitRef="usd">37210000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsGross contextRef="c2" decimals="-3" unitRef="usd">559000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="-3" unitRef="usd">559000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c2" decimals="-3" unitRef="usd">559000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="3" unitRef="pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c4" decimals="2" unitRef="pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year
Ended &lt;br/&gt;
December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Current&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;129&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deferred&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 2.85pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;129&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended &lt;br/&gt;
December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Domestic (Israel)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;129&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 2.85pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;129&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c0" decimals="-3" unitRef="usd">129000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c0" decimals="-3" unitRef="usd">129000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c0" decimals="-3" unitRef="usd">129000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c0" decimals="-3" unitRef="usd">129000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in"&gt;NOTE 10:-&lt;/td&gt;
  &lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"&gt; SHAREHOLDERS&#x2019; EQUITY&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;a.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Reverse Share Split:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;On June 21, 2020,
the Company&#x2019;s Board of Directors resolved to consolidate the Company&#x2019;s share capital by applying an additional reverse share
split and cancelling the shares&#x2019; par value (See Note 1.b).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;Following the reverse
share split and the cancellation of the par value, all Ordinary shares, Convertible Preferred shares, options, convertible loans, warrants,
exercise prices and per share data have been adjusted retroactively for all periods presented in these consolidated financial statements.&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;b.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Ordinary share capital is composed as follows:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt;
 outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt;
 outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"&gt;Ordinary shares with no par value&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,800,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19,851,833&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,800,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,756,570&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify; text-indent: 56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;c.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Controlled Equity Offering Sales Agreement (the &#x201c;Sales Agreement&#x201d;):&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;In July 2021, the
Company entered into a Sales Agreement with Cantor Fitzgerald &amp;amp; Co. (the &#x201c;Agent&#x201d;), pursuant to which the Company may offer
and sell, from time to time, its Ordinary shares, through the Agent in an at the market offering (&#x201c;ATM&#x2019;&#x201d;), as defined in Rule
415(a)(4) promulgated under the Securities Act of 1933, as amended, for an aggregate offering price of up to $45,000.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.25pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;During the year
ended December 31, 2022, the Company sold 1,065,057 Ordinary shares under the ATM for a total amount of $4,423, net of issuance cost in
the amount of $222.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.25pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;d.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Ordinary shares rights:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;The Ordinary shares confer upon their
holders the right to participate in the general meetings of the Company, to vote at such meetings (each share represents one vote), and
to participate in any distribution of dividends or any other distribution of the Company&#x2019;s property, including the distribution of surplus
assets upon liquidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;e.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Share option plan:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;The Company has
authorized through its 2012 Share Option Plan, the grant of options to officers, directors, advisors, management and other key employees
of up to 4,672,094 Ordinary shares. The options granted generally have a four-year vesting period and expire ten years after the date
of grant. Options granted under the Company&#x2019;s option plan that are canceled or forfeited before expiration become available for future
grant.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;On May 3, 2022, the annual and extraordinary
general meeting of shareholders of the Company approved a new grant of 76,120 options to the then current Chief Executive Officer of the
Company, Mr. Amir Weisberg. In addition, it was approved to accelerate the vesting of 12,906 options from an outstanding grant; in both
cases the vesting of all options will occur on June 30, 2022. As a result, the Company recognized a total share-based compensation expense
in the amount of $76.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;On May 9, 2022,
the Company&#x2019;s Board of Directors approved to increase the Company&#x2019;s options pool by an additional one million options from 3,672,094
to 4,672,094.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;As of December 31,
2022, 700,965 of the Company&#x2019;s options were available for future grants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;A summary of the
status of options to employees under the Company&#x2019;s option plan as of December&#160;31, 2022, and changes during the relevant period ended
on that date is presented below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;of options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;exercise&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&#160;&lt;b&gt;&lt;br/&gt; average&lt;/b&gt;&#160;&lt;b&gt;&lt;br/&gt; remaining&lt;/b&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;contractual&lt;br/&gt; life (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,726,911&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.25&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,323&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.44&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,124,520&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(30,206&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Forfeited and expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(517,879&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.57&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Outstanding at end of year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3,303,346&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: right"&gt;5.97&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: right"&gt;115&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: right"&gt;6.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Exercisable options&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,016,737&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.81&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;115&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.34&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Vested and expected to vest&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,303,346&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.97&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;115&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;The weighted average
grant date fair value of options granted during the year ended December 31, 2022, was $3.46.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;The Black-Scholes
assumptions used to value the employee share options at the grant dates are presented in the following table by years:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify; text-indent: 0in"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0in"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70.45-92.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72.97-78.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;74.35-84.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 0in"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.81-4.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.62-1.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.23-1.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0in"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.2-6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5-6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5-6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;These assumptions
and estimates were determined as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 1.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 38px; text-align: justify"&gt;o&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Fair Value of Ordinary Shares - Prior to the IPO, the fair value was determined by the Company&#x2019;s Board of Directors, with input from management and third-party valuation specialists. After the IPO, the fair value of each Ordinary share was based on the closing price of the Company&#x2019;s publicly traded Ordinary shares as reported on the date of the grant.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 1.25in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 38px; text-align: justify"&gt;o&lt;/td&gt; &lt;td style="text-align: justify"&gt;Dividend Yield - The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. As a result, an expected dividend yield of zero percent was used.&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;o&lt;/td&gt; &lt;td style="text-align: justify"&gt;Expected Volatility - As the Company has a short trading history for its Ordinary shares, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company&#x2019;s industry that the Company considers to be comparable to its own business over a period equivalent to the option&#x2019;s expected term.&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in; text-align: left"&gt;e.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Share option plan: (Cont.)&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 1.25in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 38px"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;o&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Risk-Free&#160;Interest Rate - The risk-free rate for the expected term of the options is based on the Black-Scholes option pricing model on the yields of United States of America Treasury securities with maturities appropriate for the expected term of employee share option awards.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;o&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;Expected term - The expected term represents the period that options are expected to be outstanding. For option grants that are considered to be &#x201c;plain vanilla,&#x201d; the Company determines the expected term using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the options.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;The total share-based
compensation expense recognized by the Company&#x2019;s departments for the three years ended December&#160;31, 2022, 2021 and 2020, was comprised
as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year Ended &lt;br/&gt;
&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,081&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,203&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,806&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Marketing and business development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;317&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,843&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,230&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,631&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -11.35pt; padding-left: 14.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="text-decoration:underline"&gt;Total&lt;/span&gt; share-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,307&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,750&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,577&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;As of December 31,
2022, there were unrecognized compensation costs of $6,379, which are expected to be recognized over a weighted average period of approximately
2.5 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;f.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Options issued to non-employees (including directors and consultants):&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;Outstanding options
granted to non-employees as of December&#160;31, 2022, were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Grant date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Options&lt;br/&gt; outstanding &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;as of &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt; 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Average&lt;br/&gt; Exercise &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;per share ($)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;exercisable&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;as of &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt; 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercisable through&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;October 2013&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;5,719&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;5.06&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;5,719&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 30%; text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;October 2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;September 2014&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,719&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.06&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,719&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;September 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;April 2016&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;April 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;December 2016&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;December 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;June 2017&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;197,722&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;197,722&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;June 2027&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;November 2017&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,925&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,925&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;November 2027&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;August 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;August 2029&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;June 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;June 2030&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;April 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;April 2031&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;August 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;August 2031&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;December 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;December 2031&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;May 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65,625&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;May 2032&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"&gt;November 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;1.05&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; text-indent: -5.6pt; padding-left: 5.6pt"&gt;November 2032&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -12pt; padding-left: 12pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-indent: -5.6pt; padding-left: 5.6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;534,826&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;470,710&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -5.6pt; padding-left: 5.6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;No options were exercised by non-employees
during the year ended December&#160;31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;g.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Warrants:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;&lt;span style="font-weight: normal"&gt;During
the year ended December 31, 2020, 2,106,879 D-2 warrants were exercised into 885,377 Ordinary shares on a cashless basis. As of December
31, 2020, 648,519 D-2 warrants were outstanding. In addition, 53,775 A warrants were exercised into 53,775 Ordinary shares for a total
consideration of $13. As of December 31, 2022, &lt;span style="-sec-ix-hidden: hidden-fact-127"&gt;no&lt;/span&gt; A warrants were outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;&lt;span style="font-weight: normal"&gt;Further
to the discussion in Note 7, as of April 26, 2022 and July 19, 2022, the Company measured the fair value of the warrants to purchase Ordinary
shares (a Level 3 valuation) using the Black-Scholes option pricing model. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;g.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Warrants: (Cont.)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;As of April 26, 2022 and July 19,
2022, the relative fair value of the warrants to purchase Ordinary shares issued to Kreos was $468 and $120, respectively, which was calculated
using the following assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;July 19,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;April 26,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Share price ($)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Adjustment to risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expected life (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.6pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;&lt;span style="font-weight: normal"&gt;During
the year ended December 31, 2021, 580,028 D-2 warrants were exercised into 115,982 Ordinary shares on a cashless basis. In addition, 68,491
D-2 warrants were exercised into 68,491 Ordinary shares for a total consideration of $632. As of December 31, 2022, no D-2 warrants are
outstanding. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;&lt;span style="font-weight: normal"&gt;Since
the IPO and as of December 31, 2022, all warrants are exercisable into Ordinary shares, in which the outstanding issued warrants to purchase
Ordinary shares as of December&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Grant date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Warrants&lt;br/&gt;
 outstanding &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;as of &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;
2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Average&lt;br/&gt;
 Exercise &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;per share ($)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Warrants&lt;br/&gt;
 exercisable&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;as of &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercisable through&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: center"&gt;August 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;200,596&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;15.95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;200,596&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 30%; text-align: center"&gt;August 2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;September 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,925&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,925&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;September 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;April 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155,794&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155,794&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;April 2029&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"&gt;July 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;38,948&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;5.14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;38,948&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; text-indent: -5.6pt; padding-left: 5.6pt"&gt;April 2029&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;413,263&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;413,263&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfCapitalLeasedAsssetsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt;
 outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt;
 outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"&gt;Ordinary shares with no par value&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,800,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19,851,833&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47,800,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,756,570&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 85.05pt 0pt 0; text-align: justify; text-indent: 56.7pt"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCapitalLeasedAsssetsTableTextBlock>
    <us-gaap:ExcessStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">47800000</us-gaap:ExcessStockSharesAuthorized>
    <us-gaap:ExcessStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">19851833</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ExcessStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">19851833</us-gaap:ExcessStockSharesOutstanding>
    <us-gaap:ExcessStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">47800000</us-gaap:ExcessStockSharesAuthorized>
    <us-gaap:ExcessStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">18756570</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ExcessStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">18756570</us-gaap:ExcessStockSharesOutstanding>
    <pypd:AggregateOfferingPrice contextRef="c88" decimals="-3" unitRef="usd">45000000</pypd:AggregateOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="c0" decimals="0" unitRef="shares">1065057</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="c0" decimals="-3" unitRef="usd">4423000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c0" decimals="-3" unitRef="usd">222000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c89" decimals="0" unitRef="shares">4672094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <pypd:StockOptionVestingPeriodDescription contextRef="c90">The options granted generally have a four-year vesting period and expire ten years after the date
of grant.</pypd:StockOptionVestingPeriodDescription>
    <pypd:ShareOptionPlanDescription contextRef="c91">On May 3, 2022, the annual and extraordinary
general meeting of shareholders of the Company approved a new grant of 76,120 options to the then current Chief Executive Officer of the
Company, Mr. Amir Weisberg. In addition, it was approved to accelerate the vesting of 12,906 options from an outstanding grant; in both
cases the vesting of all options will occur on June 30, 2022. As a result, the Company recognized a total share-based compensation expense
in the amount of $76.&#160;</pypd:ShareOptionPlanDescription>
    <pypd:NumberOfOptions contextRef="c92" decimals="-6" unitRef="shares">1000000</pypd:NumberOfOptions>
    <pypd:StockOptionShares contextRef="c93" decimals="0" unitRef="shares">3672094</pypd:StockOptionShares>
    <pypd:StockOptionShares contextRef="c94" decimals="0" unitRef="shares">4672094</pypd:StockOptionShares>
    <pypd:StockOptionsAvailableForFutureGrants contextRef="c90" decimals="0" unitRef="shares">700965</pypd:StockOptionsAvailableForFutureGrants>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;of options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;exercise&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&#160;&lt;b&gt;&lt;br/&gt; average&lt;/b&gt;&#160;&lt;b&gt;&lt;br/&gt; remaining&lt;/b&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;contractual&lt;br/&gt; life (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,726,911&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.25&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,323&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.44&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,124,520&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(30,206&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Forfeited and expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(517,879&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.57&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Outstanding at end of year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3,303,346&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: right"&gt;5.97&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: right"&gt;115&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: right"&gt;6.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Exercisable options&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,016,737&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.81&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;115&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.34&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Vested and expected to vest&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,303,346&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.97&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;115&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.14&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0.75"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c96" decimals="0" unitRef="shares">2726911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="c96" decimals="2" unitRef="usdPershares">6.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c96" decimals="-3" unitRef="usd">2323000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c97">P6Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c97" decimals="0" unitRef="shares">1124520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c97" decimals="2" unitRef="usdPershares">5.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised contextRef="c97" decimals="0" unitRef="shares">-30206</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised>
    <pypd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice contextRef="c97" decimals="2" unitRef="usdPershares">3.6</pypd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c97" decimals="0" unitRef="usdPershares">21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1 contextRef="c97" decimals="0" unitRef="shares">-517879</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled contextRef="c97" decimals="2" unitRef="usdPershares">6.57</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c98" decimals="0" unitRef="shares">3303346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="c98" decimals="2" unitRef="usdPershares">5.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c98" decimals="-3" unitRef="usd">115000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <pypd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding contextRef="c97">P6Y1M20D</pypd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c98" decimals="0" unitRef="shares">2016737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c98" decimals="2" unitRef="usdPershares">5.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c98" decimals="-3" unitRef="usd">115000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c97">P4Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c98" decimals="0" unitRef="shares">3303346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices contextRef="c98" decimals="2" unitRef="usdPershares">5.97</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c97" decimals="-3" unitRef="usd">115000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <pypd:WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest contextRef="c97">P6Y1M20D</pypd:WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest>
    <pypd:WeightedAverageGrantDateFairValueOfOptionsGranted contextRef="c0" decimals="2" unitRef="usdPershares">3.46</pypd:WeightedAverageGrantDateFairValueOfOptionsGranted>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify; text-indent: 0in"&gt;Dividend yield (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0in"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70.45-92.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72.97-78.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;74.35-84.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: 0in"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.81-4.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.62-1.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.23-1.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: 0in"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.2-6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5-6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5-6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c4" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c5" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c52" decimals="4" unitRef="pure">0.7045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c53" decimals="4" unitRef="pure">0.9267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c99" decimals="4" unitRef="pure">0.7297</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c100" decimals="4" unitRef="pure">0.7869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c101" decimals="4" unitRef="pure">0.7435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c102" decimals="4" unitRef="pure">0.8477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c52" decimals="4" unitRef="pure">0.0181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c53" decimals="4" unitRef="pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c99" decimals="4" unitRef="pure">0.0062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c100" decimals="4" unitRef="pure">0.0132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c101" decimals="4" unitRef="pure">0.0023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c102" decimals="4" unitRef="pure">0.0138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c52">P1Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c53">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c99">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c100">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c101">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c102">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <pypd:ExpectedDividendYield contextRef="c0" decimals="2" unitRef="pure">0</pypd:ExpectedDividendYield>
    <us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year Ended &lt;br/&gt;
&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,081&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,203&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,806&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Marketing and business development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;317&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,843&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,230&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,631&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; text-indent: -11.35pt; padding-left: 14.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="text-decoration:underline"&gt;Total&lt;/span&gt; share-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,307&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,750&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,577&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c103" decimals="-3" unitRef="usd">2081000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c104" decimals="-3" unitRef="usd">2203000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c105" decimals="-3" unitRef="usd">1806000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c106" decimals="-3" unitRef="usd">383000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c107" decimals="-3" unitRef="usd">317000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c108" decimals="-3" unitRef="usd">140000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c109" decimals="-3" unitRef="usd">1843000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c110" decimals="-3" unitRef="usd">2230000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c111" decimals="-3" unitRef="usd">2631000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" unitRef="usd">4307000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c4" decimals="-3" unitRef="usd">4750000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c5" decimals="-3" unitRef="usd">4577000</us-gaap:AllocatedShareBasedCompensationExpense>
    <pypd:UnrecognizedCompensationCosts contextRef="c0" decimals="-3" unitRef="usd">6379000</pypd:UnrecognizedCompensationCosts>
    <pypd:RecognizedOverWeightedAveragePeriod contextRef="c0">P2Y6M</pypd:RecognizedOverWeightedAveragePeriod>
    <pypd:ScheduleOfOutstandingOptionGrantedTablesTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Grant date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Options&lt;br/&gt; outstanding &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;as of &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt; 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Average&lt;br/&gt; Exercise &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;per share ($)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;exercisable&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;as of &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt; 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercisable through&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;October 2013&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;5,719&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;5.06&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;5,719&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 30%; text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;October 2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;September 2014&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,719&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.06&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,719&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;September 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;April 2016&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;April 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;December 2016&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;December 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;June 2017&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;197,722&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;197,722&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;June 2027&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;November 2017&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,925&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,925&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;November 2027&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;August 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;August 2029&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;June 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.62&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;June 2030&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;April 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;April 2031&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;August 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;August 2031&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;December 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;December 2031&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;May 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65,625&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;May 2032&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"&gt;November 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;1.05&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; text-indent: -5.6pt; padding-left: 5.6pt"&gt;November 2032&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -12pt; padding-left: 12pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-indent: -5.6pt; padding-left: 5.6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;534,826&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;470,710&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -5.6pt; padding-left: 5.6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Grant date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Warrants&lt;br/&gt;
 outstanding &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;as of &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;
2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Average&lt;br/&gt;
 Exercise &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;per share ($)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Warrants&lt;br/&gt;
 exercisable&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;as of &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;br/&gt;
 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercisable through&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: center"&gt;August 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;200,596&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;15.95&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;200,596&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 30%; text-align: center"&gt;August 2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;September 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,925&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,925&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;September 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;April 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155,794&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155,794&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;April 2029&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; text-indent: -12pt; padding-left: 12pt"&gt;July 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;38,948&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;5.14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;38,948&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; text-indent: -5.6pt; padding-left: 5.6pt"&gt;April 2029&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; text-indent: -12pt; padding-left: 12pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; text-indent: -5.6pt; padding-left: 5.6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; padding-bottom: 4pt; text-indent: -12pt; padding-left: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;413,263&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;413,263&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</pypd:ScheduleOfOutstandingOptionGrantedTablesTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c112" decimals="0" unitRef="shares">5719</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c112" decimals="2" unitRef="usdPershares">5.06</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:OptionsExercisable contextRef="c112" decimals="0" unitRef="shares">5719</pypd:OptionsExercisable>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c113">October 2023</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c114" decimals="0" unitRef="shares">5719</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c114" decimals="2" unitRef="usdPershares">5.06</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:OptionsExercisable contextRef="c114" decimals="0" unitRef="shares">5719</pypd:OptionsExercisable>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c115">September 2024</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c116" decimals="0" unitRef="shares">5975</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c116" decimals="2" unitRef="usdPershares">3.1</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:OptionsExercisable contextRef="c116" decimals="0" unitRef="shares">5975</pypd:OptionsExercisable>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c117">April 2026</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c118" decimals="0" unitRef="shares">7170</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c118" decimals="2" unitRef="usdPershares">3.93</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:OptionsExercisable contextRef="c118" decimals="0" unitRef="shares">7170</pypd:OptionsExercisable>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c119">December 2026</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c120" decimals="0" unitRef="shares">197722</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c120" decimals="2" unitRef="usdPershares">4.1</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:OptionsExercisable contextRef="c120" decimals="0" unitRef="shares">197722</pypd:OptionsExercisable>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c121">June 2027</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c122" decimals="0" unitRef="shares">17925</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c122" decimals="2" unitRef="usdPershares">7.7</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:OptionsExercisable contextRef="c122" decimals="0" unitRef="shares">17925</pypd:OptionsExercisable>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c123">November 2027</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c124" decimals="0" unitRef="shares">71700</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c124" decimals="2" unitRef="usdPershares">8.18</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:OptionsExercisable contextRef="c124" decimals="0" unitRef="shares">71700</pypd:OptionsExercisable>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c125">August 2029</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c126" decimals="0" unitRef="shares">64530</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c126" decimals="2" unitRef="usdPershares">6.62</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:OptionsExercisable contextRef="c126" decimals="0" unitRef="shares">53724</pypd:OptionsExercisable>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c127">June 2030</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c128" decimals="0" unitRef="shares">62741</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c128" decimals="2" unitRef="usdPershares">9.57</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:OptionsExercisable contextRef="c128" decimals="0" unitRef="shares">62741</pypd:OptionsExercisable>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c129">April 2031</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c130" decimals="0" unitRef="shares">15000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c130" decimals="2" unitRef="usdPershares">8.13</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:OptionsExercisable contextRef="c130" decimals="0" unitRef="shares">6206</pypd:OptionsExercisable>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c131">August 2031</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c132" decimals="0" unitRef="shares">10000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c132" decimals="2" unitRef="usdPershares">6.8</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:OptionsExercisable contextRef="c132" decimals="0" unitRef="shares">3300</pypd:OptionsExercisable>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c133">December 2031</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c134" decimals="0" unitRef="shares">65625</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c134" decimals="2" unitRef="usdPershares">5</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:OptionsExercisable contextRef="c134" decimals="0" unitRef="shares">32809</pypd:OptionsExercisable>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c135">May 2032</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c136" decimals="0" unitRef="shares">5000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c136" decimals="2" unitRef="usdPershares">1.05</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c137">November 2032</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c138" decimals="0" unitRef="shares">534826</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <pypd:OptionsExercisable contextRef="c138" decimals="0" unitRef="shares">470710</pypd:OptionsExercisable>
    <pypd:WarrantsDescription contextRef="c95">During
the year ended December 31, 2020, 2,106,879 D-2 warrants were exercised into 885,377 Ordinary shares on a cashless basis. As of December
31, 2020, 648,519 D-2 warrants were outstanding. In addition, 53,775 A warrants were exercised into 53,775 Ordinary shares for a total
consideration of $13.</pypd:WarrantsDescription>
    <us-gaap:PaymentsForRepurchaseOfWarrants contextRef="c68" decimals="-3" unitRef="usd">468000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants contextRef="c69" decimals="-3" unitRef="usd">120000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;July 19,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;April 26,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Share price ($)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Exercise price ($)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Adjustment to risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.07&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expected life (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.6pt; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:SharePrice contextRef="c148" decimals="2" unitRef="usdPershares">5.12</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="c149" decimals="2" unitRef="usdPershares">4.96</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c148" decimals="2" unitRef="usdPershares">5.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c149" decimals="2" unitRef="usdPershares">5.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c150" decimals="4" unitRef="pure">0.6057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c151" decimals="4" unitRef="pure">0.6081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <pypd:AdjustmentToRiskfreeInterestRate contextRef="c150" decimals="4" unitRef="pure">0.0307</pypd:AdjustmentToRiskfreeInterestRate>
    <pypd:AdjustmentToRiskfreeInterestRate contextRef="c151" decimals="4" unitRef="pure">0.0284</pypd:AdjustmentToRiskfreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c150" decimals="4" unitRef="pure">0.0311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c151" decimals="4" unitRef="pure">0.0288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c150">P6Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c151">P6Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <pypd:WarrantsDescription contextRef="c0">During
the year ended December 31, 2021, 580,028 D-2 warrants were exercised into 115,982 Ordinary shares on a cashless basis. In addition, 68,491
D-2 warrants were exercised into 68,491 Ordinary shares for a total consideration of $632. As of December 31, 2022, no D-2 warrants are
outstanding.</pypd:WarrantsDescription>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c139" decimals="0" unitRef="shares">200596</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c139" decimals="2" unitRef="usdPershares">15.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:OptionsExercisable contextRef="c139" decimals="0" unitRef="shares">200596</pypd:OptionsExercisable>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c140">August 2023</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c141" decimals="0" unitRef="shares">17925</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c141" decimals="2" unitRef="usdPershares">16</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:OptionsExercisable contextRef="c141" decimals="0" unitRef="shares">17925</pypd:OptionsExercisable>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c142">September 2024</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c143" decimals="0" unitRef="shares">155794</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c143" decimals="2" unitRef="usdPershares">5.14</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:OptionsExercisable contextRef="c143" decimals="0" unitRef="shares">155794</pypd:OptionsExercisable>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c144">April 2029</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c145" decimals="0" unitRef="shares">38948</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c145" decimals="2" unitRef="usdPershares">5.14</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <pypd:OptionsExercisable contextRef="c145" decimals="0" unitRef="shares">38948</pypd:OptionsExercisable>
    <pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration contextRef="c146">April 2029</pypd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c147" decimals="0" unitRef="shares">413263</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <pypd:OptionsExercisable contextRef="c147" decimals="0" unitRef="shares">413263</pypd:OptionsExercisable>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="c0">&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in"&gt;NOTE 11:-&lt;/td&gt;
  &lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"&gt; FINANCIAL (INCOME) EXPENSES, NET&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; font-style: italic; text-align: justify"&gt;Financial expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; width: 64%; text-align: justify"&gt;Financial expenses from loan&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,023&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify"&gt;Other financial expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify"&gt;Remeasurement of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,373&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Total&lt;/span&gt; financial expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,339&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,390&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; font-style: italic; text-align: justify"&gt;Financial income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify"&gt;Foreign currency transaction gains, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(532&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(243&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify"&gt;Interest from bank deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(267&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(468&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(474&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify"&gt;Other financial income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(76&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Total&lt;/span&gt; financial income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(799&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(570&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(793&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Total&lt;/span&gt; financial (income) expense, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;540&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(544&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,597&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year Ended&lt;br/&gt;
&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; font-style: italic; text-align: justify"&gt;Financial expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; width: 64%; text-align: justify"&gt;Financial expenses from loan&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,023&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify"&gt;Other financial expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify"&gt;Remeasurement of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,373&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Total&lt;/span&gt; financial expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,339&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,390&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; font-style: italic; text-align: justify"&gt;Financial income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify"&gt;Foreign currency transaction gains, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(532&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(243&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify"&gt;Interest from bank deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(267&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(468&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(474&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: justify"&gt;Other financial income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(76&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.25in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Total&lt;/span&gt; financial income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(799&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(570&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(793&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Total&lt;/span&gt; financial (income) expense, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;540&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(544&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,597&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:PaymentsToAcquireLoansReceivable contextRef="c0" decimals="-3" unitRef="usd">1023000</us-gaap:PaymentsToAcquireLoansReceivable>
    <us-gaap:OtherExpenses contextRef="c0" decimals="-3" unitRef="usd">316000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c4" decimals="-3" unitRef="usd">26000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c5" decimals="-3" unitRef="usd">17000</us-gaap:OtherExpenses>
    <pypd:RemeasurementOfWarrants contextRef="c5" decimals="-3" unitRef="usd">11373000</pypd:RemeasurementOfWarrants>
    <us-gaap:InvestmentIncomeInvestmentExpense contextRef="c0" decimals="-3" unitRef="usd">1339000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense contextRef="c4" decimals="-3" unitRef="usd">26000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInvestmentExpense contextRef="c5" decimals="-3" unitRef="usd">11390000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:ForeignCurrencyTransactionGainBeforeTax contextRef="c0" decimals="-3" unitRef="usd">532000</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainBeforeTax contextRef="c4" decimals="-3" unitRef="usd">44000</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainBeforeTax contextRef="c5" decimals="-3" unitRef="usd">243000</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="-3" unitRef="usd">267000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c4" decimals="-3" unitRef="usd">468000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c5" decimals="-3" unitRef="usd">474000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c4" decimals="-3" unitRef="usd">58000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c5" decimals="-3" unitRef="usd">76000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:InvestmentIncomeNonoperating contextRef="c0" decimals="-3" unitRef="usd">799000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating contextRef="c4" decimals="-3" unitRef="usd">570000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating contextRef="c5" decimals="-3" unitRef="usd">793000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNet contextRef="c0" decimals="-3" unitRef="usd">540000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c4" decimals="-3" unitRef="usd">-544000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c5" decimals="-3" unitRef="usd">10597000</us-gaap:InvestmentIncomeNet>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0">&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in"&gt;NOTE 12:-&lt;/td&gt;
  &lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"&gt; BASIC AND DILUTED NET LOSS PER SHARE&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;The following table
sets forth the computation of the Company&#x2019;s basic and diluted loss per Ordinary share:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year Ended &lt;br/&gt;
&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; font-style: italic; text-align: left; text-indent: 0pt"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; width: 64%; text-align: left; text-indent: 0pt"&gt;Allocation of net loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;39,557&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;42,601&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36,869&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt"&gt;Preferred share preference&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,933&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt"&gt;Deemed dividend&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,114&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; text-align: justify; text-indent: 0pt"&gt;Allocation of net loss attributable to Ordinary shareholders&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;39,557&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;42,601&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;42,916&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; font-style: italic; text-align: left; text-indent: 0pt"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt"&gt;Weighted average Ordinary shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,426,692&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,721,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,582,405&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139; -sec-ix-hidden: hidden-fact-138; -sec-ix-hidden: hidden-fact-137"&gt;Basic and diluted net loss per share&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.04&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.48&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;The potential ordinary
shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented
because including them would have been anti-dilutive are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Ordinary share options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,487,447&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,995,749&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,583,210&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;413,263&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;218,521&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;867,040&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,900,710&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,214,270&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,450,250&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year Ended &lt;br/&gt;
&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; font-style: italic; text-align: left; text-indent: 0pt"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; width: 64%; text-align: left; text-indent: 0pt"&gt;Allocation of net loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;39,557&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;42,601&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36,869&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt"&gt;Preferred share preference&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,933&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt"&gt;Deemed dividend&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,114&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; text-align: justify; text-indent: 0pt"&gt;Allocation of net loss attributable to Ordinary shareholders&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;39,557&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;42,601&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;42,916&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt; text-align: left; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; font-style: italic; text-align: left; text-indent: 0pt"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt"&gt;Weighted average Ordinary shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;19,426,692&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,721,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,582,405&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139; -sec-ix-hidden: hidden-fact-138; -sec-ix-hidden: hidden-fact-137"&gt;Basic and diluted net loss per share&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.04&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.48&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic contextRef="c0" decimals="-3" unitRef="usd">39557000</us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic contextRef="c4" decimals="-3" unitRef="usd">42601000</us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic contextRef="c5" decimals="-3" unitRef="usd">36869000</us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic>
    <pypd:PreferredSharePreference contextRef="c5" decimals="-3" unitRef="usd">3933000</pypd:PreferredSharePreference>
    <pypd:DeemedDividend contextRef="c5" decimals="-3" unitRef="usd">2114000</pypd:DeemedDividend>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c0" decimals="-3" unitRef="usd">39557000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c4" decimals="-3" unitRef="usd">42601000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c5" decimals="-3" unitRef="usd">42916000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c0" decimals="INF" unitRef="shares">19426692</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c4" decimals="INF" unitRef="shares">18721528</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c5" decimals="INF" unitRef="shares">9582405</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">2.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c4" decimals="2" unitRef="usdPershares">2.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">4.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Ordinary share options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,487,447&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,995,749&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,583,210&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;413,263&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;218,521&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;867,040&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,900,710&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,214,270&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,450,250&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c0" decimals="INF" unitRef="shares">2487447</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c4" decimals="INF" unitRef="shares">1995749</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="c5" decimals="INF" unitRef="shares">1583210</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <pypd:WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares contextRef="c0" decimals="INF" unitRef="shares">413263</pypd:WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares>
    <pypd:WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares contextRef="c4" decimals="INF" unitRef="shares">218521</pypd:WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares>
    <pypd:WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares contextRef="c5" decimals="INF" unitRef="shares">867040</pypd:WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares>
    <pypd:WeightedAverageNumberOfSharesIssued contextRef="c0" decimals="INF" unitRef="shares">2900710</pypd:WeightedAverageNumberOfSharesIssued>
    <pypd:WeightedAverageNumberOfSharesIssued contextRef="c4" decimals="INF" unitRef="shares">2214270</pypd:WeightedAverageNumberOfSharesIssued>
    <pypd:WeightedAverageNumberOfSharesIssued contextRef="c5" decimals="INF" unitRef="shares">2450250</pypd:WeightedAverageNumberOfSharesIssued>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0">&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.75in"&gt;NOTE 13:-&lt;/td&gt;
  &lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt"&gt; RELATED PARTIES&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;a.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Through February 2016, several management members also provided services to the Company as service providers.
As of December 31, 2022 and 2021, the Company has recorded a provision for severance pay liability for such service providers in the amounts
of $174 and $199, respectively. These amounts are included in &#x201c;Other liabilities&#x201d;.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;b.&lt;/td&gt;&lt;td style="text-align: justify"&gt;In July 2019, the Company entered into a master service agreement with a third-party provider (the &#x201c;Provider&#x201d;)
to conduct a portion of a phase 3 clinical trial in Eastern Europe. One of the Company&#x2019;s directors serves as a director and shareholder
in the Provider.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;During the
years ended December 31, 2022 and 2021, and following the agreement with the Provider, the Company recognized research and development
expenses in the total amount of $1,422 and $3,748, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;In May 2022,
the Provider was acquired by a non-related third party. As a result, the Provider no longer exists&lt;span style="font-family: Times New Roman, Times, Serif"&gt;.&lt;/span&gt;
Accordingly, the director is no longer an officer nor a shareholder of the third party or has any other connection to the third party.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;c.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On December 30, 2021, the Company&#x2019;s Board of Directors appointed Dikla Czaczkes Akselbrad, the then
current Company&#x2019;s Executive Vice President and Chief Financial Officer, as the Company&#x2019;s Chief Executive Officer (&#x201c;CEO&#x201d;),
effective July 1, 2022, replacing Amir Weisberg after 11 years.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <pypd:ServiceProvidersInAmount contextRef="c2" decimals="-3" unitRef="usd">174000</pypd:ServiceProvidersInAmount>
    <pypd:ServiceProvidersInAmount contextRef="c3" decimals="-3" unitRef="usd">199000</pypd:ServiceProvidersInAmount>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="c0" decimals="-3" unitRef="usd">1422000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="c4" decimals="-3" unitRef="usd">3748000</us-gaap:ResearchAndDevelopmentInProcess>
    <pypd:RelatedPartiesTerm contextRef="c152">P11Y</pypd:RelatedPartiesTerm>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt; width: 0.75in"&gt;&lt;b&gt;NOTE&lt;/b&gt; 14:- &lt;/td&gt;
  &lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt"&gt;SUBSEQUENT EVENTS&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;
&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in"&gt;a.&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Further to the disclosed in Note 10c, During January 2023, the Company
sold 1,949,029 Ordinary shares under the ATM for a total amount of $2,190, net of issuance costs in the amount of $90. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in"&gt;b.&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During the first quarter of 2023, the Company
decreased the exercise price of 2,021,599 options granted to all employees and a consultant under the 2012 Share Option Plan. As of the
modification date, the options can be exercised for $0.77. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt 1in; text-align: justify"&gt;The Company's Board of Directors also approved
a similar exercise price decrease of 522,507 options previously granted to the Company's CEO and Board members, subject to shareholders
approval&lt;b&gt;.&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"/&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Further to the disclosed in Note 7, on March 29, 2023, the Company
entered into an amendment to the Credit Line (the "Amendment"). Pursuant to this Amendment, 70% of the remaining principal and
interest repayments will be delayed and repaid on a monthly equal basis from August 2024 to May 2026. The amended secured credit line
now bears an interest at the rate of 10%. In addition, the Company will pay to Kreos a restructuring fee consisting of 1% on the closing
date of the Amendment and an incremental 3% at the maturity of the Amendment. In return for this additional deferral of repayment, Kreos
has the right to receive a potential Claw-Back payment on account of the then outstanding principal amount (the "Claw-Back").
This Claw-Back mechanism will be triggered by additional incoming funds from future collaboration and partnership agreements or additional
funding. If triggered, the minimum Claw-Back to be paid will be $1,500, but will not exceed $3,000.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Further to the above and to Note 10g, the outstanding warrants issued to Kreos were repriced and as a result bear an exercise price of $0.42 per share.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"/&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in"&gt;d.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On March 29, 2023, the Company entered into a concurrent private placement of unregistered pre-funded
warrants to purchase up to 10,357,139 Ordinary shares, (the &#x201c;Private Warrants&#x201d;), at a price of $0.4199 per Private Warrant
with certain of the Company&#x2019;s existing shareholders. The Private Warrants have an exercise price of $0.0001 per Ordinary share.
The gross proceeds from the concurrent private placement, before deducting private placement fees and other estimated offering expenses
payable by the Company, are approximately $4,350.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in"&gt;e.&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;&lt;p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;On March 31, 2023, the Company closed a public offering which was comprised
of 16,859,000 Ordinary shares, with no par value (inclusive of 2,199,000 Ordinary shares pursuant to the full exercise of an overallotment
option granted to the underwriters), at a public offering price of $0.42 per share (the &#x201c;Public Offering&#x201d;). The gross proceeds
to the Company from the Public Offering, before deducting underwriting commissions and other estimated offering expenses payable by the
Company, are approximately $7,081.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:InvestmentCompanyCommittedCapital contextRef="c153" decimals="0" unitRef="usd">1949029</us-gaap:InvestmentCompanyCommittedCapital>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue contextRef="c154" decimals="0" unitRef="usd">2190</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet contextRef="c154" decimals="0" unitRef="usd">90</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <pypd:ExercisePriceDecrease contextRef="c155" decimals="0" unitRef="shares">2021599</pypd:ExercisePriceDecrease>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c155" decimals="2" unitRef="usdPershares">0.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <pypd:ExercisePriceDecrease contextRef="c156" decimals="0" unitRef="shares">522507</pypd:ExercisePriceDecrease>
    <pypd:InterestRepayments contextRef="c157" decimals="2" unitRef="pure">0.70</pypd:InterestRepayments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c158" decimals="2" unitRef="pure">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges contextRef="c158" decimals="2" unitRef="pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="c158" decimals="2" unitRef="pure">0.03</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <pypd:MinimumPaidAmount contextRef="c159" decimals="0" unitRef="usd">1500</pypd:MinimumPaidAmount>
    <pypd:ExceedAmount contextRef="c159" decimals="0" unitRef="usd">3000</pypd:ExceedAmount>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c158" decimals="2" unitRef="usdPershares">0.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="c160" decimals="0" unitRef="shares">10357139</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:SaleOfStockPricePerShare contextRef="c161" decimals="4" unitRef="usdPershares">0.4199</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="c162" decimals="4" unitRef="usdPershares">0.0001</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <pypd:OfferingExpensesPayable contextRef="c161" decimals="0" unitRef="usd">4350</pypd:OfferingExpensesPayable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c163" decimals="0" unitRef="usdPershares">16859000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c164" decimals="0" unitRef="usdPershares">2199000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare contextRef="c165" decimals="2" unitRef="usdPershares">0.42</us-gaap:SharesIssuedPricePerShare>
    <pypd:OfferingExpensesPayable contextRef="c166" decimals="0" unitRef="usd">7081</pypd:OfferingExpensesPayable>
    <dei:EntityRegistrantName contextRef="c0" id="hidden-fact-0">PolyPid Ltd.</dei:EntityRegistrantName>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="c2"
      id="hidden-fact-5"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="c3"
      id="hidden-fact-6"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:DeemedDividends
      contextRef="c0"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:DeemedDividends
      contextRef="c4"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-11"
      unitRef="usdPershares">2.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c4"
      decimals="2"
      id="hidden-fact-12"
      unitRef="usdPershares">2.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="hidden-fact-13"
      unitRef="usdPershares">4.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="hidden-fact-14"
      unitRef="shares">18721528</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="hidden-fact-15"
      unitRef="shares">19426692</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="hidden-fact-16"
      unitRef="shares">9582405</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c12"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c13"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c15"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c12"
      id="hidden-fact-20"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c12"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c13"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c15"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:ConversionOfConvertiblePreferredSharesToOrdinaryShares
      contextRef="c15"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c12"
      id="hidden-fact-25"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="c12"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="c13"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="c5"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:ReclassificationOfWarrantsIntoEquity
      contextRef="c12"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:ReclassificationOfWarrantsIntoEquity
      contextRef="c13"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:ReclassificationOfWarrantsIntoEquity
      contextRef="c15"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:StockIssuedDuringPeriodExerciseOfWarrantsShares
      contextRef="c12"
      id="hidden-fact-32"
      unitRef="shares"
      xsi:nil="true"/>
    <pypd:ExerciseOfWarrants
      contextRef="c12"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:ExerciseOfWarrants
      contextRef="c13"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:ExerciseOfWarrants
      contextRef="c15"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c12"
      id="hidden-fact-36"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="c12"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="c13"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c16"
      id="hidden-fact-39"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="c15"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c12"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c13"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c15"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c12"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c13"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c14"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c17"
      id="hidden-fact-47"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c17"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c18"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c23"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c24"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c26"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:StockIssuedDuringPeriodExerciseOfWarrantsShares
      contextRef="c23"
      id="hidden-fact-53"
      unitRef="shares"
      xsi:nil="true"/>
    <pypd:ExerciseOfWarrants
      contextRef="c23"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:ExerciseOfWarrants
      contextRef="c24"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c23"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c24"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c26"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c23"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c24"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c25"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c28"
      id="hidden-fact-62"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c28"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c29"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c33"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c34"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c36"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:IssuanceOfOrdinarySharesNetinShares
      contextRef="c33"
      id="hidden-fact-68"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c33"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c34"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c36"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="c33"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="c34"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="c36"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c33"
      id="hidden-fact-75"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c33"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c34"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c36"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c33"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c34"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c35"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c38"
      id="hidden-fact-82"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c38"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c39"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:ReevaluationOfWarrants
      contextRef="c0"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:ReevaluationOfWarrants
      contextRef="c4"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="c4"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="c5"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="c4"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="c5"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="c4"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="c5"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:PrepaymentForEquipments
      contextRef="c0"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c0"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c0"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c4"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c4"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c5"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="c4"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="c5"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="c4"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="c5"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:IssuanceOfWarrants
      contextRef="c4"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c4"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c5"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c4"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c5"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:PurchaseOfPropertyAndEquipmentIncludedInTradePayable
      contextRef="c5"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:PropertyAndEquipmentPaidForInPriorPeriods
      contextRef="c5"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c4"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c5"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="c4"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="c5"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:IsraelInnovationAuthorityGrantReceived
      contextRef="c2"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c2"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c3"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:DomesticIsrael
      contextRef="c0"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:DomesticIsrael
      contextRef="c4"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:DomesticIsrael
      contextRef="c5"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c4"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c5"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c150"
      id="hidden-fact-125"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c151"
      id="hidden-fact-126"
      unitRef="pure"
      xsi:nil="true"/>
    <pypd:WarrantsOutstanding
      contextRef="c0"
      id="hidden-fact-127"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireLoansReceivable
      contextRef="c4"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireLoansReceivable
      contextRef="c5"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:RemeasurementOfWarrants
      contextRef="c0"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:RemeasurementOfWarrants
      contextRef="c4"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="c0"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:PreferredSharePreference
      contextRef="c0"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:PreferredSharePreference
      contextRef="c4"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:DeemedDividend
      contextRef="c0"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <pypd:DeemedDividend
      contextRef="c4"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-137"
      unitRef="usdPershares">2.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c4"
      decimals="2"
      id="hidden-fact-138"
      unitRef="usdPershares">2.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="hidden-fact-139"
      unitRef="usdPershares">4.48</us-gaap:EarningsPerShareDiluted>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001611842</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-23"
          xlink:label="hidden-fact-23"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-22"
          xlink:label="hidden-fact-22"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-21"
          xlink:label="hidden-fact-21"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-20"
          xlink:label="hidden-fact-20"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span>Net of issuance costs
of $6,243 (see Note&#160;1c).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-23"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-22"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-21"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-20"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-69"
          xlink:label="hidden-fact-69"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-68"
          xlink:label="hidden-fact-68"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-70"
          xlink:label="hidden-fact-70"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-71"
          xlink:label="hidden-fact-71"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span>Net of issuance costs
of $222.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-69"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-68"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-70"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-71"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M?G'D:5XO3HX_4[W;)4G,YE#4ZIS!B!+%86QQH_@Z/P!]YDKQ)+]<,AHRH5^
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M8/MMA@5>D*!L .ZOI#2[B>W!_96;_@902P,$%     @ MWY_5J$16<Q\!
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M-?)Z9^4].$=#56R#QW0%1*R+!>JR!_= 6NOYK+A[>Q6%%Q'M]R_HD;Z6Q.&
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MB:9GG>BW/'4.=?#NK)-^0+5.SR:QB.XY3N^T@^XGGD]?]FK9Q#%=T><=IL\
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MJO,9LM#G4<^P2+]WHRI]J&@A%IJ8#9W89\!JW^GZ'ZQK+*D/"\B? P34M2S
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M)GT7J5PKXL4I5>9?Y\@)+XKV;.8IJW:.Y'W.M]OOHQN<O>]+IGPB13$VB6.
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MII&@ $)>%.HV0$(C=(/T1)+8B:1F@HH$^3%M#SJ:$YPNVQ@_JR4F"0SULTM
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M/Z>(39]/Q&=(2(<)[844UR7J11R+A;9-*5%#N6J#SA&3/"U;6N0XR38HI5M
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M [E(Q[1G$V2M&$:MBTP*1B*S##4-P%Q5/90.L@VE=?H?PFRNQ8+W@AOZ0'"
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MW(XY5[8"5L8S]#[)4U]FE/K]9=_XE0)JTL8F"C>S9L#N)7UC2\ ]XSAP()@
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M965T<R]S:&5E=#$P+GAM;(U4;7/:, S^SJ_09;M]:IO$A X8Y(Z7;.W=2G-
MMWTUB2"^)G9FFY?]^]D)9.R.<OV26++TZ)%D:; 7\E5EB!H.1<[5T,FT+ONN
MJY(,"ZKN1(G<W*R%+*@VHMRXJI1(T\JIR%WB>?=N01EWPD&EBV4X$%N=,XZQ
M!+4M"BK_C#$7^Z'C.R?%G&TR;15N."CI!A>H7\I8&LEM4%)6(%=,<)"X'CHC
MOS\.K'UE\(/A7IV=P6:R$N+5"H_IT/$L(<PQT1:!FM\.)YCG%LC0^'W$=)J0
MUO'\?$+_6N5N<EE1A1.1_V2ISH9.UX$4UW2;Z[G8/^ QGX[%2T2NJB_L:]O
M&"=;I45Q=#8,"L;K/ST<ZW#FT/7><"!'!U+QK@-5+*=4TW @Q1ZDM39H]E"E
M6GD;<HS;IBRT-+?,^.DPEEA2ED)T,&U6J(#R%)YUAA(F6RF1:Q@IA5H-7&W"
M62<W.4*/:VCR!K1/X$EPG2F(>(KI_P"NX=F0)2>R8W(5<8K)';3]&R >(5?P
MVDWR[0JO_=[D1TWR<TR0[>@JM]J5TM(\GTLEJ ,$EP/8B>JKDB8X=,S(*)0[
M=,)/'_Q[[\L5^D%#/[B&'L;S*!X]3B'Z%4>S1;2 T6P*S\N': Z3E_D\FBUA
MM%A$R\4EXE>A+Q.?/2\C:/=OX=V!6Z9C6*Q,/4W76K9KMG5^ZU1X/!7^(W0Z
MQ'S]FZ#3;GT3.Y2\L(^/;G4F)-/,&)%V#SJ]^]9W-&-H1J\4BFD%MQ $K;IK
MR?')TNK) NEUP?>[+8OK=7L&G]P0WX=+M7?/9JA N:DVA8)$;+FNQZG1-LMH
M5,_@/_-ZDSU1N6%<08YKX^K=?>XX(.OM4 M:E-5$KH0V\UT=,[-045H#<[\6
M0I\$&Z!9T>%?4$L#!!0    ( +=^?U8,DE:D/ ,  *<&   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;(55VV[;.!!]]U<,U*)H :UUMQS7-N D+C;
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M_6&:."![6>P-+5HK11NA2=CLLJ0_"4KC0.>%$/K),!<<_TWSGU!+ P04
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M<#KKAC&SO?&FX(_\A?'>Y'R92H$ZHPVXOC3&;V_H@/I7GZO_ 5!+ P04
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M]8>XYUG?/ZQO873]%?Z;UX[HP5)!HI5J"W O70Z2U&9(89+<RY[BCEZ&BO,
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M FC5S[+"':/,*)R>V04D0PRV2?<&N:Z012&NZER7 #R[NHM-EA#8ZIM"B4\
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M/0_](!*)FP4+IO1H3LS%^#R,G&NU;8TX#(\/#9^."&/G MH6-)B>+[*$^YW
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MR?U%6VWYMV@W5=M6&_ZZ5A+!3@/P?%6A%MD+6F#X<>+K?P%02P,$%     @
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M@4_+&<EV%5K^T(/$N(/>Y=P()J3$,^<*D>F\,6\SQGC46%8N(@X&6<^YUIR
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M%W"&H?:;LRV<]L.K!<T G&: ?=N^V[E_TPNA_9.@O7,LSSKIE;W]J^//9;5
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M/(UK6K6=8]OMVK/F%M&R%3?3G9+7$ (3])S2AHHEC)6=_T+4)%]4R3>S@KX
M_IQJ>OA\K<#@EU2/\FZ,Y*PON+Y$/08VTE94.$T5A2BI.%EX3XUN<M"$@"+_
M@JH,AP'0O2C\NRF+*J<2['7I=,T=Y3AMJI&Y0/Y>N&5P@;Z*EJD["*S-\L;K
M<T'VK K;<\Z)*JXWP4DH"%XB2C(TIA((IP-Z1YNZO<;A1IE/7-&F%A]I[S?*
MK: ^\";(&Q@2T""$L^D/EA85)Q/X"EM$R5)L^R??'N0;HC%[TZBCTJ(>E=9-
MR?0SC<=9J-/ S,B]@TGO#9,MSTODO7/HXLUHP-8"57)C9N2U>[6E9\D\*I%
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M5V1X $S;T0 "!,MF YVMA4,N(3['5I(D($DWZ@$T[02!PA2#]S'LZDI,4<1
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M27"%&P.VE9*9IQL4^K".TN@X\('O:O(#<;YJV X?D#XV&^-Z\8!2<HG*<JW
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MQ6)2Q7MTV[G6H@0N73WOT9/;,?9IG+_V:(!J!%MKXW+J]X?ONJ8\MH7G FV
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M8"@-L>IFJSJ"%OIR6%(AKQK=3.3/ #!5(.=7E(I=1]TWS>]%^ =02P,$%
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M8:70UI6?EK:1@78&]GRM%.X7+L#0&M/?4$L#!!0    ( +=^?U:[T^"BNP(
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M4#3I^J'8!T8ZMH5*HD?2<?KO1UVB6V4FPD[V)9%DG8?4>R@>O1*7!R&_J2V
M)H])G*J+T5;KW;GCJ& +"5=CL8/4_+(6,N':[,J-HW82>)@');'#7'?N)#Q*
M1ZME?NRC7"W%7L=1"A\E4?LDX?+[%<3B<#&BHZ<#GZ+-5F<'G-5RQS=P"_KS
M[J,T>TY%":,$4A6)E$A87XPNZ;G/YEE ?L9?$1Q48YMDEW(OQ+=LYR:\&+E9
MCR"&0&<(;OX]P#7$<48R_?BGA(ZJ-K/ YO83_7U^\>9B[KF":Q%_B4*]O1@M
M1B2$-=_'^I,X_ ;E!<TR7B!BE?\EA_)<=T2"O=(B*8--#Y(H+?[SQU*(1H#A
M] >P,H!U Z9' B9EP*03<+1+TS)@^M(69F5 ?NE.<>VY<![7?+64XD!D=K:A
M91NY^GFTT2M*LX%RJZ7Y-3)Q>O6'V2=B3:XEA)$FEU+R= -F)&CRQ@/-HUB]
M);^0S[<>>7/REIP0AZ@MEZ!(E)+/::35.W/0;-]MQ5[Q-%1+1YM^970G*/MP
M5?2!'>D#)1]$JK>*^&D(84^\]TP\LP <(TBE"GM2Y8I9B;_OXS&A9^\(<QGK
MZ="U/?QR)\>$S8^&>_9P#X(QF="CX?X+6G=G?>$M,2;5$)GDO,E_&2)?\[-N
M-"3J[[X14#0Q[6\BFPW/U8X'<#$RTYT"^0"CU<\_T;G[:Y_ZF# /$^8CP5IY
MFE9YFMKH19Z"(DE\(R%/45\NK)BAN<"$>9@POX#-<UA6+Q]6=.:Z[M)YZ!%Y
M5HD\>UYD<S.4.M\+:0!1NB$[&070I_;LAVZP6:,7A8H_GD1=MWN69^W:4'F0
M8"T5YY6*<ZN*7W@VB6A%=B #,TK-(TF?=%;(T(&*"?,*V**1+W?L+MKI\I%:
M;"E\6BE\^C*%X=%('"DH!BAY8TJU)^*8RUS\HIB_[1/?RA\J/B;,*V"G#?%G
M8SKMB(_48DO\127^XF7B:Z%Y3'@B]OTSL14S5&-,F+?HG9 Z&B.UV-+XK-+X
MS*KQ%61#.$HU&+8I>,9SI.G>J"VY[IU,K+BA6F/"O )&:7LV.6.SCMQ(C;;D
MIFYM%%RKX.7C7W:8K 'ZG_.MB*$BH]*\DM8<TJ>3[JR!U61;XX89HU:-_P2=
M/5Q$2NUY:F;K0"C=+[25,UAH3)I7TII"3^?=VHC59%MH5@O-ACS&\=K3]*IM
MA0U6&Y/F/7.A=]NL\HL (%2$Q[$(N"[>\:A]K"',K/L)>S=9N$^_FF-:$&WB
M;B$0:4CNC#:!V37FGIQ0UG/BH:QWX[[G3*S+;6>Z-J_4ZKE6-T\5 AYWD*HC
M\Q:J/46E>26M78K9I'L_O8;SI+7UI';O^3Z21F)=CI2O'R"Y!]G[(L .&BPU
MJOU$I?E8M'9*:J-*9Z__VH9B6LYK5)J'2O.Q:.ULU8:8VAUQ^P8Z[ACLF,$)
M037%)6UF?XOA8S7:5KHVQM3NC#NE?\>_\_NXUS'808.U1O7 ):VI]82>=I5^
M#1-,:Q=,[3;XY4^SJ#X8E>:5M*;09[,)ZRK]&E:8UEZ8VLUPYTG-6G]1?3 J
MS4.E^5BT]A>DVB\S]_7K+T,UU*@T#Y7F8]':V:J=-[,[[_(.>KX VSF#,X+J
MO$M:<Z[Z\5N#C]5F6^G:>K-!UMM2?^V@P5*CVNZ2UI1ZT7U?A]5B6^C:^3*[
M\[W;1K(:T<I:%.RDP4JC^E]4FH]%:^>D]LEL^C\4!50+C4KS4&D^%JV=K=I"
M,_O'WM8=9*L)J"X9E>:5M.=JPFNX7U:[7V9WOVVA4Z')(=+;4/)#VJLWJ@E&
MI7DES?Z]W\=JL]#;::S_2D!N\H5WRO@M,UZ+14_5T6IQWV6^I*US_(J>7Q=+
M]&I,L6+P Y>;*%4DAK5!NN-3,V!DL0BOV-%BEZ\RNQ=:BR3?W (/068GF-_7
M0NBGG:R!:BGDZE]02P,$%     @ MWY_5M)Q,99[ P  -0L  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#0N>&ULK5;;;MLX$'WO5PS4R[9 :LFR8QNI+2"Q
MMM@"+1K$V]V'11]H:2P1I40M2=G)WW=(V:K35;0UX!>)MW.&<S@<SGPGU3>=
M(QJX+T2I%UYN3'7E^SK)L6!Z("LL:68C5<$,=57FZTHA2QVH$'X8!!._8+ST
MHKD;NU717-9&\!)O%>BZ*)AZN$$A=PMOZ!T&[GB6&SO@1_.*9;A"\Z6Z5=3S
M6Y:4%UAJ+DM0N%EXU\.K>&K7NP5_<=SIHS983]92?K.=#^G""^R&4&!B+ .C
MWQ:7*(0EHFW\N^?T6I,6>-P^L+]WOI,O:Z9Q*<7?/#7YPIMYD.*&U<+<R=T?
MN/?GTO(E4FCWA5VS=CKV(*FUD<4>3#LH>-G\V?U>AR/ \"E N >$OPH8[0&C
MGP"SX G > \8.V4:5YP.,3,LFBNY V57$YMM.#$=FMSGI3WVE5$TRPEGHJ4L
M"F[H'(T&5J:PE*7A949]^,C9F@MN.&IX':-A7.@W\!:^K&)X_>(-O !>PI^Y
MK#4!]=PWM!U+ZB=[TW%C.GS"]#"$3V0MU_![F6+ZF, G/UIGPH,S-V$OXPJK
M 8R""PB#X;1C0\M^>(S) ,+0P2==_OP"?#2T\##L\6;4'LW(\8U./9K$GDC,
M=2*DKA7"/]=K;13=H*\=F[YIC(R[C=BL<J4KEN#"H[2A46W1BUX]'TZ"=UT"
MGI,L/A/9(W''K;CC/O;HEBG#$UXQEWTJ]N!T[M*OE^=4_<Y)%C=D$T=FT_LV
M&L]FL[F_[=#ELM7ELE>7GGP@?N2#"TJM.E&\LNIUB=9KY%31SDD6][MO<B27
MBXJ5#\ U)$X-@^DS(VV0@)(/3+B,R PP4,P@R V,7MJO9H(FJ&%94MS2FUIA
M"I62:9T8$JVN@'B&0?#RL(H5LB9IJ9<I9C57F" ]A(02M:8$:Y!\,M;:QP\W
MG^^>68L#RKI*UED.E'*P6*-JT\X%E/)HDSG;(JP1;83S%*2B=S91-::#GBLT
M:4-ETJO5>TYI6_VF88/8%0.]Z%-C8/*?6 \O@S;4FZ,]D\%'8DQ;,::]8JQJ
M;F##!8UG@/=4E>E.4:;_[\>RU]*I\7XFLD84_ZC0*%!EKF"SUX2"N*DYVM&V
M)KQVI9#_8WE34'YB*N.E!H$;@@:#*5U,U11I3<?(RI4M:VFH"'+-G.I:5'8!
MS6^D-(>.-=!6RM%W4$L#!!0    ( +=^?U;BO\^#\P,  ,\6   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;+68;6_B.!#'OXJ5VSVUTAV)PV-[@-3B
MK@[I>JH6>OMBM2_<9(!HDYBSG<)*]^'/3M) :&I@Y;Z!V)GYV?-/QAG-<,/X
M=[$"D&B;Q*D8.2LIU]>N*X(5)%2TV!I2=6?!>$*E&O*E*]8<:)@[);'K>U[/
M36B4.N-A/O? QT.6R3A*X8$CD24)Y3]N(6:;D8.=EXG/T7(E]80['J[I$F8@
M']</7(W<BA)&":0B8BGBL!@Y-_B:X(%VR"W^B6 C]JZ1#N6)L>]Z, U'CJ=W
M!#$$4B.H^GN&"<2Q)JE]_%M"G6I-[;A__4+_E >O@GFB B8L_A*%<C5R!@X*
M84&S6'YFFS^A#*BK>0&+1?Z+-H5M1QD'F9 L*9W5#I(H+?[IMA1BSP'WWG#P
M2P?_T*'SAD.[=&B?ZM I'3JY,D4HN0Z$2CH><K9!7%LKFK[(Q<R]5?A1JI_[
M3')U-U)^<CQ- Y8 FM,M"'1!0-(H%I?H=_0X(^CBPR7Z@*(4S5<L$S0-Q="5
M:E'MZ@;E K?% OX;"V ?W;-4K@2Z2T,(ZP!7[;;:LO^RY5O?2"00M% ;_X9\
MS_<;-C0YW1TWN)/3W3U#-.WJ ;1S7ON\!_#U+V6'IA(2\:U)] +::8;JP^):
MK&D (T>=!@+X,SCC7W_!/>^/)L%LPH@E6$W,3B5FQT0?WP1!EF0QE1"BF FA
M)56O+V%Q3+FX;!*R /9RH#XDG\>XZV.O/W2?]R4RKGNN1)9@-8FZE41=HT0S
M264F&?^!)-TBKJ1J4J5@#/94\5I^^T 3XT+G:F()5M.D5VG2,VIRMUA _OTQ
M:F)F7'BMMO>QZ16;]%Z+65>2&-$_&7R_"KYOW/A4< HQ^GH/R1/PQL/&"#CW
ML+$)(Y9@->$&E7"#]SBY!S;%M DCEF U,:\J,:^.'DN  L;73.>?,1&O3CF<
M3C$B1XQJD6!O5U)YQE@>_Y[.[PB:S6_F=[/&BLGH?^X[8)5&;-'JVNV5H_@]
MDJJDVE+4)HW8HM45]7>*^L:W\1.$P&FL,ZI1.;\I!_!!-IG7.%L12[2Z(KN*
M&QMKT'I^HO_0?91&2988/X%FY-DOF-6*VQ:M+N>NYL:==TE9FR7UQ"J-V*+5
M%=V5Z/AXC7[JQ[!$85Q+8*_7/<S@T^S(<;MZ4+L:&YL+Y%=91[?'L\Y285Q*
M8)-&;-'J<NZJ=MQ_EZRS6LM;I1%;M+JBNW(>&PO<\[)NT)0E&+_*NM/LR'&[
M(BAWK].7 %_F'5.A-IVELNB@5;-55_8F[T4>S-_J;FW>0=QABE;O/>7+*!4H
MAH5">JV^.A!XT3TM!I*M\W[B$Y.2)?GE"J@J,K2!NK]@3+X,] )5#WO\/U!+
M P04    " "W?G]6DWVW*R4#  ".#0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970T-BYX;6S%5VUOFS 0_BL6JZ96VLH[(5V"M)1-B[1*5=-N'ZI]<. 24 %G
MMO.R?S_;$!I2BMH*J5^";>YY?/<<YYQ'6T(?6 + T2[/"C;6$LY7%[K.H@1R
MS,[)"@KQ9D%HCKF8TJ7.5A1PK$!YIEN&X>DY3@LM&*FU:QJ,R)IG:0'7%+%U
MGF/Z;P(9V8XU4]LOW*3+A,L%/1BM\!)FP.]6UU3,])HE3G,H6$H*1&$QUKZ:
M%Z%I2("R^)7"EAV,D0QE3LB#G$SCL69(CR"#B$L*+!X;N(0LDTS"C[\5J5;O
M*8&'XSW[=Q6\"&:.&5R2['<:\V2L^1J*88'7&;\AVQ]0!>1*OHAD3/VB;65K
M:"A:,T[R"BP\R-.B?.)=)<0!P/2> 5@5P#H&.,\ [ I@OQ3@5 !'*5.&HG0(
M,<?!B)(MHM):L,F!$E.A1?AI(?,^XU2\306.!],B(CF@6[P#ADY#X#C-V!GZ
MC&;B"XO7&2"RD#H"I1 CCG<(,P:<"8N[68A.3\[0"4H+=)N0-<-%S$8Z%VY)
M<CVJ7)B4+EC/N&!:Z(H4/&'H6Q%#W"3013QU4-8^J(G5R1A"=(YL\Q.R#,MJ
M<>CRY7"S!1Z^'&YT1&/7*;(5G]UWBNY_"B8TY9"S/VUI*;=UVK>5!\X%6^$(
MQIHX41C0#6C!QP^F9WQID[1/LK GLH;<3BVWT\4>W!*.LS:Y2IBG8/(XW03V
MT'4'(WUSJ,-3*\?R#+-I%;9P>;XWK*T:GKNUYVZGYZ'X3!A/(W0Z911#=H;N
MKR"? VW-?B?7:[/?)UG8$UE#0Z_6T'N?8O/ZE+M/LK GLH;<@UKNP=N*K82Y
MAP7B.X9]5&Q/K1S3'!Z59-C"Y0Y]N[W8_-ISO]-ST76(GJ+H++%.AM?FO$^R
ML">RAG+#6KGA^Y38L$^Y^R0+>R)KR&T:CRV>\;8BJW"'?T.FZ3I'1=9FY1A'
M5F&+E>][1S6F'S2J.="E:O@9BLBZX&5[5Z_6EXJOJI4^6I_(RX9J@!]IRIO*
M%:;+M& H@X6@-,X'HNYIV?R7$TY6JAV>$RZ::S5,Q(4)J#00[Q>$\/U$;E!?
MP8+_4$L#!!0    ( +=^?U9,[X+HRP,  (,.   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;+57VW+;-A#]%0R;Z20SB4F0U,V5-!/;S=0/:3R^I,\0
MN1(Y 0D5@"3G[[L *4J6(-AUW1>) '</SEDLL-SQ1L@?J@#0Y+'BM9H$A=;+
M\S!460$54V=B"36^F0M9,8U#N0C54@++K5/%PSB*^F'%RCJ8CNW<C9R.Q4KS
MLH8;2=2JJIC\>0%<;"8!#;83M^6BT&8BG(Z7; %WH!^6-Q)'88>2EQ74JA0U
MD3"?!)_I^27M&0=K\;V$C=I[)D;*3(@?9G"=3X+(, (.F380#/_6< F<&R3D
M\7<+&G1K&L?]YRWZ%RL>Q<R8@DO!_RIS74R"84!RF+,5U[=B\P>T@BS!3'!E
M?\FFM8T"DJV4%E7KC RJLF[^V6,;B#T'VC_A$+<.\:%#>L(A:1T2*[1A9F5=
M,<VF8RDV1!IK1#,/-C;6&]64M=G&.RWQ;8E^>GI=9Z("<L\>09'W5Z!9R=4'
M\HG<8<+D*PY$S$U80$K(2=E8:VN-\3:;070!I,:$PUD"\SE.*?1_N+LB[]]]
M(._0B=P78J58G:MQJ)&T63K,6H(7#<'X!$$:DZ^BUH4BO]<YY$\!0E3;28ZW
MDB]B+^(59&<DH1])',6Q@]#ER]VIAT[2[4!B\9*3>&UP3?R84J#5N2M,#4KJ
M1C&G_5PM60:3 (^S KF&8/KK+[0?_>:2^$9@3P2GG>#4ASZ]9%+^Q MHPV1.
MN$#%SK1H0/H6Q%Q&ZVF2CH;I.%SO"W%8T7@XZJR>,.QU#'M>AK>HF<FL()BR
MF/QKO.R6>'5I H]X?9[@VT#V]ICTDD'_@*[#*(X2-]M^Q[;O9?MM"9+ILEX0
M#GBA$5ZR6<E+7;IY]H\HI*/H@*9WP5>FQZ"3,W@V^(BH;/ 9QSK#ZLPM97 D
MA?8&!U*.;>+D1'H,.X9#+\-KI5:&$\F$TDYB7O]_>U:'QQLV.*%@U"D8>14X
M[APR SR30-:,KUA38;>Q=RD<'9.B4708_&.K9!#3R$V>1KN:%7GI?W\9QQ9E
M?_E/:92FPP.6+CL?S[W:2KT\[X5F?%<]=\%VLJ7'=T-O=$C5N^ K3R:-=X+B
ME]>JO7O&6;!:K#<Z!6^%]E3YKDA3;TD\NF1OOSWX]C(YSBC'9OX?59CNRC#U
MUV%'=CY3.EK YV1YEWVMK%WMIO[B_2=^BCJ.W$?SC>H4Y85STR7.#/WO0(WD
M<.]SO@*YL%V.PFJSJG7SF=O-=IW49]L_',Q?F [+M@D[F*8]^\KDHJP5)O,<
M(:.S 7*73<?3#+18VJ9A)C2V(/:QP"X1I#' ]W,A]'9@%NCZSND_4$L#!!0
M   ( +=^?U895JOA]P(  %(,   9    >&PO=V]R:W-H965T<R]S:&5E=#0X
M+GAM;*V776_:,!2&_XJ555,KK0V$CT(7(A6R:5Q40Z7=KDUR0J(F-K,=8/]^
MMA,\4H4(U-Q _/$^]GE]8@[NCK(W'@,(M,]2PB=6+,3FP;9Y$$.&^1W= )$C
M$649%K+)UC;?,,"A%F6I[70Z0SO#";$\5_<MF.?27*0)@05#/,\RS/Y.(:6[
MB=6U#AW/R3H6JL/VW U>PQ+$ZV;!9,LVE##)@/"$$L0@FEB/W0=_K.;K";\2
MV/&C9Z0B65'ZIAKS<&)UU(8@A4 H I9?6YA!FBJ0W,:?DFF9)97P^/E _ZYC
ME[&L,(<937\GH8@GULA"(40X3\4SW?V ,IZ!X@4TY?H3[8JY]P,+!3D7-"O%
M<@=90HIOO"]].!)TAR<$3BEPW@OZ)P2]4M [5] O!7WM3!&*]L'' GLNHSO$
MU&Q)4P_:3*V6X2=$'?M2,#F:2)WPYB2@&: 7O >.KGT0.$GY#;I%2YE@89X"
MHA%*BDE"3[I%KTL?75_=H"LY@%YBFG-,0N[:0NY'4>V@7'M:K.V<6+OKH"=*
M1,S1-Q)"6 78,A 3C7.(9NHT$GT([E"O^P4Y'<>IV=#L?'FW1NZ?+^\T1-,S
M9]/3O-X)GCF"GQ&JG-/CB@LFWY@ZRPMDOQZI+I$'OL$!3"QY2W!@6["\SY^Z
MP\[7.KO:A/DMP2I6]HV5_2:Z-\L9 U)K6"$<:J&Z)+<R+\>NO3WVH1%^J0\M
MP2H^#(P/@T8??(A .A'6&=&HK-\7JDN:ECC^QSD5BX;&HF&C17-SV2'8RU]7
M#G5F%8Q!8]8TKG-IUK0$JUAR;RRY;\X::0@728"NYYQA2&_J'&E$7) ^+7'\
MCW,J7HV,5Z-&KV0U(FL-4N?0Z(R<:81?$/W'.97HQR;Z<0LOS_B,*[=QG4M?
MGI9@A27V4;65 5OKJI6C@.9$%*6*Z36%\:.N!]_U3V7!7-2W_S%%M?V$V3HA
M'*40263G3M6GK*A@BX:@&UW3K:B0%:)^C&71#TQ-D.,1I>+04 N8OQ'>/U!+
M P04    " "W?G]6E)["-EP)  "[2@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970T.2YX;6RUG%UOVS@6AN_]*PAOL=L";BQ1MFQWD@!I]#$=;+9%TVXO!GO!
MR+0M5!(])&4GB_WQ2TJR)3DR'1<G!=KZ0^>A)+XBSWDIZW++^$^QHE2BQS3)
MQ%5_)>7ZPW HHA5-B;A@:YJI;Q:,IT2JMWPY%&M.R;P(2I,AMBQWF)(XZU]?
M%I]]X=>7+)=)G-$O'(D\30E_^D@3MKWJV_W=!U_CY4KJ#X;7EVNRI/=4?E]_
MX>K=<$^9QRG-1,PRQ.GBJG]C?P@=K .*+?X=TZUHO$;Z4!X8^ZG??)I?]2V]
M1S2AD=0(HO[;T%N:))JD]N.O"MK?MZD#FZ]W]* X>'4P#T306Y;\B.=R==6?
M]M&<+DB>R*]L^SNM#FBL>1%+1/$OVE;;6GT4Y4*RM I6>Y#&6?D_>:Q.1"/
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M=]R]JH3K!0)LMI3OXBQ.\]2<#(&N#8#2/%":#TH+0&DA%*TME-H/Q^-7389
M;7)0F@=*\T%I 2@MA**U-51[Y=CLE;>2H>,_G:@HS<'.<2?8FHT.[I,S-W>V
M#$#OB0>E!:"T$(K6ED'MG6.S=WY''D_/.:#>.2C- Z7YH+0 E!9"T=I"J;US
M_*K>.0;USD%I'BC-!Z4%H+00BM;64.V=8[/;^M(YY_F]V:/N.0?4% >E^:"T
M )060M':/P&O/6#'[ %7ORD1^TD'_0_]@B]L;N7<(064YH'2?%!: $H+H6AM
M+=6^L/.JOK #Z@N#TCQ0F@]*"T!I(12MK:':%W9.^,+/?CM86'"=>@'UA$%I
M'BC-!Z4%H+2PHID2A%(*P\8C=%+*E\73D02*]$_URJ?'[#_=/X'IIGCNT,'G
MGOTA*)^C5&/*QSK=$;Z,,X$2NE!(ZV*B]HJ73THJWTBV+A[4\\"D9&GQ<D6)
M&J_T!NK[!6-R]T8WL']>U?7_ 5!+ P04    " "W?G]6+./>)V$"  "-!@
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M3\W1NE$AKG,@A#S753,]>8?2QW#5)-!%3L15DV.X:A*P) =QU62'JT:L2E>
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M]@+8A"^"C:,U6*#8$J(04!.>AYJOUA Y+H[BP2\M?8!0.!$(A6- * 0(A8-
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M+W-H965T-34N>&ULK5;;<MLV$/V5'39M[9E&O.CN2IJQ96?B3CWUV+D\9/(
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MI!IXJM-,#;' =8#Z?\F8W%WH![1C\>(_4$L#!!0    ( +=^?U;%L*3#LP,
M /T,   9    >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;*U7:X_B-A3]*U:Z
MJF:D7?(@!)@"TC!IU4K=+5HZW<^>Y$*L36QJ.[#]][UV,ED>)II6? ';N>?$
MY^3ZYF9V$/*K*@ T^5:57,V]0NO=@^^KK("*JH'8 <<K&R$KJG$JM[[:2:"Y
M!56E'P5!XE>4<6\QLVLKN9B)6I>,PTH255<5E?\LH12'N1=ZKPN?V;;09L%?
MS'9T"VO0S[N5Q)G?L>2L JZ8X$3"9NX]A@]I&!B C?B+P4$=C8F1\B+$5S/Y
M+9][@=D1E)!I0T'Q;P]/4):&"??Q=TOJ=?<TP./Q*_LO5CR*>:$*GD3YA>6Z
MF'L3C^2PH76I/XO#K] *&AF^3)3*_I)#&QMX)*N5%E4+QAU4C#?_]%MKQ!$@
M3*X HA80G0/B*X!A"QB^%1"W@-@ZTTBQ/J14T\5,B@.1)AK9S,"::=$HGW'S
MW-=:XE6&.+U84L4R0GE.4E;6&G+R"9/M=Z$468$DZX)*('<I:,I*=4\^D#5F
M7EZ70,3&&-Z"\Q9<&N .@4+FC&,B$649/I#G=4KNWMV3=\1OUA1AG#QSIM5[
M7,3QGX6H%9*IF:]1F=F?G[4JEHV*Z(J*,"(?!=>%(C_S'/)3 A\MZ7R)7GU9
M1KV,*60#,@S?DRB((L>&GMX.#QWP].WPH$?-L'O*0\LWO,+WJ:Y 4BWD@\O;
M!AN[L:;P/*@=S6#N8651(/?@+7[\(4R"GUR^W)(LO1'9B6=QYUG<Q[YX+$N1
M45N<,-4YG@J3W"[_&I[$\I@ZNU\,IZ/1>.;OCXVYC(JC) A/HU('5S))IEW4
MB911)V74*V6%M12DQ//9G,:=G0//P"6GE\MM.G%EPHUXTH9G=&+O<.AV).D<
M27H=20$J,&5KSW+@N<N&7H+_8,.->-+DPH8H#&.W#>/.AO'_R'%"M9;LI=;T
M!>N\%N2/DV)>B#('Z3P)XS>=A,LHUTEP14W#Q"UXT@F>]!;"%+C M^C54CBY
M92F\)5EZ([(3UZ:=:]/>-/EBNR<\+W2/KY$MG"6$(MA0*HVO;L:WY Y?Y;9M
M4/<NAZ<7:1Q.\?$GT^@L2QR!DW$4CJ+)6:)<!DY'DR@.1NY4"8/OK5'0*WMY
MT=YT)\2T.$TM-7)34994'JTZE;=W&Q^?X$$0G\EV1EUH=D3%@WARIM@_Z@NQ
M =C:_EJ13-1<-ZU0M]KU\(^V<SU;7YK>WO:;WVF:#X./5&X95Z2$#5(&@S$^
M!]GTVLU$BYWM/E^$QE[6#@O\/@%I O#Z1@C].C$WZ+YX%O\"4$L#!!0    (
M +=^?U:6\8,_H (  !$'   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM
M;*U5;6_3,!#^*U9 B$E0)VGVHI%&:A<02(Q5JX#/;G)IK#EVL-UV_'O\DF;9
M2*=]V)?$+_<\=_><?4[W0MZI&D"C^X9Q-0MJK=M+C%510T/41+3 S4XE9$.T
MF<H-5JT$4CI0PW <AF>X(90'6>K6EC)+Q58SRF$ID=HV#9%_%\#$?A9$P6'A
MEFYJ;1=PEK9D RO0/]NE-#/<LY2T :ZHX$A"-0OFT66>6'MG\(O"7@W&R&:R
M%N+.3KZ5LR"T 0&#0EL&8GX[N +&+)$)XT_'&?0N+7 X/K!_<;F;7-9$P95@
MOVFIZUEP$: 2*K)E^E;LOT*7SZGE*P13[HOVG6T8H&*KM&@ZL(F@H=S_R7VG
MPP 0G1T!Q!T@?@I(C@"F'6#Z4D#2 9S4V*?B=,B))EDJQ1Y):VW8[,")Z= F
M?<IMV5=:FEUJ<#I;$$4+1'B)<LJV&DKTPYRU[T(IM 2)5C61@-[GH EEZ@1]
M1"MS\,HM R0J*W@'+CLPL\#6 (4L*3?G""G/L#1?KFO0M"">Z"W"?E.E6)M,
M;#RXZ*)>^*CC(U%',;H6ADZAS[R$\C$!-A+T.L0''1;QLXPY%!,TC3Z@.(SC
MD8"N7@Z/1N#YR^'A,]E,^ZI.'=_T"%]?I)L*^0K/!Q7NJWMS*)(O\WRMM#07
M<:P>WE\R[L_VIDO5D@)F@6D^"N0.@NS=F^@L_#2FY6N2Y:]$]DCGI-<Y>8X]
M.RC*S9WICWYWXBE'N6",R,'JR9BTWL6Y<V&[]"Z+)V&2XMU0LC&C^.*Q4?Z_
M43))'HQ\BGC0+!J0&]=T%2K$EFM_7_K5OJ_/73M[LKXP_=ZWYP<:_UA<$[FA
M7"$&E:$,)^>G 9*^ ?N)%JUK26NA38-SP]J\62"M@=FOA-"'B770OX+9/U!+
M P04    " "W?G]64^//#/4"  !C"   &0   'AL+W=O<FMS:&5E=',O<VAE
M970U.2YX;6RM5EMOTS 4_BM6D!!(L"3.I=UH(ZT+""1VT0;L ?'@)J>--2<.
MMM..?X_MI*&7M-H#+XTOW_?E.\?N.9FLN7B2!8!"SR6KY-0IE*HO7%=F!91$
MGO$:*KVSX*(D2D_%TI6U ));4LE<['FQ6Q):.<G$KMV)9,(;Q6@%=P+)IBR)
M^#,#QM=3QW<V"_=T62BSX":3FBSA =3W^D[HF=NKY+2$2E)>(0&+J7/I7Z2Q
MP5O #PIKN35&)I(YYT]F\B6?.IXQ! PR912(?JS@"A@S0MK&[T[3Z5]IB-OC
MC?HG&[N.94XD7''V2'-53)VQ@W)8D(:I>[[^#%T\D='+.)/V%ZT[K.>@K)&*
MEQU9.RAIU3[)<Y>'+8(?'R'@CH#W">$10M 1@I<2PHX0VLRTH=@\I$219"+X
M&@F#UFIF8)-IV3I\6IEC?U!"[U+-4\F,2)HA4N4HI:Q1D*,;?=>^<BG1'0CT
M4! !Z$T*BE FWZ+WZ$%?O+QA@/@"Y1V%&7BMX=+"B5*"SAM%YAJF..(BIY6^
M4^UVP5D.0FHI.Y435^DXC!LWZSS/6L_XB&<?HVM>J4*BCU4.^:Z JQ/09P%O
MLC##)Q53R,Y0X+]#V,-XP-#5R^G^ #U].=T[$4W0GVE@]8(C>C=-.=>'H0_H
M=I-Y>XX2_;R<2R7T?^W74-9;U7!8U=2?"UF3#*:.+C 2Q J<Y/4K/_8^#&7L
M?XJE_TEL)YMAG\WPE'IRNW-[$:]-O1J\M:U.9'5,N5TE.!R/PG T<5?;J3G$
M^>?GT2@\W\6E [AH'&#?ZW$[ 45]0-')@!Z)$*12@R%$!Z\,_0#'P5X$AS#L
MCR-S]W<".(2-XY$7'O$?]_[CD_Z_<478D/GXT-6YYXVV\M6Z'\!A/\2C/5PZ
M@ LC#T?[_MVM\EN"6-HV)E'&FTJU-:A?[3OEI6T0>^LSW4';AO=/IFV_UT0L
M:241@X66],Y&VI5H6UH[4;RV17[.E6X9=ECHKP 0!J#W%YRKS<2\H/^N2/X"
M4$L#!!0    ( +=^?U:=H%^G#@,  '4+   9    >&PO=V]R:W-H965T<R]S
M:&5E=#8P+GAM;+5676^;,!3]*Q:KIE;:0B#DHUF"U(1.Z[1J4;IN#]4>'+@$
MJQ@SVR3IOY\-A"4M16W%7A+;W'.NSS&^W,F6\7L1 4BTHW$BID8D93HV3>%'
M0+'HL!02]21DG&*IIGQMBI0##G(0C4V[VQV8%)/$<"?YVH*[$Y;)F"2PX$AD
ME&+^,(.8;:>&9>P7EF0=2;U@NI,4K^$&Y&VZX&IF5BP!H9 (PA+$(9P:%];8
M&^GX/. G@:TX&".M9,78O9Y<!5.CJS<$,?A2,V#UMX$YQ+$F4MOX4W(:54H-
M/!SOV3_GVI66%18P9_$O$LAH:HP,%$"(LU@NV?8+E'KZFL]GL<A_T;:([:N,
M?B8DHR58S2E)BG^\*WTX %B#9P!V"; ? YQG +T2T'LIP"D!3NY,(27WP<,2
MNQ/.MHCK:,6F![F9.5K))XD^]AO)U5.B<-)=0HPE!&B!N20@T*D'$I-8G*&/
MZ/;&0Z<G9^@$D03]B%@F<!*(B2E57HTV_3+'K,AA/Y/#LM$U2V0DT&420'!,
M8*H-5[NV][N>V8V,'O@=U+,^(+MKVS4;FK\<;M7 O6;XURSNH&YM]B,UO>H,
M>CE?[]5G</=-A:(K"53\KO.]X'7J>77%&(L4^S U5$D0P#=@N._?68/NISK/
MVB3S6B([\M.I_'2:V-T;Q4=\0"EG&Q( %_K]Q91EB:PSL2 ;Y&2Z2FY<:^A,
MS,VA-S4QY^?',5[CIMXHN5])[C=*7BI&S/T(J1NJRMY&E?-4%6>)8*<^$ )J
M;VW_J2A'O]!'RI\&]8;.Z)'TQLV]4?J@DCYHE#Z/"(3H<@=^IC\AZ'L8JL/G
MZ.X:Z IX[;UI9'SMO6F3S&N)[,C)8>7D\#_5H6&;?K9)YK5$=N3GJ/)SU/AF
M7E#"T1:(4*_A&DG@M,Z[1H[7>M<FF=>LSK+0@ZHYHLXH\Z AH4I\WM@)Y.L2
M7'SEJ]6J=[S(6Z9'ZS-K/"]:P'\T14-ZC?F:) +%$"K*;F>H:A OFKQB(EF:
MMSTK)E43E0\CU1<#UP'J><B8W$]T@JK3=O\"4$L#!!0    ( +=^?U; LR>-
M90<  *M*   9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;+6<6V_;-AS%
MOPKA#4,'K+$NEAUWB8$F$K4.RQHTZ_I0[(&1Z5BH+BY)YP+LPT^W6J:LL-9P
M\I+8COX_2CXG)'5$Z>PA%U_DFG-%'M,DD^>CM5*;-^.QC-8\9?(DW_"L^,LJ
M%RE3Q5MQ-Y8;P=FR*DJ3L6-9TW'*XFRT.*L^NQ:+LWRKDCCCUX+(;9HR\73!
MD_SA?&2/OGWP(;Y;J_*#\>)LP^[X#5<?-]>B>#?>499QRC,9YQD1?'4^>FN_
M"5VO+*BV^#OF#W+O-2D/Y3;/OY1OWBW/1U:Y1SSAD2H1K/AUSR]YDI2D8C^^
M-M#1KLVR</_U-SJM#KXXF%LF^66>?(J7:GT^.AV1)5^Q;:(^Y ^_\>: JAV,
M\D16/\E#O>W4&9%H*U6>-L7%'J1Q5O]FC\T7L5=@3YXI<)H"Y]@"MREPCRV8
M- 63;H'W3('7%'C'%DR;@NFQNS1K"F:56/6W6TGC,\469R)_(*+<NJ"5+RI]
MJ^I"D3@KK7BC1/'7N*A3BYOMK>1?MSQ3)+@O?DKRRN>*Q8G\F;PF'V]\\NK'
MG\_&JFBJ+!A'#3:HL<XS6)M<Y9E:2Q)D2[[LJ:?F>M=0/RX.<7><SK?CO'",
M0)]')\2U?R&.Y;@]^W-I+K]BHBBWGBWWCRAWYL^6!^;RWUEFW'EZS,X_7QX>
M_]4Y!BG<G>7<BN?^#\M]_J/8F+Q3/)7_].SI14V>])/+;ON-W+"(GX^*?EER
M<<]'BY]^L*?6KWV2(V$^$A8@810)"T$PS3B3G7$F)OHB>.0BBB4G&Q%'O!AP
MHF+PE;W=RX61--0H2)B/A 5(&*UA7@4KIS#WB^(_WO;F\[/Q_;X'0(UJ'O!V
M'O".\L"2Y)MR+B/[Q#<BAHJ/A/E(6("$T1HVVQ/?.IG-.LJ#6M24G^Z4GQJ5
MOXJS.-VF9,/B)6%IOLU4G_8U9+IW'+9G6?IQ7!I;&JHI$A8@810)"T$P3?O9
M3OO9=_[K(\Y-JL\.5'>M ]6-;0Q5'0D+D#"*A(4@F*;ZZ4[U4Z/JUX*3U;8\
M 2 /3 A63!7[M#="AO;V2)A_>C"@VI;KS6RW,Z(&R%8I$A:"8)K^\YW^<Z/^
M[U<K+N+LCO#'#<\DET7?_\1N$][G B-JJ N0,']^T#?-K%.[XP!DBQ0)"T$P
MS0&VU<83UG?Z@'*JO^&"R#43O<J;"4.EA])\*"V TBB4%C:T_0FD=V)/=C;7
M]=^+IVQS'W#/Q>NW29*KM P,WE>3?O+YBJ>W7/1&!&;@8#L@:3Z4%D!I%$H+
M433=-DYK&^?%,J8&C3(0DN9#:0&41J&T$$73#=1FE+8QR3IJW(&&D5":#Z4%
M4!IM:+:K90T3IY,UH!K5#=!FC;8Y;.SV(.8Q!QHW0FD^E!9 :11*"U$TW3%M
M,FE[+S?F0"-+*,V'T@(HC4)I(8JF&Z@-.&USPGG#$D[R%<G%,LZ8>*J'GM[,
MPTP:[!=H'@JE!79/H#N?S"VGDZ%0:+,ABJ9;H<T[;7/@^5>N6&+(.\WE@_6'
M)J-06M#0M*M2]MSJB@\-/5$T7?PV]K3-N>>?7)%8RBW+BBEHE,M^!T!C3RC-
MA]*"AK;? QSJ#PT]431=_S;VM,VYIWZ=NU=\:-H)I?E06@"E4?LPBRTZD_G!
MI:(0U:R^5JE-/1USZDESP2,FS2<=9L90$T!I/I060&D42@M1--TI;3[JV"]V
MTN% DU(HS8?2 BB-0FDABJ8;J$U*'6.0MGB7*5YP%1%\PY[*D+WWA,-,&>R5
MFG:JKS;1^V ?VF0 I5$H+431= NT6:=CSCI;"S#5.]TPUP\6W^T1W^Z*#PTP
MH30*I84HFBY^FW,ZYISS0R&\V$9J6UUIWQ0S3]Y_RFGF##;!I,<$UH$+H-DE
ME$:AM!!%TUW09I>.>5GE=:T[N^,DSB+!RW& );TV@":5#:UC [=K V@"":51
M*"U$T70;M FD8TX@.RNLC9>_S*C!1I@>+!\XO";D0]L,H#0*I84HFFZ$-G]T
MS/GCM8COB\D ^618=V=&##8 -(-L:/9$]Y/=7<L>0)NE4%J(HND>:&-(QQQ#
M?C^&,@,&.P":03:TC@,LJSO'"*#-4B@M1-%T![1!I -<@&EF#38#-)-T#G._
MB>M972= LT8H+431]#OVVD#2-0>2%SD3R_+:I!\+'JE<2&,T::8-]0*4YD-I
M 91&H;001=,]TT:3[LM%DRXTFH32?"@M@-(HE!:B:+J!VFC2-4>30^[W-*,&
M&P:Z:!-*"Z TVM#V+Z][CN-9W3O_4*WJ5MB[9=P<45[FF=PFJC@5(2Q;]HQ"
MY%\R:,6>N;W!?L'>2HZ]EQQ[,SGV;O*7R#[=-OMT)R\W0D'C4"C-A]("*(U"
M:2&*IANHC4W=X^Y&?_X4V0P8;!/HPDXH+8#2:$/3EOU-3[V>I1JH=FL+C/<>
MI9-R<5<])4F2J%R(5S]59_?I[DE,;ZOG#XW;S>O'.%TQ<1=GDB1\591:)[-B
M1T7]9*3ZC<HWU8-Y;G.E\K1ZN>9LR46Y0?'W59ZK;V_*!G;/IUK\!U!+ P04
M    " "W?G]6066)JV0#  #N%0  #0   'AL+W-T>6QE<RYX;6S=6%%OVC 0
M_BN1NTZM-#6$C)2L@+0A59JT397:A[U5ACA@R7$RQW2PQ_V>_:K]DOGBD #U
M(=:'M0S4QK[/]]WGNTOB=E#JE6"W<\:TM\R$+(=DKG7QSO?+Z9QEM+S("R8-
MDN8JH]I,U<PO"\5H4H)3)OQNIQ/Y&>62C 9RD5UGNO2F^4+J(>DW)L]>/B9#
M$D1OB6?IQGG"AN3^[/6W1:ZO7GGV>O+FY*1S?WZU:S^K@'/B.TE[!Y!>='!>
M@V'4T39UM?S4$%G'4\SMTJWH]\]?VYHV)+786A1&WC^(? \U1AP[-FMRT^X7
M)HCS9>>@(NRI 48<'%;=_?6M*^S773H:I+ELFS4DUF#BTXQY#U0,R9@*/E$<
MO%*:<;&RYBX8IKG(E:?-76($!6 I?U@XL#.X@6J>C,M<5;%M!/M[4B_? =8S
M$,B%: 1VB36,!@75FBEY;2;5XLKX"/+J\=VJ, IGBJZ";H^T#M7%!)GD*F&J
M"1.0M6DT$"P%.8K/YG#5>>$#J'6>F4'"Z2R7M-*P]J@'AG;*A+B%I\O7=(M[
MF6Y4MFH8V0R-H'IH:>P$^#?9+/<F;>])O%[!'W+]86&V(ZLYM N[42SERVJ^
M3!L!&'N L].B$*OW@L]DQNSF#PXX&M"UGS?/%?]AHD&K3(V!*>(],*7Y=-/R
M7='BCBWUNIV6*:ZY>X2:_VV>9TPR1<6F:-/[+SG+3U8<7CZ7Y.JILBO8J;$^
M,KQTD;UC$!D=@\BCZ,G^,8B,CT#DY;,]-0\7&1Y%(H,7*=*OCVL;9\*M$V%C
M]>#D/21?X*0OVJ#>9,&%YK*>S7F2,/GH8&CH-9V8/V:W^,WZA*5T(?1= PY)
M._[,$K[(XF;5#22B7M6./\'V@J@Y]IM87"9LR9)Q/56S237TS,!$K3_@L(M<
M5Q\W@OE8S(T AL7!%& ^U@N+\S_MIX_NQV*8MKX3Z:,^?=3'>KF0<?7%XKA]
M8O-Q[S2.PS"*L(R.QTX%8RQO400_;C9,&WA@<2#2W^4:KS;>(?O[ *OIO@[!
M=HIW(K93/-> N/,&'G'LKC86!SRP*F"] _'=<:"GW#YA"%7%M&%W,([$,89
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M:;?J1O-F_R7=_BO =W\!4$L#!!0    ( +=^?U;U29+, 0(  %XD   :
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MLFH4636*K#,466?_*>NCM:L_CA^?16>:_C.?C?_MN7H'4$L! A0#%     @
MMWY_5@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " "W?G]6;(,-N>\    K @  $0
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M965T-"YX;6Q02P$"% ,4    " "W?G]6>K% M\("  "0!P  &
M    @('>'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
MMWY_5A>)EZH>"0  ]$L  !@              ("!UA\  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( +=^?U;T-32J'PD  )XR   8
M          " @2HI  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " "W?G]6,E<"J9<+  "A&P  &               @(%_,@  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ MWY_5F109(\A)   (6L
M !@              ("!3#X  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( +=^?U;J-[28G (  *X%   9              " @:-B  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ MWY_5@R25J0\
M P  IP8  !D              ("!=F4  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " "W?G]6* MC]+@$  "H"@  &0
M@('I:   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( +=^
M?U;:PX]HL (  +P%   9              " @=AM  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ MWY_5MT1L$81!P   1(  !D
M         ("!OW   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " "W?G]6P)83H_X#  "N"   &0              @($'>   >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( +=^?U8#P]GS_08   X1
M   9              " @3Q\  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ MWY_5GOYN]Z=#P  J"@  !D              ("!<(,
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "W?G]6VHX\
M?@8#  "=!@  &0              @(%$DP  >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( +=^?U:B7Z4;^ ,  (L(   9
M  " @8&6  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
MMWY_5E 4X7QW!   J0D  !D              ("!L)H  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " "W?G]621C8K]<&  "\#P  &0
M            @(%>GP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( +=^?U:Z?02%M"4  *QY   9              " @6RF  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ MWY_5A%++%.% @
MAP4  !D              ("!5\P  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " "W?G]6DH.24X0"  "0!0  &0              @($3
MSP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( +=^?U;3
M_P<POP(  -<%   9              " @<[1  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ MWY_5HQG</FG P  " D  !D
M     ("!Q-0  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +=^?U9_7!W!;0,  .X'   9              "
M@4?I  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ MWY_
M5MTW.4ND!P  $B(  !D              ("!Z^P  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " "W?G]6CB8[ MT(   -0P  &0
M        @('&]   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( +=^?U9BY% :&0,   X*   9              " @=K]  !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ MWY_5N<$:LC  @  :@@
M !D              ("!*@$! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " "W?G]6F56ON'<"  "9!@  &0              @($A! $
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( +=^?U:(*LYU
MJ@,  %X1   9              " @<\& 0!X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ MWY_5N*BDQ-0 @  )@4  !D
M ("!L H! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "W
M?G]6N]/@HKL"  ">!P  &0              @($W#0$ >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( +=^?U:Z)L-FJ0(  &0'   9
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M970T-"YX;6Q02P$"% ,4    " "W?G]6XK_/@_,#  #/%@  &0
M    @(&=(@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M +=^?U:3?;<K)0,  (X-   9              " @<<F 0!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ MWY_5DSO@NC+ P  @PX  !D
M             ("!(RH! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    " "W?G]6&5:KX?<"  !2#   &0              @($E+@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( +=^?U:4GL(V7 D
M +M*   9              " @5,Q 0!X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ MWY_5BSCWB=A @  C08  !D              ("!
MYCH! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " "W?G]6
M+LY@Z\D$   T%   &0              @(%^/0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    ( +=^?U:#_I']OP,  ,L1   9
M      " @7Y" 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%
M  @ MWY_5JD\<E&I P  3A(  !D              ("!=$8! 'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " "W?G]6%'YJ5KD(  #V20
M&0              @(%42@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+
M 0(4 Q0    ( +=^?U9M^A=EF0,  -H*   9              " @413 0!X
M;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ MWY_5DTJVO?+
M P  (@\  !D              ("!%%<! 'AL+W=O<FMS:&5E=',O<VAE970U
M-BYX;6Q02P$"% ,4    " "W?G]6Q;"DP[,#  #]#   &0
M@($66P$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( +=^
M?U:6\8,_H (  !$'   9              " @0!? 0!X;"]W;W)K<VAE971S
M+W-H965T-3@N>&UL4$L! A0#%     @ MWY_5E/CSPSU @  8P@  !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "W?G]6EXJ[',     3 @  "P
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52P4&     $4 10#:$@  9GT!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>167</ContextCount>
  <ElementCount>381</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>53</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Consolidated Statements of Operations (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Changes in Convertible Preferred Shares and Shareholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Convertible Preferred Shares and Shareholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Line of Credit Arrangement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/LineofCreditArrangement</Role>
      <ShortName>Line of Credit Arrangement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Commitments and Contingent Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/CommitmentsandContingentLiabilities</Role>
      <ShortName>Commitments and Contingent Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Financial (Income) Expenses, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/FinancialIncomeExpensesNet</Role>
      <ShortName>Financial (Income) Expenses, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Basic and Diluted Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/BasicandDilutedNetLossPerShare</Role>
      <ShortName>Basic and Diluted Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://Polypid.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/Leases</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/IncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/ShareholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Financial (Income) Expenses, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/FinancialIncomeExpensesNetTables</Role>
      <ShortName>Financial (Income) Expenses, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/FinancialIncomeExpensesNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Basic and Diluted Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/BasicandDilutedNetLossPerShareTables</Role>
      <ShortName>Basic and Diluted Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Polypid.com/role/BasicandDilutedNetLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/General</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Significant Accounting Policies (Details) - Schedule of property and equipment useful life</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of property and equipment useful life</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssetsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofpropertyandequipmentTable</Role>
      <ShortName>Property and Equipment, Net (Details) - Schedule of property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/LeasesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Leases (Details) - Schedule of lease-related assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofleaserelatedassetsandliabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of lease-related assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/LeasesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Leases (Details) - Schedule of lease liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofleaseliabilityTable</Role>
      <ShortName>Leases (Details) - Schedule of lease liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/LeasesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to the lease costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheleasecostsTable</Role>
      <ShortName>Leases (Details) - Schedule of supplemental cash flow information related to the lease costs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/LeasesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - Schedule of accrued expenses and other current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details) - Schedule of accrued expenses and other current liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Line of Credit Arrangement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/LineofCreditArrangementDetails</Role>
      <ShortName>Line of Credit Arrangement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/LineofCreditArrangement</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Commitments and Contingent Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingent Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/CommitmentsandContingentLiabilities</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/IncomeTaxesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofdeferredtaxassetsTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of deferred tax assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/IncomeTaxesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Income Taxes (Details) - Schedule of deferred income taxes reflect the net tax effects</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of deferred income taxes reflect the net tax effects</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/IncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Income Taxes (Details) - Schedule of income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofincometaxesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of income taxes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/IncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/ShareholdersEquityTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Shareholders' Equity (Details) - Schedule of ordinary share capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofordinarysharecapitalTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of ordinary share capital</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/ShareholdersEquityTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Shareholders' Equity (Details) - Schedule of status of options to employees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of status of options to employees</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/ShareholdersEquityTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Shareholders' Equity (Details) - Schedule of share options at the grant date</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of share options at the grant date</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/ShareholdersEquityTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Shareholders' Equity (Details) - Schedule of share-based compensation expense recognized</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofsharebasedcompensationexpenserecognizedTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of share-based compensation expense recognized</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/ShareholdersEquityTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Shareholders' Equity (Details) - Schedule of outstanding options granted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of outstanding options granted</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/ShareholdersEquityTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Shareholders' Equity (Details) - Schedule of relative fair value of the warrants to purchase Ordinary shares issued</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of relative fair value of the warrants to purchase Ordinary shares issued</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/ShareholdersEquityTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Financial (Income) Expenses, Net (Details) - Schedule of financial (income) expenses, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable</Role>
      <ShortName>Financial (Income) Expenses, Net (Details) - Schedule of financial (income) expenses, net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/FinancialIncomeExpensesNetTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Basic and Diluted Net Loss Per Share (Details) - Schedule of basic and diluted loss per ordinary share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable</Role>
      <ShortName>Basic and Diluted Net Loss Per Share (Details) - Schedule of basic and diluted loss per ordinary share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/BasicandDilutedNetLossPerShareTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Basic and Diluted Net Loss Per Share (Details) - Schedule of basic and diluted loss per ordinary share (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable_Parentheticals</Role>
      <ShortName>Basic and Diluted Net Loss Per Share (Details) - Schedule of basic and diluted loss per ordinary share (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/BasicandDilutedNetLossPerShareTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Basic and Diluted Net Loss Per Share (Details) - Schedule of diluted loss per share attributable to ordinary shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable</Role>
      <ShortName>Basic and Diluted Net Loss Per Share (Details) - Schedule of diluted loss per share attributable to ordinary shareholders</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/BasicandDilutedNetLossPerShareTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/RelatedPartiesDetails</Role>
      <ShortName>Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/RelatedParties</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="f20f2022_polypidltd.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Polypid.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Polypid.com/role/SubsequentEvents</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f20f2022_polypidltd.htm 14665</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ResearchAndDevelopmentInProcess in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f20f2022_polypidltd.htm 17402</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 10 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  f20f2022_polypidltd.htm 17525, 17536, 17537, 17538, 17539, 17540, 17541, 17662, 17663, 17664</Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F" original="f20f2022_polypidltd.htm">f20f2022_polypidltd.htm</File>
    <File>f20f2022ex12-1_polypidltd.htm</File>
    <File>f20f2022ex12-2_polypidltd.htm</File>
    <File>f20f2022ex13-1_polypidltd.htm</File>
    <File>f20f2022ex13-2_polypidltd.htm</File>
    <File>f20f2022ex15-1_polypidltd.htm</File>
    <File>f20f2022ex2-2_polypidltd.htm</File>
    <File>pypd-20221231.xsd</File>
    <File>pypd-20221231_cal.xml</File>
    <File>pypd-20221231_def.xml</File>
    <File>pypd-20221231_lab.xml</File>
    <File>pypd-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>fin_001.jpg</File>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="614">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="43">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f20f2022_polypidltd.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 614,
    "http://xbrl.sec.gov/dei/2022": 43
   },
   "contextCount": 167,
   "dts": {
    "calculationLink": {
     "local": [
      "pypd-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pypd-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f20f2022_polypidltd.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pypd-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pypd-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pypd-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 573,
   "entityCount": 1,
   "hidden": {
    "http://Polypid.com/20221231": 31,
    "http://fasb.org/us-gaap/2022": 108,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 143
   },
   "keyCustom": 102,
   "keyStandard": 279,
   "memberCustom": 26,
   "memberStandard": 26,
   "nsprefix": "pypd",
   "nsuri": "http://Polypid.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:TradingSymbol",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://Polypid.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:TradingSymbol",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pypd:PrepaidExpensesAndOtherReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Prepaid Expenses and Other Current Assets",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pypd:PrepaidExpensesAndOtherReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://Polypid.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://Polypid.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pypd:LineOfCreditArrangementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Line of Credit Arrangement",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://Polypid.com/role/LineofCreditArrangement",
     "shortName": "Line of Credit Arrangement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pypd:LineOfCreditArrangementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Commitments and Contingent Liabilities",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://Polypid.com/role/CommitmentsandContingentLiabilities",
     "shortName": "Commitments and Contingent Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://Polypid.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Shareholders' Equity",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://Polypid.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Financial (Income) Expenses, Net",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://Polypid.com/role/FinancialIncomeExpensesNet",
     "shortName": "Financial (Income) Expenses, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Basic and Diluted Net Loss Per Share",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://Polypid.com/role/BasicandDilutedNetLossPerShare",
     "shortName": "Basic and Diluted Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://Polypid.com/role/ConsolidatedBalanceSheet",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Related Parties",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://Polypid.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://Polypid.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Accounting Policies, by Policy (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://Polypid.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://Polypid.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://Polypid.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pypd:ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://Polypid.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pypd:ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://Polypid.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCapitalLeasedAsssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Shareholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://Polypid.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCapitalLeasedAsssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Financial (Income) Expenses, Net (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://Polypid.com/role/FinancialIncomeExpensesNetTables",
     "shortName": "Financial (Income) Expenses, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Basic and Diluted Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://Polypid.com/role/BasicandDilutedNetLossPerShareTables",
     "shortName": "Basic and Diluted Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c43",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pypd:DescriptionOfReverseShareSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - General (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://Polypid.com/role/GeneralDetails",
     "shortName": "General (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c43",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pypd:DescriptionOfReverseShareSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c50",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pypd:RighttouseAssetsAndLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://Polypid.com/role/SignificantAccountingPoliciesDetails",
     "shortName": "Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c50",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pypd:RighttouseAssetsAndLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pypd:ComputersandSoftware",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Significant Accounting Policies (Details) - Schedule of property and equipment useful life",
     "menuCat": "Details",
     "order": "34",
     "role": "http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable",
     "shortName": "Significant Accounting Policies (Details) - Schedule of property and equipment useful life",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pypd:ComputersandSoftware",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c54",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets",
     "menuCat": "Details",
     "order": "35",
     "role": "http://Polypid.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable",
     "shortName": "Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c54",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://Polypid.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment",
     "menuCat": "Details",
     "order": "37",
     "role": "http://Polypid.com/role/ScheduleofpropertyandequipmentTable",
     "shortName": "Property and Equipment, Net (Details) - Schedule of property and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalLeasesIndemnificationAgreementsPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://Polypid.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalLeasesIndemnificationAgreementsPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "pypd:ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pypd:OperatingLeaseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Leases (Details) - Schedule of lease-related assets and liabilities",
     "menuCat": "Details",
     "order": "39",
     "role": "http://Polypid.com/role/ScheduleofleaserelatedassetsandliabilitiesTable",
     "shortName": "Leases (Details) - Schedule of lease-related assets and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "pypd:ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pypd:OperatingLeaseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://Polypid.com/role/ConsolidatedIncomeStatement",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "pypd:ScheduleOfLeaseLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Leases (Details) - Schedule of lease liability",
     "menuCat": "Details",
     "order": "40",
     "role": "http://Polypid.com/role/ScheduleofleaseliabilityTable",
     "shortName": "Leases (Details) - Schedule of lease liability",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "pypd:ScheduleOfLeaseLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherOperatingActivitiesCashFlowStatement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to the lease costs",
     "menuCat": "Details",
     "order": "41",
     "role": "http://Polypid.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheleasecostsTable",
     "shortName": "Leases (Details) - Schedule of supplemental cash flow information related to the lease costs",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherOperatingActivitiesCashFlowStatement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - Schedule of accrued expenses and other current liabilities",
     "menuCat": "Details",
     "order": "42",
     "role": "http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details) - Schedule of accrued expenses and other current liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c64",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LinesOfCreditCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Line of Credit Arrangement (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://Polypid.com/role/LineofCreditArrangementDetails",
     "shortName": "Line of Credit Arrangement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c64",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LinesOfCreditCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pypd:ProceedsFromParticipationPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Commitments and Contingent Liabilities (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails",
     "shortName": "Commitments and Contingent Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pypd:ProceedsFromParticipationPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxBasisOfInvestmentsCostForIncomeTaxPurposes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://Polypid.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxBasisOfInvestmentsCostForIncomeTaxPurposes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets",
     "menuCat": "Details",
     "order": "46",
     "role": "http://Polypid.com/role/ScheduleofdeferredtaxassetsTable",
     "shortName": "Income Taxes (Details) - Schedule of deferred tax assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Income Taxes (Details) - Schedule of deferred income taxes reflect the net tax effects",
     "menuCat": "Details",
     "order": "47",
     "role": "http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable",
     "shortName": "Income Taxes (Details) - Schedule of deferred income taxes reflect the net tax effects",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Income Taxes (Details) - Schedule of income taxes",
     "menuCat": "Details",
     "order": "48",
     "role": "http://Polypid.com/role/ScheduleofincometaxesTable",
     "shortName": "Income Taxes (Details) - Schedule of income taxes",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c88",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pypd:AggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Shareholders' Equity (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://Polypid.com/role/ShareholdersEquityDetails",
     "shortName": "Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c88",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pypd:AggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Operations (Parentheticals)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://Polypid.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "shortName": "Consolidated Statements of Operations (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCapitalLeasedAsssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ExcessStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Shareholders' Equity (Details) - Schedule of ordinary share capital",
     "menuCat": "Details",
     "order": "50",
     "role": "http://Polypid.com/role/ScheduleofordinarysharecapitalTable",
     "shortName": "Shareholders' Equity (Details) - Schedule of ordinary share capital",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCapitalLeasedAsssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ExcessStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c96",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Shareholders' Equity (Details) - Schedule of status of options to employees",
     "menuCat": "Details",
     "order": "51",
     "role": "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable",
     "shortName": "Shareholders' Equity (Details) - Schedule of status of options to employees",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c96",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Shareholders' Equity (Details) - Schedule of share options at the grant date",
     "menuCat": "Details",
     "order": "52",
     "role": "http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable",
     "shortName": "Shareholders' Equity (Details) - Schedule of share options at the grant date",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Shareholders' Equity (Details) - Schedule of share-based compensation expense recognized",
     "menuCat": "Details",
     "order": "53",
     "role": "http://Polypid.com/role/ScheduleofsharebasedcompensationexpenserecognizedTable",
     "shortName": "Shareholders' Equity (Details) - Schedule of share-based compensation expense recognized",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "pypd:ScheduleOfOutstandingOptionGrantedTablesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c138",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Shareholders' Equity (Details) - Schedule of outstanding options granted",
     "menuCat": "Details",
     "order": "54",
     "role": "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable",
     "shortName": "Shareholders' Equity (Details) - Schedule of outstanding options granted",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "pypd:ScheduleOfOutstandingOptionGrantedTablesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c138",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c148",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Shareholders' Equity (Details) - Schedule of relative fair value of the warrants to purchase Ordinary shares issued",
     "menuCat": "Details",
     "order": "55",
     "role": "http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable",
     "shortName": "Shareholders' Equity (Details) - Schedule of relative fair value of the warrants to purchase Ordinary shares issued",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c148",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireLoansReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Financial (Income) Expenses, Net (Details) - Schedule of financial (income) expenses, net",
     "menuCat": "Details",
     "order": "56",
     "role": "http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable",
     "shortName": "Financial (Income) Expenses, Net (Details) - Schedule of financial (income) expenses, net",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireLoansReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Basic and Diluted Net Loss Per Share (Details) - Schedule of basic and diluted loss per ordinary share",
     "menuCat": "Details",
     "order": "57",
     "role": "http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable",
     "shortName": "Basic and Diluted Net Loss Per Share (Details) - Schedule of basic and diluted loss per ordinary share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Basic and Diluted Net Loss Per Share (Details) - Schedule of basic and diluted loss per ordinary share (Parentheticals)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable_Parentheticals",
     "shortName": "Basic and Diluted Net Loss Per Share (Details) - Schedule of basic and diluted loss per ordinary share (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Basic and Diluted Net Loss Per Share (Details) - Schedule of diluted loss per share attributable to ordinary shareholders",
     "menuCat": "Details",
     "order": "59",
     "role": "http://Polypid.com/role/ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable",
     "shortName": "Basic and Diluted Net Loss Per Share (Details) - Schedule of diluted loss per share attributable to ordinary shareholders",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Changes in Convertible Preferred Shares and Shareholders\u2019 Equity (Deficit)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://Polypid.com/role/ShareholdersEquityType2or3",
     "shortName": "Consolidated Statements of Changes in Convertible Preferred Shares and Shareholders\u2019 Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pypd:ServiceProvidersInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Related Parties (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://Polypid.com/role/RelatedPartiesDetails",
     "shortName": "Related Parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pypd:ServiceProvidersInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c155",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "pypd:ExercisePriceDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://Polypid.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c155",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "pypd:ExercisePriceDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://Polypid.com/role/ConsolidatedCashFlow",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c5",
      "decimals": "-3",
      "lang": null,
      "name": "pypd:ReevaluationOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - General",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://Polypid.com/role/General",
     "shortName": "General",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://Polypid.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2022_polypidltd.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 53,
   "tag": {
    "country_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ISRAEL",
        "terseLabel": "Israel [Member]"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States of America [Member]",
        "verboseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name",
        "terseLabel": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard",
        "terseLabel": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement",
        "terseLabel": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report",
        "terseLabel": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Polypid.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expensesand Other Current Liabilities Details Scheduleofaccruedexpensesandothercurrentliabilities Line Items",
        "terseLabel": "Schedule of Accrued Expenses And Other Current Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities (Details) - Schedule of accrued expenses and other current liabilities [Table]"
       }
      }
     },
     "localname": "AccruedExpensesandOtherCurrentLiabilitiesDetailsScheduleofaccruedexpensesandothercurrentliabilitiesTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses And Other Current Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedExpensesandOtherCurrentLiabilitiesTablesLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_AccruedExpensesandOtherCurrentLiabilitiesTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities (Tables) [Table]"
       }
      }
     },
     "localname": "AccruedExpensesandOtherCurrentLiabilitiesTablesTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_AdditionalAmountOfCommercialSaleMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional amount of commercial sale milestones.",
        "label": "Additional Amount Of Commercial Sale Milestones",
        "terseLabel": "Additional amount of commercial sale milestones (in Euro)"
       }
      }
     },
     "localname": "AdditionalAmountOfCommercialSaleMilestones",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_AdditionalDevelopmentrelatedMilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional development-related milestones payments.",
        "label": "Additional Developmentrelated Milestones Payments",
        "terseLabel": "Additional development-related milestones payments (in Euro)"
       }
      }
     },
     "localname": "AdditionalDevelopmentrelatedMilestonesPayments",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_AdjustmentToRiskfreeInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to risk-free interest rate.",
        "label": "Adjustment To Riskfree Interest Rate",
        "terseLabel": "Adjustment to risk-free interest rate (%)"
       }
      }
     },
     "localname": "AdjustmentToRiskfreeInterestRate",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable"
     ],
     "xbrltype": "percentItemType"
    },
    "pypd_AggregateNetProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount related to net proceeds from initial public offering.",
        "label": "Aggregate Net Proceeds",
        "terseLabel": "Aggregate net proceeds"
       }
      }
     },
     "localname": "AggregateNetProceeds",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_AggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate offering price.",
        "label": "Aggregate Offering Price",
        "terseLabel": "Aggregate offering price (in Dollars)"
       }
      }
     },
     "localname": "AggregateOfferingPrice",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_AgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement term.",
        "label": "Agreement Term",
        "terseLabel": "Agreement term"
       }
      }
     },
     "localname": "AgreementTerm",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pypd_April2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "April2021 Member",
        "terseLabel": "April 2021 [Member]"
       }
      }
     },
     "localname": "April2021Member",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_April2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "April2022 Member",
        "terseLabel": "April 2022 [Member]"
       }
      }
     },
     "localname": "April2022Member",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_AprilTwoThousandSixteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "April Two Thousand Sixteen Member",
        "terseLabel": "April 2016 [Member]"
       }
      }
     },
     "localname": "AprilTwoThousandSixteenMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_August2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "August2019 Member",
        "terseLabel": "August 2019 [Member]"
       }
      }
     },
     "localname": "August2019Member",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_August2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "August2021 Member",
        "terseLabel": "August 2021 [Member]"
       }
      }
     },
     "localname": "August2021Member",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_BasicAndDilutedLossPerSharePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic And Diluted Loss Per Share Policy Text Block",
        "terseLabel": "Basic and diluted net loss per share"
       }
      }
     },
     "localname": "BasicAndDilutedLossPerSharePolicyTextBlock",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pypd_CashFlowsFromOperatingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "CashFlowsFromOperatingActivities",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liability Abstract",
        "terseLabel": "Cash paid for amounts included in measurement of lease liability:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilityAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheleasecostsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_CommitmentsAndContingentLiabilitiesDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingent Liabilities Description",
        "terseLabel": "Commitments and Contingent liabilities, description"
       }
      }
     },
     "localname": "CommitmentsAndContingentLiabilitiesDescription",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_ComputersandSoftware": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computers and software.",
        "label": "Computersand Software",
        "terseLabel": "Computers and software"
       }
      }
     },
     "localname": "ComputersandSoftware",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable"
     ],
     "xbrltype": "percentItemType"
    },
    "pypd_ConsolidatedFinancialStatementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated financial statements in U.S. dollars policy text block.",
        "label": "Consolidated Financial Statements Policy Text Block",
        "terseLabel": "Consolidated financial statements in U.S. dollars"
       }
      }
     },
     "localname": "ConsolidatedFinancialStatementsPolicyTextBlock",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pypd_ConsultAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consult And Directors Member",
        "terseLabel": "Consultant and Directors [Member]"
       }
      }
     },
     "localname": "ConsultAndDirectorsMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_ConversionOfConvertiblePreferredSharesToOrdinaryShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount related to conversion of Convertible Preferred shares to ordinary shares.",
        "label": "Conversion Of Convertible Preferred Shares To Ordinary Shares",
        "terseLabel": "Conversion of convertible Preferred shares to Ordinary shares"
       }
      }
     },
     "localname": "ConversionOfConvertiblePreferredSharesToOrdinaryShares",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of Convertible Preferred shares to ordinary shares, shares.",
        "label": "Conversion Of Convertible Preferred Shares To Ordinary Shares Sharesin Shares",
        "terseLabel": "Conversion of convertible Preferred shares to Ordinary shares (in Shares)"
       }
      }
     },
     "localname": "ConversionOfConvertiblePreferredSharesToOrdinarySharesSharesinShares",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "pypd_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred shares and convertible preferred shares warrant liability policy text block.",
        "label": "Convertible Preferred Shares And Convertible Preferred Shares Warrant Liability Policy Text Block",
        "terseLabel": "Convertible preferred shares and convertible preferred shares warrant liability"
       }
      }
     },
     "localname": "ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pypd_ConvertiblePreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Shares Member",
        "terseLabel": "Convertible Preferred Shares"
       }
      }
     },
     "localname": "ConvertiblePreferredSharesMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_December2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "December2021 Member",
        "terseLabel": "December 2021 [Member]"
       }
      }
     },
     "localname": "December2021Member",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_DecemberTwoThousandSixteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "December Two Thousand Sixteen Member",
        "terseLabel": "December 2016 [Member]"
       }
      }
     },
     "localname": "DecemberTwoThousandSixteenMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_DecreaseincreaseInReceivablesAndPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease (increase) in receivables and prepaid expenses.",
        "label": "Decreaseincrease In Receivables And Prepaid Expenses",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "DecreaseincreaseInReceivablesAndPrepaidExpenses",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_DeemedDividend": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount declared as dividend.",
        "label": "Deemed Dividend",
        "terseLabel": "Deemed dividend"
       }
      }
     },
     "localname": "DeemedDividend",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_DeemedDividends": {
     "auth_ref": [],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deemed dividend.",
        "label": "Deemed Dividends",
        "negatedLabel": "Deemed dividend"
       }
      }
     },
     "localname": "DeemedDividends",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator Abstract",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_DescriptionAdministration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of administration.",
        "label": "Description Administration",
        "terseLabel": "Description administration"
       }
      }
     },
     "localname": "DescriptionAdministration",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_DescriptionOfReverseShareSplit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Reverse Share Split",
        "terseLabel": "Description of reverse share split"
       }
      }
     },
     "localname": "DescriptionOfReverseShareSplit",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_DomesticIsrael": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Domestic Israel",
        "terseLabel": "Domestic (Israel)"
       }
      }
     },
     "localname": "DomesticIsrael",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_ExceedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Exceed Amount",
        "terseLabel": "Exceed amount"
       }
      }
     },
     "localname": "ExceedAmount",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_ExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of Warrants.",
        "label": "Exercise Of Warrants",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ExerciseOfWarrants",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_ExercisePriceDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Exercise Price Decrease",
        "terseLabel": "Exercise price decreased"
       }
      }
     },
     "localname": "ExercisePriceDecrease",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pypd_ExpectedDividendYield": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Dividend Yield",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ExpectedDividendYield",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pypd_FinancialExpenseIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of financial expense (income).",
        "label": "Financial Expense Income",
        "terseLabel": "Financial expense (income)"
       }
      }
     },
     "localname": "FinancialExpenseIncome",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_FinancialExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Expenses Abstract",
        "terseLabel": "Financial expenses:"
       }
      }
     },
     "localname": "FinancialExpensesAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_FinancialIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Income Abstract",
        "terseLabel": "Financial income:"
       }
      }
     },
     "localname": "FinancialIncomeAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_FinancialIncomeExpensesNetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial (Income) Expenses, Net [Abstract]"
       }
      }
     },
     "localname": "FinancialIncomeExpensesNetLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/FinancialIncomeExpensesNet"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_FinancialIncomeExpensesNetTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial (Income) Expenses, Net [Table]"
       }
      }
     },
     "localname": "FinancialIncomeExpensesNetTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/FinancialIncomeExpensesNet"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_FinancialIncomeExpensesNetTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Income Expenses Net Tables Line Items",
        "terseLabel": "Financial (Income) Expenses, Net [Abstract]"
       }
      }
     },
     "localname": "FinancialIncomeExpensesNetTablesLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/FinancialIncomeExpensesNetTables"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_FinancialIncomeExpensesNetTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial (Income) Expenses, Net (Tables) [Table]"
       }
      }
     },
     "localname": "FinancialIncomeExpensesNetTablesTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/FinancialIncomeExpensesNetTables"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_FindersFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finder's fee.",
        "label": "Finders Fee",
        "terseLabel": "Finder's fee"
       }
      }
     },
     "localname": "FindersFee",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_FirstTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Tranche Member",
        "terseLabel": "First tranche [Member]"
       }
      }
     },
     "localname": "FirstTrancheMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture And Office Equipment Member",
        "terseLabel": "Furniture and office equipment [Member]"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_GeneralDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General (Details) [Line Items]"
       }
      }
     },
     "localname": "GeneralDetailsLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_GeneralDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General (Details) [Table]"
       }
      }
     },
     "localname": "GeneralDetailsTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_GovernmentAuthorities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Guarantee by US government authority for government insured loans.",
        "label": "Government Authorities",
        "terseLabel": "Government authorities"
       }
      }
     },
     "localname": "GovernmentAuthorities",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_IncomeTaxesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) - Schedule of deferred tax assets [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsScheduleofdeferredtaxassetsLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_IncomeTaxesDetailsScheduleofdeferredtaxassetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) - Schedule of deferred tax assets [Table]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsScheduleofdeferredtaxassetsTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_IncomeTaxesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_IncurredLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Incurred Loss",
        "terseLabel": "Incurred loss"
       }
      }
     },
     "localname": "IncurredLoss",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_InterestRepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of interest repayments.",
        "label": "Interest Repayments",
        "terseLabel": "Interest repayments"
       }
      }
     },
     "localname": "InterestRepayments",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pypd_IsraelInnovationAuthorityGrantReceived": {
     "auth_ref": [],
     "calculation": {
      "http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Israel Innovation Authority grant received.",
        "label": "Israel Innovation Authority Grant Received",
        "terseLabel": "IIA deferred grants"
       }
      }
     },
     "localname": "IsraelInnovationAuthorityGrantReceived",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_IssuanceOfOrdinarySharesNetinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of issuance of Ordinary shares, net.",
        "label": "Issuance Of Ordinary Shares Netin Shares",
        "terseLabel": "Issuance of Ordinary shares, net (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesNetinShares",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "pypd_IssuanceOfWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of warrants.",
        "label": "Issuance Of Warrants",
        "negatedLabel": "Proceeds from issuance of warrants"
       }
      }
     },
     "localname": "IssuanceOfWarrants",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_July2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "July2022 Member",
        "terseLabel": "July 2022 [Member]"
       }
      }
     },
     "localname": "July2022Member",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_JuneTwoThousandSeventeenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "June Two Thousand Seventeen Member",
        "terseLabel": "June 2017 [Member]"
       }
      }
     },
     "localname": "JuneTwoThousandSeventeenMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_JuneTwoThousandTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "June Two Thousand Twenty Member",
        "terseLabel": "June 2020 [Member]"
       }
      }
     },
     "localname": "JuneTwoThousandTwentyMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_LaboratoryAndManufacturingEquipment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory and manufacturing equipment.",
        "label": "Laboratory And Manufacturing Equipment",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryAndManufacturingEquipment",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable"
     ],
     "xbrltype": "percentItemType"
    },
    "pypd_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment Member",
        "terseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_LeaseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Assets Abstract",
        "terseLabel": "Lease assets:"
       }
      }
     },
     "localname": "LeaseAssetsAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofleaserelatedassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_LeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease liability.",
        "label": "Lease Liabilities",
        "terseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofleaserelatedassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_LeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liabilities Abstract",
        "terseLabel": "Lease liabilities:"
       }
      }
     },
     "localname": "LeaseLiabilitiesAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofleaserelatedassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_LeasePrepayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease prepayments.",
        "label": "Lease Prepayments",
        "terseLabel": "Adjustments for lease repayments"
       }
      }
     },
     "localname": "LeasePrepayments",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_LineOfCreditArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line Of Credit Arrangement Abstract"
       }
      }
     },
     "localname": "LineOfCreditArrangementAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_LineOfCreditArrangementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of line of credit arrangement.",
        "label": "Line Of Credit Arrangement Text Block",
        "terseLabel": "LINE OF CREDIT ARRANGEMENT"
       }
      }
     },
     "localname": "LineOfCreditArrangementTextBlock",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pypd_LineOfCreditFacilityPeriodicPaymentOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments of both interest and principal.",
        "label": "Line Of Credit Facility Periodic Payment One",
        "terseLabel": "Third tranche not withdrawn"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodicPaymentOne",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_LineofCreditArrangementDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Arrangement (Details) [Line Items]"
       }
      }
     },
     "localname": "LineofCreditArrangementDetailsLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_LineofCreditArrangementDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Arrangement (Details) [Table]"
       }
      }
     },
     "localname": "LineofCreditArrangementDetailsTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_LongtermDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount available in long term deposits.",
        "label": "Longterm Deposits",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "LongtermDeposits",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_MarketingAndBusinessDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount related to Marketing and business development expenses.",
        "label": "Marketing And Business Development Expenses",
        "terseLabel": "Marketing and business development"
       }
      }
     },
     "localname": "MarketingAndBusinessDevelopmentExpenses",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_MarketingAndBusinessDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing And Business Development Member",
        "terseLabel": "Marketing and business development [Member]"
       }
      }
     },
     "localname": "MarketingAndBusinessDevelopmentMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofsharebasedcompensationexpenserecognizedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_MatchingContributionsAmounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Matching Contributions Amounts.",
        "label": "Matching Contributions Amounts",
        "terseLabel": "Matching in contributions amounts"
       }
      }
     },
     "localname": "MatchingContributionsAmounts",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_May2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "May2022 Member",
        "terseLabel": "May 2022 [Member]"
       }
      }
     },
     "localname": "May2022Member",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_MinimumPaidAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum Paid Amount",
        "terseLabel": "Minimum paid amount"
       }
      }
     },
     "localname": "MinimumPaidAmount",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare": {
     "auth_ref": [],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net loss attributable to Ordinary shares.",
        "label": "Net Loss Attributable To Ordinary Sharesin Dollars Per Share",
        "negatedTotalLabel": "Net loss attributable to Ordinary shares"
       }
      }
     },
     "localname": "NetLossAttributableToOrdinarySharesinDollarsPerShare",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_NonRefundableAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non refundable amount.",
        "label": "Non Refundable Amount",
        "terseLabel": "Non-refundable amount"
       }
      }
     },
     "localname": "NonRefundableAmount",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_NonroyaltyBearingGrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-royalty bearing grants.",
        "label": "Nonroyalty Bearing Grants",
        "terseLabel": "Non-royalty bearing grants amount"
       }
      }
     },
     "localname": "NonroyaltyBearingGrants",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_NonroyaltyBearingGrantsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-royalty Bearing Grants Amount.",
        "label": "Nonroyalty Bearing Grants Amount",
        "terseLabel": "Non-royalty bearing grants amount"
       }
      }
     },
     "localname": "NonroyaltyBearingGrantsAmount",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_November2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "November2022 Member",
        "terseLabel": "November 2022 [Member]"
       }
      }
     },
     "localname": "November2022Member",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_NovemberTwoThousandSeventeenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "November Two Thousand Seventeen Member",
        "terseLabel": "November 2017 [Member]"
       }
      }
     },
     "localname": "NovemberTwoThousandSeventeenMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_NumberOfOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options.",
        "label": "Number Of Options",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "NumberOfOptions",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pypd_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numerator Abstract",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_OctoberTwoThousandThirteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "October Two Thousand Thirteen Member",
        "terseLabel": "October 2013 [Member]"
       }
      }
     },
     "localname": "OctoberTwoThousandThirteenMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_OfferingExpensesPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of offering expenses payable.",
        "label": "Offering Expenses Payable",
        "terseLabel": "Offering expenses payable"
       }
      }
     },
     "localname": "OfferingExpensesPayable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_OperatingLeaseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease assets.",
        "label": "Operating Lease Assets",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseAssets",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofleaserelatedassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_OptionsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options exercisable.",
        "label": "Options Exercisable",
        "terseLabel": "Options exercisable"
       }
      }
     },
     "localname": "OptionsExercisable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "pypd_OutOfReceivedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Out of Received Amount.",
        "label": "Out Of Received Amount",
        "terseLabel": "Out of received amount"
       }
      }
     },
     "localname": "OutOfReceivedAmount",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_PaymentsForProceedsFromShorttermAndLongtermDepositsNet": {
     "auth_ref": [],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Short term and long term deposits, net.",
        "label": "Payments For Proceeds From Shortterm And Longterm Deposits Net",
        "negatedLabel": "Short-term and long-term deposits, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromShorttermAndLongtermDepositsNet",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_PreferredSharePreference": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Share Preference",
        "terseLabel": "Preferred share preference"
       }
      }
     },
     "localname": "PreferredSharePreference",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_PrepaidExpensesAndOtherReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses And Other Receivables Abstract"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherReceivablesAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_PrepaidExpensesAndOtherReceivablesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses And Other Receivables Text Block",
        "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherReceivablesTextBlock",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets [Line Items]"
       }
      }
     },
     "localname": "PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets [Table]"
       }
      }
     },
     "localname": "PrepaidExpensesandOtherCurrentAssetsDetailsScheduleofprepaidexpensesandothercurrentassetsTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_PrepaymentForEquipments": {
     "auth_ref": [],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-payment for equipment.",
        "label": "Prepayment For Equipments",
        "negatedLabel": "Pre-payments for equipment"
       }
      }
     },
     "localname": "PrepaymentForEquipments",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_ProceedsFromLinesOfCreditOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds From Lines Of Credit One",
        "terseLabel": "Second tranche amount"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCreditOne",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_ProceedsFromLinesOfCreditTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds From Lines Of Credit Two",
        "terseLabel": "Third tranche amount"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCreditTwo",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_ProceedsFromParticipationPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Participation payments received.",
        "label": "Proceeds From Participation Payments",
        "terseLabel": "Participation payments"
       }
      }
     },
     "localname": "ProceedsFromParticipationPayments",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_PropertyAndEquipmentPaidForInPriorPeriods": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property and equipment paid for in prior periods.",
        "label": "Property And Equipment Paid For In Prior Periods",
        "terseLabel": "Property and equipment paid for in prior periods"
       }
      }
     },
     "localname": "PropertyAndEquipmentPaidForInPriorPeriods",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_PropertyPlantAndEquipmentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, plant and equipment percent.",
        "label": "Property Plant And Equipment Percent",
        "terseLabel": "Furniture and office equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPercent",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable"
     ],
     "xbrltype": "percentItemType"
    },
    "pypd_PurchaseOfPropertyAndEquipmentIncludedInTradePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of property and equipment included in trade payable.",
        "label": "Purchase Of Property And Equipment Included In Trade Payable",
        "terseLabel": "Property and equipment acquired by credit"
       }
      }
     },
     "localname": "PurchaseOfPropertyAndEquipmentIncludedInTradePayable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_ReceivedTotalAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Received Total Amount.",
        "label": "Received Total Amount",
        "terseLabel": "Received total amount"
       }
      }
     },
     "localname": "ReceivedTotalAmount",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_RecentlyIssuedAccountingPronouncementsNotYetAdopted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently Issued Accounting Pronouncements and not yet adopted policy text block.",
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted",
        "terseLabel": "Recently issued accounting pronouncements, not yet adopted"
       }
      }
     },
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdopted",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pypd_ReclassificationOfWarrantsIntoEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of Warrants into equity.",
        "label": "Reclassification Of Warrants Into Equity",
        "terseLabel": "Reclassification of warrants into equity"
       }
      }
     },
     "localname": "ReclassificationOfWarrantsIntoEquity",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_RecognizedOverWeightedAveragePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognized over a weighted average period.",
        "label": "Recognized Over Weighted Average Period",
        "terseLabel": "Recognized over weighted average period"
       }
      }
     },
     "localname": "RecognizedOverWeightedAveragePeriod",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pypd_ReevaluationOfWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Re-evaluation of warrants.",
        "label": "Reevaluation Of Warrants",
        "terseLabel": "Remeasurement of warrants"
       }
      }
     },
     "localname": "ReevaluationOfWarrants",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_RelatedPartiesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties (Details) [Line Items]"
       }
      }
     },
     "localname": "RelatedPartiesDetailsLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_RelatedPartiesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties (Details) [Table]"
       }
      }
     },
     "localname": "RelatedPartiesDetailsTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_RelatedPartiesTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties term",
        "label": "Related Parties Term",
        "terseLabel": "Amir weisberg term"
       }
      }
     },
     "localname": "RelatedPartiesTerm",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pypd_RemeasurementOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Remeasurement Of Warrants",
        "terseLabel": "Remeasurement of warrants"
       }
      }
     },
     "localname": "RemeasurementOfWarrants",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_RestrictedCashIncludedInOtherLongtermAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of restricted cash included in other long term assets.",
        "label": "Restricted Cash Included In Other Longterm Assets",
        "terseLabel": "Restricted cash included in other long-term assets"
       }
      }
     },
     "localname": "RestrictedCashIncludedInOtherLongtermAssets",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_RestrictedCashPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash policy text block.",
        "label": "Restricted Cash Policy Text Block",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashPolicyTextBlock",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pypd_RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rightofuse Asset Recognized With Corresponding Lease Liability Abstract",
        "terseLabel": "Right-of-use asset recognized with corresponding lease liability:"
       }
      }
     },
     "localname": "RightofuseAssetRecognizedWithCorrespondingLeaseLiabilityAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheleasecostsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_RighttouseAssetsAndLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-to-use assets and lease liabilities.",
        "label": "Righttouse Assets And Lease Liabilities",
        "terseLabel": "Right-to-use assets and lease liabilities"
       }
      }
     },
     "localname": "RighttouseAssetsAndLeaseLiabilities",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Accrued Expenses And Other Current Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Basic And Diluted Loss Per Ordinary Share Abstract"
       }
      }
     },
     "localname": "ScheduleOfBasicAndDilutedLossPerOrdinaryShareAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Deferred Income Taxes Reflect The Net Tax Effects Abstract"
       }
      }
     },
     "localname": "ScheduleOfDeferredIncomeTaxesReflectTheNetTaxEffectsAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Deferred Tax Assets Abstract"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Ordinary Shares [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfDilutedLossPerShareAttributableToOrdinaryShareholdersAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfFinancialIncomeExpensesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Income Expenses Net Abstract"
       }
      }
     },
     "localname": "ScheduleOfFinancialIncomeExpensesNetAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfIncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Income Taxes Abstract"
       }
      }
     },
     "localname": "ScheduleOfIncomeTaxesAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Lease Liability Abstract"
       }
      }
     },
     "localname": "ScheduleOfLeaseLiabilityAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfLeaseLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Lease Liability Table Text Block",
        "terseLabel": "Schedule of lease liability"
       }
      }
     },
     "localname": "ScheduleOfLeaseLiabilityTableTextBlock",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pypd_ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Lease Related Assets And Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfLeaseRelatedAssetsAndLiabilitiesAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of lease related assets and liabilities table.",
        "label": "Schedule Of Leaserelated Assets And Liabilities Table Text Block",
        "terseLabel": "Schedule of lease-related assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfLeaserelatedAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pypd_ScheduleOfOrdinaryShareCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Ordinary Share Capital Abstract"
       }
      }
     },
     "localname": "ScheduleOfOrdinaryShareCapitalAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfOutstandingOptionGrantedTablesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Outstanding Option Granted Tables Text Block",
        "terseLabel": "Schedule of outstanding options granted"
       }
      }
     },
     "localname": "ScheduleOfOutstandingOptionGrantedTablesTextBlock",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pypd_ScheduleOfOutstandingOptionsGrantedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Outstanding Options Granted Abstract"
       }
      }
     },
     "localname": "ScheduleOfOutstandingOptionsGrantedAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Prepaid Expenses And Other Current Assets Abstract"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfPropertyAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Abstract"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfPropertyAndEquipmentUsefulLifeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Useful Life Abstract"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentUsefulLifeAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfRelativeFairValueOfTheWarrantsToPurchaseOrdinarySharesIssuedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Relative Fair Value Of The Warrants To Purchase Ordinary Shares Issued Abstract"
       }
      }
     },
     "localname": "ScheduleOfRelativeFairValueOfTheWarrantsToPurchaseOrdinarySharesIssuedAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfShareBasedCompensationExpenseRecognizedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Compensation Expense Recognized Abstract"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationExpenseRecognizedAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfShareOptionsAtTheGrantDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Options At The Grant Date Abstract"
       }
      }
     },
     "localname": "ScheduleOfShareOptionsAtTheGrantDateAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfStatusOfOptionsToEmployeesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Status Of Options To Employees Abstract"
       }
      }
     },
     "localname": "ScheduleOfStatusOfOptionsToEmployeesAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Supplemental Cash Flow Information Related To The Lease Costs Abstract"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToTheLeaseCostsAbstract",
     "nsuri": "http://Polypid.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pypd_SecondTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Tranche Member",
        "terseLabel": "Second Tranche [Member]"
       }
      }
     },
     "localname": "SecondTrancheMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_September2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "September2020 Member",
        "terseLabel": "September 2020 [Member]"
       }
      }
     },
     "localname": "September2020Member",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_SeptemberTwoThousandFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "September Two Thousand Fourteen Member",
        "terseLabel": "September 2014 [Member]"
       }
      }
     },
     "localname": "SeptemberTwoThousandFourteenMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_ServiceProvidersInAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Service Providers In Amount",
        "terseLabel": "Service providers in amount"
       }
      }
     },
     "localname": "ServiceProvidersInAmount",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_SeverancePay": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance pay.",
        "label": "Severance Pay",
        "terseLabel": "Severance pay, description"
       }
      }
     },
     "localname": "SeverancePay",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_SeverancePayExpenseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance Pay Expense Amount.",
        "label": "Severance Pay Expense Amount",
        "terseLabel": "Severance pay expense amount"
       }
      }
     },
     "localname": "SeverancePayExpenseAmount",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_SeverancePayPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance pay policy text block.",
        "label": "Severance Pay Policy Text Block",
        "terseLabel": "Severance pay"
       }
      }
     },
     "localname": "SeverancePayPolicyTextBlock",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Expiration",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiration",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised",
        "terseLabel": "Number of Options, Exercised (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercised",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited And Cancelled",
        "terseLabel": "Weighted average exercise price, Forfeited and cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndCancelled",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Cancelled1",
        "terseLabel": "Number of Options, Forfeited and cancelled (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndCancelled1",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "pypd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Prices",
        "terseLabel": "Weighted average exercise price, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrices",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "pypd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercised In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "pypd_ShareOptionPlanDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share option plan description.",
        "label": "Share Option Plan Description",
        "terseLabel": "Share option plan description"
       }
      }
     },
     "localname": "ShareOptionPlanDescription",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Ending",
        "terseLabel": "Weighted average remaining contractual life (years), Ending Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualEnding",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "pypd_ShareholdersEquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of ordinary share capital [Abstract]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofordinarysharecapitalLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofordinarysharecapitalTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_ShareholdersEquityDetailsScheduleofordinarysharecapitalTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of ordinary share capital [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofordinarysharecapitalTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofordinarysharecapitalTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of outstanding options granted [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of outstanding options granted [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofoutstandingoptionsgrantedTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of share-based compensation expense recognized [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofsharebasedcompensationexpenserecognizedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of share-based compensation expense recognized [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofsharebasedcompensationexpenserecognizedTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofsharebasedcompensationexpenserecognizedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of share options at the grant date [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of share options at the grant date [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofshareoptionsatthegrantdateTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of status of options to employees [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of status of options to employees [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofstatusofoptionstoemployeesTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_ShareholdersEquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_ShortTermDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Deposits Member",
        "terseLabel": "Short-Term Deposits [Member]"
       }
      }
     },
     "localname": "ShortTermDepositsMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_ShorttermDepositsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term deposits policy text block.",
        "label": "Shortterm Deposits Policy Text Block",
        "terseLabel": "Short-term deposits"
       }
      }
     },
     "localname": "ShorttermDepositsPolicyTextBlock",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pypd_SignificantAccountingPoliciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_SignificantAccountingPoliciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_StockIssuedDuringPeriodExerciseOfWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of Warrants, shares.",
        "label": "Stock Issued During Period Exercise Of Warrants Shares",
        "terseLabel": "Exercise of warrants (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodExerciseOfWarrantsShares",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "pypd_StockIssuedDuringPeriodSharesNewIssue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares New Issue",
        "terseLabel": "Sale of ordinary shares (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssue",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/GeneralDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pypd_StockOptionShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option shares.",
        "label": "Stock Option Shares",
        "terseLabel": "Stock option shares"
       }
      }
     },
     "localname": "StockOptionShares",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pypd_StockOptionVestingPeriodDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Vesting Period Description",
        "terseLabel": "Stock option vesting period"
       }
      }
     },
     "localname": "StockOptionVestingPeriodDescription",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_StockOptionsAvailableForFutureGrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options available for future grants.",
        "label": "Stock Options Available For Future Grants",
        "terseLabel": "Stock options available for future grants"
       }
      }
     },
     "localname": "StockOptionsAvailableForFutureGrants",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pypd_SubsequentEventsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsLineItems",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_SubsequentEventsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsTable",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_SuitFillingExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Suit filling expense.",
        "label": "Suit Filling Expense",
        "terseLabel": "Suit filling expense"
       }
      }
     },
     "localname": "SuitFillingExpense",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_TaxBenefitPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Benefit Percentage.",
        "label": "Tax Benefit Percentage",
        "terseLabel": "Tax benefit, percentage"
       }
      }
     },
     "localname": "TaxBenefitPercentage",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pypd_ThiredTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thired Tranche Member",
        "terseLabel": "Third tranches [Member]"
       }
      }
     },
     "localname": "ThiredTrancheMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_TotalLongtermLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Longterm Liabilities",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "TotalLongtermLiabilities",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_TwoThousandTwelveShareOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twelve Share Option Plan Member",
        "terseLabel": "2012 Share Option Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwelveShareOptionPlanMember",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pypd_UnrecognizedCompensationCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized compensation costs.",
        "label": "Unrecognized Compensation Costs",
        "terseLabel": "Unrecognized compensation costs (in Dollars)"
       }
      }
     },
     "localname": "UnrecognizedCompensationCosts",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pypd_WarrantsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Description.",
        "label": "Warrants Description",
        "terseLabel": "Warrants, description"
       }
      }
     },
     "localname": "WarrantsDescription",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pypd_WarrantsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Outstanding",
        "terseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "WarrantsOutstanding",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pypd_WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares": {
     "auth_ref": [],
     "calculation": {
      "http://Polypid.com/role/ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable": {
       "order": 2.0,
       "parentTag": "pypd_WeightedAverageNumberOfSharesIssued",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average effect of dilutive securities Warrants to convertible preferred shares (in Shares).",
        "label": "Weighted Average Effect Of Dilutive Securities Warrants To Convertible Preferred Sharesin Shares",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "pypd_WeightedAverageGrantDateFairValueOfOptionsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant date fair value of options granted .",
        "label": "Weighted Average Grant Date Fair Value Of Options Granted",
        "terseLabel": "Weighted average grant date fair value of options granted (in Dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageGrantDateFairValueOfOptionsGranted",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pypd_WeightedAverageNumberOfSharesIssued": {
     "auth_ref": [],
     "calculation": {
      "http://Polypid.com/role/ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Issued",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesIssued",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "pypd_WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Lifeyears Vested And Expected To Vest",
        "terseLabel": "Weighted average remaining contractual life (years), Vested and expected to vest"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeyearsVestedAndExpectedToVest",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "pypd_monthlyDepositsAtARate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly deposits percentage rate.",
        "label": "monthly Deposits At ARate",
        "terseLabel": "Monthly deposits percentage rate"
       }
      }
     },
     "localname": "monthlyDepositsAtARate",
     "nsuri": "http://Polypid.com/20221231",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board of Directors [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Polypid.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r275",
      "r394",
      "r402",
      "r423",
      "r424",
      "r434",
      "r436",
      "r442",
      "r484",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesDetails",
      "http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable",
      "http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable",
      "http://Polypid.com/role/ShareholdersEquityDetails",
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r275",
      "r394",
      "r402",
      "r423",
      "r424",
      "r434",
      "r436",
      "r442",
      "r484",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesDetails",
      "http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable",
      "http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable",
      "http://Polypid.com/role/ShareholdersEquityDetails",
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficerMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer [Member]",
        "terseLabel": "Officers [Member]"
       }
      }
     },
     "localname": "OfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r274",
      "r275",
      "r289",
      "r290",
      "r291",
      "r370",
      "r394",
      "r402",
      "r423",
      "r424",
      "r434",
      "r436",
      "r442",
      "r480",
      "r484",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesDetails",
      "http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable",
      "http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable",
      "http://Polypid.com/role/ShareholdersEquityDetails",
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r274",
      "r275",
      "r289",
      "r290",
      "r291",
      "r370",
      "r394",
      "r402",
      "r423",
      "r424",
      "r434",
      "r436",
      "r442",
      "r480",
      "r484",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesDetails",
      "http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable",
      "http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable",
      "http://Polypid.com/role/ShareholdersEquityDetails",
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r276",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r186",
      "r276",
      "r454",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable",
      "http://Polypid.com/role/ScheduleofordinarysharecapitalTable",
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r224",
      "r225",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r435",
      "r441",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r409",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r435",
      "r441",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r186",
      "r276",
      "r454",
      "r455",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable",
      "http://Polypid.com/role/ScheduleofordinarysharecapitalTable",
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r474",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Polypid.com/role/RelatedPartiesDetails",
      "http://Polypid.com/role/ShareholdersEquityDetails",
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Polypid.com/role/RelatedPartiesDetails",
      "http://Polypid.com/role/ShareholdersEquityDetails",
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r0",
      "r12"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r65",
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r7",
      "r440"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r469",
      "r470",
      "r471",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": {
     "auth_ref": [
      "r71",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.",
        "label": "Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings",
        "terseLabel": "Deemed dividend related to Series E-1 Preferred shares"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofsharebasedcompensationexpenserecognizedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r112",
      "r125",
      "r150",
      "r168",
      "r212",
      "r220",
      "r222",
      "r229",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r329",
      "r333",
      "r340",
      "r440",
      "r482",
      "r483",
      "r524"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r143",
      "r153",
      "r168",
      "r229",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r329",
      "r333",
      "r340",
      "r440",
      "r482",
      "r483",
      "r524"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/General"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeasesIndemnificationAgreementsPayments": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payments made under the terms of an indemnification agreement contained in a lease.",
        "label": "Capital Leases, Indemnification Agreements, Payments",
        "terseLabel": "Bank guarantees lease agreement"
       }
      }
     },
     "localname": "CapitalLeasesIndemnificationAgreementsPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r45",
      "r145",
      "r427"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet",
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash equivalents and short-term deposits"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r39",
      "r45",
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r39",
      "r45",
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r39",
      "r107"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash investing and financing information:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r19",
      "r119",
      "r129"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS AND CONTINGENT LIABILITIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r241",
      "r242",
      "r410",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENT LIABILITIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/CommitmentsandContingentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r469",
      "r470",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Number of Ordinary shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "terseLabel": "Ordinary shares, par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Ordinary shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r440"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary shares, no par value - Authorized: 47,800,000 shares at December 31, 2022 and 2021; Issued and outstanding: 19,851,833 and 18,756,570 shares at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers and software [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r122",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of credit risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentLiabilityReserveEstimatePolicy": {
     "auth_ref": [
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.",
        "label": "Contingent Liability Reserve Estimate, Policy [Policy Text Block]",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "ContingentLiabilityReserveEstimatePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r48",
      "r49",
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Pre funded warrants"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CumulativeEarningsDeficit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative earnings (deficits) for relevant time periods.",
        "label": "Cumulative Earnings (Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "CumulativeEarningsDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r468",
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r312",
      "r320",
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "terseLabel": "Percentage incremental"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Date of filing term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/GeneralDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Net",
        "terseLabel": "Net issuance cost"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r43",
      "r91",
      "r313",
      "r319",
      "r320",
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r3",
      "r4",
      "r114",
      "r123",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "pypd_TotalLongtermLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r89",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Net deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r89",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Carryforward losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r89",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r89",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Reserves and allowances"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepositsAssets": {
     "auth_ref": [
      "r457"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.",
        "label": "Deposits Assets",
        "terseLabel": "Short-term deposits"
       }
      }
     },
     "localname": "DepositsAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r43",
      "r63"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation of property and equipment",
        "verboseLabel": "Depreciation expenses"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow",
      "http://Polypid.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r99",
      "r100",
      "r102",
      "r103",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98",
      "r104",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block Supplement [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockSupplementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic (Israel) [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r160",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r187",
      "r190",
      "r194",
      "r197",
      "r198",
      "r202",
      "r338",
      "r339",
      "r397",
      "r400",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic and diluted net loss per Ordinary share (in Dollars per share)",
        "verboseLabel": "Basic and diluted net loss per share (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedIncomeStatement",
      "http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r160",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r190",
      "r194",
      "r197",
      "r198",
      "r202",
      "r338",
      "r339",
      "r397",
      "r400",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Basic and diluted net loss per Ordinary share",
        "verboseLabel": "Diluted net loss per share (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r55",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Grants and participations"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "BASIC AND DILUTED NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/BasicandDilutedNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r170",
      "r302",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r322",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "State corporate tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges": {
     "auth_ref": [
      "r512",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to restructuring charges.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Percent",
        "terseLabel": "Restructuring percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r512",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employees and payroll accruals"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r71",
      "r141",
      "r157",
      "r158",
      "r159",
      "r173",
      "r174",
      "r175",
      "r177",
      "r183",
      "r185",
      "r204",
      "r230",
      "r272",
      "r294",
      "r295",
      "r296",
      "r315",
      "r316",
      "r337",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r355",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails",
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of excess stock shares permitted to be issued.",
        "label": "Excess Stock, Shares Authorized",
        "terseLabel": "Ordinary shares Authorized"
       }
      }
     },
     "localname": "ExcessStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofordinarysharecapitalTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ExcessStockSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.",
        "label": "Excess Stock, Shares Issued",
        "terseLabel": "Ordinary shares Issued"
       }
      }
     },
     "localname": "ExcessStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofordinarysharecapitalTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ExcessStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of excess stock held by shareholders.",
        "label": "Excess Stock, Shares Outstanding",
        "terseLabel": "Ordinary shares outstanding"
       }
      }
     },
     "localname": "ExcessStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofordinarysharecapitalTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of relative fair value of the warrants to purchase Ordinary shares issued"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalHomeLoanBankAdvancesInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate of advances made and reported by Federal Home Loan Bank (FHLBank).",
        "label": "Federal Home Loan Bank, Advances, Interest Rate",
        "terseLabel": "Federal tax"
       }
      }
     },
     "localname": "FederalHomeLoanBankAdvancesInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r227",
      "r228",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r257",
      "r269",
      "r335",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r433",
      "r475",
      "r476",
      "r477",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable",
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "FINANCIAL (INCOME) EXPENSES, NET"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/FinancialIncomeExpensesNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainBeforeTax": {
     "auth_ref": [
      "r519",
      "r520"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain, before Tax",
        "negatedLabel": "Foreign currency transaction gains, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofsharebasedcompensationexpenserecognizedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/GeneralDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r24",
      "r159"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "negatedTotalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r169",
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r169",
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofincometaxesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofsharebasedcompensationexpenserecognizedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofsharebasedcompensationexpenserecognizedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredtaxassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r170",
      "r303",
      "r304",
      "r311",
      "r317",
      "r323",
      "r325",
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r171",
      "r184",
      "r185",
      "r211",
      "r301",
      "r318",
      "r324",
      "r401"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r156",
      "r299",
      "r300",
      "r304",
      "r305",
      "r310",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r40",
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid during the year for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r463",
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Operating lease liabilities and right-of-use assets, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseShortTermBorrowings": {
     "auth_ref": [
      "r121",
      "r425",
      "r426"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate interest expense incurred on short-term borrowings including commercial paper and Federal funds purchased and securities sold under agreements to repurchase.",
        "label": "Interest Expense, Short-Term Borrowings",
        "terseLabel": "Interest expenses"
       }
      }
     },
     "localname": "InterestExpenseShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r161",
      "r164",
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCompanyCommittedCapital": {
     "auth_ref": [
      "r134"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funds committed to investment company from investors.",
        "label": "Investment Company, Committed Capital",
        "terseLabel": "Sale of ordinary shares"
       }
      }
     },
     "localname": "InvestmentCompanyCommittedCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r28",
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest from bank deposits"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInvestmentExpense": {
     "auth_ref": [
      "r31",
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses related to the generation of investment income.",
        "label": "Investment Income, Investment Expense",
        "terseLabel": "Total financial expenses"
       }
      }
     },
     "localname": "InvestmentIncomeInvestmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r27",
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Total financial (income) expense, net"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "negatedLabel": "Total financial income"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue": {
     "auth_ref": [
      "r93",
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount on the investment owned.",
        "label": "Investment Owned, Face Amount",
        "terseLabel": "Total amount"
       }
      }
     },
     "localname": "InvestmentOwnedUnderlyingFaceAmountAtMarketValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseDepositLiability": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease.",
        "label": "Lease Deposit Liability",
        "terseLabel": "Lease deposits"
       }
      }
     },
     "localname": "LeaseDepositLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r116",
      "r127",
      "r440",
      "r467",
      "r478",
      "r518"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r144",
      "r168",
      "r229",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r330",
      "r333",
      "r334",
      "r340",
      "r440",
      "r482",
      "r524",
      "r525"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r2",
      "r115",
      "r124"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Credit line fees"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r14",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Warrants percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityDescription": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.",
        "label": "Line of Credit Facility, Description",
        "terseLabel": "Line of credit arrangement"
       }
      }
     },
     "localname": "LineOfCreditFacilityDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Bears interest an annual rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r14",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount": {
     "auth_ref": [
      "r1",
      "r2",
      "r113",
      "r115",
      "r124"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum month-end amount borrowed under the credit facility during the period.",
        "label": "Line of Credit Facility, Maximum Month-end Outstanding Amount",
        "terseLabel": "Line of credit borrowing price"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumMonthendOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityPeriodicPayment": {
     "auth_ref": [
      "r14"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments of both interest and principal.",
        "label": "Line of Credit Facility, Periodic Payment",
        "terseLabel": "Line of credit payable"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LinesOfCreditCurrent": {
     "auth_ref": [
      "r1",
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Line of Credit, Current",
        "terseLabel": "Line credit agreement"
       }
      }
     },
     "localname": "LinesOfCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r2"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "pypd_TotalLongtermLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt and Lease Obligation [Abstract]",
        "terseLabel": "LONG-TERM LIABILITIES:"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r16"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "terseLabel": "Long-term lease liabilities"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofleaserelatedassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Current maturities of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "totalLabel": "Total long-term assets"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments [Abstract]",
        "terseLabel": "LONG-TERM ASSETS:"
       }
      }
     },
     "localname": "LongTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r39",
      "r41",
      "r44"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r22",
      "r44",
      "r120",
      "r131",
      "r142",
      "r154",
      "r155",
      "r159",
      "r168",
      "r176",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r185",
      "r191",
      "r212",
      "r219",
      "r221",
      "r223",
      "r229",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r339",
      "r340",
      "r432",
      "r482"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow",
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r187",
      "r188",
      "r193",
      "r198",
      "r212",
      "r219",
      "r221",
      "r223",
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Allocation of net loss attributable to Ordinary shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Financial (income) expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of corresponding entry for the joint and several liability arrangement.",
        "label": "Obligation with Joint and Several Liability Arrangement, Corresponding Entry, Amount",
        "terseLabel": "Corresponding liabilities"
       }
      }
     },
     "localname": "ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r212",
      "r219",
      "r221",
      "r223",
      "r432"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedTotalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r521"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheleasecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current maturities of operating lease liabilities",
        "verboseLabel": "Current lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet",
      "http://Polypid.com/role/ScheduleofleaserelatedassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "pypd_TotalLongtermLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "negatedLabel": "Operating lease ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r352",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted Average Discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofleaserelatedassetsandliabilitiesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r351",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted Average Remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofleaserelatedassetsandliabilitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next 12 Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessor's operating leases.",
        "label": "Lessor, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OptionMember": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).",
        "label": "Options Held [Member]",
        "terseLabel": "Option [Member]"
       }
      }
     },
     "localname": "OptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r152",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r26",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "terseLabel": "Other financial expenses"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "pypd_TotalLongtermLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofaccruedexpensesandothercurrentliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Non-cash financial expenses, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Operating cash flows for operating leases"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofsupplementalcashflowinformationrelatedtotheleasecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedLabel": "Other financial income"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r459",
      "r479"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Other Research and Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Overallotment option [Member]",
        "verboseLabel": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/GeneralDetails",
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments for Repurchase of Warrants",
        "terseLabel": "Warrant to purchase ordinary shares (in Dollars)"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Net of issuance cost (in Dollars)"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireLoansReceivable": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the purchase of loan receivable arising from the financing of goods and services.",
        "label": "Payments to Acquire Loans Receivable",
        "terseLabel": "Financial expenses from loan"
       }
      }
     },
     "localname": "PaymentsToAcquireLoansReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleoffinancialincomeexpensesnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r117",
      "r130",
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets [Member]"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of Ordinary shares in connection with the IPO, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of Ordinary shares, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from long-term debt, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r35",
      "r466"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "First tranche amount"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r84"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r462"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r142",
      "r154",
      "r155",
      "r162",
      "r168",
      "r176",
      "r184",
      "r185",
      "r212",
      "r219",
      "r221",
      "r223",
      "r229",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r328",
      "r331",
      "r332",
      "r339",
      "r340",
      "r398",
      "r432",
      "r437",
      "r438",
      "r461",
      "r482"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "pypd_NetLossAttributableToOrdinarySharesinDollarsPerShare",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "negatedTotalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r64",
      "r147"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r66",
      "r128",
      "r399",
      "r440"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "verboseLabel": "Depreciated cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet",
      "http://Polypid.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r66",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Public Utility, Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PublicUtilityPropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilityPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, deprecation expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Public Utility, Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "PublicUtilityPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofpropertyandequipmentusefullifeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivableWithImputedInterestNetAmount": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The receivable or note face amount less the unamortized discount or premium.",
        "label": "Receivable with Imputed Interest, Net Amount",
        "negatedLabel": "Less - imputed interest"
       }
      }
     },
     "localname": "ReceivableWithImputedInterestNetAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofleaseliabilityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTIES"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r85",
      "r136",
      "r532"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, net"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofsharebasedcompensationexpenserecognizedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development, net expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r45",
      "r51",
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r456",
      "r465"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r73",
      "r126",
      "r406",
      "r407",
      "r440"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r141",
      "r173",
      "r174",
      "r175",
      "r177",
      "r183",
      "r185",
      "r230",
      "r294",
      "r295",
      "r296",
      "r315",
      "r316",
      "r337",
      "r403",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAllowances": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue recognition for sales allowances.",
        "label": "Revenue Recognition, Allowances [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionAllowances",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r350",
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset recognized with corresponding lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the entity has committed to make for future royalty guarantees.",
        "label": "Royalty Guarantees, Commitments, Amount",
        "terseLabel": "Royalty bearing grants amount"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/GeneralDetails",
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Private Warrants"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.",
        "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense recognized"
       }
      }
     },
     "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived, depreciable assets that are subject to a lease meeting the criteria for capitalization and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Capital Leased Assets [Table Text Block]",
        "terseLabel": "Schedule of ordinary share capital"
       }
      }
     },
     "localname": "ScheduleOfCapitalLeasedAsssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of supplemental cash flow information related to the lease costs"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of income taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred income taxes reflect the net tax effects"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted loss per ordinary share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/BasicandDilutedNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of deferred income taxes reflect the net tax effects"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of financial (income) expenses, net"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/FinancialIncomeExpensesNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of prepaid expenses and other current assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation.",
        "label": "Public Utility Property, Plant, and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment useful life"
       }
      }
     },
     "localname": "ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r76",
      "r79",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of status of options to employees"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of relative fair value of the warrants to purchase Ordinary shares issued"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expenses"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price ($) (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield (%)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable",
      "http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (%)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable",
      "http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (%)",
        "verboseLabel": "Interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable",
      "http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable",
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable options (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercisable options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Options, Granted (in Shares)",
        "verboseLabel": "Share option plan grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable",
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "terseLabel": "Schedule of diluted loss per share attributable to ordinary shareholders"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/BasicandDilutedNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, Ending balance (in Dollars)",
        "periodStartLabel": "Aggregate intrinsic value, Beginning balance (in Dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, Ending balance (in Shares)",
        "periodStartLabel": "Number of Options, Beginning balance (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Options, Vested and expected to vest (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Ending balance",
        "periodStartLabel": "Weighted average exercise price, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Aggregate intrinsic value, Exercised",
        "verboseLabel": "Exercise price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable",
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted",
        "verboseLabel": "Exercised options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable",
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r277",
      "r286",
      "r287",
      "r288",
      "r289",
      "r292",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Accounting for share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price ($) (in Dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "verboseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable",
      "http://Polypid.com/role/ScheduleofshareoptionsatthegrantdateTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Exercisable options (in Dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life (years), Exercisable options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life (years), Beginning Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate intrinsic value, Vested and expected to vest (in Dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Average Exercise price per share (in Dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Warrants exercise price (in Dollars per share)",
        "verboseLabel": "Price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails",
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtPercentageBearingFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.",
        "label": "Short-Term Debt, Percentage Bearing Fixed Interest Rate",
        "terseLabel": "Short-term deposit bearing interest percentage rate"
       }
      }
     },
     "localname": "ShortTermDebtPercentageBearingFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r52",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r21",
      "r71",
      "r141",
      "r157",
      "r158",
      "r159",
      "r173",
      "r174",
      "r175",
      "r177",
      "r183",
      "r185",
      "r204",
      "r230",
      "r272",
      "r294",
      "r295",
      "r296",
      "r315",
      "r316",
      "r337",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r355",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable",
      "http://Polypid.com/role/ShareholdersEquityDetails",
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r204",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "terseLabel": "Issuance of warrants"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r48",
      "r49",
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Cash paid for amounts included in measurement of lease liability"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r20",
      "r71",
      "r72",
      "r73",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Deemed dividend related to Series E-1 Preferred shares (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r71",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Ordinary shares in connection with the IPO, net (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of warrants (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "terseLabel": "Sale of ordinary shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r6",
      "r71",
      "r73",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of options (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r21",
      "r71",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of Ordinary shares in connection with the IPO, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r71",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Ordinary shares, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "terseLabel": "Total amount (in Dollars)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r71",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Share Option Plan [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofstatusofoptionstoemployeesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r60",
      "r440",
      "r467",
      "r478",
      "r518"
     ],
     "calculation": {
      "http://Polypid.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet",
      "http://Polypid.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r74",
      "r167",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r272",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r347",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r347",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r347",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r361",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/GeneralDetails",
      "http://Polypid.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flows:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of investments for Federal income tax purposes.",
        "label": "Tax Basis of Investments, Cost for Income Tax Purposes",
        "terseLabel": "Accumulated losses (in Dollars)"
       }
      }
     },
     "localname": "TaxBasisOfInvestmentsCostForIncomeTaxPurposes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r227",
      "r228",
      "r257",
      "r269",
      "r335",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r475",
      "r476",
      "r477",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r192",
      "r195",
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) from continuing operations allocated to participating securities for basic earnings (loss) per share or per unit calculation under two-class method.",
        "label": "Undistributed Continuing Operation Earnings (Loss), Allocation to Participating Securities, Basic",
        "terseLabel": "Allocation of net loss"
       }
      }
     },
     "localname": "UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r205",
      "r206",
      "r208",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdeferredincometaxesreflectthenettaxeffectsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofoutstandingoptionsgrantedTable",
      "http://Polypid.com/role/ScheduleofrelativefairvalueofthewarrantstopurchaseOrdinarysharesissuedTable",
      "http://Polypid.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants total amount"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/LineofCreditArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r189",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of Ordinary shares",
        "verboseLabel": "Weighted average Ordinary shares outstanding (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://Polypid.com/role/ScheduleofbasicanddilutedlossperordinaryshareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "auth_ref": [
      "r53",
      "r54"
     ],
     "calculation": {
      "http://Polypid.com/role/ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable": {
       "order": 1.0,
       "parentTag": "pypd_WeightedAverageNumberOfSharesIssued",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "terseLabel": "Ordinary share options"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ScheduleofdilutedlosspershareattributabletoordinaryshareholdersTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r187",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of Ordinary shares used in computing basic and diluted loss per share (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Polypid.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "10",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=6438156&loc=d3e57880-113973",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(13)(b))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.7)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=25866437&loc=d3e10491-115837",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "980",
   "URI": "https://asc.fasb.org/extlink&oid=84167750&loc=d3e42232-110370",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=126933198&loc=d3e35680-112684",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2793-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2814-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919106-209958",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888252",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(h)(2)(iv))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=126898976&loc=d3e600178-122990",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r443": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r444": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r445": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r446": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r447": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r448": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r449": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r451": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r452": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r453": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "405",
   "URI": "https://asc.fasb.org/extlink&oid=84228828&loc=SL34748401-199205",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "10",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=6431724&loc=d3e32938-113948",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "83",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126929950&loc=d3e34841-113949",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001213900-23-025399-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-025399-xbrl.zip
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M?>93E]_F //5#[VB>R]6?;M]N-5ZS3>^:[KG="<:X?-(%VJEMM['6RWE?"/
MTA0MPWZQ1V$VCOR'9BYZ!'NN?:N%FB\3=M'-PB#TT\DJP77VO@.(Y+]NM9CS
MC:EP<RANIB<M7[$Q[,3[R-DR_<J/<G6_DT8*<P_[W9_2_,5<8T/_\Z6)E.;-
MB_:O+8(@P0>?]+^/VN>'GT[/OW1:YU[SE],O%][G9N??K0NBX/\.!'+>BWI_
M:O,7<PT6';7.#SOM,R:9//;.6X=?.NV+-JSBZ<7'5L>[^-@\\5K_\P6I[.V7
MCW1!5^K\N%5T]\5<PTM'JIOK,R-\>##HHLZ))4=O7\PU<O2;GZ:&\"X-!\,5
M\)&^@]UVJV#NB_F2:A%<?KW=YARH?3G7&%*3NG'"S8[ J,["'!TE2H(]UN6Z
M=S^F:U^KO #^ IH4L6BUE]NJ:)$6WOU[F[R<:]3MJ'7<_/+IXKP!-OJOV);H
MR&MV.JUFI_FAQ27,1ZU/[9/_^=(Z.5P%T^X15HCLWI\R_N5<PW*?FQ>M#A;B
M?3X]:A^W#PES<>Y=G!)[?*?]X>,%&/:OC)W_N^>6LG\YIV:=9YW3PU;KZ+%*
MPB+7^?Z,K"_G2U-VBET4/YUK[M7#UA%ZWH]TQ1YV[]Z?Q.SE7(-[?['#T>[>
MZ]79)[/F=(YVVVTLQ;F&OYI?CMH71%;=OKAHM1P>9.P$U[EX\,VW#*3&XQ.4
M7VXC*/,E/CL]HG.T=?&Q??CP.OFO S\>WZ(?WF;1YQI:.^NT01F<@39H'AZ>
M?CFY:)Y<>,<ML;#/6YU?VX<K<$ O VCR^,3EZ#;B,E]\V']:G\_8.#_NG'XF
M\UPJNK$KPLE1LW-TCKV=O<JQ\UA%Z'$+2.LV C+?DN,OG<./S7/,PQQ/YU^\
M7WXGD6F?GW\1/H#F\7'[4YNIR.2W#]]0>*UOZK%RMQ"G5W,-<X(\G'P >3GQ
M.JT/H&<Z<#S]\V^O]W9?O3OW#L%Z;1__3@T^S.'U2$7G<0O&A]L(QERC@X>G
MG;/3#J@-[\/IKZT.NC0/WL=Z?QDDV8]/.#[>1CCF&TYLG[2\\^9Q"PX?"_!X
M</%8N8ZA2UC\]FT6?ZXQ1KO@>&: /8KG UBDK?:'$^]?8(B<'[4/);[\L7GA
MG75:OR+??ON$.D'A%P_=J>2^HK+X'-JKN88.*RFT[R>'=G_NWU=SC?W96!\X
M9Q>M56A7M[N_C(9+\U[0^U-6OIIKC.X[6M!%+M?]J>]>S36ZUOK/Q_8O[=5=
MH@61E*P&^<@U-"$':T:0&8P@:TJ0NXC=TL4\' T\/\I_?@(F6]K[^4DX@O?]
M?SL[N]M_C =/GM?N@V6_.OV/[X7!ST]\'-H3T7N+G!=75=(%.1*K8]W06Z\8
MCU7:\Y$]!0S.-B(0CKX<,JN'8V\N>N+^*+(\[$_J]+JKJRNE,$L:53V%U&_*
M0UH-WSL;PO3QR/:]7A3&=)IG.0C?YD8W3,9#/QWY/55P$[I>,H+13^ @ZA69
M"K#6+N 6D5CIFL-H5*Z"AA<E<'4T\?Q@!+?,D$<](/SP. 43+QZH8"M5D8)G
M(]]7ZH_I 9F';>T'7E*D>.$X#17"'S<WSI)H,@(E_"D<AX'7BGO^."LB'PO'
M8 KR-/Q/PTM2[^Q3"_[(56\8PU,&DVWOE.\4%+W<Z\'SB48ZHW</5 ;S!,/*
M$QAFD*HL\X(PPS%EWE68#[UA.!AZ13Q2N3=2 ;[_YD:L5)!AM>C8#U,]5GRN
M\UC^=9 6 WA2!%HS@(D8PS NX6GP4V0X^[)]ONT=)PG/RA%<ZS5EKE)Z+WHA
MO/+XJ$E_AW&<7,)7E[ P>&_W?? 5>L,05@*6%"Y3D3NMGNKW52_GV:B.-<Q*
M,Q&H")Z0RN@#ZG(&ZPC?Z,7U<G@C^._F1A;BL\.8AME-\"USF&T5P&4IO M<
MJQ<YY6DG 7"_#PI^VPRNB <XG_TT&7D9O$D*XA;X$WHY_>\1;(QAMNV!^'9A
MH KG(A_"4^M60<2MNO9#_Y*$SALGV,X4N2WP"9:9&EXW'-%JT64CT]0-^4I\
M[])'L9S@/T0J8%? W>DU&IL;8=R+"J2/\K("-B=^CQ,%\]1GSK*,EO/\O U_
MX!CAF3V5\NK ;-4,NN$=;>';_905W??<VPW^:.#:P>S[WCB\3+#SKKN9-S=@
M5/T0RRN3%!:02#SZ(E/VU5DNY2M8FTO\/"%NV62LX.;=((&E@@MPP-NU Z&]
MD-$:L.R5]V[MYDB^37H3U#?P<KX'X\SR+?Y7-TU@#K(Q3%8JA#&P!;;,!H(5
M"D$QH5S7#@8FI:1UM SCRJ 8P^N7%P9D4*^62HW88"%_AG.K%1:O58(=.(ND
MR(QH"V4A#7O+&;899>E=4^IF#<_#X;"&(5V)=\8SC[>#OBGM<UP9& <H?- 6
M\,7^#N\+LYBE56.YLD*(_P9)(FT-N@<T>QQ@#S6XM =J<'/#CA14<A;B!3GZ
MY,3[LHTUNB*V=NRR267"$*O>55[?1Q&D22(% 6-V-I4W+KH13,90@9$S]+H%
M&-5X=F1C7 )XC<T-.*94G('V@5. IC6;P!*.PMJ31(\9='$"]X,YV.*52T"0
M$FX>#J+(RYE0W<,(EJM(45OZ7^'9( MPJZ+G[$PO#;.OM# XKR&NAKT7**$<
M7W[[@8_NQV-D7, D_I:D4>!]Y%4_30=^'/Z7S[?-#9#?WSZ>-CREV]EZI,M)
M8EG64+T58URJO^_N\*MUPR@244>6/KP5B-TPR;CY>"_!?BVP9MY$^:D^G+[$
MH>D>@6=R0FH'),/?W.@7*8G'/__V>O_EP;O=W?)SJK=J%:#<%*P W#.)MSU\
MR4,R5GE''K$)H6EVF C$[%!2_8='A]67WMR@MT:[A,X<> MZ%1!@WC&X5[=\
M(<N"5S$R2W?\V&R#W0,^($X+/:OVS;?!2M8"TGU/3TQZO8+>C?3K-QH2ZLJ]
M?^"LO_@'S7,$*AT6C=@5"ECC=)"@%@AC^=2H@BM<[2O0G#RYW+&8IF5OQ]P*
M!DOG5GEHH&APP"&<@3Z\_* (T12)%1ZI^"(@*713_!LFD(_QR <S .]!DX?J
MFC0J'#X)%:&7C#</;3?0]LJ38\"9SE&2=JF3?0/_!$'23>T5Z&4X 'NT&F 1
MD]Y:JX [^!EBJ/'>KK5C0./VC8'< "$J0&5TJP>(V&1LB*&)BDL(PIN2 %:.
M-;C+,.P-Y1R$-]-GB3E'[$'K'";;RW+[OY_EA<G,>0_E5TG% B6CDVC^ZNU7
M7J,K< \4MJ= +R;SSC^V6Y^.O+;W]+QDIGW4*M[O_5F$: 48TP0V?$N;0&1>
M?B*3JNZAS]#@"<Q#0&W6FU'6[GV:)?W<RT.DI'[&FD9T:SX,4S8+^PD>(MZ?
MA9_200 WV-O9VR%S#RU",D5(Q7WV)_C5KF@UL&P]?Y JTN@@\!C'\WX!C:7(
MSJ(]@]L@'D2J;.9[^[#,14 .7%;T89.@)FYHTY45)5_!9RF?+GZ@8)3H4I#!
MK_T F!7M")"34VM9QR ^9)'"M6#+63?U!%W4V>8HOAIE=F F<#7YL%B>$GU,
M.PI$Y%R-055U%1Z:>WL-W!\^^/X%^ ?@=.?)F!PELZIDB^/$FXU3EH\9NX]?
M^OI%LYM KYD\9'.C+7<'!Q6<OMR$'T*TOE(P(\ :4'$P!D.!_&8RM>G^<%_V
M4<"@"=%ND@=G^FCFPSP.G)-8-APVY(N)9N8"70PV(=L7%R#UR5CB00VZDGVJ
M:5U?*]?XK.D#!'WT! RUI_'/!Z]?/)/YUALU4.CE9*C_>"?7O?3>_C\X8I9R
M< 7NQ\8GW_3-,^_I^.>=[=T7>SO/T)*$S9[Y8= 0KQXF"+4''(#P<Q@I)DG'
M^+XP8C^:@*\&@_JS $N2?#NK46@+YZ0KX,^#O7W\]1^P^R2P%6$H!\_&,*.)
M?_K/0?YN;X>"KB#%J,*>W7T>6:+T-)$;53[!K0S '5X<_$,O:W7J&GRG&3.'
M,[:SL[\',_8;O(S<@R((QC4F+U!DMB&VM5ZQ@'?,F^U79@!X=XIJD7'AIR-<
MG[W=79@$.)#<<1QLVV'/GH.:>\%P8=/$QF=IE+<L;R8X+!,O&R97Z.)Z^_"H
MTK:I%3/XW-CFM+@X22"[L'D4.B\9^4?HV(*'WLN3--O<>(KS SY3SPC2.X^F
M]>#5.R_^^>7KG6>EMZYN#O9Z*H,/U AD"66$1C_ V&;F]S%4!B=+/XS4M. 8
MS0O_Q,%O;L0)RJ7>6N!S@RE?9/A"% -4SCJ!*9@.:)(#^ :N)Q6673_R'_S0
MN7,^]<4ZGSHKG[I.J#[Z[3#3!CM!3[-D@FF[VIZRI&W]2S^,J'%$X.=^C3$F
MFAW.)/ -^&0F(__(&/ERAF,Z*(J2*_R(B#\PYIB7+P75-BIB,;TW-V@$)D?$
MWE2>)%^],6PJTI__\N,"CPMXC7U,UM7:B3AR>L<XN>*XBN_U(HQYI6J 9A4F
M$."0&5[YF FZ0GWJN[[#]8X!*/<1>$\4+?O%EZPA1;?IN3@O80\>DT:<&GM1
M.O>2+M<@7W< HL:/U+?-#3[R0Y5=:T$9ZPE6HWQVLF%$B0_'.M(61P/.1C"F
MKC\;7<>N]Q5F-%+!@-PQL.Y*TZ\-^)$_T=(%8QPCDR(NO2(J85A&FJTP<VQ<
M9F)2* TP#?KFL("8B,+,D0_"X41'609QL'Q[=_5PC4I+="&CSW+VZO6XDYBC
M?L9UYMM:N</U5" _&:Q-"J*,"PT'\^;&WLZ.F6<W-5$*.7H'.Y7%H!#=F'-)
M>&=G<4P"QZQ2 ]X=PT;FO>".)#BX];*B!Z:%SP.V;TCF%DXCF*C_U:]:;]51
M74I&B:TD(V$,1,[1_Z[WHFQ: 9<+YX72'';F\6<4+"TR,*E^<,ND7A5;8=.A
M9EBOM C) @07 V3M&P98>"_BCAHIK2DRC-T&.B@C,9E]*ULLI2:Q&YN0?."]
M>+'C9A>T7(+HD%/EC,%#A\E-+>J8#$85>^'8EZ%U547<=_<DF\U1[:I7C[$:
M\VKP0J,PV(+A'VQ[7^)N%-*N)^\Y'!E]1O,!JC^.S3-%(9#.[56'<.#L2]&A
MG(L+4_"DML"3 A'%(VFK&*_E\P[A&I /!2H\<'+PJ :,<6!R2)\Q,X%)#B*)
M[TWHT&Q];C9FZR*4+04C"]'F0 UB=3=;%]QQE(CGBWR8I))OV]QH5@[GS\UF
MHSZKQ</XTN!D#U_PN6FT(.>I(]*9($\].*NU3SCU5:9'&W(@!X1T@&R"+*&U
M+V@?>N%@6-H"?X'7[*4A):?EY*'KLUZ2Z@1B/4;!.1AT>A_/!+1=_ CN%W.6
M%T9E]@3ZUJ+2V2C+JW@(EL5FAJM.EE. [K=KE]4FXCBHEYK\!6;<X$E@5%!V
M'6;?[/T8[+ MQ,OP=O<E%V\>85;.L=5\7GBD^,./P3JACL_7Q. I-&PUELF!
M<UAEZ$=]K3]_= _Z/BF;MF..H8 E#M('=L-HQM(0#"X<4QK49K+PH$);F4%Z
MJ-<95R/W:GBG\ DCX1 V=Q8&9N/B,^FL2OVMO,">3)&@CP0N-O'*R+)M<S,/
M-B%NZZP6:H6;1BS8'N>]T?KCX"%(<H*X"[(002/D_C<58>@V-M@92G>C)01[
MDX JO:$:)7I(_H -1P-&$X.4WH!S0WT='X+G72GUE4!C[HX7I >/B'^8*LI]
MIVACB]%N3;-LC+ ]PO?U]111)T"&#2 ,1@Y1%RJ6T @H6GX98BX%@V'.':P=
MP0DJ =M1C)X =YL;YB6-16%?$T$#Z,W0&\$&#4),^R!,@O!_I&SI:K9XT?+5
MX+S4#T'6T=.8#733Z$]8X1RL ;6]N8$JW4C M7*C)1G-W*X"$UW!^Q=D_<!8
M<&C]0H:- #J,Z?DQS*%>C5$"DU'R#E"L8W2IX("$K<IYNT$4)ET$", G! ,L
M*5%05S$>/O3S(4.'\*WC D.?#//2*"Z043KF1'\<?CZ\?@\W]'F&QP;*FYD7
M/Q/7"Y%ABO:'ZL,5><9&V  ]5#VW@I9%TW'[,:BN55*R&K0<>^TL]6'OP*2G
MX,^*?=/UV3.3;^GD]"[@CR9L1MZW5QA!!A&3G_'EX)Z^9O3E*1Z4EF^U(EP@
M_8&-0Y0A11+1./&SP/]S<^-#E'1AL=D4<PR:;#+J)A%"C?;V=MZ=_7YV1'_N
MOGMH1,F*5_6\7$>A9T2A+]=!Z,54DUB<W#7*KU(0L[=:!3&'S2_4[[;S^^;&
MR>E%I6K^-_ASZ]/IZ;^%X<G4G"ZQ<N:Z+N?S7JLE:M-#E>9@<&$$4/<WTO9[
M0)B%TA'4G3#^B39N*,%>GQOKI-Q8!WY_#'>"HVKKF*RX+M:OJ)&)\\B) H_#
MZ/Q6E"1?"=.N^YME^IS!^[B7;&[8:^B\2_I@ X/UY*<, ?^OK5D16';U(5S,
MP8Z MCME/##4ACQ9?W051E'U,W9V]:>;&_*Q=4BG?B"1NNKGV@BK?BX8Q.K'
MV1!CQM5/T<^.@ZG1@/F'$ I],:PBP\JS<!1&8&E<P8D"HM,M<II'!,5PV!Q,
M!TJ<#%6FO,IL8X@_I_3$TJ"'U^VYE8 _7M!$S1;ES0W< ;*?RA,>P5IP:*GA
MSG2J,&^"HLJ^=T)@&'"]8+ 8+\T$ H3[<1#BI\Z/*:2$@N53.(B$ $,PL)'[
M)ES+Y3*ZEBFA:#,Z(S%Z:[8^J&'C.CWN:.UQ01E!C>&K.*L\W1TZBA,\$,S:
MWK#A>A(-##12^%9G&V2K)K;\33Q7<D_M[9^R#,,[QN['\%-00GF2DL^"SE/V
M3,"(4BF'<:A+BC U-.XB2<%]M8/*3%9*-I2\>T-/8L- @[' Q>QU#S4$(5A@
ME0T\G8)115XL!<*Q\EOD^)K-H??"H/ IT*IH.7GN$!!$1Q(E U <4J6Q891
M";.O+(R(-J1##)>8/&T*;[*/E=^P0SUTQ_PL*T9CWA#T*'2=,_Y^!)X4GBHH
MGTY]':QSA/UE)"X4<A@T#94>+G^(1[\:ZS2;(ZAYBKU7&P857JK+,SM/IJ(D
MJK9*2$!2^*B)Q:[;! XG(]="^.1]>X2V"0+[[)R1JH0S%102EIRAFF SAM1D
M8WK2NUCQ2Z6W2N?;,4X8]A$0/I+FXQC9X=Q)DI7BU*(9;C@NS%'ACQ*,Z(G*
M@\NRMRLQD[,'02P>%'D<8P Y'OS\9.<)1R+'?D__^\X#O0J#?(B7[OSCR2TH
M75QNJ1I:$Q.OOVWGPVL"_/<E0OGGW]Z\?/7&!JH>8 BHS (U1D2&P#9LAIG'
MXN)-0'+Q!R8P*+42^'$:<#&$"2DZNZ9RJCN%S:5WOR57SWIA;S,$,N,Y)I[I
M^2\ERW XU62\7F"+8"@O]9R62W;RP>OQMQE)M.O63GZ]=S#SU]_50M+"228:
MK1T_A)-##'$>2SY,DV+ F56L^"%#*>GS'&:F<=IZKRUIB?S@$I= +\XM5:&;
M1B(4F6,Q@&&0YCH1!+H:_V1BB.F=7=7.ZV5?Z+(;!T'GA1V(J1R?]>M-SC'6
M!7@]$WG3^+SUHBUKK[IY7AZ*X* ,R8A3K,;\-P@/)KB3B:8)@ABM7@?0TDV"
ML+RM3;DBVTDL$.7=VF"\)0XDZR5C01N@!R&VEBXGASM1E28#.5T<C:V)=(;H
M7M"S-:=2ZJEC3#5:21L*KFJJ15AS>!<S]1H^N#;YEF_R.4NCXLLP36)KR1.*
M8.C' TN ),PFXR3"4ESIEJL&]&"YA.@0-#S=%#]SX%!5#ZUP!!Z>0%,G[L-D
M7)3SUF.)X$&9@,.M%^[Y1/S$0EXF\@(%";.6@D.ZEJ'EJ$="ZZ<8#X9KY$!#
MJ,BW,&-X80U-66RB59D?61/ENM]0+'6B@UD2]3.XIK4.>;#UQQH>7#T>!D<C
M?4VLI#&:K"6TH%"]1C19^_P/Y/,+G&_ :!Y-!2,+:(^$M0Y=Z#+H@S#VBLQ[
M:@Y)JT*=3<81MYNB;,]P1QV>_MH^VMI]0UH6:0L0EVC[W!NNLP&*0<S5W+VU
M1[&TY>Y328K*P[*E@WA]@SQ>AV(6.(2!BIETDU",#;)L<V9!U8OAL&/I3-NM
M;-WUHBUJ"));=P &!"N Q4'J0\=A"/\LB/!LO13+BC:#D1<2.D,,"/+-F*22
MT!L36]03B7V/I>%ARGG,JG^(E"RC8N1UP\"]KH&:DW'(WGF>]+YJ%/*G3X?K
MM5[4$!SW')==H$3KS;6P(>!1-"#WZ1UNJ?4\+\PBPX"I!G@03C75*<\<N7HT
M:K*=JY&WO^W]6TV0F,_@7JGX;/>==[3M=9"$Z)AO505=TL\/MDL_E:**0^:<
M-[_ X\OY%8_EQ;9WR@ \2>T<&_1=1UV&6.1)1*P2Z95[-;AX!SP&72MU/?16
M3*)HLETO<.6N*ZL$)%GB(#K*QX)<PI8A'P<%L)$:0S(#J5T/,!NS4!?'Z+JP
M(,QZ4<)4S004DZ1L4N0W+I"M9BW3^U^&&>,04V9+(](1Q1A.BO4:X%L)RX00
M1(FAHEK78*5&/;:S'@PJ?.(L=ZM!,+H2@_@]*3P&8!-<<5Q0H52A4$"BT!<(
M#3>;F(7MVO::UWY_FSV-PD)BYF>&=AU^O[DQ!&'!Q \7CG$5%U*'PW"]I!O)
M\4.5IL1MCL6K8^) H2P2B=SUP\?J:\5I+^0N%LYK& 0ZN4[Q0 -9JBF2:Z"V
M'."]@F<@KA;AD'@/L0,)L1_Y5VMI<XD:RM1[&<.X10-<+R(8/,^QHOG6AY4^
MJP0WGI5*09(N?J:)"'&@#!I#0A-)RW@9Z)N><H&I^A.-JB8\+NX<YP8@@I<X
M3\NL)UC]M?\21X@P-3M&HP-4 !L+ [RF_(:0!++(5;-#UZ],59' NM28)D[M
M/7YC&([E<^]3'FPW*.YX-4SH7$RN8F:I@B,QQ"8CF:G@!TGK;6.CC",%VYK*
M4FWEJ] ^VA,'E![.X;^0%''"^DO?YXRR@-YYYQ/>37?S29B7GWM<(%):W$];
MN I/)>U(ZX)M(3IU4T9)_0#>QD^SFBGYN_F,V0"D^GZBU6ZII)8V9G.D$-G=
MD)!LS2.SH?JJ(F/.Z0TJ]<&E;]VAG+3/*X/!&=,_.Z>?9>Y;(O&N_G&E3+AR
MHV2ZD+B!1P:8'![6Q"M"TVLU Q=;6Z)\<"%]?AK004@K;(Q/$-H>:GQE*/8Y
M%XAD6./(IILKE"-P:- "?6@VSWXL[7#/JN-7ZZKC^JKC=='Q*K82O,T9R)'Y
M&*^PYR&9'70@9FRZDA%I3Y^&]TL2RQ]^KZ_B+ L;X&[_-^Q37==Y%B(A7\-K
M19,^?$>*%JZ<("L5%Y66&[HQE0+F%3*BC2)(EOZ$*YA"4UPB*E7[7F#R1_F0
M0+K:"$I&89X+X_U/63%^+WH:>73P'[NO#M[9SW?E<QJE>_G%Y]+WV+Y QF3
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M"1$W<6,N9E!D0\BKBZ&"009_AME0?L%VOMP.'1;V4T,.MU.:$Y/JX(L.4B6
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MFDYGF.IUVJE7L1-PV<("9445P3-HA<L]V_#.J>TZ::/J;A5;)<NJJX]->8&
M1%4\\ ?,QF5A2B5^8CSU*:>VEIB%2@R%[QK3RM[AU- R59NM,T578&@J8D&L
MX& :I7Y^U>+!ZB&AN15*).=RZ%2*VR5 :6C1G?"R#B](/IRUT5J0%JYZRLQ\
M(D).\,2JDU+-7Y4D>YH?N^>/.8H;JFL[E0C(V09IO(%**"4P,26E<"Y9%Z.F
M1O$ZQKJU#"U4AFR45R?Y^[8&U<&2(PVL1:[;^L(2=-U5$D;<U@NX'/L#=/Z8
M7'LY][G[MVXLBG&'W,+**VARUY9@YA6$HNC4YW6(=0<-S=QV]E)3*D37;VE#
M1J.?UXC;!4M&A,<T.Q.4,444D]G;C4K$I]H%0W/&WE2&/ENI+Q5IR_^+D9)5
M3NZTI9R+]J%I0%+3NEFL0-.SV;7GQ.:KM>7"3-C3MC"K7XS(&#2YFS(TS/ >
M,<+/_PJ/)?I"RMYK)JV:%NHF/U_NC(7,6%YBZ5O='/;,=ADN.66%UW)SHVUA
MJ8T9=;.-&=73.C.J;^V*-R-5.5:H[VA!!72_24-G^+&W=VJW";R?Z3YJ]LDL
M+B@G/5OBKK*Y6@9)PS:CB>>'2YJVV>LEA#Z)<# *8<].FMA-N:6**2)G!4H-
MY [>MXOMJG'1D^X?7.$)$]$DN$PIR8QI:#(:)3]+9G^(ZIC#WC!H?^!4)7/A
M:.!/D-DW0%Y=QP:UR6H_@%MDQ.W7[V/VL (6T)[%M9VB77CWR@9EEYLR%N#*
MH/ QJJ\8O&VP4K5X%=B.#NLTXSHYN1!KH]#! B"XQ1'/AD'W"H9/",;-\TJ+
MO;DAJTW0)4RGJ8R?)39$39JCA##OJH@D6-N7E(=Q1L^(&MQ,!&B2=E%).L5X
MOKE!8!@#M:%VC8[H@],38M%!V-< =53"H72*2=TZ3X*XVL&,50\3%I[+E0M*
M-["IB0L'M\5LXO:Y;E9(([/+;.D-3 L5F:%X'R=9%LK&T4AF?7=6?SV_R)1+
M%<2 <G>N6=4'=+8H!^U\$R!-3Y.@E>RNY@)T+IFP!]Q5 M^2;3F(DBY6X\#<
M)".>(YE=SA8177"8I04W.N=N%(%WF2#S$@U'X@L]1"=S/,-"UBJ8_'+C13HD
MDC0*KF!1UGJ#,YO3[;%YL=$6X26^)I5)6#*;P:R #QO>1 *@(!O#<&PVOJW%
M"*,BQ\-Z2I>0--M;;6ZX",0HA,<'C%PSN5 PD*3:,M.8O<I)0Z/1/@N:28ZV
M00",VY" -9T%YO'C"42/V#503)0[Q;=)0[;0*KE@447.)F)@C+.)<+X(#Z@G
MO8+S+'-M4^V<];\=KUL*HDI49 CIU[NSQ)T-MD(8P_QE0Y-CECD1O)^EG%#F
M+6HK< A31$EDW:<)FS7HLX/70"".3G$\GB/KS8>N@"DH*6(]-6PE8Q>#F_%X
MFB.9X'BSH*/EC@TW(/2<9AFZG4)J&HN4R)UK*M*HVZD^FZ81IF(?5*M?2(RZ
M[A0X/:3L;K+%=A1I%M5$5F%<L6JI7A2YCF@3P#X/5(:SH8W0*02V8X?JNS2<
M(\4<4)R)K6U-\:/(\W4(LNNP7OMKK)?&>AVLL5YW$+3%"3;][RXM[<W;;(M#
M:C]UWW>HP*[#@4RRG5'=':$6!6L#_/2C2J[M4,=G+B1H XKC3$[30W.:+@KG
M?,^WU-.^1/#U.T_7P?VF''26)?$GAVD,^E8H<LJ4 #KZY:"=S;E6:4LP(XZP
M_-(S?.45L$1P&+^15<OQ/K;$=:\$Z8Y OA/C\ZBY@GN)OL94E'$IH.[*-,:P
M7#=(L$8E\L[/V[H[B@-;0E.&HC]^[E/_L>J]PPPK(OYPRE)*#1]Z*?@C;CP
MC-P!^21&8K2+$1=4VT;(1*GF[B5#"G&Q Z2#;+2[N[J/!)=C)X*CSU1ZZ8#4
M)^PN<)0MD B)F8\ :^D5,=,;0]ZP48 !R!X/N3_XKE+93(50&'V,$^0^*%*J
M]BI5C)A>!TZK"W@FA2,H%FN0G#R)%"$MLR\X52$77.:K;/,>64$JF"[O-,KY
M4GB21D7N!^(ZD0(I ;=%MQ5J8%@)E1ZS#@RYU=M4,QMY 73)[!+*0CF['KOD
MB5,!S\>(A2T;(-\P<_KYRC^]'GB0:.K5-5^#L6%-.[YAYHJ*#5TOT[);*6U
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ME1@>\W^:=Q(:KW(U 1,)$?&&U,!N>Z>FZV6Y:]7F!BXF5NU:R"[5BV6:6:Y
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MJ8"#T);.E72-*'RWS2WH'J/<G T YI\B%Z#D+I0TF9C",W*2Y6-_D*);Z&P
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M1#8Q<Z9D)\FUX31AFLQ^S(+SPZK1(>R&,4.9M>%.<2HJ:ITH/]5U$&2X"'-
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MNN>U^]@NO[*YB!3Q:1&\,L-FF,@:CN4U1$<#;8S2]7UV>CZ]=?7G5^1S.^[
MO U.#Q5SH8/.>NO]0K70.Q5#I__7'M#@N)<$;F%RA+8X"!.0RZ2?5_^72.QP
M%>2V8C7Y:=CD**Y89BU3_06OR/HF_9[?7MW8,28K<%[=CW7?1MJ%=;/;%:NF
M=0&Z( /RWJZ148 32\@:P3A1==V@34'TJ;DGA#-\1XFA\,WC@HDWNF@A &S
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MOV.^E?TAW&RER1C)75L.O3 A;092'51:/R39-LDV[LJ>&BHYOT?7W(Q# J/
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MM=H35HV:$6J,][>KR/]3%[B_G!?IW1S\ES?N\K"FI9D7")-1];HXG4L6^\]
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MNG*6P,7UMJB37%N:_CHORT<T?"71.H-E$#E4G?*EK4PLC&AZAM5#SHOR"]C
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M+,,1S=H8C[W+D_)'^H;)WZ,JUV^M7XCW=WQX9O82GX; 7"><FE1^@DD<&.5
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M3DTL=7MK<WV8Q$>NMREL69K<7?F(1<]C.C)80!S_=6<]YJEQPH<^J\(0A'C
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MIYF$.)G6#'D+EY7#4+BN+H1SFGUD_Y)[7.JR)04=\GV7,L@\Z-[Q <4Z0XA
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M+TXVS%-C'*=Q,P)$Z\OU*AI*K5,RTLUR=L6T;T?S:S(>=725 &MW3 .!&72
M%IE%K^N6_(I3O,!N!T@R#"M.[O(UA-R*%A/!/&BD?\97#:D!\*T2KDLJD"G8
M),]SI;]A>?2F5JZJI+07E^E^B?6SC67N^$A\GDEI 5 EO)#WS?J^1U)W:<TK
M"19JIKAA:#LFL7Q@"ZC:93JS'.K'QCM9GEVU+8GO!.&MSY^/T!0,MZ/9?N 2
M\6(TI52L5)0ZC<%E?)E)@@B20)BUP]5=M=$?79B[ZSR1IX_Y=8\A:!>_.,3F
M@N,@4T=GQW$*W!;A'X8NT5[SEAE=)ITI;*S*V*SHX\?#T)+/;0W9_^OEBU=B
MHN42N3.9LG59W4H;2ZY%D]^9)H:%/^4UC732I_))F9R*Q]37%*9!9C5>^$ZP
M(G>Q[0M<:( _C*)?<=RY^9;X;+.G -V9C'HU9][/WA1=)+BF^]DBBZL,UWEY
MP<#.AVF6-"O7A"7D9$0[4"[LI@#?NESO ISAM('YX[T1S*(C+KBV<!NT4=+[
MS2=VC.Y!K^&*W-T6[;82)J9[Z8IFYN%9O.>R*E335?1%:5$I]+8:08<'WZOW
M("*[9.A#L\GA<=V*,2 0CV7H(O7]VYJHUXI8!HTPM$BB%3NSW' ^V>'F% %Y
MZJ/MX1*;%#WQF,-'5#XI'1]8*)Q%$"^'@+;X@6(O B(]T&ON>9,YN%J\BF@4
M?$3Q(]*"R",V8;G@Z))=X9X7:F?=%=?!MMQ4LJ4Y'KV\<$]9SF8<W[$H?Q_:
MJMM4Z]A;&2%_F ++C9&H\V[Q).%ZT'0.5PR49[<#(Q@0<8@Z$)$B6=8K/8AZ
MF-0K::0]G)X1-Y+S1HUU<!C;!,AXWI92\J5(  D3BB<(D2JH $Y!T7M: LK%
MJ1*!3G;0S!@R0S 6L\GF8K9J H/:Z"C.Z3AP9PJ]GB5J'#=#?)1&.F@]+?LE
M_BE=OMPZTX V$02*A#4OU9/?A<CWZ>,G7RS35UA3[PK2"SI[;CZIAJ(JWN(I
MZ.T>XJH=0C72JI[SA)*)XG$49E+<P.=_*,P9?*+T31;\(IPXHP__9UG<'!^]
MWE.MZ=D^'(9UL7A9<\O",VJ(EJ3ALY?/EM/!DK\0SCMZ6HCY:+3 W;'KRSV;
MB_  KM1(-S>45"(_N6O]UUN.DS&,+*1?OBN.^:NJY69QKC=M#*R(7Y/OFS/?
MBXX3#RK8K%9]5>)Q@H+2IB5?99_T.3ETK-Z,BG;V?>27%WC-\ G2@/&J;=0>
M*(TW,3L3#-#0T=FB<QU.GG%*(6VT*9DK5%Z)HS77)<T]B4*\(H[Q4A>+RX+D
M$%>4D*-34KC4J&D0_3*N ](U)WV'Y4*4%<>2,?>'FW*V<0KN>R@.Y(>B-+X\
MHS0,I?&[,TKCTT5I*+S24(=4&NH<9+XN]F74-XSI6JL-E5SLK&<R:JNA(A-+
MOFF(WIOK6F#["5*2\=#$]R=:8HD-TMS!J#_QH79C<0O>==4Q/R)ZDN.?26#8
MEK%IDU64B?1I^ZK>4H&0_G-=M>MA3VZ*-+U!=3G\-^[!<,?B[^S^Y M3O@_H
MNN)M\-LA</TQNR&R$8RX!/,[<!E+F'9=YW?6ZNBXVBCS7H,0B$@GPZR&.("%
M1&9VW]7B>Y4.V35@-VKWFL])8;R13'@Z!-!HR56:OI,LC[[4B8.3PQ>_S]%X
M*3TX[,M6:,KT,WQYH=U>7&_#K% G,4EI]VD4!I>5TUAE3>Y\7#CZYI)R:>H$
MA1G;0CU$&\>&SL+>=?!^D/J*<R)=%4 EP"-MVMV#S$_E,.Y38'O:9/CKHML?
MHO%U'& 6&SJH-">4&6DR21Q%_%+DS[YNB[H7UDGKK?UGL>>XFPU':7UP*ER
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MG1/+)HP ;MI0M2/RQXP<CN9DO-I*#DOWI/.-WW:3O.6^F"QQU(;&(COR484
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M!YBM.1((:SK6-')%8G$(94T X82,2Y WMEN2KG"8:L8+A;=%!B4LC"4_=P.
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M7:F[>IB^Z&B$AQZ>FA*-AY=ESS.=#. ;X,-KP^4LA;"&))PCVW4D=IR)V7/
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MQK<03?B/V2%+\Z;TOG.[[/E$C2%&B[V),1!+]^#+,*:)D>W[/2D:\I/CX:S
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MIR\R" 3)\=WK/!+,+;G&4QR;IY1.A1AWBX?SB4B6FRT@8X6\LV5"7OXX1SK
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M^0S!LEG7Q2;;$<\)S(+AW?'/"  JI7PU=!S%/SK78=^!DL436#$-%2N@VIN
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M6C7JGI&%XK]P4EV_]O#L=QKZHPE3GQ&^4G('1["$8.I1^RG_0KZE=J24DY_
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M2%B ?>:)>%^:JM;SL1RUQQDGC!IS@%#FH^BF1LP0.V7#$ 8O4G3!E2'P&.;
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MK".,@U\6T]6+$F*S<>\1]B>E<A(O!I<*G$8":A?H5*R%D$H\Q:IC[Z?>)(3
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MY#!?"*/A%!4Q(]Z53UIBJ2.8I!$N"Z \'&:2_<BT;?:PT.]M"(F%=%%56!8
M3-K.DW5,2(L0;2HYI?4Q5XU"H\#&%+Y*$=%A$=__(LKE%J+O4?3I5@3,J8?+
M!:7_M5^>V=$/"_(^K[J-Y2T<FIZY%N0L7597;#D=]9^TQ))QK%!?+J7'MMY,
M/[;:/GF'%7V_*TKQ!@!-E/(A1%W9@2!^15=::;21@GSD[)VQ+:("+$P?R\-"
M?2 O4P0/5"?3.8\:@4R2P):]C+GCPV*]O\6"BJFQCQGAG+H2T2T,?UE57N
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M%XMV+P;QNRTMAU5\4036&>D@(6H UWJK<>>1QX&%$$9\Y1H2XLZ8'\[C#E/
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MH_?H*> +3 KRCJMDC. +IZL% A,NFA&D^)$'GQ>.QI!FIASA7#+(4:74;92
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M9,$+-!L^QFZBAG:*!FU@$Q+T+ KZ-A>.T;U+M0K'N4N#&5!0%83'W&4#@22
MNR7\&Z:X1%DYI+63-"_\F&DL7IB"VFM^S*BS'&'^3#S"NOB4#7V'T%%DB"2Y
M$@=&>W6)04S(@WP>C"LR6:RYSM<GLMB*IEL533]>N6!;[^9*B;:,\F^'4EJ1
MQ?#[ZP,QKPGY:R0O-J#_-A?SKYL@7>"_34 _^75[L8,,E!\E4%,I4.A8!^V:
M4PIG7RLBU5)(;<:D1K<)267#QT HG%(*IR$O;V)40ZQA;>GXCDYD%0WTT/85
M2UIB:IU(V:"[23NQP1>@,C WXR]B,HC.QZ1H< A0;VWPG8;R9WW%#>TAQXTY
M4L9EK<X+V$ P =;&.5FJN(U9.=H1'F1&1=,7FO<*:D^97[MLS+L,&-TZ ?H-
MZP( -'Q;%K0.\^^%HUR6C.OO7BC*FIMXO31FRCNV$*IMI4 3DXJU[#"?F)Q
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M=/#51_,S8@6LJ?LLX6"F-00T#*'SW>@U (2SL-5#I:$E1H"J^6=;!%>T=8R
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M2\MY92'UIG&"#U*S#6L"A);M_H *J/9^,!S  (X>I&2NI\O'I&+. >TD)8=
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M[H;$S;Z'[0SP/ TB,2Y%-[4:@MDO?')'3M-H_@H8H_6UDH0-]F3 T>BY+7#
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M$N\=K"F4^R&7M@K_'X?QZ<'!UZ_RFQMUZJR 31+TZ]VW_4.Z5JTBYEY: EL
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M3E8>P\_E));8433(H)F2B07"+6X7L)PO\?*/;D5=<XQ^KQH6-'DA--U$-?0
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M 2<<]XX*D]5K50O#=J(HJ; WW(3>:%FYH<BG.'K-KG"[T8_&&AV3(8H8E^L
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MIA.1/#0GYH*P"2S=>;L3&F)DL"F?Z5"&_F1T97<25]WS)WTO*+ZQ"VG3:'H
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M9#"5)-$7I.BD:,U6>K(O1"].&*IAH$K26"\9"@U;Z+$GTI(:[6>U4 3P-1>
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M"84J.D "0V;)-#[:[]G483-/&"L)K>+:6]*%;\O4.;*R!5[W6AM%2MT)(/&
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M8MX<B>&6#0"'3&'R7?;: 1SD3+,G,6Y*DJZ73ZHKS82GN7=0&$P0KN?M+92
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MDI6F* U3MB)6T>/J+<_JAG*Y=8*]<BH."4.[S_2Z0%)BEH2?'R]:&[9U0%>
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M_+4+[HIV[3Y)-R?IO;K" %&A7)0M>I&Y@MPQ:6?4?*6_8><NQ$DLJQS"J#G
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MHF)E.4D%$3XH)3"X* C7$_RBDL!E;8@#Q7_7+""AHD2P0^IFBO%+H=CA/PN
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M;>PMDU+W2(X#T]^-/*E1L)'=3@QD?/^D/[G2'!ABF(LBC$N^!G+QAN\- S&
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M6K;%Q/UV>^M(?C_J/W=O]\&M".U61C-(%8%/O0E>!W[%Q)K)X[:WPO/V_?-
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MU!@4D0>8J 9:\B$ZOL_)MZC07K$TU+@H)D:P3, 'GSP/K\O%^6\?'^S^$/$
M4G6W!Y 0;_ JX9:U;*?8*ZI#B,W2<-29\94X0=<.(FRQP[!99]DC30F$?417
M&79U6<GBO03B]#"L%OG$Y 9SOO;;_4<&F**P@*"HO+R]#P'9&OS1AKQF<M21
MZD6<,3XOK###>"Q&4>SM[MDJ;V]]>[#[* 6!I#])@%?9LR:_G-27%FY,RZ;M
M]&F$:HGQQ7)1:U6()#YB\V&NH^<W"B>V!OY OX9!+6X&DJ_-IV$:,9_SHN/S
M3Q^W0<RAJ-5!P2Z\^ZO@ZE.=D!Y$DH3TCG#S9UGR0)S3T=[>GB@Q2Q0S"2\<
M[G@REIU]Q>JSSO-6/E)4&-GF&"AA9[)#DNW(O0[[>\E"\X37>H .'H_< I8M
MK.98!)V\RG3O5"C^,&/XX4$"/US=--0!TCLG_1UH _O'$L7K)Y^P 'V'EJ\W
MKYIL(NB!E3!VZHI0;)*Y;8>M R=<!L#\S.G*-].#Q[C' 8L(KW>^\JVQ,H2%
MU.?O;F^]$/!>NJY:>HGK5\KZ\9-U-R2GFFHK]-<QIT'I@G0H5N2AEZ>7V]XZ
M7)Z%&=5W>]![MP<?\VYB(BNX2>3;%!-N52BK4BK]IY23M@%!33[GRG[XVB>[
M!X^^XV_AC\&/PH/)F@**$GR/,!4=N7E=B4I4)VZ:=2_91W4$X77H3RXK5 ""
MYR6@1 QBAI00WA,BR\'WDJ@F#)5;I%KR,X-7A:<?U[.KXW*2'57C77IQ_<%Q
M^--YGIV\?3E2_8=%7I*@3ICBFNJ+TX(, #=J*'[3=&RC>AN/?Q>*9)SKQ[2-
MTF?+]9S1[9QG9\L<GM95O*S<33RBE\E;=3996S,L*[S.T[II=,F7+3M0 S8*
M6B:XH(#M/'BB^R7Z"3*08++"7T^T(D(=7>&W99>]+*LB^,^))UFV\<]'V?>,
MCN*\X%PU1 >WV?:6VXRTY7'Y(:U:3$13E&8?)M3V+^_FT[PMQ9^4[1]>Y2'&
M([?O8_%+YYP#339Q55_VMF_8+%T6MR_<E;WO; O0T!:HI,(S$:4/4=F*6T$J
M\:+LL8]OP,C)R3<GQ*;5PTCG7(UZ@(_02*2>'GR?(X!QPS\4*8RYMNT4YBIX
MP<#:AJ^WJ1S)>. =,*;F[+QC02^N6>?9HB;U212B9ODE43M9!:RVU+5EU3M(
M]M;+CI*BO>6DNTN[G>S+Y@4P.64[MV7MPC#."CG%[A6H#BWJ;A-9T>F2E%2
M*@K18'M>+L*LV(F *%K\O.1.J[,P5]/XE!%C=,+NFR_G;F#0<)$S'0;\[;Z[
M;T^77<PE%[\B@,F^?1#!Q2^6#4*/$6?7_71<$L0M[&&>> MZ*,(!I*\<LU=
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MJ?&KX_$HIG&M8ZKP SR2S(..?<&S *$<%86 DJ^#2A5GCAB[T-4:/'0IVB.
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M8@]$XL-6S@@)6W3*Z,)0,#7@(Y"Q)%\M)) 5'0X$\I!1FVYIFR>M]'@H+KR
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MDO/G?9H%,MBX,DV9WMJI-FE<0=.IAS2>9^OK' -353'4?!9S"!@(XT(7A?L
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M"?B0$[#-0!_@-9^SM  %F,!LO\YA9Y=DBN>^-8F&X 0-ZFN0I14#OME^KST
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MGW*)6YY2J<-8F26+ )P_L;$5C1I8].-P'L0S[?"EBN+V&'^ROGRN'$A?<7G
MXI!F72YCV%@4*/T'B>W[:F0Y*=TBB\:,I,,9_A4Q##%2U?&OT,7,@U,0/O@W
M7"88O9J6_%?^A?<"?**0G$]X$[@X4E($:AL79[3YZI]A!@['+U$^+X)X4=*:
MC8:O7L) X(9$<FQ85W1?B!TVB_)O\)B\I)_A\>'@9.![<30#1R8C[!UL2JY
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MNT)E)PVV_VVF4WR4 /2^YOAYR@ VD;@,[&]H7HXZB+'AI4SLZ X,$8*NC"$
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ML![?$5C6&TH=U<3$ES^\T_AC^8,)$"(O'H(T%FE>>//H9!Y;Y0>P#+5T%'F
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M7%A!\<"C29JD"W:JN5@(AW(N\#DU0'LZPO-OI X+8>'YV*\67W-NHFPHVHS
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M<V+74#3QO_B_M9 +U3JV7V9;V_[^;BU)?1='=H7!#/V=S;H=?J78#[[A*MJ
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M=6?#3".O#=*Q=$9M:Q(DX59(@YKTT&$Z'A)YX)_&4Q;T<^1B/^PECG26LY[
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MA[/VP_]$]U;&SJ2NA=M7J?[BD'G!'ERD2YY/P)B7#TU$8OD9CL)TJ\H.LDR
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MF*9C/Y-@88+Q-KC UYP!JB\HRN&T(_+O,Q6D&D6)M1/40<1#5JAGDAL@VMS
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M<=A!5=)N':#8=T42SA0M6MMDY 2SF_&\8@@48*TEV^.IK9,$GB+)D=\?GH*
M_5HD:=#>A3@-[6 V!?F*4FH&P@8J2](U)YG!2>;66 LYBDF*8<_ A,.:#R;H
M,00R66!HH,@D1+9[7!&]DP9X@_&;;>D.F+E@FBX-04CG@+P?7"2KY9BV:\UT
M"H!YJX12$%I"WJ(:PLU-_MS P59LI<]/T5O@MW0937.2;/Z!GB??F?P0Y&Y
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M+WG'6#9!M1D!?!!P7[CPFE5M7?]&QG?WWN37<EENIG\6YZC^)&KUS$D@L3,
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MY)"Y"V 5<#+4/SI;NCRY=O(;23]E("B8O#JDGT4"/]0K(8^;)*>XN3& PV/
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M2L^UK46HW,YG*B5+?&N7@C[LKA?R0NUW&FJ_M;I*Y4AX?^FY[*SSLEE7FQE
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MK;?:U9GM+"Z^B3/#P'AO2X=6Z?9J-:5QF5/[4R4NF7*F"V2RCY2_A)NE<EL
M^]V^P_6QQ @.A[F>8XP]'/,#?S_<D!1*#_S_ZW"##\'>\ \#2X__(O+)>^88
MMCZ/ZG;]8VSZ2'CX@>:7/&@>NYY,V#A3F[W::JP61ON(>6U+[^[O".9B%N4&
MK]V6"BT+^=N-=>= E22DG[?)^#*SF%4TCXI(1NS9L"STQNP)_>*-:<Z>K,3M
MVX>M?3'WLAHYM=W9(!+74=CYS6;Y#K*M7F0H=ZS.,7J.C489S[%]L:5SK#J<
MJM64H9NY7<Q68 B9G]U*:!>23/ M1;?]D9G8C_6W3#(I[1F95$OY)-*%VLB
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M5F^AV:TJMJ,,[H=NA"8>+(+I##N",+RL"#J<GN#A\@X)W1<'I]CP)@6XAQ&
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M]/LZT=OHNY<5@?::BYRLGIXL7]@ZU:I9%Y94>$X1]N5+6Z=8,^O2ZHU%?S6
MD$*\>%?A0\YD90V_22TY7H P=N7@T+HJQQL;WYGYMD$HQ257?@648@%0MX)W
M>!?7$,&U"&44,50%N-8<3A:-1J?U\WG-<O$TV=@>DW%C6,K0=31FID%F[0 \
MZ)=1<'#)D#=YZF#O^.0"ZYFCO-]-OC+7M9TUJF"S/[&J@8T?+-7 =C+6P'Z]
M'CQ>9T)J*68P;&+VZ3KV0 '&E-6MA7@Z)R\>)H:IE@W#]"D!1' ")!#C:A#
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MQGZ+(SB[%X>Q%:?7ZN\0&BGKV73?_]G<V+ZSZFAVB72YI4"U2 UAWUJ51=H
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M7?_S_OH6D<101-P]_7[]H%Q^>WB "Z9\'0Y^'7X=/@T%/+$P,]*"2Z699["
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MJ4E=!S-V#Z[S+,NP-PMY&KR<#_L:Q=P)43,/2[IPX$0?MQ4(-[+[K;DO9F9
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M3*ZAZ[>ZT+>7)N^5"IWD*Q7$\E9M?-6<#1ML4X8]NYK,N,<W_YZ-TY.9I>,
M?7-!Z.(\CL"39EL6;]1XJ5[FG-%-SAF=XU@6]!1M6="?$@8\IE&%?3^56^G2
M2\YEW?+TCV_%N&^ NXKV6MD=)H_\>6"'/RZ),=7EE7TG1[76Z<D6M<79&JL-
M_^2%=I\?#D;<Y9G(O=@/V]2+LFIJW'#8XSN# 3?102 E_8VM7C X(*3$325C
MH1##@(C%D(T6YU\2>WJR?F._.^1[0MC[/!M+6MP-/!4D'\_#<UCM/NAQX]T
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M+F2A*ZSCXHR.0 W %M#46X:?VB"RN':ROC -NV<8#D2A%X[+..P7#G! I6<
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M++]^!+1HECXE!OMQ0:09RQ+BA^&TY\X_'[79VSG^<F$NE?/_'U!+ P04
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M=Y2Y5XNWZ9WEXB5F>M?Y;U!+ P04    " "W?G]6SL=J*AL#   Y"P  '0
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M9-;32Z=NGKZ;M[!Y,O\&4$L#!!0    ( +=^?U:*IMO%'0,  #<+   =
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MV,$[V#.%#?OP+5["]L'\%5!+ P04    " "W?G]69:I32IH#  "I#P  '0
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M*#Z'6NH(SG&K@*$I]M\X-*4QP#OFD,<OW[_^-\+$Q[^>__;V^/\!4$L#!!0
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MYO\<3@N X 6< $LPZ!C A0"!$2!..W 4 $#<H#\#_",@+C"$FP?*RP?C_SE
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M +=^?U:TUWP#L P  '(-   -    :6UA9V5?,# Q+FIP9YV6=U#3VYO&OR%
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MV-KVIKN'U-O7/_!V9/03>6Q\8G)J89&RM/QEY>OJVM;VSYW=O?V#PZ/?7"
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M8?K%[+JZ2-9C_;WLGA>5<\#4D8ZQD[DIJ!]X:;IX?;D>[XAYZBX"MS=EK%-
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M(9*S*9YA&=I/(F%3L*]3GO^CVG]H]G]/,?__1YK]EV+_K=<"@ (#]68\&#1
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MHV3H+Z  )+EAVMRB(YZ^<?#XU!RM<L;6ZPP\U1H\OW-:9Y[J5=[6<N)_ZB%
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M&6;.Z#;8^^R]S^]\Y__5=<YXS>6XXIG[N>_[>=[W76N-L"^P.0#KD82T!("
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MT,>M',51?53!5?N)KL_V-L[MQ^Y/M@@(%I%FX:%]G1U*Q_>U;H,"'@=U\S
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M-K3HXS$:7BPHL<-P+:>MJY5W$:1>AYP8:IDEZH;7?'>N&#^4-;9<M:$O7PN
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M6?DF+!GY,<(7#9X,4-6WWT!'OB$6/IGYIBAX;T(HX@*U+!W2WE>P9Z8MZNZ
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M%-^ 3T0X"TKK/!]Y.&T:;GV+Q@1BU8[UM]5-#Q\H :+,\ (0XJ4RW]Y%1G;
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MEA"5?D7!G]B'!,#2:B$KR.EWNGC37,VM0?6#6FF5U'78$IB'SD_ @,UC>)Y
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M%6_L4'XJ<LIUY13)FE+"+H=G\_B[)7[JNPD;:^[#$V/S2R.BUBY[E3R#N?+
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M^Y,< ?;2AR#277K?Q]:Z5-AY:LQ#H$-!J^6PP/,%VXY3K1VMX#A6IDP>"56
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M)7\^3W"6(YCMJ9KT7><W+PHQS-!JMFTEB9G7>@R?&@N;39=/#M#=G7[LT6M
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M%>@ZHO_<O:4/NDQ]?#Z_2.^CYIA<])R\OHP#DNM1],4GV$S@+.\LE?QE$I/
M/MMFY.(8@SU+$C=V),?FAG+K@L]2*(88/"X-]Y76/P,#'_7JKBW0SQ$PX-=;
M\*JFL.%D<?.ITWGTH=DE?OI58"DG]LMH/8WB!"?VX?# @8Y\ U'RCW7/GX8S
MX*@?D[@W5YBX<1(P/2Q'>EJY0T5)==233Q#5A6(Y^M_H?$_&/4BX[:0.B*P
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MSQ_6<HAC%+[YRDTO8:?9P[B9VA2#Y&Y8/=R> \?-@./Z_(:K#_6&BTPO+!B
MI[C/FCIFVMS->GH[^@G*/$6L(-M9^[3T\3-.0LFYN^4E7JH[<S+&YN V"N\I
MVK1(7HJO3_9?^P:0.GCK1&DO'17!32SX'4K*BUCX[J$Z%$(.I8^K;+OV;%>Q
MAX+=>8-8GBQL7X"LD>SPW&(-A[+"?WBS#?%]GA,Z-_ P\,0N#9P=>C7?J6O$
M*S)$\CEJW&Z8JPFN4B?A$HB^Y?(7##A623TJ(H=Z]__>C_1D.[?+32@GVZB:
M^NUHF/4JW4IMI%JUWW.F;#_:_>G'I'-V1I'NK^2,9W:GG?G>Q[(Q2M )S,<J
M:5\&X#7</-X%M=/ O5%^[PT8T*D,7M9HN7L8]YO9.;,&TV?]CO;%TZ?[$QM8
M7VUF3RY6M#]J^JY0R*$'R)!^F[5/6GOGDF=\')MQ+),BEU$Y^FW3*=@O;HW-
M>_[\L6L70SH,\'T'SS1\T.T1^"H?=*5ZGQF.,."' [PS)2=6&##9IV(?U+(8
MK"U,-$B\@-8O91IH_M/-0.IA\&NV%*\#%,'MH-4% V:D.>M0O/%W:HA6>#R_
MO-DJC5!.BX:O5.\?D'_Y)QRXK1!\@TX#14R%TJ?W8]SIC(H1&[?TK)V38R_L
M:+G/R&'4^E*?1EDF]ZU%=E-%NMAL\F[1'T)HW.-FD08MWLUYE.>/LCWND58;
MVMO<$)2S!;<5_($7#J&#[^?\MN_/AZ$-:57NS &?L#NF/A-%F84!58QKB4/>
MA+C:KX8C6=N1-BEY=X3I,[E#N30+QV8B,;XBBF -]D73]2P$^PK:ZY)#Z.&B
M-JT/_(L7!JSD"2\KPP>.:/3O1%1.%9H&>>V=:ZY)YKUX)PTK8R>HD.DHI,K\
ME-*-3EJ16-<^<22%619Q!SFA.A4PJ?=62Q?A]+]1X==TZWD?*2]*62*S"X>4
MAD-F_<LW6>$P8,!"^(CP/H<<%##?J@V?\7Y,);&\U.#P3 [X_&NH/9(H.M)M
MYQ4M65N\TRK#;5Q$\Z 9P3=F[D>K[U"37_>X";H.3]677*E\ (]8_PZ4>I0+
M[R-M%OR+[?Y' 6ZY,;U?/T+]V;)<=U5&F?:7J_U&8Q<YGA%14JVZ>:6%;FZK
M.Z:2S'78)JJ71YK6^A$"59ZI5);]W@X1R0NBD/N9!"GUC!@$01:&J-) Z*Z%
MMWA2K]#AN1//QUA;^-9Z?<M^-C7("4.MK6_(,4#2M,>(H2'9!RTBN8G_$_U
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M79__C?^_\?]_CO_/5__C?X?+KIG(2%FFQ)^3)<,B47)2K7[67GGX(11>F[Q
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M<=5^PD]G69&M.-D/A4\?3*-0%VM\["U\/TYPNA:2CT?-/P,;N _O2-!/@-$
M#092YMP*P"4-@3I5KW:.>B^H!5(;EJBZM*.0 7 MW<\W?ZI15%U0R*8TO$RG
ML2B03%8\B[Q;%_G9PC 6"H-9\5;;9W2^-@JC98$U2!-E9;<8GS>,]'(A>:/T
MJ;J+UEFN&L<HS9.>F/H;T<,9^'3DS*/\@PL%AF\V#LXH[RBT]Q'M6!Z<4>A#
M\.<9N?]RI4@"KPR:.V%M.D1'0-Q9G.GLAI?C?_(84)>,RWD5*,LA,. 8HT73
M8BJ?_PJ3/>5 ;8>RJ)@U^[@P%?.>E$4O$#3G_ZU_FGCC*0"+]3D%^-,CMB24
MS?8C9PNR:%8-M\SOL/!6)-.RLBABE,AXO8J$ZFE/ <O+399[ZRY;*&%!7P3*
M>,)$"S[;'#%W*7R4Z\EK0V8>FYV&;.H-JJU9.0;$8##P4,CQ=H'#L&.^ Q)Y
M>7%XC#A8=%4)Q7+"WPU@)%EST\J?5"%O+J%\!=R-B./W+D*95V0^]7SX3$.9
MLOU9++&_>C? 2B7G@<Z%3JINYTQ3L"@\*HU9D).4J%A2700VG%XM7UC6!%VZ
M\C8XH\O9^ !?.ZO*J;6SZ$>=)=%[,R31&8>&YIB+'% YLJ@0B[,7BC?=<X:O
MJ&BZL[M.-O#G%ON+%3M-&M[5M*.J.A!-(8BU5J3.4APN-E20\9HR4!6X6.5&
MF^0^QL0,?BU;/?>TX-/84$4!AJ1Y&SYPCBNW3))TVX@ ?HN):'$C:DM'2^>.
MOYH3<H"]<MW49,:C:2'.34SGA<+-N >F:W=G.WJQ=2O#&ERMH@L%_+[Y&;UO
MZ8]!>]GDQ1 )V<@B.2'3)08-$";!Y G<F=W-^"P/I(H8:!KRD-TDDR5UWJG?
MYJ*4]A%;LWZ'^.JX=D^Z_MPIH)G+;<,Y\Y;3$\.)Q-AKE_K&JPYN.)T"RC]I
M#4IHW=RX]88I#D/ZR58Q*D2JE=L0HS=IMM@-D!SY:6@ %(4>V(@B?.5L[#]U
M]_RGO="^^?23C8[Z8^ZQ[KHD(:?[,4S&2)%' P<DFH]=Y;S+TH'*%GX,!.V=
MSU>'K9<JG@ABN[@O<3V:QUST ",HVIDY6AR+*!B5HF:HJ-)337_]C)*P8BG+
M#J5*MSU\Y</#J2KN%>^(WE- L(XB/LDR!Z8AHIWZ%9FG-\-7@%\I@[ N6\4^
MK::D6??R% \],DLGY!JSMQL$WP>U*E"LHWY^5R>'(NIY8PF8,(>D&<!<F"QY
M'QT<9LWBW*>,/^VF0MX&]A"'RL^J\:UZIY:K !AT_WV#T5'[%! 7K*!W'&U0
M8.IY''SQ,&O!GG XQPXJ\1D,/7^;C)M1[TA^ ^<EM23@K6[K*8B^S:G0R*@.
M?/+B)!-Q<)*".]#!7?(7P7MK'1]108_NQJX=U1_,3#\IZBWO/@4H?'L!<>5;
M#\%=>/WRKN71HL)^*J )UUMS"LBD/HA0^$4-+=\K=8S[UG;SY[:2HTOX<FH4
ML9'TK4T@$<UW$R[_JC=Q!)[&'@F?;&<=:P'MTG (VU- G=XI(#R;2N&[ =F?
MT)IYIA-QJF= G,/+?P#\G3(^*'-[B>^"G)IU8\("]&G>Z_VVE/]]FW)QW=6"
MS./L[ZTXQ$B<3S)=?F$P]@]D]9$"=_VFCS==NG1/LCQ/ 6!6+&/5[PC\@UV*
MS(C1/02VH5Y4[;N2X7^]6NM3@-TDOM(D/6X!?M<RR_J]K3EK6$3O6OU>!V+K
M&L'C7^[.@/A%R]GO'Z/_,?H?H_\Q^O^AT<9E954QNWQ>)OH<VFIY#_Q^.\'2
MXVX6LQ3GNLJ\-&@X#@&X NGD>1"-5U53\H(3#=PGUN<%"#.#8]9\*#8GE<V'
M*AS&'$]NKLY^7%Y.FO$CN[Y_V]$[*K6N!H'J:'[7M<$G%P"F>6]E0/'U(@D#
MO()?6G3**0L[K'.TUK^$7X*<#9ZM;LF(OB[/-.'CG43<T34XGH9>$X6-<JWG
M_NR_S>%PJO]9;= ^F^S7*6J_*(U=)ICZ/N$/N(#_:]@'+2$YJQ>2BY)\Y9HQ
M=%E*760[V6=\1Q'+A5E[HSG=*3AOS"G +W6%)FAC0Z);NTW-LN*ZK1OD^,!&
M'5UYTU],45 =1)CG0N!X=VS@)S,'NZI48^0HGQ[7@1U56SJ$F"WSXS+JY5*X
M>9ETB:3EP6>^DUU[+'X'9I8AIN]7Y&\65[D4JN7=R+_IO&"K3XZ](B@F#]W^
MNE> F=&R72OF(^W#,#::"9*[16%EJ69%7+5%H"/;UV"<BRGWTGZ%B?T.[)B-
M(/(*E-:],$9=',N99*%ZCR)8@.ZH,D:=+;/V=K[_L08/.OY2!K(<4OYH1[3&
M>3M[>>FB.@^%=,Z$M.W'Y=H_+7JD_UBHT'&X")9OQA,O6*>]_)1>..H+:QBF
MS=K(J$$FN;LH9U2I6V"<9X]K3GU./3C&$$PWL>SP.2A5.H'D?(_+KT#@[]!%
MT_M*OFJ[ @7E+V1:G'K*G-VIDR!% >FOR:(B/@[7$O;=D2B.WXT,#QY0)>Z^
M\,PX1T]@O;V5O310@5[MFG*"&N.?'3BB0N-?JP5UAT+.IU5K^-7TIJ;=L)T@
MK'1M+@$;L LTF=957)#/<E@6,*?4?0P(IT V8&:LZ#/3=;N"DG?%CO_LZ*^G
M ))5*<->H68(><(UR6D9ZXS%[9%'V@8WJ'LK'!2:TH8&W$DCU(LWOI34]3('
MSH+1*DKK<&E!A9H/5@NZO>>VU>?^S.10OZ]H@5?H%=Y!R(!^C$KTTR5CG >+
M 9Y*T!<]E9EIVNZ\XAR.-&ZS<A)SL0VGRO=*RR"A5H=)RN0GF7_>WP\A,\+G
M!,.R;/Q33)C%)E7USVS5(B<# A6E-PS>U%.L7L@=Z2^X[E3I>FV#MSG@G#_H
MP'CS.NC@,5L,G*$JSJVS-/(O>%2J(]P2Y\U!W(_?19/3BJ%D(U((0A^9H_A2
M+V[RA3ES.LQ6!*JG('K04-J&L\RQ:7'B&#;=;H[9SJMM<G^&&T[/9!VZ.[0T
MD#KY:)3JTFS?S5RXM122.AV8DLF_4Q( 5H$OAA7&L1A0D%\])^5BT9'#AQS'
ML"M^5A,[:PC[BYA^F/HXV"[HYJ"ST+G%5#.OQ1I2E<9K94GA1B.@O1T4SZ91
MV-W2VG=^X$@?<<[DVA8<T6-^<2S JSWG*9F R)\=,E6ZF;>4GS,V,:JZ 7/%
MBJC9J#>+DDP<A<^$.L%:G%;J:?*274)+JUF>5P7V7+[[-HJ>YXELS0()I[\,
M-B;T,4_HLTM0CK^P$HTC'[I>6SOH=#]%0R,T9G)RI"M>:LUP_,/"'F&<%XV)
ML?!BQIK5$8/UI.FZ>%4DY(R(EU.@B$^4>TXJUU\'=7[MYE64L//SP>P$^Z*>
M5O%::$T[ZH**RB06LOS"[[/\7F-U3U;NU0+8@Y?W.UE)Z;E%3$AO)9-Q J%X
M*DU8_L)(R8CG:O^/GM!_!SN(A,<'"6X7G V6)LUY[B_K0G&L/>(K"[M@8:Z!
M<C@@F,E B\7JWVN7;XLX!&I^*'*/%IN^599T ^(:T/\XO[[^P0'%N[:9^SF"
M8Y?R\V7ID(.%\4$?0=+ U,3]$0E[ 1CWJQ"U1X9PX8B'\(<T]*L7G%#Z*N+,
M&*"WF%ON(](R@4\E;%X4;:V&82VX;E2C*'6[^=;),/O(@5'$J@+EL46^YBT'
MU2_BS<AB-N#[F=AF@\97"2,PF:0\IA=M0)6'EIO^^S6XD,\;1PN(:.#O!8=N
MCB7?LC78&Z-O?:)I(NM7[M3AB5';[_]/XK^"4/9'6&S]ZVS_0/T&970MXZ8%
MT.C-AVSU*4<38E29G0/W"ZCI]-_@FY1M3;9F"5341><%2VEXQ5>W-TK[<WMU
M+O-PG,CJ.1U[HD:%LLW,U!R][OM735WX*1XMPFM,ZPE+;MA#*<P2;'F>4(Y,
M[[7_W'KR]U*6:XEO()#!LNEEQ91FW)M0RU(,^ 7GQ]DZW)>F0%;I(HG]QZ\B
MZRM8-8A$ZH[<T$FJP/N-('!@K0T6L_2M.3S1W,8A4TG]1ORW)L:_$WP"-G(<
MU;;>I;7WK>X.5XZYF;4Y(SUVHP6=(X6?>+^]6#Z10 ,U&<N*%:Y@]5/J+YH_
MDAMJ'E353!!HY9$[VTKQ$> W\P!]S"E_]13PS/L(=P"<5_N#I/+,)P9;$6G(
M(:S%U"3CCLR ,*1L=LLU]8)M#NA 9XJ (#YG[Z @P^=;JRTYUFM"SL)=FR01
MQN.8F,OTYUXWN8V'@\"&EC^Z03;3TVLX\)"PD)!5;2AE*#KI)J]=O"<.V]7$
M_UH9 YX'O9C<7]:K#9R[<K$2:!_J99&L#DJ]SAW?J^=??S,61PMD0O2]\\/G
MXK%;.7^4)ICJETQK]@->3HU-F>E ((L3[38<9AK ) ]^*P@T/H1-4D5O\Q00
M)2%,;3PQ9BPHZWPIQM"3S"UI[0R8$"3?FO'CG;9NVK QM3#HM6>8N6N6'S'B
MF^)J0?+1(S\Q(SX@JZH'.B+WJ7XS;5HP;'-TM*6T.%<QH,[H+;/'8G7 X&?=
M'_LT;@5WI;9?""+T)1OM7EDC%6%#G'BI.P@D!Y#FV'FXOZ=OG5>N['Q_,%6<
M+2VW:6V%1<KI,([@QUM0[OU>W]'TA:G)CYVV[-'11;7(W@=T)-:E''@ND>!2
M )V/@88PPP/)2D]DN=2X=17Z_)%SQG3'K8;0'J\&HICTL_QM/W"CS@2-;[GG
M_(DV]A;3!L09+:]9>I[F"EF75DA@RD5M&0@ IL^]9;!F:NKPB?IM^+7=P8:&
M7N2 R[T1UO"9K)MI/W!CWCI9G2C8XE'F57GN;4@TAD23Y$;D_>XTT?0O;4Y#
MXX@PF4)Y1PS$%NHZV EE;T:-SSC06X\&!80 SH):#$X!P60MTU^%+1'3W#_W
MT/V=M$<T+33F>_T#Q&9REUK>5M>)^\:]N]PB5!>97=S@ZV[\R&?SE"<Z/VF)
M+5V.> 'EKXUP-:\B478")V+,!^M_S'1[8HMGZ<KGO$))G-)H1:;K>.6U0%4Y
M[P2 _% 5?'Z )/K+*Y[JL#H_I06P"M<-\#,ZKNA1JX+$+-/V'QI, 'MN/=]]
M2R4O]M)T]V#4_2M2-[#$W[RO8%&UAS)J&>"L4_\:+0ERX8UPX#)P)6IM">A9
M2T^ )=C_#0^"F"TB Z0TY;@):R)O4Y/[(OHI60;N-1]HESA017<(;.3S"A]#
MG22U#NZ"8@I(&D*>CQ%B7N:PG9>('Q+AN[9L7QSY ^^^6HIU@^-KDQ_/RDF5
M:T):Q'A$K/R(]^]ESC]0?PEEL(^86[+*:1K)D7^FB'L(4WN+KQ-ZC-[YTO?G
ME6YV#^>))1_YOF\]LQIVAFR+MR!]LZ0A\M/ZO:HM;MYW9>EIQEDPS%H72/<K
MYM (K4QEV*=&+%H(57VFRV!UF1U0[#U$;X[ZE',COZNM7X6QPSWD?_81QK]M
M $]'_P-02P,$%     @ MWY_5I.:BVRX.0  ZSL   T   !I;6%G95\P,#4N
M:G!GQ;<%4)W-UB[XHCL$=Y? #AZ"NR>X.V$C"2XAN'L([AL-$-S=W8(3(+B[
MN[MM+M\Y__GGUM1,U;VW:FJZJZNZ5O=:W4_WTN?9YU4 2U921A* @X,#/K]T
MX'D!^ "\0D8&(2.] H% *"BO7J/AH:.AHJ(1X^!BXI&34%*0DY"148%9Z*BH
MF6G(R.AY&)A9V3@Y.2GI^(1XV059.#C9_Q$"]PH%!0T5C0@=G8C]#=D;]O_M
M]MP!8+\"O. )$."H 7AL. 1LN.=N@!( X)#@_M6 _VIP\ B(2,B@5RBO45\V
MU&(!\' ("/"("$A(B(@OJUXOZP B-A+.&S8Q9%R5+R!J.SQVOYC,5S3BE;_Q
M5<=.P1R&]M]17A,0$A&3O*6EHV=@Y.3BYN'EX__P44)22EI&5DU=0U-+^Y..
MD;&)J9FYA:6#HY.SBZN;N_^/@,"@X)!0:&Q<?$)BTL_DK.R<W+S\@L*BJNJ:
MVKKZAL:FSJ[NGMZ^_H$_XQ.34],SLW/S:^L;FUO;.[M[^V?G%Y=7US>W=_?_
MX((#$.#^T_X?<6&_X()'1$1 !/V#"P[>Y9\-V(A(;]B0<<140%_L<*G9_5[A
MB<=D5OY&H>%0/<4WM!][30#F7'M[]@^T?R'[7P/V_?\(V7\#^[]PS0-H"' O
MGX> #8@ -S]I&9CM A8->'>(>ECV?!I$3LIAM1(\C]X0GX[V>,4A;#DV.-$!
M\.IKX-M_5DES8*N/S\#]5-=^FXC%I[731^Q%1+",&Q_UVSZ]#/N5C)LR*94S
M],--<JGN1*:TROGTMZ+W&#X<JLN)7!'$ WH4PTU*QY@/!\] J>2>R$[2,]#6
M?C^U5C=ZP!^;?ZVQ7/P*Q^V]P[N% "T:&J;)[P)^D1).8[JNB5W\&JV]N>MR
M.,[DI_NNB'7N3)%VD9N4N=CQ5WAK@Y.7"N//@*W/BL&3)8_<T^]GP,OGJCCN
M-+%;@:;G\T(/74P!U=U1CF"J$Z-/L'?;U*P&<<RWQ =_V/TS<*#29/!?-U(=
M$\7^_X4,<XMZV(\X?P9&V/YU]2+9S**60L-MG'512>[PV.%7JLY:S#5_PQJS
MB?K)*-5")7]U#Y-(-)LCIOK-B*PIQ-=#&/HTE;89]IX!2@>?IO;IZ*[A=)C7
M,W"V)I4B\OCP#&QTYF<E8;E5OQS1#A.DOS![!M)]'EW5+Y41*;X^ Q<GST#4
M:\&Y9V!GY1F@P!?"@P/]AS&*V^?NYAGH"U"2 ,2V1YX!X6?@]C3[/P>HC8G^
M?R-W7!E1^.O*?R2T_UL MQ7/</0!DECT1]QHK2VZ.OK:[BW#337.R-V!BC*!
M';[<3_X<2)H"$ M!ISRI?U[#B_".Q*E].1W61+G)@!;KX3/"_42_O'(QW"[K
M;9Z'P%/_>&$S'G'T# @N7.:/B:+]>^G?Y'0)@.-_9O#" X;_O3/[7V2&2^7_
M4P$Y_R9 0X&P_VQ8M!G/$=1TBM\8<7% Q6<B)I4F6ATSU(5:$*Y'RQ Y_<4L
MQ<<O?W0OGWP&."20T--A(M;MJP9_6MK7Z<*@.ZI>\,M25E9.Z.X5FS6E,X,;
M%63I?UJYC[JUL*7=&1M%?,N)*\^T CD5:!X4MW?UK>Q;ZM\:BK.!T\^'-R^O
M"Q-Z)'*.!VJ>,/6FPF5C4 5,SO]D ?K2NCLT9+:@#Z%UU\+8ITW]3GJ*\W*5
M9 5C4'""!EU$AS$-FA$-N8*##BQS7<^GZZA86W<P;]>BEF(.KRNP[ROF+W=[
M*Z:."@LM]UT%\:ZCLP%B6L Y3QVWM?KWWEUR<$Y"D,*^(@^$I&FG6T_V&M5N
M;2^K,M0$A0.0WY4B:_PK*=*L,T_7]42H4L7?5KE.-RD%U3?/ %?##>(V,V/2
M\/88W[8M=,VXQZ3-:X9TVP745ZG4VO*!!.%YB?&C:.N%6N,T$X:L2[,UYPOL
MCXFVJF9'>"GCY9)#JR=K@U1#*R=<4Q1/CU*G5^9</L@F_(Z3N#:DD$'F<0L(
MLDO]/)/KBMECU#W_AL/.Q_*C"P+1TN[&T]K]=IL;U,)@!^&;Y.JQO;20VY-;
MV<6:8[V[69@F0:32>Y5:'^;^UT%,%RR8MJR24J7T"G6,D]#O,T;+''*ZR['E
M2WJZ2WT^AM,6WW[SX#;@3EY$)O4)7XV"0ZA!DFCY3:G38U!H$]];0D)3&0D>
MVUP0U\<P"3QEN/\,:0L+=$ UX<'(R#S/J_TIOJ",F07\M5"I.SGH@?U@2H1#
M)Q<W0;70"_O+"6)(C2\?*,HH6<650"L6@1GHFQ#9T !/'!N1AM&R@]06U_WR
M%W^^1I8O0#SW>''HA?.(%U.'^K QRB6\&'W?%;8[I3T-C)].^^D_"PY+<QKC
MCM>Y>.DFQVN^DEVQQ$J>?N[ [N>L"<[$HR>"3ZCB'ZU1D4!X39_E^W\?.#]I
M#L67X^Y#'2W>F.@:WX_^N!XMF5G3CL@.M;GVA>T6C5O4*]"PLJT^)-M<F\P4
M>9O6R8*8XA5[ EI0F1H0WD<*QQ6Z%^CZ8FP/JT-08VDRC/]L"*9=TJ;;;_D:
MWRE.#&2-$@KI]TRW+[+Y,D(\>F+JV+J<;TH:2\JHPONW7E'\V"ZUJ(OPX^QZ
MFKJ\R9G\RBN;'?^S5 )/4TI;10(/^'\;27DEEHV=?FD->/?T\*W_;78$[6?[
M[2>4V^89K\I&93CIW?D;1.(]%]9NWXZU?*)*GJ:5L\H+=7!L#+!+3:!H(#-*
MOM?TN7VL>P;\?!C/?4+U<1HBS68N9^7KSLO>&R(<5^RQ@.I!N^AR"Q]T%/2'
M"LMN84P/,N]4W]?02!:,;6!G[X#+/T3Z)Z\>7TDUFDJ<K^+@H&GNU8H)7A],
MG!>\.[3A0F;"<F,7YTG@U4UE&!$5&G9J,NAZ^&G$0WAR#?%L4JKP':T*9R*T
MB?ONQ92R'+/D[C@5*4R_TQQ/%2([\!X["ZW2T-UH;T^/-F;52_'%29\_)AA;
M4&/P\)GP,OC=R#P#EO7&9^_]!5G!H?WOGD9GSS^8=8+$;AZG-QUFR.T^J;G>
M0,Z0RXWR]TYU+$X5^QBVL6(#R=]^:P^^*E8?R@VV696<7[CEZ>2QNCZHM'-#
MRU,/P%/@7FHPG\6,0]N\#QT_#:P'A;:H6=&FY-;6!D98,T=OBP[!S/[@1:WM
M*C(2G%+Z>[XUG)F/LRE8D8&5P=$A]0^H7Q\,'$W7P\A=/>=N9;>WU ZU2&HB
M6+&N_#!?P9WXC6Q )+0W[6TTA]_A=B>7Y1;L<\^DD3=4R]FW:7\EL'7XZT[Q
MJUAVWREPWFTX8+AM=O8G+HC,'6&@I!2U4R<A_MV%KFOH^<X1#K*6B =@E'IS
MKSES[71HJ[!ER3'()*DIPHM>I"39<9FWFA ";56TJU5G;QHHT>WD#B^/]G&6
M1@ MQD*XO6G'Q]X=>4\P#=90+>&:5/JE3Z?DSUIRWWA_*RX4$S1V(!@%J-"P
ME+Q12GUJM4&@(X+,H >KY$A%K6RRG.6MWW+*;Y>:O0:#4X185R>[$,T*2E$(
M0NF' 3P5B?\>8DZP?!AB^Y!R^MD=ST/QDWG3,Z#V#, ;;-,KW3ZF/$W!:GR3
M)C3P00B4+V&G@SXK?!0N5+;8R0,]N7>B4?08ZS/NP+W:T;%14[W,FN%8PY^Z
M5_V/YJCL[CH%B=/'?D-^<&#T9X#%UM95J*BDZ3H%?0(BM"G''G[(PA&.>[N*
M-MY$$I[6/_F7'@W=+CFM$3GKVL5=*7AZ"0LZQDPKD4+#*VA6N:=;(X+C-,M%
MO-8\L0Y=<#O/#<?OO%[/4Y.>YC1YZ^B^15S.- &C,^C;X2ZT@#/S[,)#_UZ\
M K[B:@1U>Z!\)#W*"1OZ*JW72TVY+#S)T/.C0(&\U\(J:?11/;GU:O(]&6L/
M;D# XVFO[LW"?!,X@0\!S_:W=F&?(7]HS@1'W%M"4SD)ME\J+AQ("(V\>(=1
M.L9A$K0.XPDO?FD8#TZ?\O8A'8;P6&@-NWP&KD:?@3<RF(]>+WD('$S]Q6+=
M?>YW?:(S4#Y]0,-Z=9,+GQ *T&=%1R,[^(FB2O#87].(Z$]..^HB?T;A)>8=
MN,Q 8>"0E@:@KF23M-O81#ZL7ZFP;)5 N8!2C*156E/K=$D9"ZV'QZ=28$@Z
M4E/R^A)\IFP.8R7)^^7@Z!@A"?*3,==A3MPA4EL<;]2-G.%/ENV=<.KRRNMQ
ML3-R,#4V1&3/TX9;W,@U1VT(]M^F^?O@6SBP(;+#J:O ^2FWY,!+OW/[Z"BS
M,6)+_$-6V@_GXK4@7JK[">3D12>\GWC&RF_,<_JOLJE]7_0HX_7U?[Q8U@Q,
M2.MIXW$8#YAKWSA?@"$]%G71FU#YBA%13;G]AS(%V/%0@ @(8_5=W3+]S+;7
M.YUHEXU2=R*E1 +<9H)+8%1*A?[%"T7:'R/#KK71*O"%0C$:#Y5D;UK49#I&
M-F1R^AQVE.#1W\M/YLL=D;]WJ3@?.ZH$?W1<:";ST/*B"WK/-:QP8NTI0N[G
M<V?CJ04X4W-=WQ2W<9S5_W#<M/(HH)IZ[_;4_1DG_RGO2%^HT+5=O2U!J4*&
M-M%\L/[PNJINT:Q19#P('&&XN=(4)7.&-H_L.WW=%%E\O21^LMG<PFL:B+^9
M1;_&X[7HY:"\XFE94Q<LEKW[=RQC@53Q00LA#]C4BLIMR?W9SVR0&@NU-*DU
M1/A&3$=Q5[(X3"/6^K?M&5AO#RU/#2[+JC$X_DVIU'VAK27,>(9_@"M<Z]YQ
M)?Q-)%X9HE9C?#3P>^2+T@/C#RJ>,[@^NZBSPFUN=</@Y>-CW9I$%Q:1^>CT
M@P,5!-JANTC(C-T5_M?Y-0P>VUDB_2Z1)R/9Z;4/X=QP&T(5[CZ,:89WV%K#
M/Y%5+;1 U<F5!)5%"\*[3@+]%XOR+V&H>IU'4Y47=N(9_@SH*%7ZEA#7K=J^
M$G)]*2PF&CPX+>9O;WJ<7;&M7)A!8K1DWK7C>RLD7 N&!+"_TV=2FI3--A.A
M:\(#T=*?O77/W899Y]G 4"T VNV4/_0AD\ C,.8L2K3-)/*);B)':(LT]@)_
M2=LR@3]'V#I@DX?A #?PQ5BT_J!;/H&HPE<=\1Y(2S_(-.%JZPY;L^XX,HL]
M2LG6<J!\F9^]W^"L78.1W@Z[657-=!-L;\'];O(/4DD[6#DMAXQ=/7$8U!&2
MF!QJL=W,>IO<1V:5<CHTU#862\"'&E+]S[[LX5^^3/<9*'B)HN\O\*64V[P$
M%6P3JA:QL-SLKOCHTCNCQQL+I2Q[VOE;ATJM3.JFT+X$+*#/\FTY/PE,Z\'*
MDC&RC-O:6QMLJ+!MR$3>"*$@NFP(SV5MJ+0%'U1_<KD?XK:3-XR4*\RB$L1"
M:Q@VS/3O=KFNU_?._%8U5XGEJ_%*T#C]!&,*WI*0<+3/).^W(!,NT3%+CH">
M,V7<SFW8Y_%&69(4;IT%/6*:=,7&^B0&\ZPXM#_ /J:HAX/V=P2SLI<$<ER)
M O.7.?@=\[?9_E<8K!E3 BLX>]?L7+M0-[/4&GWCDRUF2PSISUX<O?PSE,6/
M8C75CGKP5BDAN.86QIV9?3XG%*GWXXTUGT_R$ODA*Q@R!?N25@L+_OC;VT%V
MG>+Y:*IBZ7%I('QG$73M/8*+ ^L\2,NRBO,G.9S7JU_$^'K'] W<-H;MC^=*
M,\W?O5M)C'QUZ[#OH#W#WY;K*J>W3\CA<K<%QE7+S&^[_'K3*J!9T5 =*=%4
M4S6QY1L0'A^JG4(7+6#W6)P^6=I"AY=0\:%8HLE"<D<*W6\R03B(:*35M8OM
M2\+;I-34BV0C\4#;+>0M$&@BE!1)(=]Q1'[F\HA0J25T_^_Q^/5?%U3J$.3/
MGKY@RL/[T&R7-715J^[(3MCTELP%^;0$]NK.:[Z1;VE7OX^0A%>I*)4N]A0"
MP"&I;D%6=5N_>QG)U/AI&"3,75S2R*8O>SB&T>SB!]V*H7APDQ7WD\DB$667
M@] )P7KIO<HEW6-&6_M??I=E+$)&JM6ADH&PO=](GTCDOV-^I5A94Q4)OD(=
MU CU\'#6:Z>I^NPK'*>S@,[UCC;*;IQKT-I,U@^C0+V[SU$-.)?U_8ZZDVT7
M*62EWV%5I0O>/D>N3E:CBV?6AO+VK_%N4-V4IU(UO..T]\J3LX!;BN@.O_Y=
M+COZ^#E?MG[B.*_)+^NKA ^"?Y?/B/QEK\.MAJ3-$=%D5TYKG\,8%ZEC]#!M
M4KO%R^OPT08/2;[JNQ3BUTSX:>=A&UN[E3]W/32(M?2KGY_M?MH[B&E91\RQ
MGFJH,OZGM]H.C^BA5$7__13D!(LVUK5ZWTY?/ 0+[90!BLSLU=A?RE+/FVK0
MZ5C/@ZTC>C%"%0DF-OWFJZ$^[;A'"T5J\QT@.79<Z2?ZJU3'A#&<,WE$(<0#
MD0LB%)?Y6 BEIHNCKN&""*":>"2,JVX=O^YBB$!>SX]4RA4(BZ<SM5BH:NTN
M";*O4"W!$"/*7WC:>W$\F3#QC&KIC61S0X40(@D-!%^V^72\$%*YUL[C.+^&
MC52,.!Q(#U$1='FARPZ_>>!A3JD_P_B?LL.LD8UE-D[N/66S)K#1F,?$/B5%
MS1Q3)<+8A5QMFJPG0?SU6[<P!"^FSL3ODK@(+=U\/ $BL%*[.%_]U336LOJ>
M<D]VBSXA+WF^\QP1XFQ$QBP7.)+@/^DR@*]I@ .1R-:QY'&N@EWY?7RE7>83
M1NZN4;@308/L!B7="N?@1G:&9Q?^,2'\5_#,@V"O_M?0..LLZRLRBJ3K')UZ
M=2.>8$&):^6S/95S:34.+ .ZK0Z**:%?N4]+[3\+5P8L!/IY)"A1?($W7L$%
M[SVU,LU-UKTTP T6@M-13Y]UT\3O/=RUWA<^?JJ)W#)0FGB;)A]-(=7I*SU"
M<8MG?_5UXI,%T:_;\=(W"UQM:>?R1%*4R=T_^B0W+XN/'$?U='18-:'&AD,M
M@#J&Z UMBP.,(#"3./9PNNB[)#NKA9R]EU!1_2/SD\WPWWYAC;_L]@S+3(7"
M?[)WW8<($Y&VFAH:/8PL87I#JFC%Y;Q."#&I_C)/[?B'@Z@Z<F3,BN2S-,+\
M^/IY+6$P L5\Y)SW;0.XG,$T29O0@TE,179+BQ83LR*]C_<1-7MX'XFF07UE
M]DN*#A+KUR9%"I[25Q8F$T8.;W/VR([7<NB; _F(P(Y[,_/Y@4S!3HA0OKP8
M,)JQQGP_!C(J12N;+BQB(QW-[<OG>.;.0%IF:_1]Z6,K38'!8=F1D0GK-0K[
M[Q<Y*2[^:;AC34[Y@T9,PNTAN>1'W0=V\)+MEB&G'[;$0+Q4DQ5Z=PZYJ66H
M)0*#A(NNO'Q%6'JD$+">WI")/>(%JRIHTB[=O1E-4P4<@=N+&^1\$"U5GEG8
M^,Z- +%4H$NH]0^I)WD'VO$]Q6R1\WPWDDDRI*$%NBG)'6^"\!VSS6(-C;M2
M.!6KXT<LFK;P9^&@^E+M!#FO*G^LF&S=*L2!G?I6-G.()H:?7S\-]:_D@INZ
MT]:6;Y](-H)_&WS=F,]HJ+=@ 6M,O@V5>JW)1;,%7"&LM,)+UUL] Q3%5R)#
M8S(6+[/!OVXO4WEQA6> ,F'E]/V6IDP)):[5=!II;9A*"XZ@90]\;Z.I(2_"
M>3EX!@:V2K[@Y$:<G</]7N!M+S+_K6M/=3,FA^&/3MJO=1'*W38RR4^F#QJS
M((+I30YONJR9Z-NH=8SV=6Y738?\N0V8T-'?3WT/"C#\X:-0.F:EY,7+J_LK
MSBZ&L*:/K3('R<,#U7F<AO4TD6-X.,H(,Q[IK1T')ZI%O5C [$Y$N\X/X<?X
MD#GIU8&.D?%4FE\5Q!U+HU0=E+^D"MOFJ:WW#>_43/E(6^VFLZV2_L2T<=J4
M>;A[F_[<E&C??A-ICTHVL1'^AJJ0(NE.% ^.5 ]$ZN/>%WN>B; <4P;^XH?W
M"X6/RJGPP\<?Q?R $$1DIY5&=]ZO.\8_K8L3J9<XUTD@;H=\,S,G?A3:<#44
ME*SBAJ6+[+E1U"/6'D8\U"K2*%I&,\@ LL<>^?"69IB!CJUR8*]%/<(+%?="
M)OPFZBPOK-B4Z2= [J90@[%.FJ5.$/H%ZD;TZ*X6L-[&(U</?KJD4FN9)?7=
M]=K[4]!%AQ[I!\%#_AX6X%#+C;;#RX=7\D?D1YXKV+%']'/$P 5 1[3IHZ,1
MA."H^$<HZF*8!&A3_^8Z*T/V;3W=[.URO#W+Y4/(X3'>Z5@=ROU]:#AS9N35
M)V3>D3]26]*QUH+5O;"(_K[*[%$2!4OWQ$#8>UWQF(7;P,6AQH7K?F3,1Q2?
M@G+U"2<K=/U976V]/COL$U(S2I5)K2'&_16.7E(A60K+O^D>7KFZJ+\8KU9_
MBCZDXF 6[$YEI4!2Q[/2^B;J1?9]5N4>>S3@-ZV^?7@_YQG3X+(2&S7><M&Y
M@IL[559:\TMSX8G6 AY\AL; -S+4&D5>W-+,8[^OIB-:BM,"US;=($!*]U(A
M-B_NV-DY&QV74R=(KX5>BC%52V;DV7>840;I6$>L3KUI,* VIR FP9J0BMAT
MHIF=3.!VZ+,A69'!GSRKI-9+$NX[^)1&?Y80OP;1NZDZ::2Y<1Y+;:;<%=H+
M@K(,</6DXK0N3B=H1E=0*[LRG*0%MI1W4^)EU,HXKKR&((IO)9^+I58*QJG-
M[%O%G/&$<_D0ZID>&S".4B[I9-X1"HW<1+4:YC:;$?4R\="XJMA\0EJ:FBZT
MGR&<P=&5WWF;PS=RB3<%DXI5<Y/FC_9N+7C]PY:HO'U0Q:$0'&QKJ[1W),GN
M_*)?C87RT<7H(T0B.A9-?I MVZZG'\.$1DU(DLL-9 B]'AYJFCP'_M#\Z;2F
M[PP=D,"1K/6H^G"?H@8AC_%)%DZFM2K^SY>"ST#J.#NT@0H]'R'5*?\9,"\#
M'9>!Q*;C:Q&_FOU5=KN+Y;0D6_ZH9SM+1^FQ[!\@(+9ZWC9%K;O [<#HMRLY
M;Y^T28?TZOXE<7<Q:J*B$:1H[;O""S[OT.YY UR1IYP6SBES:[,"]W9WHY5,
M\&(479-CWIMSCD(('13,$VV+UD[(5I"?R8(*VT=:"V->P'6Y5B-_+$V8RC<7
MK(+8IREBOF_\FT:A=Y%RAEU$_=>P^'E7J77%S+4K"+F*<>LX;'_GR?A#V\2B
MAT9/=G()>.E&Z'NOE#^D(7A/'OK'?D;:3V42@^]DY%MM-GR$XHS))IP^'WM_
MB5VT_2LN [GVJJG+!A9.R*2'W7>V"[M=*64K!?E LGCU6#(6>PX=FC3%#<-G
M(*JQ+>PQPDPF1V?94L:#SX$9XS>A-V$T)DUCOGG=3<**.>2AO>;O7Z(&74;_
M4<Q<2(C1SWPMW:.XJWN,.%2S3!VYGH3U=?HO# XXY-72209_BR%,(3237*B\
M 7-?2+@:W_FZ\ET7#[S[-:&4'XA#%(=B"$Y%4'7[6AVL";RKLUZDS*^C)S_*
ME-ZG/C-58(L>086=\Q&2!@EZ"]>"-;/M%;AJL"0+&SL.;W>$FC1NC]9^''_4
M^/JYXB#*05]O8X0L#'6OU#$LT2,Q7(+)F&B#_&Q_,BVY*BOU5Y;^&6%433GF
MT#-@8CQ5ODVL:_159E?Z0-^@\+99?WK;I;$5R@L67)!<T/!JBX_R3TV#M.-3
M18R@L0JW6A&KVQ@UX1F1]X_XZ._,1Y9PK)2/YY[[ AS?E5092L:H#&7H\MS5
M"Q0A-/JN4LZ2#C6I5YQC."%Z=P-$3Q:]'DZ?B6< ]PGO&:NHML9GP&.Y>'82
MINK5*K)-@2Q[$1YNFA6PY(\"8K15*BA$O#YT=2)U=U#"1'T&" UZ8[-5')'T
M4_8E D+D>%0&N++S7:,TQW5_"<.TE1"1^3X<A189:@$V9.Z3XJ.]I%0\?,2Y
M;A^+Q>741IE;/),GWJ55$<QO3:D=L:-/[X $\T]C#_1#D/TXWK143^$ONQ*\
M.4<.0FB ;W,W1GOUY6Y&;@V3=%\8MU%[+FU#WK0[8?-IQ>F2*\<T;1O_#;BU
M:[%FD*NR(1ZJ02NAPDA/!2*7)@]DW!H^"YU4LL'5LZ$A)<+ S#7=FR&X#_2]
M<4<\X)F'#&O&5']7HHKLFZ\-: GDS;9Y/ZA^%_=>H%4JU]Q.YL!9-4I_(O?<
M<]PP)H>^F/%S,>;%=#FIE<6Q8?-\*2,\_N]==+/%OC@HRM&/PLZR18[5*[JS
MPJ^^=57U!)5QOO5#4..*@2-1&28]PB.?C2GO_+MD^MH7'=:X3]\V+^+@%0G;
MDOJQMA2;$D?FA>Z:/13:;  ^J^,Z%/[U#(QP76Y79VI;30_8%'2;A)"ZEZWS
ME7EY$][*,R H?DE3.H&4EYK1+Z5T%H567L#V?OE24L-UENMZ>:CFJ/2*@G%$
M<'Q([A$?V4XS]?*5>(\>>K-A^(D!W/&P$2H*F$5NO]71QNPI*$GRE8"RW\!?
M2QJF?NXB 1?2R%&1^T>M4;G3^DY&>\Y%2@/6R9#3B<Z]FZ]$+_/M2#$/UVMA
MM_,R4@R(*3^^P<$'B%3X(,NYEX%(1GDF9"TQ@ CJ>"[S#.1%]!U(>Q.YRF<8
M'%[XK0Q_'>NG6'(6=C__$NR++WUM<)9/3"4);L+LUFH;.$WY/9[:EC3DM>US
M5C#R^P0QK8E7Y'JJO;>,-4J5@EH/$_Y!+T/7K4!)I)<!_>FGV,_L$>*['H^;
M1X9G /$9&*7R69E^!DA$UI1=Z6!^"#!8_>W4 [_>7/HTH[.4GU?3:!V!.@T=
MW1#>FL.W3=^]R-2*<H]G($!D->898(UZ#%W9>+GP:Y_?E)<@RINK]MX@Q41G
MD1+UPRAD:I!!TC=*40F>PU'LA@"UHWBND^+3H-^R,GITH'G3ES/31 *6<<._
M.-[TM0SYO/R'5&:.'6:1L!?!87$=7U+A;G,50TEL)MP4&88O?#[%U*7((Q/E
MZV\CUS:PCYS9:_D!DT:'[T>>N"S3Q%N;#CVO662LRQL%@ V:O1Z9.+N)UZZ\
M._@G?2^OBHK[E";I!>;-*^]<07GS9R_7ZT=I*!_"0EG?2+M9+PEMKT"Y_),0
MPP$'#N)@H\].5J3_HL_]P2[N:5_G#_^G5'N1O6QO]=+3D<[RB'FW_I/M6C*_
ME_\_>P9>T5 2[J%).M@V?.:C>63:%?V3Z((QA"]>"#X%Z3MH)U @G,)2^!6L
MC%7&Q:@?-]>"Q#D@6LDF:9EX,4L=;R/%:L="NC ]G8I5*B-D+@32[#8H0^WF
M:Q(H*(R3-[+U*9-YG\2CUD5RW<##;Y<F$[5B:V;8R6JJZK33;J_+LV=^"Y.H
MOMZM:W&\<U?UZ<1>R[)WA"@F/?QJYU?@5K>4%,),)9&>LGW5]R"%L&])V[SL
M0KM#WK_J[729[4K9A?&!.\Q<>E=6-0K1U9B51J*F?]?9YVK?ZV?^-*'1MA_9
M<2-:,,HAW^,P7T9P \YPRS72Q6/QGN:I4F 2UCQ7X8B(XS,007D:X&K,?7)H
M)7_Y4&,/^H<S7IL&3=2@'W-'P:/9F,9QS/\9T /AOQR)V@DU\PXPG3N(&^:!
MX9_\D%+"G'T&5IIJD2:#@A,_;%<7SL$[V&$] W[J4AJ5ORD</:*FVWZ^:)K'
M&N4]H/W/5LRN$Q2?4?@^V&VQ2O[L\$R!YS@7A%J2+MC]*K\LTWC1;2P:1"GD
M1?>BCP^='V"?"41NCJ-NM9:QGX%,[S[8T^B&4L64^Z^1E 0/9U+_S)UJM%'#
M>F]I9>E]J5NM<9JUFQ]^(X\TUR]<.5$=RX3!VT(X8TI5S\#5 0_2Z)@AI=IV
M;8"&3* ]AH>PSR\D4W&>'W8S?C4SXRNG/US-$'T,YS]?W5E(^0MR9\!ESY^*
M-*OU:]7K125##QU:ZW;*8$%G^=4?.PCZOG[>U!I[!D[];XV(8#W5?3:QST"Y
M;!OHM!.>\&,-< 4G<G_IP7K?>>CYD+U_'Q5DTS:7J^?&3F:C6$A7_?ZJW.8T
ML9M<H+N2&0>_9E+T+L.YP\91Z$#%$W\M\\_N=';JZ8L#Y-<XU0J,F9J1JM-4
MBW\C3?7@H!XKJ99J,CH5!A.ANW]_7G0=PC;)LLE>&>0]1DR. :*:ZB_=^ 'U
MW6K:C)6V-C1]%SAP$$BE0:P;8RAAOR9YSJK(QWGLSP6:HWX&;& /G%[0]]?/
MP$FUO%22ZT[O#)3#XOX#)ZL]Q081BQ<HU\TB0E+[5Y]@NLZ]Y$87/]<$8;I2
MH"8-](X+\_'-,IF08YC:,P#'E9J1<\7_YI/8)YJ=CS)DCS'5% M2\% YR'*F
M*MMLK(%T>8#C1R(]=D#([\5;6+DJB?FTYBZD%SP#!S,:=))I9XTCFKD6AR-)
M=/4-0&)SYST+DEEKC>CY5ENI@7K]=T_.%0_)6I%32E@K!PQ+!-5G%&<$=ELN
MSCO/-@]"/+TR/AGR++QV]6EB$![!O-%L*WD&?H ZVR_AJY^!-@:1-> T_PEX
M(9Z$3CS()IYC7^FD_XM!R22_M,:GL]L+W4OEQ0<0!HCL(IFEWS#XK,&?EO\7
MAQ);#JS#2S/_@I+U-]X.' L*N1]5Z'C ^\0$Z95=6ZO=K5.10+PM1XC8RS,4
M)G924"HUYRQ@9LUPR2N@G"!DI3)U'5'RM%WUI> R4"Z3J3GW/AIC?IT9#^I,
M1D7C3OPFE8F/\O+!48^_2T5.DB^*U/*65DO<U<]P(F,G3WW071.53R.S6-Z1
M#M7%^*;-IH$I1Z_*,P1%UM%%NMTM]6?ER:5))T0XK9>TW4/+!/'7,AI@O2^A
MM<UR."CP,N+=4@DS=9T%,EE/_-+]>*AY:&SX565QI<S?L;2?/5)DJ"A/L_.8
M*@H/S 9'+U9I]FC^7S/3@OYW_Q6H&;4WM#=>96^1TV> 9K@V%-PW1$<IY.CU
M-U0;OB#EL)5MFWWCB%Q%2^]LTK'XR%RB3* ?1!8*G*U@W/;IU%?5CI%<#+9X
M/"0E/VA'5!4$R!:J1/VJ/Q4PS*DZ0V[WLF/&U9=RX;P?.K FDA2#%PU?7(U$
M0?U])5Q[$$@?@MB=<[P$;7WRKNEX(].YSD9CXKMA=ZATGH%)E[CNW2P<8>UA
M9F*#U1+S;BUY2Y8JQFB)@RR:+3U>4M+6?49B_3W!?C)M0-;/Y+_S]W<R:5OQ
M.?5AE@2\?>!ZP,NJS"H%LYXV8=D@S9"#^:V/+YD9I9IB>TM51=VGDT\X6/N^
M%?V+?98;*[2^@OD*9P8A)2U\7-V8EJ>S<WUVCC<JS0(C?,QX#IT%QG2C=II<
M2B%-)6QZ<E9OPYV+F6$2DV=LGW"()JL*0 EFAJ"*$_WR+8G:Q$&]$M8N&T2/
M:<G*-6L:/0^' IV:XF]S'W'8"_<F$0+)7#(PK#1GRB/3UY1JP0P.KL(S=A<U
M=GU5U#M@1[T%*<YDE[!:MS8* RL73*/K2Q?I#PAD GZ]/+B!Y+8._GVR)_)V
M6' 1T@@(6[M"].=9;&[ZJFZNO</9E/& &\?M3#>*$T'.^S?0973"(^BG%,VH
M83-#N,U-ZPZZ<N*#Y'J3C??X!L,$Z:;S)MWG^C5V*R4L5%#\<(YXXK\:P;J7
M7"L^EA9!6HGR'-TV:_[#4&;[2K/O7D5"3)!Q+BV4O!&\W#<RHA(=K^[FI2I_
M9V *U=Y&K!,?O3]91N=G4F*C\K=[6SJ7,TNBC"&^BN-*D7:Y.74%=]K5S=]]
MTWQ\<IP3BC+*3D7Z0_8/)B/O.WTHRU?)C'EG(T(ERK0QZZU8WH&---?<FJ:J
M21R3.O,M:5/S'#C73WCGPHT9F.]C^]K _HK5-35ZW)"0;[21I'MBTF\C6;,C
MAE#>)H7O1+/#Y2^Y]G632.:6[JOI=MD9615 =(2@XD-CA2J-B>W@5?>K<DW6
M3@V\[@#E+<FQ .'EN#SZ$'!O3KUNN0YP;G#[R1NL1[V_KL?^:J<V[M.0-C:)
M;DT06>R-!K)2(]GDX$8[_D#!'HEA5T[IXEC.#"YG>G,\<3^\L/L1,>^(H%8N
M9&G.@&N2-6GK_.UYOD(+J -,V1%:NR71"/FCU\^:;T/EH0Q*OY7KN=]N7N==
M;0Z=M+CAGECLQN'&)&%NTR&@\V\PWIBO&#X)SDO4/9/7TF*U2*C2BWLOK*H]
M)DO-K+UZ0KSHQ33YI;722W*]EU"I%I)5$US\O<BA_K0X3=?;('&KK.M1P/6Q
M && "]WBA*6%(5NL^"[&*WS8B;>5]6ZDT\B5D@.AX:@X6;C<J]!3RHJSM<4
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MGIES@E0"CM62-QB*',V7Y28]1'AP':Z&*]T'Z[&TI6\OYG+#S>5+BKY_!3H
MQ55%15?JYGOZ#/A0^@S,Y[G_ 5!+ P04    " "W?G]65$#]($D_   E1
M#0   &EM86=E7S P-BYJ<&>ENP547-V2-GS0AF"!D 2'X,$=@D."=G"W0'!W
MMT8""8V[0W )$MPA!'=W#1J<H$&Z^3KO>^_,K/EGYG[?/X=5:^U%U:Y=]51U
M[:I#\S#_L X\EI>6DP:0D)  (\0/\+ $O 8PT-%!Z&@8(! ($Q/C$38A#C86
M%C8QP1,\0G(22@IR$C(R*EHV!BIJ%AHR,D;^ERP<G#P\/)0,KT0$N(39N'FX
M_BA!PL#$Q,;")L+!(>)Z0?:"Z__Y>?@&X&, P\BZ*$C4 #(^$@H^TD,W0 D
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M_K-(=SO-#6['-A.<_ON7)M.LYHT^GL<T5O$G5/92;^I/PR*^TQ)D51!:G!>
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M)3ZFR.&W'\_I.+N7\LM@M?87,Q@_>M?<M>N9,HC,*2V$UR=4@" W3SY B%%
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MBK($]I;.\Y2FZX32L4HJ:BWJ&B,HF5 $JY*C5;[M0BO,S?>8ERO9TAWYBS^
M<6FUI_R1+7+@$'G(/)L'(V?0?+1M^@,P Z#_N(<WE5!-U^GP6%5LC:\R=PN
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MEI@M1Y8U^^G")!0;T:1!E(I,]8E%2_H_3S%-5G9W-A2=FN:W+H[&Y(%%:=S
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MJQ5LU'HVZKG"_B'^P17]=BLW,SBLBY?J$4CU?;C.^N,9!P<5+C+&GP2A48_
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M/&.2=?M&54CY$1SZKDK)H<4A!<9"1V199H@"=%KM>.DQX]!D[9CI;G4F3><
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MD, APY]-77(_=3MG"'R_Y_;&6^&Z4/'1/.3-*A-M?:A#+?MYP;#V8IH';T6
M&]UV?5/W)]+9S^ESUT\XY30)/%'?Q 8?I@5+]#]R3^1,V!-^:C2XBEKBFV%T
M_8('Y<D8FV/[4IU,\&Q</DTV(6U7",<_@WJ>A*N8FI6E?\D/.EPC5E7)@7!Y
MGFV1AB%\.$#=> I_)@*K;%6PY_\:L\8.+'4.FW@#@MC/, J(4^ ;'KG#2G@R
M%G"T5T^LJ:GBNS6X(*<.M(SL:@T76>B;4L;%C5!-YV_@'VU0A1A.A#T$T:+B
M$Z1F.15IT38MG['<=V>KDZ'CK3I8VHWDF.XNXZ.U:;^IP]76(%YI"I^;=;A!
MJ^&CS=W!R3")F2]"3S!\R692"[](LF3.>-;SLJI(8S>"RJ\<PL@=VYH^LBUT
MCS:_O-PKD\AB8X.E;7$-ZC@D"6CMH),6/5WB9+P_RJ-Z9LE%&K:B<>I5ARD^
MK+:H0_3A>MC6U;@Q,MG(J4RUM@;GLM^4/)_U#;@RY&.;W<@>#98*A:_<FXHP
MP><&W;(@'N7<5OFJ*RQ</<?296GEL=%'P&3$@JR3HK(</E?4LT0J!EXZ,F&;
M"L3?K_@ 1EC_*//Q4'IE,Z2P]&?RW;;OJ*N=<C,W&W4 F1ZPB(_F*;BKTBPC
MN.;)C>0Y528Y/([A66NAA,,5@PF^*D5*PQ(HC;'RJ3IPFE<**>$H[D9$,0Z&
MAC8D6O_!#8G5#:URX(07RN(N9.TGDNOFMJ84/HU@=>^AU8\2MR2C:=",;(BO
MYY<]*ZT?Z*?8S [D\/<\F",/\:9<:=(*X]Z_>==@ 6/*.;^!4SLA9>.8X1W-
M*R_*#3B56('W4$W>O35SBB7EY(*MAU\)>8CM^2DCXJM1&8*6%.O>@_HFSS3;
MU?D#^[9_\K'Q=6J)CGR9&8]CQKJ\0,UE:Z4:2]@ 31M+/#PZ!?15 UYO>MF;
MIJE#"_L&)JE-99EG[FLK2[VESMUV,SQ:;+N.G*IQ8\VAY/BC9S4K5 $"#68[
M?-6F.W5F!O6IT\[')5O10ROH:-FKSU1_Y)'>*H%P_:7J!IC;22OX!>FVRCQ(
M%M46W<LZ;T*F#] <<39<]:Y(>JH,3[0[OL5Y4*$2=W&=ELJ!%P6;;<8CU,X)
M\9;Y7QD9-NFU"60A!TV5FDLUF2*F#E_23T:GI7CQH>AAG)?T,7Z:4Q$-$YZ"
ME'W??X7U8DP$W/8OF297:_C]NH*2C2?DML<;\]?W0C1_24;_T_%'CIC].V%\
MCZN@09/I[?=G"8BG<;@TBFI%M-:SR&C<[)'N2GID#C<^OZK9,*:/4[YQ-,ED
MMR4IJQWDZBYMN>^D\2Z%9TF[+,U>E.S3W>(MVHK&H/9+Q1F$YLFY$GW=+X:+
MPM WZ-,1P[9G0LT5*1M?X[BFAK<2OFY%MQ+O<T[VVSC'.;+0QHG-YT'\9=-+
MG$L8FQ7SKSF-QWOX*&2IEV<%>\OO]LN21*K'JW?&>YZ%A::Q_0S<C_)(5R@_
MTM]YP F#IKH_[)2V,;OU 7TBE!74\6^2BCVS."-!+B46R"QLR[]2I+V-9H+F
M8Z807'_K%EABD1%#%P<]8"UK[?S0FL*".O$%]:ZR\)DE_#<WS!;TM6S%7.\N
MG'9T9FT?NQT)2']!7"%<YB9^$.=SE1$8C!"/UAS-IN?TYE_$*#8C// > 208
M&QV*:,^ YTBV*&:"S\0YX/TS5*:S'+D6HNKYG1^!_8D[*3Q?Q:#74].BE"0+
M_=A28I%KDP=+2O2XH$J7]E*"-(P+]I8#W*;9<W$+@U CO0:3=Y2IKJFQQ"F)
MW8X'3;&&W^%.G2GR)O(V50PI"]8SR(OZOAHO1AXYH**A3?C.U-CKC+V]S@V1
MQ1L")TH=V433%5-,^O9#RC:UXGR\FU\;AIPPBGW7\& 41BLB,M,U:(,JV&F^
M?*CQM6*/BR_7>LY&Z']7]&7@K$D@"U:DF%#B3B)%>2O0D"G$PC+$9 A7)!F.
M5Y<BI.SM[8S(IF?>DC03W8Q\P'UYT;U9;.BD1G'Y<O&+A @<XDGONZ(W"=G)
MD>2'6'"4:6^W[^A;>-/H:>J;V$0=YZPH7&DYO.TR-?8P)&"7FFW367KQ]:/J
M9=(O]S5N L.D\ U,7WTFM$7GXE"&N4(\91-#EI1Y!-;T^^YH*+\;_>!C'C@S
M=2V:'<%[75W?;L#J?#Q?EM,;6KRVX)"[L/?#NT&'%JH*W7"28-=^2*!CB]<O
M:I[;>A.OKRG8W4Z3180(XX4\>?93.98%(,';192?N#<-D)[-$X;YC\B1*&[7
MJ^Z8Y]9-ZJ5TF=@K&@IH^<+_N+BCM;)?8)"$/+^<)@QX!)KHX'HGQBLM[A@;
MW;N8<G6U-%^%UR]PGV51C%IN.I^S=]DK_7,>_[O@+?AC\PH%_O]5]Z(4-=%K
MNFQ/!;W[+O>Q-YGNS'LW<7"Z^,)\4"2(/IIP69PLBD/PA;PAI>_] =K7BX;"
M[NW=EY%0(&<M*#<;Y1)C\\_CLV=)=F04,TB")8#Z1/6^!5T_@T7,)YV-C>@]
M:0GWM$KQ5SZB:.C3:?S?./L;3;'A/Z361.:;FX)1U"B?/976ZM;6:IZ56=%"
MF)P,JU4-6K'*2I;.@--=E3*'N\)P/_5B^UK"J=!W(K2&&]#$>,51#7=7I>E8
M=F*P5PE!+"(>K%T<=)G.YZ#>9/$ZFADC,]7ZCH4WCAV?7"-G=JI+><%;TS6Z
MF'T&X^M1A.*!HE\;K.BHMOF8%-P;;E2=],&JS^8Z3@=.$F;%_#M2$N I5A*W
M=%]%:08<<PS.85?<-B$;7[?$*EG[SC0<F>?7L9'ZX2R]R/3S>@-AHVLEY@$E
M@I*/0S+$>[[PT1BHV[5&]Z^N3O&2:LK70.A\R:,D=C5(:/QD(E'\EFJUJRWJ
M-S!&+.?6*JJW_+5EIC1CSV)8^*5ME,=-)E97.-''M[/X#I'[BK#$G4G1<SA(
MG)H#$ZE">&*I"]:3W12W%J,*1(95(],DLZ^P!MU0F]Z,46!*T0X:$KL7.3>U
M74_K.Q]X\\<IV1*F#310,2*MHM".[&O'AZX[WN)#K'%@6_:_U+"X9]),,Y_V
M?5?J'V"4U7(JE=).4_0N&/1545T\UJL/&($Y>;.)3F&V[C08!I^C6C^I'T+5
M/$1<-* >HR5V6L?GLQ3.3Z>6R6*FBLFK3^I=;G<@R'CQ;?\R<:FY=B2+7KOG
M))QGJ$]/8M#$]!RO3.A:@K<_!<9:C3:(*@D786"<.=HKF^1SGMF$M("R/QGV
M^0Y"WS A?*G[_F#HT9>"_-H&=?O]A!$66T/1XU@^W^MPUQHK]]*=0JKJ1E.&
M&#0GEXKU,IG)_HJEW7(SF7@HY)UU9%K%1I0H:^Y]#<Y+IUV>?IL"_%B[TQ?"
MH)N+4A.)DYQLC,(]:XXBZ;/KHC,*:T$,[=":I98-<G/3*+414=&^#,3HI\C9
M!?Z_8 _>*QS16#S_[&$2Q8G1TUQ%Y(@](E$F\B'N!\5!"L6S@ Q=3@5K5F8N
M'3'7B4E[^"FF98FRG*"Q"/K7\ .Z]UO[/U4HETDGV"4()7Y,)]?-!WS_I&N#
M7ARE@+<PF")*[]B2UC]NL) FL',] W-^K9K.T>>BN/=RR'I<EO4LG/N:8BI<
M_X#N<-)66R>XQ>#X\$KH-*)VUN 1,(+HYGK4Z)A2Q8XCB,_"0>4M&Y[O".1&
MBD])>?.M+2Y^;FC@BC9R5A'\?F.C_2XMHQLL/_*^K_0D9"FRI8\BHB5&!2=P
M===2<N3C6SF2CS7?LV]2:Y8]]J97?AH&<?12@X1R(QEBBDOTJAN=?3S.\\E5
MN4WA7T=?%/)DVRSPA;-GTAC!;U.#W,+<$SS7IX;V'W@$G(.EZ'+YTGADX/AE
M,Q]R:S)#]G'&]EZ.4RXH&^$,L#;Q)GNTQ@(*4U.,U8111:1>C3P#N*3/Q+83
MM\A)E/;K-BTZ\?E\4\U;6OU"<S:_$,IA[J<U*L><WS"70MDJ.&^0'K0-&OJX
M7I1*[FNFB<0.)L:DNX9V?=6NMG3Y$,)4T*U<;8>30?O%2]ZR]-NB;=<CX,?9
MH>B6IZ'%C=():KLK8NHNLH^SE3823@@87C2*"(^^VRNX0SE)9J#&,3./U*P)
MUGJ;E$HSVY,W@]VQXYAF,<VPSALK7Y?2(K-L7G&"C%R&RC[V#:JRR/]UQ/5A
MFN1V,TT81TE?TA<#2S=T.[5V'0FVJ0ZI:$0%59[]LA?!/>^SH43>O$..K':X
M<V$/Y*_&M=W#$B=7!>$Z =%>Z!NPKQM=UD(8>MHI7B*U2+$ 9_MGD([,Z0^4
MYA2Y"Q3:QJSDCDC,Z$*SJR?:VSYBG-'I/\,QM.Y3]_0^?8DXC& CZ;+KH8]I
M^N%8E\57QR,R][7VU6NR#DF6A=NRGU/&4YZ5'+"*>4DN>IMD39&5Z.[9X?NJ
M%G?BAB&]]QEN'R"\4<;JBJGU?"3GI;SX_>RNG]@DW,UML#8"C<69A2^<1[1N
M2NFPJQO&:Y=WZX:(C.L3\1']PC,$.]P3/#CFU?=SMSA\UI")W] @Y2YU]+DS
ME]RCJH6-B$SF,AFSF<[[,E(&/"MV3T%'?<MH5YO*,WV>$UKCIEQ?\]'OBY!V
MEQ.*@.*-JG+VSX774UM!R[Q9J).?$5$ZS5DN#\P)MCMF+@7LXXRH$SR=(Y[_
MI((<MBT)KE).,^0&ZW/6F-/6QG5LFJBNO'M;+C#.1;/"[G+G!S5Z$423F>#S
M/]R+!77\'#AU/DHD3'H$J&41$&J]+R58CEN>K-#]\_.&/HKF1OORJLI;_H;7
MU+$$,4*MRY8;$)5]'5^W[#G.W)O@A8QD4K@UJP11>&/%'C-S<Y3/I'QR3981
M%?<;O4\>X/"N0,V)2Q,=S4PC"8Q$&D"$R_\U=N'] T'YV(R]S75TJH;JQO;"
M>$UF$)>AVII00!9(20^IXP0^T.+\$W-WK7D'5S@?Z865;)XK)W*M]C1'$S_!
M[*#U0C;%E77>B^U93XTS"\WN>#LQOOBJ W_]S9)*E +XGT)[FLM5'-HJGLPC
M-H+S1]L&6-#07,,K>K!V@^ 1-FFV[!EA%P/KBG#A'?[;4045AH5YSC)/&"R/
MM6_,)B%$H5E%W$?FTP=,!QO-+SE1C&KM$>309 $]C]=G K&;CJ/]+UC>M-\U
MR$R%PE$V"(YYQKKBA&8/IINN<;Z?OQ0],SJ]%I<14")I0^^EGO9FL^3E#57&
M9H2?R_ATP +W+00. <63;LV!WBV80?[P'<QJU)<=U4=@2KO;;YY-EH[QM@/D
M(-B5E0^9F G2-I0)5J]E@ ;9X*%DAZ6?^1ZJ3WYF'3UJ6U-&2KW\UC]J22!-
MO!80D*M^EMKBLE7-0J.GHEN]R$1EX]=[J^R=<5W;6*2I11:84MNXWEIV5MJ2
M[3,,B0EQA([JR8P:;=92*)S?+QAQ#M)TOGN)6E-%1YWXC,X>,%IU4TI]%CXP
M09T6SK,F'0 O!X__\*Z<(\/%O90Q5=',4D5$)S!R9'?(8?J2T]%ZH1UL5D+:
MP0SA7#Z2+3B\R$&X/8S7D$S%5OQ:Z<2NPE[7%/5*W!^OG?)F'?" %KR:8H@Q
M+LU-Z80GA4Z=VX9XM>5GSP<WL[546[(UI8K9[,&JJRNA,ZYL6^:,+.%O4SX"
MDCM\D?%Q*C?! 98,ZW$<^!;[J2W>I1YG;8VF#IQVTN\/5LC#4]A"SCDFNUFY
M]?+(/,Y [8(:):8OXJ,YVJ4C&%5>7'BJW+C*\2:_6(9,GIN[K%D(S)_B*Q5I
M:1H_%_)L2OV\JS9@E*@DR\K[64N?L3>>+C5A9?&!X\#ABV?Z;F*$5?5\%LL#
M,_-*"@Z$9?O$/+$VEJ['TM*B[4/"D>J0XL^+>W,GV1/^EHM%9$]#Q/JE"D92
MO2ZBD_9.P),N<;WCI>/.8.X*(BG??=R)4]FJFPK&&%7-5(E1XP1US0*/Q^GL
M=2169!A/D(9_R/D\369^Q/]L@^O5:-%;R@\5$'N2X&-%^?'Z0RN=-+F4\Y;G
M0E"^E\'%W^7%=-S0%:_EH)M%UN)]K X.Z:_BI3O%LWCY/Q<\*&^[^BW*L;%_
M,XD,[/"-IKC:KK_:U1@B_%9BG+$@X7C$?':_PG;R@'!_D[BI,RQ%+.EBM1DF
MJG):ES' ZZAT"2FX48K[W+VUI(5C"VW3TD3ZL),G]0)GM=T</>%;)WTJWO;/
M<-<B.\</AP-?I=@PA38V'@&$"XZ,[)VZ^-'LL;9Q'6EFM;60[_)*1CZ>&-'"
MHKF!N8O2;D1A'F-.W!VE-DUW&&[W+#JQ',TXCBSSXFV]F# K(<]F]]S#R\P\
M?--?9[5I!\0=B4"IV[3U_L@_R!HO-IO.-+>]VT#AY*?]4FMW^S&0+([6AOT-
MT<E9J<M=U3T/P6@BKU^,KL8C4"I#^0DMR&5WT:F066/$BEME_L<K6R/YJ+SR
MWH\._'O366[6C0P;XWG1#L1-"984M^&G3TY^+QT1:;?Q'%JNMK,?&FR0AT]1
MF"8_I/4>ADM 3<N>NL8N%5."4$@L"%N/^*[7B6*"G\=&F8_I,L5)Z^MD=I10
M8?UG3"-11%) _&%G9%VR)\CJG=5K$_3+V.[!D"%FI-F]?!ZFR0N!R9D4RD8'
M-O^8$PJQA?O8<^P*N"_@)]_S LT6GK!J?W%J-B,,H<N&/!,M* M0% ^4Z%_Z
M8F,&O*' D* 19!S]!$MRO95^]@G6XJP1WFKI+")/T'[]9OJ!#KZZ+C(VE9)*
MTYKK6)@28P&W!D,2'XLOG=3(U6;4#:D>  !F>#.'?VTB_<\VDXC2 H^8CG6D
M6;^5U!32F"_T:YH5DA2BCS=@OR^;.BA&K!M+;T_<DO=E>3AS#3_*6]=8YHHS
MK8&VLA&,UR>@+Q;GCKWO_>CV@RXE+'$FSMREH*)RC*'=2,YZ'&*YD::35T,>
MB991A%#=8%$]FTJ(<++5?V>'U;;H+FN,W9/$>ZARU>_5%4\'G\2;MJ26P051
MY0>(4J<FER6>MUB/S743AZ48-?F^7*Q3;(]L;2$[X'FH">=?:GK+OL1/0"^.
M)]F67'LT0D9L9/@(? R+\5>H^W'S"+RO^#3B9I?&B+D>N4"*!DZ;F&X)[E@F
M#'\U,3I0.%/:VF(S+#A',I6T.H+\-9E0OD6Z#K.4_/.#"U/KK=AYZ7@B57DA
M[@Q*DD5Z>WV2'V2)>':J84O*F<04#0-.HM#5GG&A=!OR-3[R8> 2W"5 0S#-
M1(LU%$SDXV'@%IW:4'@VR[%4TMT:0QKF/(=G-<S*XSU>\SX='4>B[!#EQDR:
MU=(.7-XC.]RVCG?'JYK]4TK,'2*JMH67JG)F!%GJ:]-M ZGQP*76I0I.'2V!
MPJ9%23'N/EBC;Q">E=Y$$>J+@!6?_:\'QO\8?QA/]A^.$HKRWY\O_V?#,=\@
M$H<4&?"HX:#&3W_]<?;7E\0I)!\\5W2'4]JR\2A"Y @"MWKO+^YVS@P?;A[L
M#Y!DV.:])F4Y!8_+ML62(%<S9WEZ\MY"9G:-_L%Y0X7]Q3K1K-UX"U A/F*V
M@@$W2/_/GCUK#_Z8MW+7P[CSOMLM;SUH8M_P[DCY"^V+&S2.,N^VJ3\:?MWU
MX2437[VGN9<9.5H>;/=]5WCRR]GL']('7V8(??NNHGEOM7KXY-]/Y/VNOC0I
M='AW[.=&T%X;*QN(6ZV9>K@XKRPM90G/Y:ATZ)6O5O_^\;)I_MG^WZ]_7MZ@
M<6"!J338_2_7FF0M>2?#<V6&2$* U)SY3<D3(N/NW5W95[U[69),PE09YN;W
MLU[M@1K:9: AMQ@U-!K=6)FNY(-]O!C#='CH&&CPNF$ZD#EP']B0?G"P^1U8
MS-1 J5&3A#B2K,1,U2#MWD17Z-I7"C%3N.7*V#O+ULNLS35V9M8ZWGC8N"#Z
M ]LNKTR&;VN>BZNFO E16?3NZIG:I!>GE[[=?MKDG5),X15@GUPY<L*].U''
M66>?2."V/O9<>L-N;SW./Y;K-C-\6_4YZK#*1J\3W$<\G5].[#JUU#+NY:Q#
M2W+3^E)>BQ_/.FT^I>[<)?UW/\MX'![?2>XJW+][ZZ17'Z^LDS(V2K8-EI#O
MTU[R6T4^^[??P6=O;NZ^;3)=K.!NPV1-K372#(_5[U];>FGN/J6I&?$/N>4M
M;CKE21N+L)XS/!NU1(8KZI77B>=Y;X!E91(79*L6S;#]_YL 4$L#!!0    (
M +=^?U;2>'SL#8D  !>2   -    :6UA9V5?,# X+FIP9[2X951=79,NNG&'
MX X!-A+<G0 AN 5W=W=W$DBPC3O!W7WC[NX$=W=W.'Q?=W_=[QVWW[[GCG/F
M'O5KK5TUJV8]3SUSO?UY6P=\D!*3% - 0$  ]-]_@+<E@ @ 'A86#A8&'@X.
M#@$!'A$9"P49"0D9'P,3#8N8@)2$F("(Z".0D?HC.3T%$1$-UR=Z9A9V=G92
M:AX!;E9^1C9VUG\X@8!'0$!&0L9#0<%C)2,B8_W?7F\= '1X"!I(>R@(<@ D
M.@04.L1;#X 4 (" @?CG OS[@H"$@H:!A8-'0$1Z?Z'N P 2 @H*$AH*!@8:
M^OVIS_MS #0Z# 89BS LIH(!'+D#%FM =!8\Q9>J3FS%R7,@FZ%C( (B#BX>
M/@$E%37-)UIV#DXN;AY>D:^B8N(2DE)*RBJJ:NH:FD;&)J9FYA:63LXNKF[N
M'I[??P0%__P5$AH3&Q>?D)B4G)*=DYN77U!85%Q=4UM7#VYH;.KJ[NGMZQ\8
M')J:GIF=F_^SL+BQN;6]L[NW?W!X<7EU?7-[=__P^(^\( !0$/^Q_E_S0G_/
M"Q(:&@H:[A]Y04"Z_>,%=&@8,A98#&$%. ,'3'+6 'BL+]%959T(%&R*Y]B&
MCI.(.$#V#<J+?Z3VS\S^OR46^/\KLW\E]I]Y+0*0H2#>#P\*'2 (N$,Z,>V7
MCS=(5S0QB"8RUZDZ"EC,JYJQ<:&1J8\)P2)B[D/,^()&7GT-(%6:V[%'?@-8
M_I$\_ !1ZT,;/UT'_L514&_X\XE?HM?KLQS://;"L>%2X KP;+K@(=UNKAA8
MW.Q8/]MT,#K_NC(O5Z FZI2H-B^9O5]#?PQ,<5<5.^T "1=HY,V^MA=Z)$Z7
MM98.[_3\ ,A!\-R0K-YD5%KP<-6] >",],H**/%ZZT^6BMNW;716A8W@$S9N
MR?23^SRH(0M*F7#\!O %CW9)7Y"5%?/FLC:UAIG XS"U]GT;AA^)^P4.^D+C
ML"ILW@!(?DGR&!LJ7?.+:WQO@.@Z%R^4C/@]'!+K0([%W.?^@ZD\C1P/$HYH
MC:V^&[CX<9EY!KMBW;;(_&9MEKA#4K/HIZ; [HQR6AVJ@4ALR_';YMB=%C.8
M8%*ZR88];#O4'-R1&[7GJ1>9G BG.&65:7!\>>K#L=VBKH@/DC2$8=80\9!:
M]'P9P\Z,*Z>3CA2"1%0SS%& ]C%O0*SHBH>/,^@N1JQ-:"1&/XUFL]BGV&WJ
MYDF28+\7BRP'5^0N%/$2K8XCZ*ZEXC&O?;R*B=2<\83KJL:S(M&I*E@E!6]'
M^\0%F6U?S(J5%,,B=J1*E*V9S1KZZY\QAWEL-_DW0)1-Q8N#_#9=^GGI8NB!
M/= UFJ,BE<J$=:.J92]<U3X/%Y]K>FSE#3"PF.=1I!3Z)'4F??L$7CXL+->$
M;IDMM>.@*-(6)I?\&,@] !\@!RO&,\:3&_QZI)4J#68;M([5) P)IT;NY^X0
M^.GII^IY5/^JJ;=+&2&W>C1O4S>WQI0A4IQ=R4AP)#]SK27LP5XU3)\UO$6?
MY0AQTXNI;8EAR;O2FOMCD @=#VL+L8=HY@GVUM/N_@\X5.J@=X7/^\&C?9WP
M6A4VA%8F$6?S],&V"XV5KER3U>^7P_1U6:J$,;@.],G,8ENT6ZH;)K*HL$@^
MNG:AC&!UCE;2XN@>B_*")!7KLFNJT3TI)R@$!'\21??MPQ#\>[&2I@@5<9LR
M:Z65T)8R'.*3N*RWL$T/;.V\92E_M:4CF=1IX!M^Q%CZ=;0(_@U?Y%A@17=W
M,K5JQD"OO,R36^%F7&9;4>)Y;+FVUEO0$3."5R)1%9'33(18IZTSVSLZ'XSL
M.*9I[D(&.=(=@]T!_3271N7#UB-I.C\M"WT[3I<\P*<AL>V)ZJE SY'3UO2*
M\P9@$2'8$6B='UX2.WO,R<IN&#^!"SWMVYS:4TSA*5>ECG&!Q,?:=GBAW0>=
M*<RX.-N(;>*5I7E(HT/!V7IP;WLINIL1:TV_HOPD<DR(CEAY*I]?FR3F4&ML
M"9[,PL2!-4//QTJ7G\YSBCI42REK"[&T)8%M#ME.5Z_$^W$LP*;&)#J6^/(;
M47><=M =J_8'SA_A!\G33SYZ"5*LGD<%>8_/H8][[$3KM=,ZO$L%(VO9C2I:
M*U]L+%(5&T(83 T0>X0Z$='X'06*8@^KY>VR7\I/M=P9/UI0N\/B54(10W0,
M%MRHKL0^/^GM4H-"U1S -FI7CL]U9Q-'5IQ7.M/'MK(M5\SQRBPJ8M90R^LJ
M?L@O><>F*9M6(2(C79B"2GA/!7A;'&+2)6%V>'JI7M1-IG6_#-095^6UIX*P
MQVE:K5OYW&X0DXJ\:.1HE\?KGJYU?XK;.: L(PBTA 'E6$L+/L[4#71:>1DW
M^4:9/;'I#-)?U5+'$[M^>O:<]7^,^/V:E:>Y/&B_9G1ULFB(1&%FR[8VG^+8
M7=*FX=>M.P]O1)S(3VIV9+6X] ;H=.55-?G*V$-;.$A=F2NN@:Z#Q\H\H.\(
M7ZY()1U!\0UL-?J%K_:[=^4R>J,<+XB7)$WEA&Q)YOPE-\N.B?_/S/$W0C/B
M)GW%!-)XN[*3>VWGB[1+30NKU;LCV[[6DYOZ#%NSIG@CF77,F0PAOI0RDW)U
MO66?='QUV8@NG@\YZ(<01'/6ER\UO03"Z=01_,E $(\8O&]:I+9R.A"1T=D"
MR_=9C[R(V-XI^KJ @&6*R;7BH/T!DU]6WM,!3*^I>OB.ZVD1W]!=#+H5*1_M
M^@('1"V9X??36W3]/DX4:9GO4C*\[YRD=<*=OI*?M%"XVD/<XHEZ34_G):C7
MM'YQ ;KP/-DK:]-\A3,3=633/4QH(YY93BT,5Z1>R&OX!J15-R;5=E*S(]?Y
M/(97SL%WE^#!*Q)XR<F#R-)Q)KEQ,E_6KIC P>&K$W]3?3A_\&<U07TC)#=^
M%EU,(VD=XMORFK!E9;+ZIAE\D'*]Y,'TPSRI T?O_,^Z(P_39@1+X7#9 "K$
M/2O/T+FD\0*+1<5>-[X', L=/AYF+4BM0 H<K%"W"GYA-*T:4[/D5&U_E1VN
M_RDNZGAY"%;E?&S-C:E9Z:?!R;TAEV^,U"9Z54&^XU(\=%(?>(SM-\.R:!I!
M;HZ.&?'+D^H:O'FM?0.P[D0&3E+[S9W)M:8^@9IJJ"]@4^V<Y\[8<+]@#_6-
M%/H@0$'^SAKV8HS';X^86L<H<.]FA@L4+\*.Y]5S=]1J;LB1;N740)XJD*08
M5Q1LH;68"DO]4>?#L;:K8OUUEGLFL-IK17=HI?;A]MA*]TB5$Y.>3:KO2_.M
M6-" GE) 1U%PCJ5L(<;WVW*#]>=ELP=5V=&Z:Z[1,@MRGKE-2HREP4Y].!AY
MH^]365[[=7QK:+I?\HSB<\GDOWV)$M^EG<6K37EX7&C6VKEB<R^.CE4\+2UK
MLJ%;?3S;,;5;U14VL+SC8JH&'OX95:N>L^9 2"'TN*(AK&>-M_9<GQ7$P> 7
MX($"LA)Y/G?EA"*M2&O5M*6/+'1;AL/>P6S3LX#XE+OBB!D]/%Y)=&QUI&ZP
M_<RP?9H^EZWIQ)?:36K[1,P>Z^*G:J??6NPI.Q"9$<*-!D0OWQ4L2!<Q[(1]
M;<H-%(/<7RY<J(UL$6"V:*%3NTM(\9YDZ2\8/FVU?I5=L'E1/S(OESE,K#I(
M)/#X#<IF?!TFRN@-YD&Y9_2C!6D--X^*/3(LIB^I?>B]%<5;AJ-?S4V?H0<V
MM1_)7\$E"6L.KMW,RS5K7?(A6L< %6ICF+\J))AR ]28KPX36?=5I^49TL#H
MP[?^F;!\0L^1][->DX*W:K^L@2WI$B<*NER&7!^48TJ]0#0@0N6T]I(_E*!J
M&]'GI\LKK;:UD!GMM:5%4:SJJ@6Z8C(5AAA/YY,S5:ODQ/%I9P;F;@\^?#-_
MC&-4+)"RPU0&HK:59W"VYN/F(I]&.#H0&1<:($W"<S05FUGFM5]1,;:$5>6X
MN[,SNR3+IW/H[*Q&WI20Y9&_OZZ#9YJRLYZ@#+4+93]^\# '2II>/+I+L=(>
M=4#LBB5+VHF+$<:_WHRK//VT<EAQSX>:SLD6(\4XMGC0K*87W2R*I<:RC*4@
M"O@[,]'9=QCWG$^X4UI8YD:B^")&A)H,%_XT4^\I4)>&V7\U-(]_E1=?/>4
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MNW$Y_L57Y\EE;62V?I(B6'*GH2'ET"+[4F.'XL<U7E%M*]<3XY\.1M,4%O]
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MM=IPJ'JWG,5A9EOR>'4C0,!M=CQC.14_^RB86-[DZ;/CI8>B'M;LDKYI89
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M]?J5#>5KM10KXM>3R%0S;B+O95_V8?F?!-"\WJ[S+..NFX(,.RFNIGY1U!4
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M. $  )CA#&0PQ4R9?^JQTQ@F;T-%H0IP"\9SG.J'U+=,EMBJ=!JD@1$%268
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M5?:!D13%.@7&(-)D1_53KQ99 I]F&43807TZJ[]?*K(YTN:A/7X;_W@DFB$
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M?I.L$<OTOY.2TA4>FQP)SJFUS5O "VW=[Y5HM+ZSOBPN^V>_YR^AF,\N@R\
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MH9DLX?>3V]&S%U0;<I+T0N'AE]OB=2RP<I6"YXOW*)./#TK8&G"=+X  UA?
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MG6Z6.-]GYCY@T_?-T&Q>CL?"#0$VS?.O"@;FB7LQ2N_OI4)Z'[NP7@"-?"\
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M'79CR91[4]AR:3ZNG'X:OTMXB1K^?&=YFO7WZ4$OFSX OT(/GZ%?N7B=UA<
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M;%]3P&03IXG<&G,&52GNG\E_ 5!+ P04    " "W?G]6KG;5@7AL   +>@
M#0   &EM86=E7S P.2YJ<&?LNV507=VV-KAP#9( P2%XT."Z<7=W"QMW=X(3
MW"6XNP79N 1W"![<W8([=,[M<^X]][SWU-=?5__HKNJY:ZP_<ZTQQWB>9\PU
MQZK:K[]>UP$,:7$I<0 *"@HP_/,#7I< $0 1'AX!'@X1 0$!"0D1&17K#2H*
M"BK>VW?H6$3X),1$^(2$I!2,U*1D].2$A#2<'^D_,;.QL9%0<X.X6/@86=E8
M_N8$"A$)"14%%??-&UR6#X0?6/ZWQ^L/ !,1BA[:'@:*#(#&A(+!A'KM!4@
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M@R^=YOU_<-V6@)MG(FI&;"Y9V[I_+241,BFMUB9QCZW*$71#>*R2,7T=VL7
M/JV*LC2-%,'[DS43^D[3T5R%+>DJ5AADRHW0/D%YZRQ_F.8Z43K6.W&VNOZV
M4)^];*VDF:\XX\;SG+VM1L(KNG!R:>AR]J,@1K$S?)&2XXRB4(BB?SFJ(-Z7
MT$'AE\S(V?NYW(7G_A7L<#MVS(^&12;K917TJ?<ZS;?0!=&WBAX8'K3@E8!5
M%<:-)$)H]T//!^4;EM.0&F;;.5^'RC_RII;\2V.+$L7(FZE,-V_HW:3-$.R(
MIJ#=J94R;5!PRI# '*22M7ZZ1^C49Z&0]G)4$V6K;^!CH!Q^)_^K!U5%:I="
M_0R DSCG<//"E&$*GG(@5W#4=PW@FM,+I!ET)/2:]2]9.]-=RBS\P156F\\U
MT%GEJ8I2<JB!D1+.YUVA-D?U@[P!7?]I7CO)YSZ&>[I;>SGFU'?^^F>S15Z7
MG2_H.)<J2QV5*-;D4]-F_1$>DUU1AV1;*:P,V<Y37C.N]>W!5+Y7I3)2E<&(
MQSLGQ,0B<9@M+H XZVF.I9B[T^/0N1M"ZW!+=N(VO6L[J5FL,@/;RC_HL%/*
ML,.!%=]\-KA]WK69_F:N'*)*%C>N+9E.?4:BSP-U-_.(Y&;@43R7ZT7QLN48
MWO?X):>UQE9<[1=\5#0:"XO/1['G.SR<DTMN4C:;B96MZI&9R^EP_7Y]H>MO
MKKX.=6+&*"="TF=^&,8ON-]BF\GGJ^4M4CAY$M]?MCFTQ<)]P&!TM =UM.^K
M_I$ 9UBX1MUC5!D=LLR)W%.&L%KBZ0<CNU7ORK7OXURE!(H=B5S1[T@&E_!R
MP<TUTTO9VE^Z]7YV0- F3CG,*Y1\2JB?:ACET;;>?8Z>74??&*+.MFS^[.#"
M.LAHA,@1HHP571#I-)_S=&@BU:?;I!&9&>_KX!E.4Q'5'4Z3 _U/AIJI(1RA
MU@K)W#%_RO^J1BC9C&#Q)";DM3'1L+HL;1LN9J\X&/!)9^<@Y$2]BKHM_'Q+
MS#6"V-Q%]S<"W?W66H):[HS=36IA8^R;IJ6=1GU[P:?RVK=E\3O) ^G*7!Y2
MEWV'UVM%V?..L]$1-F8>3FX0XS0+F:\F]XD8\%!/=-*UQ]5V14UQIO6+?HQ<
MI#=#0^NSN.QOE.G<+,B2M5#>-(=F.#KR@J]+_M3:XX0>3YHXA%9)FMF"]XJ'
MEH[@44*)"3]"OS;)"&P-U2^0NK<89^N"9-B:8%41\&$G)S*J,B%N0F4Z+0;,
M6(GO8TKT[F]P?["%H%B+T)MJD&)L(!$FK\<"ZW!/![6ZA\ID1= R+:P7W;^Z
MR*FY][EAO92.#9P%*@;^L)1&AWD-$N28A7#_<I25B^KAB_88Y_&Z+OY#M]:R
MH#=D)';?46+DQUYT\7RAP&<FIC8#[:]FMP1LZE_BO-BOT"FZ5$/N51D1B>J&
M*I&'E1R\*U8S9C8+B;XIB6%3!F,I"<+]Q=31BN%;R&=6Z0KB$2Y>QE Q3Y+9
M28[XP5W@13].251$4@PO?/VD7EV1:I^JC:O"=AVIDZE5RLS03V\)4^T]!GDE
M0%&:T\?75.V:MF^.2 ,X+0AKCUU@D/;7LYJZ<M ZPG<[)C>1ZFG"/T9?+6.[
MFK?D(,!^[(?B.E)+.^MCD1W\?F^\SO%Y.&_'?MAIB+1!PEH10<<_UIZ%=VJ>
MNN20Y[DHQ5!+,,UBCLK\,XOD%PGJ[7UNM;,CM2KV&*S%]-35(6GATM!PWPI'
MUW5.6:(?+[@Y:'/A.S!W1;S?PISC0=L\]X Q@B#WA NC+Y2BF,OF/0->II%4
M(#/-=V)$9=?M+7)7>#' 556# 514Z5( :AUSV8N2DN%<>9[XA@9%I&%WG=>_
MU>OV_C=%5UXCR\M]&H#874/+O>-F ]7Z$T%%S&$\BR+DY="%90AH;KHP&OB=
MJ(0W[FD[5%#W5;LQ?FY-76<HKW&8/GE49]1[1^_A+?,=,G!<4A%%ZZ-MPXZ_
M2_$HF9DTZI=C/+0CSCJ=PQY6)E&&<B(HR&0<FN1B&!,9'>>'3NO;UA9]GX,V
M'+[+M@"9F<V3^4:!,S6X\S-J57-I8&(:;XO(JOB_5=I_&1VUTE<-JXA4AJJ\
M1Y)?*\I0)&=\IZ,$(% )C':<*@V4(."*/3 @$$X*4=X_[G3P"V+M]V,:Y;[_
MEKFL&KOLGF=U]"W;6-%CN(8SU@UQZ''Y/,,%;_TG@HZ80QS).TGC>+&$$]3)
MP="AT&E,#@F$5C]$[J.T.,8V0>, K<K=X"KCT(;!V]#89$I-L^_=VYZ[?CP/
M= D-_.0=/ZEU3KZOX6W^(HM*&2%(<=.UA<G*P)2SFL!"DC7B8PE!?@7,EBMR
MFI9_\7% 8^17F<-4Y369S;1)N4[K%-:W)F.V<$3 )/&=P1+&OX]N8F<??:$(
M*JS 7):G:$J4(1_X$9F=^)%X(/!$D"@3>WB1R*4^XE'C,M[\Y*?.\'M4 L/!
MO3,.IPGI%/F6^6S%!7IZ0\VE9VLO1XZHKVZW8>,2EL"!>14.7IMZ0OU@5(-7
MT%NVWYR#T#3=.1,CK6X"40:/"F$%*CM5"_&\(<[NGT($$9++%G:D_NR+P.%^
M%0M(I,^]5@4YOFNTUB?S.SP!$!@8*_Q@QJ=6R7C9FV!Y4^Z&W&,,'CF-:N3N
M<<H*=VH,' ?MPY3F-0O4NQ<RG4!AIGM0)PY]D_H ^TUMJTC1C+JY#-UELW6)
ME7#N4IA8?&FG[RL7C7#-! S<_0T6U,JD;J! N/3(+A09!Q I5G_9RA>8]:DS
M\ZV^>\Q>J$YK==H@$%JUPYQA>-/C GK$!X[VJP27[[)'/_5@"F)]I*(/-DA!
MQ<U.;?:._E65(&/5.)W+V?.>Z\-=O\=1.-#X'R=1; WEZ!L]CDT0C_MZFS$9
MGHG<8>6ON&5%N#*ZE+8(E9?))%O^V8\<)0U3VCN*,B&7*)[&)_V^R /1\WWH
M-E9$R[<U#.VM2T/T(E[2KC"[V(0)V2GSI3GH@GG-=8QMSB=<2TNAE!<F%GEV
MV;LHCQ!Z#SR!&,M1GJ^1^34!JI#H3>6*XX"W&8%17UV9,P*S;^0 URN-CT03
M886SJ[\&=K3#,&7[Z<\O;<EK$%"NQM0AV;V!BC)A^=_.S,%I A3!)*QVB$Z1
MJ(%-UUA0BTJZ586^FQ1S5480B-UW,J8S6)WT,RKIA\PB>9#$'M'8?"A5:H[D
M*3B<A:A(4M!4;S(#:OGDDH7FC_R:*SGV>J?8SYM#EK;C@B2'1X)'# ,C.<37
M!M@E#_FI&2R_+TDN!*5JZ_AT<A.%>'%6*PD2>3M(O#V)9A>4M\_'>M@]-CE'
MOYD6<@5S6*&O7GQ[S^NY;8_FU.^I[LSBGC<\S,71UG1 G=3<B#VH,K&RT@4*
MAI9>(JK$[ATK=X_G_<:01OU.\F*]L$.MH0R;\$HW'N6+:JW,IH[DKOMF9J&7
MRP*NW'G_8[K#J6_K_4]62%ZS#ZV> ]-)\N'["S,/_,_U3YE=0R<_P=7LZCK9
M.'*@E=9%&G_O+H*R+<\J06X$TAIC\N>YOVTR6Y7DYZAN/V6GEKFDC*7457&-
M62/!!R2DL^E?SV$U&BLMB,DT/,C5]59M^;Z7Q[LC[!T<"!*)80^DKV$1I!O&
M^>.97D8FG_3 ;XBS7IR\T%IEO^/]F#&L"']O%,EX,=F M7Z%BL &M:"DJ]>W
M%I$'<5]OC/+.QT?"9]GQQUL&AKC62?KK(;R5GKSESG6A7)]R-^GSI;(SF%\P
MWL>=]0'.JFH@>KTH#ACOQU/I79%&6Z23&,MF0;C/JX?SARTM(I\I2(S$W*O,
MNL*WR"D8T=S[T7RL'&NKV9\95^PFB[6V:Q$9#6-0#SI/ _[4'-E6W[26SKV=
M>>-[&<!16;!,L]3PD\>2_VV+<C9N&$32>9],B#,5,2DH_"B$%'LK%P\[%ZTN
M5[>"DV%'_**_2[;F<T. :N36##&KY&+G5P9;U_N&, Z$E9@L))A84,R.(.[\
M%[:VQN;.>AU)V?-5Q,J+ 71$8RVB=N3D@ZO2JC;[O*GSDV,*=#SCL,(X;%R_
MY7B%X2_Z7Q-TWAX^8-EQIH(:]D/7+K9W.M&<HE<3?]G5\]YV1'-MI S2WI(T
M#7+_Z:/'NG*0.589A M-0VU%XZ6(MC5GA4\)C2^'LS+AD<J.M@:-Z^-WV [2
M:+;4'2GE<8<GH>9GI29DU8[&W(0BC@>L65/=L)9P><7[C>0E\)!]#B<[?FXV
M(FK/@GT31A#1-@D([!$$.-QSD!NSZ*+'5[O-:A.>:>$SRB7+)LN2!ON_@"\C
MH>:QM;R=S,_(*@MBPKR_#?-\CQND5"5>Z#J:QK8%R?0TSN/4V0:-H,;K"%)$
M1E7@P@.8 [1-;"(^.:L>E^(UB-:%6MJ"WY2W"8FSF?=BIOP^QA"0\878L+AO
MB*[J2E9(?KCYS;WW^4$E]SPNXT=YX6B12H!LB7"\(&[7O3]U2:4DNQS.YB&=
MN6FC1Z'@8*X'^>[-5K[#==FM=G]<44 8,D[83:T$!AP:"Z^7"Q846M)F\HP3
M5K(174SM<ZZJ; 7A91+N7J2C0J58\5V?[2G]R6[=1_I'F.,D7?)/%%#1DEL)
MB]52I0<-[QF__VJ5C+VO [7!8%:AO!E80PC/Z:#]?:RTL"*&1.R3KR<Z9#?<
MCSC(_Y5A^D@0@SIR<?Q@<^;S"&AT"%]T6(M<[A?7N ZO@OR5_EV'9I!M'+TE
M^))(A#Z;<4$!EM#L%AR^[#7&8 1IR:+9\N@P%^E'V;YPB'RX\#FLQZ\*G3N'
M#<$=#:\@8X;[ 8Z1)6[;FO-C->@/67W'/I:.*D5O1>CX<:5!3%#JA:0]RTIX
MJ8]Y GNK/>,[!%*[?&][U#Q3=0KP@8L4/#VM] DS37IO(EMEAK[=D4?N17OY
MN%=*DM8SW\=V86@I&H?^6&Y:)P;1P&0G]%N]F6F8.DBHB*-9]N[]800%9/S^
M)#$VE5MW7F$TX'/,E<'/T7_H!GU!LS3!A31$#)D!%=9'CE&VR8ZVXM9"2S^0
M6)K7U,,A0ORP<(7)26BNB!.AQANC<J/7A1^\"T)%JR:'H\LSMF(]"!TEY*_1
MGRC=\J4YBQ Y?2U]4D8N$]]\FU@;7WZ<5VS L6@T*4"IQ]85AX<Z1(# =X\N
M13A9(,2B>7?2VTQ4\2C"ZZ=N:KKH]->'KTKN2K;MO<4,%KE%WYK8T6+:;!=B
M,&K&U)8,T2*UH[Q]LQ&^[?8#5R!FJJ6DHG*C*<TY$HD*F? A&!?F0#J9(RY7
M%!*LNO<!##C-7^9 C^_RCG#9&ME,#OLGU43N%A>HJ2J6Y:JB O! X?]YO,IM
MR=!>&+,?UC**RO"?63<M*GNOW9%IY\"0,<^<GMAH%=(XKMO+D^&IB,#KL94/
M^YE\NL[99FY==!XE&,&B!W,Z9-Q3+>2\@@XTY1-@Q[CH$KS#0JJO WN]CC[/
MIQ:AYR;8T?A>#E^8T,,C"T#CV(.]8(Y>*"V>:>.%_99Z M.L_@JHHRD8_:E/
MSZI.+[M2#YR2$&8GK#>QK($$DJ.LQ\#3(?.6LP8=5:I]D- >Y_A7\T5-MWUQ
M[GVD/O-,!:%'I6:K;ZCQPM5-%\B1Z\_V7YK8CFP41#L[.'[?LXPVK)IZ5\$:
M)_5+7B.0^=$,;/&JAZ7IN$J@E=:8:"S+A@@D!EZ"\;8@(C9;02TA'S5D,I62
M"HRFJ(?#%7&.)AZZ!O3?Z-6W_QZ5(EE8G50]RV*M QQE,.,&A'V1DWM4)QD-
M3?V$\)%0W9F#QS699-U(OZA");R/(B:=?S\7P.O0K"FZ,<QQ(S9$7  5W3N[
MHM/WT^*]P^*8]01KSRX+?40BUZ RZ#SR*D]/HV>>9<"R0Z>N=IRC7TWS*RYW
M/SH%B6<=8]W&K1V/Q4EJS[U0*LO"473J $)6(A1V2EC?7"DH\)?".\&"P<<D
M/T,H<F O=_V*7=Z <$F8P6TQWE:$)4\^\@<@20&S9LO\:VY1_R"2D2F/N3'A
M0H9%(F' VC_ASK0T4Z''ON'YQA*,0K43ZMUZ&1C+D^6K#91S1M%O&GI_=?_>
M.UC[$0_S/EUP7.KP$XBV\8FJTNE-Y\*Q-AZE^RU>@2RL!8>)_1?P?+$\JX[C
M6-ZO-C(QR%?/^KC&1* ?B8(0G,.N#U+IB;JQB=?VG@B52(GD\'(8X+HZ$<3:
M/;>HG3T[8;1I[+$CA9;<UBVS$>Y+X0;LJ/EGCEX!;"D[&QL'N*#:PK[(1LL<
MDQ3;L6:B$))LZ41+3[1\\S/[[WTW,Q@=UU K>E!=Y!F?O^KSJ!TQ*,C/V-DR
M, 0,V^3I333N]. 0")WRRR\[YZ!R\YFJ/QS"A5.)TGSG4#A#-'GK-!VP#'ZL
M3/LY#;F9<4%QD>QUX$KF#(T=C?^ $(_&0YRU6=%5:J&!LY$A@D]1J*8G@> A
M*#'K7W90=O>%X'-Y%\47:4S '<QG1_MEGVA\U4&08$:-!N)%%\BS-$[E#J_W
MKGHCJR,IE22ROED=!]I%*RD<1Q9:J)\UP]2/!YDV:;P:;$8KYF1?,WRHIWCA
M<.?SAC&I9*#<(M9 -#)NE)/4MFD,T/W[!VB8[)DV-;34,BDSRHKHFC)6'IZ$
MY)5()I5;#U!986?45J;-2OU"?K@HB^0)K1';\GLWA"P=B-Z,'5L[G0;G>PZ6
M]-1-K@RQID]BX'H27;/P=(7.*<9*JF1$HW!$> I*;.%;\JL<5/'SGC%R]LP\
M'O$E(FT38.<'*D'1)T^U;T_&(6K^UK94OG2CILJ!69*XU%F9$MBV1 :B:>?6
ME3GA0A3HO$D1R-CR:.(\>S5E3G?%0B$+C(ST)K+!JE(,,ZSDT$)X FZ!=S]A
M4SJHD\BG;"LWWUBYO)M@Q),";*"<,EP^)RQA6\F>X\TR+J[2O5>.2XD;+5.3
M=!6$Y]G.W7907K),\UF96A Q/_:71KCPBW2X9+HBQZHYPJ=LD=M1@&;H>*O
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M>C2%:HCE&FAV(H+!QIKI%$,8=CZ4X]LL+Y/L*?CLIVF,96>2K\&GORN3XI\
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MM1W]?\(T.E^!6)?Y9P??;<N;F%> 5(?I83U[4(W@%;A'T/.=?_\B7FW^"ES
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M I:91U# )A*,YO.!=$=16RC@! 70K4':&]FO]'4ERJNZC/<POU#GL_$HVQ&
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MD%5GHIP=$X^\;OP9DWI.3=T'/!>?XN^2KMCA=> PAB3%+#T.WML5PLLABAL
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M.*6LNC,K9?N@<C9;/E<T*^HE+]UP2(JKUVLV>%1C2$X?."9 TF3=\&"5QF?
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M[<>QG5;_TXAUY;C>:]%'*&"ZY70:<ABM\VRVH^/6:%\;!3M/0$^GET/')FW
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M,U>5N'WN_NEA&*[__T&A@8>:_E]02P,$%     @ MWY_5FIH*\.[(0  S"@
M  T   !I;6%G95\P,3 N:G!GS7IE5!S;NFTUC;LT[A8@6'#7! N;8,$M6'"G
M<8(D0$*0 ($$=Z>;X.X.(;@3W!V"!>O+WN/L<_8^8Y_[[KWOO/'NZC%_5-=7
MJ[Y9:ZY/:A1B&K$$X#^55Y('0" 0\.+^!R#F@,< .BHJ&BH*.AH:&@8&.B8V
M! <;"PN;G) (#T)-04M#34%%1<?$Q4+'P,%(1<4JQ,;QB(>?GY^6141"F%><
MBX^?]]=)0.@8&-A8V&0X.&2\]%3TO/_M@6@%"-!!>*!G8! #@$0  A. $)T
M+0" 4$"_#>!O X0$1D9!14/'P,2Z-ZC"!Y! 8# 2,A@%!1GY_JS__7D F0"%
MD)Y'!I5(W12-P07"&Q23B<XH6]9&K#%RQ,1GYAJ,@4E"2D9.P?R A97M(;^
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MH%=JP5MC16J9M4( :2<(8/%E=.40 I!81P#-@W)R@/)Y(@+8;&RYF,G>YT,
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M5UA5+7R$:S5Z*#4#TL0=B*YDD3P1_307Q$-+]N,.*FT7#0"5<3E4HZX)8-_
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MK5.E^,N(A/PR(KGMEC0AZA5(R-WAG;=5#P3M"9?96:LB1G*=3ZR'6S61OFB
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MCFL)%4*WOF*X-\14M(-B0NU(*: B!0[/RO!9CB2)M%43092L:<97%%7/";4
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MKN"79ITXPJ,IXJT<LW-$$/M@.T;4IJYR*=Y0>"D>Q,XQ!R^<!*GC3PG63K'
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MD0?GLC7!$^I^N3 @ITH$3":8$Q2YQ.>NR<7XBIVOBA"7ZO4\\+5OZ7Q$S5,
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MT>B1M._8/=RS&=M\<8)K)T!K6H!UP( )L=I3CN)IL,POE!K&PX?8&]EZVA'
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M> ,DR61W[H?^+)FQ1P?![X/7L<KTBP7XP;-4@BGF)H_4Y%?(/MQ[GX]UL[0
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MT_V'+V<UM?37AX+5O/Q'J74[RW-UB:UY#\R\X5YEOF0H/<4DDI+YNBK.8 T
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MY8#1=@8&TEK#(21,Z11I#)>;:86B/"HCP!57Y<MBM35<.V3W!FSZY?U"DU(
MJ/CH@23ZUF\$>!/^? (/<@VT%WM^/ 4;$PE/0G@!/DV5-:&88^9*C-WV9D,^
MP>E&=PGV.@AVVB,/^.Q([9H0A>TM@;W6H.Z=P/Y+FOT7!K-5DO_!VIMMYANQ
MOIG7OIIIAL/_D /[80S,$>P &UXQ1ZK)GE]OK'S66>MLN-JH2XJ=CXVX(>Y?
M */R&1'7H_X+8)0U#3MLGWI=:.(_6B'E1K[E!8#;6XEO<DU?M/A];@IYNSZ%
M*I_AI:X)R0Z_-#+&1;9)Z+J:6 :>0]B![E48J=,6+2_SD% &?S%@E7$IC!>'
M$@"-AFGBZ0(HQQYC@NSY%QZ4+O95-_.(P@@]5E-'3=%.F,G-*VW>XY7N5>C!
M@K*]K5O"U H#,;S^]0VCBCW^/E2B%?F#VUVH5Z8LUA_!.V<R@*0U7)S9X0O5
MF 8@3CO)QW^,UJN (DWR;(@M-M/#5SM0N#X=XF,J[V]B;,A<K =:PSH?],QN
M=B&;D.[<7"9&>KB&V2**V(B-\#;Q"BF7)\H6_R89GY(D'Q/O:1(0?I8FR'Q^
M6OWE2AZY_!]02P,$%     @ MWY_5LQA<Z-*2P  F8@$ !4   !P>7!D+3(P
M,C(Q,C,Q7V1E9BYX;6SM?6USW+:2[O?]%5[?+_?6EH]C)]D<IT[NUNC-JQS;
MHRO)R<EN;:4H$J/A,8><@.1(XU]_ 9"<(6<(H@&B"5+1AU1L640WGFX C4:_
M_.T_'E?1BPVA:9C$/[U\\Y=O7KX@L9\$87S_T\O/-Z]F-Z>7ER__X_^^>/$O
M?_O75Z]>O"<QH5Y&@A=WVQ>GR6I]XX<O;JD7IXN$KE[\[VSU?UZ\>K',LO6/
MKU\_/#S\Q6>_D_HA)6F24Y^D_ <O7KUB U9#GE+"!_SQQ04-7WSTZ(MOW[QX
M\^['MV]_?//#B\^WIR_>?O/VV^*3?_E;%,9?[KR4O&!\Q^E/+VN4'N]H])>$
MWK]^^\TWW[ZN?O%E\9L_/O(?-'[_X5OQVV_>O7OW6OSK[E?3L.T7V;!O7O_C
MXX<;?TE6WJLP3C,O]CF!-/PQ%3_\D/A>)I!4\O5"^AO\;Z^J7WO%?_3JS=M7
MW[[YRV,:[%ADOQ-D.S+U ;Y_7?SC2X[7BQ=_HTE$KLGBA9CBC]EV37YZF8:K
M=<0Y%S];4K+XZ>5ZNPX8M;=OW[PM:/TO_I/?Z>^G29PF41AP(9UX$9_SS9*0
M[.4+/O3GZ\L=&U=)M%V' 1?Q:_YOKZ6?OA;RQ^7O]RN/DCA;DBSTO2CMP>[A
M2%C<7[*5MR(W&?OSBM'3Y/CP:\8E-H?](%8,9HO_FR4;=YE$ =OESO_(PVQ[
MRP9YF]!O ?QV?%QH@76(3[UT>1$E#YI@[CY[;6O=%UM]!."C^DUK$@OOXW#!
MM"#.9KZ?Y''&CB-&-?1# E&R[N]MKMXK2M9>&)P_KDF<DM2+@SE38'J:4Z[*
MLS0E&81AT# 6]>V*)FM"LRTCQ)5ZS9??)]".+OM2,&>%MP^$'7L0T,I?M @+
M4Q::$YD8/H3>71B%&4P'X6-9G,"',";)@AE409C-*+/*[J$'B>Q+>W)EQN(J
MS/B@' RV=?%%J0TK9!1K.V!Q0-UZCR#6ZK]M4:;')Y#1L651DA=AS$RCT(N*
M&5<J#MM .CZV"-J)E_+M/S@+HYP=CFST#TF:7A$J@ &PJ1C FHI=DXB?WLST
M 2Z @P]L'F8W^5U*_LC9:CK?\ 4&T;/#3^SNQ@=']\E6_ FR #H^MKDVNPR-
M6^\NZF^NE*-84SB(J0'F7&,P6[:AQ #18+GK>YO+J;!/P(PU?MT66F K!,RF
M[HBV9E([7<&\'G^#>*<$KW;9IS9U3W[*@OE4#F$+R^ZC%LPO:!B;>[^_)$$>
M,:MYO=]22+6EY"E9Y%$4+@K*$+W0&L_:>5 G*S9SLE_9"5_9?K&RO?UFKCD9
MZ*B#R<:.1-#D$/&#@!9F7H$/(QL=;*Q:[,-&M+8W-NE6=+:&?!]\;]7@W5%*
M\S7[C(O5BWPO72ZBY"&,^9.&\.>7V&5<=053?I*:+(8>9.Q=W_;L>,59+EF;
MO51.<VB4M1^0!6'D@LQ[--V])$/87RH5H5 <MADW6=BG$?$S!EM,,OZ3Q8+]
MM<<DH&/;GUV-LC[[1Q^C*$M"&3X>W:;<6O"]=<B6J#ZO\E$0#HHT\YA=P(BN
M^>:19@EAPR1;8@*R:BP4S 5*)46/*^,]97=@_IQA, '%6'@3X,^T 7_F)IPR
MHU]N>DP!$G:Q_TH"P]E !\8Y$I,\XP_</!*@A%4@:C(;Q5 (2T.<I.&&++R0
M;KPH9S]B*O'@<<\VXR59Y]1?,GCG]?6:AFF:F\RO/S4$"!;5_:W8/ZN3."8&
M]J]J+)3%=5=>Z(+B0A>QVQPSPAL[K/Y,P(,B2 1*6_]5O3\-A.DV61"DV<9,
MP[L\XQQD28.KTB-B8-V8D[%G4Y<OX&?,3 E!$COXP.H6WN5.AG,(&@;_31K.
ML&( :QI>.&KA?#5_W^)#>?N3K09CW0-8 PSP9@MG6F,P!-<SG,^6CRQ>X8]\
MR!KK6OHMTJ,FG+7V[VP:%P?/E1JH2;ZT(-.SQ,^Y/L_8OL6T.=M>[CU" ,XZ
M/R^7@$=]*'^2L-0JJI3'HWXOV Y"1I6'#;\*F.&;1]G+%R69.KN[,<(X>\T^
M>5W^SNOCSX?A-5EY86S,:O'U7B,QF%VR(:B?WY%7.\)Z_+8-4#,P4  6P+Q:
MD=4=H9KH-C[=K2<,+KTHTN.-?[#CB.EI&(=\6;&#\TN#*_*8D3@@0<47_]@@
M*KJDQ&A%B=\@$/' \H16XT?>'8E^>IFGK^X];_W[+H1VOMB]VETEJ>!U=I=F
MU/.S8\C2:N8++[T3TR_'>\VWI]<DRM+J)V+#$A!JD2Q6M/9TBKB!*H@ A_]V
M&CN&][*>T2;K3#4J5DHMT57Q\NL%359F(LP2)5;LSD/H3R^_89^(-?"CS^Y'
M)/CI94;SNL-(6S8\S)B=-/Q_W'C8>!$_#6?9J4?IEEEBOW#WAV59P6B^WJ^>
MP:77J;%U<0'A4XK/1'37A/$5^F6L>,FL95&UTW"WK,""D8!3"N*-]75T1M9\
M=:=5B+A5*1P,7MKUH\;_$(\2^+<=P)O +F*5FE%K. NA@] $5D,73*5DOK6^
M)!K<81[W32;'*X4#0$K@OY,#;X+ZAR2^OR5T=1EOV!8H_"I()E<7)9>'MZGI
MU8F<\N PD57EX;R*O.*^W\C=L2JL3E)NUP] 8^MBZ@8-8"CK2$KXF3B#&6.P
M.M- SJFCC]P=$T" )7,%F$S&)W>Q(WY*8A_OT#ZB,7I!*"!2FE*6C@W\X\*E
M):LIBU9\(*:3N>6$8C)-1_L/;@YR,\E(W?>O2[A^J0Y"TW-.=:$&N.#U,VC/
MR%V&<YEHH^!R9U+J9MO&U(#'LA6T6Y)%$'"-P5F9+M1(^K6[;8%HNKQOZ,D+
MB"'*?:.,^TBOO"V/E[FE7H#D+NFB-"E9R?%",</F:UZ-*8SO19!)Q>T6R:?5
M3:QNOXQ<4"K8L RU8R[1S0?7EW6]PZD%'URW%S\&Q8.,"-47ZC"_B\)[$3Z!
M[0D#$I^@X:>)+II/&<:($_&Z7IA&"T!?R!#CTNP!K4AJNB8;$N<$S2<DI^/V
MO.LMO@X (:^>%JT5/'^>DM[4UR  4?5%V]@=BW>+:[NP35=(LMN:O?-.^.)O
M$\Y8Z9"7RD;R_B#]> 0^5WWH%7BH;4K#':X6G3ZK1:?[]E=(%Z4IOJ9V(H?B
MT[W)$O]+(Q >+5922FAZIGT7:J68OD=95DDL2*,$&!X.[U(L*J4\7#1-7- "
M/V=!('!@6N*%P65<;L:V_8 2*F[M-#VA2)%2F]5F89T9XY\$YQZ-V9:9SGP_
M7^4BD8:9^*$?VH_Q5!)T:#/HR0H"'E(HXC&CZ,?.I)91&SYJN[FG5Y:9'NAR
M49)S:[[IR$B-',1R^]OK9FK-/E4)/>7F, W^.0/GT*[XE#"(D(VN&HWI&<02
MK/ R</;T1"IO.LNS94)Y.1@\"1U1FNH54XH<R@/Z$<5+4?,%6TXE%=>GO24I
M59CA.#*/R,WWQ8JPY50G]42$U4 /9*X-?/H?=LDQ6]@'HR =\3(J/4Z/W8-!
M5<\7B74Y':?/9@JYM3ZM'".%E9Y)V$QX>N@9V9 H$4D*)7'K5_@N6@YO[TKU
M/,C9[$+,[KNS>%'XZ-$OA+/'2)[D:1B3-#TF#7MP@8XU=FGH 8/UM%S6TV+D
M9\&*H<3YY"7Y<-:/BIJ[6XS6 E*"!@G2[G4*%?LQ+]2.=?[4*#A<22;G3AT;
MM#ST3TF<- GBK!@YG:G8 QU(H83V[L4_JY4SO$T*CQ6*I2DE-A49J3!37DC,
M!77K/9;Z<,)VU87U5Q<9%;?W1FW9M, $"<8PS)9FXR.<+;6!I[(PZE@H7^FU
MS>(SPA@(SL)-&+!;.<S\/?QF[$BV3[3$\M\MO0T*(F7GFN8.5I6.+KPL87R6
M1)%':QWM ) ;#>S2T0L5BQEBI>Q^L&Y358_)%2G1F<CR'M1.P]V]0V,ODL!3
MBN.O=MV[OY+P?IF18+9AIML]^93S*<P71\Y*#!GIT1[[!FB(:"G6=R-Z %;T
M'?^3>80/EV/9/PUYOZJH3,9\E<($>>BUN'.5=+'?JG2IC]Q,, 855LUF@ VL
MI6TD&^5M0K]]:;[V=Y@QYL@E^Z/MJU(+@1Y;U6ZTLDL$#JN-_A_6]5G4(.Y\
M@CV213,JK@G!\>Z3Q!G3K/.BS=Q/+U-R7[2 MVE5[;@H-/$T6:V36(3N/X9H
M*M1*"TM,K46X.\76T,E6D;6#A9,>>4#KK"Q[;O=,;Z6!=0<Y*N'>*8TNQ6P<
MZ^TXH;SPMM+Z_9NAI()T/A^W < 3# ?+]@NB\""PZP&S"+*0+>$K6B;&%M;
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M^HA;/WW*@NF$#"450-SX><<PQC1F"3 Y':>FSE KK0-FG,K&@P2'RB-!G[Q
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M@L0U<(7820,M%G$C-3D!JIFW3!!I8711,HX":E[->9PX2=.$XB\'#<(NKP\
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M^[K,>+^,?:8Z; ?@IW.*LOA,.)B*4(W01:A9)=[U9[MW_?JCOLGU06.X\9^
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M0">I*5SB@&NF^3[2!2_D1M%3JMRUS)V7M^PKE&H!G:2&N69T% V J'>[O-J
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MN,LGJ1_%$?PS3S/.SFW"2]@N.NL4R\(Z5(.X?#<?4AV D,+\B./8B9[K_D]
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M/@X7/'HEF_E^DO-8Z7OV6TQ32%I_)S"YAP#&UGL_T!O1M+$'@ C\J0$^&E+
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M)8..@)WVV);E3FMR2&>C;1!MY-C#1<B-UDM>9U7:,J3VC]H*IQ$P ,UB&0T
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M9O?[02  ![4M+"!"H'#2L@Q.T1[1#O1)@UEHW*&BCT45,H2+'2(<KJIGJ,'
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MF,+$-@]4=?(@I)7OC%+EG5S$A"LSOA4;KK8]FG>"ZPKOV:B9",!I+)Z;?;2
M+I)E<V9+:J4=<&R?[F%=V_U6L&9=+6R;L4"I\A6GFX-#K4N%<MJ33BXRVZ<:
MS !.3>).S2L5?@<X_,>G31;&.,M.DCCW_/P+7MWA5" G,NQ_?Y\\_D#Z%B*"
M_+"5#/"(%L.50"( +%1M4=G8C0#H90;EOGAI.J[U9)1'<OZ$Y#Y'U*2BP$%1
MU9H'!>#C[QW$LH=7'SW0(\2V&ZK[E47+G?@?*G&HE@Y2JQ\0*G1%AHK[)86>
M<ML8VOY#57-ZJ(9.DGN1VZ1$G.UOJY@[B]!4(AL9LD;A=7=\^PSOT !9CS?T
MCYRL:&[=DB$.M?R,N4O4Q,0L"$+JCNU%U&-K'I=%ZD;!AW@N!X6Z!>2 %;>K
M/NQM>X]F>RRZN<Z+(<7(=BGLON4/"CXMW&;.O#0.XWNNZF'@MLJ=Q$4H*8\0
MN#S19K6)Z*V'W$Z7H1\Z,=G*<:I].057J2E\/GE92&ZZ99TB\_EHN^/;QT:'
M!@ 6G\\NSZYG%XY?+4&.-(' 7Y(F!F["^S@D7P$UEM4#7B41^2YP=HN?\T^1
M^8RODI.Z2/LJ1QKT0C3_?#D_GY_,+F_1[.1D\?7R=G[Y&5TM+N8G\[,;USD3
ME%C=<KB2WQ3MM*\W_@,.-A$-AV')C+_FS \--.>.ADUM.ASX >K2"N&W' ]^
M*D";#"\W$8K")79KUQV,EQ; !VVDGIEHM=Y0!I/MO4F6^1.Y_$B:AC@=+1H#
M02) &U#9E $I*QN[=.$0;7W#Y@.L4(?99!^3E/Z1QNA\\>+-TO-SELL)>-0$
M>"\SCFTH2- $(&/;D_<4:1L5"CRJ02*[=AW,@++G"A/^20*F=Q#;D<(]]$ >
MR!MRY2$;BPM7L"5113#W^=I9U%X?ESK!>L(=&&)+AL8_R_)P16^]7]D)?A$^
MCE%326%N!_GVE B$I!;UVGM(H@"%*Z(C/18I3%UGU5?G^4Z"?<5]T?*)W?%M
M)!,QQ]N& R2@U(N<OR3'LYYU2H$XZ$G]^NQJ-C]%9W^].KN\.;M!L\M3M+C]
MX]DU.OEZ?7U&+YDW-V>W-PYCEI49VO8A4]@?[3R1M6K/QC_9I/0UI\A@=4OG
M&?\BV3NQRYMC'W%25T708=LO!G:<%4T?"_Q+HM2>:1KDVM]%-4D<T/"$XA_&
M3^W>"1V4O^FC23)VP#7BY+G9/H^EEJ_KD?:9:"UI3,_WV29_2%*6$$GJQ.7W
MM)H0A$L"9-2OVR)OV]AIZB#AWM>'([Q(;?LJTUM+C_VQ$CGPY[!=A(%+A4B;
MKP,X7$L+(8^: @)>HGZX/#O4BM/L9)2#AC.!BQ>>+AD -A9B#<954".719UH
MQNX"327^T2R.=NB\.-KA](NC'4H41SO4+8[&URZJBQ<OV[-AW7)G*C=5/6&"
MY!P4W6N1?([!^B-GE4.*<_(M1=M\FF/=IY6F=E&P4YHZT-ZSN#J[OOV%V7G.
M_O)U?O7E[/+V#;H\NW5<85N9Y5+&16AGQK!^6P?E%*$X_/G?M1C4>=N7?\37
MNDR?)%G.3WH-/N W.EB/X]C.#;[79[FKZB[@AC:>Y7<6,(:P^)PFF;6WL6*R
M*3V&,8J4TJF^0?>TC_MBYA+\E!(-VRTP4]_BG68%XG?.*Q"_FWX%XG<2%8C?
MF:U _$ZS O$[YQ6(WTV_ O$[B0K$[W0K$-=&DE8.41KOC;,L2<>_QBA,;/]9
M4)XXR)YZ-KMI.3J[L)(IL[9E/5/; AW7KNU#(ILCQ2P:I;B>T_0ZI4&7^E8+
M'J@!F:,]N-57'%TJ)6XN+)'I7CEB:;8M$C9M!W4F[(:ROI:(@S90SQ3,)BIG
M4+GP\/K9/04Y% C?@PK0.+T%"39[ZWX*+$M3RVE+/H7J?]R.MOV0>41 #SM5
MTS+IL?NL@J*MK]D-KE#G#.IJ5 >:*NV!<Y7V8/HJ[4&'F] R-#_>5BI\(O75
M)32OLP,QS2%#**L;I[I[@2U@0%MJ0ZO4O] T\U6QPK$LG)Q-MKB+PGM6]6VD
MEWVUN1W8NI0(A.!6)S6+=H'GU/M;B_$M9Q+ES3%D%#O4/'$.G9\XA],_<0XE
M3IQ#DR>.UDEC]]:Y.[OHQ5_PE;L^6GJ/%)/^/N\T2S._<UZ:^=WT2S._DRC-
M_$ZW-#/?HO4SIA66R/"/Y+?W^!JOO#"N_DB/ =.U<I2G=^(4J$@D@*RJ(RI[
MHKIK*4ZH_N#:RU07#["55'*_M+V.A+-1RRQ-27'MY9@;&SLN@GG33P[!'")E
M$5QU161TQRD?=&$@#5QHF_2.TAT3;>VG/=RH#PUE/<A1CBY9HSVOI*%C WT/
MTR!SO&@C= ,9=QZFSC<T(/X+D;.KS:K*@GZZP2/Y[JM-;COD0XT\ (]DT8?3
M.IMEF2QXOY39"F.OZ-!D\_CV*?D%>ZEIKRKU^:U[8RJ3"*/SW92.7P5F:\!S
M9SL&>/G)3T@PB=V"=$O!1 5HDT88IT>O1(KR>*Z'U?:F6)"GYP0"3K&Z)<"!
M.5^=2ABL[UT7*M1FN194VSLRLBY*I@L?W<K4+0&3QFE%)8S3XU>#TUV6Z^&T
MM2.&'IR.-$W91\Y-V4?3-V4?-?DM7,;HY^/M TZQM\R-ISQ7GW^J]XTMB<)'
ML$T<E#8Q')1&FJI$EM-';VT@: BCG:W2#13K?@WO-<71>^?BZ/WTQ=%["7'T
MWHXX<B.$)BMZX-1-&4VT\>A%&XY-N)VX9[HB9X"@&6KJV!JA3[SLX3Q*GFXV
MZW7$,E1ZT3:"P5;>.S4J'.CGFJ1*O&=DC7$0+2N/EF1T%,;+)%TQARI412CD
M"<H?<(EV/\E<)YD9B")^QCSU_=52^>DTM)S.>9+.5E1KR>:Q'VT"',SC+V2#
MR5QT[MU7&K7X[8%S6'^D&T@P%"=.0<UR[='JU5XQ, %X,3+Y :VV8W.>^'YT
M920T"91M7+J!/=8VQM#D+O41,_/S\)$=E_4WEQ,Y,T+A;/EYK5NS92GK#1"I
M17=1I#UI1XXXO@.I\KV3)$QZBXS%31]K7GF.G5]YCJ=_Y3GNB"5H&9K\O*;>
M,LER4T8?76,_N8_#WW#P<Y@_G"0IX<,ZB8-*T=4[7P=/8A<I0\F%ZJG38?>2
MY=ZF"E C"F,U-'HB8Q-=L3$X?+S:QJ4ID-0@-K+#IB[Y8Z5.A69Q[TK8ET)U
M 9Z)$[BF"[.HBM:I[:M:%DC+R+V>7FIF<4!^DVYP,R1[_"P3NE0XN(1KD@J5
M]SPYN?YZ)BR:<#&??9I?S&^;%?D< '4@4%JU9 =LX?"Z"C*S6[(X:9#BU.RD
M3J^$[<DKAA"58YB,4=4$BO@6)\VMU?T<NH./XX@+S^-&=/.)@6LOMY#I6/R*
M&;8C8 4+U<7,V6H=)2\87Q>6X-&QTS^?"VVSERH 3%6_0KZMO1<R750(/R]R
M+-:D.=L$F=Q&Z,6BS+/4P]$\CI-']OI0E95X^9QZ<5X47<*!U/U<<BCK9FXY
MN@ PS><S6@T>DWT.T#WMX#0?C!J[ZINRPA8,,C8WH#E:62+!1$[,R5Q2A)4C
M)J-D]?.L8QF&5VO,%/Q!TQ3\P;DI^,/T3<$?.K(!6H9N]H<PIL^Z1%R&^2PE
MXN4>"_*L0]D@^@:QG!Z[CQXH,\S\\@PMSM')]=GI_!;-KJ]GEY_/:/)^IV^<
MLBS:II&06?X _Y239+4*<^;M0O/,)#&UO>'8MV(14YS<]AFC1A[T)K_X\F5^
M2X%7V+U.%I>W<P)%P.CEYC320T'SA-+8*WWS_SSVDQ6^]9['AZAP*A=7,Q%!
MD")]24!XAFYG?VT#S0729%C7Q%7O<K4?!;9FJ=/RDD%F44WX:]!.JD:%4Q.I
M$JD2UM'ZEA<R;J/<>\89(AL<83]GGG@QSNEO$5XNR:^<&JD&XH9O&57?4=W+
M8O%!7219=DZ650CJ#9'5Y<-;$F>?\#))<?WA$0%.?LCRT!]%M.I18MV/>@"Q
MDC7,W$GC06#H"FO]33(7QJ%9$/&=\X*([Z9?$/&=1$'$=T,+(FY%XQD3^>'C
M%C4T%1#U."':910R7%DZHC5(<7I.J]/[KWM8Z\.(?V)K[JWNL=U1$"XQ4.)L
M,-Z%4[FX\H@( @!;=6$X[)8.<(!$&08VD=:[:.V+3V?DK<\5.;E/O#1](8?T
MDY<&IC,$J,P\":#!]($1&-LVB%Q77?NC:_!:",*>#3&'R7E\E28^SK)KG&&R
MX =R(3K%CSA*UB.$32A//PET]A )>3&7C=D3?;!M/@D/$%T<"$$KLT_:R"7'
M?TI=54]Q\=]Y;,<Y67Y>VV9S:<HD2\%,YLU6F=4[=V.%7=&_.'703VVGY>_*
MXN/T,T@?<5;YWWE1-HNBY,DC.W">I*?)YBY?;J+*6V]L63N<0/M%^<PO0B"M
MZ2A,6GM5_\RU&7\\E DEN9E=5JS-I$#-2;*B_RT<?>+@$X[Q,LRSFP<OQ9_(
M1QXT&]"ZR?:_+742K=M:QU@%]#2691L*E2D$^8^)+\6O2F][C9EOCS1+,Q\Y
M+\U\-/W2S$<2I9F/=$LS5QC[R8LV!7HJ8;R+NI,'ZLLRCXO0?,-R4'EZ%_<Y
M52+E35WHCCVSL+0]16*36G-P_."DBXNF_-+:-T.5=XXTBXP?.2\R?C3](N-'
M$D7&CX86&>^<?I_3)!O]CE-,,H%["B-$F%XPZ,J3:9DP6PP3*C;;Q1HIQWJD
M68[UR'DYUJ/IEV/=;J[@X]<MQ\I!2&]=5I-" *KCZDX:R)=T;>D74&57QX*A
MI\:KPOK-9#4^TBRC>>2\C.;1],MH'DF4T3P:5$:S.YQFP<4CYP47CZ9?</%(
MHN#BT=""B[SG= M^$XZE?$T'  +R%YZ^]X:Z\$S,&-;@5Y^;A*$<&M3&E<0T
MHF&QK)U\2@-9:1&SE;15F1+K-ML!Q$KXG#5=S::2'$,;'D V5JUM&Q+Y5020
M G,9QG+/9 ZDI)@BR+VGZ.3T/BS'MU9L5O]23<N+1YS>)4,9\);W8%-+@LI?
MQ:6[RAB\>#O<B\K.-]TWFVV_DQYZ>JZWC@WCDJSCJ3Y]W[61"Y!FF9XCYV5Z
MCJ9?IN=(HDS/D6Z9'C9<%653)".18N5.%[M<;$\.?;EE(_1MT>P[-YJA8(-K
M=G+6,S3Z62G*ZIS\,[R/#1\  PAQ%SFM0RX P/*OKNV@P_$P,(:ON4NFWEDU
MZS =.:_#=#3].DQ'$G68CH;682H5W1(;ENZ7X&S64X>(Z8&\T>#+C1O1(LE$
MS@5'N/(!8:%YXO_ZD$0!8<#9/S=A_G*9Y'C\-"#R\]I&FC1ED)GMC[/KLS\N
M+D[/KF_^\S\^'.P?_PZ=_>7K_/87IU8.94:WK&I*>V(B2/G$6X>Y%S%/_F"6
ME6Z5EBIZ]4[MTAK<2YV$^3=)@S#VTA>440=4Y!=C3L80+,U[J Z7U!;I>M=>
M;E9W.%TLF?,NX.L J%= 5\L9X/A40"]:K#$K]\::.\WV)M[Z6OD2+-"<2[5F
ME9\CYU5^CJ9?Y>=(HLK/D6Z5GTI@G#W3$$9VM)5 *3+)_K:;(WAX3FK!3/9=
M& 740 &$K>,B0]L.CC-0]W.PE7NZ9^&:84R=86D,S/@8*F=QDLV<3XLD>HK&
MKHT\/5P3XJ:Q7.VGI<Z@BTV>Y1XK\30V=)I330(_#8(D091L>TP.21Q."N&T
MNWH#&1CY@65LSL6:&1W+:H@OEBY5V@19O_X/)EFF<G+NY9N,W<2*D6B!9%S5
M>IC*/6PHB/BWLT';.L"T0*>]VYVVD0'ZT\NV25FO?$83L91$_82SG"B?,8OH
M],F/MPG]5>/;_1G3&GZDS2-.O7M\C5=>&)/?4Y,_55@W7G2+T]6^Z6]L.@MS
M<99,9_G =U]U1U[1'Z75 ,C?CH"B<(G1MR_82[/OWJ!/^#Z,69L%[Z!S(18F
ML\]<\3(9Z@:>X%SAV%W')V =K 8*S<^#TS )QHC$&X-"9W+#[#IZ+6AEUS>(
M=28BX=LP1H4.^)U+K[L14=?Y2$?8<N,F% EGRY'6PO/09..4BB):DS\5M9L<
MOV2^;LR\':I)BDC*E&C:.5C.GG'JAQF^2L,M:&W);H.4V[=K6ER=K*J'RTYH
M37O5<M^](F<7ODH?M&$N&;8?F#@:S*Z0=V14C8+*OO!OQ%GDAU;(\]"#KF:Y
MU+.DN=FLE\ T1KJ\NK[]G'@*NXN'<.-HJ=]9S6[O.)]"WP=;TZ"N8^E^+V9)
MLAB^YV!YNMI3/8G+JK5NP"G_>9KGE.:SN#%*7^5-28UX%T5-K*X0^.1G]_<I
MOO=RC,(X3\,X"WV68X_[L;]&S54+PT:55W4V.0A=MK]*T:VI.&_0FFB!S-O@
M=5^>7B$$-2*VC>BNYTFZQ&&^25GZZQ.:"3.*<""7HG*TR5_=#0M:B?R%JQR!
MZH)Q@/QJ!.CZ-3D=<"#.C%W&A)QP8J:H.=NDQ^;WM3/SY&Y:.JO0O5 !GYG#
ML.]1X67ZL^(PP4Q:U ^:H04?G(<6?)A^:,&'#AR@96CFAACJBU*J0]3Y3<+I
MY(SC,2R2H+8)L^6_Z6R%)MV^BA'Y/E^.A+$C(+=EM0N6FDJ\H%DY^<AYY>2C
MZ5=./I*HG'PTN'*RF1<1BL#BJC,QC[PN?=9][DVO0/EICW:M??'_1;SR0-R9
M]*_B;_TD/K8I/1<8HOHU.LI*KFW@HV#S W8=$&89PR-]SE+O!$Y"<1I$SJMG
M(UK#"$\MM$9 J*L7OU%6H_VZUSEV3Y,HHE>A*3@WCXI0D\$K/8S13MQN]>8U
MQ= XG16\[@_;1:R;\ 1_W1^_RY V7:Z:*=CS7K/BZ'OG%4??3[_BZ'N)BJ/O
MAU8<':I*]H=43M(:(DVV_1QPEE8F;SPI1F2/A[@<DR8R>"2_YC_5O\++F"J,
M3=[&E#BFF]EL?")%-\E,ZIAP3:/E!'V.EZMKBA&( ^?/6.X!;LS[P 1W!Y0Y
M&JJ7%N17KH#G7IA.TG8#DOEZDYQT%Z-NN.D[\GD&G-=XB>M#J?GD(P!W])ZA
M)6Y\%^02SJ[@@#R1.IA-S&/Y<#5 LDGKQT0/38, J@\^4SL_Y/#BI"%K?I'-
M-&3T(RR^Y"S;K(K?6<^6-X X)P>5T25(9-)+<43&>,1H2<1F<4C17^</&)'Y
M6. V_9S69*4/A!BTFT<RG$0RTG%@V9=_;R!C[">YJH_&!F&5?#@-'\, Q\$U
M45NF8E*2IG>"R5*&K@FJ,58V02\AC@+T[?\[#4W1!AJ-6(:4MG^LR%T=XGY*
MJ*".POSEM7RA.Q2_'GNO_** C[1JC![KUNTO]5_E,^6#<O0/E<.$H0894R1>
MA]FOYRFFC@28H#J?^L?*I?>5'Z>\-0%?*FVZMR1MJ:6&-48IM=OLG*NO_7L5
MH7*TKQ5DPP13BIE8%[\Z> -5CO.2_\L"2CUCV&#+H^ATFI0G5C^AK\GAJG<U
M?0H9(6W%[.R%^7 *,GY4^!DQL\OMNJNT)Z.MB)_BI 12883F .G?,!JXZ0:J
MM\Q6R2;.LVOL)_<Q+4\UCQ?Y TXIP2E^(#2'CWA;5]J247H85>[JN RB6Z:8
M"T7+'H,+\AN0JDH.H[2>V6DXF5EX\8W+P_=:WV%Q%K&_XX"OM)5EDPU_'I*3
MNGB+D2,- /AMDGM1+[1=XEF-W4VX*FR,H2#P]W(II'C]7'M#0RKIA+RANWF3
MH&7H9O2HY5O#R:IX+"LSNC-!E@%G,.34J#RJ72PHTR=3>'H[4AWW=;^;%-^%
MCZ NA[=>?5J[9=H]O_"XWM8U_1H'.&V\[5X1SF0M?\!KJO96!9,;,2/E6[ 5
MVZ]YJJ<3*&U\;5"!S/)KXA;&G(RY;C1\]AOMQF&$X2!H32([(B<3N0#7Q>4^
M>1'-7F;'V.=H:9,Q#[I9/^3A6WHH0BEOF[Z\V]].PU=C(CLK;UMRR'FM8,YN
M *F4/LOI9CUU;9>&GN,2;UNZ=+>%M[Q6,(&EV<WB2N[&8<H:RUUQ#,SS6F*O
MMB2#CSA<J+V>>*@N\X?'-.WLFFX08_?"?Z!I<3EP;G$YF+[%Y: # &@9FA:7
M[G"'FOP\=,[/P^GS\U""GX<##1;-YS.<TWSD%Z%W1[W@0IQ]P5ZV27&PB*^Q
MOTE3HL>0!I=)G%;_))(CW'JFWV+_(0[_N<'C/G[9H=GVTYB55;F(W7!P([&*
MZN95PQX3!]HH1\NWZ+9TDBAI(6M07JF__7^^Z[],N[I*B_,(<DL"N8PDF& "
MSWY"IUC;2WLUXJN- N8G8Y$V"<81 P<$1;KDM>I9\#^;+*<SW2;4&74I=/0'
M5.S>02Q?V/OH@2R@=3>J8Z1R?O365759CM5ZN]1N# @V.2<:6.R'7C2/R;U@
M0R?*3L/,CQ*J<(RFATO.:CU&2Y(P (/G\\O9Y<E\=H&^G5^>++Z<?8?._GIU
M=GES=O,&79[=NI26BHQNJ:8*FV(DEO\2Y_.89DR@4_T1!_<XN\D)V-G,BV5-
MSQ5.ETFZHN9QH@YO?YUD(16S%W0ZJ@W;\:<<EVJWT?^CKDWB:KFL1J)Z"/4V
M_*YR6<O>H!CG;I_&[0*7[ZDY/H?T?.?J&4HWO*PR0$DI)W!OVX7>0$J@LZ!&
M; 74'YT9"'MY4*L;XE5JQI^7VG!VF\S\?V["%%\D7DQ]BG'XV'V-'"R1>Z>S
M'T[:1Y(TAA#E*HI(;]=/][),;4HKJ6W0!!ES2Z]0:QA1[;%=G,0M"J G<-JF
M<5)6F'%Z-G+9TL1$=V5ZY\PU.>F8D90B;+'\N30X2YTR4%_K[@X (5"P>+,U
MU9(J*[O3*VX/(^JC1K160SG+WVF^,;YS_L;X;OIOC.\Z'(66H?_@L-5HBQBC
M[;_'B?[IG\^%\.^E2ACS,[$#09JES4-";@=,!?<<:8J-(^=BXVCZ8N-(0FP<
M#7$U:5BK*%3TKIL[?:TK @ AO?>$PCCRHY,O7&;WNQ=-S@(-G?[O-3_C]\X_
MX_?3_XS?2WS&[\UZC!UK\O/8.3^/I\_/8PE^'AO6YB[QCE0VKK_1&:R_(7&(
MD%30=FW;;=/V!)2U!L=$ZEFUX@&/06=>2H,?LBN<LF?UL9YOX'D<^'F Q #X
M^32[F9^@V>4I.IU??+T].Z6/C.AB<7.#KLZNT<T?9]=G+N'3R\0FB,2+U_98
MJA](=L>G'G/^+ Y.PVA31?.._TBH1H4+7R,]4B7>\.YH?Y88/RA&0%&2%<Y$
M2<L3U+$CW3#$\%_GU/=22PF^W*QP2O^H=.OI]K+L\M,A "Y95K3[T65L%[C)
MM>K$7\^ T_!K'(1DI/".@H665PCC#0LCQ$6L304OFH.GS(9"WW"3*R_-0S]<
MDW_&]S?45YBY$S/T&19QHY!H77<;8Q60PUK=G0I'HN@Q<>CRN!X394VQ.-HF
MZT:;79%/ *=IF4"H^!>.=YV2 >D)=K9[ZX3( -!7-R_CP]=U!W>VHSXVU/)5
MN%9->\,IQJMMRGTISN]TL<OO]N10=0;6B.A;12MG]@;^YM;\Y*S%F-7H@Z;5
MZ(-SJ]&'Z5N-/G18"2U#WVK$'-NJ!(.S1R^,F+*<G"2K51*SM L/2120S1U#
MK5&=W;YOD2*%2MH(\O+BG&;%W/-D)V2O'-?I>Z(F/)KZB,X.*GHI =_&1TWA
M]-&Y</HX?>'T44(X?1RF,L3)BGP.JO=M7C_;RD.' E"#J%O^Z,8NT[?5#2V"
MORA3JL3Q6[VO]?BMZZ_U^.WDO];MYL)?:[D,TSD6Y2LUL\2/6578=2=[$_OC
MJ9?C.N!O7).RT[6\IB!8$PN6,&]WC-K%Q7I7@THFIT%-XJLP$FIKC-.ZQG>6
M6;+2D<LT<8J6>-$0MF->Q.3 1OH[^J2SW,WOX<ZP),>9IOF^;]E&U/]CS2SB
MQ\ZSB!]//XOXL406\6/=+.*5I-J1+15P"L#,63J;,8P2TM,Z.*9E:8."6%HR
MH\HI[O1\5&5R\RA3V@VM4V<WA^ARB?U\L60/R^$CWCZ35 $6U*X1D\9Y2(Z]
MMB4]"\O<IE)R:9R9;9]QHZP" /?/4XC/&14PM:P=;UO-'+V:Z22/G:>3/)Y^
M.LGMY@J.7MUTDI5DO:;)YJCZG^8OMP1!&1F4'A7C)R]1F=E%N) "?5!@X=G%
MC'H37LVN;^=G-V[]L308W3R!57=#OP# YB[#_]S0F*1'%N0\EN$'G,>%408B
M!C*8?/UT<_:7KV>7M^CL)_*_-VXM'WTL:UDEA$O5]4^=^?YFM6$0/<7K%/LA
M,W:0GR/,K!YQ,%LEY%3\C?W^*DW6Y(Q\H2GF<_*WLW]NPC6U?Q@&F3&RS+V'
M?BP@&>-[2I4(E*:(AYY*M\.CH#&^6S%I&DBM FLF-U0SO\,V2\3/8?XP7ZVI
ML;7*A':)\Z)2H?&C7FI2DZ>\/,SEB - ?(&S#.VAL.A59\ES?=2K\+A]RDOO
MA?8!?UK>26Z]YR)';YUNESI//'D=A\'!\).9T>"A+P\]"<( W-4-D5>U=.GR
MJL#3)MQDUZ^K%92NL/']!?8R?$VOTHOEUZS(#=T4M>.D05">WHT 5"43+!U3
M#H,B.@ZZ7GQ%'N.J2V3J0J"56T=G@P;+Q\*7BGP:C03F(PE&[E1NP"@B21C^
M&52.V+GWC*)M)]<)OF38R9.)X 9H ^L\27%X'Y]L4NKEW;S%?_;"^!->DK^3
M^0QC3'968_9 >:Q)D@9EBRAZ([_LCO)M?W1/!MA-J>D&?XI<;R6L5=B? 5%9
MW:PTA;YI&(C@- Z0!]$"0*WZ<Y&V\,Z+?Z4W9IIJ-'-[T^ACG3CY4&/- ^##
M,M_51W0Q=GD0F\^,T#.9DUN$F";)+(=%R@1'\:!JK.RD/12O7??RT,G&D,1)
M-='(HJDUE1L]3$229!J.74A-0#[Q>"C,P+&[:F7E*TOS?WP)XW"U67W!U&M!
M!CJD4P,VY%];R'3'L_A<T9D<0$+9!OVM:/5W5SH0N/F4Y_S%:!Q$;"#OV2R+
M6^/99G%S<HC%19MIL)BW^36+.XL9H&M<I7CMA4&=U3L.V %4:,AY8<.2QX#"
M":$PL8.TW-+$P5'4= !4C<"RFQ0:2CD(*D;AP,U%SFYE%+2R=ZOMEN8[#W7Y
MWA#.U8]&H\ 2FL6%OP9 "P"YJG6!M2Q9YD_449(GSAP@K(=[33B)EJV7R95L
M<L+2KKP(P0/X>L&];;LD@I1 ;WEU>X2K#EU V'8+Z^5&[1PF7J^.O]_Y)HW#
M?)/2$B>+Y3+TL0XB^D>QGQ>VCR3(YE?U8U(C83U%8+$K/=1XMLTA*[49NM=H
M]F9"X[/FJW6:/!:%=$8YC$0SV5>*!-2 O@1E#^I.4'?A@<K!B23!QN:IU+=Z
M3:WFE-S)LSST3Z@;0OHR"HSX<]@N1LVE @HN+]NB;^=9ZN'HNVFHR4)FM9Z\
MP+4.**M>OEV,"!3N% Z<1WET]+Q9N=1J9#C$>X7B@D/+PYAF(BEB7$?!17=\
M^Z=/AP9A2>ZB(:*.AA,Y;D >M5R)N8O4=HS,,"'P@683Q8\X2M:-NABCX$1F
M1@?B1((LL)!2T;-(3KOM.Q%,*7"X[1,IMQ]:88=?O/173%\7R.B?-ED8XRQK
MS*)PRY(;R7)&6BFB0 MSV9?!Z:[LW8,KV[<M)?[5-R[Y;1E@J_Z,8YQZ$74J
M#U9A3%.%>C1F<$R1)C>G_>-0BBX AV5?AD*OU7L::K82GYN"37Y3=&Q'"S]/
M2/_;I^3V(=ED9/=N'\(TQYBK= %"K7<0R_*LCQ[(V:+HA@[>[A\Z?S%3XDXM
MLJ16KILX^(:0RD9I#'].6*>(%HEA[$8=]Q,$J>551PJ9=Y.P*\KSJ,:,Y/(U
M$\O-UFD8-4:^"9\5\2(>P2Y4A+1 $72T#T7(^VD(%2F.U.CH7[%V/DE_%W7J
MV.@=Q/+)TT</F'?2K^4(!R7V\T_*L::1C%)BV;K'SI\V,6X.C&E LAI,>H:P
M_>0I)@? ".U$\7$\#2DBQY4:(1)+UE%?+^FCQ0[P-/ A,8S=<Z:?("@?7=D1
M1(KU;'32'-IFI)-;O*Y"LKG?9#G9GH\J.LAN)UL/3=S9(46#-:.<_S@%SD,;
MO54M>,O2<X;9$2^W3P0MW.<DN0.BU=^R"B$@17PR'+R=@*5-@A'0F=!9J:["
MP%16LA_[JI>,1A_;*L'._#U7B8-]]THBL,OMB\/.BG2.^$I*J+%SMY,3>=W'
MS4I>\]CI3E[#'.4M2T]>5Q<&1;9RNEEW2NO2T'^IXS+8U:U.P&%@;9IO9B^4
M@4IO8\T>UAG;FAY\[7JA[#R8 #NY^]MXN]I=C%Z6[U(55^0DIYMU=G9IZ+\R
M38*Q\)YW;D@F6%R;?ZD&J6/&;_1S9+??4B!AJ.>JR0X-]=UM[UKF=Q8XQ!2O
M^"7O]G&E%XL_X5HOYGR_KO1BZ-OEK4A'+_[3)E(]8'>ZV/U:VY.#5]D(/&!=
M7&9Y6]RXOW96I.\).Z*GHV,G1PG_QM*S<1*.&GWNC*8\&<M4X*-PO#VVBS"_
M%@7B!/&N/W4A0UKE#3IK&I0^.0Q"6F[%B_!BR7QD9\^AZ=1A\#SF#_)(  >0
M#DAA\XHR4ZP=^AMMZ>RY2YIGN_F3X05K1VF%,1GK),5!F)][/LTW]C(":L!I
M3&L,(LA 1(!A67% ]/M+;X4[>'$1B-7#J584EFBEFIDN;G(O9^%<GW%RGWKK
MA]#W(EFH]&2]@,<VKESP "(D ?0.W39S+$ZDN%.EQ1"O4UW;I&/>ACF52/.8
M%4K?&(,%?]P1E \(%%P"H"Q(M"T]8;:MN[BPC HA8RI$P(O4U$-I.!&5FB.<
M(ZVAK<@&WLQ0-A,:1L4]+IPD*^%PH96.9'=!FMS>J>MP2[J,I';R9K$D#'K(
M@'3.NC5BS1%MOPL.1WJG@&6"JAVM!6OE1*O/GQL?QUX:)J95B-:X%L\*+@%@
MW=NBB4N]LI<9'8VALS!-B3'S?1K3&\;W5TD4^B%4Y-5$%19H(L.O]R*9 5,!
M%T@I.Z"J!P%*V<>IX.CGW$[9$]'"M;V\,S\-F<ELL;S&C]1NQ**9;];DFB/Y
MZ"\<PO:+A)@<T!>@[D25SK3H5I;]S&A'A\[>,AQJN CT+E_G-8/91XH2H:>;
ME(*0E;,N*B%>XB?V)[EW2:F1+#OU21'58PMKUU+/T+=AC(H!OG/ZD*G"N>W3
MIO2&:'L!WM^G+('N)<ZOTL3'.)"K],KM:/W=DT,$= !536D>>[0N&[N$A&CK
MM^^@T IUQ$=#*C6C9)-8]839Z>WP<&E3(G&N>*T.#AT)>YG!.TPXR]7-J>EE
M#_3_:7JT1R([XYQF[[QY2-+\%J>K;?)HT[=>A8GMO\+*$P>EXB2=61*]LG>1
MD9/VWR.3KSBE#EQDY%3F?2M)I]H>Z0BJ><P*D007229W&K4Z6-9:FG.#-2^*
M)B@B;=SYS/&VM98RG67HJA04&^=1\I2=DYGK<@8S/P\?.76? (;V#F*9R7WT
MB,3!DO8KRIW4"?B15W=U&J HRZP:)E(;,2#3RTE1592F[O#2F R=G>(EN6B;
MMJ/ \SA(4P42(U5NEK5TG>2YCVVM$T2X7-UG_U-\E\]CHAMMZ.%#CR+#D.%,
MX,)IJ$L&I/;2VPZY$B_#B$H<JG^XS:$),JA=,XZ[/'TGHDHQH0.3^[-/1O7N
M\2?LT0OU>?B\+0I[33;,]!N/XNP.LBNJ40CF7MQ5<=%=,4)=1QBMZ\$1.36P
MVZ=$35BTWI$T=DY'&V9%.O-D4Q;II-HV2TD,UM($="J9<6Q?Y25H@A(TTIY[
M>;)'^I:U6=EEJRC8RB^::5N[4N!<K6#)[H@.DMA K&;'"^=J#\"FT\EJE.CN
M[)!&%/S/IKQUHF62EBC8=G.J9$/;OJUVP%ND]HG'2K (,WT:/N0D)K0612%/
MDVKB5UP6N7'K=R_-VTYEP?[-T+WQ7V,?$V4^8$7S9BOZ0"IW(''ZV0VWX5
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M@!XVRK8H*!NC%]K:&4Z$&U]C 5ZAGI#Z&J?83^[C\#<<G"0KZLQ6^ !U[2<
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M%"Y1\3TS%!7E[" >U&U+$Z/'6CO%.H_\[I:#:[2/^N*;*SU81( O6U;N/1V
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M_Z+M<E,]MNZ8>D6*"%J#*L@#:GS/@1KZ3-FQ*8AZH2@P9G&B4*RSO)=@$:[
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M5%(FG>O,^:KJVH#]"?$EK(_5E+S!2&H-3Q^!#-WRVXMZN;(>1':Q!6:B2GK
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MQW%>47E&ZI8YZ_#?.E25L9)@R3K:9LTMYU&2$:E'M&@;]9L^!RGF2TG5-\]
M'!E*?0_-->](8$!0+R+F4%<L0OPG5/J6!5^=,D7UXSA*/01# 9W>?QQF#?2!
M[0L5Z8D=FQW%I%4EGR">A"&Z9]4#;=I\?=G4&2U<YZMJ140SO*-U.%SC5+5Q
MDSK9BE^=(BK[NL[7-*2&B XR>'U!>!^+HH&12^5BQ;:^ WPGO17L6\S,D_DX
MSI/ITJ_9 WKW())F;O+F'Q<UI9=E2P&06J4#.^=2GF+.%*E;J5B.3SL8P(+
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MU?8](RKV,%%DP7#>/16V5:T5!!7(4AUQ[(2^_<5BVXPOEG)24"FPMM6/E0;
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M2'$R=U$>S:(K]GWJY\OJ;8J01,*JZO+BOJAJ/5W[ZWU5M[P46[E15=G.Z"/
M'C<2*MUF">\T'4:N ZHB0)!T%+GSJ2MGIX@.<>,1RA/O)0?CUGV).%.Z%$>5
M)2#(4!6=B'R4B!H=2ZU&!P_)[*IXS"RR*9YA8TZGRBJA.J4*2ZFR4I>E.OUO
MV!5>NC5?2T4J""/IKD79'5?S"7)G.UXC19)64^%6()FZ)NP0TD+D5&.Y_4LE
MNRE(,=GI'6J!2!<K5O72SW?"7.Y],>FD#9N=YUO*H^QY/ $H447A45Q>#@ZH
M7 3:ET781O?M/Q]H8$"8]HB!-YNU.99.NBQ7]S5][=*RG.:HMNR<K4^Z%%Y@
MB3*%F=BP:*WGY=*=G8704(&?K"S8YL3#:V*I>WW?^\8'H$Z"EZ/)[O^QECJQ
M5E*/XRER1[Y4+7VS*DG>CZ75X?R#<19'ZCO]6\8>?/\A*X82Z&RKC825;1.<
M4R/UQB^+J;@&EG)+YE?>OAJ7YYMIBY/'#"FF(I=[!<YE\4V8;T==KH"$4N?=
MF5X7CE6FG"Y[U<[@%!:]/PI9D8OBTWERQ DH%4:Q"IU9EN4N*V[H8U4[W4M=
M<)!H3$1K1+@)V^!=L4$F@ZG3\^Q1^6M/,(J>M9#I60OK 08%$G"A@QF[V3_
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MMA,,3@_$IO]&&[AXRHU:1JL*?J7AI/J"U=VF0.[)#>!/?)19"\22M=#Y+\0
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M]XWD_!,C*+EGOV'_N&47%;3XOU!+ P04    " "W?G]6'Z@!2\!+   ]S@0
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M,3UE*%;?]9&,DC5_#[E[[PC:.KYW];Q%880B)_3F5(')-"%,E2=1A&(9@J7
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M)0*8#JJ7>TC=4-Z?_#.]B20$'6^79H]^>;S#UPT-7N9B[S>.=L@A1L3?.>Q
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MP$8=D9"$E>R@640<%,S"$.]2,61-3O=\)&OZ6'6\/C:ZU)*@_F@:(,MAV\E
M;$D%+AAK%=V R$:LV+9A:.([8(:UKD?!H^=WSIZY5H<FF/TY&FKH_VBF15].
M'=**,"O<LO?:[&7$QLYS9=219@CR,@.X<)X[#382PU$WRK.0KAQ12#4J(V"
MU FM#M8P[6I!.TW0EI^<6A6,>PD:$@=I3ZES+AR(/?@R!AJ0"I#8B<'H;\BB
MG1;Q;4""--);5(C&RLZ4T^)FN0GB:CHRH*!0%/ONE!WA9&^D05X]#IL]X.29
M+^"/U5J::TR0OPI-BJP6A>6F;O)"JV<0;/O0T9A_78\(HH^A_JEP@Z/HFJY^
MBL/8#Q,_7&6)#CB,+M"2"KBXKFR3&CDX]"BQ<K9T<WY/SQQ-(<"&G>U<\'R^
ML)@MC*X@0&Y,[[0ABME/EDOZ5[";7X&%]RFFQ1K=HIC^Y"K%U/%*J(! /X!W
M<LU@Q02U='=W)YI0V4]VT)=KR>]HY*?EAYT3XHY):-1B3!U"]M0X/#G$@[Z6
MJ6"VW4M29DLTBKR)J[;2?(7$SEAW4Q=%5-DC1)FTGH3>)=JA )OH.JN,?O3*
MT,I?6UVK"BX#2:?6I?^?A?TD^<KCM7GC5)6_ C?MMM$Z61C]0_ZS[$F":2S9
M\;P__BC@!-$D"/ 3&T%,KVJ7.'F,ETF0OR.8-A7=";3;JKJS*0&0D.7A#A)+
M8K-=Z/^=K WW!77>EWX</:PI?R_H!O**O\#J+/I7.W42K48L#>B=AI!@YT^H
MJ=W/3I"DM.:;H[K&Z=H)5]18&ZE'5T9_+I<A=;X#.D,@]NET!:;-30U&R_%;
MW=W3:%/J&*MQ-Q(V+X 1OXD)+ (D=GP3X^&/\@@6^[YN:W$8I'S;!A><AZ";
M6JIW=C2[%ZGRXLWY\DM6O%F<ZY)Y,]"IBJKH!Q3CT&K[*L/AP=CV@]H+&W:#
M68!:5.?BVS7S4\/;%X@;ZE&CA\>,,[3M!?9!]1'K_6FP\"38L>Z\P%;-M[TZ
M"+H/[EE:[@%D9FNSRSBPOK<@RS3_[__KS9M7__7+YY__\M__]4]WFSS_&O[E
MH_?MA]WJUWWXY3)Y^O0#^?C#/S[\SY?%/@I^V+G?W@4_Q6_C!_33MQ^^^_K\
MWKV)W_WG]?6'AW^\W3U?3']]M_,>"/WVX_OM'/WP<_R/Z-WW/P6/WSW<[:;)
M9P>MO>7#EW7\T^J'W7Q_C>?7;R??XMM_SKZLOSW_Z>Y/:/OK][_$TXM?O-G5
MQV_;^=?)KTGR]/U^_9>/?WUX>'MY>?_A+U_6%^]WY+M9N'@WV[W]!7U^^O)Y
M>CG_TZ_?!Q__\>'YNW]&WW_X</?SQ;?W/_WP[=?_>"(__V7W5V?UGQ??W_WZ
M>?GIIR_3'^CZ_N1OOY_^L/J/:_+^[8>[^W>_?-I__VDV_7UW]]-F\N-_OYH^
MW+]Y8]L\-.AO:;QRBV(-Y0VK'\UOPV:WU["D2%M9!A5X@3=DO[WKW90-7Y[M
M+(.<7J@DU3R?**U@DSH?*Y]8SKQO$4%U?39ONAKI7EF.I?V4NYP0^Q<BR3W7
MA=EV&S)GUB*CIB=748AM3 96S++17H<HX7[HD'W$'NO<=*1:?B_2NQ;-,XC\
M^2\;TJ9Y/VH$I>$R<CAK'%!916RZ;[P_2; 5\T.*]"X(U ]7370W2@5SG9%8
M/L!E])'M]6[*\=)URI0@ ?:L:B>IEU929]]*"DJMNIM@6Q4Z5\\L#_4AQNY7
MOH@H*\CZ5FW5TKVC3P,F2P_=0 =GJ3M/$S^M-O@^H6P618EY*6=81G9PJ,DX
MYZ3=/LPG9,V3.(H=WH/8M)2+J,Y:U"6>@F:P]#QJ@\)+(LJ1+8]2Q!AE;<6Z
MOH<]<,#4X4X!+W#>KTQ[9$8[0%63**$I;?P!NC.UH5&\$'3""'XAE$%E_7E<
M7E\E';U6S;'6H^,2$9]UCMNA&:6+),QUO_>CKP9:KC2B&O !(;GMR\]H35P%
M$;:>N/FIE:JUD;X2I_!MU]*TJW=1<#7\ :_%':UV0YTD$/=:3?6O+3R9$,+R
MTIEN7.R/OY(-4)NPBMSL)"AX>K>)B>T#3I^51Q10CZ.T/>'EI[^]M]2V8(_Z
M"B3N>$OKNJR?410C;Q+RLBN73QAB/RJL]A?$<F_I[^P0<5;HZAD1UX_0'?'!
M*U4L+^9%X2$U0]]5&<[N*"QV%L;$#R/?965%0U-\,9UVWLD&J]0- M5W+>KT
M55M;']L7]PBU8^\1>SFA/V>9)NQNFCC! I'->Q/J/8R%C?*RV+XEAL%<V[7_
M7:T#;WS/VJGP#6VB,M,$A6>JTM!RA,N/,Z.;D=*BAN25 U(^V)=;4YH,*76H
M?$&-UX\.FS5?A-PL%SALYV,V 260J="_]IEIWGF/'.A7-XZZ6@9+TAA#O'J:
M""S*3%U_L),A ;;:49[J:L2?C8K;$GZFZG\=E&5N6>(U)DODQPGA[>.FK 5/
M$"#O?2\GO1#YR\'?+I],VSZ.4-MX+..PECY5K8+Y;$R>(<'D#P2V6E6#OPB"
MEQ$;>=,]"Y4T*L-<,;6?KJ["SKV$[+[>#4Z3N[_LOJ@]J';D>T3[N6P >T3X
M&#@X]6]^WWU1;5FAYEJK\4!5H[7*SFV'5[IL [*\.HGGN*N:*HTFW[=OPLXC
MT\:.3',=AGC(LF)V"\L>9";D*7WGH:X&Y9?K9,]/3P96-*0(+!#5YQ/OZEW>
MN5YW?@_K9&MACIBR-S2T%*\&0L_3Q34DU%QCNS^)65;7D:8JZJS@1<$AU"#7
M_,XO9 .-UPW25Y8F^R4/75/<N5J/ZBFN6WQ1H6+<(HWG$E.VS<=#X47G=T![
M-1=Y"L>UXY-!NM=",L_T<FA$HKFB]CY'5<()NO&7:(\<(MJ.4B85 L^YF$40
MGN<:T[FE3_\-?1A#,U8Y;,#]BB6B>TZ,NC;T88"SK39A,T-XAOLE!:S;T*<=
MH(F&/BW\D?9@NJ$QT-!'B/%DFYA;W,V &OI(ZZMLGXLVS>F]H0_KJWG/3D>@
M7J]'6$-].)';O'G/T0)O(&2C)1KYECLRPBDVV+'4[?5$X4K<KNF@HZ76G^F9
MO4DV8-PKP[-DG!K95UFQG1Z2G!#G&9;U)7B#9'UYQ= #24=K0Z&\CA$V?SI<
M'R=1E&SRZ'9Z2;CT=[Y'G?-[NLJAA'6EZ1VA7IH)Z,I+&*X;W&!4^&<<4# !
ME<-8E+A"\6"?)0:DQ54AP[D4 ]!DUM'QFB#VD(ZH!L1#U^-:>E^,L;*$[4Z+
MUXY1-^W30:5#M!,ZX*R'#EIK2*B $P MQ)'YBMT"4U ZZ8P@%Z]"-LSB$%16
MW%"5.-V)S<A&JMT?$'4),BM U^NB(J&6LJR$#-'*XC059F_';R8TK8+7_HA)
MS0V@<D&75CZ8-N7ZXTH/HZ1NV"\S*<#WI&_"-&R'3-&&G XH%;"W[^!X"U'R
MP]*Z2[TP/,U:PWH)U9<0I6":FHY<[BD+*/GK2>A=HAT*\)8ARBR2D1D",A@M
M^9V:4I+BH8W)ZI\=\A7%?KBBE%TD$3T(HZA 89UX!<>Q'"2[PR DI2;)%+C+
MI][&_(1"1)R $CGQ-G[H,X^ #;HPN37E<(Y"RHILA&N*>TX>A1'G'^:%2&M/
M30+^[\AK],.!-Y4DTB$G>6I>\(K[4);UD/,R>QZH?DRFSN)2/"1UC)MH3E4_
M@BVVF]6.DK3#,S1?O9D]0#&!%BQF)JV+<()'/"0PV9ZY+JNMLB.46[2FY^GK
MN36[]D,G='TG.(X=,Q"]$&$9\%$AM\N+!X.0E?;B4P8'Z UH=EZ+#A=E9'AB
MGIIT?G'8:TWMY;6S>,JP;>TS#0E5F&+[^9\_F?'\:WBK6(9]5K:PPC9[N70'
M0HS$9ZO0+4?[:I6U5BR"N*L:C^=NC.DF73SAQ1HG$560Q=HG,4*U)X[ 66P%
M8O=L$;*T??$VXJ0/:!MS] 6ZKG&B*A0),%8?'X12D5F_G62<R9;X08&J!_]9
M42C-$(8ICY950P<KY41QB=RJCJA+HQ7(0.U6^^*A1E>IB.2G)$1%BM".KD]-
M("T@AGHTMZT<;LR2DD!N\>Y$332$(@%FF(9+9OU0XXL4#Y)DE43QAW?O/ZJ<
M'=6/;-1*MI\6)TN#&[FCQN3*KEP\T27M]8U1Z?N!'@R-2[8Q#X;[#I2U[U5]
MI,(W0[7Z)VN#&H&B:4S4F%S]:-#&Y(3'W4> Z#B;BCRN^<QV$*_5I:SC=<^E
MP)^=/>.E4CY0\8O!\KBRL X#$;JP-_>*%'E<\]E@&5VWQ Z-_#O-.LV#&926
M=SK1F\)WP_2R:U<(V7)>Q]]0T>SJ-T/W-TY4&N)>J>A9!ZHFNO+),%6YNB[(
M9M[C?A,"2CS1CQ5VR_>O3_/B/XTF2;S&A*6,?0DI=0\Q=K^F3\QW@7,<NLE[
M3_)&'FF?U?FRT',XRRX!?IGJB^HQOEK>J%<#&Q#W !HTG)2/:B[S-%>JJ0GK
M!5KY(6MN>.$$;#YC/U7$EI8V0@/>OCV&PEQKV2&GG>/EWKI//SL;^UG'$EN5
M)]H=':Z>MS[AORR?Z-H1SV!++=3$#\)RN.?@_I/F"0IX.<[2\<F.M5? RWB-
MGM)LMBC&VX2X:[KX.:$<=<B>ER)$?A0E7?/J[S/,A\8.\^5BC;(\NFB![RJ8
M4V,]XY@U4^]!4';(RBOVL$ Q&R=^XSN/K&N0CZ+/R(D2JCCS\!ZY"2%I@=PM
M#DG^5ZJ$?L2^YRJP0.XZ]']/4%23P-\]]=DDJ=KNGR&J3DS#L)EX4RPVL%AK
M +F#2QGI1K>)I8J%0\%D>FZQXP:']*^1@0S=9EQ6 U%]F,"2X]_,=I@:AY<T
M^D:92ZE^>S(]T/OG'T#IS1^3$)GQVO$?8W-&BZ- STU9VL,CY7&>$-5%]CM7
M#G(T;3NA?U05-"1VV]58+VV%!]-6^(Q4O+'Q,$3P4BD+P?N?)(H9Q0O,FLDN
M&]L%B](2VH!8+MCM46?:^0D;=1R&37OI]C\*Y>Q1!Z"J>NSK^$L3]1<=;VRS
MWCVG[:7+NAZA?]3KEMD^[!HIA#M$'K'5)F++O.6'S]L<9CW6HA#%'4=Z%GJ)
M,,!9O[7H%L6:CYD2 %5MP@%D#DR)-/'7UN=3RC.?[9$&-D!VQU,VU=DVC!9X
MXOZ>^ 3=8(>>*<A%_L[ $W K.CO.0*N2%LU<.\OLYC/.XS4B^4* Y5>&;>L1
M2$E<%78 QNU4A'-/#T!^Z#+5F2_S!VTI(RCZ=M#L%RX8*IBDU[!^A]((2&JT
MCW\WTR:V'=^@9:C -DN1H\HAK.=;5+ZU/U%$T[6H\L#V$\4U)LA?A5-ZI4"A
MNU]0 Q!1PB@G/SE^>(&6]-\7SC-T@I0D5BM/!2WZ6GIPE^6>AK?Q,15SB%:L
M>W-G09_:AS048=R:9FB&+DHQ?S2V*+#LN'LTWR*6>!RN2@:'VAL3[J,8F:4[
MG8(DV[BEX=P(Y FQ#V]QB'-:#>_%$BKK3HWZEBRS2L.;$6]+$$F";\4Z#);[
MC*NY/8VL@GVQ[C=<^.A$ONN$GN<'"56E $<1U4Q<+);H5B7!@KLNFVN4(KBA
M".ZH52MF5&O&#U4@:YQ9M\F&;5%,E,@[_<I2H5$7 ?!^'*?+MQMI^A)Z;/:.
M_\A6,<4A-9X)+V!$:1G3E4-8D6+$%IC-"F&O"?C.(;'O^EMN;1_8FP-_EN!L
M 39S1DBT8B>%RE\TAF8D8B5"?9<CRA))V=_H14@NZT?X\?!$)UZGI5#E)4*;
M8\J$%+LKGPR/R=4U6<IHR[<I]5%29X7OPYWC!^Q 7^ IWFQPR*O%LXI4$S91
M%?M(CTMM9MOH5GZ)0KRAZU%U;NJ^L^S&:XJKE@.V!S96FC#D34RRI:7%AX76
M#< ;516[G8W:H+JE BQ55NI['2<I'WK"SYTEJKUY.A:X+:['8;<&MZ.]%;!-
M_X7(?@:/[)7\MSO.WC6BSK031'^\&[I(!S)TAC=/CL7^"Q[P%CJP#]HF]KN-
MRMN';QLG3F^K;/?$N+2C,J?LD".GFR57ED'*^P+6!2Z))<.JN;VZX=(,^PM.
MUF)K!!-'ES1:ZZEZ(!H@X<O4<-Q*Z*3:.FRY1&Z<L<'?H6-\Y]A78XI#^LNQ
M3]E1#DA$?M;23&HGF,%\/@ID2#*6(D42VT!':VKAG*T.U'.MP\47QTY@X9C_
MA$*ZGB!KGO:Z0T8"63FA_XW31)4_PH'OI:(.O;L"O84'PT,W$,&YW3UQ 80F
M53M>9JG\3.VZ[[KAOE&:>BWZUG;3&%#-8ENY5D#V9AP_)(^1[_G,!CG,9/'8
MIHE>4$(\EJQTPT8I%2B)^6.Q:5.!EEMGPQJ>'5/]C(QJE4!HM8]"JQJ79"K!
MO9/1KGHY.7=S(XVUCG#'P_4"+^!\3RUG@3I1["&;)P"9G/$NQ&.YT%-); W<
M G\1'8[Y%[HR,+.X%=_Y(I?XV]3+N$<[QCON^3]L U_VR:\1Q"!D<.(OIB]\
MS6N'[<DG&29DVR6]=%TFK/*9WNU\G%VP;]$3_R>Y(* 4)#M/=!+"D62$'6L_
M6:T(3ZR]1?$=P2Y"GMQ-I/;#X>Z0^G7:J)@K[-6)M_%#EE4FWPU>_/5P>=^P
M8JCB-AT'9^I$:_8?ZW.ZHR=\R)LY/*PQB5EKA&/V,_0E3P'Q8(V:#A-MS/R>
MA:SO1AI<E-I@I0\&R_[RLN#&=ZNPEHG].L!/T36E^E"Y,Z'WPQT/M$NQNQ7(
M8$70OGP[H[L/.S/9)&G']_S-^Q(M?;?J"G>W9D(\PSV1)'@$.!1<1WJ7Z#&>
MA?2@3'A706I*@<56@\!6$%E!8'5L@1H;WEO6AK\*_27+>HHGKHL35DJPHK]%
M]0Y%A4<>';4Y!6CHV:8!D>H]48(=\@\T\M ,D*GVEJ,&T?;0UU;%XE==>5F"
M/ MH]4XXUD+F=L3 0XX(B[4$.M5=5FJ8(&*9Q;<=_ABQ9(D ]+J!R(XN)%R5
M*EUS4J,%!1?5_Y.15R!0TJQ.PFC>*D45@15'MV>EP^WS$FUQY,>1REASP;>V
M']@E1"%<-EAD444($8E_X_,W98TK_:"PN>C?CANK#,M*"K^.^:RPH.\I+ ?T
M\L]V,C*PO"%J]:K$[9I!1,K. @/VV0_]3;(!XUX9GB5_KI%]E17;>9'@A#C/
ML*POP1LDZ\LKAGLS'H>I5+Q=Z3\;=$X$.QZRC_$=(B[CZ@I=((>][%W[S\@S
MVC)>#?MP-: QRJ/,9#O-.NY9MG&,DZC0"APY%-RQ'[B4SRD#QU:2MJXHI7AC
MYX#A=-P1M,VZ#4O)Z.2CH7JAM=(X7;+E-@V\V]L]91Q=])I5\Z$="O#67+]8
M"81VBON[VDH93@*VD%5LS<PZ=R-OP0HG)ANV.CF#6//=N*13NW*KTW'N\=X)
MXOVGQ&'53PA%K$F'GS[-UXFF\XZ30#@NF:IP$NY%7K&/&PY)2E[F+'WBM6X*
M>Z\9PK@DUL(-L/=Y%0G-DYBE:*;F04$N==^-2QJU*P=[9@?8)5WVQZ ?=E0V
M!]Q[NEYW5I<P7_42I?^?A=QK];V\92EW=X!/*DFDHY.P*E,SP7^T-6D@(R=M
M*2:U&06?CBSL(6) ?CWN-6U_X3Q?H! M_4+@14H6M1^.+6Q1O_I<$'UW 9BL
M"$+U^5_"K/SB%Z.S6)4%YWSO'J50] [NT3()/1:D5O.<3[X;EX=6N_)<" #1
M R7=]SR?\8KE!1XB&@0%K ?\9S] 48Q#%-VIQ/ 408XJPJ?*KERJW8,1VG)-
M%6R^9-=G:FQ92P G0$=B%67:"FYD7H$*HW)I=HXW:$66J,*%";I'+'<G+6];
M8K*A+@V:/P;^JJ:XJ7MP20KGR"2NR-!<Z #U!4IRW^ P7@?[/,MH$D].7SH%
MNU7PZ<CD)&) +I#.P0RE9#=6[<M4@]KV[/Z@X+.(OQZ;Y][ AUPNW2L$%/,0
M"R0I2V-LFZ*\V)SEG6,)*OS^[,1T1>&*36?@W</8M.M4">2<B48 H[M,-;,C
M?P"V,QSY>([]XL?KG[!/%\<2AYD.!7F.P+XPX'R**7G1%O,.UE=T07LCCU9P
M=(U.70R()M<QJ#F9?51GW1$VK2S>.Z'':IKY/>H6Q<>Z+!UUSX'>!0[GY@&R
MH>JL=GP=*B^HWT,0O848<.M+H.T<@,HB*Y<G%ED#UU*Z)]WG:4+%$D1-!?$C
M-\!L0O6"XK\(6-LD,WK>A$F_<-K9^JS1)V?&C')ODQI4KGQY@%(0>0+H#:&$
MW&9UD(28RYTBU-AJI;_SX1#,Z_DYN892TFIQC$BB B9!EAOU8O6H-X274TJD
M'Q?<&KT3GP&;GP)3:GK?!D/Q6M2\/OG2:ADXZI?D9J@GGFH'"F]*M=2];S))
MS>#INC(2L]<,M[B2:\=-[P/P)=1"--;$)[F+BC92S"N+M=-U1-TPBTF,U$.W
MHK/KZ;>I<YLXRYRK5!VJ)<*0*&:%U.ZZMF93F 1S\IGM:F49EM:MUDY!R -R
M<>BI,[[N.ZN-AF787KM82]4@B[5/\:@SONZ[P3.^=K& E1E#/Q&E';V^Z^2+
M0HQR*4Y9>SWP\'(MBD&*KS%$7,\IN"),/?GE;5U9/[X2A?#!50&>\4FR@6>
MDX^4Q"DD:1[*3BAO &#+,]*043,C;,WO%5*U>,+=Q,, G(-X."-LE5PV>21Y
MCPF6OD+O+(61P$;>4K5(L',5['@6JC/::BEH'<G'&L9KA$29_T940H1Y1*9
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M &9I;E\P,#$N:G!G4$L! A0#%     @ MWY_5K37? .P#   <@T   T
M         ( !/EH$ &EM86=E7S P,2YJ<&=02P$"% ,4    " "W?G]6B;RH
M:K]'  #*3   #0              @ $99P0 :6UA9V5?,# R+FIP9U!+ 0(4
M Q0    ( +=^?U:9^X3* 5P  'UX   -              "  0.O! !I;6%G
M95\P,#,N:G!G4$L! A0#%     @ MWY_5M%IFZ!N60  #',   T
M     ( !+PL% &EM86=E7S P-"YJ<&=02P$"% ,4    " "W?G]6DYJ+;+@Y
M  #K.P  #0              @ '(9 4 :6UA9V5?,# U+FIP9U!+ 0(4 Q0
M   ( +=^?U940/T@23\  "5$   -              "  :N>!0!I;6%G95\P
M,#8N:G!G4$L! A0#%     @ MWY_5AY1-F_N0P  H4X   T
M ( !']X% &EM86=E7S P-RYJ<&=02P$"% ,4    " "W?G]6TGA\[ V)   7
MD@  #0              @ $X(@8 :6UA9V5?,# X+FIP9U!+ 0(4 Q0    (
M +=^?U:N=M6!>&P   MZ   -              "  7"K!@!I;6%G95\P,#DN
M:G!G4$L! A0#%     @ MWY_5FIH*\.[(0  S"@   T              ( !
M$Q@' &EM86=E7S Q,"YJ<&=02P$"% ,4    " "W?G]6]/2#D,HB  "-*0
M#0              @ 'Y.0< :6UA9V5?,#$Q+FIP9U!+ 0(4 Q0    ( +=^
M?U8=\A_F?1P  )YI 0 1              "  >Y<!P!P>7!D+3(P,C(Q,C,Q
M+GAS9%!+ 0(4 Q0    ( +=^?U:7>$5>-@L  #AT   5              "
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8;6Q02P4&     !@ &  3!@  Y^D(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
